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Preface 
 
The issue of drug availability and accessibility is a matter of immense concern for health 
services all over the world, especially in developing countries. Commonly, a large 
proportion of the health budget is spent on medications, often unnecessarily, and thus adding 
financial burdens on sometimes already over-burdened health care systems, and contributing 
to the problem of iatrogenic diseases as well. Over-prescribing, multi-drug prescribing, 
misuse of drugs, use of unnecessary expensive drugs and overuse of antibiotics and 
injections are cited in the literature as the most common problems of irrational use by 
prescribers as well as consumers.  
 
Strategies aimed at improving the quality of primary health care services and reducing 
medical and health care costs are linked to the promotion of rational drug use. These 
considerations prompted the World Health Organization (WHO) to develop its policy for 
rational drug use,  which by now is widely accepted as essential for improving health care 
quality and reducing health care costs at the same time. However, a rational drug  policy is 
not merely the production of an Essential Drug list, although such a list is a step in the right 
direction, but only one of many. The essential drug concept entails series of orchestrated 
measures and steps encompassing the development of national drug policies, with selection, 
procurement, quantification, quality assurance, inventory control, distribution, financing, and 
rational drug use by prescribers supported by treatment guidelines, all integrated within an 
overall scheme. All these measures and steps entail a good amount of training/re-training, 
and effective supervision aimed at changing prescribing and dispensing practices at different 
levels. 
 
Parallel to and in support of the initiative recently taken by the Palestine Ministry of Health 
in developing an Essential Drug List and Drug Formulary, the Institute of Community and 
Public Health embarked on field research to identify the most commonly used medications at 
the Primary Health Care level. The rationale for such an activity entailed the fact that drug 
misuse also takes place within the private sector which did not adopt the Palestine Ministry 
of Health Essential Drug List. The other rationale is that health professionals working in all 
health sub-sectors continue to need training and re-training in rational prescribing so that the 
old prescribing practices would diminish and new ones would replace them. While the List 
and the Formulary  are very good steps taken in the right direction, they cannot solve the 
problem of antibiotic over-prescribing, for instance, nor the numerous other encountered 
problems engrained in local medical practices, and that to a large extent stem from 
insufficient knowledge of drugs and their appropriate use and lack of training in rational 
practices. 
 
Thus combining many of the essential medications listed in the Palestinian Drug Formulary 
with selected others that were found to be very commonly used by private practitioners, this 
training aid and self/learning reference manual was compiled with the aim of providing the 
prescriber with essential information on the proper use of these commonly used medications. 
It specifically addresses the identified weaknesses in the current local prescribing and 
dispensing practices. Utilizing classical texts and references, including key WHO 
publications, the compilation led to the production of an initial draft. The initial draft was 
circulated for review and comments to about 20 local experts: physicians and pharmacists 
 x 
specialized in particular fields, and working within the different sub-sectors of health 
services (governmental, UNRWA, NGO services and private practitioners). Much 
discussion, re-drafting and re-modification ensued, ending up with the production of the 
final version of this training/self-learning manual in 2003. 
 
We hope that this initiative will contribute to improved practices by physicians, pharmacists 
and nurses in Palestine. 
 
 
Rita Giacaman, PharmD, M.Phil. 
Director  
Institute of Community & Public 
Health, Birzeit University 
June 2003 
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How to Use this Manual: 
 
This manual is divided into 13 chapters organized according to therapeutic categories.  Each 
of the chapters is divided into groups and subgroups to facilitate comparisons of drugs. Some 
drugs with multiple uses may be listed in more than one section of this manual.   
 
Each chapter starts with an overview of the therapeutic category, then each drug is presented 
in the drug monographs that include: 
• Drug summary: A small description of the drug. 
• Indications:  Approved indications, mainly on the primary care level. 
• Contraindications: Specific conditions in which the drug should not be used. 
• Dosage forms: Available dosage form on the primary health care level. 
• Recommended dosage: Recommended dosage regimens and directions for 
administration. 
• Use in special cases: Which includes use of these drugs in pregnancy, lactation, 
children, and patients who have any renal or liver disease.  
• Precautions and warning: This section lists conditions in which use of the drug may be 
hazardous, and the medical team may need to use alternative dose regimens or drugs. 
• Adverse drug reactions: Reported side effects of the drug. 
• Interactions:  A summary of documented drug-drug interactions. 
• Overdosage: The clinical symptoms of toxicity or an accidental overdose, and initial 
method of treatment. 
• Brands: The known brand names of the drug in the Palestinian market, and the 
companies that manufacturers them.   
 
One can find the abbreviations and pregnacy categories included in the chapters in the first 
few pages.  The appendix at the end of the manual include the Price list, the definitions, and 
general index.   
 
The Price List, listing medications by generic name, brand name, concentration, dosage 
form, packaging and price list based on 2002 lists obtained locally (needless to say, the price 
list needs to be updated regularly, and we are setting up the infrastructure for such a task).  
This list represent an attempt at introducing several elements in the prescribing process at 
once: The use or remembering of generic names - a gradual process of using generic names 
of prescription is ultimately desired - the use of the correct dose and dosing interval - as we 
know that this is also a local problem - as well as paying attention to the cost, given that 
particular attention should be paid to the unit cost given the same drug quality, when 
prescribing. Note that local drug companies and wholesalers do produce price lists of 
available drugs, but those include merely the brand name and not the generic name nor the 
strength of the medication. These lists are used for commercial reasons at the level of the 
pharmacy, and are usually not accessible to doctors. 
 
The Reference List includes the detailed books, and articles or journals that have been used 
to obtain the information compiled for the monographs. 
 
 
 xii 
The Index at the end provides a list of all the drugs that have been listed or mentioned in this 
reference. Brand names are written in italic font, while the proprietary/generic name in small 
letters.  
 
 
The drugs mentioned in the Palestinian MOH EDL (2000) are indicated by (P), while the 
drugs mentioned in the WHO EDL 1999 are identified as (WHO) after each drug name.  It 
should be emphasized that the resemblance with the previously mentioned lists is by the 
generic name ONLY, and not the concentration or dosage form. 
 
 xiii 
Abbreviations 
 
0BGeneral Abbreviations 
ACE Angiotensin-Converting 
Enzyme 
AIDS Acquired Immunodeficiency 
Syndrome 
AST Aspartate Amino-
Transferase  (a high blood 
level of AST can occur with a 
heart attack or liver disease...) 
ALT Alanine Amino Transferase  
AV Atrio-Ventricular 
BBB Blood Brain Barrier 
B.P.  British Pharmacopoeia 
BNF British National Formulary 
BP Blood Pressure 
BUN Blood Urea Nitrogen 
CBC Complete Blood Count 
CDC Center for Disease Control 
cGMP cyclic Gaunine Mono-
Phosphate 
CHF Congestive Heart Failure 
Cl cr Creatinine Clearance 
CNS Central Nervous System 
COPD Chronic Obstructive 
Pulmonary Disease 
CSF Cerebrospinal Fluid 
CVA Cerebrovascular Accident 
(leads to a stroke) 
CVS Cerebrovascular System 
e.g. for example 
ECG Electrocardiogram: 
recording of the electrical 
activity of the heart 
EEG Electroencephalogram: 
measures the electrical 
current within the brain 
ENT Ear, Nose, and Throat 
EPI Expanded Program on 
Immunization 
ERT Estrogen Replacement 
Therapy 
FDA Food & Drug 
Administration 
G6PD Glucose-6-Phosphate 
Dehydrogenase 
GABA Gamma Aminobutyric Acid 
GH Growth Hormone 
GI tract Gastrointestinal Tract 
GU Genitourinary 
GERD Gastro-Esophageal Reflux 
Disease  
GFR Glomerular Filtration Rate  
HDL High-Density 
Lipoprotein(s) 
Hgb Hemoglobin 
Hib Haemophilus influenzae 
type B 
HPA Hypothalamic Pituitary 
Adrenocortical 
I.U. International Unit 
ICD 10 The International Statistical 
Classification of Diseases 
and Related Health 
Problems, tenth revision 
IOP Intra-Ocular Pressure 
IUD Intra-Uterine Device 
LDL Low-Density Lipoprotein 
LVF Left Ventricular Failure 
MAO Mono-Amine Oxidase 
MAOI Mono-Amino Oxidase 
Inhibitor 
meq Milliequivalent 
MI Myocardial Infarction 
mg Milligram  
NSAIDs Nonsteroidal Anti-
Inflammatory Drugs 
OC/ OCs Oral Contraceptive/s 
Oint. Ointment 
OTC Over the counter 
PKU Phenylketonuria 
PT Prothrombin Time 
REM Rapid Eye Movement 
RTS Respiratory Tract System 
SA Sinoatrial 
SLE Systemic Lupus 
Erythematosus 
 xiv 
S.O.B. Shortness of Breath 
SPF Sun Protection Factor 
SSRI Selective Seretonin 
Reuptake Inhibitors 
SR Sustained Release 
STD Sexually Transmitted 
Diseases 
Supp. Suppository 
Susp. Suspention 
Syr. Syrup  
t ½  Therapeutic half life 
Tab./tabs. Tablet, tablets 
TCA Tricyclic Antidepressants 
TIA Transient Ischemic Attack 
(Stroke) 
ug or mcg Microgram 
U.S.P. United States 
Pharmacopoeia 
UNRWA United Nations Relief and 
Works Agency 
UNICEF United Nations Children’s 
Fund 
UTI Urinary Tract Infections 
Vit. Vitamin 
WHO World Health Organization 
1BCompany Name Abbreviations 
BMS Bristol Meyer Squibb 
BPC Birzeit Palestine Company 
Eastern 
Chem. 
Eastern Chemical Company 
GSK Glaxo Smith Kline 
HMR Hoechst Marion Rousel 
JCL Jordan Chemical 
Laboratory./ Beit-Jala 
JePharm Jerusalem Pharmaceuticals 
Company 
Pharmacare Pharmacare Ltd. Company 
 
 
2BPharmacy Abbreviations 
a.c. before meals 
b.i.d. two times a day 
d day 
h., hrs. hour, hours 
h.s. at night, or at bedtime 
ID intradermal 
IM intramuscular 
IV intravenous  
min. minute 
mon. month 
PO by mouth/ orally 
prn / p.r.n. when needed 
q.d. once every day 
q.i.d. four times daily 
q.o.d. every other day 
q. 4 h. every four hours 
q. 4 w. every four weeks 
SC subcutaneous  
SL sublingual 
® Brand name 
Rx Prescription 
tbsp. tablespoonful 
t.i.d. three times a day 
tsp.  teaspoonful 
wk week 
y., yrs. year, years 
 xv 
Pregnancy Categories 
 
 
 
 
Category 4BExplanation 
3BA 
Controlled studies in women fail to demonstrate a risk to the fetus in 
the first trimester (and there is no evidence of a risk in later trimesters), 
and the possibility of fetal harm appears remote. 
B 
Either animal reproduction studies have not demonstrated a fetal risk, 
but there are no controlled studies in pregnant women, or animal-
reproduction studies have shown an adverse effect (other than a 
decrease in fertility) that was not confirmed in controlled studies in 
women in the first trimester (and there is no evidence of a risk in later 
trimesters). 
C 
Either studies in animals have revealed adverse effects on the fetus 
(teratogenic or embryonic effects or other) and there are no controlled 
studies in women, or studies in women and animals are not available.   
Drugs should be given only if the potential benefit justifies the 
potential risk to the fetus. 
D 
There is positive evidence of human fetal risk, but the benefits from 
use in pregnant women may be acceptable despite the risk (e.g. if the 
drug is needed in a life-threatening situation or for a serious disease for 
which safer drugs can not be used or are ineffective). There will be an 
appropriate statement in the “warnings” section of the labeling.   
X 
Studies in animals or human beings have demonstrated fetal 
abnormalities or there is evidence of fetal risk based on human 
experience, or both, and the risk of using the drug in pregnant women 
clearly outweighs any possible benefit.   
The dug is contraindicated in women who are or may become 
pregnant. There will be an appropriate statement the 
“contraindications” section of the labeling. 
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Chapter  1 :   ANALGESICS,  
ANTIPYRETICS,  ANTI- INFLAMMATORY 
AND ANTIGOUT DRUGS  
 
 
 
 
A)  ANALGESIC, ANTIPYRETIC, AND ANTI-INFLAMMATORY AGENTS 
1.  ACETYLSALICYLIC Acid (Aspirin) 
2.  PARACETAMOL (Acetaminophen) 
3.  Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 
   (Ibuprofen, Diclofenac, Indomethacin, Piroxicam) 
 
B)  ANTIGOUT AGENTS 
1.  Allopurinol  
2.  Sulfinpyrazone 
3.  Colchicine 
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A)  ANALGESICS, ANTIPYRETICS, AND ANTI-INFLAMMATORY 
AGENTS 
 
In this section, drugs that have analgesic, 
anti-inflammatory and/or antipyretic action 
will be discussed. These are heterogeneous 
compounds, often chemically unrelated 
(although most of them are organic acids), 
but nevertheless share certain therapeutic 
actions and side effects. In many textbooks 
Aspirin is the prototype of this group; 
hence these compounds are often referred 
to as aspirin-like drugs. More frequently 
they are known as non-steroidal anti-
inflammatory drugs (NSAIDs). 
There is no internationally agreed upon 
classification of analgesics/antipyretics. 
Most textbooks classify them depending on 
their efficacy, dividing them into two 
groups; Non-narcotic analgesics (for the 
mild to moderate pain, some of which may 
also have antipyretic actions), and 
narcotic/opioid analgesics (which are 
principally used in the relief of severe pain, 
and may produce dependence). Many 
analgesics also have marked anti-
inflammatory actions and therefore are used 
for the treatment of arthritis and other 
inflammatory conditions.  Most exhibit 
their effect, at least in part, by the inhibition 
of prostaglandin synthesis.  
At the primary health-care level, non-
narcotic analgesics are of major concern 
because of their wide use. 
Analgesics are drugs used to relieve pain- 
“pain killers”.  Pain is one of the most 
common symptoms, and one of the most 
frequent reasons why people seek medical 
care.  
Antipyretic activity results in lowering 
the temperature, and is considered to 
involve the hypothalamus. Normal body 
temperature varies according to the 
individual’s age, sex, level of physical and 
emotional stress, the environmental 
temperature, time of the day, and the 
anatomical site at which the temperature is 
measured. Body temperature may be 
measured at rectal, axillary, oral, or 
tympanic (ear canal) sites. The method used 
to measure the temperature should be 
indicated in the reported patient’s 
temperature. Paracetamol, aspirin, and 
ibuprofen have similar antipyretic activity.  
Product selection should be based primarily 
on patient acceptance, the side effects of 
each agent, concurrent diseases that may 
prohibit the use of each agent, convenience 
of administration, and cost of therapy. 
Anti-inflammatory agents are drugs that 
alleviate symptoms of inflammation, but do 
not necessarily deal with the cause.  
NSAIDs have been shown to be as 
effective as aspirin (ASA), but not superior. 
Cross-sensitivity between aspirin and 
NSAIDs is high (can be up to 97% with 
ibuprofen). If a person is severely allergic 
to ASA, avoid use of NSAIDs. 
Clinically, there are no clear guidelines 
to assist in selecting the most appropriate 
agent for a patient. Base for selection 
depends on clinical experience, patient 
convenience, side effects and cost.  
NSAIDs’ action is due to the inhibition of 
cyclo-oxygenase activity and prosta-
glandin synthesis (see table 1.1) for specific 
indications). NSAIDs may mask usual 
signs of infection, therefore, cautious use in 
case there is an existing controlled 
infection. Always take a detailed drug 
history prior to starting therapy to avoid 
cross-sensitivity effects. Single ingredient 
preparations should be prescribed because 
compound preparations rarely have any 
advantage, and have a higher incidence of 
side effects. 
Some current analgesic preparations 
contain medications that have been pulled 
off the market in developed countries, but 
are still used inappropriately at the primary 
care level. One example of such are 
pyralozones or butazones (phenylbutazone, 
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oxyphenbutazone). Dipyrone is a sodium 
sulphonate derivative of amidopyrine or 
aminopyrin, a member of the pyrazolone 
group of chemicals, marked by different 
generic and brand names: Analgin, 
Novalgin, Baralgan, Cibalgin, Metamizol . . . 
and many more. No matter what it is 
called, it is no longer an accepted drug. 
This medication has a potentially fatal risk 
of agranulocytosis; a severe loss of white 
blood cells, which leaves the victim 
susceptible to many diseases. Its use should 
be justified only in serious or life-
threatening situations where no alternative 
anti-inflammatory medications have been 
effective. 
______________________ 
 
 
 
1)  Acetylsalicylic Acid WHO,P  
 
• DRUG SUMMARY:   
Acetylsalicylic Acid (ASA), Aspirin, is a 
salicylate that relieves headaches, muscular 
and joint pains, and reduces inflammation. 
ASA has been considered the drug of 
choice in the treatment of arthritis, but its 
anti-inflammatory action occurs only 
when given in large doses (3-4 g/day). At 
these large doses, ASA produces adverse 
effects that are the main disadvantage 
when used for arthritis conditions. NSAIDs 
tend to be more appropriate for arthritis 
conditions. The mechanism of action of 
ASA is that it inactivates cyclooxygenase 
irreversibly, it inhibits prostaglandin 
synthesis and inhibits platelet aggregation. 
• INDICATIONS: 
Used for pain, fever, inflammatory 
conditions such as rheumatic fever, 
rheumatoid arthritis, osteoarthritis, dys-
manorrhea and symptomatic relief of the 
common cold pain and fever.  It is used for 
reducing the risk of recurrent Transient 
Ischemic Attacks (TIA/stroke), or 
Myocardial Infarctions (MI/heart attack) at 
low doses. 
• CONTRAINDICATIONS: 
In patients with history of hypersensitivity, 
asthma, peptic ulcer/dyspepsia, those with 
bleeding tendencies or disorders. 
• DOSAGE FORMS: 
Tablets. 
• RECOMMENDED DOSAGE: 
Adult:  
350 - 650 mg q. 4 h. for minor aches and 
pain. 
500 - 1000 mg  q. 4-6 h.; max. 4 g/24 h., for 
moderate to severe pain. 
75 - 325 mg/day q.d. continued indefinitely 
for: Ischemic stroke & TIA, and the 
prevention of recurrent MI, unstable angina 
pectoris, chronic stable angina pectoris 
(FDA, 1998). 
Child: Use not recommended, unless for 
certain conditions. (Refer to special cases). 
 
Directions: Take with or after food to avoid 
GI disturbances (including ulcers).   
*The drug is hydrolyzed in the stomach, 
and primarily absorbed in the stomach and 
upper small intestine. Peak level is within 
15 minutes to 2 h., so patient should expect 
the drug effect to be noticed within 15 
minutes from taking the medication. 
*ASA should not be used for self-
medication of pain for longer than 10 days 
in adults or 5 days in children, unless 
directed by a physician. 
*ASA preparations should not be used if a 
strong vinegar-like odor is present. 
• USE IN SPECIAL CASES: 
Pregnancy- Contraindicated at analgesic 
doses. ASA crosses the placenta, and may 
harm the fetus (Category D). Paracetamol 
may be a better choice for analgesia. ASA 
may be used in low doses (100 mg) as 
anticoagulant and for prophylaxis of pre-
eclampsia in high-risk pregnant women. 
(Refer to the anticoagulants in cardio-
vascular chapter for further information 
about use). 
Lactation- Salicylates are excreted in breast 
milk in low concentrations, but no adverse 
effects on infants have been reported.  Use 
caution. 
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Children- Use is not recommended specially 
for undiagnosed fever when influenza is 
suspected, due to risk of Reye’s syndrome (a 
rare disorder presented by symptoms of 
encephalitis combined with evidence of 
liver failure). This potentially fatal condition 
occurs following certain viral infections like 
chickenpox, or those with minor febrile 
illness. It is characterized by vomiting and 
lethargy that may progress to delirium and 
coma. Paracetamol should be used instead. 
(see recommended doses).  
[Some of the USES IN SPECIAL CASES in 
children that ASA should be used in are 
Juvenile Arthritis (60-110mg/kg/d q.6-8 h.), 
Rheumatic Fever, and Kawasaki disease 
that are not usual cases seen at the primary 
health care level.] 
Renal Disease- Caution in these patients, 
ASA may aggravate chronic kidney disease, 
fluid retention, increased risk of GI bleeding. 
In severe cases avoid. In minor cases reduce 
the dose. (50% of the dose is eliminated in 
the urine.) 
Liver Disease- The drug is metabolized in the 
liver. Use caution in patients with impaired 
liver function, pre-existing hypopro-
thrombinemia and vitamin K deficiency may 
increase risk of bleeding. 
• PRECAUTIONS AND WARNINGS: 
-Not to be taken on an empty stomach. 
Prolonged use (see directrion) requires 
medical supervision. 
-Avoid ASA for at least 1 week prior to 
surgery. Patients should inform the dentist 
or doctor of taking this medication before 
doing any lab or dental work. 
-Avoid alcohol while taking this medication 
since it increases the risk of GI ulceration 
and bleeding. 
• ADVERSE EFFECTS: 
Dizziness, cinchonism (ringing in the ear), 
skin eruptions, epigastric discomfort, peptic 
ulceration and bleeding, increase bleeding 
tendency, hypersensitivity reactions. 
• INTERACTIONS:   
Overview  of  ASA 
Drug-Drug Interaction 
Drug Interaction 
ACE 
inhibitors 
Hypotensive and vasodilator 
effect of ACEI may be reduced
Monitor patients, and 
discontinue ASA if possible. 
Anti-
coagulants  
Anticoagulant effect 
enhanced. Effect of ASA on 
gastric mucosa and platelet 
function may enhance 
possibility of hemorrhage. 
Avoid concomitant use.  
β-blockers Their antihypertensive 
effectiveness may be 
decreased. Use with caution. 
Cortico-
steroids 
Corticosteroids will reduce 
serum salicylate levels and 
decrease salicylate 
effectiveness.  
Monitor plasma salicylate 
concentration when adding or 
withdrawing corticosteroids. 
NSAIDs Pharmacological effects of 
certain NSAIDs may be 
decreased.  Increased risk of GI 
disturbances if used 
concomitantly.  
Oral hypo-
glycemics 
ASA increases hypoglycemia 
effect of sulfonylureas. 
Monitor the patient’s blood 
glucose, if hypoglycemia 
occurs, decrease sulfonylurea 
dose. 
• OVERDOSE:   
Can be fatal, particularly in children. Acute 
lethal dose is approximately 10-30 g for 
adults, and 4 g in children. Requires 
immediate referral to hospital. It presents 
with confusion, rapid deep breathing, 
sweating, tinnitis (noises in the ear), 
deafness followed in severe cases by 
unconsciousness. Induce vomiting if 
possible (patient is conscious) with syrup of 
ipecac. Activated charcoal decreases 
absorption if given within 2 hrs. after 
ingestion. 
Chronic Salicylate toxicity may occur when 
> 100 mg/kg/d is ingested for 2 or more 
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days. It is more difficult to recognize and is 
associated with increased morbidity and 
mortality. Compared to acute poisoning, 
hyperventilation, dehydration, systemic 
acidosis and severe CNS manifestations 
occur more frequently. Treatment includes 
supportive measures. 
• BRANDS: 
Acetosal (Rekah), Aspirin (Bayer), Aspro 
(Nicholas), Alka Seltzer (Agis), Baby Aspirin 
(JCL), Buffered Aspirin (Pennex), Bufsa 
(GAMA), Cartia (Smith Kline). 
__________________________ 
 
2)  Paracetamol WHO,P  
 
• DRUG SUMMARY: 
Paracetamol or Acetaminophen (N-Acetyl-p-
amino-phenol-APAP) is a non-narcotic CNS 
agent. It is equivalent to aspirin in relieving 
pain and reducing fever, but it has little 
effect on platelet function, does not affect 
bleeding time and generally produces no 
gastric bleeding or ulcers. It has no anti-
inflammatory action in usual doses. 
Paracetamol reduces fever by direct action 
on the hypothalamus heat-regulating center 
with consequent peripheral vaso-dilatation, 
sweating and dissipation of heat.   
• INDICATIONS:  
Used for pain and fever. Good substitute 
for ASA, when ASA is not tolerated or is 
contraindicated. 
• CONTRAINDICATIONS: 
In patients with history of hypersensitivity. 
In patients with severe liver and kidney 
damage. 
• DOSAGE FORMS: 
Tablets, capsules, suspension, 
suppositories. 
• RECOMMENDED DOSAGE: 
Adult: PO: 325-650 mg q. 4-6 h. as 
needed;  max. 4 g/24 hours. 
Child: PO or PR:  10-15 mg/kg/dose.   
 
AGE DOSE * 
0-3 mon 10mg/kg (5mg/kg if jaundiced) 
3 mon-1 y 60-120 mg 
1-5 y 120-250 mg 
6-12 y 250-500 mg 
* Martindale, 1996:82. 
 
* The doses may be repeated q. 4-6 h. not to 
exceed 4 doses in 24 hours. 
 
Directions:  
*Can be taken with fluids, but before meals 
or 2 hours after meal, 4 times daily for 2-3 
days or as required. 
*The drug is completely absorbed from the 
GI tract, less complete absorption takes 
place from rectal suppository. 
*Peak effect occurs within 0.5-2 h., and 
duration is 3-4 h.   
*If fever does not subside within 3 days, 
patient has to contact the physician. 
• USE IN SPECIAL CASES: 
Pregnancy- Safe if used as directed (Category 
B). It is the drug of choice in pregnant women 
for aches and pains, or fever. It does cross the 
placenta, but no reports of harmful effects 
have been noted. 
Lactation- APAP is excreted in low 
concentration in breast milk. No harm on 
infants has been noted. It is safe when used as 
recommended. 
Children- Can be used prophylactically (30 
min. before) in children receiving DPT 
vaccination to decrease incidence of fever and 
injection site pain. Use caution and do not 
exceed the recommended doses. 
Renal Disease- Kidney tubular necrosis may 
occur with chronic use of very high doses of 
the drug ( > 4 g/d). 
Liver Disease- The drug is exclusively 
metabolized in the liver. Hepatotoxicity and 
severe hepatic failure occurred in chronic 
alcoholics following therapeutic doses. Avoid 
large dose in liver cases. (< 2 g/d is 
acceptable for these patients). 
• PRECAUTIONS AND WARNINGS: 
-Do not exceed recommended doses. 
Chronic excessive use (> 4 g/d) eventually 
may lead to transient hepatotoxicity.  
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-If pain or fever persists for more than 3 
days consult a physician.   
-Use caution when patients are taking other 
drugs that might affect the liver. 
• ADVERSE EFFECTS: 
If used as directed it rarely causes any side 
effects. 
Heavy alcoholics and smokers are more 
susceptible to liver toxicity. Skin rashes and 
neutropenia are very rare. 
• INTERACTIONS: 
Overview of APAP 
Drug-Drug Interaction 
Drug Interaction 
Alcohol, 
Barbiturates,  
Carba-
mazepine, 
  and  
Rifampin 
The potential hepatotoxicity 
of APAP may be increased 
by large doses or long term 
use of the these agents due 
to hepatic microsomal 
enzyme induction 
 
• OVERDOSE: 
Symptoms: Acute poisoning symptoms 
include nausea, vomiting, drowsiness, 
confusion, liver tenderness, low blood 
pressure, cardiac arrhythmia, jaundice and 
acute hepatic and renal failure.   
Treatment: Refer to the emergency room as 
soon as possible. There are no early specific 
symptoms, careful monitoring of blood levels 
is needed  to estimate potential for 
hepatotoxicity.   
Oral N-acetylcysteine is a specific antidote 
for APAP toxicity. Administration of 
activated charcoal will adsorb 
acetylcysteine, so avoid administration. 
Follow special directions for administration 
of N-acetylcysteine antidote and monitor 
the patient for several days. 
• BRANDS: 
Abrol (Rekah), Abrolet, (Rekah), Dexamol 
(Dexxon), Acamol (Teva), Acamoli (Teva), 
Aldolor (CTI), Febramol (BPC), Panadol 
(Whinthrop), Otamol (JePharm), Paracare 
(Pharmacare), Pamol (Eastern Chem.), Paramol 
(JCL), Paracetamol (Rekah), Paramolan 
(Trima), Razimol (Al-Razi), Tylenol (McNeil). 
__________________________ 
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Table 1.1:  NSAIDs of Summary of Indication #  
INDICATION Diclofenac Ibuprofen Indomethacin Naproxen / Naproxen  Na Piroxicam 
Rheumatoid arthritis 
(RA) 9 9 9 9 9 
Osteoarthritis  (OA) 9 9 9 9 9 
Ankylosing spondylitis 9  9 9  
Mild to moderate pain 8 9  9  
Primary dysmenorrhea  9 8 9 8 
Juvenile rheumatoid 
arthritis 8 8  9 8 
Tendinitis, Bursitis 
   9 9  
Acute gout 
   9 9  
Acute painful shoulder 8  9   
Pre-menstrual 
syndrome  8  8 / Naproxen Na  
Fever 
  9  8  
Migraine/Cluster 
headache   8 8  
 9-  Labeled use (approved by FDA for this indication) 
 8 -  Unlabeled use (not approved by FDA for this specific indication, but is used by doctors.) 
 Blank - is not usually used. 
 # Drug Facts and Comparisons.  2000: p. 836. 
 
 
 
 
 
3)  Non-Steroidal Anti-
Inflammatory Drugs 
(NSAIDs) 
 
All NSAIDs are antipyretic, analgesic, and 
anti-inflammatory, but there might be some 
differences in their individual activities. 
Thus a patient may do well on one 
propionic acid (i.e. Ibuprofen) derivative, 
but not on another. The reasons for such 
differences are not fully understood, but 
differential sensitivity of enzymes in the 
target tissues may be the reason. When 
employed as analgesics, these drugs are 
usually effective against pain of low-to-
moderate intensity. Although their maximal 
effect is much lower than opioids, they lack 
the unwanted effects of the opioids on the 
CNS, including respiratory depression and 
the development of physical dependence.   
In addition to sharing many therapeutic 
activities, current NSAIDs share several 
unwanted effects. The most common is the 
tendency to induce gastric or intestinal 
ulceration that can sometimes be 
accompanied by anemia from the resultant 
blood loss. Other reported side effects 
include disturbances in platelet function, 
water retention, increased blood pressure, 
the delayed onset and prolongation of 
gestation or labor, and changes in renal 
function. 
Newer agents of NSAIDs that are 
cyclooxygenase-2 (COX-2) inhibitors are 
being produced and sold on the market, as 
having lower GI side effects. Until further 
safety reports through post marketing 
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surveillance are studied, cost-benefit 
decisions should be made before 
recommending such agents. 
In general, NSAIDs work only on 
symptomatic relief of fever, pain and 
inflammation associated with the disease. 
 
 
a)  Ibuprofen WHO  
 
• DRUG SUMMARY:   
Ibuprofen (IBP) is a proprionic acid 
derivative. Comparable to aspirin (ASA) in 
its analgesic action, but higher doses are 
required for anti-inflammatory effect. It has 
been reported to have less GI symptoms 
than aspirin in equi-effective doses.   
Cross-sensitivity with ASA and other 
NSAIDs has been reported. IBP inhibits 
platelet aggregation and prolongs bleeding 
time, but does not affect prothrombin or 
whole blood clotting times. 
• INDICATION:   
Refer to table-1.1. 
• CONTRAINDICATIONS: 
In patients who are hypersensitive where 
urticaria, severe rhinitis, bronchospasm, 
angioedema, are precipitated by ASA or 
other NSAIDs. Active peptic ulcer or 
bleeding abnormalities. 
• DOSAGE FORMS: 
Tablets, suspension (100 mg/5ml), gel 5%. 
• RECOMMENDED DOSAGE: 
Adult:  200-400 mg PO q. 4-6 h.,  
max. 1800 mg/24 hours for pain and fever. 
400-800 mg t.i.d. or q.i.d.;  max. 3200 mg/d 
for inflammation. 
Emulgel dose: A thin layer of the gel is 
applied to affected area as needed, up to 
three times daily.  
Child: Use is not recommended for 
children under 6 months; 
 
Doses of  IBP  in Children 
1-12 y:  give 5-10 mg/kg q. 4-6 h. 
or 
6 - 11 mon.    25-50 mg 6 - 8 y.        125-250 mg 
12 - 23 mon  50-100 mg 9 - 10 y.     150-300 mg 
2 - 3 y.             75-150 mg 11 - 12 y.    200-400 mg 
4 - 5 y.            100-200 mg (all given  q . 4-6 h.  prn) 
 
Maximum daily dose is 40 mg/kg/d. 
 
Directions: IBP should be taken with food 
or milk if GI disturbances occur.  
*80% of the drug is absorbed from the GI 
tract.  Peak effect is 1-2 h.   
*Onset for analgesia is 0.5 h., and for anti-
rheumatic action is 7 days. 
*If patient misses a dose, take as soon as 
they remember unless it is too close to the 
following dose, so they need to skip the 
following dose and continue with the usual 
schedule.  Dose should not be doubled. 
• USE IN SPECIAL CASES: 
Pregnancy- Better to avoid use (Category B). 
Paracetamol is a better choice for analgesia. 
Lactation- Safe. IBP has not been detected in 
breast milk in analgesic doses. 
Children- Safety and efficacy has not been 
established for children < 6 mon old. 
Normally, not recommended for children < 1 
year or less than 7 kg.   
Renal Disease- Use with caution. Reduce 
dose. NSAID metabolites are excreted by 
kidney into urine. 
Liver Disease- Use with caution, and decrease 
the dose. The drug is metabolized in the liver. 
There is an increased risk of GI bleeding or 
fluid retention. 
• PRECAUTIONS AND WARNINGS: 
-Patients with history of cardiac 
decompensation should be observed closely 
for evidence of fluid retention and edema. 
-Instruct patient to report immediately any 
passage of dark tarry stool, coffee-ground 
emesis, blood or protein in urine. This can 
be an indication for GI bleeding.  
Medication should be stopped and patient 
should be re-evaluated. 
Analgesics, Antipyretics, Anti-Inflammatory and Antigout Drugs 
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-Caution if skin rash, itching, visual 
disturbances or persistent headache should 
occur.  
-Caution in hypertension, chronic renal 
failure and patients with SLE. Advise 
patient not to drink alcohol, to avoid 
increased risk of GI ulceration and 
bleeding. 
• ADVERSE EFFECTS: 
GI disturbances are most common; i.e. 
heartburn, nausea and dyspepsia, 
abdominal distress, gastritis and ulceration. 
Also, dizziness, drowsiness, jaundice, and 
fatigue may occur. Side effects are dose 
related. Incidence or aggravation of 
epilepsy and parkinsonism have been 
reported with use of NSAIDs. 
• INTERACTIONS: 
Overview of Ibuprofen 
Drug-Drug Interaction 
Drug Interaction 
Oral anti-
coagulants, 
and  
heparin 
May prolong bleeding time. 
Avoid concomitant use. 
Lithium, 
digoxin  
and  
methotrexate 
Increased toxicity of these 
drugs with concomitant 
NSAIDs use. Monitor each 
drug serum levels and adjust 
dose as needed. 
 
• OVERDOSE: 
Symptoms: May include drowsiness, 
dizziness, mental confusion, lethargy, 
vomiting, abdominal pain, tinnitus, 
convulsions, hypotension, tachycardia, and 
metabolic acidosis.   
Treatment: Induce emesis or perform gastric 
lavage to recover undigested tablets, include 
supportive measures. Since NSAIDs are 
strongly bound to plasma, hemodialysis or 
peritoneal dialysis may be of little value. 
Charcoal tends to reduce the absorption of the 
drug.   
• BRANDS: 
Adex 200 (Dexxon), Advil (Whitehall), Artofen 
(Teva), Brufen 400 (Boots), Ibufen (Dexxon), 
Isofen (BPC), Motrin (Upjohn), Nurofen 
(Boots), Trufen (JePharm). 
____________________ 
 
b)  Diclofenac  P 
 
• DRUG SUMMARY:   
An acetic acid derivative. It has analgesic, 
antipyretic, and anti-inflammatory proper-
ties. At therapeutic doses it has little effect 
on platelet aggregation. Patients not 
responding to IBP can be given diclofenac 
instead. Do not co-administer with other 
NSAIDs or salisylates. 
• INDICATION:  
Refer to table-1.1. (It is also used as an 
ophthalmic agent for cataract surgery). 
• CONTRAINDICATION: 
Same as IBP. 
• DOSAGE FORMS: 
Tablets, sustained release tablets, 
suppositories, emulgel and ampoules. 
• RECOMMENDED DOSAGE: 
Adult: 75-150 mg/24h given by mouth in 
divided doses. Total daily dose should not 
exceed 150 mg/d, such doses have not been 
studied. 
Suppository form is given in a dose of 75-
100 mg each evening. 
The emulgel form 1% should be applied to 
painful site, 2-4 gm, 3-4 times daily. 
Therapy should be reviewed after 14 days. 
Child: Not recommended for children < 1 
y. unless JRA. 
Child > 1 y. for RA: 1-3 mg/kg in divided 
doses by mouth or rectum. 
 
Directions: Diclofenac is readily absorbed 
from the GI tract, and 50-60% reaches the 
systemic circulation.  Peak effect is within 
2-3 h. 
*Absorption is delayed by food, take with a 
full glass of water. For chronic use take 
after food to avoid GI problems. 
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*Sustained release forms are given once or 
twice daily. 
*If simple GI disturbances occur, an 
antacid may be used, but not administered 
at the same time of the drug intake. 
*If patient misses a dose, this dose should 
be taken as soon as remembered, unless it is 
too close to the following dose, so skip and 
maintain schedule. Do not double the dose. 
• USE IN SPECIAL CASES: 
Pregnancy- Should not be used unless there 
are compelling reasons for doing so, 
(Category B). 
Lactation- Do not use in nursing mothers 
because of possible effects on infant’s 
cardiovascular system.  
Children- Use in child < 1 year is not 
recommended. Safety and efficacy in children 
have not been established. 
Renal Disease- NSAID metabolites are 
eliminated by the kidneys, 50-60% excreted 
in urine. Reduce dose to avoid accumulation. 
Liver Disease- Effects are not known. 
Metabolism of the drug occurs in liver. Use 
caution to avoid increased risk of GI bleed. 
• PRECAUTIONS, WARNINGS & 
OVERDOSE: 
Same as IBP. 
• ADVERSE EFFECTS: 
Similar to IBP, but with higher incidence. 
• INTERACTIONS: 
See overview table. 
 
Overview  of  Diclofenac 
Drug-Drug Interaction 
Drug Interaction 
Lithium, 
digoxin  
and  
methotrexate 
Increased toxicity of these 
drugs with concomitant 
NSAIDs use. Monitor each 
drug serum levels and adjust 
dose as needed. 
Diuretics May decrease blood pressure 
lowering effects of diuretics. 
May lead to an increase in 
serum K+, if using K+ sparing 
diuretics. 
 
• BRANDS: 
Abitren (Abic), Betaren/Betaren S.R (Dexxon), 
Diclofen (JePharm), Rhumacare (Pharmacare), 
Rufenal (BPC), Voltin (Eastern Chem.), 
Voltaren/ Voltaren S.R. (Ciba-Geigy).  
________________________ 
 
 
c)  Indomethacin P 
 
• DRUG SUMMARY: 
A very potent arylacetic acid NSAID 
derivative. Because of its high potential to 
cause side effects when used in high doses, 
it should be carefully considered for active 
disease unresponsive to adequate trials with 
salicylates. It has equal or a little superior 
action than naproxen, but higher incidence 
of side effects. This medication will enable 
reduction of steroid doses in severe forms 
of Rheumatoid Arthritis. (In this case 
reduce steroid dose slowly!). 
• INDICATION:   
Refer to table-1.1 in the beginning of this 
chapter. (Also used as IV for Patent Ductus 
Arteriosus in premature infants.) 
• CONTRAINDICATION:  
Same as IBP.  
Also in patients with recent rectal bleeding 
or proctitis if using suppositories. 
• DOSAGE FORMS: 
Capsules, suppositories, gel. 
• RECOMMENDED DOSAGE: 
Adult:  Rheumatoid Arthritis:  
25-50 mg b.i.d. or t.i.d., or 75 mg sustained 
release 1-2 times a day;  max. 200 mg/d. 
 Dysmenorhea: up to 75 mg daily.  
 Acute Gout: 50 mg t.i.d. until pain is 
tolerable (usually within 2-3 days), then 
taper off to 25 mg t.i.d. until total resolution 
of attack. 
(If administering both PO and rectal dosage 
forms combined, dose should not exceed 
200 mg/d). 
Child: Not recommended due to effect on 
liver function. 
Directions: Administer immediately after 
meals, or with food, milk or antacid to 
minimize GI side effects. (Food or antacid 
may cause somewhat delayed and reduced 
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absorption, but advantage of safety 
outweighs risk of impaired absorption.) 
*If patient misses a dose, take as soon as 
remembered unless it is too close to the 
following dose, so skip and maintain 
schedule. Never double doses.  
• USE IN SPECIAL CASES: 
Pregnancy- Category B in the 1st and 2nd 
trimester, and D in 3rd trimester. 
Lactation-  Use not recommended. 
Children- Contraindicated for children < 14 
yrs. Hepatotoxicity including fatalities has 
occurred in children with juvenile rheumatoid 
arthritis when taking this medicine. 
Renal Disease- Use caution. 
Liver Disease- Use caution, better to use 
lower doses, high risk of GI bleeding. 
• PRECAUTION AND WARNINGS: 
Same as IBP. Indomethacin has been 
reported to aggravate depression or other 
psychiatric disturbances, epilepsy and 
parkinsonism. Extreme caution should be 
taken in susceptible patients. In case of 
hemorrhoids, caution use or avoid rectal 
administration. 
• ADVERSE EFFECTS: 
Same as IBP, but with higher incidence. 
• INTERACTIONS: 
*Same as IBP, as well as:  
Overview of Specific Indomethacin 
Drug-Drug Interaction 
Drug Interaction 
Probenecid Increases in plasma 
concentration of 
indomethacin; enhancing the 
pain relief effect, but 
increasing its adverse 
effects. Use caution. 
Sympatho-
mimetics 
Concomitant use may result 
in increased blood pressure. 
Monitor patient.  
 
• OVERDOSE: 
Treatment is symptomatic and supportive. 
The stomach should be emptied as quickly 
a possible if the ingestion is recent. If 
vomiting has not occurred spontaneously, 
the patient should be induced to vomit with 
syrup of ipecac. If the patient is unable to 
vomit or unconscious, gastric lavage should 
be performed. Once the stomach has been 
emptied, 25-50 gm of charcoal may be 
given. Follow patient for several days 
because of GI ulceration and hemorrhage 
complications. 
• BRANDS: 
Indocaps (JCL), Indocin (Merk), Indocin 
(Eastern Chem.), Indolin (BPC), Indomed/ 
Indomed S.R. (Assia), Indopharm (JePharm), 
Indotard (CTI), Indovis (CTI). 
______________________ 
 
d)  Piroxicam 
 
• DRUG SUMMARY: 
An oxicam NSAID derivative. Is as 
effective as naproxen, and has a prolonged 
duration of action which permits once daily 
administration. Use is not recommended 
unless other NSAIDs have failed or patient 
compliance would be improved with once 
daily dose. 
• INDICATION: 
Refer to table-1.1, at the beginning of this 
chapter. 
• CONTRAINDICATIONS: 
Same as IBP. 
• DOSAGE FORMS: 
Capsules, suppositories. 
• RECOMMENDED DOSAGE: 
Adults: 10-20 mg PO 1-2 times/day. 
For acute gout, 40 mg initially, then 40 mg 
daily in single or divided doses for 2 days, 
then 20 mg q. d. for 7-14 days. 
Child:   Not to be used. 
Directions: Take with or after food. Peak 
effect is 3-5 hrs. for analgesia, and 2-4 weeks 
for anti-rheumatic action. Onset is 1 h. for 
analgesia, and 7 days for anti-rheumatic 
action.  Duration is 48-72 hrs. 
*If patient misses dose, it should be taken as 
soon as remembered unless it is too close to 
the following dose, so skip and maintain 
schedule. Do not double dose. 
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• USE IN SPECIAL CASES: 
Pregnancy- Category B in 1st and 2nd 
trimester, and Category D in 3rd trimester. 
Lactation + Children-  Not established. 
Renal Disease- Use with caution to avoid risk 
of accumulation. 
Liver Disease- Use with caution to avoid risk 
of GI bleedings. 
• PRECAUTIONS AND WARNINGS, 
ADVERSE EFFECTS, INTERACTIONS 
AND OVERDOSE:      All Similar to IBP. 
• BRANDS: 
Felcol (Eastern Chem.), Feldene (Pfizer), Pirox 
(JePharm). 
____________________ 
 
 
B)  ANTIGOUT AGENTS 
 
Gout is a disorder of uric acid metabolism. 
It is manifested by hyper-uricemia, acute or 
chronic recurrent arthritis, and deposits of 
monosodium urates. Although hyper-
uricemia is a precursor of gout, it is not a 
disease by itself, and not diagnostic of gout. 
The diagnosis of acute gouty arthritis is 
confirmed when large numbers of 
polymorphonuclear leukocytes and mono-
sodium urate crystals are demonstrated in 
synovial fluid aspirated from the inflamed 
joint.  
Most acute attacks have no obvious 
precipitating events, but trauma, excessive 
alcohol intake, drug induced (in therapy of 
diuretics, aspirin, anti-tuberculosis agents 
like pyrazinamide or ethambutol), or 
initiation of a hyperuricemic agent may 
contribute to an acute attack.  
In an acute attack, the goals of treatment 
are to immediately relieve pain and 
inflammation, and not to decrease the 
serum uric concentration. This can be 
effectively treated by a NSAID; i.e. 
indomethacin or naproxen. (refer to 
individual drug monographs for more 
details). Aspirin should not be used, since 
salicylates increase urate concentration. 
Acute attacks should never be treated with 
allopurinol or uricosurics (probenecid, 
sulfinpyrazone), this may prolong the 
attack indefinitely. Colchicine is an 
alternative to NSAIDs in patients with heart 
failure. 
After the initial attack of acute gout, the 
interval between subsequent attacks varies 
from a few days to several years. Some 
patients may never experience another 
acute attack. Antihyperuricemic 
medications should be initiated only when 
gouty patients have frequent acute attacks, 
urate tophi, or evidence of renal damage. 
Therapy starts when the acute attack 
completely subsides. Once started, such 
therapy usually is continued indefinitely. 
Initiation of treatment may precipitate an 
acute attack therefore the colchicine or an 
NSAID could be used prophylactically for 
at least one month after the hyperuricemia 
has been corrected. If an acute attack 
develops while the patient is taking 
treatment, the treatment should be 
continued at the same dosage, and 
treatment for the acute attack should be 
initiated on its own. 
 
 
1)  Allopurinol WHO,P  
 
• DRUG SUMMARY: 
Allopurinol is an agent that inhibits uric 
acid synthesis by inhibiting xanthine 
oxidase, the enzyme responsible for the 
conversion of hypoxanthine (end product of 
purine catabolism) to uric acid, so it 
reduces endogenous uric acid production. It 
is used for patients who overproduce uric 
acid. It has no analgesic, anti-inflammatory, 
or uricosuric actions, therefore, it is not 
useful for acute gouty attacks and may 
actually aggravate and prolong it. 
• INDICATIONS: 
To control primary hyperuricemia that 
accompanies severe gout, and to prevent 
possibility of flare-ups of acute gouty 
attack. To prevent recurrent calcium 
oxalate stones, prophylactically to reduce 
severity of hyperuricemia associated with 
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antineoplastic and radiation therapies, both 
of which greatly increase plasma uric acid 
levels in the body. 
• CONTRAINDICATIONS: 
Hypersensitivity, patients who have 
developed a severe reaction should not be 
restarted on the drug. Discontinue 
medication at first appearance of skin rash 
or other signs of allergic reactions. 
Contraindicated as initial treatment for 
acute gouty attack, or for asymptomatic 
hyperuricemia. 
• DOSAGE FORMS:  
Tablets. 
• RECOMMENDED DOSAGE: 
Adult: Hyperuricemia; 
100 mg daily initially, may be increased by 
100 mg/wk; max. 800 mg daily. 
Serum uric acid level of ≤ 6 mg/dl should 
be attained.   
Control of gout, and secondary 
hyperuricemia; 
200-300 mg/day for mild gout, 
400-600 mg/day for moderate to severe.  
Initially 100 mg daily as a single dose, after 
food, gradually the dose is increased over 
1-3 wks according to the plasma or urinary 
uric acid concentration to about 300 mg.  
Usual maintenance dose is 200-600 mg/d.;  
max. 800 mg daily. 
Recurrent calcium oxalate stones; 
200-300 mg/day in single or divided doses, 
as well as modification in the diet. 
 
Renal impairment: 
Creatinine 
Clearance (Clcr) 
Recommended Dose 
Clcr 60 ml/min. 200 mg/day 
Clcr 40 ml/min. 150 mg/day 
Clcr 20 ml/min. 100 mg/day 
Clcr 10 ml/min. 100 mg on alternate days 
Clcr < 10 ml/min. 100 mg 3 times a week. 
 
Child:  Secondary hyperuricemia 
(associated with malignancy or neoplastic 
therapy), 
(6-10 y):  100 mg PO t.i.d. 
(< 6 y):  50 mg PO t.i.d.  or  10 mg/kg/day 
divided q. 6 h. 
 
Directions: Doses of > 300 mg/day should 
be divided, taken with food or milk.  
*Normal serum levels of uric acid are 
usually achieved in 1-3 weeks, with a 
normal range being 3.6-8.5 mg/dl for men, 
and 2.3-6.6 mg/dl for women.   
*A sudden decrease in serum level can 
precipitate an acute gouty attack, start with 
low dose and increase by 100 mg/week. 
*It is advisable to maintain sufficient fluid 
intake to yield a daily urinary output of at 
least 2 L. The patient needs to drink at least 
10-12 glasses of water daily. 
*Advise patient to contact health care 
provider if any of these symptoms occur; 
skin rash, painful urination, blood in the 
urine, irritation of the eyes, or swelling of 
the lips and mouth occurs. Discontinuation 
of the medication may be recommended. 
*Advise patient to limit high-purine foods: 
kidney, liver, anchovies, sardines, salmon, 
meat soups, peanuts, dried peas and beans, 
cauliflower, peppers and spinach.   
*For oxalate stone treatment, need to avoid 
foods such as tea, chocolate, spinach, nuts, 
beets, figs, and excessive Ca intake. Also 
need to increase oral fluids and dietary fiber 
intake. 
• USE IN SPECIAL CASES:  
Pregnancy- Use only when clearly needed 
(Category C). There are no adequate and 
well-controlled studies in pregnant women. 
Lactation- Allopurinol and its metabolites 
have been detected in breast milk. No adverse 
reactions have been reported, but use with 
caution. 
Children- Allopurinol is rarely indicated for 
use in children, with the exception to those 
with hyperuricemia secondary to malignancy 
or certain rare inborn errors of purine 
metabolism. 
Renal Disease- Need to reduce dosage for 
patients with renal disease, to avoid 
accumulation of allopurinol and its 
metabolites. For moderate to severe renal 
impairment refer to recommended doses. 
Liver Disease- Use caution. Perform periodic 
liver function tests during early stages of 
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therapy, particularly in patients with 
preexisting liver disease. 
• PRECAUTIONS AND WARNINGS:   
-Hypersensitivity; need to discontinue drug 
at first appearance of skin rash or other 
signs of allergic reactions. In some cases, 
rash may be followed by more severe 
reactions such as fever, exfoliative, 
urticarial or purpuric lesions, irreversible 
hepatotoxicity and rarely, death. 
-Need to emphasize the importance of 
increasing fluid intake to avoid the 
theoretic possibility of formation of 
xanthine calculi under the influence of 
allopurinol therapy. 
• ADVERSE EFFECTS:  
Drowsiness, headache, nausea, vomiting, 
diarrhea, abdominal discomfort, photo-
sensitivity, urticaria, pruritic maculo-
papular rash, jaundice, increased alkaline 
phosphatase, AST and ALT liver enzymes, 
hepatotoxicity, xanthine renal calculi, 
agranulocytosis, aplastic anemia, bone 
marrow depression have all been reported. 
• INTERACTIONS: 
Overview  of  Allopurinol 
Drug-Drug Interaction 
Drug Interaction 
ACE 
inhibitors 
Captopril co-administration 
may increase risk of toxicity; it 
is better to space-out time 
interval of drug administration. 
Alcohol May inhibit renal excretions of 
uric acid; warn patient against 
drinking alcohol. 
Ampicillin 
and 
amoxicillin 
Co-administration increases risk 
of skin rash. Start allopurinol 
therapy after antibiotic therapy 
has been completed for a couple 
of weeks. 
Antacids; 
Aluminum 
hydroxide 
May inhibit the GI absorption 
of allopurinol. This effect can 
be avoided by administering 
allopurinol  3 or more hours 
before Aluminum hydroxide. 
Thiazides May increase the risk of 
allopurinol toxicity and 
hypersensitivity, (especially 
with impaired renal function); 
so use caution. 
Warfarin Allopurinol may enhance 
anti-coagulant effect of 
warfarin, use with caution. 
Large doses 
of vitamin C
May increase the possibility 
of kidney stone formation due 
to urinary acidification. 
 
• OVERDOSE: 
Symptoms may include headache, nausea, 
vomiting, epigastric pain, jaundice and 
other adverse side effects.   
Treatment: Need to evaluate patient, and a 
dose reduction may be necessary if not 
discontinuation of the medication.  
In accidental overdose, need to induce 
vomiting if it has not occurred already. 
Refer to hospital for supportive or 
symptomatic care. 
• BRANDS: 
Allopurinol (Abic), Alloril (Dexxon), Caplenal 
(Berk), Uricnase (BPC), Zylol (Teva), Zyloric 
(GlaxoWellcome). 
_________________________ 
 
2)  Sulfinpyrazone 
 
• DRUG SUMMARY: 
A potent pyrazolidine derivative, uricosuric 
agent for gout. At therapeutic doses 
promotes urinary secretion of uric acid and 
reduces serum urate levels by competitively 
inhibiting renal tubular re-absorption of 
uric acid. It is used for patients who are 
under-excretors of uric acid. As it has no 
apparent analgesic or anti-inflammatory 
activity, it is not used for relief of acute 
gout. 
• INDICATIONS: 
Maintenance therapy in chronic gouty 
arthritis and tophaceous gout. Unlabeled 
uses include; drug induced hyperuricemia, 
and to decrease platelet aggregation. 
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• CONTRAINDICATIONS: 
Hypersensitivity to butazones or other 
pyrazoles, active peptic ulcer, or symptoms 
of GI inflammation or ulceration, as well as 
blood dyscrasias. 
• DOSAGE FORMS: 
Tablets. 
• RECOMMENDED DOSAGE: 
Adult:  Use in gout; 
100-200 mg 1-2 times a day, for 1 wk, then 
increase to 200-400 mg twice a day 
increased over 1-3 wks. It may be reduced 
to 200 mg after serum urate levels are 
controlled. Maximum dose is 600 mg/d, 
rarely 800 mg/d. 
Child: Use not commonly indicated for 
children. 
Directions: May cause GI upset, take with 
food, milk, or an antacids if needed. 
*Patient needs to increase fluid intake to at 
least 10-12 glasses (8 ounces each) daily if 
possible. 
*Sulfinpyrazone therapy should be 
continued without interruption even when 
the patient has an acute gouty attack, which 
may be treated with full therapeutic doses 
of the appropriate anti-inflammatory agent. 
• USE IN SPECIAL CASES:  
Pregnancy- Use only when clearly needed 
and when the potential benefits outweigh the 
potential hazards to the fetus (Category C). 
Lactation- Avoid use, unless clearly needed 
and potential benefits outweigh potential 
hazards to the nursing infant. 
Children- Not commonly prescribed for 
children. 
Renal Disease- Use caution. Renal failure has 
occurred in predisposed patients. Assess renal 
function periodically to avoid complications. 
Liver Disease- Use caution. This drug is 
metabolized to active and inactive 
metabolites in the liver.  
• PRECAUTIONS AND WARNINGS:   
-Use caution in patients who had a history 
of peptic ulcer, may reactivate or aggravate 
peptic ulcer. 
-Need blood cell counts, as well as renal 
function evaluation periodically. 
-Sulfinpyrazone may increase the 
frequency of acute gouty attacks during the 
first 6-12 months of therapy, even when 
serum urate levels appear to be controlled.  
The physician may prescribe colchicine 
prophylactically, concurrently during the 
first 3-6 months to decrease the severity of 
the acute attack. 
• ADVERSE EFFECTS: 
Most frequent include: upper GI 
disturbances, nausea, diarrhea, blood loss, 
reactivation or aggravation of peptic ulcer, 
precipitation of acute gout attacks. Less 
frequently: rash and jaundice. Rarely: blood 
dyscrasias, i.e. anemia, agranulocytosis, 
aplastic anemia, bronchoconstriction in 
patients with aspirin-induced asthma. 
• INTERACTIONS: 
Overview of Sulfinpyrazone 
Drug-Drug Interaction 
Drug Interaction 
Salicylates These suppress/antagonize the 
uricosuric action of 
sulfinpyrazone. Do not 
administer aspirin or salicylates 
to patients.  
(These do not antagonize 
allopurinol, but are nevertheless 
NOT indicated in gout.) 
Sulfonyl-
ureas 
May be displaced by sulfin-
pyrazone, increasing risk of 
hypoglycemia. 
Theophylline Theophylline plasma clearance 
may be increased, thus 
lowering plasma levels. 
Monitor patient closely to 
determine dosage adjustments 
if needed. 
Verapamil Increase in clearance and 
decrease in bioavailability may 
occur. Use with caution. 
Warfarin Anticoagulant activity of 
warfarin will be enhanced. 
Hemorrhage could occur. Use 
extreme caution. 
 
• OVERDOSE: 
Symptoms include: Nausea, vomiting, 
diarrhea, epigastric pain. Labored 
respiration, convulsion, and coma may 
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occur. Possible symptoms seen after over-
dosages may include anemia, jaundice or 
ulceration. There is no specific antidote for 
treatment. Induce vomiting if possible. 
Refer to a hospital emergency room for 
general supportive care.   
• BRANDS: 
Anturane (Ciba), Pyrocard (Trima). 
____________________ 
 
 
3)  Colchicine WHO,P  
 
• DRUG SUMMARY: 
An antigout agent that is not an analgesic, 
not a uricosuric, and will not prevent 
progression of gout to chronic gouty 
arthritis. Its exact mechanism of action is 
not clear, but it reduces inflammatory 
response to the deposited crystals and also 
diminishes phagocytosis. Its prophylactic, 
suppressive effect helps reduce the 
incidence of acute attack. It is a good 
alternative to NSAIDs, and probably as 
effective. It is of value in patients with 
heart failure since unlike NSAIDs it does 
not induce fluid retention, also it can be 
given to patients receiving anticoagulants. 
• INDICATIONS: 
For pain relieve of acute attacks of gout. 
Short term prophylaxis during initial 
therapy with allopurinol or uricosuric 
drugs. It is also used for amyloidosis, 
Behcet’s syndrome, Familial Mediterranean 
fever, idiopathic thrombocytopenic 
purpura, primary biliary cirrhosis, and 
various skin disorders. 
• CONTRAINDICATIONS: 
Hypersensitivity to colchicine, serious GI, 
renal, hepatic or cardiac disorders, blood 
dyscrasias, and pregnancy. 
• DOSAGE FORMS: 
Tablets. 
• RECOMMENDED DOSAGE: 
Adult:  Use in gout; 
1 mg PO initially, given at the first warning 
of an acute attack, followed by 0.5-1 mg q. 
2-3 h. till relief of pain is obtained, or 
vomiting or diarrhea occur; max. 10 
mg/day. 
One should wait 3 days before initiating a 
second course to minimize the possibility of 
cumulative toxicity. 
 Use as prophylaxis or maintenance of 
recurrent gouty arthritis; 
0.5-1 mg PO once or 3 times daily. 
 Use in Familial Mediterranean fever; 
1-3 mg/day, to prevent frequency and 
severity of acute febrile episodes and to 
prevent amyloidosis. 
Child: Not commonly prescribed for 
children, unless under direct specialist 
supervision for rare cases. 
Directions: Treatment should be started at 
the first sign of an attack, and stopped as 
soon as pain is relieved or at the fist sign or 
vomiting or diarrhea. 
*Medication should be discontinued if the 
patient reports any of the following: rash, 
sore throat, fever, unusual bleeding, 
bruising, weakness, numbness or tingling. 
• USE IN SPECIAL CASES:  
Pregnancy- Contraindicated use (oral: 
Category C, parenteral: D). Colchicine can 
cause fetal harm, and should be avoided. 
Lactation- Avoid use, unless clearly needed 
and potential benefits outweigh potential 
hazards to the nursing infant. It is not known 
if this drug is excreted in breast milk. 
Children- Safety and efficacy not established. 
Renal + Liver Diseases- Use caution in mild 
cases, there is an increased risk of toxicity. 
Use is contraindicated in severe cases of 
hepatic/renal dysfunction. 
• PRECAUTIONS AND WARNINGS:   
For patients receiving long-term therapy, 
periodic blood count should be performed. 
Hepatic and renal function impairment: 
increased colchicine toxicity. Myopathy 
and neuropathy have been noted in patients 
with altered renal function. 
• ADVERSE EFFECTS: 
GI effects; vomiting, diarrhea, abdominal 
pain and nausea may occur, especially with 
maximum doses, and particularly 
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troublesome in the presence of peptic ulcer 
or spastic colon. Bone marrow depression 
with aplastic anemia, agranulocytosis, 
myopathy, loss of hair, reversible 
azospermia (fertility impairment), hyper-
sensitivity, and dermatoses have all been 
reported. 
• INTERACTIONS: 
Overview of Colchicine 
Drug-Drug Interaction 
Drug Interaction 
Cyclosporin Increased risk of 
nephrotoxicity and myotoxicity 
due to increased plasma 
cyclosporin concen-tration. 
Observe patients closely for 
severe adverse effects if 
coadministration is necessary,  
and adjust the dose 
accordingly. 
Erythromycin May increase serum colchicine 
concentration; toxicity may  
occur.  Use with caution. 
 
• OVERDOSE: 
Symptoms: Usually there is a latent period 
of several hours between overdosage and 
symptom onset. First symptoms to appear 
include nausea, vomiting abdominal pain 
and diarrhea. Myocardial injury, profound 
shock and respiratory failure, leukopenia, 
alopecia may also occur. 
Treatment: Begin with gastric lavage (if not 
too much time has passed), and measures to 
prevent shock. Hemodialysis or peritoneal 
dialysis may be used. Continue with 
supportive measures. 
• BRANDS: 
Colchicine (RAFA, Abbott). 
 
 
________________________ 
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A)  ANTIHYPERTENSIVES 
 
The actual level of blood pressure that can 
be considered hypertensive is somewhat 
difficult to define; it depends on a number 
of factors, including the patient’s age, sex, 
race, and life style. In general, hypertension 
is defined as a systolic blood pressure 
(SBP) that is > 140 mmHg diastolic blood 
pressure (DBP) of > 90 mmHg. 
Hypertension is classified into three 
stages as indicated in table-2.1. Patients are 
divided into risk groups based on their 
blood pressure as well as to the presence or 
absence of target organ disease and 
additional risk factors (for further 
information see: Report of the Joint National 
Committee- JNC 6-1997, and the WHO-ISH 
1999 guidelines, note that the JNC 7-2003 
report has changed the categories, but will 
not be adopted in this chapter). 
Life style modification is the first step in 
therapy for most patients, this includes, 
weight reduction if overweight, regular 
physical activity on regular bases, 
reduction of sodium intake, adequate intake 
of potassium, calcium and magnesium, 
limited alcohol intake and smoke 
cessations.  
Periodic blood pressure measurements 
should be done for patients after starting 
with life style modifications, then the 
initiation of antihypertensive therapy.  
Drug therapy should be individualized, 
especially that there are several groups of 
pharmacological therapy as seen on table 
2.2. But in general, for uncomplicated 
hypertension a diuretic and/or a beta-
blocker are the first choice of treatment. 
For patients with other health problems 
such as diabetes mellitus or heart failure, 
starting with Angiotensin converting 
enzyme (ACE) inhibitors might be more 
appropriate. See table 2.3, as well as each 
drug monograph for specific indications. 
The aim of antihypertensive therapy is to 
lower and maintain blood pressure to a 
level within the normal range of the 
patient’s age and sex.   
 
In the following pages the most commonly 
prescribed categories will be discussed. 
 
 
Table-2.1.  Classification of Blood Pressure  
For Adults > 18 Years of Age 
Category SBP  (mmHg)  
DBP 
(mmHg) 
Optimal < 120 and < 80 
Normal < 130 and < 85 
High normal 130 - 139 or 85-89 
Hypertension *    
Stage 1   (Mild) 140 - 159  or 90 - 99  
Stage 2   (Moderate) 160 - 179   100 - 109 
Stage 3   (Severe)  > 180 or > 110 
 
*Based on the average of > 2 readings taken at each of > 2 visits after an 
initial screening.  
*When systolic and diastolic blood pressures fall into different categories 
select the higher category to classify the individual’s blood pressure status. 
Reference: Drug Facts & Comparisons 2000, Treatment Guidelines, p. A-5. 
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There are three general approaches for 
the pharmacological treatment of primary 
hypertension. These approaches are 
summarized in table-2.2. 
 
 
Table-2.2:  Pharmacological Approaches to Treatment of Hypertension 
CATEGORIES EXAMPLE 
 
I.    Diuretics to reduce blood volume:  
        A.  Thiazide diuretics Hydrochlorothiazide 
        B.  Loop diuretic Furosemide 
        C.  Potassium sparing diuretics Spironolactone 
 
II.  Drugs that interfere with the renin-angiotensin system: 
         A. Converting enzyme inhibitors  Captopril 
         B. Angiotensin-receptor antagonists Saralasin 
 
III. Drugs that decrease peripheral vascular resistance and/or cardiac output: 
         A. Direct vasodilators  
                 1. Calcium channel blockers Nifedipine 
Verapamil 
Diltiazem 
                 2. Potassium channel activators Minoxidil 
                 3. Elevation of cGMP Nitroprusside 
                 4. Others Hydralazine 
         B. Sympathetic nervous system depressants  
                 1. α-Blockers Prazosin 
                 2. β-Blockers 
                       (Non-selective) 
                       (β1 selectivity) 
 
Propranolol 
Atenolol 
                 3. Norepinephrine synthesis inhibitors Metyrosine 
                 4. Norepinephrine storage inhibitors Reserpine 
                 5. Transmitter release inhibitors Guanethidine 
                 6. Centrally acting (decrease sympathetic outflow) α-Methyldopa 
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Table-2.3:  Comparison of the Clinical Effects of Antihypertensive Drugs 
Feature β-Blockers 
Thiazide 
Diuretics 
ACE 
Inhibitors 
Ca 
antagonists 
α-
Blockers 
Efficacy in coexisting disease states 
-Angina pectoris 9 8 8 9 8 
-CHF/LVF 8 9 a 9  9 
-Supraventricular 
arrhythmias 9 8 8 9 
b 8 
-Raynaud’s 
phenomenon 8 8 8 9 9 
-Asthma 8 9 9 9 9 
Effect on the heart rate ↓ ↔ ↔ ↔↑ ↔ 
Effect on total peripheral 
resistance ↑, ↓ 
c ↔ ↓ ↓ ↓ 
Effect on left ventricular 
hypertrophy ↓ ↔ or ↑ ↓ ↓ ↓ 
Effect on serum lipids Generally adverse d Adverse 
Neutral/ 
favorable Favorable Favorable 
Effect on glycemic 
control 
Generally 
adverse e Adverse None 
Generally 
none None 
 
 
a. A loop diuretic may be more suitable if CHF/LVF is predominant. 
b. Some agents only (verapamil) 
c. β-blockers initially cause a reflex increase in total peripheral resistance followed by a decrease towards 
or slightly below pretreatment levels with long term use.  However, β-blockers with vasodilator activity 
(labetalol or celiprolol) cause a reduction in total peripheral resistance. 
d. Not all β-blockers have adverse effects on the serum lipid profile (carvediolol, labetalol, pindolol) have 
not shown any adverse effects. 
e. β-blockers may mask some of the warning signs of hypoglycemic episodes. 
f. Symbols: 9: indicated use, 8: not indicated, ↔: no significant effect, ↑: effect increased, ↓: decreased. 
* References: Speight & Holford. Avery’s Drug Treatment, 4th ed. Adis International, New Zealand,1997. 
    Drug Facts & Comparisons, 2000, p. A9. 
 
_____________________ 
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1)  DIURETICS 
 
Diuretics are agents that increase the rate of 
urine formation, as the term used “for 
diuresis”. They are divided into Thiazide, 
Loop and Potassium-sparing diuretics, each 
working on a specific segment of the renal 
system.  One drug from each group will be 
discussed as the prototype. 
 
a)  Thiazide Diuretics: 
 
      Hydrochlorothiazide WHO,P 
 
• DRUG SUMMARY: 
Hydrochlorothiazide is a very potent 
thiazide diuretic, classified as a cardio-
vascular, antihypertensive agent. It is the 
drug of choice for primary hypertension. 
Thiazides mainly increase excretion of Na 
and Cl, by inhibiting their reabsorption 
from the thick ascending limb of Loop of 
Henle and the early distal tubules.  
(Other drugs in this group include 
Benzthiazide, Chlorothiazide, Chlorthalidone, 
Indapamide, Metolazone, etc.). 
• INDICATIONS: 
Thiazides are mainly used to relieve edema 
due to heart failure and, in lower doses, to 
reduce blood pressure. 
• CONTRAINDICATIONS: 
Anuria, hypercalcemia, severe renal and 
hepatic impairment, hepatic coma or 
precoma, hypersensitivity to thiazides or 
other sulfonamides, Addison’s disease, 
porphyria. 
• DOSAGE FORMS:  
Tablets. 
• RECOMMENDED DOSAGE: 
Adult: For Edema; 
Start with 50-100 mg PO daily. 
Maintenance 25-50 mg on alternate days. 
For Hypertension; 
25 mg PO daily, can be increased to 50-75 
mg if necessary. In elderly patients, an 
initial dose of 12.5 mg may be sufficient.  
Directions: It can be taken with food or 
milk to reduce GI upset.  
*It acts within 1-2 h. of oral administration, 
and has a duration of 12-24 h. 
*It is advisable to eat a banana or have a 
glass of orange juice to prevent 
hypokalemia.  
*It should be administered early in the 
morning after eating.  If it is to be given in 
two doses, schedule the second dose no 
later than 3 pm., so diuresis does not 
interfere with sleep. 
*100 mg PO doses for hypertension are 
rarely recommended. Doses > 25 mg/d in 
older patients, or > 50 mg in young patients 
do not increase blood pressure lowering 
effect of the medication (plateau effect).  
• USE IN SPECIAL CASES:  
Pregnancy- Diuretics are not used to treat 
hypertension in pregnancy since they might 
affect placental perfusion due to decreasing 
the extracellular volume. Thiazides may 
cause neonatal thrombocytopenia (Category 
B). 
Lactation- The amount excreted in breast 
milk is too small to be harmful to nursing 
infant;  large doses may suppress lactation. 
Children- Not established. 
Renal Disease- If there is a moderate renal 
dysfunction, avoid thiazide diuretics. If the 
GFR < 25 ml/min. one should use loop 
diuretics (furosemide), which will be more 
effective. Thiazides are not effective in these 
cases. 
Liver Disease- Use with caution since 
hypokalemia may precipitate coma. Also 
there will be a risk of hypomagnesemia in the 
case of alcoholic cirrhosis. 
• PRECAUTIONS AND WARNINGS:   
-It may cause hypokalemia. Potassium 
supplements may be recommended in these 
cases: symptomatic hypokalemia, patient 
with an abnormal resting ECG, patient with 
history of arrhythmias, ischemic disease or 
severe heart failure, during concomitant 
digitalis therapy, and with planned general 
anesthesia. For prevention, potassium 
chloride doses of 2-4 g (approx. 25-50 
mmol) PO per day are suitable in patient 
taking a normal diet.  Smaller doses must 
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be used if there is renal insufficiency 
(common in elderly). If patient can’t 
tolerate side effects, do not use thiazide 
diuretics, and switch to a potassium sparing 
diuretic. 
-Aggravation of diabetes and gout may 
occur. May raise LDL-cholesterol, and drop 
HDL-cholesterol. Take caution in the case 
of bronchial asthma, hepatic cirrhosis, renal 
dysfunction, and history of SLE. 
• ADVERSE EFFECTS: 
Impotence (reversible on withdrawal of 
treatment), hypokalemia, hypomagnesemia, 
hyponatremia, hypercalcemia, hypo-
chloremic alkalosis, hyperuricemia, gout, 
hyperglycemia, and increases in plasma 
cholesterol concentration. 
• INTERACTIONS: 
Overview of Thiazide 
Drug-Drug Interaction 
Drug Interaction 
Analgesics Diuretics increase the risk of 
nephrotoxicity of NSAIDs. 
Use with caution. 
Anion-
exchange 
resins 
Cholestyramine reduces the 
absorption of thiazide 
diuretics. Give them at least 
two hours apart. 
Anti-
arrhythmics 
Toxicity of many 
antiarrhythmic drugs increased 
if hypokalemia occurs. Use 
with caution. 
Anti-
depressants 
Increased risk of postural 
hypotension with TCAs. 
Anti-
diabetics 
Hypoglycemic effect is 
antagonized by thiazide 
diuretics. Use with caution. 
Anti-
histamines 
Hypokalemia increases the risk 
of ventricular arrhythmia with 
astemizole & terfenadine. 
Calcium 
salts 
Risk of hypercalcemia. Avoid 
use concomitantly. 
Cardiac 
glycosides 
Increased toxicity if 
hypokalemia occurs. 
Cortico-
steroids 
Increased risk of hypokalemia; 
antagonism of diuretic effect. 
Use with caution. 
Lithium Lithium excretion reduced by 
thiazides. Monitor patients. 
Sex 
hormones 
Estrogens and combined OCs 
antagonize diuretic effect. 
Counsel women on use of 
alternative method instead of 
hormonal therapy if needed. 
 
• OVERDOSE: 
Symptoms: changes due to plasma volume 
depletion (e.g. orthostatic hypotension, 
dizziness, drowsiness, etc.), and signs of K 
deficiency (e.g. confusion, dizziness, 
muscular weakness, GI disturbances). 
Treatment: Perform gastric lavage or 
induce emesis, give activated charcoal. 
Avoid cathartics since they may enhance 
electrolyte and fluid loss. Always refer the 
patient for further investigations. 
• BRANDS: 
Esidrex (Ciba-Geigy), Disothiazide (Dexxon). 
_____________________ 
 
 
b)  Loop Diuretics 
 
      Furosemide WHO,P 
 
• DRUG SUMMARY: 
Loop diuretics are used in pulmonary 
edema due to left ventricular failure and in 
patients with long standing heart failure 
who no longer respond to thiazides. These 
drugs inhibit the reabsorption of Na and Cl 
ions from the ascending Loop of Henle in 
the renal tubule, and are powerful diuretics. 
Hypokalemia may develop, and care is 
needed to avoid hypotension. It is a good 
choice for patients who do not respond to 
thiazide diuretics, or have impaired renal 
function.  
The most important example of these 
diuretics is furosemide/frusemide. It is a 
powerful diuretic that acts within 1 hour of 
oral administration and diuresis is complete 
within 6 hours. The degree of diuresis 
associated with these drugs is dose related.  
(Other drugs in this group include Ethacrynic 
acid, Bumetanide and Torsemide). 
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• INDICATIONS: 
Edema, oliguria due to renal failure, and 
hypertension. 
• CONTRAINDICATIONS: 
Precomatose states associated with liver 
cirrhosis; porphyria; history of 
hypersensitivity to furosemide; anuria; 
increasing oliguria; fluid and electrolyte 
depletion states; and hepatic coma. 
• DOSAGE FORMS: 
Tablets, injection. 
• RECOMMENDED DOSAGE: 
Adult: For Edema; 
Initially, start with 40 mg PO in the 
morning adjusted as necessary according to 
patient’s response.  
Maintenance for mild cases: 20 mg PO 
daily, or 40 mg on alternate days. 
Some patients may require doses of 80 mg 
or more daily given in 1 or 2 doses.   
(Only in very severe cases dose may be 
titrated up to a maximum of 600 mg/d; in 
such case a specialist in this field is needed). 
For Hypertension; 
40-80 mg PO daily either alone or in 
conjunction with other antihypertensives. 
Child: For Edema and Hypertension; 
1-3 mg/kg PO daily may be increased 
according to response but for a maximum 
of 40 mg/24 h. Doses over 6 mg/kg are not 
recommended. 
 
Directions: Furosemide can be taken with 
food or milk to reduce possibility of gastric 
irritation.   
*Drug effects are evident within 30 min. to 
1 hr. after an oral dose, and lasts for about 
4-6 h. 
*Schedule doses to avoid nocturia and 
sleeping disturbance (example: when given 
once daily it should be administered in the 
morning; when given twice daily it should 
be given at 8 am. and 2 pm.). 
• USE IN SPECIAL CASES:  
Pregnancy- Avoid use. Diuretics are not 
usually used to treat hypertension during 
pregnancy, since it might affect placental 
perfusion thus decreasing the extracellular 
volume (Category C). 
Lactation- Furosemide is excreted in breast 
milk. Because of the potential adverse 
reactions in nursing infants, decide whether to 
discontinue breast-feeding or to discontinue 
the drug, taking into account the importance 
of the drug to the mother. 
Renal Disease- In case of moderate renal 
impairment, higher doses of furosemide may 
be needed. In renal failure, use is 
contraindicated. 
Liver Disease- Avoid use in severe cases of 
liver dysfunction. Hypokalemia may 
precipitate coma;  potassium-sparing diuretics 
should be used to prevent this; increased risk 
of hypomagnesemia in alcoholic cirrhosis.  
• PRECAUTIONS AND WARNINGS:   
-These agents are potent diuretics; excess 
amounts can lead to profound diuresis with 
water and electrolyte depletion. Careful 
medical supervision is required and dosage 
should be individualized.  
-Caution use in case of infants, elderly 
patients, hepatic cirrhosis, nephrotic 
syndrome, cardiogenic shock associated 
with MI, history of SLE, history of gout, 
patients receiving digitalis glycosides or 
potassium-depleting steroids. 
• ADVERSE EFFECTS: 
Hyponatremia, hypokalemia, hypochlor-
emic alkalosis, increased calcium excretion, 
hypotension; less commonly nausea, GI 
disturbances, hyperuricemia and gout may 
occur; and hyperglycemia (less common 
than thiazides). 
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• INTERACTIONS: 
Overview of Loop Diuretics 
Drug-Drug Interaction 
Drug Interaction 
Analgesics Diuretics may increase the risk 
of nephrotoxicity of NSAIDs, 
if used for long periods of 
time. Monitor patients, 
especially those at risk of 
kidney disease. 
Anti-
arrhythmics 
Toxicity of many anti-
arrhythmic drugs might increase 
if hypokalemia occurs. Use 
caution. 
Anti-
depressants 
Increased risk of postural 
hypotension with TCAs. Warn 
patients against suddenly 
changing posture to upright 
position (when standing up) to 
avoid feeling dizzy and falling. 
Anti-
diabetics 
Hypoglycemic effects of 
antidiabetic drugs may be 
antagonized by furosemide. 
Use caution. 
Anti-
histamines 
Hypokalemia increases the risk 
of ventricular arrhythmia with 
astemizole and terfenadine. 
Avoid use with such 
antihistamines. 
Cardiac 
glycosides 
Increased toxicity if 
hypokalemia occurs. 
Cortico-
steroids 
Increased risk of hypokalemia; 
antagonism of diuretic effect. 
Lithium Loop diuretics reduce lithium 
excretion, but they are safer 
than thiazides. 
Sex 
hormones 
Estrogens and combined OCs 
antagonize diuretic effect. 
Counsel women on use of 
alternative method instead of 
hormonal therapy if needed. 
 
• OVERDOSE: 
Symptoms: Acute profound water loss, 
volume and electrolyte depletion, 
dehydration, reduction of blood volume, 
and circulatory collapse with a possibility 
of vascular thrombosis and embolism. 
Treatment: Replace fluid and electrolyte 
losses by careful monitoring of the urine 
and electrolyte output and serum electrolyte 
levels. Always refer the patient for further 
investigations. 
• BRANDS: 
Diasix (JCL), Furovite (Vitamed), Fusid (Teva), 
Lasix (Hoechst), Miphar (Pharbita), Urix 
(BPC). 
________________________ 
 
c)  Potassium Sparing 
Diuretics 
 
 
     Spironolactone WHO,P 
 
• DRUG SUMMARY: 
Potassium-sparing diuretics are another 
class of diuretics that have been used to 
avoid hypokalemia associated with thiazide 
and loop diuretics. Spironolactone is a 
potassium sparing-diuretic that acts by 
antagonizing aldosterone. It is of value in 
the treatment of the edema of cirrhosis of 
the liver, and is effective in edema of heart 
failure, particularly when congestion has 
caused hepatic engorgement. It is also used 
in Conn’s syndrome (primary hyper-
aldosteronism). Good choice for patients 
who are very susceptible to hypokalemia 
complications, or can not tolerate the other 
diuretic agents.  
(Other agents in this group include Amiloride 
and Triamterene). 
• INDICATIONS: 
Edema and ascites in cirrhosis of the liver, 
malignant ascites, nephrotic syndrome, 
congestive heart failure; primary aldos-
teronism. 
• CONTRAINDICATIONS: 
Hyperkalemia, severe renal impairment; 
pregnancy and breast-feeding; Addison’s 
disease; and porphyria. 
• DOSAGE FORMS: 
Tablets. 
• RECOMMENDED DOSAGE: 
Adult: For Edema; 
25-200 mg/24 hrs. PO in divided doses; 
continued for at least 5 days; dose adjusted 
to optimal response; if no response, a 
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thiazide or a loop diuretic may be added 
without changing spironolactone dosage. 
For Hypertension; 
50-100 mg/24 hrs. PO in single or divided 
doses; continued for at least 2 wks.; dose 
adjusted to optimal response. 
For Primary Aldosteronism; 
100-400 mg/day in divided doses. 
Child: For Edema; 
3.3 mg/kg/day PO in single or divided 
doses continued for at least 5 days; dose 
needs to be adjusted till optimal response. 
For Hypertension; 
1-2 mg/kg PO given twice daily. 
 
Directions: Administer with food to 
enhance absorption.  
*Tablets may be crushed (unless package 
advises against) before administration and 
taken with fluid of patient’s choice.   
*It may produce drowsiness and lack of 
coordination; observe caution while driving 
or performing other tasks requiring 
alertness, coordination or physical 
dexterity, until effects of the medication is 
fully known. 
• USE IN SPECIAL CASES:  
Pregnancy- Do not use.  Spironolactone or its 
metabolites may cross the placenta barrier. 
Feminization occurs in male rat fetuses. In 
general diuretics are not used to treat 
hypertension in pregnancy since it might 
affect placental perfusion due to decrease of 
extracellular volume (Category D). 
Lactation- One of the metabolites of 
spironolactone appears in breast milk, an 
alternative method of infant feeding should be 
instituted when using spironolactone.  
Renal Disease- use with caution. Use of 
spironolactone may cause a transient 
elevation of BUN, especially in patients with 
preexisting renal impairment. The drug may 
cause mild acidosis. 
Liver Disease- use with caution, since it is 
metabolized in the liver. 
• PRECAUTIONS AND WARNINGS: 
-Use caution with patients with  BUN of 40 
mg/dl or greater and if there is a hepatic 
disease since it is metabolized in the liver. 
• ADVERSE EFFECTS: 
GI disturbances, gynecomastia and hyper-
kalemia. 
• INTERACTIONS: 
Overview  of  Spironolactone 
Drug-Drug Interaction 
Drug Interaction 
Ammonium 
chloride 
Combination of spironolactone 
and acidifying doses of 
ammonium chloride may 
produce systemic acidosis.  
Avoid concomitant use. 
Aspirin Diuretic effect of spirono-
lactone may be antagonized by 
aspirin and other salicylates.  
Avoid concomitant use. 
Potassium 
supplements
Hyperkalemia may result from 
the use of spironolactone along 
with potassium supplements. 
Avoid concomitant use. 
ACE 
inhibitors 
Both medications may cause 
hyperkalemia that might cause 
complete heart block.  
Do not use together. 
 
• OVERDOSE: 
Symptoms: The most likely signs are 
dehydration and electrolyte imbalances. 
Other symptoms may include GI cramping, 
vomiting, diarrhea, headache, drowsiness, 
and mental confusion. 
Treatment: discontinue therapy and observe 
patient closely. Induce emesis or perform 
gastric lavage. Treatment is symptomatic 
and supportive. If hyperkalemia occurs, 
emergency procedures are to be 
implemented. 
• BRANDS: 
Aldactone (Searle), Aldosprine (Teva), 
Sincomen (Schering). 
________________________ 
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2)  BETA – BLOCKERS 
 
β-adrenergic receptor blocking agents 
competitively antagonize the responses to 
catecholamines that are mediated by the β-
receptors. Some agents are more selective 
than others, and all have differences in their 
pharmacokinetic profiles. β-blockers are 
the drugs of choice in: youth, hyperkinetic 
circulation, angina pectoris, post-
myocardial infarction (cardioprotective 
effect), migraine head-aches, senile tremor.  
Table-2.4 gives an overview of drugs in 
this class and indicates the selectivity in 
their action 
 
Table- 2.4:  Summary of Available 
β-Blockers 
Drug Adrenergic receptor blocking activity 
Acebutolol β1  (β2 at higher doses) 
(ISA* activity) 
Atenolol β1   (β2 at higher doses) 
Bisoprolol β1   (β2 at higher doses) 
Esmolol β1   (β2 at higher doses) 
Metoprolol β1    (β2 at higher doses) 
Oxprenolol β1    β2       (ISA activity) 
Pindolol β1    β2       (ISA activity) 
Propranolol β1    β2    (non-selective) 
Timolol β1    β2    (non-selective) 
Labetolol β1     β2     α1 
 
*ISA- Intrinsic Sympathomimetic Activity; 
tend to cause less bradycardia than other β-
blockers, and may cause less coldness of the 
extremities. 
-Other drugs produced include: Carteolol, 
Celiprolol,  Nadolol, Penbutolol, Sotalol. 
Reference: Drug Facts & Comparisons, 2000, p. 
468. 
 
 
a)  Propranolol P 
 
• DRUG SUMMARY: 
Propranolol is a non-selective β-blocker of 
both cardiac (β1) and bronchial (β2) 
adrenoreceptor blocking activity. As a 
result of blocking β1-receptors within the 
heart, the following effects will occur: 
reduction of the heart rate, reduction of 
myocardial irritability (class II anti-
arrhythmic agents), and reduction of the 
force of myocardial contraction. 
Propranolol also blocks bronchodilator 
effect of catecholamines leading to 
bronchoconstriction. 
• INDICATIONS: 
Management of cardiac arrhythmias; 
myocardial infarction; tachyarrhythmias 
associated with digitalis intoxication, for 
anesthesia and thyrotoxicosis; angina 
pectoris due to coronary atherosclerosis; in 
the treatment of hypertension alone or in 
combination with other anti-hypertensive 
agents; and for migraine prophylaxis. 
• CONTRAINDICATIONS: 
It is contraindicated in the following cases: 
1. Greater than first-degree heart block. 
2. CHF or Cardiogenic shock. 
3. Significant aortic or mitral valvular disease. 
4. Bronchial asthma or bronchospasm. 
5. Allergic rhinitis during pollen season. 
6. Concurrent use of adrenergic 
augmenting psychotropic drugs or within 
two weeks of MAO inhibitors therapy. 
7. Sick sinus syndrome. 
• DOSAGE FORMS: 
Tablets 
• RECOMMENDED DOSAGE: 
Adult: For Hypertension; 
Initially 40-80 mg PO b.i.d.; increased at 
weekly intervals to 160-320 mg/24hrs in 
divided doses;  max. 640 mg/d. 
For Angina; 
40 mg PO b.i.d. or t.i.d.; may need 120-320 
mg/24 h in divided doses;  max. 320 mg/d. 
For Arrhythmias; 
10-30 mg PO, t.i.d. or q.i.d. up to 320 mg/d. 
For Acute MI;  
40 mg 4 times a day for 2 to 3 days then 80 
mg twice daily;  max. 240 mg/d or  
180-240 mg/24 h. in divided doses.  
For Migraine Prophylaxis; 
40-80 mg in divided doses daily; increased 
at weekly intervals; may require up to 160-
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240 mg/d. If there is no response after 4-6 
weeks then therapy should be discontinued. 
Child: For Hypertension; 
1 mg/kg/24h PO in 2 divided doses, 
increased to 2 to 4 mg/kg/24hrs. 
 
Directions: It is recommended to be taken 
before meals and at bedtime. Food 
enhances bioavailability of propranolol, so 
advise patients to be consistent with regard 
to taking propranolol with food or on an 
empty stomach to minimize variations in 
absorption.  
*If a dose is missed, take as soon as 
remembered. If too close to next dose, 
ignore and continue with the regimen. The 
next dose should not be doubled. 
• USE IN SPECIAL CASES:  
Pregnancy- If it is administered in the third 
trimester it may cause intra-uterine growth 
retardation, neonatal hypoglycemia, and 
bradycardia; risk greater in severe 
hypertension (Category C). 
Lactation- Propranolol is excreted in breast 
milk but in concentrations too low to have 
significant side effects on nursing child 
compared to other β-blockers. Peak 
concentrations occur 2-3 hours after a dose. 
Although no reported toxicity effects have 
been noted with β-blockers, the child should 
be observed specially if the drug is used for 
long term. The American Academy of 
Pediatrics considers propranolol to be 
compatible with breast-feeding. 
Children- Safety is not established. 
Renal Disease- In severe cases, start with 
small dose; higher plasma concentrations 
after oral administration; may reduce renal 
blood flow and adversely affect renal 
function in severe impairment. 
Liver Disease- Reduce oral dose. 
• PRECAUTIONS AND WARNINGS: 
-Use caution in special risk patients with:  
peripheral arterial insufficiency, patients 
prone to non-allergenic bronchospasm (e.g. 
chronic bronchitis, emphysema), major 
surgery, renal and hepatic impairment, 
Myasthenia Gravis, Wolff-Parkinson-White 
syndrome. 
-Diabetes mellitus, since β-blockers prevent 
premonitory signs of hypoglycemia in 
diabetics and may also augment hypo-
glycemia by interfering with 
catecholamine-induced glycogenolysis. On 
the other hand propranolol may block 
insulin release from the pancreas with 
resulting hyperglycemia. Use caution in 
patients prone to hypoglycemia. 
-Avoid abrupt withdrawal in angina. 
• ADVERSE EFFECTS:  
Bradycardia, heart failure, bronchospasm, 
peripheral vasoconstriction, gastrointestinal 
disturbances, fatigue, sleep disturbances, 
rare reports of rashes and dry eyes 
(reversible on withdrawal). 
• INTERACTIONS: 
Overview of  β-Blockers 
Drug-Drug Interaction 
Drug Interaction 
Alcohol & 
anesthetics 
Enhance the hypotensive 
effect. Use with caution and 
warn patient of this effect. 
NSAIDs Antagonize hypotensive effect. 
If the patient has to take an 
NSAID, advise to use caution 
and move slowly when 
changing postural positions, to 
decrease the chances of 
dizziness or falling. 
Anti-
arrhythmics 
Increased risk of myocardial 
depression and bradycardia 
and increased risk of lidocaine 
toxicity. Do not administer 
concomitantly. 
Rifampicin Accelerates the metabolism of 
propranolol. Do not administer 
at the same time. 
Antidiabetics Enhances the hypoglycemic 
effect (masking of warning 
signs such as tremor). Use 
caution. 
Anti-
psychotics 
Plasma concentration of 
chlorpromazine is increased by 
propranolol. Dose adjustment 
is required if patient has 
increased side effects. 
Anxiolytics 
& hypnotics 
Enhance the hypotensive effect 
of β-blockers. 
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Cardiac 
glycosides 
Propranolol may potentiate 
bradycardia due to digoxin. 
Cortico-
steroids & 
sex 
hormones  
(Estrogens and combined OC). 
Antagonism of the 
hypotensive effect of 
propranolol. 
Muscle 
relaxants 
Propranolol enhances the 
effect of muscle relaxant. 
Sympatho-
mimetics 
Severe hypertension with 
adrenaline and noradrenaline; 
Severe hypertension is also 
possible with 
sympathomimetic anorectics 
and cough and cold remedies. 
Theophyl-
line 
β-blockers should be avoided 
on pharmacological grounds 
(bronchospasm). 
Thyroxin Metabolism of propranolol is 
accelerated with thyroxin 
(reduced effects). Dose 
adjustment of propranolol may 
be needed. 
Cimetidine Plasma concentration of 
propranolol is increased by 
cimetidine. Do not administer 
at the same time. 
Calcium-
channel 
blockers 
Increased risk of bradycardia 
and AV block with diltiazem; 
severe hypotension and heart 
failure occasionally with 
nifedipine; asystole, severe 
hypotension, and heart failure 
with verapamil. They should 
not be used together. 
 
• OVERDOSE: 
Therapeutic overdoses of β-blockers may 
cause lightheadedness, dizziness, and 
possibly syncope due to impaired 
circulation secondary to bradycardia and 
hypotension; heart failure may be 
precipitated or exacerbated.  
Acute massive overdoses must be managed 
in hospital and expert advice should be 
obtained. Maintenance of a clear airway 
and adequate ventilation is mandatory.  
• BRANDS: 
Blocardril 10 (BPC), Deralin (Abic), Slow 
Deraline (Abic), Prolol (Dexxon). 
_________________ 
 
b)  Atenolol WHO, P 
 
• DRUG SUMMARY: 
In therapeutic doses atenolol selectively 
blocks β1-adrenergic receptors located 
chiefly in cardiac muscle.  With large doses 
preferential effect is lost and inhibition of 
β2-adrenergic receptors (especially in 
bronchial and vascular musculature) may 
lead to increased airway resistance, 
especially in patients with asthma. It is less 
lipophilic (lipid soluble) than propranolol 
thus it does not readily cross the blood-
brain barrier, therefore it is not associated 
with mental depression. It is not as heavily 
metabolized in the liver. It has a longer 
antihypertensive effect than propranolol 
thus permitting once-a-day dosing. 
• INDICATIONS: 
Used in the management of hypertension 
(1st choice drug) as a single agent or 
concomitantly with other antihypertensive 
agent, especially a diuretic. As an anti-
arrhythmic agent and for thyrotoxicosis. 
Treatment of stable angina pectoris and MI. 
• CONTRAINDICATIONS: 
Atenolol is contraindicated in the following 
cases: 
1. Sinus bradycardia. 
2. Greater than first degree heart block. 
3. Uncontrolled cardiac failure. 
4. Cardiogenic shock. 
• DOSAGE FORMS: 
Tablets. 
• RECOMMENDED DOSAGE: 
Adult: For Hypertension; 
50 mg PO once daily initially, used alone or 
added to a diuretic, may be increased to 100 
mg/d. The full effect is seen within 1-2 
weeks. Doses over 100 mg/day are unlikely 
to produce any further benefit. 
For Angina; 
50-100 mg PO daily in 1 or 2 doses. 
For Arrhythmias; 
50-100 mg PO daily. 
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For MI; 
Patient would be under emergency 
treatment where IV doses would be 
administered, then switched to PO as 
needed. 
 
Directions: If necessary, tablet may be 
crushed (unless manufacture’s package 
strictly advises against that) before 
administration and taken with fluid of 
patient’s choice. 
*If patient misses a dose, it should be taken 
as soon as remembered. If too close to next 
dosing time, just continue with the regimen. 
The next dose should not be doubled. 
• USE IN SPECIAL CASES:  
Pregnancy- If atenolol is administered in the 
3rd trimester it may cause intra-uterine 
growth retardation, neonatal hypoglycemia, 
and bradycardia; risk is greater in severe 
hypertension (Category C). 
Lactation- Monitor infant; possible toxicity 
due to β-blockade but amount of most beta-
blockers excreted in milk is too small to 
affect the infant.  Atenolol is excreted in 
higher amounts than propranolol.  
Children- Not established. 
Renal Disease- In the case of moderate renal 
impairment, one should reduce the dose of 
atenolol, since atenolol is excreted unchanged 
in the urine. If it is severe (Clcr < 15), start 
with a small dose; higher plasma 
concentrations after oral administration; may 
reduce renal blood flow and adversely affect 
renal function in severe impairment; max 
dose is 25 mg/d. 
Liver Disease- It is not metabolized in the 
liver. So there is no need for dosage 
adjustment in the case of hepatic dysfunction. 
• PRECAUTIONS AND WARNINGS:   
Use with caution in the following cases: 
-Hypertensive patient with CHF controlled 
by digitalis and diuretic. 
-Asthmatic patient. 
-Diabetic patient. (Refer to propranolol) 
-Impairment of renal function. 
• ADVERSE EFFECTS, INTER-
ACTIONS, OVERDOSE: 
Refer to propranolol.  
• BRANDS 
Apo-atenol (Apotex), Ateni (Generics), 
Normiten (Abic), Corotenol (JePharm), 
Normalol (Dexxon). 
_________________________ 
 
 
3)  ANGIOTENSIN CONVERTING 
ENZYME INHIBITORS (ACEI) 
 
The essential effect of these agents on the 
renin-angiotensin system is to inhibit 
conversion of the relatively inactive 
angiotensin I to the active angiotensin II by 
blocking the angiotensin converting 
enzyme (ACE). The converting enzyme 
inhibitors are highly specific drugs. 
Although they inhibit the degradation of 
Bradykinin and potentiate its hypotensive 
action, the principal pharmacological and 
clinical effects of ACE inhibitors are quite 
specific at the level of the enzyme. In 
addition, recent studies suggest that ACE 
inhibitors may also affect other enzymes, 
including those involved in the generation 
of prostaglandins. 
Many agents on the market are in this 
group, which differ in their 
pharmacokinetic profiles, but do not add 
much benefit over each other. Table-2.5 
compares some of the locally available 
drugs.   
 
Captopril will be the prototype for 
discussion on ACE inhibitors group. 
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Table-2. 5:  Available ACE Inhibitors Chart of Comparisons 
Pharmacokinetic Parametersa 
Drug Prodrug t max  
(h) 
t 1/2  
(h) 
Vd  
(L) 
PB  
(%) 
Principal 
route(s) of 
elimination 
Benazepril Yes  1.5 2-3 (22)b 8.4 > 95 Renal 
Captopril No 1.0 2.0 49 c 30 Renal 
Cilazapril Yes 3.0 2(40-50) 35 - Renal 
Enalapril Yes 3-4 5 (35)b - 50 Renal 
Lisinopril No 6.0 12 (30)b 124 < 1 Renal 
Quinapril Yes 2.0 2-3 - 97 Renal 
Ramipril Yes 3.0 3.0 (110)b 90 56 Renal/Hepatic 
 
a  Values shown are for active metabolite if compound is a prodrug. 
b  Terminal phase elimination half-life.        C At steady state. 
Abbreviations:  tmax = time to peak plasma concentration, t1/2 = elimination half-life, Vd = 
apparent volume of distribution, PB = protein binding. 
-Other produced drugs in this group include: Delapril, Fosinopril, Moexiprol, Perindopril, 
Spirapril, Trandolapril, Zofenopril.  
Reference: Speight & Holford. Avery’s Drug Treatment, 4th ed. Adis International, New 
Zealand 1997. 
 
a)  Captopril WHO,P 
 
• DRUG SUMMARY: 
Captopril is an angiotensin-converting 
enzyme (ACE) inhibitor, cardiovascular, 
antihypertensive, vasodilating agent. It 
lowers blood pressure by specific inhibition 
of the angiotensin-converting enzyme that 
leads to the formation of angiotensin-II that 
is a vasoconstrictor. ACE inhibitors have 
been considered for treatment of 
hypertension when thiazides and beta-
blockers are contraindicated, not tolerated, 
or fail to control blood pressure. ACE 
inhibitors are a good choice for 
hypertension in insulin-dependent diabetics 
and for patients with cardiac heart failure. 
• INDICATIONS: 
Used in mild to moderate essential 
hypertension alone or with thiazide 
therapy; severe hypertension resistant to 
other treatment. 
For congestive heart failure (CHF) in 
conjunction with digitalis and diuretics. 
Also in diabetic nephropathy in insulin-
dependent diabetes. 
• CONTRAINDICATIONS: 
It is contraindicated in the following cases: 
Hypersensitivity to ACE inhibitors, known 
or suspected renovascular disease, aortic 
stenosis or outflow tract obstruction, 
porphyria, and pregnancy. 
• DOSAGE FORMS:  
Tablets. 
• RECOMMENDED DOSAGE: 
Adult: For Hypertension; 
Initially, 12.5 mg b.i.d. would be started if 
using it alone.  
Initially 6.25 mg b.i.d. if used in addition to 
a diuretic, in elderly, or in renal 
impairment.  
Usual maintenance dose is 25 mg b.i.d.;  max. 
50 mg t.i.d.  (rarely: 50 mg t.i.d. is used as in 
severe hypertension). 
For Heart Failure; 
Initially 6.25-12.5 mg t.i.d.  
Start as early as 3 days after infarction, then 
increase over several weeks to 150 mg in 
divided doses;  max. 450 mg/day. 
 
Directions: Administration of first dose in 
therapy should be started at night, at 
bedtime to avoid hypotensive side effects. 
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*Food decreases its absorption; so it should 
be taken one hour before meals or 2 hours 
after meals. 
*If a dose is missed, it should be taken as 
soon as remembered. If too close to second 
dosing time, it should be ignored and the 
patient should continue with the usual 
regimen. The next dose should not be 
doubled. 
• USE IN SPECIAL CASES:  
Pregnancy- The use of ACEIs during the 2nd 
and 3rd trimesters has been associated with 
fetal and neonatal injury, including 
hypotension, neonatal skull hypoplasia, renal 
failure and death. When pregnancy is 
detected, ACEIs should be discontinued as 
soon as possible. (Category C in 1st trimester, 
Category D in 2nd & 3rd trimesters). 
Lactation- Use with caution. It is excreted in 
breast milk, but in amounts too small to be 
harmful to the nursing infant. Use the lowest 
possible dose of drug. Peak concentration 
levels occur at 4 hrs, so nursing should be 
avoid then. 
Children- Safety of captopril in children has 
not been established. 
Renal Disease- ACE inhibitors are excreted 
by the kidney, and occasionally cause 
impairment of renal function which may 
progress and become severe. At particular 
risk are those with pre-existing renal disease 
or impairment, the elderly, those with 
bilateral renal artery stenosis. 
Note:-  
Concomitant treatment with NSAIDs 
increases the risk of renal damage, and 
potassium-sparing diuretics or use of 
potassium-containing salt substitutes 
increase the risk of hyperkalemia. Renal 
function and electrolytes should be checked 
before starting an ACE inhibitor, and 
monitored during treatment. 
-In general, with mild renal impairment, 
reduce dose and monitor response, but avoid 
if possible. In the case of renal impairment, 
even mild, hyperkalemia and other side 
effects are more common (but specialized 
role in some forms of renal disease). 
Liver Disease- Some hepatic metabolism 
occurs, but it seems to be safe to be used in 
hepatic disease.  
• PRECAUTIONS AND WARNINGS 
-Use caution if administered with diuretics. 
-First dose may cause hypotension 
especially in patients: taking diuretics, on a 
low sodium diet, on dialysis, or dehydrated. 
-Monitor renal function before and during 
treatment (refer to USE IN SPECIAL CASES). 
-ACE inhibitors should be used with 
particular caution in patients with 
peripheral vascular disease or generalized 
atherosclerosis, as such patients may have 
clinically silent renovascular disease. 
-White cell counts and urinary protein 
estimations are needed.  
-In the case of patients on dialysis, avoid 
the combination of ACEI therapy with the 
use of high flux polyacrylonitrile 
membranes, since anaphylactic reactions 
have been reported. 
-Take caution in patients receiving 
immunosuppressants or other drugs that 
cause leukopenia or agranulocytosis, 
coronary or cerebrovascular disease. 
• ADVERSE EFFECTS: 
Persistent dry cough, throat discomfort, 
voice changes are very common. Taste 
disturbances (loss of taste), sore mouth, 
abdominal pain, rash, angioedema, 
hypotension; proteinureai, thrombo-
cytopenia, neutropenia, agranulocytosis, 
hyperkalemia (all are more common in 
renal impairment); increases in liver 
enzymes, liver damage, and cholestatic 
jaundice; renal impairment. 
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• INTERACTIONS: 
Overview  of  ACEI 
Drug-Drug Interaction 
Drug Interaction 
Alcohol, 
anesthetics, 
anxiolytics, 
hypnotics, 
muscle 
relaxants 
(baclofen), 
corticosteroids, 
& anti-
depressants 
 
Enhance the hypotensive 
effect. Use with caution. 
β-blockers, 
Ca-channel 
blockers, 
nitrates, & 
levodopa 
 
Enhance the hypotensive 
effect. Use with caution. 
Analgesics Antagonize the hypotensive 
effect and increased risk of 
renal failure with NSAIDs; 
hyperkalemia with Indo-
methacin and possibly other 
NSAIDs. 
Anti-
psychotics 
Severe postural hypotension 
with chlorpromazine and 
possibly other phenothiazines. 
Avoid concomitant use. 
Cardiac 
glycosides 
Plasma concentration of 
digoxin possibly increased by 
captopril. Monitor closely 
when initiating captopril 
therapy. May need to reduce 
dose of glycoside. 
Diuretics Enhanced hypotensive effect 
(can be extreme); 
hyperkalemia with 
potassium-sparing diuretics. 
Use with caution. 
Lithium ACE inhibitors reduce 
excretion of lithium (increase 
its plasma concentration). 
Potassium 
salts 
Patients will be at increased 
risk of hyperkalemia. Avoid 
concomitant use. 
Sex hormones Estrogen and combined oral 
contraceptives antagonize 
hypotensive effect. Dose 
adjustment of ACE inhibitors 
may be needed if patient not 
responding to therapy. 
Uricosurics Probenecid reduces excretion 
of captopril. Use with 
caution. 
 
• OVERDOSE: 
Hypotension is the most common symptom 
of overdose. Systolic blood pressure of 95-
80 mmHg in hypertensive patients have 
been reported. Treatment includes usual 
supportive measures, with correction of 
hypotension being the primary choice.   
• BRANDS: 
Capoten (Squibb), Cardopril (BPC), Inhibace 
(Pharmabest). 
____________________ 
 
 
4)  CA CHANNEL BLOCKERS 
 
Calcium channel blockers (less correctly 
called Ca antagonist) interfere with the 
inward displacement of Ca ions through the 
slow channels of active cell membranes. 
They influence the myocardial cells, the 
walls within the specialized conduction 
system of the heart, and the cells of the 
vascular smooth muscle. Thus, myocardial 
contractility may be reduced, the formation 
and propagation of electrical impulses with 
the heart may be depressed, and coronary 
or systemic vascular tone may be 
diminished. They should be avoided in 
heart failure because they may further 
depress cardiac function and cause 
clinically significant deterioration. Ca 
channel blockers differ in their action, 
therefore their therapeutic effects are much 
variable within the group as compared to 
the other classes of drugs. 
(Drugs in this category include:  Nifedipine, 
Verapamil, Diltiazem, Isardipine, 
Felodipine, Nicardipine, Nisoldipine, and 
Nimodipine). 
 
The major agents that will be discussed 
include nifedipine, verapamil and 
diltiazem. 
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a)  Nifedipine WHO,P 
 
• DRUG SUMMARY: 
Nifedipine relaxes vascular smooth muscle 
and dilates coronary and peripheral arteries 
(hypotensive effect), in greater effect than 
that produced by verapamil or diltiazem 
and usually results in reflex tachycardia. It 
has more influence on vessels and less on 
the myocardium than does verapamil, and 
unlike verapamil has no anti-arrhythmic 
activity. It rarely precipitates heart failure.  
• INDICATIONS: 
Prophylaxis and treatment of angina; 
hypertension; Raynaud’s phenomenon. 
• CONTRAINDICATIONS: 
Cardiogenic shock; advanced aortic 
stenosis; and porphyria. 
• DOSAGE FORMS: 
Tablets, soft gelatin capsules. 
• RECOMMENDED DOSAGE: 
Adult: Use for Angina; 
10-20 mg PO t.i.d. up to 180 mg/24 hrs. 
Use for Hypertension; 
10-20 mg t.i.d. up to 180 mg/24 hrs. or 30-
90 mg sustained release once/day. 
Use for Hypertensive Emergency; 
10-20 mg PO q. 20-30 min. if necessary. 
Child:  Safety and efficacy not established. 
 
Directions: In a hypertensive emergency, 
nifedipine capsule may be swallowed 
whole or contents may be given SL. 
Puncture capsule with a pin and squeeze 
contents under the tongue (puncture about 
10 times). The punctured capsule may also 
be chewed.  
*If a dose is missed, it should be taken as 
soon as remembered. If too close to second 
dosing time, it should be ignored and the 
patient should continue with the usual 
regimen. The next dose should not be 
doubled. 
• USE IN SPECIAL CASES:  
Pregnancy- Avoid use during pregnancy 
unless clearly indicated (Category C). May 
inhibit labor (and has been used for treatment 
in premature labor under intensive 
observation). 
Lactation- Amount excreted in breast milk is 
too small to be harmful, but manufacturers 
advise to avoid. Delay breast-feeding by 3-4 
hrs after a dose, to decrease the amount of 
drug ingested by infant. 
Renal Disease- In the case of moderate renal 
impairment, start with a small dose; 
reversible deterioration in renal function has 
been reported. 
Liver Disease- Reduce dose in case of hepatic 
impairment. 
• PRECAUTIONS AND WARNINGS: 
Withdraw medication if ischemic pain 
occurs or existing pain worsens shortly 
after initiating treatment; heart failure or 
significantly impaired left ventricular 
function; severe hypotension; diabetes 
mellitus; may inhibit labor. 
• ADVERSE EFFECTS:   
Adverse side effects that may occur: 
headache, flushing, dizziness, lethargy; also 
gravitational edema, rash, nausea, increased 
frequency of micturition, eye pain, gum 
hyperplasia, tachycardia and palpitation, 
tremor, leg cramps; depression has been 
reported as well as teleangectasia. 
• INTERACTIONS: 
Overview of Nifedipine 
Drug-Drug Interaction 
Drug Interaction 
Anti-
arrhythmics 
Increased risk of 
bradycardia, AV block, and 
myocardial depression. 
Nifedipine reduces plasma 
concentration of quinidine. 
Anti-
bacterials 
Rifampicin possibly 
increases metabolism of 
nifedipine (reduce plasma 
concentration). 
Anti-
diabetics 
Nifedipine may occasionally 
impair glucose tolerance. 
Use with caution and warn 
diabetic patients. 
Anti-
epileptics 
Nifedipine increases plasma 
concentration of phenytoin. 
Effect of nifedipine reduced 
by carbamazepine. 
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Antihyper-
tensives & 
Anti-
psychotics 
Enhanced hypotensive 
effects. Warn patient. 
β-blockers Occasionally severe hypo-
tension and heart failure with 
nifedipine. Safer to avoid use 
concomitantly unless clearly 
indicated. 
 
• OVERDOSE: 
Symptoms include nausea weakness, 
dizziness, drowsiness, confusion and 
slurred speech. Hypotension, bradycardia 
and AV block may occur. Death can occur.   
Treatment: If the patient is seen shortly 
after oral ingestion of nifedipine, employ 
emetics or lavage and cathartics. Dialysis is 
not likely to help since these drugs are 
highly protein-bound. Treatment is 
supportive. Refer the patient for further 
control and investigation. 
• BRANDS: 
Adalat (Bayer), Angilat (BPC), Aprical 
(Rentshler), Corotrend (Siegfried), Osmo-Adala 
(Pharma-Clal), Pressolat (Agis), Megalat (Agis). 
___________________ 
 
b)  Verapamil WHO,P 
 
• DRUG SUMMARY: 
Verapamil inhibits the calcium ion influx 
through slow channels into cells of 
myocardial and arterial smooth muscles 
(both coronary and peripheral blood 
vessels). It dilates coronary arteries and 
arterioles and inhibits coronary artery 
spasm; thus myocardial oxygen delivery is 
increased (antianginal effect).  It decreases 
and slows SA and AV nodes conduction 
(antiarrhythmic effect) without effect on 
normal arterial action potential or 
intraventricular conduction. By vaso-
dilatation of peripheral arterioles, drug 
decreases peripheral vascular resistance and 
reduces arterial BP at rest.  It reduces the 
cardiac output and it may slightly decrease 
the heart rate.  It may precipitate heart 
failure and exacerbate conduction disorder. 
• INDICATIONS: 
- Supraventricular arrhythmias. 
- Angina. 
- Hypertension. 
• CONTRAINDICATIONS: 
Hypotension, bradycardia, second- and 
third-degree heart block, sick sinus 
syndrome, cardiogenic shock, cardio-
megaly, sino-atrial block; history of heart 
failure or significantly impaired left 
ventricular function, even if controlled by 
therapy; Wolff-Parkinson-White syndrome 
including atrial flutter or fibrillation; 
porphyria, digitalis toxicity. 
• DOSAGE FORMS: 
Tablets. 
• RECOMMENDED DOSAGE:   
Adult:  
For Supraventricular Arrhythmias; 
40-120 mg PO, 3-4  times daily. 
For Angina; 
80-120 mg 3 times daily. 
For Hypertension; 
240-480 mg PO daily in 2-3 divided doses. 
 
Directions: Administer oral dose with food 
to reduce gastric irritation. 
*Sustained action dosage forms should not 
be opened, crushed or chewed. Capsule 
should be swallowed as a whole 
*If a dose is missed, it should be taken as 
soon as remembered. If too close to second 
dosing time, it should be ignored and the 
patient should continue with the usual 
regimen. The next dose should not be 
doubled. 
• USE IN SPECIAL CASES: 
Refer to Nifedipine. Verapamil crosses the 
placenta.  
In lactation, verapamil or its metabolites 
have not shown any adverse effects on 
nursing children. 
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• PRECAUTIONS AND WARNINGS:   
-Caution use in the following cases: 1st 
degree heart block; acute phase of 
myocardial infarction (avoid if bradycardia, 
hypotension, or left ventricular failure 
present); aortic stenosis, as well as in 
patients with hepatic and renal impairment.  
• ADVERSE EFFECTS: 
Constipation; less commonly nausea, 
vomiting, flushing, headache, dizziness, 
fatigue, and ankle edema. Other reported 
effects include pruritis, AV block, 
bradycardia, and rarely gynecomastia and 
gingival hyperplasia after long term 
treatment. 
• INTERACTIONS: 
Overview of Verapamil 
Drug-Drug Interaction 
Drug Interaction 
Anesthetics Verapamil increases 
hypotensive effect of general 
anesthetics and risk of AV 
delay. 
Anti-
arrhythmics 
Increased risk of bradycardia, 
AV block, and myocardial 
depression. Verapamil raises 
plasma concentration of 
quinidine (extreme 
hypotension may occur). 
Anti-
bacterials 
Rifampicin increases 
metabolism of verapamil 
(reduce plasma concentration). 
Anti-
depressants 
It increases plasma 
concentration of imipramine 
and other tricyclics. 
Anti-
epileptics 
The effect of carbamazepine is 
enhanced by verapamil; effect 
of verapamil reduced by 
phenobarbitone and phenytoin. 
Anti-
hypertensives 
Enhanced hypotensive effects. 
Caution patients to slowly 
change position when standing 
up or sitting down, so they 
won’t feel dizzy. 
Anti-
psychotics 
Enhanced hypotensive effects. 
Use with caution. 
Beta-
blockers 
Asystole, severe hypotension, 
and heart failure. It should be 
usually avoided. 
Cardiac 
glycosides 
Plasma concentration of 
digoxin may be increased by 
verapamil, also there will be 
an increased risk in AV block 
and bradycardia. 
Lithium Neurotoxicity may occur 
without any increase in plasma 
lithium concentration. Monitor 
patients taking Li. 
Theophylline Verapamil enhances the effect 
of theophylline. Use caution, 
monitor patient response 
closely when starting therapy. 
 
• OVERDOSE: 
Refer to nifedipine. 
• BRANDS: 
Ikacor/Ikapress (Teva), Verac (Dexxon). 
____________________________ 
 
 
c)  Diltiazem 
 
• DRUG SUMMARY: 
A slow calcium channel blocking, cardio-
vascular agent. It is effective in most forms 
of angina; the longer acting formulation is 
also used for hypertension. It may be used 
in patients for whom beta-blockers are 
contraindicated or ineffective. It has a less 
negative inotropic effect than verapamil 
and significant myocardial depression 
occurs rarely. Nevertheless because of the 
risk of bradycardia it should be used with 
caution in association with beta-blockers. It 
does not alter total serum calcium levels. 
• INDICATIONS: 
Prophylaxis and treatment of angina and 
hypertension (long acting formulations). 
• CONTRAINDICATIONS: 
Severe bradycardia, left ventricular failure, 
second- or third-degree AV block (unless 
pacemaker fitted), sick sinus syndrome; 
pregnancy; and porphyria. 
• DOSAGE FORMS: 
Tablets. 
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• RECOMMENDED DOSAGE: 
Adult: For Angina; 
30 mg PO q.i.d.;  may increase q. 1-2 d. as 
required; usual dose range 180-360 mg/day 
in 3-4 divided doses. Sustained release 
doses: start with 120-180 mg once daily; 
then titration may be carried out over a 7-
14 day period to 360-480 mg/d. 
For Hypertension; 
60-120 mg sustained-release b.i.d. (usual 
range: 240-360 mg/d). 
Child:  No recommendations. 
 
Directions: Administer oral drug before 
meals and at bedtime. 
*If using sustained release forms, do not 
chew, open or crush the tablet. Swallow as 
whole.   
• USE IN SPECIAL CASES:  
Pregnancy- May inhibit labor.  
Manufacturers advise that diltiazem is 
teratogenic in animals, therefore should not 
be used in pregnant women (Category C). 
Lactation- Significant amount is excreted in 
breast milk but not known to be harmful to 
the nursing infant. Benefit-risk ratio should 
be made on whether do discontinue the drug 
or stop breast-feeding. 
Children- Diltiazem safety and efficacy not 
established. 
Renal Disease- Start with smaller dose. 
Liver Disease- Reduce dose in hepatic 
impairment.  
• PRECAUTIONS AND WARNINGS:   
-Reduce dose of diltiazem in hepatic and 
renal impairment; heart failure or 
significantly impaired left ventricular 
function, mild bradycardia (avoid if 
severe), first degree AV block, or 
prolonged PR interval. 
• ADVERSE EFFECTS: 
Bradycardia, sino-atrial block, atrio-
ventricular block, hypotension, malaise, 
headache, flushing, gastrointestinal 
disturbances, constipation, ankle edema; 
rarely rashes (toxic erythema reported); 
altered liver function tests; hepatitis, 
amnesia and depression have been reported.  
• INTERACTIONS:  
Same as nifedipine. [Refer to nifedipine.] 
• OVERDOSE: 
Refer to verapamil. 
• BRANDS: 
Dilatam/Dilapress (Abic), Levozem (Dexxon). 
__________________________ 
 
 
B)  ANTIARRHYTHMICS 
 
The exact mechanisms underlying rhythm 
disturbances are complex, and for the most 
part, unknown. Arrhythmia may result from 
abnormal impulse formation (automaticity), 
abnormal impulse conduction, or a 
combination of both processes.  
Accurate diagnosis and appropriate 
therapy of disturbances in cardiac rhythm 
require gradual analysis of patient’s history 
(specially relating to new use of drugs 
affecting the heart), physical exam as well 
as laboratory and ECG results. Diagnosis of 
such cases is usually done by a cardiologist. 
The most widely used classification of 
antidysrhythmic drugs is based on the 
electrophysiologic action, (refer to table 2.6 
on classification). 
At the primary level, physicians will not 
prescribe such medications, but they may 
see patients who are taking such drugs. 
Therefore, knowledge about these agents is 
needed.
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Table- 2.6:  Classification of Antiarrhythmic Drugs 
Class I 
Drugs with local anesthetic effects and membrane stabilizing 
properties.  These are subdivided depending on the magnitude of their 
effects on the different cardiac phases. 
   Type IA Affecting both atrial and ventricle muscle. Quinidine, Procainamide, Moricizine, Disopyramide. 
   Type IB Usefulness is confined to ventricular rhythm disorders. Lidocaine, Tocainide, Mexiletine, Phenytoin. 
   Type IC 
Indicated primarily in ventricular dysrhythmias, can be used in atrial 
arrhythmia. 
Encainide, Flecainide, Lorainide, Propafenone. 
Class II 
β-adrenergic blocking agents, general myocardial depressants for both 
supraventricular and ventricular rhythm disturbances. 
Propranolol, Esmolol, Acebutolol. 
Class III 
No membrane stabilizing effects, selectively increases action potential 
duration.    
Amiodarone, Bretylium, Sotalol. 
Class IV Calcium channel blockers, and others.   Verapamil, Adenosine. 
# The drugs in bold have been discussed in this chapter. 
 
1)  Amiodarone 
 
• DRUG SUMMARY: 
Amiodarone is an iodine-containing 
benzofuran derivative that possesses 
cardiac electrophysiological actions that 
differ fundamentally from those of 
currently available antiarrhythmic agents. It 
is a Class III antiarrhythmic with a very 
long half-life. 
Toxicity associated with amiodarone has 
led the FDA to recommend that the drug 
be reserved for use in patients with life-
threatening arrhythmias. 
• INDICATIONS: 
It is used for the treatment of both vent-
ricular and supraventricular arrhythmias.  
Mainly used for the treatment of 
tachycardia associated with the Wolff-
Parkinson-White syndrome. Also it can be 
used in the following arrhythmias when 
other drugs are ineffective or contra-
indicated; paroxysmal supraventricular, 
nodal and ventricular tachycardias, atrial 
fibrillation and flutter, and ventricular 
fibrillation. 
• CONTRAINDICATIONS: 
Sinus bradycardia, SA heart block; unless 
pacemaker fitted; avoid in severe 
conduction disturbances or sinus node 
disease; avoid IV use in severe respiratory 
failure, circulatory collapse, severe arterial 
hypotension, congestive heart failure; 
thyroid dysfunction; pregnancy and breast 
feeding; iodine sensitivity; and porphyria. 
• DOSAGE FORMS:   
Tablets. 
• RECOMMENDED DOSAGE:   
Adult: For Arrhythmias; 
Loading dose (administered initially in 
hospital): 800-1600 mg/d PO in 1-2 doses for 1-
3 wks.  Maintenance dose: 400-800 mg/d PO in 
1-2 doses. 
Child:  No recommendations. 
 
Directions: GI symptoms occur commonly 
during high-dose therapy, especially with 
loading doses. Symptoms usually respond 
to dose reduction or to administration in 
divided doses and with food, including 
milk. 
* Use the lowest effective dose to prevent 
the occurrence of side effects. 
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*Be alert to pulmonary toxicity presenting 
with; progressive dyspnea, fatigue, cough, 
pleuritic pain and fever.  
• USE IN SPECIAL CASES: 
Pregnancy- Use only if no alternative is 
available (Category D). If it is given in the 
second or third trimester there will be a 
possibility of neonatal goiter. 
Lactation- Avoid use even though no adverse 
effects were observed. Breast feeding should 
be avoided in mothers currently taking the 
drug or have taken it chronically within the 
past several months. 
Children- Safety and efficacy for use in 
children have not been established, therefore 
amiodarone is not recommended for use. 
Renal Disease- With moderate renal 
impairment, Iodine will be accumulated and 
there will be a risk of thyroid dysfunction.  
Liver Disease- It is contraindicated in severe 
hepatic impairment.  
• PRECAUTIONS AND WARNINGS: 
-Liver function and thyroid function tests 
required in long-term therapy. Amiodarone 
interferes with tests of thyroid function.   
-Use caution in heart failure, renal 
impairment, elderly, severe bradycardia and 
conduction disturbances in excessive 
dosage. 
-IV use may cause moderate and transient 
fall in blood pressure (circulatory collapse 
precipitated by rapid administration or 
overdose).  
-Also take caution in the case of congestive 
heart failure, electrolyte imbalance, and 
preexisting lung disease. 
• ADVERSE EFFECTS: 
Reversible corneal microdeposits 
(sometimes with night glare); peripheral 
neuropathy and myopathy (usually 
reversible on withdrawal), bradycardia and 
conduction disturbances; phototoxicity; 
blue-grey discoloration of the skin 
(specially nose and ears), hyper- or 
hypothyroidism; diffused pulmonary 
alveolitis and fibrosis; hepatitis; 
anaphylaxis on rapid injection, also 
bronchospasm or apnea in respiratory 
failure. 
• INTERACTIONS:  
Overview of Amiodarone 
Drug-Drug Interaction 
Drug Interaction 
Other anti-
arrhythmics 
Increased myocardial depres-
sion risks.  Use with caution. 
Anti-
coagulants 
Metabolism of nicoumalone 
and warfarin inhibited 
(enhanced anticoagulant 
effect). Monitor patient 
closely. 
Anti-
epileptics 
Metabolism of phenytoin 
inhibited (increased plasma 
concentration).  Monitor 
blood levels of patient 
closely. 
Anti-
histamines 
Increased risk of ventricular 
arrhythmias with astemizole 
and terfenadine. Avoid use of 
these antihistamines while on 
therapy. 
β-blockers Increased risk of 
bradycardia, AV block, and 
myocardial depression. 
Calcium-
channel 
blockers 
Diltiazem and verapamil 
increase risk of bradycardia, 
AV block, and myocardial 
depression.  Use with 
caution. 
Cardiac 
glycosides 
Increased plasma concent-
ration of digoxin (half 
digoxin maintenance dose). 
Diuretics Toxicity increased if 
hypokalemia occurs. Monitor 
patient closely, especially 
when starting them on the 
medication. 
Ulcer-
healing 
drugs 
Cimetidine increases plasma 
concentrations of 
amiodarone. Use with 
caution, do not administer at 
the same time-interval if 
needed. Other ulcer healing 
medication have not shown 
this interaction, but no 
sufficient data is available. 
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• OVERDOSE: 
The most likely effects of amiodarone 
overdose are: hypotension, cardiogenic 
shock, bradycardia, AV block, and 
hepatotoxicity.  
Treatment includes usual supportive 
measures. In addition, monitor the patient’s 
cardiac rhythm and blood pressure; if 
bradycardia occurs, a β-adrenergic agonist 
may be used. Always refer the patient. 
• BRANDS: 
Amiodacore (CTI), Cordorone (Labaz/ C.T.S.), 
Procar (Unipharm). 
_______________________ 
 
2)  Lidocaine WHO,P 
 
• DRUG SUMMARY: 
It was introduced as a local anesthetic and 
is still used extensively for that purpose.  In 
contrast to quinidine and procainamide, 
lidocaine acts primarily on disturbances of 
ventricular origin and has a narrow 
spectrum of antiarrhythmic effects. Use is 
only in injection form, in clinical settings. 
Indicated for ventricular arrhythmias 
especially after an MI. No adequate and 
well controlled studies available on 
pregnancy (Category B), lactation or use in 
children. 
_______________________ 
 
3)  Quinidine WHO,P 
 
• DRUG SUMMARY: 
Quinidine, a Cinchona derivative, is a class 
IA antiarrhythmic, cardiovascular agent. It 
acts as a depressant of myocardial 
excitability, conduction velocity and 
contractility. There are differences in the 
anhydrous quinidine alkaloid content 
among the various salts. Make sure that the 
patient does not switch brands without your 
consultation. It should be prescribed only 
when other agents have failed or cannot be 
available. Quinidine, may itself precipitate 
rhythm disorders, so it should be used on 
specialist advice only. 
_______________________ 
 
C)  ANTIANGINA 
 
Angina pectoris is a symptom of 
myocardial ischemia, which is usually 
secondary to atherosclerosis of the coronary 
arteries. Although angina usually implies 
severe chest pain or discomfort, its 
presentations are variable. Angina may 
occur predictably with strenuous exercise 
(stable angina), or at other times 
unexpectedly with little or no exercise 
(unstable angina). Both reflect underlying 
narrowing of coronary arteries. Classical 
Prinzmetal variant angina (vasospastic 
angina) occurs in patient without coronary 
heart disease, and is due to a spasm of the 
coronary artery that decreases myocardial 
blood flow.   
Specific treatment of ischemic disease is 
directed toward improving myocardial 
oxygen supply, reducing myocardial 
oxygen demand, and treating precipitating 
factors or concurrent disorders that may 
aggravate ischemia. The selection of an 
effective therapeutic regimen depends on 
the severity of symptoms, the presence of 
associated disease (e.g. pulmonary or renal 
disease) the patient’s age and activity level, 
and the underlying pathophysiologic 
mechanism that is responsible for the 
ischemia.   
Nitrates remain important first-line 
agents for the treatment of angina. They 
have different mechanisms of action that 
result in vasodilatation action. Nitrate 
tolerance and reduction in therapeutic 
response may occur with all the nitrate 
preparations. To restore antianginal 
efficacy, nitrates need to be absent from the 
body for several hours, therefore, patients 
need a nitrate-free interval of at least 10-12 
hours to enhance treatment efficacy. When 
nitrates cannot be discontinued, even for a 
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short time, increased doses may be required 
to overcome tolerance.   
Beta-adrenergic blockers (i.e. 
propranolol, metoprolol) are also important 
in the management of stable angina.  They 
reduce the frequency of anginal episodes by 
reducing myocardial oxygen demand, and 
raise the anginal threshold. Choice of 
selective or non-selective β1- or β2 
antagonists depends on individual patients; 
type of angina, concurrent cardiac 
problems, side effects, etc.  (refer to β-
blockers in antihypertensive section). 
Calcium channel blockers (i.e. 
nifedipine, verapamil, diltiazem) are also 
used as antiangina agents. The antianginal 
effects of these agents are due to direct 
coronary vasodilatation and an 
improvement in the efficiency of 
myocardial performance. They are 
indicated in the management of stable and 
unstable angina, and are the agents of 
choice in patients unable to tolerate β-
adrenergic antagonists and nitrates. Refer to 
individual monographs for each drug. 
(Refer to calcium channel blockers in 
antihypertensive section.) 
________________ 
 
1)  Isosorbide Dinitrate WHO,P 
 
• DRUG SUMMARY: 
Isosorbide dinitrate, a short-acting nitrate, 
is one of the most effective drugs for 
providing rapid symptomatic relief of 
angina. It is active sublingually, and is 
more stable than glyceryl trinitrate for those 
who only require nitrates infrequently. It is 
also effective when given PO for 
prophylaxis; although the effect is slower in 
onset, it may persist for several hours. 
Duration of action up to 12 hrs is claimed 
for modified-release preparations. 
Isosorbide mononitrate is a major active 
metabolite of the dinitrate that attributes to 
the activity, and is available in the market 
as a separate preparation.  
• INDICATIONS: 
Prophylaxis and treatment of angina; left 
ventricular failure. 
• CONTRAINDICATIONS: 
Marked anemia, head trauma, cerebral 
hemorrhage, closed angle glaucoma. 
• DOSAGE FORMS:  
Tablets, skin patches. 
• RECOMMENDED DOSAGE:  
Adult:  For Angina; 
Sublingually:  5-10 mg. 
By mouth:  30-120 mg in divided doses. 
For Ventricular Failure; 
40-160 mg PO, up to 240 mg if required. 
 
Directions: Regular oral forms are best 
taken on an empty stomach (one h. before 
meals or two hrs. after meals).  
*Patient should not eat, drink, talk, or 
smoke while sublingual tablet is under 
tongue.  Sublingual tablet should be placed 
under the tongue at first sign of anginal 
attack. If pain is not relieved, repeat dose at 
5 to 10 min. intervals to a maximum of  3 
doses.  Beware of possible MI. 
*Patient should be sitting while taking 
rapid-acting forms of isosorbide dinitrate 
(sublingual and chewable tablets) because 
of the possibility of fainting. 
*If tolerance should develop in treating 
angina, establish a short drug free period of 
10-12 hrs. If the drug cannot be 
discontinued for a short period of time, 
reduce dosing intervals, i.e. if giving 3-4 
times/d, give 2-3 times/d. 
*Patients using SL preparations should 
always carry the pills with them. 
• USE IN SPECIAL CASES:  
Pregnancy- Safety for use during pregnancy 
has not been established. Use only when 
clearly needed and when the potential 
benefits outweigh the potential hazards to the 
fetus (Category C). 
Lactation- Exercise caution when 
administering to a nursing woman.  It is not 
known whether nitrates are excreted in breast 
milk. No available data. 
Children- Safety and efficacy for use in 
children have not been established. 
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Renal + Liver Disease- Use caution. In case 
of liver disease use of the mononitrate is 
recommended instead of the dinitrate form. 
• PRECAUTIONS AND WARNINGS: 
-Take caution in the case of hypotensive 
conditions, with concomitant use of 
medications that cause hypotension, and in 
the case of hyperthyroidism.   
-In some patients there is a possibility of 
developing tolerance (reduced therapeutic 
effects).  Refer to directions. 
• ADVERSE EFFECTS: 
Throbbing headache, flushing, dizziness, 
postural hypotension, and tachycardia. 
These are more prominent at the beginning 
of treatment, and will be reduced with time. 
• INTERACTIONS: 
Overview of Isosorbide Dinitrate  
Drug-Drug Interaction 
Drug Interaction 
Alcohol, 
anesthetics, 
anxiolytics, 
hypnotics, β-
blockers, Ca-
channel 
blockers, 
muscle 
relaxants 
(baclofen), 
cortico-
steroids,  
dopa-
minergics 
(levodopa), 
anti-
psychotics, 
diuretics, & 
anti-
depressants 
 
 
 
All these drugs enhance the 
hypotensive effect. Need to 
warn your patients if taking 
any of these during the time 
of nitrate therapy. 
Analgesics NSAIDs antagonize the 
hypotensive effect. Use 
with caution. 
Anti-
depressants 
Tricyclics may reduce effect 
of sublingual nitrates 
(owing to dry mouth). 
Sex hormones Estrogen and combined OC 
antagonize hypotensive 
effect. Use with caution. 
 
• OVERDOSE: 
Signs and symptoms result mainly from 
vasodilation and methemoglobinemia; also, 
hypotension, tachycardia, flushing, 
perspiring skin, vertigo, syncope, vomiting 
(possibly with colic and bloody diarrhea), 
dizziness, moderate fever and paralysis, as 
well as convulsions and death due to 
cardiovascular collapse.   
If nitrates were ingested, induce emesis or 
perform gastric lavage followed by 
charcoal administration; however, nitrates 
are usually rapidly and completely 
absorbed. Gastric lavage may be of use if 
the medication has only recently been 
swallowed. Passive movement of the 
extremities may aid venous return. Refer to 
emergency room for symptomatic care. 
• BRANDS: 
Cordil (Dexxon), Isocardide (Sam-On), Isordil 
(Wyeth Ayerst), Isotard (CTI/C.T.S.). 
____________________________ 
 
 
D)  ANTICOAGULANTS 
 
Blood coagulation resulting in the 
formation of a stable fibrin clot involves a 
cascade of proteolytic reactions involving 
the interaction of clotting factors, platelets 
and tissue materials.  Although most cases 
of thromboembolic disease are idiopathic, 
several clinical conditions have been 
associated with and increased risk of 
thrombosis.  Such factors include: inherited 
deficiencies of factors like antithrombin III, 
protein C, and protein S, and clinical 
conditions that may predispose patients like 
pregnancy, malignancy, immobilization, 
congestive heart failure, cigarette smoking, 
or immunologic disorders. 
Prior to initiation of anti-coagulant 
therapy, patients must be screened for the 
presence of relative contraindications to 
therapy (refer to table 2.7) because the 
failure to detect such contraindications 
could result in fatal hemorrhage. 
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Aspirin and warfarin will be discussed 
in this section. 
 
 
Table- 2.7:  Relative Contraindications to 
Anticoagulant Therapy  
Active bleeding  
  (e.g., active peptic ulcer disease). 
Bleeding tendency  
  (e.g., hemophilia, thrombocytopenia). 
Uncontrolled hypertension. 
Cerebrovascular hemorrhage. 
Recent surgery or invasive procedures  
  (e.g. arterial or lumbar puncture). 
Pericarditis or pericardial effusion. 
Severe trauma. 
Pregnancy (primarily related to warfarin). 
Patients prone to falling  
  (e.g., elderly or debilitated patients). 
Inadequate laboratory facilities. 
Unsatisfactory patient compliance. 
 
1)  Aspirin WHO,P 
 
• DRUG SUMMARY: 
Aspirin is recommended in treatment of 
cardiovascular, cerebrovascular and 
rheumatologic conditions. Studies have 
shown that it is effective in the treatment of 
TIA, ischemic stroke, angina, acute MI, 
recurrent MI with low doses of 50-365 mg, 
depending on case.   
Low-dose aspirin may also help in 
preventing pre-eclampsia/toxemia in 
pregnant women. The rationale for use of 
ASA prophylaxis is the inhibition of 
synthesis of prostaglandin thromboxane, 
which has been found to be elevated in 
severe pre-eclampsia. As of today, studies 
do not support the routine use of low-dose 
aspirin in pregnant women for prevention 
of pre-eclampsia or its complications. 
Further studies are needed. 
Doses: a single dose of ASA is given as 
soon as possible after an ischemic event: 
150-300 mg after MI, and 300 mg after 
TIA/stroke. After the initial dose, 
maintenance treatment with aspirin ranges 
from  75-325 mg daily, depending on case. 
(For other details on ASA, refer to analgesics 
chapter). 
__________________ 
 
2)  Warfarin WHO,P 
 
• DRUG SUMMARY: 
Warfarin, a coumarin derivative anti-
coagulant, indirectly interferes with blood 
clotting by depressing hepatic synthesis of 
vitamin K-dependent coagulation factors. 
Has no effect on already synthesized 
circulating coagulation factors or on 
circulating thrombi. It does not reverse 
ischemic tissue damage, and has no effect 
on platelets. It takes 2-3 days for the 
anticoagulant effect to develop fully. 
• INDICATIONS: 
Prophylaxis for embolization in patients 
with rheumatic heart disease and atrial 
fibrillation; prophylaxis after insertion of 
prosthetic heart valve; prophylaxis and 
treatment of venous thrombosis and 
pulmonary embolism; transient brain 
ischemic attacks. 
• CONTRAINDICATIONS: 
Pregnancy, peptic ulcer, severe 
hypertension, bacterial endocarditis, 
hemorrhagic tendencies, vitamin C or K 
deficiency, hemophilia, active bleeding, 
open wounds, severe hepatic or renal 
disease. 
Note: Oral anticoagulant should not be 
used in cerebral thrombosis or peripheral 
arterial occlusion, but may be of value in 
patients with transient brain ischemic attacks 
whether due to carotid or vertebrobasilar 
arterial disease. If these patients also have 
severe hypertension, anticoagulants are 
contraindicated, and antiplatelet drugs are an 
alternative. 
• DOSAGE FORMS: 
Tablets. 
 
 
44 
• RECOMMENDED DOSAGE: 
Adult: Whenever possible, the base-line 
prothrombin time should be determined 
before the initial dose is given. Treatment is 
very highly individualized. Control dosage 
by periodic determination of Prothrombin 
Time (PT) or the International Normalized 
Ratio (INR). 
Induction dose: The typical induction dose 
is 10 mg daily for 2 days.  On the other 
hand, less than 10 mg should be given if 
base-line prothrombin time is prolonged, 
abnormal liver-function tests, patient in 
cardiac failure, parenteral feeding, less than 
average body weight, or over 80 years of 
age.  
Maintenance dose: It depends upon the 
prothrombin time. The currently 
recommended therapeutic ranges are:  PT 
ratio of 1.3 to 1.5; and INR of 2 to 3 except 
for cases of mechanical prosthetic valves 
and recurrent systemic embolism where 
therapeutic ranges are PT 1.5 to 2, and INR 
3 to 4.5 
The daily maintenance dose of warfarin is 
usually 3 to 9 mg (taken at the same time 
each day or every other day).  
Directions: Tablet may be crushed before 
administration and taken with fluid of 
patient’s choice. 
*If a dose is missed, it should be taken as 
soon as remembered. Do not double the 
dose on the next dosing scheduled time. 
*It is essential that the PT or INR be 
determined: daily or on alternate days in 
early days of treatment, then at longer 
intervals (depending on response) then up to 
every 8 weeks. 
 
• USE IN SPECIAL CASES:  
Pregnancy- Oral anticoagulants are 
teratogenic and should not be administered 
specially in the first trimester of pregnancy 
(Category D). Women at risk of pregnancy 
should be warned of this danger; difficult 
decisions may have to be made, particularly 
in women with prosthetic heart valves or with 
a history of recurrent venous thrombosis or 
pulmonary embolism.  
Lactation- Use caution. Warfarin appears in 
breast milk in an inactive form. Infant nursed 
by warfarin-treated mothers had no changes 
in their PT. Warfarin has been considered 
safe for use. 
Children- Safety and efficacy in children < 
18 years old have not been established. 
Heparin use might be safer. Use of oral 
anticoagulants in children is only indicated in 
children with rare thromboembolic disorders 
secondary to other diseases. 
Renal Disease- Use with caution. If there is 
severe renal impairment this drug should be 
avoided. 
Liver Disease- Use with caution. If there is 
severe hepatic impairment it should be 
avoided. 
• PRECAUTIONS AND WARNINGS:   
-Need to use caution in special risk patients 
such as:  hepatic and renal disease, recent 
surgery, alcoholism, during menstruation, 
and nursing mothers.   
-Table 2.8 is a list of endogenous factors 
that may increase or decrease prothrombin 
time response (enhance or decrease 
anticoagulant effect respectively). 
• ADVERSE EFFECTS: 
Hemorrhage from any tissue or organ. 
• INTERACTIONS: 
Note: Change in patient’s clinical 
condition, particularly associated with liver 
disease, intercurrent illness, or drug 
administration, necessitates more frequent 
testing.  Major changes in diet (especially 
involving green leafy vegetables; lettuce, 
cabbage, spinach, broccoli…) may also affect 
warfarin control as well as herbal and 
botanical (ie. garlic, ginseng, licorice, 
capsicum) preparations. 
*Phenytoin and cholestyramine may 
enhance or reduce warfarin anticoagulant 
effect. Do not administer at the same time, 
and monitor patients blood levels closely. 
*Antiplatelet drugs: Aspirin increases risk 
of bleeding due to antiplatelet effect. Avoid 
use. Warn patient not to take OTC 
medications containing aspirin.  
See table on list of drugs-interactions. 
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Table 2.8 
Endogenous factors that may increase 
prothrombin time response 
(enhance anticoagulant effect) 
Carcinoma. 
Congestive heart failure. 
Collagen diseases. 
Hepatic and renal insufficiency. 
Diarrhea. 
Fever. 
Pancreatic disorders. 
Mal-nutrition. 
Vitamin K deficiency. 
Alcoholism. 
Endogenous factors that may decrease 
prothrombin time response 
(decrease anticoagulant response) 
Edema. 
Hypothyroidism. 
Hyperlipidemia. 
Hypercholesterolemia. 
Chronic alcoholism. 
Hereditary resistance to coumarin therapy. 
 
The following is a list of drugs that exhibit 
hazardous interactions with warfarin and 
they should not be given concomitantly:  
 
Enhance Warfarin Effect 
Alcohol. 
Anabolic steroids. 
Analgesics: e.g. aspirin increases risk of 
bleeding due to antiplatelet effect. 
Antiarrhythmics: e.g. amiodarone, quinidine. 
Antibacterials: e.g. chloramphenicol, 
cotrimoxazole, erythromycin, metronidazole, 
sulfonamides.  Others as tetracycline, 
trimethoprim, and ampicillin may enhance 
warfarin effect. 
Antifungals:  e.g. miconazole. 
Ulcer-healing drugs:  e.g. cimetidine. 
Influenza vaccine. 
Reduce Warfarin Effect 
Antibacterials:  e.g. Rifampicin. 
Antiepileptics: e.g. carbamazepine, 
phenobarbitone. 
Antifungals:  e.g. griseofulvin. 
Barbiturates. 
Oral contraceptives. 
Vitamin K: major changes in diet (especially 
involving vegetables). 
 
• OVERDOSE: 
Early symptoms include: excessive 
menstrual bleeding, melena, oozing from 
superficial injuries, bleeding from gums 
after brushing teeth, excessive bruising.  
Hemorrhage is the principal adverse effect. 
Other symptoms may include nausea, 
vomiting, headache, and malaise.   
Treatment includes discontinuation of 
therapy with the medication. If necessary 
give small doses of oral phytomenadione 
(Vit. K1) 2.5 to 10 mg. In persistent 
bleeding or severe hemorrhage cases refer 
to emergency room for supportive care as 
needed. 
• BRANDS: 
Coumadin (Taro). 
____________________________ 
 
E)  CONGESTIVE HEART 
FAILURE DRUGS 
 
Heart failure is the inability of the heart to 
maintain an adequate output to meet the 
metabolic demands of the body.  
The clinical manifestations of heart 
failure vary depending on the rapidity of 
decompensation, underlying etiology, and 
age of the patient. Signs and symptoms of 
low cardiac output include fatigue, exercise 
intolerance, decreased peripheral perfusion 
decreased urine output, confusion and 
lethargy, and ultimately shock.  
Precipitating factors that cause heart 
failure include: coronary artery disease, 
hypertension, dilated cardiomyopathy (due 
to toxins like alcohol, viral or parasitic 
infection or collagen vascular disease), 
valvular heart diseases, restrictive cardio-
myopathy, constrictive cardiomyopathy, 
and high-output heart failure due to chronic 
anemia, atrioventricular shunts or 
thyrotoxicosis. 
 
Nonpharmacologic therapeutic measures 
are important to employ in conjunction 
with the specific pharmacological 
measures. These include:  
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A) Restriction of physical activity and bed 
rest to reduce myocardial workload. Simple 
exercise to improve functional capacity in 
selected patients. Need to decrease 
emotional stress.  
B)   Weight loss, specially in obese patients, 
C) Dietary sodium restriction (≤ 2.0 g 
Na+/day), and fluid and water restriction (≤ 
1.5 L/day). 
D) Discontinuation of negative inotropic 
medications (e.g. beta-adrenergic 
antagonists, verapamil, diltiazem, type IA 
and IC antiarrhythmics) if possible. 
E) Complete cessation of cigarette smoking 
is also important to optimize oxygen-
carrying capacity and to reduce the risk of 
coronary disease. 
 
Pharmacological therapy principles 
include: control of sodium and fluid 
retention, vasodilator therapy and inotropic 
support, in conjunction with the non-
pharmacologic measures.   
Diuretics are first line drugs. Their goal 
is to produce a maximum net loss of 0.5 to 
1.0 liter of fluid per day to prevent 
intravascular volume depletion.  Need to 
monitor patients for complications of 
electrolyte imbalances and volume 
depletion. Hypokalemia may be life 
threatening in patients receiving digoxin or 
predisposed to ventricular arrhythmias.  
Digitalis glycosides are used to increase 
myocardial contractility. The principal 
actions of the cardiac glycosides are: an 
increase in the force of the myocardial 
contraction and a reduction of the 
conductivity of the heart. Digoxin is most 
efficacious in management of heart failure 
associated or caused by atrial fibrillation or 
flutter (or other supraventricular tachycardias 
that respond to digoxin), or in patients with 
dilated left ventricles and impaired systolic 
function. Other cardiac agents may be used 
depending on the patients’ condition. 
Always refer patients to a specialist for 
further management when patient is not 
responding to initial treatments. 
Since the Renin-angiotensin system 
becomes increasingly more active in 
cardiac failure, ACE inhibitors are being 
promoted with a diuretic (thiazide or loop 
diuretics since they potentiate the blood 
pressure lowering effects of ACEI) to be 
first-line.  The beneficial effects of these 
drugs have been demonstrated in mild, 
moderate and severe dysfunction. Since 
they are less toxic and do not require as 
much monitoring, their use has been 
accepted widely. They have a particularly 
valuable role when cardiac failure develops 
during or after a myocardial infarction.   
 
 
1)  Digoxin WHO,P 
 
• DRUG SUMMARY: 
The most widely used glycoside of digitalis 
lanata, acts by increasing the force and 
velocity of myocardial systolic contraction; 
increases contractility (positive inotropic 
effect). Action is more prompt and less 
prolonged than that of digitalis and 
digitoxin. In patients with mild failure a 
loading dose in not required, and a 
satisfactory plasma concentration can be 
achieved over a period of about a week. 
• INDICATIONS: 
Heart failure and supraventricular 
arrhythmias (particularly atrial fibrillation). 
• CONTRAINDICATIONS: 
Digitalis hypersensitivity, ventricular fib-
rillation, ventricular tachycardia unless due 
to congestive heart failure, supraventricular 
arrhythmias caused by Walff-Parkinson- 
White syndrome. 
Note: Full digitalizing dose is not given 
if the patient has received digoxin during 
the previous week, or if slowly excreted 
cardiotonic glycoside has been given during 
previous 2 weeks. 
• DOSAGE FORMS: 
Tablets, elixir (0.05mg/ml). 
Cardiovascular  Drugs 
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• RECOMMENDED DOSAGE: 
Adult: Digitalizing Dose; 
10-15 µg/kg (1-1.5 mg) PO/IV in divided 
doses over 24-48 hrs. 
Maintenance dose; 
125-250 micrograms daily, (elderly 125 ug) 
Children: should be treated and monitored 
by a pediatrician/cardiologist. Premature 
and newborn infants display considerable 
variability in tolerance, and are very 
sensitive; therefore doses are individualized 
according to infant’s degree of maturity. 
 
Directions: Make sure that the patient will 
not stop taking the medication without the 
doctor’s consultation. 
*If the patient misses a dose, it should be 
taken as soon as remembered. If too close 
to the next dose, it could be ignored and the 
required dosing schedule should be 
continued.   
*Warn patient about the possible side 
effects. In case symptoms are severe or 
unmanageable, the patient should report to 
you as soon as possible, to manage the 
toxicity effects. 
• USE IN SPECIAL CASES:  
Pregnancy- Use only when clearly indicated 
(Category C). It passes through the placenta 
and has been used to treat fetal tachycardia 
and CHF. 
Lactation- Use with caution. The amount 
appearing in breast milk is too small to be 
harmful, and no data of adverse effects have 
been reported in nursing infant. 
Renal Disease- Digoxin excretion is delayed 
in renal insufficiency since it is eliminated by 
the kidneys. Doses will need adjustment 
depending on Clcr and lean body weight, 
maintenance dose will be lowered. 
Liver Disease- No dosage adjustment is 
required. 
• PRECAUTIONS AND WARNINGS: 
Cautious use in: renal insufficiency, 
hypokalemia, advanced heart disease, acute 
MI, incomplete AV block, cor-pulmonale, 
hypothyroidism, lung disease. Dose should 
be reduced in the case of elderly patients. 
• ADVERSE EFFECTS:  
Anorexia, nausea, vomiting, diarrhea, 
abdominal pain, visual disturbances, 
headache, fatigue, drowsiness, confusion, 
delirium, hallucination, arrhythmias, and 
heart block.  
• INTERACTIONS:   
Overview of Digoxin 
Drug-Drug Interaction 
Drug Interaction 
Analgesics NSAIDs may exacerbate heart 
failure, reduce GFR and 
increase plasma-cardiac 
glycoside concentrations. 
Avoid concomitant use. 
Anion-
exchange 
resins 
Digoxin absorption is reduced 
by cholestyramine and 
colestipol. Administer 2 hours 
after or before taking resins. 
Anti-
arrhythmic 
drugs 
Plasma concentration of 
digoxin is increased by 
amiodarone, propafenone, and 
quinidine (use half the 
maintenance dose of digoxin). 
Anti-
bacterials 
Erythromycins enhance the 
effect of digoxin. Use caution. 
Anthyperten-
sives 
Captopril possibly increases 
plasma concentration of digoxin.
Anti-
malarials 
Quinine, chloroquine, and 
hydroxychloroquine raises 
plasma concentration of 
digoxin. Use half the 
maintenance dose of digoxin. 
β-blockers Increased risk of AV block and 
bradycardia. 
Calcium-
channel 
blockers 
Plasma concentration of 
digoxin increased by 
diltiazem, nicardipine, and 
verapamil; increased AV block 
and bradycardia with 
verapamil. 
Diuretics Increased toxicity occurs with 
acetazolamide, loop diuretics, 
and thiazides;  effects of 
digoxin enhanced by 
spironolactone. 
Muscle 
relaxants 
Arrhythmias with suxameth-
onium. Avoid concomitant use. 
 
 
48 
Potassium K antagonizes digitalis prep-
arations. A decrease in K level 
favors digoxin binding, 
increasing likelihood of 
digitalis toxicity.  Increased K 
level decreases digitalis 
binding and decreases 
digitoxin effect. Be very 
careful.  
 
• OVERDOSE: 
Symptoms of toxicity include exaggerated 
side effects. 
In the case of overdose one should 
discontinue digoxin until all signs of 
toxicity are abolished. Always refer the 
patient for further medical investigation and 
symptomatic care. 
• BRANDS: 
Digoxin-Zori (Teva), Lanoxin (Glaxo Wellcome). 
____________________________ 
 
 
F)  LIPID LOWERING DRUGS 
 
The relationship between the risk of 
atherosclerotic heart disease and serum 
lipoprotein is well established. Elevated 
levels of total cholesterol and low-density 
lipoprotein (LDL), and low levels of high-
density lipoprotein cholesterol (HDL) are 
associated with increased risk for cardiac 
disease. See table-2.9 for classification of 
blood cholesterol levels. 
 
Table-2.9:  Classification  of   
Blood  Cholesterol  Levels in Adults 
Classifi-
cation 
Total 
Chol. 
LDL 
Chol. 
HDL
Chol.
TGs 
Desirable  
blood 
concentration  
(mg/dl) 
< 200 < 130 ≥ 35 
Borderline-
high (mg/dl) 
200-
239  
130-
159   
High    
(mg/dl) ≥ 240  ≥ 160   
Male: 
40-160 
 
 Female:  
35-135 
 
Drug Facts and Comparisons, 2000, p. 532. 
 
Table 2.10 lists the common risk factors 
for heart disease. If no family history of 
high cholesterol levels, ask about any 
medication intake that might contribute to 
elevating their cholesterol or triglycerides 
(TGs) levels, such as: alcohol intake, OCs, 
corticosteroids, nicotinic acids, spirono-
lactone or thiazide diuretics.  
 
Table- 2.10:  Cardiac Risk Factors  
Male sex 
Family history of CHD 
Cigarette smoking 
Hypertension 
HDL-cholesterol below 35 mg/dl (on 
more than one measurement) 
Diabetes mellitus 
Hypothyroidism 
Presence of cerebrovascular or peripheral 
vascular disease 
Severe obesity  (> 30 % over-weight) 
 
The rationale for therapy is to reduce the 
risk of atherosclerotic cardiovascular 
disease. Diet, weight loss and exercise are the 
most important therapy to start with.  Diet is 
the initial therapy, and in most cases, 
should be tried for several months before 
drug therapy is considered. Cessation of 
smoking and reduction of blood pressure 
are also important.  
Lipid lowering agents should be 
reserved for patients in whom severe 
hyperlipidemia is inadequately controlled 
by the modified fat diet. Choice of 
medication depends on the individual 
patient and type of disorder. Some drugs 
are used to lower cholesterol, others lower 
both cholesterol and triglycerides. 
WHO recognizes the value of the lipid 
lowering drugs, but has not included any 
specific agent on the EDL. 
Bile sequestrant resins (cholestyramine 
and colestipol) are usually first-line choice, 
while HMG-CoA reductase inhibitors 
(Fluvastatin, lovastatin, paravastatin, and 
simvastatin) and fibric acid derivatives 
(bezafibrate, clofibrate and gemfibrozil) are 
second choice. (Long term safety and 
efficacy for second line agents have not 
been established.) 
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Table- 2.11:  Effects of Selected Antihyperlipidemic Drugs  
on Serum Lipids and Lipoproteins 
Lipids Lipoproteins  
Drug Cholesterol Triglycerides VLDL LDL HDL 
Cholestyramine Ð ÎÏ ÎÏ Ð ÎÏ 
Clofibrate Ð Ð Ð ÎÐ ÎÏ 
Gemfibrozil Ð Ð Ð ÎÐ ÎÐ 
Lovastatin Ð Ð Ð Ð Ï 
Nicotinic Acid Ð Ð Ð Ð Ï 
Probucol Ð Î Ð Ð Ï 
Simvastatin Ð Ð Ð Ð Ï 
 Ð-  decrease, Ï- increase, Î- unchanged. 
 Adapted from Drugs Facts and Comparisons 2000, p. 532. 
 
 
Measurement of LDL-cholesterol levels 
should be at 4-6 wks, and at 3 mons. If the 
response is inadequate, refer this patient to 
a lipid disorder specialist. Experience with 
combination therapy is limited.   
For menopausal women with high serum 
cholesterol, estrogen replacement therapy 
can be considered as an alternative choice, 
since estrogen lowers LDL and raises HDL 
cholesterol levels. 
Table 2.11 summarizes the effects of 
selected antihyperlipidemic drugs on serum 
lipids and lipoproteins. 
 
1)  Fibric Acids 
 
a)  Bezafibrate 
 
• DRUG SUMMARY: 
It belongs to a group known by the 
clofibrate group (refer to introduction). It 
can be regarded as broad-spectrum lipid-
modulating agent in that although their 
main action is to decrease serum TGs they 
also tend to reduce LDL-cholesterol and to 
raise HDL-cholesterol. This group can 
cause a myositis-like syndrome, especially 
in patients with impaired renal function. In 
addition, clofibrate predisposes to 
gallstones by increasing biliary cholesterol 
excretion; it is therefore only indicated in 
patients who have had a cholecystectomy. 
• INDICATIONS: 
Hyperlipidemias types IIa, IIb, III, IV, and 
V in patients who have not responded 
adequately to diet and other appropriate 
measures.  
• CONTRAINDICATIONS: 
Hypoalbuminemia, primary biliary 
cirrhosis, gall bladder disease, nephrotic 
syndrome, pregnancy and breast feeding, 
and severe renal or hepatic impairment. 
• DOSAGE FORMS:   
Tablets 
• RECOMMENDED DOSAGE: 
Adult:  200 mg PO t.i.d., may be reduced 
to 200 mg b.i.d. in hypertriglyceridemia. 
Directions:  It may be taken with or after 
food if GI upset occurs. 
• USE IN SPECIAL CASES:  
Pregnancy- Avoid in the case of pregnancy 
since there is a theoretical possibility of 
interference with embryonic growth and 
development due to anticholesterol effect. 
Strict birth control procedures must be 
exercised by women of child-bearing 
potential. Since no controlled studies on 
women have been performed, weigh the 
possible benefits of the drug to the patient 
against possible hazards to the fetus. 
Lactation- Avoid. No available data, but 
animal studies suggest drug excretion into 
breast milk.   
Children- Safety and efficacy in children 
have not been established. 
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Renal Disease- If there is mild to moderate 
renal impairment, reduce dose since it might 
cause further deterioration in renal function. 
If there is severe renal impairment, avoid 
bezafibrate. 
Liver Disease- Avoid in severe liver disease. 
• PRECAUTIONS AND WARNINGS: 
Some patients might not be responsive to 
clofibrate or its derivatives.  
There has been no indication that these 
drugs cause a reduction in the incidence of 
fatal myocardial infarctions in patients.  Be 
selective when choosing patients to start on 
therapy. 
• ADVERSE EFFECTS: 
Nausea, abdominal discomfort; rarely 
myositis-like syndrome, pruritis, urticaria, 
impotence;  and headache reported. 
• INTERACTIONS: 
Overview of Bezafebrate 
Drug-Drug Interaction 
Drug Interaction 
Anti-
coagulants 
Enhancement of effect of 
nicoumalone and warfarin. 
Anti-
diabetics 
May improve glucose 
tolerance and have positive 
additive effect. Monitor 
glucose levels if therapy is 
started. 
 
• OVERDOSE: 
Symptoms include excessive side effects. 
Institute symptomatic supportive measures. 
• BRANDS: 
Bezalip (Boehringer), Norlip (Unipharm). 
________________________ 
 
2)  Bile Acid Sequestrants 
 
a)  Cholestyramine 
 
• DRUG SUMMARY: 
A quaternary ammonium anion exchange 
resin (bile acid sequestrant) used for its 
cholesterol-lowering effect.  
• INDICATIONS: 
As adjunct to diet therapy in management 
of patients with primary hyper-
cholestrolemia (type IIa hyperlipidemia), 
with a significant risk of arthersclerotic 
heart disease and MI. Also has been used 
for relief of pruritus associated with partial 
biliary obstruction, and to control diarrhea 
caused by excess bile acids in colon for 
hyperoxaluria. 
• CONTRAINDICATIONS: 
Hypersensitivity to bile acid sequestering 
resins and in complete biliary obstruction. 
• DOSAGE FORMS: 
Tablets, powder. 
• RECOMMENDED DOSAGE: 
Adult: For Hypercholesterolemia and 
Hyperlipoproteinemia; 
4-8 g PO b.i.d. to q.i.d., a.c. and h.s.   
May need up to 24 g/d;  max. 32g/d).  
 
Directions: Medication is taken before 
meals, and at bedtime. 
*If using powder, dissolve one packet, or 
one level scoop in at least 120-180 ml of 
water or other preferred liquid. Permit drug 
to hydrate by standing without stirring 1-2 
min., then stir until suspension is uniform.  
Rinse glass with small amount of liquid to 
ensure entire dose is taken. 
*Determine cholesterol level frequently 
during the first few months of therapy.  
Serum levels are reduced within 24-48 hrs., 
and continue to decline for a year. If 
response is unsatisfactory after 3 months of 
treatment, the drug is usually withdrawn. 
(See Precautions and Warnings). 
• USE IN SPECIAL CASES:  
Pregnancy- Use only when clearly needed, 
and the potential benefit outweighs the 
potential hazards to the fetus (Category C). 
Safety for use during pregnancy has not been 
established. Even though these agents do not 
get absorbed systematically, they interfere 
with fat-soluble vitamins that are essential to 
the growing fetus. 
Lactation- Exercise caution. The possible 
lack of proper fat-soluble vitamin absorption 
may have an effect on the nursing infant. 
Children- Doses have not been established 
in children. Safety and efficacy in children 
< 6 yrs old are not established.  
 
 
Cardiovascular  Drugs 
51 
Renal Disease- Use with caution. 
Liver Disease- Use with caution. Cholesty-
ramine interferes with absorption of fat-
soluble vitamins and may aggravate 
malabsorption in primary biliary cirrhosis. 
• PRECAUTIONS AND WARNINGS:   
-Carcinogenesis: The incidence of intestinal 
tumors in studies was greater in 
cholestyramine-treated rats than in controls. 
Before instituting therapy, vigorously 
attempt to control serum cholesterol by an 
appropriate dietary regimen and weight 
reduction. 
-Resins may interfere with normal fat 
absorption of digestion and may prevent 
absorption of fat-soluble vitamins A, D, E, 
and K. Chronic use of resins may be 
associated with increased bleeding time due 
to vitamin K deficiency.  Supplementation 
with the vitamins may be given in a water 
miscible form or administered parenterally 
if needed. 
-Reduction of serum or red cell folate has 
been reported with chronic administration.  
Consider supplementation with folic acid if 
needed. 
-Use caution with patients with preexisting 
constipation.  Fecal impaction may occur, 
and hemorrhoids may be aggravated.  Need 
to avoid constipation (causing strain on 
defecation) in patients with symptomatic 
coronary artery disease. Increased fluid 
intake may be sufficient, if not, the patient 
can use a laxative or stool softener. 
• ADVERSE EFFECTS:  
Most common are: constipation, and in 
severe cases may be accompanied by fecal 
impaction and aggravation or bleeding of 
hemorrhoids. Others may be, abdominal 
pain, flatulence, bloating sensation, nausea, 
indigestion, heartburn, belching, urticaria, 
asthma, and general backache or joint 
pains.  
• INTERACTIONS: 
 
Note: 
Most medications should be taken 
at least 1 hour before, 
or 4-6 hours after cholestyramine- 
or colestipol- administration. 
 
Overview of Cholestyramine 
Reported Drug-Drug Interaction 
Drug Interaction 
Anti-
coagulants 
The anticoagulant effect may 
be decreased by cholestyramine. 
Digitalis 
glycosides 
Serum level of glycosides may 
be reduced, reducing the 
therapeutic effect. 
Analgesics Piroxicam elimination is 
enhanced, and paracetamol 
absorption is reduced leading 
to subtherapeutic effects. 
Propranolol The plasma concentration of 
propranolol and its metabolite 
is reduced. 
Thiazide 
diuretics 
Absorption and serum level of 
thiazides may be decreased. 
Thyroid 
Hormones 
Loss of efficacy of thyroid and 
potential hypothyroidism with 
concurrent use of choles-
tyramine. 
Vitamins 
A, D, E, K 
Malabsorption may occur with 
chronic use of resins.   
 
• OVERDOSE: 
The chief potential harm would be GI tract 
obstruction. Location and degree of 
obstruction and status of gut motility 
determine treatment. No ill effects have 
been reported. 
• BRANDS:  
Chol-Less (Rafa), Questran (Bristol Labs/ Mead 
Johnson). 
______________ 
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3)  HMG-COA  Reductase 
Inhibitors   
 
a)  Simvastatin 
 
• DRUG SUMMARY: 
Simvastatin is an inhibitor of 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA), 
classified as a cardiovascular, lipid 
lowering agent. It is more potent than 
lovastatin. A response is noted within 1-2 
wks.  
[Several statins have been shown to reduce 
fatal and myocardial infarction, stroke, the 
need for coronary by-pass surgery and all-
cause mortality. (WHO EDL. 1997)]. 
• INDICATIONS: 
Hypercholesterolemia, familial hyper-
cholestrolemia. 
• CONTRAINDICATIONS: 
Hypersensitivity to these agents, pregnancy 
and nursing mothers, active liver disease. 
• DOSAGE FORMS:  
Tablets. 
• RECOMMENDED DOSAGE: 
Adult:  5-40 mg q.d. 
Directions:  Can be given without regard to 
meals.  Better given in the evenings. 
* Liver function tests should be performed   
q. 4-6 wks. during the first 3 mons. of 
therapy, then every 6-8 wks. for the next year.  
(PT may be prolonged). 
• USE IN SPECIAL CASES:  
Pregnancy- Contraindicated use (Category 
X). Evidence in skeletal malformation in 
animal studies has been reported. 
Lactation- It is not known if simvastatin is 
excreted in human breast milk, but because 
of the potential for serious adverse reaction 
in nursing infants it is inadvisable to use it.  
Children-  Safety and efficacy in children   
< 18 years old have not been established.  
Avoid use. 
Renal Disease- Use with caution. Higher 
systemic exposure of simvastatin may 
occur in severe renal insufficiency. 
Liver Disease- Avoid use in patients who 
consume substantial quantities of alcohol or 
who have a history of liver disease. 
• PRECAUTIONS AND WARNINGS:   
-Use with caution in patients who consume 
substantial quantities of alcohol or who 
have a history of liver disease. Liver 
function tests should be performed in all 
patients before initiating therapy. 
Elevations of liver enzymes should be 
monitored closely. If levels of transaminase 
rise to 3 times the normal levels and are 
persistent, discontinue the drug. 
-Carcinogenesis/fertility impairments, have 
been noted in animal studies of these agents 
at high doses. 
• ADVERSE EFFECTS: 
Angina, dizziness, headache, vertigo, 
insomnia, nausea, vomiting, diarrhea, 
flatulence, photosensitivity, transient 
elevations of liver transaminases, rhabdo-
myolysis, gynecomastia and erectile 
dysfunction, progression of cataracts. 
• INTERACTIONS: 
Overview of Simvistatin 
Major Drug-Drug Interaction 
Drug Interaction 
Warfarin The anticoagulant effect of 
warfarin may be increased. 
Monitor prothrombin time. 
Cyclosporin Increased risk of Myopathy 
or rhabdomyolysis may 
occur with concurrent 
administration. 
 
• OVERDOSE: 
Few cases of overdosage have occurred 
with simvastatin, no patients had any 
specific symptoms, and all recovered. Treat 
symptomatically as required. 
• BRANDS: 
Simovil (Assia/Riesel), Zocor (Merck). 
 
__________________________
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A)  ANTACIDS & ULCER HEALING MEDICATION 
 
Gastro-intestinal tract (GIT) disorders are 
very common. Important clues to determine 
what type of problem is present can be 
found by asking patients about time of 
symptoms occurrence (in relation to meals 
and night time), if pain is localized, if 
symptoms are acute or chronic . . . etc.  
The following table shows some common 
GIT disorders with the associated 
symptoms and characteristics: 
 
Summary of Selected GI Disorders 
Gastroesophageal Reflux Disease  
Heartburn/pain in lower chest. 
Pain is worse after meals & when lying down. 
Pain may wake patient at night. 
Pain is often relieved by antacids. 
Pain may be worse after certain foods, 
smoking, alcohol, caffeine, and medications 
that reduce lower esophageal sphincter tone. 
Gastric Ulcer 
Variable epigastric pain. 
Unpredictable pattern. 
Food may worsen pain. 
Weight loss is common. 
May be relieved by antacids. 
History of chronic NSAID use. 
Duodenal Ulcer 
Aching epigastric pain. 
Well-localized, predictable pattern. 
Begins 1-2 hrs. after eating,  
worse before next meal. 
Relieved by food or antacids. 
Weight gain common. 
May wake patient at night. 
History of smoking. 
Acute Gastritis 
Burning epigastric pain. 
Possible association with anorexia,  
nausea, and vomiting. 
History of alcohol binge or NSAID use. 
 
There are many factors that disrupt the 
gastric mucosal barrier, which lead to acid-
peptic disorders. These factors include: 
Helicobacter pylori (H. pylori) bacteria, 
drugs, e.g. NSAIDs, corticosteroids, 
alcohol, caffeine and smoking.  Healing can 
be promoted by minimizing these factors 
when possible. 
The primary aim of pharmacological 
therapy for such disorders has been either 
to neutralize existing acid (using antacids), 
reduce the secretion of acid (using 
anticholinergic agents, H2-antagonists or 
proton pump inhibitors), or to eradicate H. 
pylori bacteria. Table-3.1 indicates a 
summary of the most common therapeutic 
classes, their mechanism of action and 
some examples. 
Antacids are useful for the short-term 
relief of indigestion, heartburn and 
excessive eating and drinking, as well as 
for the long-term management of gastro-
esophageal reflux and peptic ulcer disease.  
They give symptomatic relief, promote 
healing and reduce reoccurrence. There are 
2 kinds of antacids. Absorbable antacids: 
these provide rapid, complete neutra-
lization, but continuous use may cause 
milk-alkali syndrome that can progress to 
irreversible kidney damage if unrecognized. 
Examples include sodium bicarbonate, 
calcium carbonate. Non-absorbable 
antacids are relatively unsoluble salt of 
weak bases and have fewer side effects. 
They interact with gastric HCL forming 
non-absorbable salts thus increasing gastric 
pH. Examples like Aluminium hydroxide 
and Magnesium hydroxide. 
Dual and triple therapy regimens have 
been implemented to provide higher 
eradication rates. Dual therapy such as use 
of amoxicillin plus omeprazole, or 
clarithromycin plus omeprazole have an 
overall lower efficacy rates compared to 
triple therapy. Also after treatment failure, 
in patient who remain H. pylori positive 
resistance has developed. Therefore, 
experts no longer advocate dual therapy as 
first-line treatment (Gitnick, 1997). The 
effectiveness of regimens may be due to 
antibiotic resistance. Therefore, the 
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patients’ prior antibiotic exposure should be 
considered when selecting a regimen. 
Examples of used regimens adopted 
from Drug Facts and Comparisons are 
shown in table-3.2. 
 
 
 
 
Table-3.1:  Summary of the Most Common Therapeutic Classes for Treatment of Ulcers 
Therapeutic 
Class Mechanism of Action Example Notes 
Antacids 
Neutralize existing acids, 
without affecting the amount 
or rate of gastric secretion. 
They react with acids to form 
salt and water. 
Na bicarbonate, 
Ca carbonate, 
Aluminium salts, 
Magnesium salts. 
These products differ in 
potency, GI side effects, 
systemic complications 
and drug interactions. 
H2- 
antagonists 
Reduce acid secretion 
without enhancing mucosal 
defenses. 
Cimetidine, 
Ranitidine, 
Famotidine, 
Nizatidine. 
These products are 
almost equally effective 
with some differences in 
side effects. 
Proton pump 
inhibitors 
Blocks the final step in acid 
production. 
Omeprazole, 
Lansoprazole, 
Pantoprazole, 
Rabeprazole. 
These products are 
comparable in effective-
ness with some 
differences in drug-drug 
interactions.  
 
 
 
 
Table-3.2:  Regimens Used in the Eradication of  H. Pylori 
Regimens Dosing Duration 1 Eradication 
Metronidazole 
Omeprazole 
Clarithromycin 
500 mg twice daily with meals 
20 mg twice daily with meals 
500 mg twice daily with meals 
1 - 2 weeks 87% to > 91% 
Amoxicillin 
Omeprazole 
Clarithromycin 
1 gram twice daily with meals 
20 mg twice daily with meals 
500 mg twice daily with meals 
1 - 2 weeks 77% to 83% 
 
1 Extending therapy to 10-14 days in the above regimens may provide additional benefit.  H2 
blockers may be used with two antibiotics, but a longer treatment course (10-14 days), higher 
antibiotic doses and 3 times daily administration are required. 
Reference: Drug Facts and Comparisons, 2000; A-10,11. 
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1)  Mg/Al Salt WHO,P 
 
• DRUG SUMMARY: 
Many commercially available antacid 
products contain a combination of 
aluminium (Al) and magnesium (Mg) salts, 
hydroxide, trisilicate. Because constipation 
from Al and diarrhea from Mg are dose 
related, combining these two agents allow 
for a potent neutralizing capacity with 
lower doses of each agent. The constipating 
effect of Al should balance the diarrheal 
effect of Mg, and vice versa. These agents 
do not cause alkalosis or rebound 
hyperacidity as NaHCO3. 
• INDICATIONS: 
Hyperacidity; symptomatic relief of 
stomach upset, dyspepsia, heartburn, acid 
indigestion, GERD, and hyperacidity 
associated with peptic ulcer.   
• CONTRAINDICATIONS: 
Known sensitivity to any of the 
components of the products. 
• DOSAGE FORMS: 
Tablets, suspension. 
• RECOMMENDED DOSAGE:  
Adult: For Indigestion and Heart Burn; 
1 or 2 tabs or 1 or 2 tbsp. when needed. 
For Ulcers; 
Take 1-2 tabs or 1-2 tbsp., one hour a.c. and 
at h.s. 
Child:  Use is not recommended. 
Directions: Antacids should be taken 1 h. 
after meals when needed, which will give a 
duration of action for up to 3 hrs. 
*If using the suspension, shake bottle well 
before use. 
*Chewable tablets should be chewed well, 
and followed by a full glass of water. 
*Advise patient to contact physician if relief 
of heartburn or indigestion is not obtained, 
or if any sign of bleeding such as black tarry 
stool or/and “coffee ground” vomitus occur. 
This could be an indication of a serious 
problem or GI bleed. 
*Warn patient that smoking and alcohol 
may increase their risk of peptic ulcer 
disease, and they should stop these habits if 
possible to avoid such problems. 
*Warn patient of possible drug interactions. 
(Refer to drug interactions). 
• USE IN SPECIAL CASES:  
Pregnancy- This type of antacid are generally 
considered safe during pregnancy as long as 
chronic high doses are avoided. It is better to 
avoid use unless clearly needed.  
Lactation- Safe if using in small dose, for a 
very short period of time. Avoid use 
chronically, the cations are secreted in breast 
milk, and can cause side effects in the 
neonate such as hypermagnesemia. 
Children- Such products are not intended for 
children < 6 yrs. old. 
Renal Disease- Patient with renal disease are 
susceptible to toxicity of antacid (especially 
products containing Mg and Al) due to 
decreased clearance. Use caution, and reduce 
doses. Avoid chronic use of such product.  
Liver Disease- Use caution.  
• PRECAUTIONS AND WARNINGS:   
-Prolonged use or aluminium-containing 
antacid may result in hypophosphatemia, 
especially in patients with inadequate 
phosphate intake. Severe forms of this can 
lead to anorexia, malaise, muscle weakness, 
and osteomalacia. 
• ADVERSE EFFECTS: 
Diarrhea (usually due to Al) or constipation 
(due to Mg) may occur.   
• INTERACTIONS: 
Patient should space doses of antacids at 
least 2 hrs apart from interacting drugs. 
 
Summary of  Mg-Al  Combination  
Drug Interactions 
DRUG Effect DRUG Effect 
Benzodiazepines ↓ Ketconazole ↓ 
Captopril ↓ Levodopa ↑ 
Corticosteroids ↓ Phenothiazines ↓ 
Digoxin ↓ Quinidine ↑ 
Fluoroquinolones ↓ Salicylates ↓ 
H2-antagonist ↓ Sulfonylureas ↑ 
Hydantoins ↓ Tetracyclines ↓ 
Iron salts ↓ Valproic acid ↑ 
↓  Pharmacological effect decreased by antacid 
↑  Pharmacological effect increased by antacid 
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• OVERDOSE: 
No intentional overdose with antacids has 
been reported. If a child took an overdose 
of antacid, take immediately to the 
emergency room for supportive care. Do 
not induce vomiting at home. 
• BRANDS: 
Maalox (Rorer), Magnagel (JePharm), Simigel 
(BPC), Stomagel (JCL). 
___________________ 
 
2)  Ranitidine WHO,P 
 
• DRUG SUMMARY: 
An H2-receptor antagonist; antisecretory, 
GI agent. It is a potent antiulcer drug that 
competitively and reversibly inhibits 
histamine action at the H2-receptor sites on 
parietal cells, thus reducing acid secretion. 
Ranitidine has no analgesic effect, and 
should not be taken for relieve of 
intermittent epigastric pain. 
• INDICATIONS: 
Short-term treatment and maintenance 
therapy of active, benign gastric and 
duodenal ulcers. For hypersecretory 
conditions (Zollinger-Ellison syndrome), and 
GERD. 
• CONTRAINDICATIONS: 
Hypersensitivity to ranitidine, or other H2-
antagonists. 
• DOSAGE FORMS: 
Tablets. 
• RECOMMENDED DOSAGE: 
Adult: For Duodenal, Gastric Ulcers 
and GERD: 
150 mg PO b.i.d. or 300 mg PO h.s. 
Maintenance Therapy: 
150 mg PO h.s. 
Zollinger-Ellison syndrome: 
150 mg PO t.i.d. Doses up to 6 g daily in 
divided doses have been used. 
Child: Use is not recommended. 
Directions:  
*Food does not reduce oral ranitidine 
absorption or serum concentrations, so can 
take medication without regard to food. 
*Patients should not use OTC remedies for 
gastric distress or pain without physician’s 
advice (e.g. antacids reduce ranitidine 
absorption). If antacid is required in 
addition, administer the antacid 2 hrs. 
before or after ranitidine intake. 
*Symptoms are usually relieved within 1 
week. Most patients have healed ulcers by 
4 weeks, however; if healing cannot be 
confirmed, treatment may be continued for 
up to 8 weeks. Advise patient to complete 
course of therapy as needed. 
*Smoking has been shown to decrease 
ranitidine efficacy and adversely affects 
ulcer healing. Urge patient to stop smoking. 
This is more important in preventing ulcer 
recurrence than the medication. 
• USE IN SPECIAL CASES:  
Pregnancy- Administer only when clearly 
needed and potential benefit outweighs 
potential risk. There are no well-controlled 
studies in pregnant women (Category B). 
Lactation- Ranitidine is excreted in breast 
milk. No reports of adverse effects 
documented, but use caution if need to 
administer to nursing mothers. 
Children- Not recommended. Safety and 
efficacy are not established. 
Renal Disease- May need to reduce dose. The 
drug is excreted primarily via the kidneys, 
and decreased creatinine clearance (CLcr) 
may occur. CLcr is monitored if renal 
dysfunction is present. When less than 50 
ml/min, can reduce dose to 150 mg gradually 
to once every 24 hours.  
Liver Disease- Caution, the drug is 
metabolized by the liver. 
• PRECAUTIONS AND WARNINGS:  
-Symptomatic response to ranitidine 
therapy does not preclude the presence of 
gastric malignancy. 
-Use caution in patients with hepatic and 
renal diseases. 
• ADVERSE EFFECTS: 
Headache, malaise, dizziness, insomnia, 
agitation, depression (mainly in the elderly) 
may occur (due to penetration through the 
BBB, but less than cimetidine). 
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Occasionally gynaecomastia has been 
reported (with other H2 antagonists). Rarely 
constipation or diarrhea, nausea, abdominal 
pain, rash, thrombocytopenia, and 
hepatotoxicity or anaphylaxis have 
occurred. 
• INTERACTIONS: 
*Ranitidine weakly binds to cytochrome 
P450 (an enzyme responsible for oxidation 
reactions in the mitochondria), therefore 
serious drug interactions are less than 
cimetidine. Raise of aminotranferase may 
be observed.  
 
Overview  of  Ranitidine 
Drug-Drug Interaction 
Drug Interaction 
Sulfonyl-
ureas- 
(glipizide) 
H2-antagonists in general 
inhibit sulfonylurea hepatic 
metabolism causing accum-
ulation of sulfonylureas 
resulting in hypoglycemia but 
this is mainly seen in 
cimetidine. Ranitidine has 
been reported to increase the 
hypoglycemic effect of 
glipizide. Monitor blood 
glucose and adjust dosage of 
sulfonylurea as necessary.  
Warfarin Ranitidine may interfere with 
warfarin clearance, increasing 
its effects. Do not administer 
concomitantly. 
• OVERDOSE: 
Symptoms: There is no experience with 
deliberate over-dose. In animals, toxic 
doses caused rapid respiration, tachycardia, 
muscle tremor, vomiting pallor of mucous 
membranes or redness, miosis and diarrhea.   
Treatment: Induce emesis and employ 
supportive therapy. 
• BRANDS:  
GI-Care (Pharmacare), Randin (JePharm), 
Ratidine (BPC), Zantab (Teva), Zantac (Glaxo 
Wellcome). 
____________________________ 
 
3)  Omeprazole 
 
• DRUG SUMMARY: 
Omeprazole is a substituted benzimidazole, 
which does not exhibit anticholinergic or 
H2-antagnostic properties. It belongs to the 
class of antisecretory compounds: a gastric 
proton pump inhibitor. It blocks the final 
step in acid production. Onset of action 
occurs within 1 hour. Omeprazole, as with 
other agents in this group, is a new drug 
with limited use due to its high costs and 
lack of sufficient long-term studies. But it 
can prevent NSAID-associated ulcers 
specially in very elderly patients for whom 
NSAIDs can’t be withdrawn. 
• INDICATIONS: 
Short-term use (4-8 weeks) for gastro-
esophageal reflux disease, gastric and 
active duodenal ulcers, and erosive 
esophagitis. Used if there is a poor response 
to H2-receptor antagonists in treating 
GERD. Long-term use should be limited to 
conditions such as Zollinger-Ellison (ZE) 
syndrome, multiple endocrine adenomas, 
and systemic astocytosis. It is indicated 
with amoxycillin or clarithromycin to 
eradicates H. pylori (refer to introduction). 
• CONTRAINDICATIONS: 
Hypersensitivity to the drug. 
• DOSAGE FORMS: 
Capsules. 
• RECOMMENDED DOSAGE: 
Adult: Duodenal ulcer & GERD (GERD 
if poorly responsive to H2 antagonists): 20 
mg PO q.d. for 4-8 wks. 
Gastric ulcer: 40 mg q.d.  for 4-8 wks. 
Hypersecretory conditions: the dose 
should be individualized. Initial dose is 60 
mg/d. Doses up to 120 mg t.i.d. have been 
administered. Daily doses > 80 mg should 
be divided. Some patients with Zollinger-
Ellison syndrome have been treated 
continuously for > 5 yrs. 
Directions: Take one capsule before eating. 
Antacids may be used concomitantly.   
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*Do not open, crush, or chew capsule. Take 
as whole with full glass of water. 
• USE IN SPECIAL CASES:  
Pregnancy- Avoid use. Omeprazole passes 
the blood-placenta barrier. In animal 
studies, toxicity to the fetus has been noted. 
Use only when benefit justifies the risk to 
the fetus (Category C). 
Lactation- Avoid use. It is not known if 
omeprazole is excreted in breast milk. 
Lactating women should discontinue 
lactation prior to taking this drug. 
Children- Avoid use. Safety and efficacy in 
children has not been established. 
Renal Disease- Use caution, even though no 
dosage adjustment is necessary. 80% of drug 
is excreted in urine. 
Liver Disease- The drug is metabolized in the 
liver. In liver diseases, not more that 20 mg 
daily should be administered. 
• PRECAUTIONS AND WARNINGS: 
-Symptomatic response to therapy with 
omeprazole does not preclude gastric 
malignancy. 
-The safety and efficacy for treatment in 
humans for more than 8 weeks is not 
established. Carcinogenesis; it has been 
noted in animal studies that there is a 
higher (increase of) incidence with long-
term use (more than 2 years). 
• ADVERSE EFFECTS:  
Omeprazole is generally well tolerated. 
Most common side effects include 
headache, dizziness, fatigue, diarrhea, 
abdominal pain, nausea, and rash. 
Erythema, fever, chest pain, pancreatitis, 
acute inerstitial nephritis, glucosuria, 
anemia, thrombocytopenia, hypoglycemia, 
bronchospasm, as well as testicular pain 
have been noted. 
• INTERACTIONS:   
Overview  of  Omeprazole 
Drug-Drug Interaction 
Drug Interaction 
Diazepam, 
Phenytoin 
and 
Warfarin 
Increased plasma concen-
trations of these drugs when 
used concomitantly with 
omeprazole have been noted,  
avoid administering any of 
these medications with 
omeprazole. 
Drugs 
where 
gastric pH 
is important 
Omeprazole may interfere 
with absorption of drugs 
where gastric pH is important, 
because of its profound and 
long lasting inhibition of 
gastric acid secretion (i.e. 
ketoconazole, ampicillin 
esters, iron salts). 
 
Propranolol or Theophylline: No reports of 
interactions with these drugs. 
• OVERDOSE:  
Reports have been rare. 
Symptoms: Confusion, drowsiness, blurred  
vision, tachycardia, headache, dry mouth, 
and flushing.  
Treatment: No specific antidote is known. 
Can administer syrup of ipecac to induce 
vomiting before reaching the hospital. 
Treatment should be symptomatic and 
supportive. Since omeprazole is extensively 
protein bound, it is not readily dialyzable.   
• BRANDS:  
Losec (Abic), Locid (JePharm), Mepral (BCP), 
Prelosec (Astra Merk). 
_____________________ 
 
B)  ANTISPASMODICS/ 
ANTICHOLINERGICS 
 
Anticholinergic agents (agents that 
decrease/antagonize/prevent the effect of 
the neurotransmitter acetylcholine), also 
known as antimuscarinic drugs (i.e. 
atropine/hyoscyamine, scopolamine/ 
hyoscine, belladonna alkaloids, 
tridihexethyl, dicyclomine . . . etc.).  These 
agents are used primarily as antispasmodics 
by decreasing smooth muscles tone 
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(motility) in the GI, biliary and urinary 
tracts. These antimuscarinc/antispasmodic 
drugs may be useful as adjunctive treatment 
in non-ulcer dyspepsia, in the irritable 
bowel syndrome, and in diverticular 
disease. 
 
1)  Hyocine N-butyl Bromide P 
 
• DRUG SUMMARY: 
A quaternary ammonium compound, 
classified as an antimuscarinic/ anti-
cholinergic, antispasmodic agent. It is a 
more powerful suppressant of salivation 
than atropine, and usually slows rather than 
increases heart rate, especially in low 
doses. 
• INDICATIONS: 
Antispasmodic for GIT and UT disorders 
characterized by smooth muscle spasm.  
Also, can be used for motion sickness and 
dysmenorrhea.  
• CONTRAINDICATIONS: 
Hypersensitivity to the drug, narrow-angle 
glaucoma, prostatic hypertrophy, 
obstructive disease of the GI (i.e. paralytic 
illues, severe ulcerative colitis, pyloric 
obstruction), tachycardia, or myasthenia 
gravis. 
• DOSAGE FORMS:  
Tablets,  injection. 
• RECOMMENDED DOSAGE: 
Adult:  Orally: 20 mg 4 times daily. 
IM or IV (acute spasm): 20 mg, repeated 
after 30 min. if necessary 
Child (6-12 y):  10 mg PO t.i.d. 
 
Directions: Taken  30 to 60 min. a.c. 
• USE IN SPECIAL CASES:  
Pregnancy- Avoid use. Safety for use has not 
been established (Category C). Parenteral 
administration before onset of labor has 
caused CNS depression and hemorrhage in 
the neonate.   
Lactation- Better to avoid in nursing mothers 
as it is excreted in breast milk. Risk-benefit 
decisions must be considered.   
Children- Do not use in children less than 6 
years old. 
Renal Disease- Use with caution, drug is 
excreted in urine, bile and feces unchanged. 
Liver Disease- Use with caution, drug 
metabolized in the liver. 
• PRECAUTIONS AND WARNINGS:  
-Use in geriatrics: The elderly may respond 
to usual doses of the drug with excitement, 
agitation, drowsiness, or confusion. They 
are more susceptible to the antimuscarinic 
side effects. Also there is more incidence of 
glaucoma as well, so need to use caution 
when using this agent. 
-Use caution in urinary retention, prostatic 
enlargement, cardiac insufficiency, liver or 
kidney dysfunction. 
• ADVERSE EFFECTS: 
Confusion, blurred vision, (avoid perform-
ing hazardous activities until full effect of 
the medication is known); depression, 
psychotic reactions, constipation (patient 
should increase fluid intake), abdominal 
distension, urinary retention, dry skin, fever 
(specially children), dry mouth, difficulty in 
swallowing, palpitation, bradycardia. 
• INTERACTIONS:   
Overview of  Hyocine N-butyl Bromide 
Drug-Drug Interaction 
Drug Interaction 
Alcohol and 
other CNS 
depressants 
These have additive sedative 
effects if used with 
antispasmodics. Caution use. 
Antacids These will decrease absorp-
tion from the GI tract; allow  
2 h interval between the two 
medications. 
Anti-
histamines, 
Anti-
cholinergics, 
Pheno-
thiazine, 
and TCAs 
Concurrent use results in 
additive anticholinergic side 
effects. Avoid concurrent 
administration. 
Digoxin Increased digoxin level and 
toxicity have been noted.  Do 
not administer together. 
 
• OVERDOSE: 
Symptoms are exaggerated adverse effects.   
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Treatment includes inducing emesis or 
performing gastric lavage.  May administer 
activated charcoal after emesis. Use 
supportive and symptomatic therapy as 
needed in hospital setting. 
• BRANDS: 
Scobutyl (JePharm), Scopal (BPC). 
_________________________ 
 
 
C)  ANTIEMETICS 
 
Vomiting (emesis) is an important defense 
mechanism by which the body attempts to 
get rid of a variety of toxins and poisons. 
Travelling (motion sickness) or pregnancy 
can also cause vomiting.   
Antiemetics are useful in limited 
situations, but should always be used with 
caution because of the potential danger of 
masking the symptoms of more severe 
disease; i.e. acute viral gastroenteritis, head 
trauma, toxic ingestion, CNS infection, and 
GI obstruction, specially in children. They 
are also harmful in cases such as diabetic 
ketoacidosis, or in excessive digoxin or 
antiepileptic dosage. 
Therapy should start by identifying and 
removing the cause if possible, replacing 
fluids and electrolytes, counseling if there 
is a problem like bulimia, then starting drug 
therapy. Some medications that can be used 
include: prochlorperazine and haloperidol 
in severe cases, lorazepam to relieve 
anxiety related nausea and vomiting, 
antihistamines like promethazine and 
meclizine, and metoclopramide. The choice 
of which medication to use depends on the 
cause and the patient's health. 
Nausea and vomiting in pregnancy are 
common in the first trimester. It is 
recommended to use non-pharmacological 
approaches to the pregnant women before 
starting any medication. Eating small, 
frequent meals, lower the fat content of 
meals, ingesting crackers before arising in 
the morning, lying down, can all help to 
alleviate symptoms.  
If nausea and/or vomiting continue 
despite such measures or are severe, then 
an antihistamine like meclizine can be 
prescribed. If symptoms have not settled in 
24 to 48 hours, then a specialist’s opinion 
should be sought. 
 
 
1)  Metoclopramide WHO,P 
 
• DRUG SUMMARY: 
Metoclopramide (MTP) is a potent central 
dopamine receptor antagonist, classified as 
an autonomic nervous system agent; direct-
acting cholinergic, antiemetic and GI agent. 
Exact mechanism of action is not clear. It 
has a spectrum of activity similar to 
phenothiazines, but has less peripheral 
action on the gut in addition to its central 
effect. Therefore, it may be superior to the 
phenothiazines in the emesis associated 
with gastroduodenal, hepatic and biliary 
disease. It does not stimulate gastric, or 
pancreatic secretions. 
• INDICATIONS: 
Management of diabetic gastric stasis 
(gastroparesis), to prevent nausea and 
vomiting due to different etiologies; 
mainly in cancer chemotherapy, and in 
gastro-esophageal reflux, short term (4-12 
weeks).   
 
[For patients under 20 years; use is 
restricted to severe intractable vomiting of 
known cause, vomiting after radiotherapy 
and cytotoxics, and aid to gastrointestinal 
intubation, pre-medication:  BNF, 2001]. 
• CONTRAINDICATIONS: 
Sensitivity or intolerance to MTP, allergy 
to sulfiting agents, history of seizure 
disorders (epilepsy), concurrent use of 
drugs that can cause extrapyramidal 
symptoms, mechanical GI obstruction or 
perforation, history of breast cancer; pheo-
chromocytoma to avoid hypertensive crisis. 
• DOSAGE FORMS: 
Tablets, syrup. 
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• RECOMMENDED DOSAGE:  
Adult:  10-15 mg PO q.i.d.;  a.c. and h.s. 
Young adult (15-19 yrs under 60 kg):  
10 mg PO t.i.d., a.c. 
Child (6-14 y):  2.5-5 mg PO t.i.d.,  a.c.; 
max. dose for young adult and children 500 
ug/kg/d. 
Directions: Take medication 30 min. a.c. 
*Need to report any involuntary 
movement of eyes, face or limbs. Might 
need to discontinue MTP therapy. 
• USE IN SPECIAL CASES:  
Pregnancy- Use only when clearly needed 
and benefit outweighs potential risk. MTP 
crosses the placenta, however there are no 
adequate studies in pregnant woman 
(Category B), and reports on safety are 
conflicting. 
Lactation- Exercise caution. MTP is excreted 
into breast milk. There appears to be no 
serious risk to the nursing infant, but side 
effects may include intestinal discomfort and 
possible CNS effects.  
Children- Use caution, due to increased risk 
in children and young adults of extra-
pyramidal side effects (involuntary 
movements of limbs or facial muscles).  Limit 
use to severe or persistent vomiting of known 
etiology. 
Renal Disease- Reduce dose, and use with 
caution.  MTP is excreted in urine mainly. 
Liver Disease- Use with caution. The drug is 
minimally metabolized in the liver. 
• PRECAUTIONS AND WARNINGS:   
-Depression has occurred in patients with 
and without prior history of depression. Use 
only if the expected benefits outweigh the 
potential risks. 
-Carcinogenesis evidence has not been 
conclusive with MTP use. Elevated 
prolactin levels persist during therapy, and 
approximately 1/3 of human breast cancers 
are prolactin-dependent. Evaluate patient 
history carefully before prescribing. 
• ADVERSE EFFECTS: 
These are usually mild, transient and 
reversible upon drug withdrawal. Sedation, 
fatigue, restlessness, agitation, insomnia, 
extrapyramidal symptoms (especially in 
children/young adults), hypotension, 
nausea, diarrhea, sometimes constipation, 
dry mouth, galactorrhea, amenorrhea, 
impotence, methemoglobinemia, and 
altered drug absorption have been reported. 
• INTERACTIONS:   
Overview  of  Metoclopramide 
Drug-Drug Interaction 
Drug Interaction 
Alcohol Alcohol rate of absorption is 
increased by MTP, increasing 
side effects. Discourage 
patient from alcohol intake. 
Analgesics, 
and  
anti- 
cholinergics
These may antagonize effect 
of MTP on GI motility, and 
enhance effect of aspirin and 
paracetamol. 
Cyclosporine An increase in the immuno-
suppressive and toxic effects 
may result. Avoid use of 
MTP. 
Digoxin Plasma levels of digoxin may 
be decreased, decreasing its 
therapeutic effect. Monitor 
patients, the dose of digoxin 
may need to be increased. 
Pheno-
thiazines 
Extrapyramidal symptoms 
may occur. Do not administer 
concurrently. 
 
• OVERDOSE: 
Symptoms: drowsiness, disorientation, and 
extrapyramidal reactions which are self 
limiting and usually disappear within 24 h. 
Muscle hypertonia, irritability and agitation 
are common.   
Treatment: an anticholinergic or anti-
parkinson drug to help control 
extrapyramidal reaction. Refer to hospital 
for management. 
• BRANDS: 
Emestop (BPC), Novomit (JePharm), Pramin 
(Rekah), Reglan (Robins). 
____________________________ 
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2)  Meclozine/Meclizine 
 
• DRUG SUMMARY: 
A long-acting piperazine antihistamine. 
Classified as a H1-receptor antagonist, GI 
agent, antihistamine and antiemetic agent.  
• INDICATIONS: 
Prevention and treatment of nausea, 
vomiting and dizziness (also in pregnancy) 
and/or motion sickness. Can also be used 
for the management of vertigo associated 
with diseases affecting the vestibular 
system. 
• CONTRAINDICATIONS: 
Hypersensitivity to the medication. 
• DOSAGE FORMS:  
Tablets. 
• RECOMMENDED DOSAGE: 
Adult: For Motion Sickness; 
25-50 mg PO 1 h. before travel, may repeat 
q. 24 h. if necessary for duration of journey. 
For Vertigo Problems; 
25-100 mg/d in divided doses (b.i.d.). 
Child: Not recommended for children 
under 12 years. 
 
Directions: Meclizine can be given without 
regard to meals. Onset of action takes 1 h., 
while duration is for 12-24 h. 
*Pyridoxine (vitamin B6) has been shown 
to be effective in treatment of nausea and 
vomiting associated with pregnancy. So 
you might find it in some formulations as a 
combination with meclizine. 
• USE IN SPECIAL CASES:  
Pregnancy- Use only when clearly needed. 
Meclizine presents the lowest risk of 
teratogenicity, and is the drug of choice in 
treating nausea and vomiting during 
pregnancy (Category B). Large-scale human 
studies have not demonstrated teratogenic 
effects.  
Lactation- Safety for use in nursing mothers 
has not been established. There is no 
available data. 
Children- Safety and efficacy for use in 
children have not been established. Not 
recommended for use in children < 12 years 
(Drug Facts & Comparisons, 2000). 
Renal + Liver Disease- Use with caution. 
Safety has not been established.  
• PRECAUTIONS AND WARNINGS:   
-Due to possible anticholinergic effects, use 
caution in patients with glaucoma, 
obstructive disease of the GI or GU, and in 
elderly males with possible prostatic 
hypertrophy.  
• ADVERSE EFFECTS: 
Drowsiness, dry mouth, blurred vision, and 
fatigue. (Warn patient against performing 
hazardous activities like driving or 
operating machinery until the full effect of 
the medication is known.)   
• INTERACTIONS:   
Alcohol and other CNS depressants will 
enhance side effects. Avoid concomitant 
use. 
• OVERDOSE: 
Symptoms: Moderate overdose may cause 
hyperexcitability alternating with drowsi-
ness. Massive overdose may cause 
convulsions, hallucinations and respiratory 
paralysis. 
Treatment: Inducing emesis, and 
performing gastric lavage. Take to hospital, 
do not use morphine or other respiratory 
depressants. 
• BRANDS: 
Ancozine (BPC), Antivert (Roerig), Bonine 
(Leeming), Paravomine (JCL). 
________________ 
 
 
D)  DRUGS USED IN DIARRHEA 
 
Diarrhea is a symptom that is characterized 
by an increased frequency or consistency of 
stools during a limited time period. 
Epidemiological studies define it as the 
passage of three or more loose or watery 
stools in a 24 hour period, a loose stool 
being that would take the shape of a 
container. Variability in the causes of 
diarrhea makes identification of the 
pathophysiologic mechanism difficult. The 
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etiology may be psychogenic, neurogenic, 
surgical, endocrine, irritant, dietary, allergic, 
malabsortpive, infectious or inflammatory.  
Simple and effective treatment measures 
are available that can markedly reduce the 
number of deaths caused by diarrhea, make 
admission to the hospital unnecessary in 
most cases and prevent the adverse effects 
of diarrhea on nutritional status. Practical 
preventive measures can also be taken that 
substantially reduce the incidence and 
severity of diarrheal episodes. 
It is important to know that passing 
several loose stools daily or with every 
feeding in breast-fed infants is normal 
provided that the infant is steadily gaining 
weight. Mothers should be reassured that 
the infant doesn’t need treatment, and 
should continue breast-feeding. 
 
Causes of Diarrhea:  
1. Food-borne diarrhea: Table-3.3 sum-
marizes the most common pathogenic 
bacteria. Infectious diarrhea may be treated 
with fluid and electrolytes, since it is self-
limiting. Only in certain cases initiation of 
antimicrobial therapy may be necessary;  
i.e. doxycycline, trimethoprim/ sulfa-
methoxazole, or a fluoroquinolone.  
2. Remember that antimicrobial drugs 
are not indicated for the routine treatment 
of acute diarrhea. Their indiscriminate use 
must be discouraged, not only because they 
are often of no therapeutic value, but also 
they are needlessly expensive and can be 
harmful. 
3.  Food intolerance:  It may be caused 
by a food allergy, or by ingestion of foods 
that are excessively fatty or spicy that 
contain high amount of roughage or many 
seeds.  Need to advise patient to monitor 
the cause, and to avoid.  Lactose deficiency 
in infants or adults who develop intolerance 
to whole milk or milk-based products, can 
reduce/ eliminate their problem by intake of 
lactase enzyme. 
4. Viral diarrhea is a common problem 
in infants and young children. Children 
aged 6-24 months are most susceptible to 
viral gastro-enteritis. Respiratory illness 
such as otitis media or tonsillitis may occur 
concurrently.  
During the 12-24 hour incubation period 
vomiting, watery diarrhea and low-grade 
fever may occur. The illness tends to be 
self-limiting, lasting 5-8 days, and 
treatment should be restricted to 
symptomatic therapy, mainly to prevent 
dehydration complications. 
5. Protozoal diarrhea, table-3.4 summa-
rizes the main protazoal organisms. 
Effective therapy consists of metronidazole, 
after the confirmation of the causing agent 
by stool analysis. 
6.  Drug-induced diarrhea can occur 
with administration of medication. 
Commonly prescribed antibiotics that have 
a broad spectrum of activity; i.e. ampicillin, 
clindamycin, erythromycin, tetracycline, 
and fluoroquinolones can produce diarrhea 
as a side effect.  Other drugs that may cause 
diarrhea and cramping include; stimulant 
cathartics, anticancer agents, colchicine, 
antacid containing magnesium, methyldopa 
and metoclopramide. If diarrhea does not 
subside within few days of starting any 
medication, reduction of the dose might be 
necessary. 
Gastrointestinal Drugs 
 
 65
 
Table- 3.3:  Summary of the Most Common Pathogenic Bacteria # 
Type  History Symptoms Treatment Prognosis 
Salmonella spp. Ingestion of 
improperly cooked or 
refrigerated poultry 
products, immuno-
compromised host. 
Onset of  24-28 h, 
diarrhea, fever, 
and chills 
Fluid and electrolytes;  
no antibiotics needed 
Self-
limiting 
Shigella spp. Ingestion of 
contaminated 
vegetables or water, 
immunocompromised 
host. 
Onset of  24-48 h, 
nausea, vomiting, 
diarrhea 
Fluid and electrolytes; 
antibiotics 
(cotrimoxazole, 
ampicillin, 
ciprofloxacin) 
Self-
limiting 
Enterotoxigenic 
Escberichea 
coli (Travelers’ 
diarrhea) 
Ingestion of 
contaminated food or 
water, recent travel 
outside the country. 
Onset of  8-72 h, 
watery diarrhea, 
fever, abdominal 
cramps 
Fluid and electrolytes; 
in moderate or severe 
cases, antibiotics; 
(fluoroquinolones) 
Self-
limiting 
Campylobacter 
jejuni 
Ingestion of 
contaminated water, 
fecal-oral route, 
immunocompromised 
host. 
Nausea, 
vomiting, 
headache, 
malaise, fever, 
watery diarrhea 
Fluid and electrolytes;  
in severe or persistent 
diarrhea, antibiotics 
(erythromycin, 
fluoroquinolones) 
Self-
limiting 
Clostridium 
difficile 
Antibiotic-associated 
diarrhea. 
Watery or 
mucoid diarrhea, 
high fever, 
cramping 
Water and electrolytes; 
discontinuation of 
offending agent;   oral 
vancomycin, oral 
metronidazole, 
bacitracin, 
cholestyramine 
Good, if 
treated 
Staphylococcus 
aureus 
Ingestion of 
improperly cooked or 
stored food. 
Nausea, vomiting, 
watery diarrhea 
Fluid and electrolyte;  
no antibiotics 
Self-
limiting 
# Handbook of Nonprescription Drugs, 10th ed., 1993: p. 204-5. 
 
Table-3.4:  Summary of Protozoa Organisms that Cause Diarrhoea # 
Type  History Symptoms Treatment Prognosis 
Giardia 
lamblia 
Ingestion of water 
contaminated with 
human or animal 
feces, immuno-
compromised host 
Chronic watery 
diarrhea, abdominal 
distension 
Metronidazole, 
furazolidone 
Good, if treated 
Cryptosporidia  
Contaminated water, 
AIDS, 
immunocomp-
romised host 
Chronic watery 
diarrhea 
Fluid and 
electrolytes 
Self-limiting, 
except in AIDS 
or other 
immunocomp-
romised patients 
Entamoeba 
histolytica 
Fecal soiled food or 
water, 
immunocomp-
romised host 
Chronic watery 
diarrhea, blood 
mucous, abdominal 
cramps, maybe fever 
Fluid and 
electrolytes; 
metronidazole; 
iodoquinol 
Need stool 
culture to 
confirm. Good, 
except for 
immunocomp-
romised patients 
# Handbook of Nonprescription Drugs, 10th ed., 1993: p. 204-5.
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1)  Oral Rehydrating Salts WHO,P 
 (ORS) 
 
• DRUG SUMMARY: 
Oral Rehydrating Salt (ORS) solutions are 
the first line treatment in acute diarrhea, 
especially in infants and in frail/elderly 
patients. They are a simple and effective 
way to markedly reduce the number of 
deaths caused by diarrhea. ORS are 
balanced mixtures of glucose and 
electrolytes. Intestinal absorption of sodium 
and water is enhanced by glucose, to 
replace what has been lost through diarrhea, 
and restore acid-base balance.  
The WHO criteria for an oral replacement 
fluid contains (per liter)  
*Total substance concentration (including 
that contributed by glucose) should be 
within the range of 200-310 mmol/l. 
* The individual substance concentration: 
- Glucose - should at least equal that of Na 
but should not exceed 111 mmol/l 
- Sodium - should be within the range of 
60-90 mEq/l 
- Potassium - should be within the range 
of 15-25 mEq/l 
- Citrate - should be within the range of  
8-12 mmol/l 
- Chloride - should be within the range of 
50-80 mEq/l. 
 
No commercial product currently available 
strictly fulfils WHO recommendation. Still, 
available products are more convenient and 
seem to be potentially safer because they 
are premixed and there is less chance of 
error in preparation. 
• INDICATIONS: 
To prevent dehydration in cases of electro-
lyte and water depletion as in diarrhea or 
vomiting. Severe cases need hospitalization 
and require parenteral therapy. 
• CONTRAINDICATIONS: 
None;  see warnings. 
• DOSAGE FORMS:  
Packages to be dissolved in certain amount 
of water as directed. 
• RECOMMENDED DOSAGE: 
Mild/Moderate Diarrhea (not more than 
one stool q. 2 h. or longer): 
100 ml/kg body weight per day until 
diarrhea stops. 
Severe Diarrhea    (more than one stool 
q. 2 h.):  10-15 ml/kg body weight per hour, 
until diarrhea stops. 
 
Directions: Need to dissolve package in 
required amount of water. Do not add sugar 
or boil after mixing. The prepared solution 
should be discarded after 24 hours, and 
replaced with a fresh one to avoid spoilage. 
*Drink slowly, small amount initially 
especially if vomiting is present.  
*Administering fluid without electrolytes is 
potentially dangerous because of the risk of 
inducing hyponatremia. 
• USE IN SPECIAL CASES: 
Pregnancy- Use caution, might need to refer 
to hospital for monitoring. 
Lactation- Safe if taken for short period of 
time as directed. 
Children- Safe when used according to 
directions and under supervision as indicated 
for use. 
Renal Disease- Warning. Special care is 
needed during usage because electrolyte or 
fluid imbalances might be aggravated if 
kidney is malfunctioning.   
Liver Disease- Use with caution.   
• PRECAUTIONS AND WARNINGS:   
-Severe continuing diarrhea or other critical 
fluid loss such as intractable vomiting, 
prolonged shock, should be referred to 
hospital, and will require parenteral 
therapy. 
-Use caution in patients with diabetes, 
cardiac failure, hypertension (specially 
patients on low sodium diet), impaired 
renal function and in peripheral or 
pulmonary edema. Such solutions will 
aggravate their condition. 
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• ADVERSE EFFECTS:  
Dizziness, nausea, or skin rash may occur. 
Vomiting may occur if the solution is given 
too rapidly or forcefully to the infant. 
• INTERACTIONS: 
Electrolytes affect a lot of medications 
when given concomitantly. It is advisable 
not to take any medication the same time as 
the preparation, unless clearly needed and 
under direct supervision of doctor. 
• OVERDOSE: 
Serious electrolyte disturbances will occur 
if there is an ingestion of large amount of 
preparation; due to the electrolytes (Na & 
K) included. Cardiac and respiratory 
functions could be serious. Refer to hospital 
for symptomatic and supportive care. 
• BRANDS: 
Electrosubs (BPC), Hydran 60 (Teva), Orset 
L.S. (Ciba), ORS (UNICEF), Rehidrat (Searle). 
____________________________ 
 
2)  Antidiarrheal Agent -  
Loperamide  P 
 
• DRUG SUMMARY: 
Loperamide is a synthetic piperidine 
derivative, chemically related to 
diphenoxylate and to meperidine, but 
possesses a more favorable side effects 
profile than the opiate and opiate-like 
agents. Classified as a GI, antidiarrheal 
agent. It slows intestinal motility and 
affects water and electrolyte movement 
through the bowel. It inhibits peristalsis, 
prolongs transit time of intestinal contents, 
increases consistency of stools, and reduces 
fluid and electrolyte loss. Tolerance to the 
antidiarrheal effect has not been observed. 
• INDICATIONS: 
Acute non-specific diarrhea, chronic 
diarrhea associated with inflammatory 
bowel disease, and to reduce fecal volume 
from ileostomies. 
• CONTRAINDICATIONS: 
Hypersensitivity to the drug, in patients 
who must avoid constipation, severe colitis, 
acute diarrhea caused by broad spectrum 
antibiotics or associated with micro-
organisms, body temperature > 38.3 °C, 
and bloody diarrhea, in children < 4 years. 
• DOSAGE FORMS: 
Capsules, drops. 
• RECOMMENDED DOSAGE: 
Adult: For Acute Diarrhea; 
4 mg followed by 2 mg after each loose 
stool, for not more than 5 days, 
usual dose 6-8 mg/d, max. 16 mg daily. 
For Chronic Diarrhea; 
4 mg PO followed by 2 mg after each loose 
stool until diarrhea is controlled. Continue 
administration if diarrhea cannot be 
controlled with diet or specific treatment. 
Child:  Do not use for children < 4 y old.   
If oral rehydration solutions fail, can 
administer 0.1 mg/kg after each loose stool, 
usually 1 mg for acute diarrhea, for not 
more than 2 days. 
Directions: Loperamide is administered 
after each unformed stool, up to a 
maximum of 16 mg/d for adults. 
*Include appropriate fluid and electrolyte 
therapy to prevent dehydration and further 
complications. Advise patient to drink 
plenty of fluids. 
*In acute diarrhea, loperamide should be 
discontinued if there is no improvement 
after 48 hrs. of therapy. 
*The doctor should be notified if 
abdominal pain or distention, or fever 
occurs. Discontinuation of the medication 
may be needed. 
• USE IN SPECIAL CASES:  
Pregnancy- Avoid use of Loperamide. No 
available well controlled studies on pregnant 
women. Safety has not been established 
(Category B). 
Lactation- It is not known if loperamide is 
excreted in breast milk. Safety has not been 
established. 
Children- Not to be used in children < 4 yrs. 
Use special care if you have to use for young 
children (6-12 yrs). Rehydration is usually 
sufficient. 
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Renal Disease- The drug is primarily excreted 
in feces. Small amounts are excreted by the 
kidneys, thus use caution. 
Liver Disease- Warning. Patients with hepatic 
dysfunction have reported increased CNS 
toxicity because of large first-pass bio-
transformation. Avoid use unless clearly 
needed.  
• PRECAUTIONS AND WARNINGS:   
-Antiperistaltic agents should not be used in 
acute diarrhea associated with organisms 
that penetrate the intestinal mucus (tissue 
invasive); entroinvasive E-coli, salmonella, 
or shigella; or in pseudomembranous colitis 
associated with broad-spectrum antibiotics. 
-If clinical improvement of acute diarrhea 
is not observed in 48 hours, or abdominal 
distension occurs, discontinue the 
medication. Recommended dosage should 
not be exceeded. 
• ADVERSE EFFECTS: 
Adverse experiences are generally minor 
and self-limiting. Drowsiness, fatigue 
dizziness are reported, therefore; need to 
caution patient while driving or performing 
hazardous jobs. Abdominal discomfort or 
pain, bloating, constipation, nausea, 
anorexia, dry mouth can also occur; patient 
should drink plenty of fluids to help prevent 
dehydration. May cause skin rash. In severe 
cases toxic megacolon (mainly in patients 
with ulcerative colitis) may occur. 
• INTERACTIONS: 
No major drug-drug interactions reported. 
• OVERDOSE: 
Symptoms: usually include constipation, 
CNS depression and GI irritation. Nausea 
and vomiting may occur.   
Treatment: activated charcoal administered 
promptly after ingestion can reduce amount 
of drug absorbed into systemic circulation. 
Take to hospital for supportive, 
symptomatic management. 
• BRANDS: 
Diacare (Pharmacare), Imodium (Janssen), 
Lipastop (Eastern Chem.), Loperid (Vitamid), 
Stopit (Rafa). 
_________________________ 
E)  LAXATIVES 
 
Constipation is generally defined as a 
decrease in the frequency of fecal 
elimination and is characterized by the 
difficult passage of hard, dry stools. (In 
other words incomplete evacuation or 
feeling of it.) It usually results from the 
abnormally slow movement of feces 
through the colon with a resultant 
accumulation in the descending colon, and 
increased water resorption. In elderly 
persons, constipation occurs due to 
inappropriate diet, lack of exercise, 
medication use, or lack of muscle tone in 
the colon. Constipation in pregnancy is also 
common, due to increasing size of uterus, 
or intake of mineral supplements that 
contain iron and calcium that tend to be 
constipating.  
Patients should be counseled about non-
pharmacological methods before a drug is 
prescribed; proper diet, adequate fluid 
intake (6-8 glasses/day) and reasonable 
exercise to alleviate or prevent this 
problem. If the patient is still constipated, 
and the constipation is not secondary to an 
underlying undiagnosed complaint, a 
laxative may be used. The laxative 
facilitates the passage and the elimination 
of feces from the colon and rectum. In 
children, the introduction of fruit and 
vegetable puree into the diet may be 
sufficient to regulate bowel action. 
Persistent constipation should be fully 
investigated.  
Abuse of laxatives may lead to 
hypokalemia and an atonic non-functioning 
colon. It is important to recognize that the 
improved mobility and the provision of 
time and privacy for going to the toilet may 
be all that is required. 
Laxatives are classified into different 
categories. Table-3.5 indicates the 
properties of each type: 
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Table-3.5:  Classification and Properties of Laxatives1 
Laxatives Onset of Action (hrs) 
Site of  
Action 
Systemic 
Absorption Use in Pregnancy 
Sa
lin
e 
Magnesium citrate 
Magnesium-OH 
Magnesium  SO4 
3 
----------------------- 
Na-biphosphate 
0.5 - 3 
 
2-4 
--------------- 
0.03 - 0.25 2 
Small & large 
intestine 
 
----------------- 
Colon 
 
Yes Avoid, possible 
dangerous 
electrolyte 
imbalances. 
Ir
rit
an
t/s
tim
ul
an
t 
Cascara 
Senna 
Phenolphthalein  
Biscodyl tabs. 
----------------------- 
Biscodyl supp. 
----------------------- 
Castor oil 
 
 
6 - 10 
 
--------------- 
0.25 - 1 
--------------- 
2 - 6 
 
 
Colon 
 
 
 
----------------- 
Small 
intestines 
 
 
Yes 
 
 
 
------------- 
Yes 
 
 
Avoid, unless under 
direct M.D. 
supervision. 
 
----------------------- 
Avoid, premature 
labor. 
B
ul
k-
fo
rm
in
g 
Bran 
Methylcellulose 
Polycarbophil 
Psyllium 
 
12-24 
(up to 72) 
 
Small & large 
intestine 
 
No 
 
Safe 
   
Lu
br
ic
an
t 
Mineral oil 
(Liquid parafin) 6 - 8 
 
Colon 
Yes, 
minimal 
amount 
Do not use for long 
time, loss of vitamin 
absorption. 
Su
rf
ac
ta
nt
  
Docusate 
 
 
24 - 72 Small & large intestine Yes 
OK.  
Best in anorectal 
painful-conditions. 
M
is
c.
 Glycerin supp. 
----------------------- 
 
Lactulose 
0.25 - 0.5 
--------------- 
 
24 - 48 
Colon 
? 
----------- 
 
È amount 
Caution use. 
 
-1 Reference: Drug Facts and Comparisons.  2000, p. 1166. 
-2 2-15 minutes. 
-3 Magnesium sulphate (Epsom salt) is available in packs. Dissolve in water and use before breakfast. 
-Stimulant laxatives should not be used regularly. If obstruction is suspected, do not use laxative. 
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1)  Bisacodyl  P 
 
• DRUG SUMMARY: 
A stimulant laxative, GI agent. Induces 
peristaltic contractions by direct stimulation 
of sensory nerve endings in the colonic 
walls. It also expands intraluminal fluid 
volume by increasing epithelial 
permeability.   
• INDICATIONS: 
Temporary relief of acute constipation and 
for evacuation of colon before surgery, or 
radiological examinations. Also used to 
empty colon before delivery and to relieve 
constipation in patients with spinal cord 
injury. 
• CONTRAINDICATIONS: 
Hypersensitivity to the drug. Acute surgical 
abdomen, nausea, vomiting, abdominal 
cramps, intestinal obstruction, fecal 
impaction, ulcerative lesions of the colon. 
Use of rectal suppository in presence of 
anal or rectal fissures, or ulcerated 
hemorrhoids.  
• DOSAGE FORMS: 
Tablets, suppositories. 
• RECOMMENDED DOSAGE: 
Adult: 5-15 mg PO p.r.n. up to 30 mg for 
special procedures. 
10 mg PR once daily p.r.n. 
Child (6 to 12 y):  5 mg PO or PR p.r.n. 
Directions: Administer PO drug in the 
evening or before breakfast. Suppository 
may be inserted at time bowel movement is 
desired. 
*Tablets are enteric coated, therefore, to 
avoid gastric irritation, they should be 
swallowed whole, and not cut, crushed or 
chewed. They are preferably taken with a 
full glass of water or other liquid. 
*Advise patient not to take medication 
within 1 hour of antacids or milk 
administration. These substances may cause 
premature dissolution of the enteric coating, 
resulting in gastric irritation. 
• USE IN SPECIAL CASES:  
Pregnancy- Avoid use (Category C). Bulk 
forming or surfactant laxatives are a better 
choice.  
Lactation- Better to avoid. Excreted in small 
amounts in breast milk. 
Children- Avoid use in children < 6 years 
old. Safety has not been established. Other 
agents may be safer for use. 
Renal Disease- Use with caution. Drug is 
excreted in urine.  
Liver Disease- Use with caution. Drug is 
metabolized in the liver. 
• PRECAUTIONS AND WARNINGS: 
-Abuse/dependency; chronic use of 
stimulant laxatives such as bisacodyl, may 
lead to laxative dependence, which in turn 
may result in fluid and electrolyte 
imbalances, osteomalacia, vitamin and 
mineral deficiencies. Use not recommended 
for long term ( > 1 week). 
• ADVERSE EFFECTS: 
Systemic effects not reported. Rarely: mild 
cramping, nausea, vertigo, diarrhea, fluid 
and electrolyte disturbances; especially 
potassium and calcium. Suppositories may 
cause proctitis (inflammation of rectum). 
• INTERACTIONS: 
Milk and Antacids cause early dissolution 
of enteric-coated tablets, resulting in 
abdominal cramping. Do not use within 1 h 
of antacid intake. 
• OVERDOSE: 
There is no specific antidote, however, 
supportive care may be required to prevent 
dehydration or electrolyte imbalances. 
• BRANDS: 
Bisalax (JCL), Laxadin (Teva). 
____________________________ 
 
2)  Castor Oil 
 
• DRUG SUMMARY: 
Castor oil is also a stimulant laxative GI 
agent.  Indicated for constipation; bowel 
evacuation before radiological procedures, 
endoscopy or surgery. It is one of the 
Gastrointestinal Drugs 
 
 71
widely abused laxatives, and should be 
seldom used routinely for constipation.   
It is contraindicated in abdominal pain, 
intestinal obstruction, nausea or vomiting. 
Should be avoided during pregnancy, since 
it provokes premature labor. It should not 
be used for more than one week of regular 
therapy. Chronic abuse may lead to 
“cathartic colon”, a poorly functioning 
colon.  
Misuse may lead to severe cramping, 
enteric loss of protein, excess loss of fluid 
and electrolytes, and inhibition or 
absorption of fat-soluble vitamins. 
Dose ranges for adults:  15-60 ml/day. 
Children (2-12):  5-15 ml/day. 
It is most effective when given on empty 
stomach, and produces evacuation within 2-
6 hours after ingestion. It should not be 
given at bedtime. Can be given with fruit 
juice to mask the unpleasant taste. 
__________________________ 
 
3)  Glycerin  P 
 
• DRUG SUMMARY: 
A GI agent; hyperosomotic laxative. It 
produces an irritant effect, and by 
absorbing water from tissues it creates 
more mass, therefore stimulates peristalsis. 
• INDICATIONS: 
To relieve constipation.  
• CONTRAINDICATIONS: 
Hypersensitivity to the drug. 
• DOSAGE FORMS: 
Adult and pediatric suppositories. 
• RECOMMENDED DOSAGE: 
Adult:  For Constipation; 
1 supp. when needed, inserted high into the 
rectum. 
Child:  1 supp. when needed. 
Directions:  Insert suppository high into the 
rectum and retain 15 minutes. Onset 
requires 15-30 minutes. 
*Store in cool place, preferably the 
refrigerator. 
• SPECIAL CASES:  
Pregnancy- Use with caution. Only use if 
under medical supervision. It is safer to use 
bulk forming agents or surfactants when 
needed. 
Lactation- It is not known whether glycerin 
used rectally is excreted into breast milk. 
Safety not established, since there is no 
available data.  
Children- Glycerin suppositories are used in 
children and infants often to initiate 
defecation. Adverse effects are minimal.  
• PRECAUTIONS AND WARNINGS: 
-Laxative use should only be used 
temporarily. 
• ADVERSE EFFECTS:  
Abdominal cramps, rectal discomfort. 
• INTERACTIONS: 
No drug-drug interactions have been 
reported. 
• BRANDS: 
Glycerol (various). 
_________________________ 
 
4)  Psyllium 
 
• DRUG SUMMARY: 
A bulk-forming laxative, GI agent. Usually 
seen as a highly refined colloid of blond 
psyllium seed with equal amount of 
dextrose added as dispersing agent. On 
contact with water, produces bland, 
lubricating gelatinous bulk that promotes 
peristalsis and natural elimination. 
Reportedly, chronic use may reduce plasma 
cholesterol, possibly by interfering with 
reabsorption of bile acids. 
• INDICATIONS: 
Orally as self-treatment of constipation. For 
atonic or spastic constipation and 
constipation associated with rectal 
disorders of anorectal surgery, irritable 
bowel disease and hemorrhoids. 
• CONTRAINDICATIONS: 
In nausea, vomiting, undiagnosed 
abdominal pain, intestinal obstruction, 
appendicitis, ulceration or stenosis, and 
diarrhea. 
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• DOSAGE FORMS:  
Powder. 
• RECOMMENDED DOSAGE: 
Adult: 1-2 rounded tsp.  or  1 packet 1-3 
times/d. 
Child ( ≥ 6 y): 1 tsp. in water h.s. 
 
Directions: Need to stir dose into a full 
glass (240 ml) of water, fruit juice or other 
liquid, and drink.  
*Additional fluids should be taken during 
the day, fecal impaction can occur if fluid 
intake by mouth is insufficient. 
*Drug may reduce appetite if it is taken 
before meals. 
*Laxative effect generally occurs in 12-24 
hours, however some patients may require 
2-3 days of medication; inform patient.  
*NOTE: if there is discomfort or abdominal 
fullness, patients should take smaller doses.   
• USE IN SPECIAL CASES:  
Pregnancy- Bulk-forming laxatives seem to 
be the safest laxatives to use during 
pregnancy. There are no well-controlled 
studies in pregnant women. 
Lactation- Generally safe.   
Children- Laxative use in children should not 
be encouraged. Psyllium preparations might 
not be acceptable by children due to taste or 
form. Increasing both fluid and bulk contents 
of the child’s diet are usually sufficient to 
improve bowel habits. High fiber cereal, 
vegetables and fruits should be enough. 
Unbuttered popcorn is a good bulk-containing 
snack for children. 
Renal or Liver Disease- Safe when used 
properly without abuse.  
• PRECAUTIONS AND WARNINGS: 
-Impaction or obstruction may be caused by 
bulk-forming agents, if patient does not 
drink sufficient fluids, or has an obstructive 
problem in the GI passage. 
-Rectal bleeding or failure to respond to 
therapy may indicate a serious condition 
that requires further medical attention. 
• ADVERSE EFFECTS:  
Diarrhea, nausea, fecal impaction, 
esophageal obstruction. 
• INTERACTIONS:   
None has been reported. 
• OVERDOSE: 
No reported cases.  Need supportive care to 
prevent obstruction or impaction. 
• BRANDS:  
Metamucil (Searle). 
_______________ 
 
F)  ANTI-HEMORRHOIDAL 
 
Hemorrhoids (also known as piles) are 
abnormally large bulging, symptomatic 
conglomerates of veins, supporting tissue, 
and overlying mucous membranes or skin 
of the anorectal area. They are classified as 
external (occur below the anorectal line) or 
internal (occur above the anorectal line). 
Many factors have been implicated in 
the etiology of hemorrhoidal disease, such 
as: heredity, erect posture, pregnancy, pro-
longed standing, lack of dietary bulk, heavy 
lifting, constipation, portal hypertension, 
pelvic tumors and anal infections. 
Symptoms include burning sensation, 
pain, itching, inflammation, irritation, 
swelling in the anorectal region and general 
discomfort. Some potentially serious 
anorectal disorders, including fissures, 
fistulas, inflammatory bowel disease and 
tumors may present hemorrhoidal like 
symptoms and should be taken seriously by 
the physician.  
Pharmacological agents recommended 
to relieve symptoms of anorectal disease 
include; 
1) Local Anesthetics: Temporarily relieve 
pain, burning, itching, and irritation by 
preventing transmission of nerve impulses.  
Examples; Benzocaine 5-20 %, benzyl 
alcohol 5-20 %, dibucaine 0.25-1 %, and 
lidocaine 2-5 %. 
 
2) Vasoconstrictors: They cause constric-
tion of arterioles, shrink swollen hemor-
rhoidal tissue a little, as well as relieve 
some itching. [These need to be avoided in 
patients with diabetes, hyperthyroidism, 
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hypertension, prostatic enlargement, 
cardiovascular disease, and patients taking 
MAO Inhibitors]. Examples; aqueous 
solution of ephedrine sulfate, epinephrine, 
phenylephrine and epinephrine base. 
 
3) Protectants: These prevent irritation of 
the anorectal area, and water loss from the 
stratum corneum. Examples; Aluminium 
hydroxide gel, cocoa butter, glycerine in 
aqueous solution, mineral oil, white 
petrolatum. 
 
4) Astringents: They provide relief from 
local anorectal irritation and inflammation. 
Examples; Calamine and zinc oxide in 
concentrations of 5-25 %. 
 
5) Hydrocortisone: Reduce itching, 
inflammation, and discomfort by producing 
vasoconstriction, lysosomal membrane 
stabilization and antimiotic activity. 
Topical hydrocortisone-containing products 
are indicated for temporary relief of minor 
external anal itching due to minor irritation 
or rash. 
6) Other agents that may be used include: 
counter irritants (camphor, menthol), 
wound healers (Peruvian balsam, vitamin 
A, vitamin D), antiseptics (boric acid, 
phenol, sodium salicylic acid) and bulk 
forming laxatives (to relief constipation 
contributing to hemorrhoids). These agents 
have not been proven to be safe or effective 
for hemorrhoidal preparations. 
 
For intra-rectal use, the only approved 
ingredients are protectants, vaso-
constrictors, and astringents.   
As a general rule, products containing 
the least number of recommended 
ingredients are the best, since you minimize 
undesirable interactions and maximize 
effectiveness. Scented or tinted products 
used, (whether preparations or toilet paper) 
should be avoided, since they can cause 
allergic reactions. 
The importance of maintaining normal 
bowel function by eating properly, drinking 
adequate amount of fluids, avoiding 
excessive laxative use, as well as proper 
anal hygiene should be emphasized as a 
way of preventing anorectal disease. 
 
 
1)  Anusol (or other equivalent 
preparation WHO,P) 
 
• DRUG SUMMARY: 
This antihemorrhoidal preparation contains 
an astringent (Phenylephrine HCl 0.25%), a 
protector (vegetable oil base) in suppository 
form. Ointment contains; an anesthetic 
(pramoxine HCl 1%), astringents (zinc 
oxide 12.5% + balsam nicarague 3.0%), as 
well as mineral oil.  Anusol helps to relieve 
pain, itching and discomfort arising from 
irritated anorectal tissue.  
• INDICATIONS: 
Hemorrhoids. 
• CONTRAINDICATIONS: 
History of hypersensitivity to product. 
• DOSAGE FORMS: 
Suppository, ointment. 
• RECOMMENDED DOSAGE: 
Adults:  Apply small amount of ointment 
at night and morning, and after defecation.   
Insert suppository up the anus after 
defecation and at bedtime. 
Directions: For maximum effect, anorectal 
products should be used after, rather than 
before defecation. 
*Before the product is applied, the 
anorectal area should be washed with mild 
soap and warm water, rinsed thoroughly, 
and gently dried by patting or blotting with 
toilet tissue or a soft cloth.  Proper anal 
hygiene is very important to emphasize to 
patients. 
*Suppository should be inserted into 
rectum, while ointments should only be 
used externally and applied sparingly. 
*If hypersensitivity reactions occur, 
seepage, bleeding, severe pain resulting 
from the medication, or symptoms worsen 
or do not improve after 7 days of treatment, 
discontinue use. May need further 
evaluation or a different product. 
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• USE IN SPECIAL CASES:  
Pregnant + Lactating women- only use 
products for external use.   
Children- Safety and efficacy has not been 
established. Children with hemorrhoids or 
other anorectal disease should be evaluated 
for cause, and treated accordingly. Use of 
local anesthetic should be only for short 
time (no longer than 3-4 days), since may 
cause sensitization of the anal skin.  
• PRECAUTIONS AND WARNINGS: 
-Approved ingredients for intra-rectal use 
are vasoconstrictors, protectant and astrin-
gents. Other ingredients might cause 
irritation to the inner mucosa. 
-Vasoconstrictors should be avoided in 
patients who have diabetes, hyper-
thyroidism, hypertension, difficulty in 
urination due to prostate enlargement, 
cardiovascular diseases, and in those 
patients who are taking monoamine oxidase 
inhibitors. Topical anorectal products 
containing ephedrine sulphate may cause 
nervousness, tremor, sleeplessness, nausea, 
and loss of appetite. 
-In case of local infection, treat with an 
appropriate antibiotic.  
• ADVERSE EFFECTS: 
Hypersensitivity reactions manifested by 
local redness, skin irritation, and rash. 
• BRANDS:  
Anusol (Park Davis), Hemoral H.C. (JCL), 
Procyoxylene (BCP). 
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RESPIRATORY DISORDERS  
Diseases of the respiratory tract may be due 
to viruses, bacterial infections, allergens … 
etc. causing common cold, allergic rhinitis, 
upper respiratory tract infections and 
asthma. For the proper diagnosis, the doctor 
should be able to differentiate between 
these disorders (bacterial vs. viral 
infections, or allergy vs. asthma) so that the 
minor self-limiting conditions can be 
managed differently from the potentially 
serious ones that need immediate action.  
The common cold is one of the most 
common causes for which patient seek 
medication. The course of the symptoms is 
5-7 days, if no complications occur, and the 
disease is self-limiting since there are no 
curative remedies. Influenza A may also 
mimic a cold and needs to be treated 
promptly.  
Whereas the common cold and influenza 
are caused by viruses, allergic rhinitis is 
caused by pollen and mold spores.  
Weather conditions as well as temperature 
and rainfall cause the seasonal pattern of 
occurrence. Allergic rhinitis and asthmatic 
attacks may be precipitated by the same 
agents. If symptoms of allergic rhinitis are 
prolonged, persistent cough, asthmatic 
wheezing or a feeling of constriction in the 
chest may follow. These are dangerous 
signals, or a warning of possible asthma 
onset. 
Patients with allergic rhinitis may 
develop complications of chronic nasal 
inflammation, including recurrent otitis 
media with hearing loss, sinusitis, and loss 
of epithelial cilia. These are more 
prominent in children. 
For the symptomatic treatment of the 
runny nose, cough, congestion and pain due 
to the mentioned disorders, there are 
various OTC medications available.   
Misuse or overuse of these products can 
lead to complications. Anti-infective 
medications should be limited to the 
bacterial infections. 
Single-agent therapy offers the ability to 
design a specific regimen directed at each 
symptom. However, many products contain 
multiple medications. These combination 
products may be effective and provide a 
convenient dosage form when the patient 
has multiple symptoms. However, com-
bination products are usually more 
expensive, are limited by fixed doses in the 
preparation, and may have additive adverse 
effects.   
There is no evidence that show that 
incorporating secondary agents or other 
ingredients of the same pharmacological 
classes in a sub-therapeutic dose provide 
more relief or even as much relief as one 
agent at its full therapeutic dose. Two or 
more antihistamines do not increase 
efficacy of product. A decongestant may be 
added to an antihistamine in a product for 
allergic rhinitis, it may provide additional 
relief of symptoms, and counter act some 
drowsiness produced by the antihistamine. 
Combination products containing 
analgesic and antipyretics should not be 
generally recommended since they carry 
the risk of masking a fever that might 
indicate bacterial infections. 
 
In this chapter, the most common agents 
used in the respiratory system are 
discussed, noting some of the agents that 
are misused as well. 
 
 
Notes concerning certain agents: 
1) Sodium chloride 0.9% (normal saline) 
given as nasal drops may relieve nasal 
congestion by helping to liquefy mucous 
secretions. 
2) Inhalations of warm moist air is useful in 
the treatment of symptoms of acute infective 
conditions, and the use of compounds 
containing volatile substances such as 
menthol and eucalyptus may encourage their 
use. 
3) There is no evidence that nasal 
preparations containing antihistamines in 
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combination with anti-infective agents have 
any therapeutic effect. 
4)  Douching the nose with salt and water is 
not recommended. 
5) There is no evidence that topical anti-
infective nasal preparations have any 
therapeutic value. Elimination of organisms 
such as staphylococci from the nasal 
vestibule can be achieved by the use of a 
cream containing chlorhexidine and 
neomycin, but re-colonization frequently 
occurs. A nasal ointment containing 
mupirocin is also available; but it should be 
kept in reserve for resistant cases. 
6) Chronic use of topical decongestants which 
produce after-congestion may aggravate 
chronic rhinitis (rhinitis medicamentose) if 
used continuously.  
7) Sodium cromoglycate is the first choice in 
children with allergic rhinitis. 
 
 
A)  ANTIHISTAMINES 
 
Antihistamines are chemical agents that 
exert their effect in the body primarily by 
competitively blocking the action of 
histamine at H1-receptor sites. They do not 
prevent histamine release.  These have no 
therapeutic effect on the common cold.  
Their continued popularity stems from their 
drying effect. Differences in antihistamines 
may be seen in table-4.1. 
 
1)  Chlorpheniramine WHO,P 
 
• DRUG SUMMARY: 
Chlorpheniramine maleate will be used as 
the prototype of commonly used anti-
histamines. It is a H1-receptor antagonist, 
that generally produces less drowsiness 
than other antihistamines, but side effects 
involving CNS stimulation may be more 
common. It also has some antitussive, 
anticholinergic and local anesthetic action, 
but no antiemetic properties.  
• INDICATIONS: 
Symptomatic relief of various allergic 
conditions, hay fever, urticaria, insect 
stings, conjunctivitis, angioedema, as well 
as adjunct in the emergency treatment of 
anaphylactic shock and severe angioedema. 
• CONTRAINDICATIONS: 
Hypersensitivity to antihistamines, pre-
mature or newborn infants, nursing 
mothers, narrow-angle glaucoma, 
obstructive prostatic hypertrophy or other 
bladder neck obstruction, GI 
obstruction/stenosis, asthmatic attack, and 
during or within 14 days of MAO inhibitor 
therapy. 
• DOSAGE FORMS:  
Tablets, drops, syrups, capsules. 
• RECOMMENDED DOSAGE: 
Adult: 2-4 mg PO t.i.d. or q.i.d.,  or 
8-12 mg b.i.d or t.i.d.; max. 24 mg/24 hrs. 
[For anaphylaxis: can be given by slow SC 
or IM injection over 1 min., 10-20 mg 
repeated if required (max 40 mg/24hrs).] 
Child (6-12 y): 2 mg q. 4-6 h., max. 12 mg/d.   
          (2-6 y):  1 mg q. 4-6 h., max. 6 mg/d. 
 
Directions:  If GI upset occurs, can take 
with food and a full glass of water. 
*Peak action occurs in 2-6 h., about 45% of 
dose reaches systemic circulation. 
*Driving and other potentially hazardous 
activities should be avoided until drug 
response has been determined. 
*Antihistamines have additive effects with 
alcohol or other CNS depressants.  Caution 
your patient about this. 
• USE IN SPECIAL CASES:  
Pregnancy- Use chlorpheniramine only 
when clearly needed, and avoid during the 
third trimester (Category B). Safety during 
pregnancy has not been established. Several 
associations with malformation have been 
found with the use of some antihistamines, 
but significance is unknown. 
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Table – 4.1:  Comparison of Selected Antihistamines 
Antihistamine 
Adult 
Single Dose 
(mg) 
Dosing 
Interval 
(hour) 
Sedative 
Effects 
Anti- 
histaminic 
Activity 
Anti-
cholinergic 
Activity 
Antiemetic 
Effects 
Ethanolamines  
Clemastine 1 12 + + + to + + + + + ++ to +++ 
Diphenhydramine 25 - 50 6 - 8 + + + + to + + + + + ++ to +++ 
Ethylenediamines  
Pyrilamine 25 - 50 6 - 8 + + to + + + - 
Tripelennamine 25 - 50 4 - 6 + + + to + + + - 
Alkylamines  
Brompheniramine 4 4 - 6 + + + +  + + - 
Chlorpheniramine 4 4 - 6 + + + + + - 
Dexchlorpheniramine 2 4 - 6 + + + + + + - 
Triprolidine 2.5 4 - 6 + ++ to +++ + + - 
Phenothiazines  
Promethazine 12.5 - 25 6 - 24 + + + + + + + + + + + + + 
Trimeprazine 2.5 6 + + ++ to +++ + + + + + + + 
Piperidines  
Azatadine 1 - 2 12 + + + + + + - 
Cyproheptadine 4 8 + + + + + + - 
Phenindamine 25 4 - 6 - + + + + - 
Miscellaneous  
Acrivistine 8 8 + ++ to +++ + - 
Astemizole # 10 24 + ++ to +++ + - 
Loratadine 10 24 + ++ to +++ + - 
Terfenadine § 60 12 + ++ to +++ + - 
 ++++ = very high, +++ = high, ++ = moderate, + = low,  + = low to none, - = none. 
 * Drug Facts and Comparisons 1997; 1135. 
  # Withdrawn from USA market 1999 voluntarily by the brand manufacturer Janssen since alternative 
available medications have less risk, § Withdrawn from USA and other European markets in 1998. 
__________________________________ 
 
Lactation- Avoid use, unless clearly 
needed. Antihistamines in general are 
excreted in breast milk. Also can reduce 
milk flow. 
Children- Use of chlorpheniramine in 
children < 2 years should be avoided. Use 
caution in children, they may experience 
paradoxical excitation.   
Renal Disease- Use caution in simple cases, 
reduce dose if patient can’t tolerate. Avoid 
in patients with urinary retention or severe 
renal disease.  
Liver Disease- Avoid use. Some antihist-
amines have been reported to precipitate 
coma in hepatic dysfunction. 
• PRECAUTIONS AND WARNINGS:   
-In elderly (> 60 yrs.), antihistamines are 
more likely to cause dizziness, excessive 
sedation, toxic confusional states and 
hypotension. Dosage reduction may be 
required.  
-Use caution in patients with convulsive 
disorders, increased intraocular pressure, 
hyperthyroidism, diabetes, cardiovascular 
disease, hypertension, G6PD deficiency. 
• ADVERSE EFFECTS:    
Chlorpheniramine has a low incidence of 
side effects. Possible side effects include:  
Drowsiness, headache, tinnitus, disturbed 
coordination, nervousness, restlessness, 
mild hypotension, tachycardia, dryness of 
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mouth, nose and throat, blurred vision, 
diplopia, epigastric distress, nausea, 
constipation or diarrhea, or urinary 
retention.  
• INTERACTIONS:   
Overview of Chlorpheniramine 
Drug-Drug Interaction 
Drug Interaction 
Alcohol and 
other CNS 
depressants 
These potentiate the side 
effects of the medication. 
Caution patients. 
MAO 
inhibitors 
Intensify and prolong the 
anticholinergic effects of the 
antihistamines.  May cause 
severe hypotension and extra-
pyramidal reactions. Avoid 
use of antihistamines within 
14 days of MAO inhibitor 
therapy. 
 
• OVERDOSE: 
Symptoms may vary from mild CNS 
depression (sedation, diminished mental 
alertness, tinnitus) and cardiovascular 
collapse, to stimulation (insomnia, halluc-
inations, convulsions, severe hypotension) 
and respiratory depression leading to coma, 
especially in children and geriatric patients.  
Death may occur. 
Treatment: Induce emesis even if emesis has 
occurred spontaneously, using syrup of 
ipecac. Following emesis administer activated 
charcoal as a slurry with water and a cathartic 
to minimize absorption. Do not induce emesis 
in unconscious patients. Continue with 
supportive and symptomatic treatments as 
needed. 
• BRANDS: 
Ahiston (Teva), Allergon (JCL), Anaphyl (Sam-
On), Artix (Megapharm) Cloroyate 
(Pharmacare), Disoramin (Dexxon). 
________________________ 
 
2)  Astemizole 
 
• DRUG SUMMARY: 
(Astemizole and Terfenadine have been 
withdrawn from some countries due to the 
risks of death of irregular heart rhythms 
when taken with certain other drugs and 
when used at higher than recommended 
doses). 
Astemizole is a long acting selective 
histamine H1-receptor antagonist. It binds 
preferentially to peripheral rather than 
central H1-receptors. It does not block 
histamine release, antibody production or 
antigen-antibody interactions. Has little or 
no anticholinergic and sedative effects 
compared with diphenhyramine. 
Astemizole has a slow onset of action and 
is more appropriate for use on a regular 
basis than when symptoms occur. 
Good choice for people who cannot tolerate 
the sedative or anticholinergic effects of 
other antihistamines that are indicated for 
rhinitis, as well as having the benefit of 
once a day dose. The downside to its use, is 
the high cost, potential rare but possible 
adverse cardiac events including death, as 
well as the serious side effects that can 
result from drug-drug interactions. 
• INDICATIONS: 
Relief of symptoms associated with 
seasonal allergic rhinitis and chronic 
idiopathic urticaria. 
• CONTRAINDICATIONS: 
Same as chlorphineramine. 
Also in patients with significant hepatic 
dysfunction, concomitant erythromycin, 
ketoconazole or itraconazole therapy, 
patients with hypokalemia and other 
electrolyte imbalances. 
• DOSAGE FORMS:  
Tablets, syrup. 
• RECOMMENDED DOSAGE:  
Adult and child > 12 yrs:  10 mg PO q.d.   
Child 6-12 yrs:  5 mg daily.   
Child < 6 yrs:  Not recommended. 
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Directions: DO NOT EXCEED RECOM-
MENDED DOSE. 
*Should be taken on empty stomach, since 
absorption is 60% decreased with food. 
Take at least 2 hrs. after a meal. Have no 
food for 1 h. after taking the drug. 
*If syncope occurs, astemizole should be 
discontinued and patient evaluated for 
potential arrhythmias. 
• USE IN SPECIAL CASES:  
Pregnancy- Safety and efficacy have not 
established. Toxicity has been reported in 
animal studies, manufacturers advise that 
women of child-bearing potential should use 
contraception while taking astemizole and for 
several weeks after stopping (owing to its 
long t½ ), to avoid any potential risks to the 
fetus (Category C). 
Lactation- Avoid use, due to the increased 
risk or adverse effects in infants in general. 
Children- safety of use in children < 6 yrs. 
old has not been established.   
Renal Disease- Use caution, this drug has a 
long half-life, 20-24 hours, metabolites 12-
20 days, and is 25-50% excreted in urine. 
Liver Disease- Astemizole is contra-
indicated in patients with significant 
hepatic dysfunction or liver cirrhosis. 
• PRECAUTIONS AND WARNINGS:   
-Cardiovascular effects; QT interval pro-
longation/ventricular arrhythmias, includ-
ing death, cardiac arrest, torsade de pointes 
have all been observed in clinical setting. 
-Severe arrhythmias have been preceded by 
episodes of syncope. Syncope in patients 
receiving astemizole (or terfenadine) 
should lead to discontinuation of treatment 
and evaluation of potential arrhythmias. 
• ADVERSE EFFECTS:  
These may include; headaches, dizziness, 
appetite increase, weight gain, nervousness, 
depression, nausea, diarrhea, abdominal 
pain, angioedema, arrhythmias, photo-
sensitivity, or rash. 
• INTERACTIONS:  
Overview  of  Astemizole 
Drug-Drug Interaction 
Drug Interaction 
Anti-
arrhythmic 
Do not prescribe at the same 
time. Medication use 
increases the risk of 
ventricular arrhythmias if 
astemizole is added.  
Azole 
antifungals 
(Fluconazole, 
 itraconazole, 
ketoconazole, & 
miconazole) 
Use is contraindicated. 
These increase astemizole 
(and terfenadine) plasma 
levels, which may lead to 
serious cardiovascular 
effects. [see warnings].  
Fluvoxamine  Use is contraindicated. 
Increased concentration of 
the astemizole/ terfenadine 
increasing its cardiotoxicity.  
Macrolide 
antibiotics  
Use is contraindicated. 
Erythromycin coadminis-
tration increases risk of 
cardiac toxicity.  
Other macrolides may have 
the same risk. Loratidine 
antihistamine may be a safe 
alternative. 
Tricyclic anti-
depressants 
Increased antimuscarinic 
and ventricular arrhythmia 
risks. Avoid use if possible. 
 
 
• OVERDOSE: 
Symptoms: Serious ventricular arrhythmias 
have occurred following astemizole doses 
of > 200 mg, including severe forms of side 
effects.  
Treatment: Need to induce emesis even if it 
has occurred spontaneously, using syrup of 
ipecac. Followed with activated charcoal as 
a slurry with water, and a cathartic to 
minimize absorption. Follow with 
supportive and symptomatic care. 
• BRANDS: 
Hismanal (Janssen), Hismal (Eastern Chem.), 
Lahistan (BPC). 
___________________ 
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B)  NASAL DECONGESTANTS 
 
Decongestants are sympathomimetic 
amines administered directly to swollen 
membranes (e.g. via spray or drops), or 
systematically via the oral route. Oral 
agents are not as effective as topical 
products especially on an immediate basis, 
but generally have a longer duration of 
action, cause less local irritation and are not 
associated with rebound congestion as do 
topical products (see table 4.2 & 4.3 for 
summary of topical and oral nasal congestion 
agents). 
 
Treatment of nasal congestion not only 
relieves the discomfort, but also prevents 
excessive blowing, which may further 
irritate mucous membranes and nostrils.  
Topical decongestants are used to relieve 
nasal stuffiness in colds and allergies.  It is 
very important to tell patient to strictly 
follow the decongestant’s directions 
regarding the frequency and duration of 
use. When these agents are misused or 
overused, a rebound phenomenon (rhinitis 
medicamentosa) may occur. The nasal 
mucosa  
becomes more congested and edematous 
as the drugs vasoconstrictor effect subsides. 
 
 
Table – 4.2:  Topical Nasal Decongestant Dosages (Drops or Sprays) 
Drug Concentration (%) 
Adult dosage Children  
6-12 y 
Children  
2 to < 6 y 
Ephedrine 0.5 2-3  (≥ 4 h.) 1-2  (≥ 4 h.)  - 
0.05 2  (≥ 4-6 h.) Not recommended - Naphazoline 
Hydrochloride 0.025 - 1-2  (≥ 6 h.) - 
0.05 2-3  (morning and evening) Same as adult - Oxymetazoline
Hydrochloride 0.025 - - 2-3  (morning and evening) 
1.0,  0.5 1-2  (≥ 4 h.) Not recommended (refer to 0.25%) 
Not recommended 
(refer to 0.125%) 
0.25,  0.2 1-2  (≥ 4 h.) 1-2 (≥ 4 h.) Not recommended (refer to 0.125%) 
Phenylephrine 
Hydrochloride 
0.125 - - 1 drop  (≥ 4 h.) 
0.1 2-3  (8-10 h.) Not recommended(refer to 0.05) 
Not recommended 
(refer to 0.05%) Xylometazoline Hydrochloride 0.05 - 2-3  (8-10 h.) 2-3  (8-10 h.) 
 (-): There is no recommended dosage for children, except under direct supervision of physician.  
  Only drops should be used in children under 2 to 6 years of age. 
 
 
Table – 4.3.  Oral Nasal Decongestant Dosages  (maximum/24 hours): 
Drug Adult Children 6 to 12 y Children 2 to < 6 y 
Phenylephrine 10 mg q. 4 h.   (60 mg) 
5 g q. 4 h. 
(30 mg) 
2.5 mg q. 4 h. 
 (15 mg) 
Phenylpropanolamine 25 mg q. 4 h.  (150 mg) 
12.5 mg q. 4 h.  
(75 mg) 
6.25 mg q. 4 h.  
(37.5 mg) 
Pseudoephedrine 60 mg q. 6 h.   (240 mg) 
30 mg q. 6 h. 
(120 mg) 
15 mg q. 6 h.   
(60 mg) 
There is no recommended dosage for children under 2 years old, unless under direct medical supervision. 
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1)  Oxymetazoline 
 
• DRUG SUMMARY: 
Oxymetazoline is an imidazoline-derivative 
sympathomimetic agent, an autonomic 
nervous system, alpha-adrenergic agonist. 
Oxymetazoline is a longer acting topical 
nasal decongestant, with an effect that may 
last 5-6 hours or longer, with a gradual 
decline thereafter. It can be used twice a 
day. (Xylometazoline is a similar nasal 
decongestant). 
• INDICATIONS: 
Relief of congestion of the upper 
respiratory tract. As adjunctive therapy of 
middle ear infections, to decrease 
congestion around the Eustachian ostia. 
• CONTRAINDICATIONS: 
Hypersensitivity, and use with MAO 
inhibitor therapy or within 14 days of 
therapy. 
• DOSAGE FORMS: 
Drops or sprays. 
• RECOMMENDED DOSAGE: 
Adults and children > 6 yrs:  2-3 drops or 
2-3 sprays of  0.05% solution into each 
nostril b.i.d. (q. 12 h.) for up to 3-5 days. 
Children 2-5 yrs:  2-3 drops of 0.025% 
solution into each nostril b.i.d. for up to 3-5 
days.   
 
Directions: Administer in the morning and 
at bedtime. Effects appear within 30 
minutes and last about 6-7 hours. 
*Nasal spray is delivered with patient in 
upright position. Instruct patient to place 
spray nozzle in nostril without occluding it, 
and to bend head slightly forward and sniff 
briskly during administration. 
*Lateral, head-low position is recom-
mended for instillation of nose drops.   
*Instruct patient to rinse dropper or spray 
tip in hot water after each use to prevent 
contamination of solution by nasal 
secretion. 
*Wash hands after use, and avoid rubbing 
eyes with contaminated fingers, can 
develop anisocoria (inequality of pupil size 
and blurred vision). 
• USE IN SPECIAL CASES:  
Pregnancy- Use oxymetazoline if clearly 
needed (Category C). It is not known if 
topical agents cause fetal harm. 
Lactation- Exercise caution. It is not known 
if topical agents are secreted in breast milk. 
Children- Can use the 0.025% concentration 
solution in children 2-6 yrs of age for not 
more than 3-5 days. There is no 
recommended dosage for children ≤ 2 yrs. 
Direct supervision of a physician is required 
if it is decided that it is necessary to use this 
medication, to monitor for any toxicity. 
Renal + Liver Diseases- Use caution. There 
should be no hazards, if used as directed in 
these patients. 
• PRECAUTIONS AND WARNINGS:   
-Use caution with hypertensive patients as 
they might experience a change in blood 
pressure because of the added 
vasoconstriction. 
-Use caution in special risk population, 
patients with hyperthyroidism, cardio-
vascular disease, coronary artery disease, 
increased intraocular pressure. Sympatho-
mimetics may cause CNS stimulation or 
hypotension.  
• ADVERSE EFFECTS: 
Burning, stinging, dryness of nasal mucosa, 
and sneezing are common. With excessive 
use: headaches, light-headedness, drow-
siness, insomnia, palpitations, and rebound 
congestion. Stop use of medication 
immediately if severe effects occur. 
• INTERACTIONS: 
Overview  of  Oxymetazoline 
Drug-Drug Interaction 
Drug Interaction 
MAO 
inhibitors 
Concurrent use may result in 
severe headache, hyper-
tension, hyperpyrexia, and 
possibly a hypertensive crisis. 
Avoid use concurrently or 
within 14 days of MAOI 
therapy. 
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• OVERDOSE: 
Hypertension or rebound hypotension may 
occur, heart palpitations, headache and 
dizziness.  Treat symptomatically. 
• BRANDS: 
Alrin (Teva), Nasivin (Merck), Nosacare 
(Pharmacare), Rhinoclir (Agis) 
______________________ 
 
2)  Pseudoephedrine 
 
• DRUG SUMMARY: 
An autonomic nervous system agent, α-
adrenergic and β-adrenergic agonist, sym-
pathomimetic decongestant amine.  Unlike 
ephedrine, it acts directly on smooth 
muscle, has fewer side effects, less presser 
action, and longer duration of action.  It 
produces little, if any, rebound congestion 
or irritation that occur with nasal sprays and 
solutions. 
• INDICATIONS: 
Symptomatic relief of nasal congestion 
associated with rhinitis, coryza, sinusitis 
and Eustachian tube congestion. 
• CONTRAINDICATIONS: 
Hypersensitivity to sympathomimetic 
amines, severe hypertension or coronary 
artery disease, use within 14 days of MAO 
inhibitors, glaucoma, hyperthyroidism, 
prostatic hypertrophy. The use of sustained 
release tablets in children < 12 years old is 
also contraindicated.  
• DOSAGE FORMS: 
Tablets, syrup (in combination with other 
agents). 
• RECOMMENDED DOSAGE: 
Adult:  60 mg PO q. 4-6 h. (or 120 mg SR 
q. 12 h.); max. 240 mg/24h. 
Child (6-12y):  30 mg q. 4-6 h.;  max. 120 
mg/24h.  
Child: (2-6y): 15 mg q. 4-6 h.; max. 60 
mg/24h. 
 
Directions: May take with food if GI upset 
occurs.  
*Do not exceed recommended doses, 
higher doses may cause nervousness, 
dizziness, and sleeplessness. 
*The drug acts as a stimulant, advise the 
patient to avoid taking it within 2 hours of 
bedtime. 
• USE IN SPECIAL CASES:  
Pregnancy- Give only when clearly needed 
(Category C). It is not known whether these 
agents can cause fetal harm. 
Lactation- Oral pseudoephedrine has been 
detected in breast milk, avoid use to eliminate 
possible side effects to the nursing infant. No 
reports of side effects have been found. 
Children- Safe if used as recommended.  
Renal + Liver Disease- Use with caution.  
The medication is metabolized in the liver, 
and excreted in the urine, but there have been 
no reported risks when used as recommended. 
• PRECAUTIONS AND WARNINGS:   
-Special populations; administer with 
caution to patients with hyperthyroidism, 
diabetes mellitus, cardiovascular disease, 
coronary artery disease, ischemic heart 
disease, prostatic hypertrophy, and 
increased intraocular pressure. Sympatho-
mimetics may cause CNS stimulation and 
convulsions or cardiovascular collapse 
-Use caution with hypertensive patients as 
they might experience a change in blood 
pressure because of the added vaso-
constriction. 
-Elderly (≥ 60 yrs) are more likely to 
experience adverse reactions to 
sympathomimetics. Hallucinations, convul-
sions, CNS depression and death have been 
noted. Short acting sympathomimetics may 
be safer than the sustained release 
formulation in this population. 
• ADVERSE EFFECTS:    
Transient stimulation, tremors, anxiety, 
difficulty in voiding, arrhythmia, 
palpitation, tachycardia, nervousness, 
headache, dizziness, insomnia, sweating, 
anorexia, dry mouth, nausea or vomiting, 
photophobia have all been reported. 
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• INTERACTIONS: 
Same as oxymetazoline. 
• OVERDOSE: 
Symptoms include: somnolence, sedation 
accompanied by profused sweating, 
hypotension or shock.   
Treatment: For accidental overdose, refer 
to hospital for supportive and symptomatic 
care. 
• BRANDS: 
Pseudoephedrine is mostly available in 
combination with other antihistamines, 
antitussives, analgesics or expectorants. 
(Refer to price list in Appendix.) 
_________________________ 
 
 
C)  EXPECTORANTS 
 
Expectorants are periphery-acting anti-
tussives that produce their effect by 
increasing the volume and reducing the 
viscosity of bronchial secretions, thus 
facilitating their removal by productive 
cough. Use of expectorants in clinical 
practice is controversial because of 
doubts regarding their therapeutic 
efficacy. There is a lack of strong, 
supportive, objective data showing that an 
expectorant truly decreases sputum 
viscosity or eases expectoration.  Increasing 
fluid intake (6-8 glasses) and maintaining 
adequate humidity of the inspired air are 
important for the production and 
expectoration of respiratory tract fluid 
mucus. 
 
 
1)  Ammonium Chloride 
 
Ammonium chloride is primarily used as an 
acidifying agent. Allegedly, it increases the 
removal of respiratory tract secretions by 
reflex stimulation of bronchial mucous 
glands that result from irritation of the 
gastric mucosa, which makes it a common 
ingredient in cough mixtures. But it has 
questionable efficacy. In the presence of 
renal, hepatic or chronic heart diseases, 
Ammonium Cl doses of 5 gm have caused 
severe poisoning. Symptoms of toxicity 
including nausea, vomiting, thirst, rash, 
headache, bradycardia, mental confusion, 
hyperventilation, hyper-reflexia and 
electroencephalogram abnormalities. A 
relative contraindication for use in patients 
with hepatic, renal or pulmonary 
insufficiency exists. Use in diabetics should 
also be avoided. Doses larger than those 
recommended may predispose the patient to 
hyperammonemia and metabolic acidosis. 
[Need to warn such patients who are 
predisposed to toxicity.] Since ammonium 
Cl acidifies the urine, it may also affect the 
excretion of other drugs when given in large 
doses; (i.e. amphetamines, methadone, 
ephedrine, pseudoephedrine, sulfonylureas 
and salicylates). 
The expectorant safe dosing recommen-
dation to be used are; 
Adults:  300 mg q. 2-4 h. 
Child (6-12 y):  150 mg q. 2-4 h.,  
Child (2 to < 6 y):  75 mg q. 2-4 h.   
Most companies include ammonium Cl in 
their cough products, and list it as a non-
active ingredient. Use caution in 
susceptible patients. 
_________________ 
 
2)  Guaifenesin 
 
• DRUG SUMMARY: 
Guaifenesin (glyceryl guaiacolate) is 
claimed to enhance the output of 
respiratory tract fluid by reducing 
adhesiveness and surface tension 
facilitating the removal of viscous mucus. 
As a result nonproductive cough becomes 
more productive and less frequent. There is 
a lack of convincing studies to document 
efficacy just like any other expectorant. 
• INDICATIONS: 
For the symptomatic relief of respiratory 
conditions characterized by dry, non-
productive cough, and in the presence of 
mucus in the respiratory tract. 
 
 
Respiratory Drugs 
 
 85
• CONTRAINDICATIONS: 
Hypersensitivity to the product, no other 
absolute contraindications to its use. 
• DOSAGE FORMS: 
Syrup 100 mg/5 ml. 
• RECOMMENDED DOSAGE: 
Adults and children (≥ 12 y):  200-400 
mg PO q. 4 h.   
Do not exceed 2400 mg/24h.   
Child (6-12 y): 100-200 mg q. 4 h.  Do not 
exceed 1200 mg/24h. 
Child (2-5 y): 50-100 mg q. 4 h.  Do not 
exceed 600 mg/24h. 
Directions: Drug is most effective if taken 
q. 4 h. around the clock or during waking 
hours. May take dose with a full glass of 
water if needed. 
• USE IN SPECIAL CASES:  
Pregnancy- No sufficient data is available. 
Use if clearly needed (Category C). 
Lactation- Exercise caution. Use only when 
clearly needed. 
• PRECAUTIONS AND WARNINGS:   
-Do not use for persistent cough such as 
cough that occurs with smoking, asthma or 
emphysema, or where cough is 
accompanied by excessive secretions. 
• ADVERSE EFFECTS:    
These are uncommon, but may include: 
nausea, vomiting, headache, and rash. 
• INTERACTIONS:   
Guaifenesin may increase risk of 
hemorrhage in patients receiving heparin 
therapy. 
• OVERDOSE: 
Symptoms: Overdosage may cause nausea 
and vomiting. 
Treatment: Induce vomiting if it has not 
occurred already. Use supportive and 
symptomatic care. 
• BRANDS: 
Resyl (Ciba-Geigy), Robutussin (Robins 
Consumer). 
_____________________ 
D)  ANTITUSSIVES/ COUGH 
SUPPRESSANTS 
 
Cough suppressants are centrally acting 
antitussives, suppressing the medullary 
cough center. The drawbacks of prescribing 
cough suppressants are really outweighed 
by the benefits of treatments and only 
occasionally are useful, for example if sleep 
is disturbed by dry cough. Cough 
suppressants may cause sputum retention 
and this may be harmful in patients with 
chronic bronchitis and bronchiectasis. The 
use of cough suppressants containing 
codeine or similar opioid analgesics are not 
generally recommended in children and 
should be avoided altogether in those under 
1 year of age. 
 
1)  Codeine 
 
• DRUG SUMMARY: 
An opium derivative made by methylation 
of morphine. It is classified as a CNS, 
narcotic agent, analgesic, and antitussive. 
The dose required to suppress cough is 
lower than the doses required for analgesia. 
• INDICATIONS: 
For suppression of cough induced by 
chemical or mechanical respiratory tract 
irritation. Also for relief mild to moderate 
pain since it is a narcotic analgesic.  
• CONTRAINDICATIONS: 
Hypersensitivity to the drug, acute asthma, 
acute alcoholism, premature infants or 
during labor when delivery of a premature 
infant is anticipated. 
• DOSAGE FORMS: 
Tablets.  Syrup in combination products. 
• RECOMMENDED DOSAGE: 
Adult: 10-20 mg PO q. 4-6 h.; max. 120 
mg/24h. 
Child (6-12 y):  5-10 mg q. 4-6 h.; max. 60 
mg/24h.   
Child (2-6 y): 2.5-5 mg q. 4-6 h.;  max. 30 
mg/24h. 
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Not to be used in premature infants. Safety 
and efficacy in newborn infants have not 
been established. 
 
Directions: Take with food or milk to 
reduce possibility of GI distress. 
*Not to be administered to patients with 
persistent or chronic cough; as occurs with 
smoking, asthma or emphysema, or where 
cough is accompanied by excessive 
secretion.   
Treatment is directed toward decreasing 
frequency and intensity of cough, without 
abolishing protective cough reflex that 
serves the important function of removing 
bronchial secretions.  
• USE IN SPECIAL CASES:  
Pregnancy- Avoid use (Category C). 
Dependence has been reported in newborns 
whose mothers took opiates during 
pregnancy. Signs such as irritability, 
excessive crying, tremors, fever, vomiting 
and diarrhea, usually appear during the first 
few days of life. Use only if potential 
benefits outweigh the potential hazards to 
the fetus. Also codeine may prolong labor; 
avoid use especially if a premature infant is 
anticipated. 
Lactation- Exercise caution. Use when 
clearly indicated. Studies have reported 
detectable amounts of codeine in breast 
milk, but no adverse effects were reported 
with the recommended doses for cough.   
Children- Do not use opiates, including 
codeine, in premature infants. Opiates cross 
the immature BBB, producing respiratory 
depression. Codeine should be given to 
infants and small children only with great 
caution since safety and efficacy have not 
been established. 
Renal Disease- Use with caution. 
Antitussive doses are not reported to be 
hazardous. 
Liver Disease- Use caution. The drug is 
metabolized in the liver, may need to 
reduce dose if patient can not tolerate the 
recommended dose. 
• PRECAUTIONS AND WARNINGS:   
-Head injury and increased intracranial 
pressure;  the respiratory depressant effects 
of codeine and their capacity to elevate 
cerebrospinal fluid pressure may be 
markedly increased in the presence of such 
cases. Exercise caution. 
-Should not be given to patients with or at 
risk of developing respiratory failure. 
-Drug abuse and dependence; potential of 
abuse is less than that of heroin or 
morphine, but use caution in patients with a 
history of drug abuse. Psychological and 
physical dependence, and tolerance may 
occur. Be alert to over-prescribing. 
• ADVERSE EFFECTS: 
In usual oral antitussive doses, codeine has 
mild side effect. Nausea, vomiting, 
sedation, dizziness, constipation are most 
common. Other effects may include: CNS 
depression, respiratory depression, biliary 
tract spasms, tachycardia, palpitation, 
faintness, orthostatic hypotension, urinary 
retention, antidiuretic effect, hallucination, 
disorientation, lightheadedness, euphoria, 
weakness, convulsions, as well as allergic 
reactions have been reported. 
Warn patients against performing tasks that 
require full alertness and coordination (i.e. 
driving or operating machines) until the full 
effect of the medication is known.   
Instruct patients to make position changes 
slowly, particularly from recumbent to 
upright posture, and to lie down immediately 
if light-headedness/dizziness occur, especially 
in elderly patients, to avoid falling down. 
• INTERACTIONS:   
Overview  of  Codeine 
Drug-Drug Interaction 
Drug Interaction 
CNS 
depressants, 
and alcohol 
Including other opiates, general 
anesthetics, phenothiazines, 
tricyclic anti-depressants, 
tranquilizers; all have additive 
effects when given 
concomitantly with codeine. 
Avoid, or use extreme caution.  
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• OVERDOSE: 
The lethal oral dose of codeine in an adult 
is in the range of 0.5 to 1 g.  Infants, 
children, and elderly are more sensitive, 
and comparatively intolerant.  
Symptoms include CNS depression, miosis, 
and respiratory depression.  
Treatment: Transfer immediately to the 
emergency room for supportive and 
symptomatic care. Naloxone is the 
antagonist of choice in narcotic agonist 
overdoses. 
• BRANDS:   
Codical (Sam-On), Codeine Phosphate (Trima). 
________________________ 
 
2)  Dextromethorphan HBr WHO 
 
• DRUG SUMMARY: 
Dextromethorphan is a non-narcotic 
derivative of levorphanol classified as an 
antitussive. Chemically related to morphine 
but without the capacity to cause tolerance 
or addiction. It controls cough spasms by 
depressing the cough center in the medulla. 
It does not depress respiration or inhibit 
cilliary action. Antitussive activity 
comparable to that of codeine, but it is less 
likely to cause constipation, drowsiness, or 
GI disturbances. 
• INDICATIONS: 
Temporary relief of cough spasms in non-
productive coughs due to colds, pertussis 
(whooping cough), and influenza. 
• CONTRAINDICATIONS: 
Hypersensitivity to dextromethorphan, or any 
component of the product. 
• DOSAGE FORMS: 
Tablets, syrup. 
• RECOMMENDED DOSAGE: 
Adult:   10-20 mg PO q. 4 h. or  30 mg   q. 6-
8 h.;  max. 120 mg/24h. 
Child (6 - 12 y);  5-10 mg q. 4 h. or 15 mg q. 
6-8 h.;  max. 60 mg/24h. 
Child (2 - 6 y);  2.5 mg q. 4 h. or 7.5 mg q. 6-
8 h.;  max. 30 mg/24h. 
Directions: Drink some water after 
administration. If GI upset occurs, the 
medicine may be taken with food. 
*Unnecessary cough may be lessened by 
avoiding irritants such as smoking, dust, 
fumes, and other air pollutants. Humidi-
fication of air may provide some relief. 
*Increasing the dose does not increase the 
antitussive effect, but may extend its 
duration of action. 
• USE IN SPECIAL CASES:  
Pregnancy- Use if clearly needed (Category 
C). No sufficient data is available. 
Lactation- It is advisable to avoid the 
medication, unless clearly needed. 
Children- Not recommended for children < 2 
years of age, unless under direct medical 
supervision (administered in hospital or 
clinic). 
Renal Disease- Use with caution. 
Liver Disease- Use with caution. 
• PRECAUTIONS AND WARNINGS:   
-Should not be used for persistent or 
chronic cough, e.g. asthma, smoking 
emphysema, or where cough is 
accompanied by excessive secretions, or to 
patients with risk of developing respiratory 
failure.   
-Cases of abuse of dextromethorphan-
containing cough/cold products have been 
reported, but there is no sufficient data to 
prove potential dependency on this drug. 
• ADVERSE EFFECTS:  
Side effects are rare, but may include; 
dizziness, drowsiness, CNS depression, GI 
upset, constipation and abdominal 
discomfort. 
• INTERACTIONS:   
Overview of Dextromethorphan 
Drug-Drug Interaction 
Drug Interaction 
MAO 
inhibitors 
Dextromethorphan should not 
be given to patients taking 
MAOI. Patient may develop 
hypotension, nausea, myo-
clonic leg jerks or coma 
following co-administration. 
Do not co-administer. 
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• OVERDOSE: 
Symptoms: Children may experience ataxia, 
respiratory depression and convulsion with 
accidental overdose. Adults symptoms 
include altered sensory perception, ataxia, 
slurred speech, and dysphoria.   
Treatment: There is rapid recovery after 
emesis with activated charcoal. 
• BRANDS:  
Dextromethorphan is mostly available in 
combination with other antihistamines, 
decongestants, analgesics or expectorants.  
Refer to price list for products. 
____________________________ 
 
 
E)  MUCOLYTICS 
 
Mucolytics are often prescribed to facilitate 
expectoration, since they reduce the 
viscosity of the bronchial secretions by 
breaking down their structure. They 
supposedly reduce sputum viscosity in 
chronic asthma and bronchitis. Experts 
have suggested that “mucolytics are 
probably no more effective than steam 
inhalation . . .  A productive cough may be 
helped by a warm drink and/or steam 
inhalation” specially in the case of cough 
and cold medications. Available mucolytics 
include: acetylcysteine, carbocysteine, 
methyl-cysteine, and bromhexine. 
 
1)  Acetylcysteine 
 
• DRUG SUMMARY: 
Acetylcysteine is a derivative of the 
naturally occurring amino acid L-cysteine.  
It is used as adjunct therapy in patients with 
abnormal viscid, or inspissated mucous 
secretions, and in pulmonary complications 
of cystic fibrosis, surgery, and atelectasis. 
Also used in acute paracetamol 
(acetaminophen) overdoses or toxicity. It is 
found in various cough/ expectorant 
preparations.  
It can be administered by mouth or by 
inhalation. It should be avoided in patients 
with hypersensitivity, or risk of gastric 
hemorrhage. (No contraindications if used 
as an antidote for poisoning cases). Safe 
use in pregnancy (Category B) and 
lactation is not established. Use extreme 
caution in patients with asthma (if 
bronchospasm progresses, the doctor needs 
to discontinue medication immediately). 
Most common side effects include nausea, 
vomiting, bronchospasm, rhinorrhea, and 
burning sensation when given as inhalation. 
____________ 
 
2)  Bromhexine 
 
• DRUG SUMMARY: 
A mucolytic agent used in the treatment of 
respiratory disorders associated with 
excessive mucus. It is usually given by 
mouth in a dose of 4-16 mg three times a 
day. Safety of use in pregnancy or lactation 
is not established. Do not administer to 
patients with history of peptic ulcer disease. 
__________________________ 
 
 
F)  BRONCHODILATORS & 
ASTHMA MEDICATION 
 
There has been an increase in morbidity 
and mortality from asthma worldwide in 
the last decade. This has been a major 
concern. Expert panels were established to 
provide guidelines for the diagnosis and 
management of asthma. Asthma is defined 
as an inflammatory airway obstruction 
that is reversible (but not completely in 
some patients).  It is a familial disease, 
inherited like other allergic disorders.  It is 
episodic in nature, were an episode may 
last from a few minutes to several days.  
Patients with chronic bronchitis and 
emphysema are often described as having 
irreversible airway obstruction, and should 
be treated differently by a specialist. 
 
 
Respiratory Drugs 
 
 89
Therapy is directed at preventing severe 
attacks and normalizing an asthma patient’s 
lifestyle. Severe asthma can be fatal. It is 
characterized by persistent dyspnea poorly 
relieved by bronchodilators, exhaustion, a 
high pulse rate (usually over 110/min.), and 
a very low forced expiratory volume (FEV1 
or PEF < 60% predicted, and PEF 
variability > 30%).  
The respiration is so shallow that 
wheezing may be absent. Such patients 
should be immediately taken to the 
emergency rooms for prompt therapy with 
oxygen and corticosteroids. 
Treatment of asthma has been 
undergoing major changes in recent years 
with the unrevealing of specific causes at 
the cellular level, and production of new 
classes of drugs such as the leukotriene 
modifiers.   
This chapter will discuss an overview of 
available products only at the primary level, 
and give summary of classification and 
updated treatment of asthma.   
National Asthma Education and 
Prevention program has adopted a 
classification of Asthma severity and 
treatment, this classification is as follows: 
 
-Severe persistent: continual daytime 
symptoms, frequent night symptoms, 
FEV1/PEF<60%. 
-Moderate persistent: daily daytime 
symptoms, > 5 nights/month with 
symptoms, FEV1/PEF = 60-80%. 
-Mild persistent: 3-6 days/week with 
symptoms, 3-4 nights/month with 
symptoms, FEV1/PEF > 80%. 
-Mild intermittent: < 2 days/week 
with symptoms, < 2 nights/month with 
symptoms, FEV1/PEF > 80%. 
 
Patient is classified according to the 
worst symptomatology that he has, and he 
can be moved from one scale to another 
depending on his symptomatology.  A 
summary of classification of asthma is 
presented in table-4.4. 
Pregnancy and Breast-Feeding: It is 
particularly important that asthma be well-
controlled during pregnancy. Inhalation has 
particular advantage as means of drug 
administration during pregnancy because 
the therapeutic action can be achieved 
without the need for plasma concentrations 
liable to have a pharmacological effect on 
the fetus. Severe exacerbation of asthma 
can have adverse effects on pregnancy and 
should be treated promptly with 
conventional therapy, including oral or 
parenteral administration of corticosteroids 
(Prednisolone preferred) and a selective β2-
agonist. Although theophylline has been 
given without adverse effects during 
pregnancy or breast-feeding, there have 
been occasional reports of toxicity in the 
fetus and neonate. 
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Table 4.4:  Summary of Treatment of the Different Classes of Asthma in Adults 
Classification Long Term Control Quick Relief 
Mild 
intermittent 
No daily medication Inhaled  β-2 
agonist 
Mild 
persistent 
One daily medication 
• Either inhaled corticosteroids (low dose) or cromolyn  
• Sustained release theophylline: not a preferred alternative. 
Inhaled  β-2 
agonist 
Moderate 
persistent 
Daily medication 
• inhaled corticosteroid (medium dose) or 
• inhaled corticosteroid (low-medium dose) and add 
either long acting inhaled β-2 agonist, sustained release 
theophylline or long acting β-2  agonists tablets especially 
for nighttime symptoms   
if needed medium-high dose inhaled corticosteroids can 
be used  
Inhaled  β-2 
agonist  
Severe 
persistent 
Daily medication 
•  inhaled corticosteroids (high dose) and 
•  either long acting inhaled β-2 agonist, sustained 
release theophylline or long acting β-2 agonist tablets 
and 
• Corticosteroid tablets or syrup long term (2mg/kg/d) 
Inhaled  β-2 
agonist 
Summary of Treatment of the Different Classes of Asthma in Children 
Classification Long Term Control Quick Relief 
Mild 
intermittent 
No daily medication is needed Bronchodilator either: 
-inhaled short acting β-2 agonist 
by nebulizer or spacer or 
chamber 
-oral  β-2 agonist 
Mild 
persistent 
-cromolyn (nebulizer is preferred or MDI) 
or nedocromil (MDI only) 
(infants and young children usually begin with 
cromolyn or nedocromil)  
or low dose inhaled corticosteroids with spacer 
or aerochamber. 
Bronchodilator as needed  
Moderate 
persistent 
-medium dose inhaled corticosteroid with 
spacer or aerochamber. 
Bronchodilator as needed for 
symptoms up to 3 times a day 
Severe 
persistent  
-high dose inhaled corticosteroid with spacer or 
aerochamber 
-if needed add systemic corticosteroids (2 
mg/kg/day) and reduce to the lowest daily or 
alternate–day dose.  
Bronchodilator as needed for 
symptoms up to 3 times a day  
-Adapted from: National Asthma Education and Prevention Program, National Heart, Lung and 
Blood Institute, Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. 
NIH publication No. 97-4051, July 1997, updated 2002).  
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1)  Theophylline WHO,P 
 (or soluble salt derivatives) 
 
• DRUG SUMMARY: 
Theophylline is a methyl-xanthine 
derivative. It is classified as a broncho-
dilator, respiratory and cerebral stimulant, 
xanthine.  Unlike sympathomimetic agents, 
tolerance to bronchodilator effects of 
theophylline derivative rarely develops. 
Theophylline inhibits the enzyme phospho-
diesterase, resulting in the relaxation of the 
smooth muscle of the bronchi that are 
constricted, thus relieving the difficulty in 
breathing. Because of differing 
theophylline content, the various salts and 
derivatives are not equivalent on a weight 
basis (refer to dosage). Theophylline is 
considered third line therapy because of its 
narrow therapeutic window. It is reserved 
for patients who are unresponsive to β2-
agonists or steroids. 
• INDICATIONS: 
Prophylaxis and symptomatic relief of 
bronchial asthma, as well as bronchospasm 
associated with chronic bronchitis and 
emphysema.  (Also used for emergency 
treatment of paroxysmal cardiac dyspnea 
and edema of CHF.) 
• CONTRAINDICATIONS: 
Hypersensitivity to xanthines or any 
derivatives (caffeine), coronary artery 
disease or angina pectoris when myocardial 
stimulation might be harmful, severe renal 
or liver impairment.  
• DOSAGE FORMS:  
Tablets, syrup, capsules, suppository 
(adults and infants). 
• RECOMMENDED DOSAGE:   
All doses are individualized, based on lean 
body weight. Dosages are based and 
adjusted on clinical response and 
improvement in pulmonary function with 
careful monitoring of serum levels.  
Monitoring of serum levels should be done 
during chronic therapy at 6-12 months 
intervals or when toxicity is suspected, it 
should be measured 1-2 hours after 
administration of immediate release 
products and 5-9 hours after the morning 
dose for sustained release formulations.  
Therapeutic range of 10-20 mcg/ml 
(narrow therapeutic range) plasma 
theophylline concentration should be 
maintained to avoid toxicity.  
(see table- 4.5,6,7 for equivalent doses, 
guidelines for dosing). 
*Better to take before meals, but if GI 
upset occurs, can take with food, and full 
glass of water. Take at same time each day, 
and adhere to the proper intervals between 
doses. 
*A low-carbohydrate, high-protein diet 
increases theophylline elimination, and a 
high-carbohydrate, low-protein diet 
decreases it. Charcoal-broiled foods may 
increase elimination and reduce the half-life 
as much as 50%. 
*Do not chew or crush enteric coated or 
sustained release tablets or capsules, unless 
specific product information identifies that 
capsule may be opened. 
*Avoid large amounts of caffeine-
containing beverages; i.e. tea, coffee, 
cocoa, cola or large amounts of chocolate, 
which may increase side effects. 
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Table – 4.5:  Theophylline Content and Equivalent Dose of  
Various Theophylline Salts 
Theophylline salt Theophylline % Equivalent Dose 
Theophylline anhydrous 100 100 mg 
Theophylline monohydrate 91 110 mg 
Aminophylline anhydrous 86 116 mg 
Aminophylline dihydrate 79 127 mg 
 *Drug Facts & Comparisons  2000, p. 655. 
 
 
Table – 4.6:  Dosage Guidelines for Rapid Theophyllinization*   
(patients not receiving theophylline) 
Patient Group Oral Loading Dose  
Maintenance 
Dose 
Maximum Daily 
Dose 
Children 1 to 9 years 5 mg/kg 4 mg/kg q.6h. 24 mg/kg/d 
Children 9 to 16, and young adult 
smokers 5 mg/kg 3 mg/kg q.6h. 20 mg/kg/d 
Otherwise healthy non-smoking 
adults 5 mg/kg 3 mg/kg q.8h. 
Older patients, patients with 
corpulmonale 
5 mg/kg 2 mg/kg q.8h. 
Patients with congestive heart 
failure 
5 mg/kg 1-2 mg/kg 
q.12h. 
13 mg/kg/d  
not to exceed 
dose, or 900 mg, 
whichever less. 
* Drug Facts & Comparisons 2000, p. 654. European countries may use different dosing regimens. 
 
 
Table – 4.7:  Dosage Adjustment After Serum Theophylline Measurement 
If serum theophylline is: Directions 
Too  low 5 to 10 mcg/ml  
Increase dose by about 25% at 3 day intervals until 
either the desired clinical response or serum 
concentration is achieved. 
Within desired 
range 10 to 20 mcg/ml 
Maintain dosage if tolerated.  Re-check serum 
concentration at 6-12 days. 
20 to 25 mcg/ml Decrease doses by about 10%.  Re-check doses after 3 days. 
25 to 30 mcg/ml Skip next dose and decrease subsequent doses by 25%.  Recheck level after 3 days. Too  high 
> 30 mcg/ml Skip next 2 doses and decrease subsequent doses by 50%.  Recheck levels after 3 days. 
 
• USE IN SPECIAL CASES:  
Pregnancy- Risk-benefit evaluation, use only 
if clearly needed (Category C). Theophylline 
seems to cross the placental barrier, but is not 
known if it can cause fetal harm. Neonatal 
irritability and apnea have been reported. 
Lactation- Theophylline distributes readily 
into breast milk. May cause irritability and 
other signs of toxicity in nursing infants. It 
might be advisable to nurse the infant just 
before the mother takes the drug. If side 
effects are apparent, a decision should be 
made whether to discontinue nursing or 
discontinue the drug, taking into account the 
importance of the drug to the mother. 
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Children- Use only when necessary.  Infants 
< 1 year of age have not been studied 
sufficiently, need to use extreme caution. 
Exercise caution in young children who 
cannot complain of minor side effects, and 
may experience toxicity. There has been 
some concern about the impact of 
theophylline on learning, attention and 
cognitive functions, but studies have not 
proven any real problems.  
Renal Disease- Use with caution, drug 
metabolites are excreted by the kidneys. 
Liver Disease- Need to use reduced doses for 
hepatic disease. The drug is extensively 
metabolized in the liver, and plasma 
clearance is reduced with hepatic function 
impairments leading to toxicity. 
• PRECAUTIONS AND WARNINGS:   
-Status asthmaticus is a medical emergency 
and is not rapidly responsive to usual doses 
of medication. Need intensive care setting. 
-Cardiac effects: Theophylline may cause 
dysrhythmias or worsen pre-existing 
arrhythmias. Any significant changes in 
cardiac rate or rhythm should be monitored. 
Use extreme caution in patients with 
cardiac disease. 
-Use caution in patients with hypoxemia, 
hepatic disease, peptic ulcer disease, 
hypertension, alcoholism, heavy smokers, 
the elderly (particularly males) due to 
decreased plasma clearance of medication, 
and neonates. All are candidates for toxicity 
effects. 
• ADVERSE EFFECTS:  
CNS stimulation; irritability, restlessness, 
insomnia, headache, tremor, palpitations, 
tachycardia, flushing, hypotension, nausea, 
vomiting, anorexia, epigastric or abdominal 
pain, diarrhea, activation of peptic ulcer, 
transient urinary frequency, kidney 
irritation, fever, dehydration, and in severe 
cases drug-induced seizures, circulatory 
failure or respiratory arrest. 
• INTERACTIONS: 
Drug effects on Theophylline levels; 
 
Agents that Decrease Level 
β-agonist sympathomimetics 
Barbiturates           Benzodiazepines 
Hydantoins             Ketoconazole 
Rifampin 
Smoking (cigarettes or marijuana) 
May Increase or Decrease 
Carbamazepine 
Influenza virus vaccine 
Isoniazid                  Loop diuretics 
Agents that Increase Level 
Allopurinol           Ca channel blockers 
Cimetidine            Corticosteroids 
Macrolides 
Non-selective β-blockers 
Oral contraceptives 
Thyroid hormones 
 
Caution should be used when using these 
medications with theophylline, adjust 
dosage of theophylline accordingly. 
• OVERDOSE: 
Symptoms include the adverse side effects, 
mainly: anorexia, nausea, vomiting 
nervousness, insomnia, irritability, tachy-
cardia, tachypnea, tonic/clonic convulsions, 
life-threatening ventricular arrhythmia, 
respiratory arrest. 
Overdose with sustained release prep-
arations may cause a dramatic increase in 
serum theophylline concentrations with 
time (≥ 12 hrs.). Early treatment will help 
but will not prevent these delayed elevated 
levels.   
Treatment: Transport to hospital as soon as 
possible. If seizure has not occurred induce 
vomiting, even if emesis has occurred 
spontaneously, ipecac syrup is preferred. 
Take precautions against aspirations 
especially in infants and children. If 
vomiting is unsuccessful or contraindicated 
(patient is unconscious), need to perform 
gastric lavage. If seizure occurs, establish 
an airway; administration of oxygen may 
be needed. Need to provide supportive 
measures as required and dialysis if needed. 
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• BRANDS: 
Asthma ‘T’ (Sam-On), Glyphillin (Teva), 
Somophyllin CRT (Fisons), Theo-dur (Key 
Pharmaceuticals), Theopharm (JePharm) 
Theotard (CTI), Theotrim (Trima). 
____________________________ 
 
 
2)  Salbutamol / Albuterol WHO,P 
 
• DRUG SUMMARY: 
Salbutamol, also called albuterol, is a 
synthetic sympathomimetic amine and 
moderately selective β2-adrenergic agonist 
with comparatively long action. Classified 
as an autonomic nervous system agent, β-
adrenergic agonist and a bronchodilator 
(respiratory smooth muscle relaxant). It has 
minimal or no effects on α-adrenergic 
receptors. It is effective as isoproterenol 
and metaproterenol, but produces more 
prolonged bronchodilation with little direct 
cardiac stimulation. 
• INDICATIONS: 
To relieve bronchospasm associated with 
acute bronchospasm or chronic asthma, 
bronchitis, or other reversible obstructive 
airway disease. Prophylaxis in exercise 
induced bronchospasm. 
• CONTRAINDICATIONS: 
Hypersensitivity to any component (allergic 
reactions are rare), cardiac arrhythmias 
associated with tachycardia. 
• DOSAGE FORMS: 
Tablets, syrup, aerosol, solution for nebulizer. 
• RECOMMENDED DOSAGE: 
Adults ≥ 12 y: PO:  2-4 mg t.i.d. or q.i.d.  
May increase, max. 32 mg/24h. 
Inhaled:     1-2 inhalations q. 4-6 h. 
Nebulized: 2.5-5mg q.i.d. 
Children 6-12 y: PO: 2 mg t.i.d. or q.i.d., 
may increase;  max. 24 mg/24h. 
Inhaled: 1-2 inhalations q. 4-6 h. 
Nebulized: 2.5mg q.i.d 
Children < 6 y:  PO: 0.1 mg/kg t.i.d. may 
be increased to 0.2 mg/kg t.i.d.,  
max. 12 mg/24h. 
Nebulized: 0.15 mg/kg q.i.d. 
Directions: Give explicit directions for use 
of inhaler to the patient.  Periodically check 
the adequacy of patient’s technique and 
compliance, especially if no improvement 
is observed. 
Proper nebulizer use: Dilute the dose of 
solution for nebulizer in sterile normal saline 
to a total volume of 3 ml and administer over 
5-10 minutes period. 
Metered dose inhaler: shake the inhaler with 
canister in place for 5-10 seconds, breathe out 
to the end of a normal breath, hold the inhaler 
system upright, place the mouth piece into the 
mouth, close the lips tightly or position the 
mouth piece 2-3 fingers width from the open 
mouth and tilt head slightly backwards. While 
activating the inhaler, take a slow deep breath 
for 3-5 seconds, hold breath for 10 sec and 
exhale slowly. Allow 1 min between 
inhalation.    
*If the required effective dose fails to 
provide relief, it could be a sign for 
seriously worsening asthma, which requires 
reassessment of therapy. Patient should not 
increase the number or frequency of 
inhalations without medical advice. 
*If the patient is to receive beclomethasone 
inhalation treatment, salbutamol should be 
administered 20-30 minutes before. 
For infants and young children, inhaled 
medications can be delivered through 
aerochamber or babyhaler and to older 
children through spacer.   
• USE IN SPECIAL CASES:  
Pregnancy- There are no adequate studies in 
pregnant women (Category C). Salbutamol 
may cross the placental barrier. Use if 
potential benefit outweighs potential risk to 
the fetus. Oral salbutamol has delayed pre-
term labor, avoid use. 
Lactation- It is not known whether 
salbutamol is excreted in breast milk. Use 
only when benefit outweighs the potential 
risk on the nursing infant. 
Children- This drug has been used in young 
children even though its safety and efficacy 
has not been established for children < 2 yrs. 
old for syrup and nebulizer, 6 yrs. for tablets. 
Note that children appear to be more 
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susceptible to experience CNS stimulation; 
hyperactivity, excitement, and insomnia. 
Renal Disease- Use with caution. The drug is 
eliminated in the urine in 3 days.  
Liver Disease- Use with caution. Salbutamol 
is metabolized in the liver. 
• PRECAUTIONS AND WARNINGS:   
-Special risk patients; use caution with 
patients with diabetes mellitus, hyper-
thyroidism, and severe cardiovascular 
disease. 
-A common adverse effect associated with 
the oral form of drug is fine tremor in 
fingers, which may interfere with precision 
handwork. Keep informed of any unusual 
symptoms. 
• ADVERSE EFFECTS: 
Tremor of the hands, anxiety, nervousness, 
headache, palpitation, hypertension or 
hypotension, dilated pupils, hoarseness, 
nausea, muscle cramps, and possible 
hypersensitivity reactions such as rash 
(rarely with inhaled salbutamol). The 
patient should be warned about such things.  
In severe cases can cause convulsions and 
reflex tachycardia. 
• INTERACTIONS:   
Overview  of  Salbutamol 
Drug-Drug Interaction 
Drug Interaction 
Epinephrine, 
or other 
sympatho-
mimetic 
broncho-
dilators 
An additive effect when 
administered with these might 
occur. Patients should be 
advised to avoid OTC drugs, 
such as cold remedies, 
without consulting a doctor or 
pharmacist. 
Beta-
adrenergic 
blockers 
These antagonize the effects 
of sympathomimetics. Do not 
administer both medications 
together. 
Tricyclic anti-
depressants 
May potentiate the action of 
sympathomimetics on the 
vascular system, use caution. 
 
• OVERDOSE: 
Symptoms due to inhalation include an 
exaggeration of the side effects listed in 
adverse effects. Seizures, hypokalemia and 
hypertension may result.   
Treatment includes general supportive 
measures. Sedatives (barbiturates) may be 
given for restlessness. Use of a cardio-
selective β-receptor blocker (i.e. 
metoprolol) is suggested, bearing in mind 
the danger of inducing an asthmatic attack.  
Dialysis is not appropriate. 
Symptoms due to oral absorption; 
palpitation, tachycardia, heart block, 
delirium, chills, nausea and vomiting, as 
well as the above symptoms can occur.   
Treatment: Emesis, gastric lavage or 
charcoal may be useful following overdose 
with the oral agent.  Need to use supportive 
measures. 
• BRANDS: 
Aerolin (3M), Asmalin (Agis), Fedral (Eastern 
Chem.), Salbuvent (Leiras), Ventocare 
(Pharmacare), Ventolin/ Volmax (Glaxo), 
Ventomin (Megapharm). 
____________________ 
 
3)  Cromolyn WHO,P 
     (Cromoglycate) Sodium 
 
• DRUG SUMMARY: 
Cromolyn sodium, also known as 
cromoglycate, is a synthetic antiasthmatic, 
antiallergic, mast cell membrane stabilizer. 
It has no antichlolinergic, antiinflam-
matory, or vasoconstrictor activity. It is of 
no value in the treatment of an acute 
attack/quick relief.  Regular inhalation can 
reduce the incidence of asthma attacks, and 
allow dosage reduction of bronchodilators 
and oral corticosteroids, and is best used for 
the prevention of exercise induced asthma 
especially in children. 
• INDICATIONS: 
Primarily used for prophylaxis of mild to 
moderate seasonal and perennial bronchial 
asthma and allergic rhinitis.  Also used for 
prevention of exercise related broncho-
spasm (prevent bronchoconstriction), 
prevention of acute bronchospasm induced 
by known pollutants or antigens.  Used as 
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ophthalmic preparations for allergic ocular 
disorders. 
• CONTRAINDICATIONS: 
Hypersensitivity to cromoyln or any of its 
components. 
• DOSAGE FORMS: 
Inhalation, syrup. 
• RECOMMENDED DOSAGE: 
See table-4.8. 
 
Directions: It is important to inform the 
patient that effectiveness of therapy 
depends upon administration at regular 
time intervals.   
*Onset of action requires 1 week for full 
effectiveness. Duration of effect lasts 4-6 
hrs., and may last as long as 2 weeks. 
*A trial of 8-12 wks. should be conducted 
before determining that cromolyn is 
ineffective. 
*Treatment with cromolyn 15 minutes 
before doing protracted exercises, it 
reportedly blunts the effects of vigorous 
exercise as well as cold air.   
 
 
*Advise patient to clear as much mucus as 
possible before inhalation treatments. 
*Inform patient that throat irritation, cough, 
hoarseness can be minimized by gargling 
with water. Drinking a few swallows of 
water will help. 
*Cromolyn does not eliminate the 
continued need for therapy with 
bronchodilators, expectorants, antibiotics, 
or corticosteroids, but the amount and 
frequency of use of these medications may 
be reduced. 
 
 
 
 
 
 
 
 
 
 
 
Table - 4.8:  Recommended Doses of Cromolyn 
(Aerosol inhaler) Asthma Bronchospasm‡ 
Adults and children  
≥ 5 y 
2 puffs inhaled, 4 times 
a day 
2 sprays inhaled 10-15 min before 
exposure to the precipitating factor 
Children ≤ 4y  Safety  and  efficacy  has not been established 
(Ketotifen may be used under a specialist’s supervision) 
Nebulizer solution & 
Inhalation capsules via 
spinhaler  
Asthma Bronchospasm‡ 
Adults and children  
(> 5 y for capsules, and 
 ≥ 2 y for nebulizer 
solution) 
20 mg (1 amp. or 1 cap.) 
4 times a day at regular 
intervals 
20 mg (1 amp. or 1 cap.) 
No more than 1 hour before 
exposure to the precipitating factor. 
‡ Bronchospasm due to exercise or environmental agents. 
* Drug Facts & Comparisons 2000, p. 681. 
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• USE IN SPECIAL CASES:  
Pregnancy- Use Cromolyn only when benefit 
outweighs potential risk. Safe use during 
pregnancy has not been established. Animal 
studies have demonstrated adverse fetal 
effects (Category B). 
Lactation- Use caution. Safety for use in 
nursing mothers has not been established. 
Children- Safety and efficacy have not been 
established for aerosol in children < 5 y. and 
for nebulizer in < 2 y. Oral use should be 
cautiously used in children < 2 y. under direct 
pediatrician’s supervision.    
Renal + Liver Disease- Decrease of dose or 
discontinuation may be advisable in severe 
cases of renal or hepatic impairment. 
• PRECAUTIONS AND WARNINGS:   
-Cromolyn has no role in the treatment of 
acute asthma, make sure to inform the 
patient about this. 
• ADVERSE EFFECTS:  
Dizziness, headache, lacrimation, rash, 
joint pain and swelling, nausea, nasal 
itching or burning, sneezing, dry or irritated 
throat, urinary frequency, and cough have 
all been reported. 
• INTERACTIONS:   
No interactions have been reported. 
• OVERDOSE: 
Stop administration of medication. In 
accidental overdose, no action other than 
medical observation should be necessary. 
• BRANDS: 
Cromunal Inhaler (Agis), Lomudal Spin 
Capsules (Fison), Lomudal Nebuliser Solution 
(Fisons), Nalcrom Oral Capsules (Fisons), 
Vicrom Inhaler (Fisons). 
________________________ 
 
4)  Beclomethasone 
Dipropionate WHO,P 
 
• DRUG SUMMARY: 
A synthetic corticosteroid structurally 
related to hydrocortisone, with potent 
glucocorticoid (anti-inflammatory) and 
weak mineralocorticoid activity. Unlike 
hydrocortisone, therapeutic doses do not 
suppress the hypothalamic-pituitary-
adrenocortical function or produce other 
systemic effects. Because asthma is 
predominantly an inflammatory disease, 
inhaled corticosteroids are becoming 
important in chronic asthma therapy. They 
are not to be used during an acute asthma 
attack because they don’t give fast relief 
like salbutamol. They are not to be used for 
chronic bronchitis or emphysema either. 
• INDICATIONS: 
Oral inhalation to treat chronic asthma 
adjunctively with other therapy (sympatho-
mimetics, xanthines), when these are 
insufficient in controlling asthma. Relief of 
symptoms of seasonal or perennial rhinitis 
in those cases poorly responsive to 
conventional treatment. Allergic and 
vasomotor rhinitis. 
• CONTRAINDICATIONS: 
Hypersensitivity to the drug or any 
component of the product.   
Untreated localized infections involving the 
nasal mucosa (i.e. fungal infections of 
Candida albicans), and status asthmaticus. 
• DOSAGE FORMS: 
Aerosol (50 mcg/metered dose: 1-inhalation), 
nasal spray, inhalation caps. 
• RECOMMENDED DOSAGE: 
Refer to table 4.4. 
For inhalation for asthma; 
Adults:  
Low dose: 200-500 mcg/day (4-10 puffs) in 
2-4 divided doses 
Medium dose: 500-800 mcg/day (10-16 puff) in 
2-4 divided doses 
High dose: > 800 mcg/day (16 puffs) in 2-4 
divided doses  
Max. 20 inhalations/24 h. 
Children (<12 yrs):  
Low dose: 100-300 mcg/day (2-6 puffs) in 
2-4 divided doses. 
Medium dose: 300-600 mcg/day (6-12 
puffs) in 2-4 divided doses. 
High dose:  > 600 mcg (> 12 puffs) 
(200 mcg/dose is not indicated for children). 
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For allergic Rhinitis; 
Adults: 1 spray in each nostril b.i.d. to q.i.d. 
Children (6-12 yrs): 1 spray in each nostril 
3 times a day  
(< 6 yrs): no recommended dosage since no 
sufficient data is available. 
 
Directions: Clear nasal passages of 
secretions prior to use. If nasal passages are 
blocked, use a decongestant before 
administration to ensure adequate 
penetration of the spray.  
*Use the bronchodilator (salbutamol) 
several minutes before inhaling the 
corticosteroid, to enhance penetration of the 
steroid into the bronchial tree. 
*Effects are not immediate and benefit 
requires regular use and usually occurs 
within 1-4 weeks. 
• USE IN SPECIAL CASES:  
Pregnancy- Topical administration of 
recommended dosage is unlikely to achieve 
significant systemic levels; however, use 
these agents during pregnancy only if the 
potential benefits outweigh the potential 
hazards to the fetus (Category C). 
Lactation- Use caution when administering to 
nursing women. It is not known whether 
these inhaled drugs are excreted in breast 
milk. 
Children- the most recent guidelines issued 
by the National Asthma Education & 
Prevention Program use this drug in children 
< 6 yrs., even though there is no safety and 
efficacy reports for use; therefore the drug 
should be used with caution. Growth 
retardation does not seem to be a problem 
associated with inhalation administration in 
recommended doses. Spacer devices may 
improved delivery in this age group, and 
reduce possible adverse effects of the inhaled 
corticosteroid. 
• PRECAUTIONS AND WARNINGS:   
-Localized fungal infections with Candida 
albicans or Aspergillus niger have occurred 
in mouth, pharynx and occasionally in the 
larynx. Decrease or discontinue aerosol 
steroid treatment and use appropriate 
antifungal therapy. 
• ADVERSE EFFECTS: 
Sneezing after administration; rarely 
dryness and irritation of nose and throat, 
and epistaxis. Hoarseness and oral 
candidiasis may occur, these effects may be 
minimized by using a spacer device or by 
rinsing the mouth after each usage. 
• INTERACTIONS:   
No major interactions have been reported 
when using the inhalation in the 
recommended doses. 
• OVERDOSE: 
If recommended doses of intranasal 
beclomethasone are exceeded or if 
individuals are particularly sensitive or 
predisposed by virtue of recent systemic 
steroid therapy, symptoms of hyper-
cortisolism may occur, including, very 
rarely, menstrual irregularities, acneiform 
lesions and cushingoid features. If such 
changes occur, discontinue slowly, 
consistent with accepted procedures for 
discontinuing oral steroids. 
• BRANDS: 
Bacloforte Inhaler (Glaxo), Beconase Nasal 
Aerosol (Glaxo), Becotide Inhaler (Glaxo), 
Viarex Inhaler (Schering USA). 
____________________________ 
 
 
5)  Prednisolone WHO,P 
 
Refer to the Endocrine chapter under 
prednisone for further details. 
Acute attack of asthma should be treated 
with short course of oral corticosteroid  
Dose in acute asthma: 1-2 mg/kg/day PO in 
2-3 divided doses for 5-7 days. No need to 
taper it if it is used less than 1 week. Some 
schools recommend a short course of 3-5 
days, given once in the morning with no 
tapering (Nelson, 2001).   
Alternate day administration has not been 
successful in the management of asthma 
because control tends to diminish during 
the second 24 hours. Dosage should always 
be titrated to the lowest dose that control 
symptoms.  
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Patients who have been taking long-term 
oral corticosteroids can be transferred to an 
inhaled product, but the transfer should be 
done slowly with gradual reduction in the 
oral dose, at a time when the asthma is well 
controlled.  
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Chapter  5 :   ANTI- INFECTIVE  DRUGS 
 
 
 
 
A)  ANTI-BACTERIALS 
1. Penicillins 
2. Cephalosporins 
3. Tetracyclines 
4. Macrolides 
5. Sulphonamides and Trimethoprim 
6. Nitrofurantoin (UTI) 
7. Nalidixic Acid (UTI) 
8. Fluoroquinolones (UTI) 
 
B)  ANTI-TUBERCULOSIS 
1.  Isoniazid 
2.  Rifampicin 
3.  Pyrazinamide 
4.  Ethambutol 
 
C)  ANTI-PARASITICS 
1.  Metronidazole 
2.  Diloxanide Furoate 
3.  Mebendazole 
4.  Niclosamide 
5.  Albendazole (hydatid disease) 
 
D)  ANTI-FUNGALS 
1.  Nystatin 
2.  Miconazole 
3.  Griseofulvin 
 
C)  ANTI-VIRALS 
1.  Acyclovir 
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ANTI-INFECTIVES 
 
Anti-infectives are those agents that are 
used for the treatment of infections by 
suppressing or destroying the causative 
microorganisms (bacteria, mycobacteria, 
fungi, protozoa, or viruses).  
 
Anti-infective agents should be used only 
when: 
a. A significant infection has been 
diagnosed or is strongly suspected. 
b.  An established indication for prophy-
lactic therapy exists. 
 
Abuse of these agents causes super-
infections, cross-sensitivity and cross-
resistance, resulting in inappropriate 
treatment and in consequent advserve 
reaction in adition to wastage of money. 
 
DEFINITIONS: 
◊ Bacteriostatic agents: Agents that 
inhibit the growth of the microorganisms 
by producing reversible changes. This 
delay in the growth will give the immune 
system the chance to get rid of the 
microorganism. 
◊ Bactericidal agents: Agents that kill the 
microorganism.  
(Being a bactericidal or a bacteriostatic 
agent depends on the mechanism of action 
of the antibacterial agent and on its 
concentration.) 
◊ Narrow spectrum: The range of activity 
for agents that kill the micro-organism is 
small. It affects 1-2 classes of micro-
organisms only. For example, Penicillin-G 
affects G+ve organisms and Neisseriae. 
◊ Broad spectrum: The range of activity 
extends to many micro-organisms. For 
example, Tetracyclines depress G+ve, G-
ve, Rickettsiae and Chlamydiae. 
 
Separation between narrow and broad-
spectrum activity is not clear due to the 
emergence of many resistant strains due to 
the overuse of these antibiotics. Broad-
spectrum antibiotics should be restricted to 
treatment of specific infections caused by a 
few organisms or even a single species of 
organism. The property of broad specifica-
tion should not be confused with a free  
license for broad-nonspecific use. 
◊ Superinfection (suprainfection): Is the 
appearance of both microbiological and 
clinical evidence of a new infection with 
pathogenic microorganisms or fungi not 
sensitive to the used drugs during 
antimicrobial treatment of a primary 
disease. The body's natural resistance is 
compromised, making it more susceptible 
to secondary infections by more dangerous 
strains. 
◊ Auto-infection: Infection by an 
organism existing within the body or 
transferred from one part of the body to 
another. 
 
ABUSE OF ANTIMICROBIAL AGENTS: 
Antibacterials are valuable drugs if used 
appropriately.  They are very effective in 
treating infections if used in appropriate 
doses, at appropriate intervals and for the 
appropriate period of time against sensitive 
microorganisms. 
  
They should not be used in the following 
cases: 
1. To treat all infections (e.g. viral infections 
or nonspecific inflammation).  
2. For minor infections (e.g. superficial 
bruises).  
3. Just because it is a new agent on the 
market, while there is already another 
effective and cheaper alternative in use. 
 
BACTERIAL RESISTANCE: 
Antimicrobial agents are loosing their 
effectiveness because of the spread of drug-
resistant strains. Therefore, there might 
come a time when such agents are no 
longer useful to combat diseases. 
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The problem of microbial resistance is 
global and is the result of widespread and 
indiscriminate use of antimicrobial drugs in 
man, animal and agriculture. Some bacteria 
are naturally resistant to certain antibiotics 
(e.g. Staphylococcus), but often resistance 
is acquired. Bacteria can become resistant 
by incorporating a “resistance factor” into 
their genes to render the antibiotic 
ineffective. This can pass quickly to other 
bacteria and this is called cross-resistance. 
Multiple resistance, where bacteria are 
resistant to several antibiotics, can also be 
transferred from one species to another (i.e. 
Mycobacteria). 
Emerging bacterial resistance is 
increasing world wide. For example, 
methicillin resistant Staph. aureous 
(MRSA), vancomycine resistant staphylo-
coccus, and Strep. pneumonia resistant to 
penicillins. Culture analysis is required to 
identify proper treatment in these cases. 
Antibiotics given concurrently are 
useful in very specific circumstances (e.g., 
as part of a mixed drug treatment in 
tuberculosis).  Fixed-ratio combinations of 
antibiotics (other than co-trimoxazole) have 
few indications. The US FDA has 
withdrawn almost all fixed dose 
combinations. There is only one drug kept 
(co-trimoxazole) on the WHO list of 
essential drugs.  According to the WHO, 
“Special mention must be made of the use 
of preparations containing two or more 
antibiotics in fixed ratio.  Their spectrum of 
activity is often so wide that they have 
undesirable effects on the body, few of them 
have notable therapeutic advantages and 
they are generally costly.”  
 
SELECTING AN ANTI-INFECTIVE 
AGENT: 
When you want to choose an anti-infective 
agent, you should take into consideration 
the following parameters: 
 
a. The spectrum of activity of the anti-
infective agent: It should be active against 
the causative pathogen.  This can be known 
by carrying the susceptibility tests or by a 
good clinical experience in treating a given 
syndrome that will help in suggesting a 
potential effective agent. 
b. Patient factors: These factors play a very 
important role in the selection of a specific 
anti-infective agent, determination of the 
appropriate drug dosage and route of 
administration,...etc. Those factors include: 
1. History of drug allergy or adverse 
reactions. Anaphylaxis or reactions due to 
immunoglobulin E (IgE) may be life 
threatening when taking penicillins. 
2. Age: A drug’s pharmacokinetic 
properties vary widely in patients of 
different age groups. 
3. Underlying disease:  
-A pre-existing kidney and liver disease. 
-CNS disorder. 
-Neuromuscular disorders. 
4. Immunological status: Patients with 
impaired immune system require a 
bactericidal agent rather than a bacterio-
static one. 
5. Pregnancy and lactation. 
6. Genetic traits. 
7. Presence of a foreign body: It has been 
found that the presence of prosthetic joints 
or valves, cardiac pacemakers, and various 
internal shunts may reduce the 
effectiveness of many anti-infective agents. 
 
DURATION OF ANTI-INFECTIVE 
THERAPY: 
Acute cases: Treatment of acute 
uncomplicated infections generally should 
continue until the patient has been afebrile 
and asymptomatic for at least 72 hours 
(minimum 5 days in most cases). Other 
cases as in Strep. throat (Streptococcal 
pharyngitis) should be treated for 7-10 
days. Some infections require a proof of 
eradication by culture. 
Chronic cases: Treatment of chronic 
infections (e.g., endocarditis, osteomyelitis) 
may require a longer duration (4 to 6 
weeks), with a follow-up culture analysis 
afterwards.  
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LACK OF THERAPEUTIC EFFECT-
IVENESS: 
This problem arises due to one or more of 
the following reasons: 
 
a. Misdiagnosis (inappropriate indication): 
Either a doctor’s or a lab’s error of identified 
organism (the causative agent of the specific 
infection). 
b. Improper drug regimen: Either the dose 
or the route of administration, or dosing 
frequency, or the duration of therapy is 
inappropriate. 
c. Inappropriate choice of antibiotic agent: 
Occurs when the patient’s factors and the 
agent’s spectrum, or the agent’s 
pharmacological properties, are not taken into 
consideration or when another agent might be 
more suitable for the case.  
d. Using a combination of bacteriostatic 
and bactericidal agents: Each one will 
eliminate the effect of the other. Bactericidal 
agents need the microorganism to be active in 
order to kill it while a bacteriostatic agent 
inhibits the growth of the microorganisms. 
e.  Microbial resistance. 
f. Unrealistic expectations: For example, 
fever should not be treated by antibiotics 
since it may occur due to other non-infectious 
causes. In cases where surgical drainage is 
required or renal calculi are present, antibiotic 
failure is expected. 
g. Infection by two or more micro-
organisms (mixed infection). 
h. Improper formulation of the final dosage 
form, the raw materials quality and storage, 
or improper manufacturing procedures; such 
as compression and coating, that will interfere 
with the bioavailability of the final product. 
i. Patient compliance: Patients frequently 
discontinue antibiotic therapy when they feel 
better. Unfortunately these individuals may 
then self-prescribe the remaining antibiotic 
for themselves or for others at some other 
time. On the other hand patients might forget 
to take all of the scheduled doses or find it 
difficult to wake up for a dose. All of these 
problems with patient compliance might lead 
to lack of therapeutic effectiveness. 
j. Unpleasant side effects that the patient 
cannot handle for example diarrhea, 
constipation, stomach upset ...etc. 
 
STORAGE OF THE ANTI-INFECTIVE 
AGENTS: 
Generally, antibiotics should be stored in a 
cool dry place and protected from sunlight 
as they undergo degradation in high 
temperatures. Most suspended forms should 
be kept in the refrigerator after being mixed 
with water (check individual packages). 
 
EXPIRATION DATE OF THE ANTI-
INFECTIVE AGENTS: 
Tablets, capsules:  As indicated on the box. 
Dry suspensions: The expiry date that is 
indicated on the box is for the dry powder 
before suspending or diluting with purified 
water. 
After dilution: Normally, the bottle of 
medication should be used within 5-7 
days.  Refer to the label on the bottle. If 
the diluted suspension lasted for more 
than the assigned time duration, this 
might be an indication of misuse or wrong 
dilution. The suspension left should not be 
used after 7-14 days from the day of 
dilution (always check the manufactures 
label). 
_____________________________ 
 
 
A)  ANTI-BACTERIALS 
 
Antibacterials are divided into subgroups, 
and are presented as such: Penicillins, 
cephalosporins, tetracyclines, macrolides, 
sulphonamides and trimethoprim, and 
antibiotics used in urinary tract infection 
(UTI). 
 
1)  Penicillins (β-Lactam) 
Agents of this group are characterized by 
the presence of a β–lactam ring in their 
structure. This ring is the one responsible 
for their activity.  
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Penicillins are the drugs of choice for the 
treatment of a wide variety of infections 
caused by various susceptible micro-
organisms. The three major groups of 
penicillins are: 
a. Benzylpenicillin & phenoxymethyl-
penicillin (natural penicillin) 
b. Cloxacillin & flucloxacillin (penicillinase 
resistant penicillin) 
c. Ampicillin & Amoxicillin (amino-
penicillin) 
 
Penicillins are bactericidal agents that 
produce their antibacterial activity via 
inhibiting the synthesis of the bacterial cell 
wall. 
 
a)  Benzylpenicillin WHO,P &  
     Phenoxymethyl penicillin WHO,P 
 
• DRUG SUMMARY: 
These two are known as the natural 
penicillins. They are the first two 
penicillins that were discovered and are still 
in use. Natural penicillins are narrow 
spectrum antibiotics and are only active 
against facultative gram-positive cocci, 
rods and gram-negative cocci. Several 
anaerobic gram-negative rods are sensitive 
to penicillin, with the notable exception of 
Bacteroides fragilis. 
Benzylpenicillin (Pen. G) is the drug of 
choice in streptococcal, pneumococcal, 
gonococcal, and meningococcal infections. 
It is also used in anthrax, diphtheria, gas-
gangrene, leptospirosis, syphilis, tetanus, 
yaws, and in the treatment of lyme disease 
in children. It is inactivated by the gastric 
fluids, and absorption from the gut is low; 
therefore it is best given by injection. In 
addition to the use of Pen. G as sodium or 
potassium salts (soluble Pen. G), it is also 
available in two other salts that are 
commonly used.  They are: 
a- Procaine penicillin: a sparingly soluble 
salt of benzylpenicillin. It is used in intra-
muscular depot preparations that provide 
therapeutic tissue concentrations for up to 
24 hrs. It is the preferred choice for the 
treatment of syphilis, but neurosyphilis 
requires special consideration. 
b- Benzathine penicillin: a benzylpenicillin 
salt with a very low solubility, giving a 
prolonged action after intramuscular 
injection. Its duration of action is 20 days. 
 
Phenoxymethyl penicillin (Pen. V) has 
a similar antibacterial spectrum as Pen. G, 
but it is less active. It is gastric acid stable 
so it is suitable for oral administration. It 
should not be used for serious infections 
because absorption can be unpredictable 
and plasma concentrations are variable.  
• INDICATIONS: 
Benzylpenicillin is mainly indicated for the 
treatment of: throat infections, otitis media, 
streptococcal endocarditis, meningococcal 
and pneumococcal meningitis (if caused by 
susceptible microorganism), and as a 
prophylactic agent after limb amputation. 
Also it is used in combination with other 
agents if more than one organism are 
suspected. 
Phenoxymethyl penicillin is indicated 
principally for respiratory tract infections in 
children, for Streptococcal tonsillitis and for 
continuing treatment after one or more 
injections of Pen. G when clinical response 
has begun. It should not be used for 
meningococcal or gonococcal infections. It is 
used prophylactically against rheumatic fever 
following streptococcal infections. 
• CONTRAINDICATIONS: 
They are contraindicated in the case of 
hypersensitivity to any of the penicillins or 
cephalosporins. Procaine penicillin is also 
contraindicated in the case of hyper-
sensitivity to procaine or any other “caine-
type” local anesthetic. 
• DOSAGE FORMS: 
Benzylpenicillin:  vial. 
Phenoxymethyl penicillin:  tablet, suspension. 
 
Directions: It is recommended that 
performance of a skin sensitivity test as well 
as taking a good history, before giving 
penicillins be done; adrenaline, dexa-
methasone and aminophylline injections 
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should readily be available for treatment in 
case of anaphylactic shock.  (Reported 
incidence of anaphylactic shock is between 
0.015-0.04%.) 
Food increases the breakdown of such 
penicillins in the stomach. These agents are 
best taken on an empty stomach either one 
hour before meal or two hours after. 
• USE IN SPECIAL CASES: 
Pregnancy- Natural penicillins cross the 
placenta with low concentrations, and in 
general are safe during pregnancy 
(Category B). Nevertheless, these agents 
should be used only when it is clearly 
indicated.  
Lactation- Compatible. Penicillins are 
excreted in breast milk in low 
concentrations; use may cause diarrhea, 
candidiasis or allergic response in the 
nursing infant. 
Liver diseases-  Use with caution. 
Kidney diseases- Cautious use, since the 
kidney excretes penicillins. Avoid benzyl-
penicillins in renal failure. 
• PRECAUTIONS AND WARNINGS: 
Caution should be taken in case of:  history 
of or suspected allergy (asthma, eczema, 
hay fever, hives), myasthenia gravies, 
epilepsy, neonates, young infants.  
If Pen. G Na is to be administered, take 
caution in patient with restricted Na intake. 
Benzylpenicillins may cause convulsions 
after high doses by IV or in renal failure. 
• ADVERSE EFFECTS: 
For most people it is one of the safest 
drugs.  
Some side effects that have been reported: 
in the case of parenteral penicillin, injection 
site reactions might occur. Electrolyte 
disturbances might occur with penicillin-G 
Na and K salts due to accumulation of these 
salts in the body. 
In the case of phenoxymethyl penicillin one 
might suffer from the following side 
effects: Nausea, vomiting, diarrhea, 
epigastric distress, hypersensitivity reactions 
(flushing, pruritus, urticaria or other skin 
eruptions, eosinophilia, anaphylaxis), 
hemolytic anemia, leukopenia, thrombo-
cytopenia, neuropathy, superinfections. 
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• RECOMMENDED DOSAGE: 
 
Penicillin 
Derivative Indication Age 
Route of 
administ-
ration 
Dose 
Adult IV/IM 1.2-2.4 million IU divided   q. 4-6 h. 
 
Moderate to severe 
infections* 
Child IV/IM 25,000-300,000 IU/kg divided q. 4 h. 
Adult  IV/IM 1.2 g 
> 10 y. IV/IM As for adults 
Child;  
1-10 y. IV/IM 600 mg 
 
Benzyl- 
penicillin 
(Pen. G) 
If meningococcal disease 
is suspected GP are 
advised to give a single 
injection of benzyl-
penicillin before sending 
the patient to the hospital Infants IV/IM 300 mg 
Adult IM 1,200,000 IU once/d  
Mild to moderate 
infections * (including 
tonsillitis) 
Child IM > 27 kg: 900,000 IU once/d. 
< 27 kg, or < 5 yrs: 300,000-
600,000 IU single dose. 
Syphilis Adult IM < 1 y duration: 
2,400,000 IU as single dose. 
> 1 y duration: 
2,400,000 IU/wk for 3 wk. 
 Child IM Congenital: 50,000 IU/kg as single dose. 
Adult IM 1,200,000 IU every 4 weeks 
 
Benzathine 
penicillin 
Prophylactic for 
rheumatic fever Child IM 1,200,000 IU once for 
prevention, and every 3-4 
weeks for prevention of 
recurrence. 
Adult IM 600,000-1,200,000 IU  once/day for 10-14 days. 
Moderate to severe 
infections * 
Child IM 300,000  IU (0.3 g) once/day 
Pneumococcal Pneumonia Adult IM 600,000 IU q. 12 h. 
 
Procaine 
penicillin 
Uncomplicated 
Gonorrhea (if sensitive to 
penicillins) 
Adult IM 4,800,000 IU divided 
between two different 
injection sites at one visit, 
preceded by 1 g of 
probenecid 30 min. before 
inj. 
 Syphilis Adult IM Primary, secondary, latent: 
600,000 IU/day for 8 days.  
Late latent, tertiary, 
neurosyphilis:  600,000 IU 
/day for 10 to 15 days. 
  Child IM 500,000-1,000,000  IU/m2,  
once/day. 
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Adult PO 125-500 mg q. 6 h.  Mild to moderate 
infections * Child 
< 12 y 
PO 15-50 mg/kg/d in 3-6 
divided doses. 
Adult PO 2 g 30-60 min. before 
surgical procedure; then 
500 mg q. 6 h. for 8 doses. 
 
Phenoxy- 
methyl 
penicillin 
(Pen. V) 
Endocarditis Prophylactic 
Child PO < 30 kg;  1 g 30-60 min. 
before procedure; then 250 
mg q. 6 h. for 8 doses. 
* Moderate to severe infections include: Otitis media, Streptococcal throat infections, 
Meningococcal and Pneumococcal Meningitis, and Strep.Endocarditis. 
 
 
• INTERACTIONS: 
Overview  of  Penicillins 
Drug-Drug Interactions 
Drug Interaction 
Erythro-
mycin 
Coadministration effect of a 
penicillin and erythromycin is 
unpredictable.  Some studies 
have shown antagonist effect, 
while others showed a 
synergistic effect when 
bactericidal effects are 
desirable.  
Use combination only when 
either drug alone has failed. 
Oral contra-
ceptive 
Pen. G decreases the efficacy of 
these agents. Use additional 
methods (e.g. condoms). 
Potassium 
sparing 
diuretics  
May cause hyperkalemia with 
Pen. G potassium.  Avoid 
concomitant use. 
Probenecid It decreases renal elimination of 
penicillins producing higher 
and more prolonged plasma 
concentration. This is beneficial 
in treatment of gonorrhea. 
 
Large doses of penicillin may cause false 
positive test results with Benedict’s solution, 
in urine glucose test; but not with glucose 
oxidase method. 
• OVERDOSE: 
This may arise with the use of massive 
doses of IV penicillin (40 to 100 million 
units/day). Penicillins overdose can lead to 
neuromuscular hyper-excitability or 
convulsive seizures. It is more commonly 
to occur in patients with severe renal 
impairment.  
Symptoms may include: agitation, 
confusion, hallucinations, stupor, coma, 
seizures, and encephalopathy. Hyper-
kalemia is also possible.  
Management is by symptomatic treatment.  
Hemodialysis may be used in severe cases. 
• BRANDS: 
Bepen V.K. (BPC), Fenoxypen (Novo Nordisk), 
Mega (Rafa), Rafapen V-K (Rafa), Rafapen 
Oracillin (JePharm) 
________________________ 
 
b) Cloxacillin WHO,P & flucloxacillin 
    (Penicillinase resistant penicillins)  
 
• DRUG SUMMARY: 
Most staphylococci are now resistant to 
benzylpenicillin because they produce 
penicillinases.  
Cloxacillin and flucloxacillin are not 
affected by such enzymes, so they are 
effective in infections caused by penicillin 
resistant staphylococci, but they are less 
potent than Pen. G against penicillin 
sensitive microorganisms, and generally 
ineffective against G-ve bacteria and 
methicillin resistant staphylococci. The 
only difference between cloxacillin and 
flucloxacillin is that flucloxacillin has a 
higher bioavailability than cloxacillin after 
oral administration. Another two examples 
of this group are Methicillin and 
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Temocillin. However, only the first two 
will be discussed. 
Notes: Sulbactam is another β-lactamase 
inhibitor that is used in combination with 
ampicillin. Two commonly used 
combinations in the market are ampicillin 
with flucloxacillin (Megacare, Magnicillin) and 
amoxicillin with cloxacillin (Clamoxin). 
• INDICATIONS: 
Cloxacillin and flucloxacillin are indicated 
for the treatment of infections caused by 
penicillinase producing Staphylococci. 
• CONTRAINDICATIONS: 
Hypersensitivity to penicillin. 
• DOSAGE FORMS: 
Cloxacillin:  Capsules and suspension.   
Flucloxacillin: Not available in a separate 
formulation, but as combination with 
ampicilin in Capsules. 
• RECOMMENDED DOSAGE: 
 
Mild to Moderate Upper Respiratory & 
Localized Skin and Soft Tissue Infections 
Adults and children 
(> 20 kg) 250 mg q. 6 h. 
Children  
(< 20 kg) 
50 mg/kg/day in 
equally divided 
doses q. 6 h. 
Severe Infections  
(Lower Respiratory Tract or Disseminated 
Infections) 
Adult and children 
(> 20 kg) 500 mg q. 6 h. 
Children  
(< 20 kg) 
100 mg/kg/day in 
equal doses q. 6 h. 
 
Another suggested cloxacillin dosage for 
infants and children is 50 to 100 
mg/kg/day, up to a maximum of 4 g/d, 
divided q. 6 h. 
• USE IN SPECIAL CASES: 
Pregnancy- Use only when clearly indicated 
(Category B). 
Lactation- Use with caution; safety not 
established, but it is excreted in breast milk. 
Neonates-  Safety not established. 
Liver diseases- Use with caution since they 
are metabolized in the liver. 
Kidney diseases- Use with caution since they 
are primarily excreted in the urine. 
• PRECAUTIONS AND WARNINGS: 
Cautious use in history of or suspected 
allergy (asthma, eczema, hives, hay-fever), 
renal or hepatic function impairment, 
history of allergy to cephalosporins. 
• ADVERSE EFFECTS: 
GI: Nausea, vomiting, flatulence, diarrhea. 
Hematologic: Eosinophilia, leukopenia, 
agranulocytosis. 
Hypersensitivity: Pruritus, urticaria, rash, 
wheezing, sneezing, chills, drug fever, 
anaphylaxis. 
Others:  Super-infections.  
• INTERACTIONS: 
Refer to penicillin drug-drug interactions. 
• OVERDOSE: 
Refer to penicillin G. 
• BRANDS: 
Cloxapen (Eastern Chem.), Loxavit (Vitamed), 
Orbenil (Teva). 
______________________ 
 
c)  Ampicillin WHO,P &  
Amoxicillin WHO,P (aminopenicillins) 
 
The commonly used penicillins are 
ampicillin and amoxicillin. In our 
community, amoxicillin is mostly used.  An 
important drug in this group is Co-
amoxiclav (combination of amoxicillin and 
clavulanate) which will be discussed later.  
Other examples of this group are 
bacampicillin and pivampicillin, which 
are esters of ampicillin. 
• DRUG SUMMARY: 
Aminopenicillins are active against some 
G+ve and G-ve organisms but inactivated 
by penicillinases, including those produced 
by Staphylococcus aureus, and by common 
G-ve bacilli such as Escherichia coli. 
International studies indicate that all 
Staphylococci, 50% of E. coli strains and 
15% of Haemophilus influenzae strains are 
now resistant.   
Amoxicillin is a derivative of ampicillin 
that differs only by one hydroxyl group. 
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Unlike ampicillin it can be given 3 times 
daily without regard to food. 
• INDICATIONS: 
They are principally indicated for the 
treatment of chronic bronchitis and mild 
ear infections, both of which are usually 
due to Streptococcus pneumoniae and 
Haemophilus influenzae. They are also 
indicated for: urinary-tract infections, otitis 
media, sinusitis, chronic bronchitis, 
invasive salmonellosis, and gonorrhea. 
Amoxicillin is also used for typhoid fever 
and endocarditis prophylaxis. 
• CONTRAINDICATIONS: 
They are contraindicated in the case of 
hypersensitivity to penicillins. 
• DOSAGE FORMS: 
Capsules, suspensions and injections. 
• RECOMMENDED DOSAGE: 
These are shown in table-5.2. 
 
Directions: Absorption of ampicillin is 
affected by the presence of food in the 
stomach, so it should be taken one hour 
before or two hours after the meal.  
But this is not the case of amoxicillin that is 
not affected by the presence of food, so it 
can be given without regard to food. 
• USE IN SPECIAL CASES: 
Pregnancy- Use if clearly needed, risk-benefit 
must be considered (Category B). Animal 
reproductive studies have failed to 
demonstrate a risk to the fetus and there are 
no adequate and well-controlled studies in 
pregnant women. Penicillins in general have 
been considered safer than other antibiotics in 
pregnancy. Use lowest effective dose when 
needed. 
Lactation- Compatible in general. They are 
excreted in breast milk, use may lead to 
sensitization of infants; therefore, risk-benefit 
must be considered.  
Liver disease-  It can be given safely. 
Kidney disease- Caution use in the case of 
severely impaired renal function.  Increase 
dosing interval to 12 hrs. if creatinine 
clearance < 10 ml/min. 
• PRECAUTIONS AND WARNINGS: 
Avoid use in patients with a history of or 
suspected allergy (hives, eczema, hay fever, 
asthma), severely impaired renal function, 
and with history of cephalosporin allergy. 
 
 
Table – 5.2:  Recommended Doses of Ampicillin and Amoxicillin# 
Ampicillin 
PO 250-500 mg q. 6 h. Adult 
IM/IV 250 mg - 2 g q. 6 h. 
PO 25-50 mg/kg/d  divided q. 6 h. 
Systemic infections 
Child 
IM/IV 25-100 mg/kg/d  divided q. 6 h. 
Adult IV 150-200 mg/kg/d  divided q. 4-6 h. Meningitis 
Child IV Same as for adult 
PO 3.5 g with 1 g  probenecid x 1 Gonorrhea Adult 
IM/IV 500 mg q. 8-12 h. 
Amoxicillin 
Adult PO 250-500 mg q. 8 h. Mild to moderate 
infectionsM Child PO 20-40 mg/kg/d divided q. 8 h. 
Gonorrhea Adult PO 3 g as single dose with 1 g probenecid. 
 
#   Reference:  Drug Facts & Comparisons 2000. 
M Including infections of ear, nose, throat, GU, and lower RTI caused by Strep., 
penicillinase & non-penicillinase producing Staph., and H. influenzae. 
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• ADVERSE EFFECTS: 
Similar to other penicillins, including: 
-GI: diarrhea, nausea, vomiting, pseudo-
membranous colitis (rare). 
-CNS:  convulsive seizures. 
-Skin: pruritus, urticaria, or other skin 
eruptions. 
-Hematological: hemolytic anemia, thrombo-
cytopenia, purpura, eosinophilia, leukopenia, 
agranulocytosis. 
-Others: superinfections, cojunctival 
ecchymosis. 
• INTERACTIONS: 
Overview  of  Aminopenicillins 
Drug-Drug Interactions 
Drug Interaction 
Tetracyc-
lines 
May inhibit activity of 
amoxicillin & ampicillin. 
Avoid concomitant 
administration. 
Probenecid Prolongs the activity of 
amoxicillin; may be beneficial 
in some cases. 
Allopurinol Increases incidence of rash 
with ampicillin. Avoid 
concomitant use. 
Chloram-
phenicol, 
erythro-
mycin 
May reduce the bactericidal 
effects of ampicillin, this 
interaction is significant 
primarily when low doses of 
ampicillin are used. 
Oral contra-
ceptives 
Ampicillin reduces the oral 
contraceptive effectiveness. 
Female patients should be 
advised to consider 
nonhormonal contraception 
while on antibiotics. 
β- blockers Ampicillin may reduce the 
bioavailability of atenolol. 
Case reports indicate that β-
blockers may potentiate 
anaphylactic reactions of 
penicillin. 
 
• OVERDOSE: 
In the case of renal function impairment 
aminopenicillins can be removed by 
hemodialysis, but not peritoneal dialysis. 
• BRANDS: 
Ampicillin: Ampicillin Balapharm (Ciba-Geigy), 
Ampitricine (JCL), Ampipharm (JePharm), 
Broadacillin (BPC), Penibrin (Teva), Pentrexyl 
(Bristol), Vitapen (Vitamed). 
Amoxicillin: Amoxi (Genmedics), Amoxicare 
(Pharmacare), Amoxitid (BPC), Apomoxyn (Curex), 
Hiconcil (Mead Johnson), Moxypen (Teva), 
Moxepharm (JePharm), Moxyvit (Vitamed). 
____________________________ 
 
d)  Amoxicillin with Clavulanic 
Acid (Co-amoxiclav) WHO,P 
 
• DRUG SUMMARY: 
Co-amoxiclav consists of amoxicillin and 
the β-lactamase inhibitor clavulanic acid. 
Clavulanic acid itself has no significant 
antibacterial activity, but by inactivating 
penicillinase, it makes the combination 
active against penicillinase-producing 
bacteria that are resistant to amoxicillin.  
These include Staph. aureus, E. coli strains, 
and of H. influenzae strains, as well as 
many Bacteroides and Klebsiella spp.  
• INDICATIONS: 
Infections caused by susceptible β-
lactamase producing organisms: lower 
respiratory tract infections, otitis media, 
sinusitis, skin and skin structure infections, 
and UTI. 
• CONTRAINDICATIONS: 
Hypersensitivity to penicillins. 
Infectious mononucleosis. 
• DOSAGE FORMS: 
Tablets and suspension. 
• RECOMENDED DOSAGE: 
See table-5.3. 
Directions: May be taken without regards 
to meal.  
*Reconstituted suspension should be 
refrigerated and discarded within 10 days. 
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Table – 5.3:  Recommended Doses of Co-amoxiclav 
Patient Dosage  
Adult 250 mg or 500 mg tab. q. 8 h. 
Children (< 40 kg) 
Children's dose is based on the amoxicillin content.  
Usually 20 mg/kg/day, in divided doses q. 8 h.  
Because of the different amoxicillin to clavulanic acid ratios in 
the 250 mg (250/125) tabs. vs. 250 mg chewable tabs. (250/62.5), 
do not use 250 mg tab. until the child’s weight  > 40 kg. 
Children (>40 kg) Dose according to the adult recommendations. 
Severe infections and respiratory 
tract infections (adult) One 875 mg tab. q. 12 h.   or   one 500 mg  tab. q. 8 h. 
Otitis media*, sinusitis, lower 
respiratory infections and severe 
infections 
Children (< 40 kg): 40 mg/kg/day, in divided doses q. 8 h. 
 
*Co-amoxiclav has been used for short-term treatment in otitis media, (400/75 mg suspension) twice daily for 
children 2 mon-12 yr. (BNF 2001 Sep., p. 261). 
 
 
 
 
Note:  Since both the 250 and the 500 mg 
tablets contain the same amount of 
clavulanic acid (125 mg as potassium salt), 
two 250 mg tablets are not equivalent to one 
500 mg tablet.  Tablets containing 875 mg 
amoxicillin also contain 125 mg clavulanic 
acid.  
• USE IN SPECIAL CASES: 
Pregnancy- Co-amoxiclav should be used 
only when clearly indicated (Category B). It 
crosses the placenta in very small amounts. 
Use of a single agent penicillin may be safer. 
Lactation- Cautious use; it is excreted in the 
breast milk in very small amounts.  
Liver diseases- Dose with caution and 
monitor hepatic function at regular intervals, 
since the drug is metabolized in the liver. 
Kidney diseases- Does not generally require a 
dose reduction unless impairment is severe. 
Severely impaired patient with a GFR of < 30 
ml/min should not receive the 875 mg tablet. 
Patients with GFR between 10-30 ml/min 
should receive 500 or 250 mg tablet q. 12 h., 
depending on the severity of infection. 
Patients with GFR <10 ml/min should receive 
500 or 250 mg tablet q. 24 h., depending on 
the severity of infection. Hemodialysis 
patients should receive 500 or 250 mg tablet 
q. 24 h., they should receive additional dose 
both during and at the end of the dialysis. 
• PRECAUTIONS AND WARNINGS: 
Lactation and pregnancy. See amoxicillin. 
• ADVERSE EFFECTS: 
GI: diarrhea, nausea, vomiting. 
Skin:  rash, urticaria. 
Others: candidal vaginitis, moderate increase 
in serum ALT and AST, bone marrow 
depression (rare), and glomerulonephritis. 
• INTERACTIONS: 
Similar to those of amoxicillin. 
• OVERDOSE: 
Refer to benzylpenicillin. 
• Brands: 
Augmentin (Smithkline Beecham), Curam 
(Biochemi), Ogmin (BPC). 
________________ 
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2)  Cephalosporins                    .  
 (β - Lactam) 
 
These are broad-spectrum antibiotics. There 
are many cephalosporins where individual 
agents have slightly different activities 
against certain organisms. They have a 
similar mechanism of action as penicillins; 
they inhibit the bacterial cell wall synthesis, 
so they are bactericidal agents.  
Cephalosporins are not first-line drugs. 
They should be used only to treat specific 
infections that are resistant to 
antimicrobials of primary use. For this 
purpose, they would be considered 
essential.  For example, some are suitable 
for the treatment of H. influenzae type b 
meningitis where there is evidence that 
strains are resistant to chloramphenicol and 
benzyl penicillin.  
Cephalosporins are divided into four 
groups called generations. This 
classification is based on the spectrum of 
activity of these agents.  Only the first three 
generations will be discussed (See table-
5.4). 
 
Note: Each generation of cephalosporins 
has shifted toward increased G-ve 
activity but has lost activity toward G+ve 
organisms. 
 
Cephalosporins are not considered as the 
first line of treatment because they are:  
1. Broad spectrum. 
2. Expensive. 
3. Resistance will develop easily and 
rapidly for such agents (since they are 
broad spectrum).  Most are not active 
orally, instead IV or IM routes should be 
used (this is the case for all third generation 
cephalosporins and second generation ones;  
except cefaclor and many first generation 
agents). 
  
Cephalexin, Cefaclor, Cefadroxil are the 
three orally active ones & should be used as 
2nd line therapy, due to the reasons 
mentioned above. 
 
 
CephalexinP, Cefadroxil and 
Cefaclor 
 
• DRUG SUMMARY: 
Cephalexin and cefadroxil are orally active 
first generation cephalosporins while 
cefaclor is an orally active 2nd-generation 
cephalosporin. For the spectrum of activity 
refer to the previous table. Cefaclor has a 
good activity against Hemophilus 
influenzae, but it is associated with 
protracted skin reactions especially in 
children. Cefadroxil has a longer duration 
of action than other cephalosporins but 
poor activity against H. influenzae. 
 
Tables 5.4 & 5.5 give an overview and 
comparison of the three agents. 
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Table – 5.4:  Summary of the Main Three Generations of Cephalosporins. 
Class First-generation  Second-generation Third-generation  
Spectrum of 
activity 
1. Most G+ve cocci 
(exept enterococci) 
 
2. Enteric aerobic  
G-ve bacilli  (E. coli, K. 
pneumoniae, and 
Proteus mirabilis). 
1. The same organisms 
covered by 1st  generation.  
 
2. Extended G-ve coverage 
(including β-lactamase-
producing strains of 
Hemophilus influenzae. 
1. Wider activity against  
G-ve bacteria as: 
Enterobacter, Citrobacter, 
Serratia, Providencia, 
Neisseria and Hemophilus 
spp. (including β-lactamase 
producing organisms.)  
Examples Cefadroxil, cefazolin, 
cephalexin, cephalothin, 
cephapirin, cephradine. 
Cefaclor, cefamandole, 
ceforanid, cefonicid, 
cefoxitin, cefuroxime. 
Cefoperazone, cefotaxime, 
cefotetan, ceftazidime, 
ceftizoxime, ceftriaxone, 
moxalactam. 
Indications 1. Serious Klebsiella 
infections & G+ve & 
some G-ve infections in 
patients with mild 
penicillin allergy. 
 
2. Preoperative 
prophylaxis. 
 
1. Urinary tract infections 
resulting from E. coli  & 
gonococcal disease caused 
by organisms-resistant to 
other agents. 
 
2. Cefaclor is useful in otitis 
media & sinusitis in patients 
allergic to aminopenicillins.
 
3. Cefoxitin can be used for 
mixed aerobic-anaerobic 
infections as in intra-
abdominal infection. 
 
4. Cefamandole & 
cefuroxime used in 
community-acquired 
pneumonia.  
1. Since they penetrate the 
blood brain barrier they 
are used for the treatment 
of meningitis caused by 
microbes as 
Meningococci, 
Pneumococci,  
H. influenzae, and enteric 
G-ve bacilli. 
 
2. To treat sepsis of 
unknown origin in 
immunosuppressed 
patients, or to treat fever 
in neutropenic immuno-
suppressed patients 
(where it is used in 
combination with 
aminoglycosides) 
 
3. As empiric therapy* for 
life-threatening infection 
in which resistant 
organisms are the most 
likely cause. 
 
4. Initial therapy of mixed 
bacterial infections (e.g., 
sepsis).  
* Empirical therapy: is the therapy given before the identification of the infecting organism in life-
threatening conditions. 
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Table – 5.5:  Monograph Summary of Selected Oral Cephalosporins 
Drug Cephalexin Cefadroxil Cefaclor 
Indications 
To treat infections caused 
by susceptible pathogens 
in the respiratory and 
urinary tracts, middle ear, 
skin, soft tissue, and bone. 
 
Primarily in the treatment 
of urinary tract infections 
caused by E. coli, Proteus 
mirabilis, and Klebsiella 
spp.; infection of the skin 
and skin structures caused 
by Staph. and Strepto-
cocci; and group A β-
hemolytic Streptococcal 
pharyngitis and tonsillitis. 
Treatment of otitis 
media and infections of 
upper and lower 
respiratory tract, 
urinary tract, and skin 
and skin structures 
caused by ampicillin-
resistant H. influenzae, 
acute uncomplicated 
UTI. 
Contra-
indications Hypersensitivity to cephalosporins and related antibiotics (i.e. penicillins). 
Dosage forms  Caps, susp. 
Pregnancy Use if clearly needed as no well-controlled studies have been established (Category B). They are used for the treatment of urinary tract infections. 
Lactation 
They are excreted in breast milk in small quantities, however, consider the 
following problems in the nursing infant:  modification/alteration of bowel 
flora; pharmacological effects; interference with the interpretation of culture 
results if a fever/infection investigational testing is needed. 
Children Consider the relative benefit to risk before using the drug. In neonates, accumulation of cephalosporin antibiotics has occurred. 
Liver disease Safe in general. 
Kidney disease 
Cephalosporins may be nephrotoxic; use with caution in the presence of 
markedly impaired renal function (Crcl < 50 ml/min/1.73 m2 ).  In elderly and 
in patients with known or suspected renal impairment, monitor carefully prior 
to and during therapy. If renal impairment is severe the dose of cephalexin 
should not exceed 500 mg/day and if renal impairment is moderate the dose 
of cefadroxil should be reduced. 
Precautions 
and warnings 
Cautious use in history of hypersensitivity to penicillins or other drug allergy. 
Severely impaired renal function. 
Possible 
adverse effects 
Diarrhea (generally mild), nausea, vomiting, anorexia, abdominal pain, 
dizziness, headache, fatigue, hypersensitivity reactions (rash, pruritis, . .), 
interference with blood clotting factors leading to bleeding tendency. 
Interactions 
*Probenecid: decreases renal elimination of cephalexin. 
*Aminoglycosides: nephrotoxicity risk is increased when both drugs are used 
together.  Avoid, or monitor renal function closely if needed. 
*Anticoagulants:  Bleeding complications may occur.  Use caution. 
Overdose 
It occurs mainly with parenteral administration of cephalosporins, particularly 
if the patient suffers from severe renal impairment. Seizures may occur. Treat 
accordingly. 
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Table – 5.6:  Recommended Doses of the Selected Cephalosporins 
Drug Indication Age Route Dosage 
Adult PO 250-500 mg q. 6 h. Mild to moderate 
infections Child PO 25-50 mg/kg/d in 4 divided doses 
Skin/skin structure 
infections 
Adult PO 500 mg  q. 12 h. 
Cephalexin 
Otitis media Child PO 75-100 mg/kg/d in 4 divided doses 
Adult PO 1-2 g/d in 1-2 divided doses Uncomplicated UTI 
Child PO 30 mg/kg/d in 2 divided doses 
Adult PO 1 g/d in 1-2 divided doses Skin/skin structure 
infections, 
Streptococcal 
pharyngitis, tonsillitis 
Child PO 30 mg/kg/d in 2 divided doses 
Adult PO 1 g q. 24 h. 
Cefadroxil 
Renal impairment 
(Crcl < 25 ml/min) Child PO 15 mg/kg q. 24 h. 
Adult PO 250-500 mg q. 8 h. Cefaclor Mild to moderate 
infections Child PO 20-40 mg/kg/d divided q. 8 h. 
(max. 1 g/d) 
 Acute bacterial 
exacerbation of 
chronic bronchitis 
Adult PO 500 mg q. 12 h. (for 7 days). 
 
Direction: It is important to inform the 
patient that the full course of therapy 
should be completed. Duration of therapy 
should be for a minimum of 48-72 hours 
after evidence of bacterial eradication has 
been obtained. 
*If GI upset occurs, may take the oral 
preparation with food or milk. 
• BRANDS: 
Cephalexin: Cefacare (Pharmacare), Cefalex 
(BPC), Ceforal (Teva), Cefovit (Vitamed), 
Keflex (Lilly), Jeflex (JePharm). 
Cefaclor:  Ceclor (Lilly). 
Cefadroxil: Biodroxil (Biochemi), Cefadrox 
(BPC), Duracef (Mead-Johnson). 
___________________ 
 
3)  Tetracyclines 
 
Tetracyclines are broad-spectrum 
antibiotics whose values have decreased 
due to increasing bacterial resistance. There 
is a large number of tetracyclines in the 
market (i.e. doxycyclineWHO,P minocycline, 
chlortetracycline). The tetracyclines have 
similar antimicrobial spectra, and cross-
resistance is common.  Tetracycline will be 
used as the prototype for this group.  
 
Tetracycline (TC) 
 
• DRUG SUMMARY: 
TC is a broad spectrum, bacteriostatic, 
antibiotic. It acts by interfering with the 
bacterial protein synthesis process. Its 
usefulness has decreased due to the 
widespread bacterial resistance. It remains 
however the drug of choice in some 
infections (see indication below). TC is one 
of the cheapest antibiotics. 
• INDICATIONS: 
It is the drug of choice in the treatment of 
infections caused by chlamydia (trachoma, 
psittacosis, salpingitis, nongonococcal 
urethritis, inclusion conjunctivitis, and 
lymphogranuloma venereum), rickettsia 
(including Q-fever, Rocky Mountain 
spotted fever, typhus), mycoplasma e.g. 
Mycoplasma pneumoniae (respiratory and 
genital infections). 
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1. Spirochetal infections (relapsing fever 
- Borrelia burgdorferi - Lyme disease), 
leptospirosis in penicillin hypersensitivity 
(as an alternative to erythromycin), 
Syphilis (in penicillin hypersensitivity 
patients). 
2. Amebiasis. 
3. G-ve bacterial infections (e.g., 
brucellosis, shigellosis, cholera, 
Gonorrhea [in penicillin hypersensitivity 
patients], granuloma inguinale, tularemia). 
4. G+ve infections (e.g. tetanus). 
5. Used orally and topically (solution) 
for inflammatory acne vulgaris. 
6. Topical ointment used for superficial 
skin infections. 
7. Ophthalmic use. 
8. Exacerbation of chronic bronchitis 
(because of their activity against 
Haemophilus influenzae). 
9. As a sclerosing agent for pleural 
effusions due to malignancy or cirrhosis. 
• CONTRAINDICATIONS: 
Hypersensitivity to tetracyclines or to any 
ingredient in the formulation. 
Severe renal or hepatic impairment, 
common bile duct obstruction, use during 
tooth development, during infancy and 
children < 8 yrs., pregnant and nursing 
women.  
Safety of the use of tetracycline topically in 
children 8-11 yrs. has not been established. 
• DOSAGE FORMS: 
Capsules, ointment. 
• RECOMMENDED DOSAGE: 
 
Dosage of Tetracycline 
 
Systemic Infections 
Adult PO 250-500 mg b.i.d. to 
q.i.d. (1-2 g/d). 
Child PO > 8  yrs :  25-50 
mg/kg/d  in  2-4  
divided doses .  
 
Acne 
PO 500-1000 mg/d in 4 
divided doses. 
Adult 
and 
Child > 
8 yrs 
Topical Apply to cleansed 
areas twice daily. 
 
Direction: The drug may be taken with 
food if GI upset occurs, with a full glass of 
water. Do not take with dairy products. 
(Doxycycline’s absorption is less likely to be 
affected by food or dairy products, but it has 
to be taken with plenty of fluid and an hour 
before lying down to sleep.) 
• USE IN SPECIAL CASES: 
Pregnancy- Avoid use during pregnancy 
(Category D). It readily crosses the placenta 
and can have toxic effects on the developing 
fetus especially early in pregnancy 
(retardation of skeletal development).  
Lactation- It is excreted in breast milk. A 
dosage of 2 g/d for 3 days has achieved a 
milk plasma ratio of 0.6 to 0.8.  Because of 
the potential for serious adverse reactions, 
decide whether to discontinue nursing or to 
discontinue the drug.  
Children- It should not be used in children 
under 8 years of age, unless other drugs are 
not likely to be effective, or are 
contraindicated. 
Teeth: The use of tetracycline during the 
period of tooth development (from the last 
half of pregnancy to the eighth year of life) 
may cause permanent discoloration (yellow-
gray-brown) of deciduous and permanent 
teeth. This adverse reaction is more common 
during long-term use of the drug, but has 
been observed following repeated short-term 
courses. Enamel hypoplasia has also been 
reported. 
Bone: Tetracycline forms a stable calcium 
complex in any bone-forming tissue.  A 
decrease in the fibula growth rate has been 
observed in premature infants given oral 
tetracycline in doses of 25 mg/kg q 6 h. This 
reaction was reversible when the drug was 
discontinued. 
Liver diseases- Avoid use. Dose related 
toxicity especially with IV administration.  
Kidney diseases- Avoid use. One can use 
doxycycline or minocycline. 
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• PRECAUTIONS AND WARNINGS: 
Cautious use in the case of history of renal 
or hepatic dysfunction, myasthenia gravis, 
history of allergy, asthma, hay fever, 
urticaria, undernourished patients. 
• ADVERSE EFFECTS: 
Gastrointestinal upset, glossitis, stomatitis, 
rashes, proctitis, and infections due to 
Candida albicans, Proteus, Pseudomonas, 
or Staphylococci. It is deposited in 
calcifying areas of bone, nails and teeth, 
resulting in irreversible damage. 
Photosensitization and hypersensitivity 
reactions including anaphylactic shock can 
occur. May have hepatotoxic and 
nephrotoxic effects. Erythema (discontinue 
treatment). Headache and visual disturbances 
that may indicate benign intracranial 
hypertension, and pseudo-membranous 
colitis. 
• INTERACTIONS: 
Overview  of  Tetracyclines 
Drug-Drug Interactions 
Drug Interaction 
Antacids Calcium, magnesium bind to 
tetracycline in the gut and 
decrease its absorption. 
Anti-
diarrheal 
agents 
The ones with kaolin and 
pectin may decrease TC 
absorption. 
Food Dairy products and iron 
supplements decrease 
tetracycline absorption. Space 
administration within 2 hrs. 
of tetracycline intake. 
Meth-
oxyflurane 
May produce fatal nephro-
toxicity. Avoid concomitant 
use. 
Oral antico-
agulants 
Coadministration may 
potentiate hypoprothrom-
binemia. 
Oral contra-
ceptives 
Effectiveness of OC 
decreases.  Backup methods 
should be used. 
Penicillin Bacteriostatic drugs (e.g. 
tetracycline) may interfere 
with the bactericidal action of 
penicillins; avoid 
concomitant administration. 
 
• BRANDS: 
Brimocyclin (BCP), Tetrapharm (JePharm), 
Tevacycline (Teva). 
_____________________ 
 
4)  Macrolides 
 
Macrolide antibiotics include erythro-
mycin, clarithromycin, azithromycin, 
dirithromycin and troleandomycin. These 
may be bacteriostatic or bactericidal 
depending on factors such as drug 
concentration. Macrolides are weak bases, 
their activity increases in alkaline pH. This 
is important when using for UTI. They 
enter pleural fluid, ascitic fluid, middle ear 
exudates and sputum.  Erythromycin is the 
most commonly used macrolide. 
 
a)  Erythromycin WHO,P 
 
• DRUG SUMMARY: 
Erythromycin has an antibacterial spectrum 
that is similar but not identical to that of 
penicillin; it is thus a good alternative to 
penicillin, in penicillin-allergic patients.  It 
can be a bactericidal or a bacteriostatic 
agent depending on its concentration. It 
produces its antibacterial activity by 
inhibiting bacterial protein synthesis.  
Erythromycin is active against many G+ve 
organisms, including streptococci (e.g., 
Streptococcus pneumoniae), Coryne-
bacterium and Neisseria species, some strains 
of Mycoplasma, Legionella, Treponema, and 
Bordetella. Some S. aureus strains that 
resist penicillin G, are susceptible to 
erythromycin. 
• INDICATIONS: 
a.  Erythromycins are the preferred drugs for 
the treatment of Mycoplasma pneumoniae 
and Campylobacter infections, legionnaires 
disease, chlamydial infections, diphtheria, 
and pertussis. It is also used for the treatment 
of sinusitis, chronic prostatitis and acne 
vulgaris. 
b. In patients with penicillin allergy, 
erythromycin is an important alternative in 
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the treatment of pneumococcal pneumonia, S. 
aureus infections, syphilis, and gonorrhea. 
c. Erythromycin may be given prophy-
lactically before dental procedures to prevent 
bacterial endocarditis. 
d.  It has activity against gut anaerobes and 
has been used with neomycin for prophylaxis 
before bowel surgery. 
* (Clarithromycin is indicated as part of 
therapy for eradication of Helicobacter pylori 
-peptic ulcer- with other agents). 
• CONTRAINDICATIONS: 
-Hypersensitivity to macrolide antibiotics. 
-Porphyria. 
-Erythromycin estolate is contraindicated in 
liver disease. It produces cholestatic 
jaundice. 
• DOSAGE FORMS: 
Tablets and suspensions. 
• RECOMMENDED DOSAGE: 
Adult:  250-500 mg q. 6 h. or 0.5-1 g q. 12 
h. up to 4 g daily in severe infections. 
Early syphilis: 500 mg q. 6 h. for 14 days. 
Children: Age, weight, and severity of the 
infection are important factors in deter-
mining the proper dosage.  The usual 
dosage for children is 30-50 mg/kg/day in 
equally divided doses q. 6 h.   
In mild to moderate infections the usual 
dosage of erythromycin base is as table-5.7 
indicates. 
 
Table-5.7:  Erythromycin Base  
Dosages in Children 
Body  
Weight 
Total Daily  
Dose 
Under 4.5 kg  
(under 10 lb.) 
30-50 
mg/kg/day 
4.5 to 6.8 kg   
(10-15 lb.) 200 mg 
7.0 to 11.5 kg  
(16-25 lb.) 400 mg 
11.6 to 22.7 kg  
(26-50 lb.) 800 mg 
22.8 to 45.5 kg  
(51-100 lb.) 1200 mg 
Over 45.5 kg  
(over 100 lb.) 1600 mg 
 
Directions: Erythromycin dose is doubled 
in severe infections. 
*It should be given on an empty stomach  
(1 hour before or 2 hours after meals).   
*If GI upset occurs may administer with 
food.   
*There is no interaction between milk and 
erythromycin preparations. 
 
• USE IN SPECIAL CASES: 
Pregnancy- Use only when clearly indicated 
(Category B). Only small amounts cross the 
placental barrier of erythromycin base. Side 
effects have only been reported when using 
erythromycin estolate. Do not use 
erythromycin estolate in pregnant women. 
Lactation- Only small amount is excreted in 
breast milk and no infant adverse effects are 
reported. But problems that may occur in 
nursing infants include modification of bowel 
flora and interference with the interpretation 
of culture results if a fever work-up is 
required. The American Academy of 
Pediatrics considers erythromycin to be 
compatible with breast-feeding. 
Renal Disease- If severe case, the maximum 
possible dose to be given is 1.5 g daily. 
Ototoxicity (hearing loss) or transient hearing 
loss has been reported in such cases. (Refer to 
BNF42; 2001). 
Liver Disease- Erythromycin is principally 
excreted by the liver. One must take caution 
during the administration of erythromycin to 
patients with impaired hepatic function. There 
have been reports of hepatic dysfunction with 
or without jaundice. Erythromycin estolate is 
contraindicated in liver disease. 
• PRECAUTIONS AND WARNINGS: 
- Hepatic and renal impairment. 
- Superinfections might occur. 
• ADVERSE EFFECTS: 
Nausea, vomiting, abdominal discomfort, 
diarrhea after large doses, reversible 
hearing loss also reported after large doses.  
If given for more than 14 days it may 
occasionally cause cholestatic jaundice. 
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• INTERACTIONS: 
Overview   of   Erythromycin 
Drug-Drug Interactions 
Drug Interaction 
Astemazole 
and 
terfenadine 
Inhibit the metabolism of 
astemazole and terfenadine 
leading to cardiotoxicity. 
Contraindicated use. 
Bromo-
criptine 
Serum level may be increased 
due to erythromycin 
inhibiting hepatic 
metabolism. Monitor patient, 
and adjust bromocriptine dose 
accordingly.  
Carba-
mazepine 
Inhibit the metabolism of 
carbamazepine, leading to an 
increase in its plasma level. 
Cyclosporins Inhibit the metabolism of 
cyclosporins. 
Digoxin Enhance the effect of 
digoxin. Use with caution. 
Theophyline Inhibit the metabolism of 
theophyline, leading to an 
increase in its plasma level, 
use with caution. 
Warfarin Enhanced effect of warfarin. 
Monitor prothrombin (PT) 
levels and caution the patient. 
 
• OVERDOSE: 
Symptoms may include nausea, vomiting, 
epigastric distress and diarrhea. Reversible 
pancreatitis, hearing loss with or without 
tinnitus and vertigo especially in patients 
with renal or hepatic insufficiency.  
Treatment includes usual supportive 
measures. GI decontamination is not 
necessary unless five times the normal dose 
has been ingested. Hemodialysis and 
peritoneal dialysis are not particularly 
effective. 
• BRANDS: 
Bristamycin (Bristol), E-Mycin (Upjohn), Eryc 
(Taro), Erytab (Abbot), Erythrocare (Pharmacare), 
Erythrocin Filmtab (Abbot), Erythroped (Abbot), 
Erythrolet (BPC), Erythropharm (JePharm), 
Erythroteva (Teva). 
_________________________ 
 
 
5)  Sulphonamides and 
Trimethoprim P 
 
The importance of sulphonamides as 
chemotherapeutic agents has decreased due 
to the increase in bacterial resistance and 
their replacement by antibiotics which are 
generally more active and less toxic. 
Sulphamethoxazole is the most commonly 
used sulphonamide, it is used in 
combination with trimethoprim (TMP) for 
the treatment of some infections. Increasing 
bacterial resistance to sulphonamides and 
the high incidence of sulphonamide-related 
side effects, have limited the value of use of 
this drug alone.  TMP has been used in 
combination because of the synergistic 
activity, leading to less bacterial resistance. 
The combination is indicated as first line 
treatment in many cases.  This combination 
is called co-trimoxazole (TMP-SMZ). 
• DRUG SUMMARY: 
Co-trimoxazole combination contains five 
parts of SMZ and one part of TMP. 
• INDICATIONS: 
1. Urinary tract infections and prostatitis (if 
sensitive organisms). 
2. Bone and joint infections due to 
Haemophilus influenzae. 
3. Invasive salmonellosis and typhoid fever. 
4. Sinusitis and exacerbation of chronic 
bronchitis. 
5. High doses of co-trimoxazole are used 
for Pneumocustis carinii infections. 
It is no longer recommended for the 
treatment of gonorrhea. 
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Table – 5.8:  Dosage of Co-trimoxazole in Systemic Infections * 
UTI,  
Acute otitis media, 
Acute exacerbation of 
chronic bronchitis 
160 mg TMP/800 mg SMZ (1 double 
strength [DS] tablet) q. 12 h. for 10-14 
days. 
Shigellosis 160 TMP/800 SMZ q. 12 h. for 5 days 
Adult PO 
Travelers diarrhea 160 TMP/800 SMZ q. 12 h. for 5 days 
> 2 month, less 40 kg 8 mg/kg TMP/ 40 mg/kg SMZ  divided q. 12 h. for 10 days 
Child PO 
> 40 kg 160 TMP/800 SMZ (1 DS tablet) q. 12 h. 
* Reference: Drug Facts & Comparisons, 2000, p 1352-54. 
 
• CONTRAINDICATIONS: 
1. Hypersensitivity to TMP, SMZ, sulphon-
amides, or bisulfites. 
2. Jaundice, blood disorders, porphyria, 
megaloblastic anemia (due to folate 
deficiency). 
3. Infants 2 mon. (except in treatment or 
prophylaxis of pneumocystis pneumonia). 
4. Renal and hepatic failure. 
• DOSAGE FORMS: 
Tablets and suspension. 
• RECOMMENDED DOSAGE: 
See the table-5.8. 
Directions: Take each oral dose with a full 
glass of water. If GI distress occurs when 
taken on empty stomach, take with food or 
milk.  
*Advise patient to maintain adequate fluid 
intake. 
*Duration of therapy should be 7-10 days 
for uncomplicated cases (i.e. acute cystitis). 
For moderate infections (i.e. pyelonephritis, 
bronchitis), duration should be 10-14 days. 
*3 day regimens may be used in; 1st 
episode of UTI, non-diabetic, young 
patients. But relapse or recurrence may 
occur or an upper UTI may be missed. 
Evaluate your patient. 
*Severe cases should be referred to hospital 
for IV treatment. 
• USE IN SPECIAL CASES: 
Pregnancy- Avoid use (Category C). 
Cardiovascular defects have been reported 
when used in the first trimester. Use of 
aminopenicillins or cephalosporins is safer. 
Lactation- Avoid use.  Since there is a small 
risk of kernicterus in jaundiced infants and of 
hemolysis in G6PD deficient infants (due to 
the sulphamethoxazole ingredients). 
Children- It is contraindicated in children 
under 2 months, since there is a risk of 
kernicterus in these infants.  
There is limited data on safety of repeated 
use for OM in children < 2 yrs;  not indicated 
for prophylactic use of prolonged 
administration (Facts & Comparisons 2000; 
1352). 
Renal Disease- If there is a moderate renal 
impairment, one should reduce the dose (Clcr 
15-30 ml/min: ½ dose). Rashes (including 
Stevens-Johnson syndrome) and blood 
disorders may cause further deterioration of 
renal function.  In the case of renal failure (or 
Clcr < 15 ml/min) it is contraindicated. 
Liver Disease- Use is contraindicated in the 
case of hepatic failure. 
• PRECAUTIONS AND WARNINGS: 
− Group A β-hemolytic Streptococcal 
pharyngitis: Avoid use of this combination 
for such cases, since there has been high 
incidence of bacteriologic failure than with 
penicillins.  
− Special care should be taken in patients 
who may be folate deficient such as, old 
patients, chronic alcoholics, patients on 
anticonvulsant therapy and ones receiving 
prolonged treatment or high doses of the 
drug. 
− It should be used with care in the elderly 
and preferably only if there is no acceptable 
alternative. Since there has been recent 
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reports of death in patients over 65 years 
old using co-trimoxazole. 
− Special care should be taken in patients 
with G6PD deficiency. 
− In patients receiving the drug for a long 
time, blood counts should be monitored  
− One should stop treatment if rashes 
appear. 
• ADVERSE EFFECTS: 
Most common are GI disturbances.  Other 
rare but possible effects include: rash, 
Stevens-Johnson syndrome (erythema 
multiforme), eosinophilia, agranulocytosis, 
granulocytopenia, purpura, leucopenia, 
thrombocytopenia, aplastic or mega-
loblastic anemia due to trimethoprim, 
pseudomembranous colitis, jaundice and 
hepatic necrosis (rare but have been 
reported). 
• INTERACTIONS: 
Overview  of  Co-trimoxazole 
Drug-Drug Interactions 
Drug Interaction 
Cyclosporin The risk of nephrotoxicity 
increases if co-trimoxazole is 
given along with cyclosporin. 
Phenytoin Co-trimoxazole has been 
found to cause an increase in 
the plasma concentration of 
phenytoin. This might lead to 
toxic effects because of the 
narrow therapeutic index. 
Sulphonyl-
urea 
The effect of sulphonylurea 
has been found to be 
enhanced by co-trimoxazole, 
i.e.  may cause 
hypoglycemia. 
Warfarin The effect of warfarin has 
been found to be enhanced by 
co-trimoxazole, i.e. increase 
the anticoagulant effect. 
Monitor Prothrombin time 
(PT) and adjust dose 
accordingly. 
 
 
 
• OVERDOSE: 
Symptoms:  
Acute: Signs and symptoms observed with 
either TMP or SMZ alone includes: 
Anorexia, colic, nausea, vomiting, 
dizziness, headache, drowsiness, 
unconsciousness, pyrexia, hematuria, 
crystalluria, depression, and confusion. 
Chronic: High doses or use for extended 
periods may cause bone marrow depression 
manifested as thrombocytopenia, leuko-
penia or megaloblastic anemia. Leucovorin 
(Ca-Folinate); 5 to 15 mg/day has been 
recommended to treat this case. 
Treatment includes usual supportive 
measures. Perform gastric lavage or emesis, 
force oral fluids and administer IV fluids if 
urine output is low and renal function is 
normal. Acidifying the urine will increase 
the renal elimination of TMP. Monitor 
patient with blood counts and appropriate 
blood chemistries, including electrolytes.  
If significant blood dyscrasia or jaundice 
occurs, institute specific therapy for these 
complications. Peritoneal dialysis is not 
effective and hemodialysis is only 
moderately effective in eliminating co-
trimoxazole. 
• BRANDS: 
Bactrim (Roche), Diseptyl (Rekah), Pathoprim 
(BPC), Pharmaprim (Pharmacare), Resprim 
(Teva), Sulfatrim (Vitamed), Sulprim 
(JePharm). 
______________________ 
 
 
6)  Nitrofurantoin WHO,P 
 
• DRUG SUMMARY: 
Nitrofurantoin is a synthetic nitrofuran that 
is bacteriostatic in low concentrations (5-10 
mcg/ml) and bactericidal in higher 
concentrations. 
Most G-ve bacilli and G+ve cocci 
associated with urinary tract infections are 
susceptible. Some strains of Enterobacter 
and Klebsiella are resistant. Most strains of 
Proteus and Serratia species are resistant.  
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It has no activity against Pseudomonous 
spp. Susceptible strains do not develop 
resistance during therapy. 
• INDICATIONS: 
Urinary tract infections due to susceptible 
strains of E. coli, Enterococci, S. aureus 
(not for treatment of pyelonephritis or 
perinephric abscesses) and certain strains of 
Klebsiella and Enterobacter spp. 
• CONTRAINDICATIONS: 
-Renal function impairment if creatinine 
clearance < 60 ml/min. Anuria or oliguria 
as risk of toxicity might increase.  
-Hypersensitivity to nitrofurantion. 
-Pregnant patients at term, during labor and 
delivery, and in infants under 1 month. 
• DOSAGE FORMS: 
Capsules. 
• RECOMMENDED DOSAGE:  
Adult: 50-100 mg 4 times/day a.c. and h.s. 
For long-term suppressive therapy, reduce 
dosage: 50-100 mg at bedtime. 
Child: 5-7 mg/kg/24 hrs. given in 4 divided 
doses. For long term suppressive therapy, 
doses as low as 1 mg/kg/24 hrs., given in 
single or in 2 divided doses, may be 
adequate. 
Directions: Administration with food or 
milk decreases GI disturbances and 
enhances bioavailability.  
*Duration: Continue for at least 1 week or 
3 days after sterile urine analysis. 
*It may cause brown-orange discoloration 
of the urine. 
*There are no suspension preparations in 
the local market, which requires pharmacist 
to specially prepare it. 
• USE IN SPECIAL CASES:  
Pregnancy- Safety for use in pregnant women 
has not been established, Category B; low 
incidence of minor malformation has been 
reported in mice. Contraindicated in pregnant 
women at term. Do not give to pregnant 
women with G6PD deficiency because of the 
risk of hemolysis. 
Lactation- It is excreted into milk in very low 
concentrations. Infants with G6PD deficiency 
are adversely affected, and may develop 
hemolytic anemia upon exposure. Safety for 
use in nursing mothers has not been 
established. 
Children- Contraindicated in infants < 1 mon. 
(< 3 mon.: in BNF 2001), due to risk of 
hemolytic anemia.  
Renal Disease- Exercise caution.  Refer to 
contraindications. 
• PRECAUTIONS AND WARNINGS:   
-Culture and susceptibility testing should be 
performed prior to and during treatment. 
-Peripheral neuropathy may occur and 
become severe or irreversible. Pre-
disposing factors like renal impairment, 
anemia, diabetes, electrolyte imbalance, 
vitamin B deficiency and debilitating 
diseases may enhance these problems. 
-Overuse may result in bacterial and fungal 
overgrowth and non-susceptibility that may 
cause super infections.  
-Pulmonary reactions, acute, sub-acute or 
chronic, may occur (i.e. pulmonary fibrosis 
like symptoms). 
-Hematological disorders may occur such 
as hemolytic anemia. 
• ADVERSE EFFECTS:  
GI, hepatic and pulmonary disturbances 
may occur. Some lab tests abnormalities 
may be found, such as increased AST, 
ALT, decreased hemoglobin, increased 
serum phosphorus. 
• INTERACTIONS: 
 
Overview  of  Nitrofurantoin 
Drug-Drug Interactions 
Drug Interaction 
Anti-
cholinergics
Nitrofurantoin bioavailability 
will increase;  clinical 
interventions may not be 
necessary. 
Magnesium 
salts 
Nitrofurantoin absorption 
may be delayed or increased. 
Avoid concomitant use. 
Uricosurics Nitrofurantoin renal clearance 
will decrease and serum level 
increase- leading to toxic 
effects. 
 
Drug/lab tests interactions: A false-
positive glucose test in urine may occur 
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with Benedict`s and Fehling`s but not with 
the glucose enzymatic tests. 
Drug/food interactions: food intake 
increases the drug bioavailability. 
• OVERDOSE: 
Symptoms: no specific or serious 
symptoms have been reported except for 
vomiting.  
Treatment: Induction of emesis and 
increase fluid intake to enhance excretion. 
The drug is dialyzable. 
• BRANDS: 
Furadantin/Macrodantin (Proctor&Gamble), 
Macrofuran (BPC), Urantoin (Rafa). 
__________________________ 
 
7)  Nalidixic Acid WHO,P 
 
• DRUG SUMMARY: 
Nalidixic acid is a bactericidal quinolone 
agent that interferes with DNA 
polymerization. It is effective against G-ve 
bacteria, i.e. Proteus mirabilis, Proteus 
morganii, Proteus vulgaris, Providencia 
rettgeri, E. coli, Enterobacter and 
Klebsiella species. Pseudomonus strains are 
generally resistant. 
• INDICATIONS: 
Treatment of urinary tract infections caused 
by susceptible G-ve microorganisms, 
including the majority of Proteus strains, 
Klebsiella and Enterobacter spp. and E. 
coli, if the patient did not respond to, or is 
not sensitive to co-trimoxazole. 
• CONTRAINDICATIONS: 
Hypersensitivity to nalidixic acid, history 
of convulsive disorders. 
• DOSAGE FORMS: 
Tablets and suspension. 
• RECOMMENDED DOSAGE:  
Adult: Initial therapy: 1.0 g 4 times daily 
(total of 4 g/d) for 1 or 2 weeks. 
Prolonged therapy: may be reduced to 2 
g/day after the initial treatment period. 
*Under dosage (< 4 g/d) during initial 
therapy may predispose to emergence of 
bacterial resistance. 
Child (3 mon. - 12 yrs. of age):  
Initial therapy: 55 mg/kg/d  in 4 equally 
divided doses. 
Prolonged therapy: may be reduced to 33 
mg/kg/day. 
Do not administer to infants < 3 months 
of age. 
 
Directions:  Should be taken with food to 
prevent GI disturbances. 
*May produce drowsiness or dizziness; 
caution the patient against hazardous 
activities such as driving till full effect of 
the medication is known. 
• USE IN SPECIAL CASES:  
Pregnancy- Not recommended, since safety 
for use during the first trimester has not been 
established (Category B). No congenital 
defects have been reported. If benefit 
outweighs risks to the fetus, and the drug is 
used, need to discontinue the drug prior to 
delivery because of the theoretical risk that 
exposure in utero may lead to significant 
blood levels in the neonate immediately after 
birth.  
Lactation- Data is little on nalidixic acid. 
Milk to plasma ratios are 0.08 to 0.13. 
Although small amounts, but hemolytic 
anemia was reported in one case.   
Children- Use care in prepubertal children; as 
erosions of the cartilage in weight bearing 
joints in animals were reported.  
Renal Disease- Exercise caution if Clcr is 2-8 
ml/min. 
Liver Disease- Exercise caution. 
• PRECAUTIONS AND WARNINGS:   
-Periodic blood counts, renal and liver 
function tests should be performed if 
treatment is continued for > 2 weeks. 
-Photosensitivity may occur, advise patient 
against prolonged exposure to sunlight. 
-May produce drowsiness and dizziness; 
exercise caution while driving or operating 
dangerous machines. 
-It might cause hemolytic anemia in patients 
with or without G6PD deficiency.  
• ADVERSE EFFECTS: 
CNS disturbances (i.e. drowsiness, 
headache) and ophthalmic disturbances 
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might occur but are reversible upon 
discontinuation. GI disturbances (i.e. 
nausea, diarrhea) might occur. 
• INTERACTIONS:   
The effects of anticoagulants may be 
enhanced by nalidixic acid, hemorrhage 
could occur. A decrease in dose of warfarin 
may be required. 
Drug/Lab test interactions: The urinary 
metabolites of nalidixic acid liberate 
glucuronic acid and produce false-positive 
urinary glucose results with Benedict’s or 
Fehling’s or Clinitest’s tests. 
• OVERDOSE: 
Symptoms: Toxic psychosis, convulsions, 
increased intracranial pressure, metabolic 
acidosis, vomiting, nausea and lethargy 
may occur in patients taking more than the 
recommended dosage. 
Treatment: Reactions are short lived (2-3 
hrs.) because the drug is rapidly excreted. 
Gastric lavage is indicated if the 
overdosage was noticed early. If absorption 
has occurred, increase fluid administration 
and have supportive measures. Anti-
convulsants may be indicated in severe 
cases. 
• BRANDS: 
Granexin (Dexxon), NegGram (Sterling-
winthrop), U-Gram (JePharm), Urigram 
(Trima). 
________________________ 
 
8)  Fluoroquinolones 
 
Fluoroquinolones are synthetic, broad-
spectrum antibacterial agents related to the 
1st generation quinolones; nalidixic acid 
and cinoxacin. Ciprofloxacin, is the main 
2nd generation quinolone, others include 
enoxacin, lomefloxacin, norfloxacin, and 
ofloxacin. Newer 3rd generation quinolones 
include levofloxacin and sparfloxacin. 
Fluoroquinolone agents are bactericidal. 
They may not be indicated as essential or 
1st line therapy drugs, but are of real value 
as reserve agents when other agents have 
failed. 
 
Ciprofloxacin WHO,P 
 
• DRUG SUMMARY: 
A fluoroquinolone antibacterial agent with 
a wide spectrum of activity, mainly for    
G-ve bacteria (i.e. Salmonella spp., 
Shigella spp., Brucella melitensis . . .), 
including Enterobacteriaceae, Pseudo-
monas aeruginosa, Heamophilus, Neisseria 
spp., Staphylococci, and some other G+ve 
bacteria. Most anaerobic organisms are not 
susceptible. (It may be used for infections 
that were resistant to other antibiotics 
including penicillins, cephalosporins and 
aminoglycosides). 
• INDICATIONS: 
Mainly used for urinary tract infections due 
to G-ve and some G+ve susceptible 
bacteria.   
May be used for lower respiratory 
infections, gonorrhea and chancroid, 
typhoid fever, salmonella, severe 
shigellosis, and hospital-acquired infections 
when other agents have failed. 
• CONTRAINDICATIONS: 
Hypersensitivity to ciprofloxacin or other 
quinolones. 
• DOSAGE FORMS: 
Tablets. 
• RECOMMENDED DOSAGE:  
Adult (>18 yrs):  250-500 mg b.i.d. 
Child: Use not recommended in growing 
children < 18 yrs. (adolescents).  
 
Directions: Should be administered for at 
least 3 days after signs and symptoms of 
infection have disappeared. 
*Ensure adequate fluid intake (advise 
patient to drink fluids) to prevent 
crystaluria.  
*Milk decreases the absorption of 
quinolones; space out interval between 
milk-product ingestion and quinolones 
intake as much as possible.  
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• USE IN SPECIAL CASES: 
Pregnancy- Not to be used in pregnant 
women (Category C). Animal studies have 
shown teratogenic effects. 
Lactation- Use not recommended. It is 
excreted in milk, and the potential for 
arthropathy and other toxicities to occur in 
the nursing infant are high. Levels of this 
drug are undetectable after 36-48 hours, 
therefore if there is a clear indication for use, 
do not breast feed until 48 hours after the last 
dose of a fluoroquinolone. 
Children- Avoid use in children < 18 yrs. and 
adolescents [Some references use 12 yrs.]. 
Reports of bone disorders in animal studies 
have been established. 
Renal Disease- Dose should be reduced if 
creatinine clearance is < 20 ml/min. 
Liver Disease- Exercise caution.  
• PRECAUTIONS AND WARNINGS:   
-Avoid use in pregnancy, lactation and 
growing children. 
-Exercise caution in patients with G6PD 
deficiency. 
-Should be used with caution in patients 
with epilepsy or with history of CNS 
disturbances, and in patients with 
myasthenia gravis. Fluoroquinolones may 
induce convulsions in such patients. 
-Rupture of the shoulder, hand and Achilles 
tendons that required surgical repair have 
been reported with use of fluoroquinolones. 
Treatment should be discontinued if the 
patient experiences pain, inflammation or 
rupture of the tendon. 
• ADVERSE EFFECTS:  
GI, CNS disturbances and some derma-
tological reactions as well as photo-
sensitivity reactions. Superinfections with 
organisms not very susceptible to 
ciprofloxacin may occur.  
 
• INTERACTIONS: 
Overview   of   Fluoroquinolones 
Drug-Drug Interactions 
Drug Interaction 
Antacids Quinolones pharmacological 
effect is decreased due to 
decreased absorption. If 
necessary antacids may be 
given at least 6 hrs. before or 
2 hrs. after quinolone 
administration. 
Didanosine Quinolones effect may be 
decreased. If concurrent use 
cannot be avoided, give 
didanosine at least 6 hrs. 
before  or  2 hrs. after the 
quinolone. 
Iron & 
calcium 
salts 
These reduce fluoro-
quinolones absorption; thus, 
ciprofloxacin should not be 
administered 4 hrs. within 
taking these preparations. 
Sucralfate It decreased absorption of 
quinolones. If needed, give 
sucralfate at least 6 hrs. after 
quinolone administration. 
Warfarin Enhanced anticoagulant 
effect may occur. Use with 
caution. 
 
• BRANDS: 
Ciprocare (Pharmacare), Ciprogis (Agis), 
Ciproxin (Bayer), Floxin (JePharm). 
__________________ 
 
 
B)  ANTI-TUBERCULOSIS 
 
Tuberculosis is one of the most serious 
infections that are showing a comeback. 
Control of this epidemic will require a 
number of initiatives on the part of 
clinicians and health care workers. 
Because of the slow growth rate of 
mycobacteria and their intracellular 
location, drugs must be administered for a 
longer period of time than in other 
infectious diseases. The risk of adverse 
reactions must be a major consideration in 
drug selection. Furthermore, to prevent the 
emergence of resistant strains that occur 
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naturally at very low frequencies, it is vital 
to employ combined therapy with at least 
two agents to which the organism is 
susceptible. 
Antituberculosis drugs are classified 
into first-line and second-line drugs, on the 
basis of their efficacy, activity, and risk of 
adverse reactions. The four first-line drugs 
are: Isoniazid (INH), Rifampin/rifampicin, 
Pyrazinamide (PZN) and Ethambutol (see 
table-5.9 for standard dosing regimens).  
Second-line drugs are indicated only when 
the Mycobacterium tuberculosis organisms 
are resistant to the first-line agents. In 
general the drugs with similar toxicities 
should not be used together. 
 
Table-5.9:  Recommended dosage for 
standard unsupervised 6-month regimen 
Isoniazid 
(INH) 
(for 6 months) 
Adult: 300 mg/d 
Child: 10 mg/kg/d 
(max. 300 mg). 
Rifampicin 
(for 6 months) 
Adult < 50 kg: 450 mg/d  
Adult ≥ 50 kg: 600 mg/d 
Child: 10 mg/kg/d 
Pyrazinamide 
(PZN)  (for first 
2 months only) 
Adult < 50 kg: 1.5 g /d   
Adult ≥ 50 kg: 2 g /d 
Child:  35 mg/kg/d 
 
Tuberculosis is treated in two phases: an 
initial phase using at least three drugs and a 
continuation phase using two drugs. 
Treatment requires specialized knowledge, 
particularly where the disease involves 
resistant organisms or non-respiratory 
organs. 
Initial phase: The concurrent use of at 
least three drugs during the initial phase is 
designed to reduce the population of viable 
bacteria as rapidly as possible and to 
prevent the emergence of drug resistant 
bacteria.  Treatment of choice for the initial 
phase is the daily use of INH, rifampicin, 
and/or PZN; ethambutol is added if drug 
resistance is a problem. 
Continuation phase: After the initial 
phase, treatment is continued with INH and 
rifampicin; longer treatment may be 
necessary for bone and joint infections, for 
meningitis, or for resistant organisms. 
Pregnancy and breast feeding:  
The standard regimen (table-5.9) may be 
used during pregnancy and breast-feeding; 
pyridoxine supplements are advisable.  
Monitor infant for possible toxicity and 
theoretical risk of convulsions and 
neuropathy. Prophylactic pyridoxine is 
advisable in mother and infant. 
Children:  
As for adults, children are given INH, 
rifampicin, and PZN for the first two 
months followed by isoniazid and 
rifampicin during the next 4 months. If 
PZN is omitted from the initial phase, then 
treatment with isoniazid and rifampicin 
should be given for 9 months. Except in 
exceptional circumstances (e.g. drug 
resistance). Ethambutol should be avoided 
in young children because of the difficulty 
in testing eyesight and in obtaining reports 
of visual symptoms. 
Non-compliant patients:  
Treatment needs to be fully supervised in 
patients who cannot be relied upon to 
comply with the treatment regimen. These 
patients are given INH, rifampicin, and 
PZN three times a week under supervision 
for the first two months followed by INH 
and rifampicin three times a week for a 
further four months. 
Immunonocompromised patients: 
Immunocompromised patients may develop 
tuberculosis owing to reactivation of 
previously latent disease or to new 
infection. Multi-resistant Mycobacterium 
tuberculosis may be present or the infection 
may be caused by other mycobacteria. Here 
a culture should be always carried out and 
the type of organism and its sensitivity 
should be confirmed. A minimum duration 
of treatment of 9 months is currently 
recommended. 
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1)  Isoniazid (INH) WHO,P 
 
• DRUG SUMMARY: 
INH is a bactericidal agent that is cheap 
and highly effective. It should always be 
included in any antituberculosis regimen 
unless there is a specific contraindication. 
Its only common side effect is peripheral 
neuropathy which is more likely to occur 
where there are pre-existing risk factors, 
such as diabetes, alcoholism, chronic renal 
failure, and malnutrition. In these circum-
stances pyridoxine 10 mg daily should be 
given prophylactically from the start of the 
treatment. 
• INDICATIONS: 
-Treatment of all forms of active TB caused 
by susceptible organisms. 
-Preventive therapy in high-risk persons 
(e.g., household members, persons with 
positive tuberculin skin test reactions). 
• CONTRAINDICATIONS: 
History of INH-associated hypersensitivity 
reactions including: hepatic injury, acute 
liver damage of any etiology, and 
porphyria. 
• DOSAGE FORMS: 
Tablets. 
• RECOMMENDED DOSAGE: 
 
Treatment 
Adult PO/IM 5 mg/kg up to 300 
mg/day. 
Child PO/IM 10-20 mg/kg up to 
300-500 mg/d. 
Preventive Therapy 
Adult PO 300 mg/day 
Child PO 10 mg/kg up to 300 
mg/day or 15 mg/kg 
three times/wk.  
 
Directions: It should be taken 1 hour before 
meals, since food decreases rate and extent 
of isoniazid absorption. 
• USE IN SPECIAL CASES: 
Pregnancy- Category C. Refer to the 
introduction of antituberculosis drugs. 
Lactation- Monitor infant for possible 
toxicity, theoretical risk of convulsions and 
neuropathy. Prophylactic pyridoxine is 
advisable in mother and infant. Refer to the 
introduction of antituberculosis drugs. 
Children- Refer to the introduction of 
antituberculosis drugs. 
Renal Disease- If severe renal impairment is 
present, the maximum dose to be given is 200 
mg daily; since increase risk of peripheral 
neuropathy. 
Liver Disease- Avoid. Idiosyncratic hepato-
toxicity is more common. 
• PRECAUTIONS AND WARNINGS: 
Caution should be taken in the case of: 
impaired liver and kidney function, 
epilepsy, history of psychosis, alcoholism, 
breast-feeding, and patients > 35 years old. 
• ADVERSE EFFECTS: 
Nausea, vomiting, hypersensitivity 
reactions including rashes, peripheral 
neuritis (with high doses), convulsions, 
psychotic episodes, agranulocytosis; 
hepatitis (especially > 35 years); systemic 
lupus erythematosus-like syndrome. 
• INTERACTIONS: 
Overview  of  Isoniazid 
Drug-Drug Interactions 
Drug Interaction 
Alcohol Ingestion on a daily basis 
increases risk of 
hepatotoxicity.  
Antacids 
and 
adsorbants 
Those reduce absorption of 
INH. INH should be 
administered 2 hrs. before 
administration of these. 
Anti-
epileptics 
Metabolism of carbamaze-
pine, ethosuximide, and 
phenytoin is inhibited leading 
to an increase in the plasma 
concentrations of such agents. 
Monitor liver functions with 
carbamazepine use. Use INH 
with caution. 
Rifampicin Coadministration may result 
in a higher rate of hepato-
toxicity. If coadministration 
is necessary, monitor liver 
function tests. If alterations 
occur, consider 
discontinuation of one or both 
of the agents. 
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Theophyl-
line 
INH possibly increases 
plasma theophylline 
concentration. Use with 
caution. 
 
• OVERDOSE: 
Symptoms of an overdosage occur within 
30 minutes to 3 hours. Nausea, vomiting, 
dizziness, slurring of speech, blurring of 
vision and visual hallucinations (including 
bright colors and strange designs) are 
among the early manifestations. With 
marked overdosage, respiratory distress and 
CNS depression will occur along with 
severe, intractable seizures. 
Isoniazid overdosage can be fatal, but good 
response has been reported in most patients 
adequately treated within the first few 
hours after drug ingestion.  
Treatment: Secure the airway and establish 
adequate respiratory exchange, gastric 
lavage is advised within the first 2 to 3 hrs., 
but do not attempt it until convulsions are 
under control. Supportive and symptomatic 
care should be implemented as needed. 
• BRANDS: 
Isoniazid (Rekah). 
___________________ 
 
2)  Rifampicin WHO,P 
 
• DRUG SUMMARY: 
Rifampicin, a bactericidal agent, is a key 
component of any antituberculosis regimen. 
Like isoniazid it should always be included 
unless there is a specific contraindication. 
During the first two months of rifampicin 
administration transient disturbance of liver 
function with elevated serum transaminases 
is common, but generally it does not 
require interruption of treatment.  
Occasionally more serious liver toxicity 
requires a change of treatment particularly 
in those with pre-existing liver disease.  
Rifampicin is a potent hepatic enzyme 
inducer which accelerate the metabolism of 
several drugs. 
• INDICATIONS: 
1. Tuberculosis. 
2. Leprosy. 
3. Brucellosis, legionnaires’ disease, and 
serious staphylococcal infections. 
4. Prophylaxis of Meningococcal 
meningitis and Haemophilus influenzae 
(type B) infections. 
• CONTRAINDICATIONS: 
Jaundice and other obstructive biliary 
diseases. In patients with porphyria. 
• DOSAGE FORMS: 
Tablets. 
• RECOMMENDED DOSAGE: 
 
 
Pulmonary Tuberculosis 
Adult  
< 50 kg 
PO 450 mg/day in 
conjunction with other 
antituberculous agents. 
Adult  
≥ 50 kg 
PO 600 mg/day in 
conjunction with other 
antituberculous agents. 
Child PO 10-20 mg/kg daily (max 
600 mg/day). 
 
Meningococcal Carriers 
Adult PO 600 mg b.i.d. for 2 
consecutive days. 
Child PO 10-20 mg/kg twice daily 
for 2 consecutive days 
(max. 600 mg/day). 
 
Prophylaxis for H. influenzae type B 
Adult PO 600 mg/day for 4 days. 
Child PO 10-20 mg/kg/day for 4 
days;  max. 600 mg/day. 
 
Dapsone-Sensitive Multibacillary Leprosy 
Adult PO 600 mg once/month with 
clofazimine and dapsone 
for minimum of 2 years. 
 
Directions: It could be taken with food to 
avoid gastric distress, but it is 
recommended to be taken 1 hour before or 
2 hours after meal. 
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• USE IN SPECIAL CASES: 
Pregnancy- There are evidences of 
teratogenic effect, in animal studies, if it 
has been used during the first trimester. 
The risk of neonatal bleeding may be 
increased if rifampicin has been 
administered during the third trimester.   
Lactation- Rifampicin is excreted in breast 
milk with a milk/plasma ratio of 0.2 to 0.6. 
Decide whether to discontinue nursing or 
to discontinue the drug, taking into account 
the importance of the drug to the mother. 
Children- Data is not available to determine 
dosage for children < 5 yrs. of age. 
Renal Disease- No dosage adjustment is 
required in the case of renal failure. 
Liver Disease- Avoid use or do not exceed 
8 mg/kg daily because elimination might 
be reduced and the risk of hepatotoxicity 
might be increased. 
• PRECAUTIONS AND WARNINGS: 
1. Reduce dose in hepatic impairment- 
look at special cases. 
2. Carry out liver function tests and blood 
counts in the case of hepatic disorders and 
on prolonged therapy. 
3. It discolors soft contact lenses. 
4. Cautious use in the case of alcoholism 
or concomitant administration of another 
hepatotoxic agent. 
• ADVERSE EFFECTS: 
Heartburn, anorexia, nausea, vomiting, 
diarrhea, epigastric distress, flatulence, 
cramps, transient elevation in liver function 
tests (bilirubin, BSP, alkaline phosphatase, 
ALT, AST), thrombocytopenic purpura, 
flushing, urticaria and rashes, saliva and other 
body secretions will be colored orange-red. 
• OVERDOSE: 
Signs and symptoms: Nausea, vomiting and 
increase lethargy will probably occur 
within a short time after ingestion; 
unconsciousness may occur with severe 
hepatic involvement. Brownish-red or 
orange discoloration of the skin, urine, 
sweat, saliva, tears and feces is proportional 
to the amount ingested.  Liver enlargement 
and jaundice may develop rapidly. 
Treatment: Gastric lavage is probably 
preferable to induction of emesis.  
Activated charcoal slurry instilled into the 
stomach following evacuation of gastric 
contents can help absorb any remaining 
drug in the GI tract.  Antiemetic medication 
may be required to control severe nausea 
and vomiting.  
• INTERACTIONS: 
Overview  of  Rifampicin 
Drug-Drug Interactions 
Drug Interaction 
Rifampicin induces hepatic enzymes which 
accelerate the metabolism of several drugs 
including:  
estrogens, corticosteroids, phenytoin, 
sulphonylurea, anticoagulants, 
antiarrhythmics, chloramphenicol, anti-
depressants, antipsychotics, anxiolytics, 
hypnotics, β-blockers, Ca-channel 
blockers, cardiac glycosides, theophylline, 
thyroxine and cimetidine. 
Monitor patients and plasma levels when 
applicable, and adjust dosage regimens as 
needed. 
Oral contra-
ceptives 
(OC) 
The effectiveness of OC is 
reduced; alternative family 
planning method should be 
offered. 
Antacids They reduce absorption of 
rifampicin. 
Alcohol,  
and 
isoniazid 
Coadministration of any one 
of these increases the risk of 
hepatotoxicity. Refer to INH. 
Para-amino-
salicylic acid
Effectiveness of rifampicin is 
reduced. If necessary to 
administer, give apart at an 
interval of 8-12 hrs. 
 
• BRANDS: 
Mycobutin (Farmitalia/Agis), Rimactan (Ciba-
Geigy). 
_______________________ 
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3)  Pyrazinamide WHO,P 
 
• DRUG SUMMARY: 
Pyrazinamide (PZN) is a bactericidal drug, 
only active against intracellular dividing 
forms of Mycobacterium tuberculosis; it 
exerts its main effect only in the first two to 
three months. It is particularly useful in 
tuberculous meningitis because of good 
meningeal penetration. It is not active 
against M. bovis.   
• INDICATIONS: 
Tuberculosis in combination with other 
drugs. 
• CONTRAINDICATIONS: 
Liver damage, porphyria. 
• DOSAGE FORMS: 
Tablets. 
• RECOMMENDED DOSAGE: 
Adult  
< 50 kg PO 1.5 g daily 
Adult   
≥ 50 kg PO 2 g daily 
Child PO 35 mg/kg daily. 
 
• USE IN SPECIAL CASES: 
Pregnancy- Pyrazinamide should be used 
only if it is clearly indicated (Category C). 
Lactation- It is found in small amounts in 
breast milk, therefore, one should take the 
risk-benefit ratio of this therapy into account. 
Children- PZN regimens employed in adults 
are probably equally effective in children. 
PZN appears to be well tolerated in children. 
Renal Disease- No dosage adjustment is 
required. 
Liver Disease- Patients with preexisting liver 
disease should be followed up closely, and 
one should discontinue PZN if signs of 
hepatocellular damage appear. 
• PRECAUTIONS AND WARNINGS: 
One should take caution in the case of: 
impaired renal function, diabetes, gout, or 
history of peptic ulcer. 
• ADVERSE EFFECTS: 
Hepatotoxicity including: fever, anorexia, 
hepatomegaly, jaundice, or liver failure; 
nausea, vomiting, arthralgia, sideroblastic 
anemia, and urticaria. 
• INTERACTIONS: 
It inhibits the renal secretion of urates.  
PZN antagonizes the effect of probenecid 
and sulphinpyrazone which are uricosuric 
agents. 
• OVERDOSE: 
Overdose experience is limited. 
• BRANDS: 
No brand names available in our market. 
___________________ 
 
 
4)  Ethambutol WHO,P 
 
• DRUG SUMMARY: 
Ethambutol, a bacteriostatic agent, is 
included in the treatment regimen of 
tuberculosis when resistance to other agents 
is suspected.  
• INDICATIONS: 
Tuberculosis in combination with other 
drugs. 
• CONTRAINDICATIONS: 
- Renal function impairment. 
- Poor vision of optic neuritis. 
- Children under 13 years old. 
• DOSAGE FORMS: 
Tablets. 
• RECOMMENDED DOSAGE: 
Directions: Absorption is not affected by 
food. Can be taken with food in order to 
minimize stomach upset. 
 
Unsupervised Treatment with Ethambutol 
25 mg/kg daily in the initial phase followed 
by 15 mg/kg daily in the continuation phase 
(or 15 mg/kg daily throughout). 
Fully Supervised Intermittent Treatment 
30 mg/kg three times a week or 45 mg/kg 
twice a week 
 
• USE IN SPECIAL CASES: 
Pregnancy- It should be used only when 
clearly indicated (Category B). 
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Lactation- The amount excreted in breast 
milk is too small to be harmful to the nursing 
baby. 
Children- It is contraindicated in children less 
than 13 years old. 
Renal Disease- Dose should be reduced if the 
degree of impairment is mild. 
Liver Disease- No dosage adjustment is 
required in the case of hepatic dysfunction. 
• PRECAUTIONS AND WARNINGS: 
-Reduce dose in the case of renal 
impairment. 
-Cautious use in the case of: gout, cataract, 
recurrent ocular inflammatory conditions, 
diabetic retinopathy, and the elderly. 
• ADVERSE EFFECTS: 
-Visual disturbances. 
-Optic neuritis, red/green color blindness, 
peripheral neuritis. 
• INTERACTIONS: 
Aluminum salts may delay and reduce the 
absorption of ethambutol, so separate their 
administration by several hours. 
• OVERDOSE: 
Experience with overdose is limited. 
• BRANDS: 
Myambutol (Lederle). 
____________________ 
 
 
C)  ANTI-PARASITICS 
 
Parasitic infections are a major world wide 
health problem, particularly in less 
developed countries (i.e., malaria, schis-
tomsomes, amoebiasis . . . etc.). Different 
factors contribute to this increase such as 
population crowding, poor sanitation and 
lack of health education, inadequate control 
of parasite vectors, contaminated water 
supplies, increased world travel, population 
migrations, as well as development of 
resistance to agents used to treat these 
infections. 
Antiparasitics or anthelmintics are drugs 
used to rid the body of worms known as 
helminths. The term anthelminitc applies to 
agents that act either locally to expel worms 
from the GI tract or systemically to 
eradicate species and developmental forms 
of helminths that invade organs and tissues.   
The common antiparasitic drugs used in 
our community are discussed in this 
section. 
 
 
1)  Metronidazole WHO,P 
 
• DRUG SUMMARY: 
Metronidazole is an antimicrobial drug with 
a high activity against anaerobic bacteria 
and protozoa. It is the drug of choice for 
acute invasive amoebic dysentery, since it 
is very effective against vegetative 
amoebae in ulcers at a dosage of:  800 mg 
every eight hours for five days. It is also 
effective against amoebae which may have 
migrated to the liver. 
• INDICATIONS: 
-Anaerobic infections (including brain 
abscess). 
-Protozoal infections including: 
a: Trichomoniasis. 
b: Amoebiasis (not for cystic form). 
c: Gardiasis (not for cystic form). 
-Bacterial vaginosis (as Gardnerella 
vaginalis infections and Trichomonas 
vaginalis). 
-Surgical and gynecological sepsis in which 
its activity against colonic anaerobes, 
especially Bacteroid fragilis, is important. 
-Treatment of pseudomembranous colitis 
(in a dose of 400 mg by mouth three 
times/day). 
-Topical metronidazole reduces the odor 
produced by anaerobic bacteria in fungating 
tumors. 
• CONTRAINDICATIONS: 
Blood dyscrasias, active CNS disease, first 
trimester of pregnancy, nursing mothers.  
• DOSAGE FORMS: 
Tablets, suspension, gel or cream. 
• RECOMMENDED DOSAGE: 
See table-5.10. 
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Directions: Administer oral preparations 
immediately before, with, or immediately 
after meals. If GI distress occurs, one can 
take the drug with food or with milk. 
• USE IN SPECIAL CASES: 
Pregnancy- Metronidazole is contraindicated 
in first trimester.  It should be used only when 
it is clearly indicated. If benefit outweighs 
risk for use, avoid high-doses regimens, or 
single doses (Category B). 
Lactation- Stop lactation during treatment as 
significant amount of the administered drug 
appears in the breast milk and it may give a 
bitter taste to the milk. A nursing mother 
should discard any breast milk produced 
while she is on the drug, and resume nursing 
24 to 48 hours after the drug is discontinued. 
Children- Safety and efficacy in children 
have not been established, except for the 
treatment of amebiasis. There is a decrease in 
elimination in newborns. 
Renal Disease- No dosage adjustment is 
required in the case of renal impairment. 
Liver Disease- Reduce the dose in the case of 
severe liver dysfunction. 
• PRECAUTIONS AND WARNINGS: 
-Metronidazole is carcinogenic in rodents 
after long term use; avoid unnecessary use. 
-It causes disulfiram-like reaction if it is 
administered with alcohol. 
-Cautious use in the case of liver 
impairment. 
-Cautious use in the case of alcoholism and 
coexistent candidiasis. 
• ADVERSE EFFECTS: 
Nausea, vomiting, unpleasant taste, GI 
disturbances, rashes, urticaria and angio-
edema, drowsiness (rare), headache, 
dizziness, ataxia, and darkening of urine. 
• INTERACTIONS: 
Overview  of  Metronidazole 
Drug-Drug Interactions 
Drug Interaction 
Alcohol Disulfiram-like reaction. 
Warn patient against alcohol 
or alcohol containing product 
intake. 
Disulfiram Concomitant administration 
will cause acute psychosis 
Phenobar-
bitone and 
cimetidine 
These inhibit the metabolism 
of metronidazole. 
Phenytoin Metronidazole inhibits the 
metabolism of phenytoin, this 
might lead to toxic effects. 
Warfarin Metronidazole enhances the 
anticoagulant effect. Use with 
caution. 
 
• OVERDOSE: 
Symptoms: Nausea, vomiting, ataxia, and 
neurotoxic effects. 
Treatment: No specific antidote for metro-
nidazole is available. Treatment consists of 
usual supportive measures.  
• BRANDS: 
Entogyl (JePharm), Flagy (Specia), Metrocare 
(Pharmacare), Metrogyl (Teva), Metrozole 
(BPC), Trichonazole (Vitamed), Zadstat 
(Lederle). 
_______________________ 
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Table – 5.10:  Recommended Doses of Metronidazole * 
Disease Age Route Dosage 
Adult PO An initial dose of 800 mg followed by 
400 mg  q. 8 h. for 7 days. 
Anaerobic 
infections 
Child PO 7.5 mg/kg q. 8 h. for 7 days. 
Leg ulcers and 
pressure sores 
Adult PO 400 mg q. 8 h. for 7 days. 
Bacterial 
vaginosis 
Adult PO 400-500 mg twice daily for 7 days   or  
2 g as a single dose. 
Adult  PO 200 mg  q. 8 h. for 3–7 days. 
Child (1- < 3 y) PO 50 mg  q. 8 h.  for three days. 
Child (3- < 7 y) PO 100 mg  q 12 h for three days. 
Acute  
ulcerative 
gingivitis 
Child (7- 10 y) PO 100 mg  q. 8 h. for three days. 
Acute dental 
infections 
Adult PO 200 mg  q. 8 h.  for 3-7 days. 
Adult PO 800 mg  q. 8 h. for 5 days. 
Child (1- < 3 y) PO 200 mg  q. 8 h. for 5 days. 
Child (3- < 7 y) PO 200 mg  q. 6 h. for 5 days. 
Invasive 
intestinal  
amoebiasis 
Child (7- 10 y) PO 400 mg  q. 8 h. for 5 days. 
Adult PO 800 mg  q. 8 h.  for 7-10 days Amoebiasis 
(including  
liver abscess) 
Child PO 35-50 mg/kg/d given in 3 divided doses, 
q. 8 h.  for 7-10 days. 
Adult PO 400-500 mg q. 12 h. for 5-7 days Urogenital 
trichomoniasis Child PO 15mg/kg/d  given in 3 divided doses for 7 
days. 
Adult PO 2 g daily for 3 days and a further 2 g dose 
may be given if no clinical improvement,  
or 400 mg q. 8 h. for 5 days, 
or 500 mg q. 12 h. for 7-10 days. 
Giardiasis 
Child PO 35-50 mg/kg/d given in 3 divided doses, 
q. 8 h.  for 7-10 days. 
*Reference: BNF 2001 (Sept), pp. 286,316. 
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2)  Diloxanide Furoate WHO                  . 
 
• DRUG SUMMARY: 
Diloxanide furoate, a dichloroacetamide 
derivative, is a luminal amoebicide acting 
principally in the bowel lumen and is used 
in the treatment of intestinal amoebiasis. It 
is given alone in the treatment of 
asymptomatic cyst-passers, and in 
conjunction with an amoebicide that acts in 
the tissues, in patients with invasive 
amoebiasis. Good choice for recurrent or 
chronic amoebae. 
• INDICATIONS: 
Treatment of asymptomatic carriers (E. 
histolytica cyst-passers) in nonendemic 
areas (metronidazole and tinidazole are 
relatively ineffective for such cases. Refer 
to BNF 2001:316). Eradication of residual 
amoebae in the colonic lumen following 
treatment of invasive disease with 
metronidazole or other amoebicides.  
• CONTRAINDICATIONS: 
Hypersensitivity to diloxanide. 
• DOSAGE FORMS: 
Tablets. 
• RECOMMENDED DOSAGE:   
Adult:  500 mg 3 times daily for 10 days. 
Child:  20 mg/kg daily in 3 divided doses 
for 10 days.  
Directions: If necessary a second course 
may be given immediately following the 
first. 
*May be taken without regard to meals. 
• SPECIAL CASES:  
Pregnancy- Use only if clearly indicated. 
Treatment is best deferred until after the 
first trimester. 
Lactation- Use with caution. Safety has not 
been reported. 
Children- It has been used safely in children. 
Renal + Liver Disease- Use with caution. No 
special adjustments reported. 
• PRECAUTIONS AND WARNINGS: 
It is not effective against hepatic 
amoebiasis. 
• ADVERSE EFFECTS: 
Mild GI tract symptoms, particularly 
flatulence, may be troublesome. Vomiting, 
pruritus and urticaria have been reported. 
• INTERACTIONS: 
None reported. 
• OVERDOSE: 
Symptoms:  Nausea and vomiting. 
Treatment: Induces emesis if not already 
occurred.  Gastric lavage may be used. Use 
supportive symptomatic care. 
• BRANDS: 
Furamide (Knoll). 
_________________________ 
 
3)  Mebendazole WHO 
 
• DRUG SUMMARY: 
Mebendazole is effective in threadworm 
infections (the commonest one is the 
pinworm “Enterobius vermicularis”), but 
its use needs to be combined with hygienic 
measures to break the cycle of auto-
infection. All members of the family 
require treatment.  Mebendazole is the drug 
of choice for patients of all ages over two 
years. It is given as a single dose; as 
reinfection is very common, a second dose 
may be given after 2-3 weeks.  Also, it is 
used in the treatment of infection caused by 
other types of helminths as roundworm 
(Ascaris), whipworm, and hookworm 
infections. 
• INDICATIONS: 
Treatment of infections caused by 
threadworm, roundworm, whipworm, and 
hookworm. 
• CONTRAINDICATIONS: 
Hypersensitivity to mebendazole. 
• DOSAGE FORMS: 
Tablets and suspension. 
• RECOMMENDED DOSAGE: 
Doses are summarized in the table below. 
Directions: It may be given without regard 
to food. The tablet may be chewed, 
crushed, or swallowed. 
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Recommended Doses of Mebendazole 
Threadworms’ infection 
(Enterobius vermicularis) 
Adult & 
children 
over 2 years 
PO 100 mg as a single 
dose; if reinfection 
occurs a second 
dose may be 
needed after 2-3 
weeks. 
Other infestations 
Adult & 
children 
over 2 years 
PO 100 mg twice 
daily for 3 days. 
If no cure, 
another course 
may be given. 
 
• USE IN SPECIAL CASES: 
Pregnancy- Use not recommended for 
pregnant women (Category C); benefit-risk 
issue. 
Lactation- Use not recommended. Safety in 
nursing mother has not been established. 
Children- Not recommended for children 
under 2 years. 
Renal Disease- Minimally absorbed from the 
GI tract, safely used in the case of renal 
disease, when used as directed.  
Liver Disease- Minimally absorbed from the 
GI tract, can be used in the case of liver 
disease. 
• ADVERSE EFFECTS: 
Abdominal pain and diarrhea which are 
rare. 
• INTERACTIONS: 
*Carbamazepine and hydantoins may 
reduce the plasma level of mebendazole, 
leading to a decrease in its therapeutic 
effectiveness. 
• OVERDOSE: 
GI complaints lasting to a few hours may 
occur.  Induce vomiting and purging. 
• BRANDS: 
Vermacare (Pharmacare), Vermazol (JePharm), 
Vermox (Abic), Wormex (Megapharm). 
________________ 
 
 
4)  Niclosamide  
 
• DRUG SUMMARY: 
Niclosamide is a halogenated salicylanilide 
derivative anthelminitic. It is the most 
widely used drug for tapeworm infections.  
It is not effective against larval worms, and 
it affects the cestodes of the intestine only.  
The fact that fasting is not necessary, 
makes it more preferred by patients 
particularly in the treatment of children. 
• INDICATIONS: 
Intestinal tapeworm (cestode) infections, 
example Taenia saginata (beef tapeworm), 
Diphyllobothrium latum (fish tapeworm), 
Hymenolepis nana (dwarf tapeworm), 
Hymenolepis diminuta (rat tapeworm), 
Dipylidium caninum (dog or cat tape-
worm). 
• CONTRAINDICATIONS: 
Hypersensitivity to niclosamide or any of 
its components. 
• DOSAGE FORMS: 
Tablets. 
• RECOMMENDED DOSAGE: 
 
Beef and Fish Tapeworm 
Adult PO 2 g as a single dose 
Child  
(> 34 kg) 
PO 1.5 g as a single 
dose 
Child 
(11-34 kg) 
PO 1 g as a single dose 
Dwarf Tapeworm 
Adult PO 2 g/d as a single 
dose for 7 days 
Child 
(>34 kg) 
PO 1.5 g/d as a single 
dose for 6 days 
Child  
(11-34 kg) 
PO 1 g as a single dose 
on day 1, then 500 
mg once/d for next 
6 days. 
 
Directions: It should be taken after a light 
meal. Instruct the patient to chew tablet 
thoroughly, then swallow with a little 
water.   
*For young children, tablet may be crushed 
to a fine powder and mixed with sufficient 
water to form a paste for ease of ingestion. 
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• USE IN SPECIAL CASES: 
Pregnancy- Use during pregnancy only when 
it is clearly indicated (Category B). 
Lactation- Its use during lactation has not 
been established. 
Children- Its use in children less than 2 years 
has not been established. 
Renal Disease- Minimally absorbed from the 
GI tract, therefore, safely used in the case of 
renal disease.  
Liver Disease- Minimally absorbed from the 
GI tract, may be used in the case of liver 
disease.  
• ADVERSE EFFECTS: 
Occasional GI upset, light-headedness, and 
pruritus. 
• OVERDOSE: 
In the events of the overdose, do not induce 
vomiting. Refer to the hospital and give a 
fast-acting laxative and enema. 
• BRANDS: 
Yomesan (Bayer). 
_____________________ 
 
5)  Albendazole WHO 
      (hydatid disease) 
 
Cysts caused by Echinococcus granulosus 
grow slowly and asymptomatic patients do 
not always require treatment. Surgical 
treatment remains the method of choice in 
many situations.  Albendazole is used in 
conjunction with surgery to reduce the risk 
of recurrence or as primary treatment in 
inoperable cases.  
Alveolar echinococcosis due to E. 
multilocularis is usually fatal if untreated. 
Surgical removal with albendazole use is 
the treatment of choice, when effective 
surgery is impossible, repeated cycles of 
albendazole (for a year or more) may help. 
 Careful monitoring of liver function is 
particularly important during drug 
treatment. 
________________________ 
D)  ANTI-FUNGALS 
 
Fungal infections are frequently associated 
with a defect in host resistance which 
should, if possible, be corrected; otherwise 
drug therapy may fail.  Treatment of 
dermatophyte infections may be 
unsuccessful until the animal source has 
been removed or controlled.  Fungal 
infections are traditionally divided into two 
classes; superficial and systemic. The most 
common fungal infections are superficial 
and are treated with topical agents or with 
oral agents. Most current drugs (i.e. 
imidazoles and triazoles) may be used 
systemically or topically. Systemic mycotic 
infections are often found in debilitated or 
immunosuppressed patients.  
 
(For topical use of antifungal agents refer 
to the dermatological section). 
 
 
1)  Nystatin WHO,P 
 
• DRUG SUMMARY: 
It is not absorbed when it is given by mouth 
and is too toxic for parenteral use. It is 
active against a number of yeast and fungi 
but is principally used for Candida albicans 
infections of skin and mucous membranes. 
It is also used in the treatment of intestinal 
candidiasis. 
• INDICATIONS: 
Candidiasis. 
• CONTRAINDICATIONS: 
It is contraindicated in the case of 
hypersensitivity to nystatin, and in the case of 
vaginal infections caused by Gardnerella 
vaginalis or Trichomonas spp.  
• DOSAGE FORMS: 
Tablets, suspension, vaginal tablets. 
• RECOMMENDED DOSAGE:  
Refer  to the following table: 
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Recommended Doses of Nystatin 
Candida Infections 
Adult PO 50,000-1,000,000 IU 
three times daily. 
1-4 troches 4-5 times/d. 
Suspension: 400,000-
600,000 IU 4 times daily. 
 Vagi- 
nal 
1-2 tablets daily for 2 
weeks. 
Child PO Suspension: 400,000-
600,000 IU  4 times daily. 
Infants PO 100,000-200,000 IU 4 
times daily. 
 
Directions: In the case of oral suspension: 
rinse the mouth with 1-2 tsp of nystatin oral 
susp., keep it in the mouth as long as 
possible then expectorate or swallow 
(better for children and infants). Avoid 
food and drink for at least 30 min. after 
administration. 
*Avoid the direct contact of the drug with 
hands. 
*Store vaginal suppositories in refrigerator 
below 15° C. 
*Treatment of candidiasis should be 
continued for at least 48 hours after the 
disappearance of symptoms.  
• USE IN SPECIAL CASES: 
Pregnancy- Category A. No adverse effects 
or complications have been attributed to 
nystatin in infants born to women treated 
by nystatin. 
Lactation- It is poorly absorbed from the GI 
tract, therefore it should not have any 
adverse effects on the nursing infant. 
Renal and liver Diseases- It is poorly 
absorbed from the GI tract, and passes 
unchaged in the stool, therefore no special 
precautions are recorded.  
• ADVERSE EFFECTS: 
Nausea, vomiting, diarrhea at high doses. 
• BRANDS: 
Nystatin (Taro), Candistan (BPC). 
____________________ 
 
2)  Miconazole WHO,P 
 
• DRUG SUMMMARY: 
Miconazole is mainly used for local 
treatment and can be given by mouth for 
oral and intestinal infection; it can also be 
given parentally for systemic infections 
including aspergillosis, candidiasis, and 
cryptococcosis but the injection contains 
polyethoxylated caster oil which may give 
rise to hypersensitivity reactions. 
• INDICATIONS: 
Mainly used to treat severe systemic fungal 
infections. 
• CONTRAINDICATIONS: 
Hypersensitivity to miconazole. 
• DOSAGE FORMS: 
Tablets. 
• RECOMMENDED DOSAGE:  
 
 
Oral and Intestinal Fungal Infections 
By mouth 
as tablets 
250 mg q. 6 h. for 10 days or up 
to two days after symptoms 
clear. 
Adult 5-10 ml in the mouth 
after food q. 6 h.; 
retain near lesions 
before swallowing. 
Child  
< 2 yrs. 2.5 ml  b.i.d. 
Child 
2-6 yrs. 5 ml  b.i.d. 
By mouth 
as oral 
gel 
Child  
> 6 yrs. 5 ml 4 times daily. 
 
Vaginal Infections 
Intra-
vaginal 
Vaginal 
cream 
or 
vaginal 
supp. 
1 applicator full of 
cream or one 100 mg 
supp. at bedtime for 7 
days or one 200 mg 
supp. at h.s. for 3 
days.  
 
Directions: Oral preparations should be 
taken after food. In the case of oral gel, 
smear the affected area with a clean finger 
and hold it in the mouth for a while before 
swallowing.  
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• USE IN SPECIAL CASES:  
Pregnancy- Category B after the first 
trimester.  It should be used only when 
clearly indicated. 
Lactation- No available data on use.  Avoid 
use, unless clearly indicated.  
Children- Safety in children under 1 year of 
age has not been established. 
Renal Disease- Cautious use in the case of 
renal impairment. 
Liver Disease- Cautious use in the case of 
hepatic impairment. 
• PRECAUTIONS AND WARNINGS: 
Hepatic and renal impairment. 
• ADVERSE EFFECTS: 
Nausea, vomiting, pruritus, and rashes. 
• INTERACTIONS: 
Overview  of  Miconazole 
Drug-Drug Interactions 
Drug Interaction 
Warfarin, 
sulphonyl-
ureas and 
phenytoin 
Miconazole enhances the 
effect of these.  Monitor 
patients and adjust their doses 
as needed. 
Ampho-
tericin 
Miconazole antagonizes its 
effect. Use with caution. 
 
• BRANDS: 
Dakatrin Oral Gel (Abic), Daktazol Oral Gel 
(JePharm), Gyno-Daktarin (Abic), Gyno-
Daktazol (JePharm), Gyno-Daktazol Ovules 
(JePharm). 
_______________________ 
 
 
3)  Griseofulvin WHO,P 
 
• DRUG SUMMARY: 
May be produced by the growth of certain 
strains of Penicillium griseofulvum or by 
other means. It is selectively concentrated 
in keratin and is the drug of choice for 
widespread or intractable dermatophyte 
infections. It is well absorbed from the gut 
but is inactive when applied topically. It is 
more effective in skin than in nail 
infections and treatment must be continued 
for several weeks or even months. Side 
effects are uncommon. 
• INDICATIONS: 
Dermatophyte infections of the skin, scalp, 
hair and nails, where topical therapy has 
failed or is inappropriate. It is effective 
against various species of Epidermophyton, 
Microsporum, and Trichophyton (has no 
effect on other fungi, including Candida 
spp., bacteria, and yeast).  
• CONTRAINDICATIONS: 
In porphyria, hepatic failure, and systemic 
lupus erythematosus. 
• DOSAGE FORMS: 
Tablets 
• RECOMMENDED DOSAGE: 
 
Tinea Corporis, Tinea Cruris, and 
Tinea Capitis 
Adult PO 500 mg microsize or 330-
375 mg ultramicrosize 
daily in single or divided 
doses. 
Tinea Pedis, Tinea Unguium 
Adult PO 0.75-1 g microsize or 660-
750 mg ultramicrosize 
daily in single or divided 
doses; microsize dose 
should be decreased to 
500 mg/d after response is 
noted. 
Child PO 11 mg/kg/d microsize or 
7.3 mg/kg/d ultramicrosize 
in single or divided doses. 
 
Directions: It should be taken with or after 
the meal. Continue taking the medication 
for entire course of therapy even if 
beneficial effects may not be noticeable. 
*Duration of treatment depends on the 
thickness of the keratin layer:  2-6 wks. for 
hair and skin, up to 6 mon. for fingernails, 
and 12 mon. or more for infections of the 
toenails. 
• USE IN SPECIAL CASES: 
Pregnancy- Use it only when it is clearly 
indicated (Category C). Griseofulvin was 
embryotoxic and teratogenic rates.  Cases of 
conjoined twins have been reported in 
patients taking griseofulvin during the first 
trimester of pregnancy. 
Lactation- Use caution. No available data. 
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Children- Safety not established in children 
less than two years old. 
Liver Disease- It is contraindicated in the 
case of hepatic failure. 
• PRECAUTIONS AND WARNINGS: 
-Use caution in the case of penicillin-
sensitive patients since there is a possibility 
of the presence of cross-sensitivity between 
penicillin and griseofulvin. 
-It may impair performance of skilled tasks 
(e.g. driving). 
-It enhances the effect of alcohol. 
• ADVERSE EFFECTS: 
Headache, nausea, vomiting, rashes, 
photosensitivity, dizziness, fatigue, 
agranulcytopenia and leucopenia have been 
reported; lupus erythematosus, erythema 
multiforme, peripheral neuropathy, 
confusion, and impaired co-ordination.  
• INTERACTIONS: 
Overview  of  Griseofulvin 
Drug-Drug Interactions 
Drug Interaction 
Anti-
coagulant 
Griseofulvin increases the 
metabolism of nicoumalone 
and warfarin leading to a 
decrease in their 
anticoagulant activity. 
Oral contra-
ceptives 
Griseofulvin increases the 
metabolism of OCs. 
Pheno-
barbitone 
It increases the metabolism of 
griseofulvin, leading to a 
decrease in its anti-fungal 
activity. 
 
• BRANDS: 
Grifulin Forte (Teva), Sporofulvin (JCL). 
____________________________ 
 
 
C)  ANTIVIRAL AGENTS 
 
Specific therapy of viral infections is 
generally unsatisfactory, and treatment is 
primarily symptomatic. Most agents are 
active against the virus, but do not 
eradicate them. Infections that do not 
respond to antivirals include mumps, 
poliomyelitis, rabies and rubella.  
With the increased number of HIV 
infected people world wide, there are many 
antiviral drugs that are specific for this 
causative agent of AIDS. AIDS 
medications will not be discussed in our 
book at this time, since AIDS patients in 
our community seek special medical 
supervision, and will rarely be treated at the 
primary healthcare level.   
This section will discuss the antiviral 
agent Acyclovir. 
 
 
1)  Acyclovir 
 
• DRUG SUMMARY: 
Acyclovir, written as aciclovir in British 
English, is an antiviral agent (a synthetic 
purine nucleoside derivative) that inhibits 
the viral replication by inhibiting DNA 
synthesis. It is active against Herpes 
simplex virus 1&2, Varicella zoster, 
Epstein-Barr and Cytomegalovirus.  
• INDICATIONS: 
For the treatment of initial episodes and 
management of recurrent genital herpes in 
certain patients. It is also used for the acute 
treatment of Herpes zoster (shingles) and 
Varicella (chickenpox).  
• CONTRAINDICATIONS: 
Hypersensitivity to acyclovir or any of its 
components. 
• DOSAGE FORMS:   
Tablets, capsules, suspension, ointment.  
• RECOMMENDED DOSAGE: 
Adult:  *Herpes simplex: 
Initial genital herpes: 200 mg PO q. 4 h.; 5 
times a day for 10 days. 
Chronic/recurrent disease: 400 mg b.i.d. 
for up to 12 months followed by 
reevaluation of the case.  Reevaluation will 
determine if there is a need to continue or 
discontinue the medication. 
Intermittent therapy: 200 mg q. 4 h.; 5 
times a day for 5 days. Therapy should start 
as soon as the first symptom of recurrence 
occurs. 
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*Herpes zoster, acute treatment: 800 mg 
q. 4 h.; 5 times a day for 7 to 10 days. 
Child:  *Chicken pox:  
20 mg/kg (not > 800 mg) q. 6 h. for 5 days.   
Therapy should be started at the earliest 
sign or symptom. 
• USE IN SPECIAL CASES:  
Pregnancy- There are no adequate studies in 
pregnant women (Category C). Use during 
pregnancy only if the potential benefit 
outweighs the potential risk to the fetus.  
Lactation- Acyclovir is excreted in the breast 
milk, but there have been no reports of 
adverse effects. Exercise caution when 
administering to a nursing woman.  
Children- Safety and efficacy of oral 
acyclovir in children < 2 years of age have 
not been established. 
Renal Disease- Dosage adjustment is required 
with renal function impairment depending on 
the creatinine clearance as indicated in the 
table below: 
 
Oral Acyclovir Dosage 
In Renal Function Impairment 
Normal 
dosage 
regimen 
(5 x daily) 
CLcr 
(ml/min/ 
1.73 m2) 
Adjusted 
dosage 
regimen 
200 mg  
q. 4 h. 
> 10 
 
0-10 
200 mg q.4 h., 
5 x dly 
200 mg q.12 h. 
400 mg  
q. 12.h. 
> 10 
0-10 
400 mg q. 12 h. 
200 mg q. 12 h.  
800 mg  
q. 4 h. 
> 25 
 
10-25 
0-10 
800 mg q. 4 h.,  
5 x daily 
800 mg q. 8 h. 
800 mg q. 12 h. 
 
 
• PRECAUTIONS AND WARNINGS: 
-In the case of genital herpes, the patient 
should avoid sexual intercourse when 
visible lesions are present because of risk 
of infecting the other partner. 
-Acyclovir does not eliminate latent herpes 
simplex virus and is not a cure. It only 
decreases the frequency and the severity of 
recurrences. Resistance might develop 
when acyclovir is used continuously over 
an extensive period of time. Another type 
of antiviral should be used in this case.  
-Dosage depends on the estimated 
Creatinine clearance (CLcr). Continuous 
checking of CLcr is recommended for 
patients using acyclovir for long periods of 
time.  
• ADVERSE EFFECTS: 
Several adverse effects may occur such as: 
nausea, vomiting, diarrhea, headache, skin 
rash, dizziness, edema, leg pain, sore 
throat, flatulence, constipation, and 
malaise.  
• INTERACTIONS:   
Overview  of  Acyclovir 
Drug-Drug Interactions 
Drug Interaction 
Probenecid Acyclovir may increase its 
effect. 
Zidovudine Acyclovir interacts with  
zidovudine and causes severe 
drowsiness and lethargy. Use 
with caution. 
 
• OVERDOSE: 
Overdose may be treated with hemo-
dialysis.  Renal failure might result from 
the overdose. In such cases, hemodialysis 
should continue until renal function is 
restored. 
• BRANDS: 
Zovirax (Wellcome). 
___________________ 
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A)  ANTIDIABETIC DRUGS 
 
Diabetes Mellitus (DM) is a complex 
disease characterized by symptoms of 
glucose intolerance, as well as changes in 
lipid and protein metabolism.  Over the 
long term, these metabolic abnormalities, 
particularly hyperglycemia, contribute to 
the development of complications such as 
retinopathy, nephropathy and neuropathy.  
The Expert Committee on the Diagnosis 
and Classification of Diabetes Mellitus has 
developed new criteria for the diagnosis of 
DM [Diabetes Care, 1997(Jul); 20(7)]. 
There are two major types of diabetes: 
Type 1 previously known as insulin 
dependent diabetes mellitus (IDDM) or 
juvenile form, and Type 2 previously 
known as non-insulin dependant diabetes 
mellitus (NIDDM) or adult/maturity onset 
form. 
There are three major components for 
the treatment of DM; diet, exercise, and 
drugs. Each of these components interacts 
with the other to the extent that no 
assessment and modification of one can be 
made without knowledge of the other two. 
The goal of therapy is to keep the patient 
free of symptoms associated with 
hyperglycemia or hypoglycemia, to prevent 
glucose toxicity, to eliminate or minimize 
all other cardiovascular risk factors and 
further macrovascular and microvascular 
diseases, and to maintain normal growth 
and development in children. 
Diet, exercise, and insulin must be 
delicately balanced in type 1.  If diet and 
weight loss have failed in type 2 patients, 
an oral hypoglycemic agent can be used. If 
drugs are used properly they can be both 
safe and effective. 
There are six categories of drugs 
approved for the management of diabetes 
mellitus (see table-6.1).  Some of these 
agents maybe used as single therapy or in 
combination. The proper choice between 
them is not completely clear.  The factors 
that should be considered when choosing a 
drug include cost, contraindications, side 
effects, amount of glycemic-lowering 
needed to get the patient to the desired 
glucose range, ability for compliance, the 
patient’s weight and ideal weight, and the 
lipid profile (White, 1998). 
   
Table 6.1: Antidiabetic Drugs 
Category Examples 
Insulins Regular insulin 
Lispro insulin 
Isophane insulin 
Sulfonylurea 
1st generation: 
 
Acetohexamide  
Chlorpropamide 
Tolazamide 
Tolbutamide 
2nd generation: Glipizide 
Glibenclamide 
(glyburide) 
Gliclazide 
Liquidone 
Glimepiride 
Thiazolidinediones Pioglitazone 
Rosiglitazone 
Troglitazone*  
Meglitinides Repaglinide Nateglinide 
Biguanides Metformin 
Alpha-Glucosidase 
Inhibitors 
Acarbose 
Miglitol 
(*removed from market due to reports of 
serious hepatic injury.) 
 
The 1st generation sulfonylureas are 
considered equally effective, but differ with 
respect to their pharmacokinetic properties 
and adverse effects profile. The 2nd 
generation agents are approximately 100 
times more potent than the first generation 
drugs on a mg-to-mg basis, and have a 
lower profile of side effects and drug-drug 
interactions. For this reason, a second-
generation agent (glibenclamide) was 
recommended over first generation agents 
to be discussed in this chapter. A 
comparison between sulfonylureas and the 
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biguanide Metformin can be seen in table-
6.2. 
The newer agents, thiazolidinediones, 
meglitinides, and alpha-glucosidase 
inhibitors differ in their mode of action and 
effects. Even within a class, there are 
differences in terms of toxicities and effect 
on lipid profiles. It is important to note that 
not all these agents have long-term data and 
comparative studies yet. 
One should emphasize to the patient the 
importance of testing and recording urine 
and blood glucose levels, as well as 
keeping records of medications, doses, diet 
and exercise for unstable patients to 
improve their diabetic control.  Proper urine 
or blood testing for glucose and ketones are 
important for them to know their blood 
glucose levels and to prevent any diabetic 
ketoacidosis.   
Also, note the importance of general 
hygiene, foot, dental and eye care since DM 
patients are more susceptible to have 
problems in these areas than the average 
person. Warn your patients of symptoms of 
hypoglycemia and hyperglycemia as noted 
in table-6.3. 
 
Various medications may cause 
symptoms of hyperglycemia or hypo-
glycemia, or clinically significant drug 
interactions (use caution in such cases) as 
noted in table-6.4. 
 
Table – 6.3:  Symptoms of 
Hyperglycemia  vs  Hypoglycemia 
Hyperglycemia Hypoglycemia 
-Flushed, dry skin 
-Excessive thirst 
-Excessive urination 
-Low blood pressure 
-Drowsiness 
-Lethargy 
-Urinary glucose 
ketones 
-Fatigue 
-Headache/Dizziness 
-Excessive hunger 
-Profuse sweating 
-Numbness of 
extremities or mouth 
-Visual disturbances 
-Delirium 
-Coma 
 
Table – 6.2:  Summary of Oral Sulfonylureas vs. Metformin 
CHARACTERISTIC ORAL SULFONYLUREA METFORMIN 
Indication NIDDM not controlled NIDDM, mostly obese patients 
Diet and Exercise extremely important extremely important 
Dosing Intervals  q.d.  or  b.i.d. b.i.d.  or  t.i.d. 
Adverse Side Effects 
 - Lactic acidosis 
 - Hypoglycemia 
 - Cardiovascular mortality 
 - Weight reduction 
 - GI disturbances 
 
none 
very common 
decrease mortality 
might cause weight gain 
mild-moderate 
 
possible 
uncommon 
no record, but possible 
help decrease weight 
moderate- severe 
Pregnancy  
(avoid both if possible) 
category B + C category B 
Lactation excreted, discontinue drug excreted, not recommended 
Children not used not used 
Renal Disease use caution and monitor contraindicated 
Hepatic Disease use caution and monitor use not recommended 
Alcohol Intake disulfiram reaction lactic acidosis 
Administration with Insulin possible possible 
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Table –6.4:  Clinically  Significant  Drug  Interactions  in  DM  Patients (1) 
 
 Drug-Induced Hyperglycemia   Drug-Induced Hypoglycemia 
 -  Glucocorticoids    -  Ethanol  (Alcohol) 
 -  Diuretics     -  High dose salicylates 
 -  Pentamidine*     -  Pentamidine* 
 -  High dose phenytoin in NIDDM  -  Propranolol* 
 -  Oral contraceptives    -  Disopyramide 
 -  β-Adrenergic Blockers                                          -  Phenobarbital 
 -  Nicotinic acid/ Niacin    -  Sulfonamide antibiotics  
              -  Sympathomimietics (epinephrine) 
 
* can cause either hyperglycemia or hypoglycemia. 
(1) Adapted from:   Herfindal G, eds.  Clinical Pharmacy and Therapeutics, 5th ed.  Williams and 
Wilkins, Baltimore.  1992. 
 
 
 
Table 6.5: Pharmacokinetics and Compatibility of Various Insulins 
Type Insulin -preps. Onset  (hr) 
Peak  
(hr) 
Duration 
(hr) 
Compatibly 
mixed with 
Rapid-acting 
Regular (clear soln.) 
Semilente 
Lispro 
0.5-1.0 
1.0-1.5 
0.25 
3-4 
6-10 
0.5-1.5 
6-8 
12-15 
6-8 
All 
Lente 
Ultralente+ NPH 
Intermediate Isophane- NPH Insulin Zinc-Lente 
1.0-1.5 
1.0-2.5 
6-12 
8-14 
18-24 
18-24 
Regular 
Regular + semilente 
Long-acting PZI Ultralente 
4.0-8.0 
4.0-8.0 
12-24 
12-30 
36 
36-42 
Regular 
Regular + semilente 
 
1)  Insulin WHO,P 
 
• DRUG SUMMARY: 
Insulin is a hormone that is secreted by 
islets of Langerhans by the beta-cells of the 
pancreas. It is the principal polypeptide 
hormone required for proper glucose use in 
normal metabolic processes. It plays an 
important role in the metabolism of 
carbohydrate, fat and protein. Insulin is 
biosynthetically prepared by recombinant 
DNA technology using E. coli.   
• INDICATIONS: 
Type 1 DM, and Type 2 DM that cannot be 
properly controlled by diet, exercise and 
weight reduction. In hyperkalemic 
emergencies to produce a shift of potassium 
into cells and lower serum potassium levels. 
Only the regular insulin can be given IV or 
IM in severe ketoacidosis or diabetic coma. 
Also, for administration to pregnant and 
nursing diabetics, as well as during stressful 
conditions or severe infections.   
• CONTRAINDICATIONS: 
Hypersensitivity to insulin animal proteins 
or preservatives. 
• DOSAGE FORMS:  
Injection: 100 units/ml, in 10 ml vials. 
• RECOMMENDED DOSAGE: 
The type of insulin used and its dose and 
frequency of administration depends on the 
particular needs of each individual patient. 
 
Table-6.6 lists different regimens that are 
commonly recommended.  Any of them can 
be used depending on the patient’s needs. 
Individualize dosing regimens.  
 
Dose guidelines for adult and children 0.5-1 
unit/kg/24 h.   
 
Adjust dose to achieve pre-meal and 
bedtime blood glucose levels of 80-140 
mg/dl, and for children < 5 yrs. levels of 
100-200 mg/dl. 
Insulin requirements may be increased by 
infection, stress, accidental or surgical 
trauma, puberty, and during pregnancy.  
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Requirements may be decreased in patients 
with renal or hepatic impairment and in 
those with some endocrine disorders or 
celiac disease. 
 
Table-6.6:  Some Examples of Common 
Recommended Insulin Regimens* 
Insulin Regimen 
1. Short-acting mixed 
with intermediate-
acting insulin: 
- twice daily (15-
30 min. a.c.). 
2. Short-acting mixed 
with intermediate-
acting insulin: 
- before breakfast 
only, will be 
sufficient in some 
patients. 
3. a) Short-acting 
mixed with 
intermediate- acting 
insulin: 
    b) Short-acting: 
     
    c) Intermediate acting
- before breakfast. 
 
 
 
- before evening 
meal. 
- bedtime (onset of 
action is 1-2 hrs.). 
4. a) Short-acting 
insulin: 
 
 
   b) Intermediate 
acting insulin: 
- t.i.d. (15-30 min. 
before breakfast,  
midday and 
evening meals). 
- at bedtime. 
* BNF  2001(Sep); (42): 323. 
 
Directions: Patients should be given the 
following advice about the uses and 
administration of insulin: 
*Patients should use the same type and 
brand of insulin and syringe unit to avoid 
any dosage errors. 
*Store vials in refrigerator if not in use. Do 
not freeze. 
*Do not inject cold insulin, it can lead to 
lipodystrophy, reduced rate of absorption 
and local irritation.  
Can keep the vial in use at room 
temperature (up to 30 days), away from 
direct sunlight or temperature extremes. 
*Agitate vial by rolling between palm of 
hands, do not shake vial vigorously. 
*If mixing insulin, always measure Regular 
(clear) before NPH (cloudy)! 
*Rotate administration/injection sites to 
prevent lipodystrophy. 
*Insulin requirements may change in 
patients who become ill, especially with 
vomiting or fever. Also there is a need to 
reduce the dose when caloric intake is 
reduced, or abnormally high physical 
activity is undertaken, to avoid hypo-
glycemia. 
*Need to emphasize to the patient the 
importance of properly monitoring their 
blood glucose levels, and maintaining 
proper diet and exercise. 
*Occasionally, redness, swelling and 
itching at the injection site may develop. 
This could occur if injection is not properly 
made; the skin may be sensitive to the 
antiseptic solution, or if the patient is 
allergic to insulin or insulin additives 
(preservative). This condition usually 
resolves in a few days. If not, may need to 
switch type of antiseptic or insulin. 
• USE IN SPECIAL CASES: 
Pregnancy- Pregnancy may make the 
management of diabetes more difficult. 
Insulin is the drug of choice for controlling 
glucose levels during pregnancy; even in type 
2 DM. Requirements may increase during the 
2nd or 3rd trimester of pregnancy. The patient 
should be kept under experienced medical 
supervision. Following delivery, insulin 
requirements may drop for 24 to 72 hrs., 
rising towards the normal pre-pregnancy dose 
during the next 6 weeks. 
Lactation- Insulin does not pass into breast 
milk. Breast-feeding may decrease insulin 
requirements despite the increase in necessary 
caloric intake. 
Children- Safe when following the correct 
dosage and use. 
Renal Disease- In severe cases, doses should 
be reduced. Insulin requirements fall, since 
the compensatory response to hypoglycemia 
is impaired. 
Liver Disease- Use caution, the drug is 
metabolized primarily in the liver. 
• PRECAUTIONS AND WARNINGS: 
-Lipodystrophy is the breakdown of 
adipose tissue at the insulin injection site, 
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causing a depression in the skin. This may 
be the result of an immune response.  
Advise patient to rotate the injection site. 
-Diabetic ketoacidoses (DKA) is a 
potentially life-threatening condition, 
requiring immediate treatment.  May result 
from stress, illness, insulin omission, or 
may develop slowly after a long period of 
poor insulin control. Treatment involves 
administration of fluids, correction of 
acidosis and hypotension, and low dose 
regular insulin IM or IV in an emergency 
room. 
-Hypoglycemia may result from excess 
insulin dose, or: increased work load or 
exercise without eating, food not being 
absorbed because of skipping a meal or in 
illness with vomiting, fever or diarrhea.  
Insulin requirements decline. 
Refer to table-6.7 for summary of 
difference between Ketoacidosis and 
Hypoglycemia. 
• ADVERSE EFFECTS: 
-Hypersensitivity; usually occurs when 
insulin is at peak action, localized allergic 
reactions at the injection site, general 
uricaria and rash. 
-Hypoglycemia / hyperinsulinism (refer to 
introduction of this chapter for symptoms). 
-Post-hypoglycemia or rebound hyper-
glycemia may occur:  
♦ Somogyi Effect, a morning (3-7 am), 
phenomenon caused by counter-
regulatory hormone release. This can be 
avoided by decreasing insulin dosage for 
critical time period, reduce insulin dose 
for the overnight, or increase pre-bedtime 
snack. 
♦ Dawn Phenomenon, an early morning 
rise in plasma glucose due to greater 
surge of growth hormones in diabetics 
predisposing patient to development of 
hyperglycemia. Need to increase the 
overnight insulin coverage. 
 
(Test blood glucose levels at 3 am to 
differentiate between the two 
phenomenon.) 
 
 
 
Table – 6.7. Summary of  Hypoglycemia vs. Ketoacidosis 
Reaction Hypoglycemia (insulin reaction) DKA (diabetic coma) 
Onset sudden gradual, hours or days 
Urine glucose/acetone 0/0 * +/+ 
CNS symptoms fatigue, weakness, confusion, headache, 
diplopia, convulsions, dizziness, 
unconsciousness 
drowsiness, dim vision 
Respiration rapid, shallow air hunger 
Mouth /GI numb, tingling, hunger, nausea thirst, acetone breath, nausea, 
vomiting, loss of appetite 
Skin pallor, moist, shallow or dry dry, flushed 
Miscellaneous normal pulse, eyeball normal rapid pulse, soft eyeballs 
 *    0/ 0 not found.    +/+ found 
Professional Guide to Patient Drug Facts &Comparisons. St. Loius :Facts and Comparisons 2000. 
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• INTERACTIONS: 
Decrease  Hypoglycemic 
Effect of Insulin 
Corticosteroids Oral contraceptives 
Dextrothyroxine Smoking 
Diltiazem Thiazide diuretics 
Epinephrine Thyroid hormone 
Increase  Hypoglycemic 
Effect of Insulin 
Alcohol  MAO inhibitors 
Anabolic steroids Phenylbutazone 
Colifibrate Salicylates 
Non-selective β-
blockers 
Tetracyclines 
 
• OVERDOSE: 
Symptoms: Insulin overdose causes 
hypoglycemic symptoms; refer to adverse 
effects. 
Treatment: Eating sugar or sugar-
sweetened product will correct simple 
conditions and prevent serious symptoms.  
Refer to emergency room if it cannot be 
controlled. Glucose and dextrose 
administration, or glucagon, may be 
necessary.  
• BRANDS: 
Humulin-N, Humulin-R, Humulin-U, Humulin 
70/30 (Lilly),  
Novolin-N, Novolin R, Insulin Actrapid HM, 
Insulin Mixtard ... (Novo Nordisk) 
See price list for other preparations.  
_______________________ 
 
2)  Glibenclamide  
      (Glyburide) WHO,P 
 
• DRUG SUMMARY: 
Glibenclamide is one of the most potent 
sulfonylurea, hypoglycemic agents. It is a 
2nd generation sulfonylurea with a potency 
of more than a 100-fold over first 
generation agents. Glibenclamide appears 
to lower the blood glucose acutely by 
stimulating the release of insulin from the 
pancreas, an effect dependent upon 
functioning beta cells in the pancreatic 
islets. With chronic use, the blood glucose 
lowering effect persists despite a gradual 
decline in the insulin secretory response to 
the drug. Extrapancreatic effects may play a 
part in the mechanism of action of oral 
sulfonylurea drugs. In addition to the 
blood-glucose lowering action, this drug 
produces mild diuresis by the enhancement 
of free water renal clearance. 
• INDICATIONS: 
Glibenclamide is indicated as an adjunct to 
diet to lower blood glucose in patients with 
type 2 DM when diet and weight reduction 
alone fail to control their hyperglycemia. 
• CONTRAINDICATIONS: 
Known hypersensitivity to the drug.  As 
single therapy in type 1, uncontrolled 
patients complicated by ketoacidoses; with 
or without coma. Diabetes when 
complicated by pregnancy. 
• DOSAGE FORMS: 
Tablets 5 mg. 
• RECOMMENDED DOSAGE: 
Adult: 2.5-5 mg daily with breakfast or 
first main meal (for patients very sensitive 
to the agent start with 1.25), increase by 2.5 
mg every 1-2 weeks if needed.  Doses of 15 
mg in 2 divided doses can be given, but 
unlikely to produce additional effects. 
Do not exceed 20 mg/24 hours. 
Child: Not to be used for children. 
Directions:  To be taken 30 minutes before 
meals provided that the patient has no GI 
disorders, if so can give with food. Onset of 
action is about 1.5 hrs. 
*Advise patients not to discontinue 
medication abruptly, not to take any OTC 
medications without consulting a health 
care professional, and to monitor their 
blood or urine glucose levels. 
*Diet and weight control should be 
emphasized as the primary form of 
treatment for all patients.  
*Use of this medication is by no means a 
substitution for diet control or avoidance of 
physical activity. 
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• USE IN SPECIAL CASES: 
Pregnancy- Use of insulin is recommended 
during pregnancy. Sulfonylureas have been 
teratogenic in animals (except glyburide), 
no studies have been done on pregnant 
women. Use only if clearly needed.  
If used, it should be stopped at least 2 days 
– 4 weeks before expected delivery date to 
prevent severe hypoglycemia in newborn 
(Category B). 
Lactation- Avoid. It is not known whether 
glibenclamide is excreted in human milk. 
Some sulfonylureas are excreted, and had 
potential for hypoglycemia in nursing 
infants. If the drug is discontinued and diet 
alone is inadequate for controlling blood 
glucose, insulin therapy should be 
considered. 
Children- Safety and efficacy haven’t been 
established. Use is not recommended. 
Renal Disease- Avoid use in severe cases. 
Need dosage adjustments Clcr is < 30 
ml/min. Renal impairment may cause 
decreased elimination of the drug leading to 
hypoglycemia. [Can use tolbutamide 
(Orinase, Tolanase®), or glipizide (Glucotrol, 
Glibenese®); they are a better choice in renal 
failure.] 
Liver Disease- Drug is metabolized 
extensively in the liver. Increased risk of 
hypoglycemia in severe liver disease, so 
avoid use or use small doses. Can produce 
jaundice.  
• PRECAUTIONS AND WARNINGS:   
-Use caution in renal or hepatic 
insufficiency, elderly (more susceptible to 
side effects), malnourished patients, adrenal 
or pituitary insufficiency.  
-Diet and exercise remain the primary 
consideration in NIDDM patient 
management.  
Drugs are an adjunct to, not a substitute for 
them. Dietary regulations should be taught 
to patients, as well as monitoring methods 
to keep patients well controlled. 
-The administration of oral hypoglycemic 
drugs has been associated with increased 
cardiovascular mortality as compared to 
treatment with diet plus insulin. The 
patients have to be informed of potential 
risk. 
-Patients needs to contact the physician if 
any side effects such as fever, sore throat, 
rash, unusual bruising or bleeding occurs, 
as well as frequent episodes of 
Hypoglycemia or Hyperglycemia (refer to 
introduction of this chapter for symptoms). 
• ADVERSE EFFECTS: 
Hypoglycemia: all sulfonylureas may 
produce severe hypoglycemia, more likely 
to occur when caloric intake is deficient, 
after severe or prolonged exercise, when 
alcohol is ingested. Administer a simple 
sugar as soon as possible if patient feels 
dizzy and ready to faint. 
Other symptoms: GI disturbances; epigastic 
fullness, weight gain, heartburn, nausea, 
jaundice; pruritis, erythema, skin eruptions 
(if skin reactions persist, discontinue the 
drug), photosensitivity, joint pain, leg 
cramps, elevated liver function tests, and 
blood dyscraisis. 
• INTERACTIONS: 
Overview of Glibenclamide 
Drug-Drug Interaction 
Drug Interaction 
Alcohol It causes disulfiram-like 
reaction; facial flushing, 
occasional breathlessness, 
sometimes nausea and 
vomiting. Avoid drinking 
alcohol or eating foods that 
contain it, while taking this 
medication. 
β-blockers, 
hydantoins, 
rifampin, 
thiazide 
diuretics,  
and  
steroids 
These may diminish the 
hypoglycemic effect.  
Monitor blood glucose of 
patients closely and adjust 
the sulfonylurea dosage 
accordingly. 
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Chloram-
phenicol,  
Co-trimox-
azole, 
tetracyclines, 
butazones, 
salicylates,  
and 
sulfonamides 
These increase the 
hypoglycemic effect of the 
medication. Monitor blood 
glucose concentrations and 
observe for symptoms of 
hypoglycemia. Use with 
caution, if needed adjust 
dose of sulfonylurea 
accordingly. 
Digitalis 
glycosides 
Concurrent administration 
increases digitalis serum 
levels, caution use. For 
patients who start therapy, 
monitor serum digitalis 
levels carefully until levels 
are stabilized. 
Oral anti-
coagulants 
Metabolic degradation of 
sulfonylurea is slowed by 
dicumarol, leading to a 
greater risk of 
hypoglycemia. 
 
• OVERDOSE: 
Symptoms: An acute overdose may produce 
hypoglycemia as well as tingling of the lips 
and tongue, nausea, diminished cerebral 
function (lethargy, confusion, agitation, 
nervousness), increased sympathetic 
activity (tachycardia, sweating, tremor, 
hunger) convulsions, stupor and coma. 
Treatment: Treat mild hypoglycemia with 
oral glucose and adjustment in drug dosage 
or meal patterns. Severe cases require 
immediate hospitalization, administration 
of dextrose IV, and close monitoring. 
• BRANDS: 
Daonil (Hoechst), Declamide (JCL), Diabeta 
(Hoechst-Roussel), Glibetic (Teva), Gluben 
(Dexxon), Glucocare (Pharmacare), Gluconil 
(JePharm). 
____________________ 
 
3)  Metformin WHO,P 
 
• DRUG SUMMARY: 
Metformin is a biguanide oral antihyper-
glycemic drug used in the management of 
type 2, NIDDM. It is not chemically or 
pharmacologically related to the oral 
sulfonylureas. With metformin therapy, 
insulin secretion remains unchanged while 
fasting insulin levels and daylong plasma 
response may actually decrease. In clinical 
studies, the drug has shown a favorable 
effect on serum lipids, which are often 
abnormal in type 2. 
Metformin has a different mode of 
action than the sulfonylureas. It is also used 
for type 2 patients in adjunction to diet 
when all methods of glycemic control have 
failed.  Metformin has been associated with 
weight loss, which seems to be the only 
advantage over the sulfonylurea agents, 
which has made it the drug of choice in 
obese (≥ 20% ideal body weight) diabetic 
patients. Cases of lactic acidosis, which can 
be fatal, is its major hazard, especially in 
renal disease patients. Metformin costs 
more than sulfonylureas, and has a more 
serious adverse effects profile. It may be 
best used in obese patients, or in cases 
when an oral sulfonylurea alone is 
ineffective. It could then be used alone or in 
combination with a sulfonylurea (refer to 
table-6.2). 
• INDICATIONS: 
In type 2 DM. Metformin is used in the 
treatment when strict dieting and sulfonyl-
ureas have failed to control patients, 
especially in overweight patients, in whom 
it may if necessary, be used first. 
It could be used concomitantly with a 
sulfonylurea when diet and metformin or 
sulfonylureas alone do not give control. 
• CONTRAINDICATIONS: 
Renal disease or dysfunction, or abnormal 
Clcr which may result from conditions such 
as cardiovascular collapse, acute MI and 
septicemia. 
Hypersensitivity to metformin. Acute or 
chronic metabolic acidosis. 
Temporarily withhold metformin in 
patients undergoing radiological studies 
involving parenteral administration of 
iodinated contrast materials because these 
may result in acute changes in renal 
function. 
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• DOSAGE FORMS:  
Tablets. 
• RECOMMENDED DOSAGE: 
Adult:  500 mg PO t.i.d., or 850 mg b.i.d.;  
max. 3000 mg/day. 
Child:  Do not use in children. 
Directions: Dosage should be 
individualized on basis of both 
effectiveness and tolerance. Give in divided 
doses with or after meals.   
*Start with low dose 500 mg b.i.d., and 
gradually increase to identify the minimum 
dose required for adequate glycemic 
control.  
*Use fasting plasma glucose to determine 
therapeutic response to metformin. 
Thereafter, measure glycosylated hemo-
globin at intervals of ∼ 3 months.   
*Short-term administration may be 
sufficient during periods of transient loss of 
control on diet alone. 
*Inform the patient about the importance of 
adherence to dietary instructions, regular 
exercise, regular blood glucose testing, 
renal function and hematological tests.  
• USE IN SPECIAL CASES: 
Pregnancy- Avoid use. Safety has not been 
established (Category B). Use of insulin is 
recommended instead. 
Lactation- Studies in rats show that it is 
excreted in milk. Safety in humans has not 
been established, exercise caution, and take 
into account the importance of the drug to the 
mother when discontinuing use. Use of 
insulin may be safer. 
Children- Use not recommended. Safety and 
efficacy have not been established. 
Renal Disease- Contraindicated. Do not use 
even in mild conditions due to the increased 
risk of lactic acidosis. The drug is excreted 
primarily unchanged in the urine. 
Liver Disease- Avoid use due to increased 
risk of lactic acidosis. 
• PRECAUTIONS AND WARNINGS: 
-Lactic Acidosis: LA is a rare, but serious, 
metabolic complication that can occur due 
to metformin accumulation during 
treatment. When it occurs, 50% of cases are 
fatal.  It is characterized by elevated blood 
lactate levels (> 5 mmol/L), decreased 
blood pH, electrolyte disturbances with an 
increased anion gap. The risk of LA 
increases with the degree of renal 
dysfunction and the patient’s age. Onset is 
often difficult to detect, and accompanied 
only by nonspecific symptoms such as 
malaise, respiratory distress, abdominal 
distress and hypotension. 
-There is an increased risk or cardio-
vascular mortality with administration of 
oral anti-diabetic drugs. This warning may 
also apply to metformin although no 
sufficient data is available. 
-Hypoglycemia does not usually occur 
under usual circumstances, but could occur 
with deficient caloric intake, excessive 
exercise not compensated by caloric 
supplementation, or during concomitant use 
with other glucose lowering agents or 
ethanol. 
• ADVERSE EFFECTS: 
GI side effects are very common, and are 
mainly dose related; diarrhea, nausea, 
vomiting, abdominal bloating, flatulence 
and anorexia. Temporary reduction in dose 
may be useful, until the symptoms are 
controlled. Some patients may experience 
metallic taste, this may resolve 
spontaneously.  Vitamin B12 absorption 
may be impaired, administration of supple-
mentation may be done if necessary. Test 
levels every 2-3 years to prevent any 
anemia complications. 
• INTERACTIONS: 
 
Overview  of  Metformin 
Drug-Drug Interaction 
Drug Interaction 
Alcohol It enhances the effect of 
metformin on lactate 
metabolism; advise patients 
against excess intake whether 
acute or chronic use, to avoid 
precipitation of lactic acidosis. 
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Cationic 
drugs 
Such as:  
amiloride, digoxin, morphine, 
quinidine, ranitidine, 
trimethoprim, vancomycin, 
which are eliminated by renal 
tubular secretion, have a 
potential for increasing levels 
of metformin.   
Use with caution. 
Cimetidine Caused a 60% increase in 
peak metformin plasma level. 
Do not administer 
concomitantly. 
Furosemide It increases level of 
metformin, while the half-life 
of furosemide was decreased.  
Use with caution. 
 
• OVERDOSE: 
No hypoglycemia has been seen even with 
ingestion of up to 85 g of metformin.  
Lactic acidosis has occurred. If suspected, 
refer to hospital, hemodialysis is indicated. 
• BRANDS: 
Glucomet (BPC), Glucomin (Dexxon), 
Glucophage (Bristol-Myers Squibb). 
___________________ 
 
 
B)  THYROID DRUGS 
 
The hormones synthesized and released by 
the thyroid gland affect such basic 
processes as oxygen consumption, heat 
production and metabolism of 
carbohydrates, fats and protein. Thyroid 
hormones are recognized as the regulators 
of the metabolic level in most tissues, and 
are required for normal growth and 
differentiation. They are required for the 
functioning of other hormones such as 
catecholamines, corticosteroids and anti-
diuretic hormone. 
Inadequate or excessive secretions of 
these hormones result in the clinical 
conditions called hypothyroidism and 
hyperthyroidism respectively.  
Hypothyroidism requires thyroid 
replacement therapy; using thyroxine and 
levothyroxine (T4). The majority of patients 
require lifelong replacement therapy. 
Hyperthyroidism requires anti-thyroid 
agents; such as propylthiouracil and 
methimazole. Generally after 1-2 years of 
control, medication can be stopped. 
 
 
1)  Thyroxine WHO,P 
 
• DRUG SUMMARY: 
Thyroxine sodium (the levothyroxine-T4 
isomer) is the treatment of choice for 
maintenance therapy in hypothyroidism. 
Administration of levothyroxine alone may 
produce normal levels of both T4 and T3, 
since it is converted to T3 naturally in the 
body. Drug action is not clearly understood, 
but is known to increase the metabolic rate 
of all body tissues.   
• INDICATIONS: 
Hypothyroidism, as replacement therapy of 
any etiology, including: cretinism, 
myxedema, non-toxic goiter, total or partial 
absence of thyroid gland, or the effects of 
surgery, radiation or drugs.  May be also 
used with anti-thyroid drugs to treat 
thyrotoxicosis. 
• CONTRAINDICATIONS: 
Hypersensitivity to active or extraneous 
constituents.  Acute myocardial infarction, 
and adrenal insufficiency.  
• DOSAGE FORMS:  
Tablets. 
• RECOMMENDED DOSAGE: 
Adult:  Doses are usually individualized 
depending on the basis of clinical response 
and biochemical tests. However the starting 
dose is 25-50 ug/24h (0.025-0.050 mg/24h) 
increased by 50-100 ug/24h every 3-4 
weeks till response (usual recommended 
dose 100-200 ug/24h). 
Patients > 50 yrs or with cardiac disease 
start with the lower dose (25 ug/24h) and 
titrated up more slowly. 
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Child:  Recommended Pediatric Dosages 
for Congenital Hypothyroidism: 
 
Age Dose/day (mcg) 
Daily dose/ 
kg (mcg) 
0 - 6 mon. 25 - 50 8 - 10 
6 - 12 mon. 50 - 75 6 - 8 
1 - 5 yrs 75 - 100 5 - 6 
6 - 12 yrs 100 - 150 4 - 5 
> 12 yrs > 150 2 - 3 
  
Directions: Administer as a single dose, 
preferably before breakfast to prevent 
insomnia.  Food interferes with absorption. 
*Onset of actin requires 3-5 days. 
*If a dose is missed, tell the patient to take 
it as soon as remembered, then to continue 
with the regular schedule. Do not 
administer a double dose. 
*For children who can’t swallow; tablets 
can be crushed and suspended in a small 
amount of water, then administered by 
spoon or dropper. The prepared suspension 
should not be stored for any period of time. 
Crushed tablets may also be sprinkled over 
a small amount of food such as apple-
sauce. 
*Inform the patient to report any signs of 
toxicity. 
*Patient should be advised not to change 
brands of medications, due to the a narrow 
therapeutic window of thyroid hormone 
therapy, since there may be differences in 
bioequivalence between products. 
*Caution patient to avoid OTC medications 
unless approved by the physician. 
• USE IN SPECIAL CASES:  
Pregnancy- Compatible (Category A). 
Thyroid hormones do not readily cross the 
placenta. Do not discontinue medication in 
hypothyroid women during pregnancy. 
Lactation- Use caution. Minimal amounts of 
thyroid hormones are excreted in breast milk. 
They are not associated with serious adverse 
reactions. 
Children- Partial loss of hair may be 
experienced in the first few months of 
therapy, it is a usual transient phenomenon 
that later is recovered. 
Renal Disease- Use with caution. 
Liver Disease- Use with caution. 
• PRECAUTIONS AND WARNINGS:   
-Use caution in cardiovascular disease, 
angina pectoris, hypertension, and in 
impaired renal function. 
-In endocrine disorders, thyroid hormone 
therapy in patients with concomitant 
diabetes mellitus or insipides or adrenal 
insufficiency (Addison’s disease) 
exacerbates the intensity or their symptoms. 
Appropriate adjustments in therapy in these 
cases are required. 
-Long-term levothyroxine therapy has been 
associated with decreased bone density in 
the hip and spine in pre- and post-
menopausal women. These effects may be 
avoided by using minimal dose required 
and periodically monitoring the patient. It 
may be beneficial to obtain a basal bone 
density measurement, and monitor closely 
for osteoporosis development. 
• ADVERSE EFFECTS: 
Adverse side effects other than those 
indicating hyperthyroidism due to 
therapeutic overdosage, either initially or 
during maintenance period are rare. 
• INTERACTIONS: 
Overview  of  Thyroxin 
Drug-Drug Interaction 
Drug Interaction 
Choles-
tyramine & 
colestipol 
These decrease efficacy of 
thyroid hormone and cause 
potential hypothyroidism.  
Administer 4-6 hrs. apart. 
Estrogen May decrease response to 
therapy in patients with non-
functioning thyroid gland.  
Use with caution. 
Anti-
coagulants 
Thyroid hormones increase 
action of anticoagulants, 
there might be a need to 
decrease the anticoagulant 
dose if necessary. 
Digitalis 
glycosides 
Serum level of digoxin may 
be reduced.  Monitor levels. 
Epinephrine 
& norepi-
nephrine 
Increase risk of cardiac 
insufficiency.  Avoid 
concomitant use. 
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• OVERDOSE: 
Symptoms are those of hyperthyroidism and 
may include: palpitations, tachycardia, 
angina, tremors, nervousness, insomnia, 
diarrhea, vomiting, weight loss, sweating, 
heat intolerance and fever. 
These agents rarely result in clinical 
toxicity. 
Treatment is aimed at reducing GI 
absorption of the drug, and controlling side 
effects that arise, cardiac, fluid loss, fever, 
and hypoglycemia.  
• BRANDS:  
Eltroxine (Glaxo). 
____________________ 
 
2)  Propylthiouracil WHO,P 
 
• DRUG SUMMARY: 
Propylthiouracil (PTU) is a synthetic, 
thioamide derivative, anti-thyroid agent. It 
interferes with iodine and blocks synthesis 
of thyroxin; T3 and T4. 
• INDICATIONS: 
Hyperthyroidism. 
• CONTRAINDICATIONS: 
Hypersensitivity to anti-thyroid drugs, and 
nursing mothers. 
• DOSAGE FORMS:  
Tablets 
• RECOMMENDED DOSAGE: 
Adult: Initially 300-600 mg/24h. in divided 
doses, depending on the severity of the 
disease, then the dose is reduced after 
euthyroid state to maintenance dose. 
May need to increase 600-900 mg/day in 
some patients. 
Maintenance- usually 100-150 mg/day in 
three equally divided doses. Max. 1200 
mg/d. 
Child: > 10 years; initial dose 150-300 
mg/24h. 
  6-10 years;  50-150 mg/24h. 
  neonates;     5-10 mg/kg/24h. 
Maintenance- determined by patients’ 
response. 
 
Directions: Administer 3 equal doses at 
approximately 8 hrs. intervals, with food or 
milk to reduce stomach upset. 
*Advise patient not to change time 
intervals throughout therapy. 
Most patients achieve euthyroid state 
within 6-12 wks, depending on severity of 
the disease state. 
*Clinical response is monitored through 
changes in weight and pulse.  Advise 
patient to chart weight 2-3 times weekly. 
Teach them to take pulse accurately. 
*They should report any signs of tremor, 
tachycardia, increased pulse rate, fever, 
diarrhea, vomiting, weight loss and anxiety 
states, which may be due to inadequate 
therapy.  Adjust dosage accordingly. 
*Caution use of iodized salt or of seafood 
in the diet.   
• USE IN SPECIAL CASES:  
Pregnancy- Can use when clearly needed. 
The potential benefit for the mother is more 
than the potential risk. It readily crosses the 
placenta and can induce goiter in developing 
fetus. Still these agents are effective drugs in 
hyperthyroidism complicated by pregnancy, 
and should be used if the problem arises 
(Category D). The thyroid dysfunction 
diminishes as the pregnancy proceeds, thus 
making a reduction of dose possible.   
Lactation- Post-partum patient receiving anti-
thyroid preparations should not nurse their 
babies. But if necessary, it is acceptable to 
use PTU after a month or two. 
Children- PTU has caused hepatotoxicity in 
pediatric patients. Discontinue the drug 
immediately if signs and symptoms of hepatic 
dysfunction develop. 
Renal Disease- Use with caution; need to 
monitor patients. Cases of nephritis have been 
reported. The drug is excreted in the urine. 
Liver Disease- Use with caution. The drug is 
rapidly metabolized and inactivated in the 
liver.  Can cause jaundice. 
• PRECAUTIONS AND WARNINGS:   
-Agranulocytosis is potentially the most 
serious side effect of therapy that may 
occur (rarely) in the first few months of 
treatment if at all.  Instruct patient to report 
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any symptoms such as: hay fever, sore 
throat, skin eruptions, fever, consistent 
headaches or general malaise. The drug 
should be discontinued in such case, and a 
WBC count and differential should be 
made. 
-Hemorrhagic effects: PTU may cause 
hypoprothrombinemia and bleeding.  
Monitoring of prothrombin time during 
therapy is advised. 
-Treatment generally lasts 1-2 years.  After 
control, medication can be stopped 
gradually. Relapse after one course of anti-
thyroid drug therapy usually indicates the 
need for another form of treatment. 
• ADVERSE EFFECTS: 
Occur in < 1 % of patients. Agranulo-
cytosis  is the most serious effect. 
Possible side effects: headache, vertigo, 
CNS stimulation, nausea and vomiting, 
epigastric distress, loss of taste, skin rash, 
exfoliative dermatitis, aplastic anemia, 
jaundice, nephritis, abnormal hair loss, 
edema, or drug fever. 
• INTERACTIONS: 
None reported. 
• OVERDOSE: 
Symptoms include: nausea, vomiting, 
epigastric distress, fever, headache, pruritis, 
edema,  possible; agranulocytosis, hepatitis, 
CNS stimulation or depression. 
Treatment: need to protect patient’s airway 
and support ventilation and perfusion till 
reach emergency room where general 
management of acute overdose is applied. 
• BRANDS: 
Propylthiocil (Teva). 
__________________ 
 
 
C)  CORTICOSTEROIDAL DRUGS 
 
The naturally occurring adrenal cortical 
steroids have both anti-inflammatory 
(glucocorticoid) and salt retaining (mineral-
ocorticoid) properties.  Glucocorticoids are 
adrenocortical steroids, both naturally 
occurring or synthetic, and cause profound 
and varied metabolic effects. In addition, 
they modify the body’s immune responses 
to diverse stimuli. Due to their 
glucocorticoid character, they are widely 
used in inflammatory conditions. 
Hydrocortisone (cortisol) and cortisone, 
are used as replacement therapy in 
adrenocortical insufficiency states and may 
be used for their anti-inflammatory effects 
in severe cases. The synthetic steroid 
compounds prednisone, prednisolone and 
fludrocortisone also have both gluco-
corticoid and mineralocorticoid activity, 
and are used primarily for their gluco-
corticoid effects.  The rest of the synthetic 
compounds are distinguished by the 
absence of any significant salt-retaining 
activity, and are very potent anti-
inflammatory agents. 
As can be seen from table-6.8, the major 
differences among the corticosteroids are 
potency of medication and variation in some 
secondary effects. If a patient is allergic to 
one corticosteroid, chances are they are 
allergic to all, and the use of such 
medication should be avoided.  
Corticosteroids are prescribed for a wide 
variety of disorders from skin rash to 
cancer. If patients are not producing enough 
adrenal hormones, corticosteroids may be 
used as replacement therapy. They may 
also be prescribed to treat the following: 
bursitis, arthritis; severe skin reactions 
(such as psoriasis), severe respiratory 
diseases, blood disorders, gastrointestinal 
diseases (including ulcerative colitis), and 
inflammation of the nerves, heart and other 
organs. 
In this section Prednisone will be 
considered the prototype drug of the 
corticosteroids. For other corticosteroids 
used in asthma, dermatology or ophthalmic 
preparations refer to individual chapters. 
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Table 6-8.  Glucocorticoid Equivalencies § 
Glucocorticoid 
Approximate 
equivalence 
dose (mg) 
[Potency] 
Relative anti-
inflammatory 
(Glucocorticoid) 
potency 
Relative Na+ 
retaining 
(mineralocorticoid) 
potency 
Plasma  
half-life  
(min.) 
Short-acting    
Cortisone 25 0.8 2 30 
Hydrocortisone 20 1 2 80-118 
Intermediate-acting     
Prednisone 5 4 1 60 
Prednisolone 5 4 1 115-212 
Triamcinolone 4 5 0 200 
Methylprednisolone 4 5 0 78-188 
Long-acting     
Dexamethasone 0.75 20-30 0 110-210 
Betamethasone. 0.6-0.75 20-30 0 300 
      § Drug Facts & Comparisons,  2000; p. 321. 
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1)  Prednisone WHO,P                                       . 
 
• DRUG SUMMARY: 
Prednisone is an intermediate acting 
adrenal corticosteroid, a synthetic analog of 
hydrocortisone. Prednisone is inactive and 
is metabolized to prednisolone WHO,P in the 
body.   
• INDICATIONS: 
Prednisone (or other intermediate acting 
corticosteroids) is indicated in the 
following conditions; 
1. Endocrine disorders: primary or 
secondary adrenocortical insufficiency, 
congenital adrenal hyperplasia, hyper-
calcemia associated with cancer, 
autoimmune thyroiditis. 
2. Rheumatic disorders: As adjunctive 
therapy for short term administration, 
psoriatic arthritis, rheumatoid arthritis, 
ankylosing spondylitis, acute and subacute 
bursitis, acute and nonspecific 
tenosynovitis [post traumatic osteoarthritis]. 
3. Collagen disease: systemic lupus 
erythematosus, systemic dermato-
myosisitis, cranial arteritis, acute rheumatic 
carditis. 
4. Dermatologic diseases: Pemphigus, 
bullous dermatitis herpetiformis, severe 
erythema multiform, exfoliative dermatitis, 
mycosis fungoides, severe psoriasis, severe 
seborrheic dermatitis 
5. Allergic states: seasonal or perennial 
allergic rhinitis, bronchial asthma, contact 
dermatitis, atopic dermatitis, drug 
anaphylactic and hypersensitivity reactions. 
6. Respiratory diseases: symptomatic 
sarcoidosis, Loeffler’s syndrome not 
manageable by other means, berylliosis, 
aspiration pneumonitis. 
7. Opthalmic disease: Severe acute and 
chronic allergic and inflammatory process 
involving the eye, allergic corneal marginal 
ulcers, anterior segment inflammation, 
allergic conjunctivitis, keratitis, optic 
neuritis, iritis and iridocyclitis. 
8. Hematological disorders: Idiopathic 
thrombocytopenic purpura in adults, 
acquired autoimmune hemolytic anemia, 
erythroblasopenia, congenital hypoplastic 
anemia. 
9. Gastrointestinal disease: Ulcerative 
colitis, Crohn’s disease, regional enteritis. 
10. Renal disease: glomerulonephritis 
(minimal lesion). 
11. Other: Only under specialists 
supervision: i.e., multiple sclerosis, 
neoplastic disease, edematous states, 
tuberculous meningitis, trichinosis with 
neurologic or myocardial involvement. 
• CONTRAINDICATIONS: 
Known hypersensitivity to the drug and 
systemic fungal infections. 
• DOSAGE FORMS: 
Tablets. 
• RECOMMENDED DOSAGE: 
Adult:  5 - 60 mg/d PO in single or divided 
doses, depending on the disease being 
treated. [When administered on alternate 
days; twice the usual daily dose is given 
every other day.] 
Child: 0.1 - 0.15 mg/kg/d in single or 
divided doses. 
 
Directions: Oral medication is administered 
at meal times or with a snack to reduce 
gastric irritation. 
*Inform the patient to take the drug as 
prescribed and not to alter dosing regimens 
or stop medication without consultation 
with the treating physician.  
*Single doses or alternate day doses should 
be taken in the morning prior to 9 am.  
Multiple doses should be evenly spaced at 
intervals throughout the day. 
*Inform your patient of signs of adrenal 
insufficiency: fatigue, anorexia, vomiting, 
diarrhea, weight loss, dizziness and low 
blood sugar. Dosage reduction or with-
drawal of therapy may be needed. 
*For high doses or long-term therapy, avoid 
abrupt withdrawal of therapy, which may 
result in withdrawal symptoms. Withdrawal 
symptoms include myalgia, fever, malaise, 
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fatigue, dizziness, hypotension, and 
hypoglycemia. It is important to taper the 
dose over several days to weeks to prevent 
withdrawal symptoms. 
*Small doses of corticosteroids or use for a 
short period (< wk.) may not produce 
withdrawal symptoms when the drug is 
discontinued, still, tapering the dose is 
advisable.   
• USE IN SPECIAL CASES:  
Pregnancy- Pregnant women should not 
take corticosteroids unless the benefits 
outweigh the potential risks. Prednisone has 
the poorest transport in crossing the 
placenta compared to the other 
corticosteroids (Category C) and may be 
used in such cases. Chronic use of 
corticosteroids during the first trimester can 
lead to birth defects (i.e., hypoadrenalism, 
cleft palate). When using, the dose should 
be tapered of as for any other patient. 
Lactation- Corticosteroids appear in breast 
milk, but small doses (< 20 mg/d) for a short 
period of time (< 10 days) may not harm the 
infant. Advise mother to wait 3-4 hours after 
the dose before breast-feeding. If larger doses 
are needed, advise mother against breast-
feeding.  
Children- Growth and development of infants 
and children on prolonged corticosteroid 
therapy, should be carefully observed. 
Renal Disease- Use with caution. Edema may 
occur in the presence of renal disease with a 
fixed or decreased glomerular filtration rate. 
Liver Disease- Use with caution. Use smaller 
doses in patients with liver problems. 
• PRECAUTIONS AND WARNINGS:   
-Infections: Corticosteroids may mask the 
signs of infection, and new infections may 
appear during their use. If an infection 
occurs during therapy, it should be 
promptly controlled by suitable anti-
microbial therapy. 
-Use the lowest possible dose.  Make a 
benefit/risk decision in each individual case 
as to the size of dose, duration of treatment 
and the use of daily or intermittent therapy, 
since complications of treatment, and side 
effects are dependent on these factors. 
-Corticosteroid products often contain 
tartrazine dyes (color) and sulfites 
(preservatives) that many people are 
allergic to. If the coloring and the 
preservatives are not indicated on the box, 
the patient or doctor can ask the 
manufacture of the product for this 
information. 
• ADVERSE EFFECTS:  
Most common possible side effects may 
include: nausea, vomiting, stomach upset, 
may lead to peptic or duodenal ulcers. 
Other common side effects: edema, heart 
failure, fluid and electrolyte disturbances, 
potassium loss, muscle weakness, loss of 
muscle mass, calcium loss (osteoporosis in 
severe cases), growth suppression in 
children, slow wound healing, allergic skin 
rash, convulsions, headache, insomnia, and 
dizziness. 
Less common side effects: irregular 
menstrual cycles, adrenal and/or pituitary 
gland suppression (specially following 
chronic doses > 7.5 mg/d), cushinioid state, 
hirsutism, hyperglycemia, precipitation of 
diabetes mellitus, cataracts, leukocytosis, 
increased appetite, euphoria, mood swings, 
personality changes, depression in patients 
with existing psychological problems. 
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• INTERACTIONS: 
Overview  of  Prednisone 
Drug-Drug Interaction 
Drug Interaction 
Anti-
tubercular 
medications 
Rifampin accelerates the 
metabolism of 
corticosteroids reducing 
their effect. Isoniazid 
serum concentrations may 
be decreased with 
corticosteroid use. Use 
caution and do not 
administer concomitantly. 
Barbiturates 
and  
antiepileptics 
These decrease the 
pharmacological effect of 
the corticosteroids.  Use 
with caution. 
Digitalis 
glycosides 
Co-administration may 
enhance the possibility of 
digitalis toxicity associated 
with hypokalemia. 
Diuretics; 
Potassium 
depleting 
agents 
Patients who are on these 
agents and are 
administered cortico-
steroids should be 
monitored for 
hypokalemia. Use with 
caution. 
 
 
 
 
• OVERDOSE: 
Symptoms of overdosage may include 
anxiety, depression and/or stimulation, 
stomach bleeding, increased blood sugar, 
high blood pressure, and water retention. 
Treatment: Patient should be taken to a 
hospital for supportive and symptomatic 
care. Gastric lavage or emesis can be 
applied.  Prolonged use of large doses will 
results in Cushinoid symptoms (moonface, 
central obesity, hirsutism, acne, etc.).  
Gradually taper of the medication, to the 
lowest dose that will control of the original 
disease symptoms. 
• BRANDS: 
Deltasone (Upjohn), Prednisone (Vitamed), 
Prednitab (BPC). 
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A)  CONTRACEPTIVE DEVICES AND BARRIERS 
1.  Intra-Uterine Devices (IUDs) 
2.  Spermicides and Condoms 
 
B)  HORMONAL PREPARATIONS 
1.  Estrogenic and Combined Oral Contraceptives:  
(Ethinylestradiol, Norethindrone and Desogestrel) 
2.  Progestin-Only Products: (including oral, injectables and implants) 
(Norethindrone, Levonorgestrel, Medroxyprogestogene acetate) 
3.  Emergency Pills  
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CONTRACEPTIVES 
 
Several contraceptive methods are 
available. In order to decide which is the 
most appropriate method to choose, the 
following factors should be considered: 
age, general health, frequency of 
intercourse, whether the reason for use is to 
prevent or to postpone pregnancy, personal 
preference, medical contraindication, 
expected efficacy, safety, and if the method 
provides protection against STD and HIV. 
The ideal contraceptive should be highly 
effective, safe, well tolerated, easily 
accessible, fully reversible and cheap. 
The available methods and their 
effectiveness, risk of side effects, and 
protection against STD and HIV can be 
seen in the table-7.1. (Effectiveness 
depends mostly on the degree of 
compliance and user reliability). 
Other methods like douching are not 
effective. The postcoital contraception used 
for emergencies has a failure rate of about 
1%.  
Natural family planning methods as 
calendar, basal body temperature, cervical 
mucus and sympatothermal, each requires 
keeping detailed records of women’s 
menstrual cycle and other symptoms related 
to cyclic hormonal levels. The effectiveness 
of these methods depends on several 
unreliable factors like the presence of mild 
cold, infections or cycle irregularities. 
 
 
A) CONTRACEPTIVE DEVICES & 
BARRIERS  
 
1)  Intra-Uterine Devices (IUDs)  
This category is the most commonly used 
method. Copper IUDs are all effective in 
preventing pregnancy for up to 5 years, but 
can not provide full protection (refer to the 
table-7.1).  
 
IUDs interfere with the implantation of 
the fertilized ovum. It is known that IUDs 
are most commonly used and are suitable 
for parous women (who have had at least 
one child). 
The IUDs that contain progestogene, 
which should be changed every year, have 
lower risk of ectopic pregnancy and the 
pre-existing heavy menses may be 
alleviated. The progestogene that is 
released close to the site of action (on 
cervical mucus and endometrium) will 
decrease the progestinic side effects and 
interactions, in particular, the enzyme- 
inducing drugs are unlikely to have much 
influence on the contraceptive effect. 
IUDs are contraindicated in cases of 
history of ectopic pregnancy, abnormalities 
of the uterine cavity, vaginal or cervical 
infections, acute pelvic inflammatory 
diseases (PID), genital malignancy, 
abnormal vaginal bleeding, previous tubal 
surgery, immunosupressive therapy and in 
women who are allergic to copper. 
The most common side effects are 
menstrual irregularities with discharge and 
discomfort. One of the primary concerns is 
the relation between IUDs and PIDs. 
Recent studies have shown that increased 
incidence of PID occurs almost exclusively 
in the first 4 months after insertion (others 
mentioned after the first 20 days of 
insertion) and among women who are 
exposed to STDs. Some explains that this 
might be due to the septic techniques used 
during the insertion or to the pre-existing 
reproductive tract infections. Careful 
screening of potential IUD users can 
minimize complications related to PID. 
Moreover, education about the symptoms 
of PID can also help in reducing the 
complications after seeking early treatment. 
 
 
Contraceptive Preparations 
 163
 
Table – 7.1:  Pregnancy Rates for Various Means of Contraception (%)
1 
Method of Contraception Lowest expected2 Typical
3
 
Risk of 
side effects # 
Protect against 
STD/HIV# 
Oral contraceptives  (in general) 
Combined 
Progestin-only 
 
0.1 
0.5 
3 
nd 
nd 
 
medium 
medium 
 
no 
no 
Mechanical/Chemical 
Levonorgestrel implant 
Medroxyprogesterone injection 
IUD 
   Progesterone 
   Copper T 380A 
Condom 
   Without spermicide 
   With spermicide
4
 
Spermicide alone 
Diaphragm (with spermicide 
cream or gel) 
Vaginal sponge 
   Nulliparous 
   Multiparous 
Female condom 
 
0.2 
0.3 
 
2 
0.8 
 
2 
1.8 
3 
6 
 
 
6 
9 
2-4 
 
0.2 
0.3 
 
nd 
nd 
 
12 
4-6 
21 
18 
 
 
18 
28 
12-25 
 
medium/high 
medium/high 
high 
 
 
low 
 
 
low 
low 
 
low 
 
 
low 
 
no 
no 
no 
 
 
yes 
 
 
yes/no 
yes/no 
 
yes/no 
 
 
yes/no 
Periodic abstinence* 1-9 20 - no 
Sterility 
   Vasectomy 
   Tubal ligation 
 
0.1 
0.2 
 
0.15 
0.4 
 
low 
medium 
 
no 
no 
No contraception 85 85 - - 
  nd= No data available. 
 1  During first year of continuous use. 
2
 Best guess of percentage expected to experience an accidental pregnancy among couples who 
initiate a method and use it consistently and correctly. 
 
3
 A typical couple who initiate a method and experience an accidental pregnancy. 
 
4
 Used as a separate product (not in condom package). 
 * Includes rhythm and sympatothermal methods. 
       Source: Health Action International, 1993. 
       Drugs Facts & Comparisons, 2000. 
 
 
2)  Spermicides and Condoms   
Barriers (e.g. diaphragm, condom) may be 
preferred for older women who continue to 
smoke in whom there is a greater risk of 
side effects from OCs. 
Spermicides kill sperms and have an 
antiseptic effect.  They are considered as an 
additional safeguard but do not give 
adequate protection if used alone. They 
have 2 components: spermicide and a 
vehicle which itself may have some 
inhibiting effect on sperm activity. 
Moreover, spermicides may provide 
protection against STD.  
The most commonly used products are 
Nonoxinol ‘9’ and Benzylkonium chloride.  
Both can be used alone or with barrier 
methods like a condom. 
Nonoxinol‘9’ is available in different 
dosage forms (foam, pessaries, gel, jelly, 
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cream). When used alone, it should be 
applied high in the vagina. It is 
contraindicated in people who are allergic 
to it. The main side effects are sensitization 
and irritation to mucous membranes. 
Products like petrolatum jelly, baby oil 
and oil based vaginal and rectal 
preparations are likely to damage condom 
and diaphragms made from latex rubber, 
thus less protection even from STD. 
 
B)  HORMONAL PREPARATIONS 
 
In this section, hormonal contraceptives 
will be discussed: combined oral 
contraceptives (OCs) and progestin-only 
products. Generally healthy women take 
these products, therefore, they should be 
extremely safe as well as effective. 
 
1)  Estrogenic and Combined 
OCs WHO,P 
 
• DRUG SUMMARY: 
The combined OCs contain different 
estrogen-progestin combinations. They 
suppress ovulation by imitating the 
feedback effects of the woman’s own 
estrogens and progesterones on the pituitary 
and the hypothalamus, thus inhibiting the 
secretions of FSH and LH. Additionally, 
these agents cause changes in the genital 
tract. The cervical mucous becomes thick 
(which inhibits sperm penetration) and the 
endometrium becomes thin and hypoplastic 
(which reduces the likelihood of 
implantation).  The effect and the relative 
potency of these combined agents depend 
on the type and the relative combination of 
estrogenic and proges-tational activity.  
The addition of progestins in a preparation 
may modify the effects of estrogens. These 
changes depend on the type or amount of 
progestin present and the ratio of progestin 
to estrogen.  
The total estrogenic potency of OCs is 
based on the combined effects of the 
estrogen and the estrogenic/ antiestrogenic/ 
androgenic effect of the progestin.  
The main advantages of OCs include: 
effectiveness, avoidance of dysmenorrhea, 
less iron deficiency anemia for women with 
heavy menstruation, avoidance of pre-
menstrual tension, less benign breast 
disease, decrease the risk against pelvic 
inflammatory disease, provides protection 
against endometrial and ovarian cancer, and 
possible decreased risk of Alzheimer’s.  
Note: 
• Estrogens have been reported to increase 
the risk of endometrial carcinoma.  
However, the risk appears to be decreased 
in OC users due to progestin component. In 
fact it has a protective effect, where users 
appear about half as likely to develop 
ovarian and endometrial cancers as women 
who have never used OCs. 
• In spite of many studies, the relationship 
between OCs use and breast and cervical 
cancers, a cause and effect relationship has 
not been established.  
There are 3 types of combined OC: 
monophasic, biphasic and triphasic.  
Monophasic: Fixed dosage of estrogen to 
progesterone throughout the cycle.  
Biphasic: The amount of estrogen is fixed 
for the first 21 days of the cycle. Progestin: 
estrogen ration is decreased in the first half 
of the cycle allowing endometrial 
proliferation. The ration is increased in the 
second half to provide adequate secretory 
development.   
Triphasic: Estrogen amount remains the 
same or varies throughout the cycle. 
Progestin amount varies. 
The biphasic and triphasic OCs are 
intended to deliver hormones in a similar 
way as the physiological process. 
 
The most commonly used estrogens are 
ethinylestradiol and mestranol. Pills 
containing > 50 mcg of estrogens are not 
currently used as their use is associated 
with an unacceptable incidence of venous 
thromboembolism. 
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Different progestinic derivatives are 
used. The progestogens desogestrel, 
gestodene and norgestimate in combination 
with ethinylestradiol have been reported to 
have less adverse effects on lipids than 
ethynodiol, levonorgestrel and norethisterone 
in combination with ethinylestradiol. 
However, desogestrel, gestodene have also 
been associated with an increased risk of 
venous thrombo-embolism. 
• INDICATIONS: 
-As contraceptive agents.  
-Some products might be used in 
emergency contraception in high doses as a 
postcoital contraceptive or “morning after” 
pill, but they are not licensed or packed for 
postcoital contraceptives (more details can 
be found under emergency pill in this 
chapter). 
• CONTRAINDICATIONS: 
Absolute: Pregnancy, thromboembolic 
disease, certain cardiac abnormalities, 
thalassemia major, porphyria, familial 
hyperlipidemia, carcinoma of breast, 
idiopathic jaundice of pregnancy, liver 
diseases. 
Relative: Diabetes mellitus, hypertension, 
osteosclerosis, secondary amenorrhea, 
undiagnosed vaginal bleeding, sickle cell 
disease, lactation, multiple sclerosis, 
obesity, depression, migraine, epilepsy, 
varicose vein, and in smokers > 35 yrs. old. 
• DOSAGE FORMS: 
Tablets in different strengths depending on 
the estrogenic/ progestinic derivative used. 
• RECOMMENDED DOSAGE:  
Start new patients with preparations 
containing ≤ 35 mcg estrogens. 
 
Directions for use: 
- One tablet should be taken at the same 
time every day with a meal or at bed time. 
Efficacy depends on strict adherence to the 
dosage schedule. 
- 21-Day regimen: Day 1 of the cycle is the 
first day of bleeding. Take one pill daily for 
21 days starting on day 5 of the cycle. No 
tablets are taken for 7 days; whether 
bleeding stopped or not, start a new course 
of 21 days.  Withdrawal flow will normally 
occur about 3 days after the last pill is 
taken. 
- 28-Day regimen: To eliminate the need to 
count the days between cycles, some 
products contain 7 inert or iron-containing 
tablets (21+7) to permit continuous daily 
dosage during the entire 28-day cycle. Take 
the 7- tablets on the last 7 days of the cycle. 
- Biphasic and triphasic OCs: One tablet is 
taken daily; as the color of the tablet 
changes, the strength changes too (i.e., the 
estrogen/progestin ratio changes). Usually, 
it is clearly indicated on the package where 
to start and in what order to take the pills 
(marked with arrows), along with the 
appropriate week numbers.  
 
- Missed pills: There is little likelihood of 
ovulation and consequent pregnancy 
occurring if only 1 tablet is missed, but the 
possibility of spotting and bleeding is 
increased. If 2 consecutive tablets are 
missed, the possibility of ovulation 
increases. In general, other contraception 
precautions should be taken for the balance 
of the cycle until tablets have been taken for 7 
consecutive days. 
∗ If one tablet is missed: take as soon as 
you remember, and the next one is at your 
normal time.  
If you are late by 12 hours or more 
(especially if it is the first in the package) 
the pill may not work for this cycle. 
However, continue your normal pill taking 
whenever you remember and other safety 
precautions should be taken into account 
especially in the next 7 days.  If these 7 
days run beyond the end of the packet, start 
the second one immediately after finishing 
the present one without any lag period, this 
means that you will not have a period until 
after the 2 packets, but this would not be a 
problem. Nor does it matter if you see some 
bleeding during taking the tablets. If you 
are using every day pills, miss out the 7 
inactive ones. 
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∗ If 2 consecutive tablets are missed: Take 
2 tablets as soon as remembered with the 
next pill at the usual time, or take 2 tablets 
daily for the next 2 days, then resume the 
regular schedule. 
∗ If 3 consecutive tablets are missed: begin 
a new packet of tablets starting day 1 of the 
cycle after the last pill was taken or starting 
7 days after the last pill was taken. 
 
- Switching brands: wait 7 days before 
starting the new pack (after the 21-day 
regimen) or start the next pack on the day 
after the last “reminder” pill (after the 28-
day regimen). 
- Postpartum administration in non-nursing 
mothers: it may begin at the first 
postpartum examination (4-6 weeks), 
regardless to whether spontaneous 
menstruation has occurred.  Also, start no 
earlier than 4-6 weeks after a mid-trimester 
pregnancy termination. Immediate 
postpartum use is associated with increased 
risk of thromboembolism. 
- Changing from progestogen-only tablet: 
start on first day of menstruation or any day 
if amenorrhea present and pregnancy has 
been excluded. 
- After abortion or miscarriage: start on the 
same day. 
• USES IN SPECIAL CASES:  
Lactation- Not recommended. Oral pro-
gestogen-only contraceptives are preferred. 
Liver Disease- Exercise caution as steroids 
metabolism decreases in liver impairment 
conditions. 
• PRECAUTIONS AND WARNINGS:   
A complete, detailed and clear medical and 
family history prior to initiation of therapy 
should be done. 
a) Smoking: The risk of cardiovascular side 
effects increases with OCs in heavy 
smokers ( > 15 cigarette/d) who are > 35 
yrs. old.  Women who use OCs should not 
smoke. 
b) Missed pill: see “RECOMMENDED 
DOSAGE”. 
c) Diarrhea and vomiting: may interfere 
with the absorption and limit the 
effectiveness. Additional precautions 
should be used during and for 7 days after 
recovery. If this happens during the last 7 
tablets, the next pill free interval should be 
omitted. 
d) The administration of OC should be 
stopped if any of the following symptoms 
occur: sudden severe pain in the chest, 
sudden breathlessness or cough with blood-
stained sputum. Severe pain in calf of the 
leg or in the stomach. Unusual severe, 
prolonged headache (especially if it 
happens for the first time or if it increases 
gradually), diplopia, dysphasia, vertigo, bad 
fainting attack or collapse, weakness, 
numbness, motor disturbances. 
e) Bleeding that resembles menstruation 
occurs rarely.  Persistent bleeding requires 
patient’s re-examination; consider non-
hormonal causes. If pathology has been 
excluded, time or changing the formulation 
may solve the problem. 
f)  Missed menstrual period: 
∗ If one period is missed (patient did not 
adhere to prescribed regimen): consider 
possible pregnancy, withhold OCs until 
ruling out pregnancy.  
∗ If two consecutive periods are missed 
(patient adhered to the prescribed regimen): 
rule out pregnancy before continuing the 
contraceptive regimen. 
∗ If menstrual bleeding is minimized: this 
might be due to long usage of medication 
for several months and not due to 
pregnancy. 
g) Surgery: estrogen-containing OC should 
be stopped 4 weeks before major elective 
surgery and all leg surgeries. They are 
recommended again after the first menses 
occurring at least 2 weeks after 
mobilization. When discontinuation is not 
possible (i.e., after trauma) then sub-
cutaneous heparin should be given 
prophylactically. 
h) Contact-lens wearers who develop 
changes in vision or lens tolerance should 
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be assessed by an ophthalmologist; 
consider permanent or temporary cessation 
of wear. 
i) OCs do not protect against HIV infection 
or other STDs (inform patients). 
• ADVERSE EFFECTS:  
The aim of the prescriber should be to keep 
the level of both the estrogenic and the 
progestinic derivative as low as possible 
consistent with maximal effectiveness and 
minimal discomfort for the patient.  Side 
effects that have been reported include: 
-CVS (Serious): Thrombophlebitis and 
venous thrombosis with and without 
embolism; pulmonary embolism; coronary 
thrombosis; MI; cerebral thrombosis or 
hemorrhage; hypertension;  mesentric 
thrombosis.  
-GU: breakthrough bleeding, spotting; 
change in menstrual flow; amenorrhea; 
change in cervical erosion and cervical 
secretions; invasive cervical cancer; vaginal 
candidiasis. 
-Breast changes: tenderness; enlargement; 
secretion; diminution in lactation when 
given immediately postpartum. 
-GI: Nausea; vomiting; abdominal cramps; 
cholestatic jaundice. 
-CNS: migraine; mental depression. 
-Ophthalmic: changes in corneal curvature; 
contact lens intolerance; neurocular lesions. 
-Miscellaneous: photosensitivity may 
occur; edema; weight changes; reduced 
carbohydrate tolerance; prevalence of 
cervical clamydia trichomatis may be 
increased; gallbladder disease; hepatic 
adenoma. 
• INTERACTIONS:  
(1) The following drugs will decrease OCs 
effectiveness, which means that pregnancy 
may occur. (Another contraceptive method 
should be used during treatment.) 
a) Hepatic enzymes inducers such as 
barbiturates, hydantoin, rifampicin, 
carbamazepine.  
b) Note: Rifampicin is a potent enzyme 
inducer, that even if a course lasts for 
less than 7 days, the additional 
contraceptive precautions (e.g. IUD) 
should be continued for at least 4 
weeks after stopping it. Changes in the 
strength or the regimen of the pills 
may be done. 
c) Antibiotics such as penicillins, 
tetracylines and griseofulvin. 
(2) Allopurinol, cimetidine, chloram-
phinicol, isoniazid and the phenothiazines 
may potentiate the actions and adverse 
effects of oral contraceptives. 
(3) Coadministration of OCs with the 
following drugs will result in: 
a) Anticoagulants effect would decrease. 
b) Antidepressants (TCA), β-blockers, 
caffeine, corticosteroids, theophylline 
effects or toxicity may be increased.   
c) Benzodiazepines effect or toxicity 
may be increased for some derivatives 
and decreased for lorazepam, 
oxazepam and temazepam. 
d) Clofibrate effect may be decreased as 
its elimination is increased. 
e)  Salicylate effect may be decreased.  
 
Drug /lab test interactions: 
Estrogen-containing OCs may cause 
alterations in serum, blood or plasma 
concentrations of some hormones or 
clotting factors, etc. This means that 
continuous monitoring is needed, which 
may require a specialist clinic and not the 
general primary health care facility. 
• OVERDOSE: 
Serious events have not been reported 
following acute overdosage. In case of 
overdose, one might get nausea.  
Withdrawal bleeding may occur in female 
children after accidental ingestion. 
• BRANDS: 
Gynera (Schering/Agis), Microdiol (Organon), 
Nordette (Wyeth Ayerst). 
_____________________ 
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2)  Progestin-Only Products 
 
Progesterone is the primary principle of 
corpous luteum. It causes the 
transformation of the proliferative 
endometrium into secretory endometrium. 
Synthetic exogenous progesterone inhibits 
gonadotropines secretion, thus prevents 
maturation of the follicle and ovulation and 
results in endometrial thinning. Thus, 
exerting its contraceptive action.  
These products are more suitable in the 
following cases:  
• When estrogens are contraindicated.  
• For women over the age of 40 years in 
whom fertility has declined so that the 
small risk of pregnancy is reduced even 
further.  
• For patients with diabetes mellitus and 
migraine.  
• Women with a history of thrombo-
embolism and valvular heart disease.  
• Women who have previously developed 
hypertension with combined pills. 
• Breast feeding mothers.  
• Women over 35 who smoke. 
 
The dose of the progestin derivative in 
progesterone-only products is very much 
lower than the daily dose of progesterone in 
combined pills. Therefore, progestin-only 
products have a higher failure rate than 
combined preparations (refer to table-7.1).  
However, side effects are considered to be 
less. They are more likely to cause 
alteration in the menstrual patterns: 
Amount and duration of the flow, cycle 
length, BTB, spotting and amenorrhea 
varies. Although menstrual irregularities 
are more common than with OCs; but tend 
to resolve on long term treatment. 
Another advantage is that a decline in 
serum HDL has occurred with progestins. 
The progestin-only products are divided 
into oral (e.g. levonorgestrel, ethynodiol 
acetate), injections (medroxyprogesterone 
acetate), implants (levonorgestrel), and are 
added to IUD (levonorgestrel). 
 
a)  Oral Progestogen-only 
      Preparations 
 
• DRUG SUMMARY: 
These products are suitable for use as an 
alternative to combined oral contraceptives 
if estrogens are contraindicated and before 
major elective surgery. 
• INDICATIONS: 
To prevent pregnancy.   
(Refer to the introduction.) 
• CONTRAINDICATIONS: 
Pregnancy, thrombophlebitis, thrombo-
embolic disorders, undiagnosed vaginal 
bleeding, liver diseases, breast and genital 
tract carcinoma. 
• DOSAGE FORM:  
Tablets. 
• RECOMMENDED DOSAGE:  
Directions: 
- Daily administration: starting on the first 
day of menstruation.  Take one tablet at the 
same time each day, every day of the year.  
And preferably, few hours before 
intercourse to obtain full effectiveness. 
-Postpartum administration: may be 
initiated no earlier than 4 weeks 
postpartum. The risk of thromboembolic 
disease that is associated with the 
postpartum period should be considered. 
Moreover, heavy and irregular postpartum 
bleeding may occur. 
-Missed dose:  
∗One tablet: take as soon as remembered 
(within 3-4 hrs), then take next tablet at 
regular time. Extra precautions should be 
taken for the next 48 hrs. 
∗Two consecutive tablets: DO NOT take 
the missed tablets; discard and take the next 
tablet at the regular time, or take one of the 
missed tablets, discard the other and take 
daily tablet at usual time. 
∗Three consecutive tablets: discontinue 
immediately. 
Use additional protection methods of 
contraception if 2 or more tablets are 
 
Contraceptive Preparations 
 169
missed until menstruation appears or 
pregnancy is ruled out. If menses does not 
occur within 45 days, regardless of 
circumstances, discontinue the drug, rule 
out pregnancy and use a non-hormonal 
method of contraception. 
Because of the slightly higher failure of 
the progestin-only products, a more 
conservative approach is to discontinue the 
regimen if only one tablet is missed and use 
other non-hormonal contraceptive methods 
until menses occurs or pregnancy is ruled 
out.  
• PRECAUTIONS AND WARNINGS:   
Pretreatment physical examinations, which 
include breast and pelvic organs, should be 
performed. 
Women using progestin-only pills should 
be monitored for any manifestations or for 
the onset of any of the following 
symptoms: thrombotic disorders, fluid 
retention, depression, photosensitivity and 
ophthalmologic disorders. 
• ADVERSE EFFECTS:  
Menstrual irregularities, nausea, vomiting, 
headache, breast discomfort and weight 
changes.  
• INTERACTIONS:   
Effectiveness of oral progestogen-only 
products is not affected by broad-spectrum 
antibiotics but is reduced by enzyme-
inducing drugs: Barbiturates, phenytoin, 
carbamazepine, ethosuximide, rifampicin, 
chlorpromazine, and griseofulvin. 
• OVERDOSE: 
Refer to OCs. 
• BRANDS: 
Femulen (Searle). 
________________________ 
 
b)  Injectables:  Medroxy-
progesterone acetate WHO,P 
 
• DRUG SUMMARY: 
It is a long acting progestogene given IM. It 
is useful for short-term interim contra-
ception (e.g. before vasectomy becomes 
effective). For long-term contraceptive for 
women who have been appropriately 
counseled concerning the likelihood of 
menstrual disturbances (amenorrhea, heavy 
uterine bleeding) and the potential for a 
delay in return to full fertility, which is 
unrelated to the duration of use, but there is 
no evidence of permanent infertility. 
• INDICATIONS: 
Prevention of pregnancy. It is a long-term 
contraceptive injection in women when 
administered at 3 months interval. Cautious 
use as severe side effects may persist 
during and longer than 3 months.  It should 
be clear to the woman that these effects are 
irreversible once it is administered for at 
least 3 months. 
• CONTRAINDICATIONS: 
As for oral progestogene. 
• DOSAGE FORMS: 
Injections of 150 mg/3 months. 
• RECOMMENDED DOSAGE:  
Directions: 
-The woman should fill and sign the 
informed consent first. 
-The first injection should be given only 
during the first 5 days after the onset of 
normal menstrual period, within 5 days 
postpartum (this might affect bleeding 
pattern) if not breast feeding and at sixth 
week postpartum if breast feeding.  
-Shake well before use to ensure 
homogenous dose. The recommended dose 
is 150 mg/3 months administered deep IM 
in the gluteal or deltoid muscle (do not 
massage). 
-If the period between injections is > 14 
weeks, rule out pregnancy before new 
administrations. 
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• USES IN SPECIAL CASES:  
Lactation- It is detected in milk. Milk 
composition, quality and amount are not 
adversely affected. No adverse effects on 
breast-fed infants. 
Children- Children exposed to medroxy-
progesterone acetate in utero and followed to 
adolescence did not show any abnormal 
physical, intellectual, sexual or social 
development. 
Liver Disease- Steroids metabolism may be 
affected in liver impairment cases. 
• PRECAUTIONS AND WARNINGS:   
-Diabetic patients should be observed 
carefully as the therapy might result in a 
decrease in glucose tolerance. 
-Blood pressure should be checked before 
each injection. 
• ADVERSE EFFECTS:  
The most common side effect is menstrual 
irregularities (amenorrhea, bleeding) as 
well as delay of return to fertility. 
• INTERACTIONS:   
As for oral progesterones. Moreover, 
aminoglutethimide decreases the efficacy 
of medroxyprogesterone.  
• OVERDOSE: 
Refer to OCs. 
• BRANDS: 
Depo-Provera  (Upjohn). 
________________________ 
 
c)  Implants:  Levonorgestrel 
 
• DRUG SUMMARY: 
Levonorgestrel is a synthetic and 
biologically active progestin that exhibits 
no significant estrogenic activity and is 
highly progestational.  Unlike injectables, 
implants are almost reversible upon 
removal.  The efficacy of the implant does 
not depend on the patient compliance. 
The main disadvantages of the implants are 
the cost and the fact that the woman is 
dependent on the health professional for 
insertion and removal. 
• INDICATIONS:  
Prevention of pregnancy, up to 5 years. It is 
a reversible contraceptive system. The 
capsules should be removed by the end of 
the 5th year.  New capsules may be inserted 
at that time if continuing contraceptive 
protection is desired. 
• CONTRAINDICATIONS: 
As for oral progestins. 
• DOSAGE FORMS:  
Implants; the package consists of a set of six 
flexible closed capsules made of silastic, each 
containing 36 mg of the progestin 
levonorgestrel contained in an insertion kit to 
facilitate implantation. These capsules are 
sealed and sterilized. 
• RECOMMENDED DOSAGE: 
The initial released dose from the inserted 
implant is about 85 mcg/day, followed by a 
decline to about a 50 mcg/day and to about 
35 mcg/day by 18 months, with a further 
decline thereafter to about 30 mcg/day. 
Directions:   Insertion and removal: 
* A specific training should be conducted 
for health workers who are involved in this 
procedure. 
− An informed consent should be obtained 
before insertion. The capsules are inserted 
during the first 7 days of the cycle or 
immediately following an abortion. Before 
insertion, pregnancy should be ruled out. 
Insertion is not recommended before 6 
weeks postpartum in breast feeding women. 
− Healthcare professionals should provide 
proper insertion that will also provide 
proper and easy removal. Sterility is the 
major concern during this process. 
− Proper insertion and removal should 
result in minimal scaring.  If all capsules 
cannot be removed at the first time, try 
removal later when the site has healed.  
Bruising may occur at the implant site 
insertion or removal. In some women, 
hyper-pigmentation occurs over the 
implantation site but is usually reversible 
following removal.  
− Aseptic techniques should be followed 
during insertion to prevent infections.  Use 
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proper medication to treat infections but if 
it persists, capsules should be removed. 
− Expulsion of capsules is uncommon. 
− Provisions for removal: women should 
be advised that the capsules might be 
removed upon request at any time or at the 
end of the 5 years. 
• USES IN SPECIAL CASES:  
Lactation- Levonorgestrel has been identified 
in breast milk.  No significant effects were 
observed on those infants whose mothers 
used the implants beginning 6 weeks after 
parturition in comparative studies with 
mothers using IUDs or barrier methods. 
Liver Disease- Steroid hormones metabolism 
may be decreased in liver impairment 
conditions. 
• PRECAUTIONS AND WARNINGS:   
-A full medical examination and follow up 
should be performed before insertion and at 
least annually during its use. 
-Women with strong family history of 
breast cancer or who have breast nodules 
should be carefully monitored. 
-There may be an affect on carbohydrate 
and lipid metabolism. Women with hyper-
lipidemia should be carefully monitored 
since the level of LDL may be altered. 
• ADVERSE EFFECTS: 
The most common side effect is menstrual 
irregularities: Irregular, frequent bleeding, 
spotting, amenorrhea.  
Other side effects are breast discharge, 
cervicitis, vaginitis, musculoskeletal pain, 
abdominal discomfort, pain, itching, 
infection at the implant sight. 
• INTERACTIONS:  
-Carbamazepine and phenytoin (hepatic 
enzyme inducers) will reduce the efficacy 
of levonorgestrel, thus pregnancy may 
occur. 
-Lab/Drug test interactions: certain 
endocrine tests may be affected, e.g. 
thyroxine concentration may be decreased. 
• OVERDOSE:  
It can happen if > 6 implants are in situ.  
All implanted capsules should be removed 
before new insertion. Overdosage may 
cause fluid retention and uterine bleeding 
irregularities. 
• BRANDS: 
Norplant (Discotrade). 
_______________________ 
 
 
3)  Emergency Pills 
 
Today, emergency contraception (EC) is 
the most commonly used term to describe 
the post-coital use of levonorgestrel alone 
or the combination of ethinyl estradiol and 
levonorgestrel within 72 hrs of unprotected 
sexual intercourse to prevent pregnancy. It 
should not be confused with other agents 
such as mifepristone (also known as RU-
486 or the "French abortion pill") that, 
unlike emergency contracption pills, can be 
used to terminate an existing pregnancy.  
Just as with the daily use of oral 
contraceptives, EC pills prevent pregnancy 
primarily due to inhibition or delay of 
ovulation, and possibly by inhibition of 
fertilization or implantation. Once 
endometrial implantation has occurred, 
pregnancy is initiated and EC has no effect. 
A combined tablet of 50 mcg ethinyl 
estradiol and 500 mcg norgestrel, or 50 
mcg ethinyl estradiol and 250 mcg 
levonorgestrel is to be taken 2 tablets 
immediately, followed after 12 hours by 
another 2 tabs.  This method is considered 
effective if taken within 72 hrs after 
intercourse but it is less effective than 
insertion of an IUD. 
These tablets should not be 
administered if menstrual bleeding is 
overdue or if protected intercourse occurred 
more than 72 hours previously. 
 
• These tablets are contraindicated in 
pregnancy, women with a history of 
thrombosis or who have focal migraine at 
that time. 
• If vomiting occurs during 2-3 hrs after 
taking the tablets, 2 other tablets should be 
taken instead with antiemetic.  
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• The patient should be informed that 
there might be early or delayed period, also 
to use barrier methods till the next period. 
The doctor should ask about any abdominal 
pain or heavy bleeding or any menstrual 
irregularities. 
 
_________________ 
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Chapter  8 :   PSYCHOTHERAPUTIC  DRUGS 
 
 
 
PSYCHOACTIVE DRUGS: 
A)  ANTIDEPRESSANTS 
1.  Amitriptyline 
2.  Imipramine 
3.  Fluoxetine 
 
B)  HYPNOTICS AND ANXIOLYTICS 
1.  Diazepam 
2.  Lorazepam 
 
C)  NEUROLEPTICS  
1.  Chlorpromazine 
2.  Haloperidol 
 
ANTICONVULSANT / ANTIEPILEPTIC DRUGS:  
1.  Carbamazepine 
2.  Clonazepam 
3.  Ethosuximide 
4.  Phenobarbital 
5.  Phenytoin 
6.  Valproic Acid 
7.  Diazepam 
 
ANTIPARKINSONISM  DRUGS: 
A)  ANTICHOLINERGIC DRUGS 
1.  Benztropine Mesylate 
2.  Trihexyphenidyl (Benzhexol) 
 
B)  DOPAMINERGIC DRUGS: 
1.  Amantadine 
2.  Bromocriptine 
3.  Carbidopa / Levodopa 
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Psychoactive drugs: 
A)  ANTIDEPRESSANTS  
 
Depressive illnesses should not be confused 
with the transient feelings of unhappiness 
that everyone experiences; the periods of 
sadness associated with unhappy events and 
failures, or the emotional letdown that 
occur. Suicide is the most serious 
complication of depressive illnesses.  
Depression can be a symptom secondary 
to organic brain syndrome, schizophrenia, 
anxiety disorders, obsessive compulsive 
disorders, hyperthyroidism, drug 
dependence, mental disorders, anemia, 
cardiovascular problems, or use of 
depressant drugs.  
The American Psychiatric Association 
uses criteria for mood disorders (DSM-R), 
while the European community use the 
(ICD10), that permit clinicians to 
consistently distinguish between 
pathological states and normal changes in 
emotion in everyday life. The most 
common mood disorders are major 
depression (unipolar disorders) and manic-
depressive illness (bipolar disorder).  
Psychotherapy (talk therapy) has 
resulted in very positive outcomes in 
combination with pharmacotherapy. Drugs 
with clinically useful antidepressant effect 
include the tricyclic antidepressants 
(TCAs), the selective serotonin reuptake 
inhibitors (SSRIs), and the mono-amine 
oxidase inhibitors (MAOIs), as well as 
others included at the end in table-8.1.   
The TCAs and the SSRIs are preferred 
over the MAOIs because they are more 
effective and do not show the dangerous 
interactions with some foods (that contain 
tyramine) and fewer major drug-drug 
interactions. 
The SSRIs also have fewer anti-
muscarinic side-effects than the older 
tricyclics, and they are less cardiotoxic in 
overdose. Although they are not more 
effective, they may be preferred where 
there is a major risk of overdose. 
Each drug group has similar 
characteristics, contraindications, and side 
effects, but their pharmacokinetics profiles 
may differ, resulting in one drug having 
more or less side effects or indication for 
use than the other.  
Drug selection is based on side effect 
profile, concomitant disease state (i.e. 
benign prostatic hypertrophy, insomnia, MI, 
arrhythmias, obesity, glaucoma, hypertension, 
sexual dysfunction, suicide potential, etc.), 
drug-drug interaction, cost, ease of use, and 
previous therapy.  
 
 
 
 
Table-8.1:   Examples  of  Antidepressant  Drugs 
TCAs 
Tertiary 
Amines 
TCAs 
Secondary 
Amines 
SSRIs MAOIs Miscellaneous Agents 
Amitriptyline --→
Clomipramine 
Doxepin 
Imipramine   ---→
Trimpramine 
*Nortriptyline 
Amoxapine 
Protriptyline 
*Desipramine 
Lofepramine 
Citalopram 
Fluoxetine 
Fluvoxamine 
Paroxetine 
Sertraline 
Isocarboxide 
Moclobemide 
Phenelzine 
Tranylcypromine 
Bupropion 
Maprotiline 
Nefazodone 
Trazodone 
Venlafaxine 
  Amitriptyline → metabolized to * Nortriptyline. 
  Imipramine  → metabolized to * Desipramine. 
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Lithium salts are used in the treatment of 
mania, affective disorders, and the 
prevention of recurrent attacks of manic-
depressive illness. Lithium is not a 
sedative, nor a depressant or euphoriant. 
Lithium prescribing requires a specialist’s 
advise, and should not be prescribed unless 
facilities for monitoring serum 
concentration levels are available.  Abrupt 
withdrawal increases risk of relapse, and if 
there is a need for discontinuation, the dose 
should be reduced gradually over a period 
of a few weeks with caution. A specialist 
subscribes it to patients with normal 
sodium intake, and with normal cardiac and 
renal functions. Lithium is not suitable for 
children. Lithium will not be discussed in 
this chapter. 
Prescribing more than one anti-depressant 
at the same time is not recommended. 
Compound preparations of an 
antidepressant and an anxiolytic are not 
recommended because the individual 
component should be adjusted separately.  
Where as antidepressants are given 
continuously over several months, 
anxiolytics are prescribed on a short-term 
basis. 
Patients who are suicidal or potentially 
suicidal are prescribed only small quantities 
of medication to avoid possible overdose, 
until the patient is stabilized. 
Treatment should be continued for 2 weeks 
before suppression of symptoms can be 
expected, and should be maintained at the 
optimum level for at least another month 
before the attempt is made for dose 
reduction. Treatment may last between 3 
months to a year or more.  Some patients 
appear to benefit from maintenance therapy 
with about half the therapeutic dosage for 
several months to prevent relapse. 
Besides depression, many of these agents 
have other uses, which will be mentioned 
as each drug is discussed. 
_________________ 
 
1)  Amitriptyline WHO,P 
 
• DRUG SUMMARY:  
Amitriptyline is a CNS agent, psycho-
therapeutic, tricyclic (tertiary amine) 
antidepressant. Among the most active 
TCAs in inhibition of serotonin uptake, also 
inhibits nor-epinephrine reuptake to a 
moderate degree. TCAs could occasionally 
be used as hypnotic because of their 
sedative property; this effect may be useful 
in the initial therapy of a depressed patient 
who is not sleeping well. 
• INDICATIONS:  
Depressive illness, particularly where 
sedation is required. 
Has been used for enuresis, but there is 
more experience with imipramine (refer to 
special cases for children, under 
imipramine). 
• CONTRAINDICATIONS: 
Hypersensitivity to any tricyclic drug. Use 
following a recent MI or arrhythmias, 
concomitant use of a MAOI s (may 
precipitate hyperpyrexic crisis), history of 
seizure disorders. 
• DOSAGE FORMS:  
Tablets. 
• RECOMMENDED DOSAGE:  
Adult: 50-75 mg/day PO in divided doses 
or as a single dose at bedtime, may increase 
to 150 mg/day. 
(Elderly and adolescents start 25-50 
mg/day: 10 mg t.i.d. and 20 mg h.s.). 
Child:  Not recommended for children < 12 
years. 
Directions: When increasing the dose, start 
with the night dose. Therapeutic 
antidepressant effect may take as long as 30 
days to develop. 
*Drug may be taken with or immediately 
after food to reduce possibility of GI 
irritations. Tablets may be crushed if 
patient is able to swallow. 
*Advise patient not to discontinue therapy, 
or take other drugs or OTCs that may 
interact with the medication. Abrupt 
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discontinuation may cause nausea, 
headache and malaise. The dosage should 
be diminished slowly over 2 weeks. 
*Maintenance regimen is usually continued 
for at least 3 months to prevent relapse. 
Therapy typically lasts 6 months to 1 year. 
*Advise patient to stop taking this 
medication and get emergency help if any 
of the following occur: Seizures, difficult or 
fast breathing, fever with increased 
sweating, high or low blood pressure, loss 
of bladder control, severe muscle stiffness 
and unusual weakness.  
*Elderly patients maybe more susceptible 
to the anticholinergic, antihistaminic and 
cardiovascular side-effects of amitryptyline 
and imipramine. If the patient can’t tolerate 
these, desipramine and nortiptlyine are used 
for such patients. 
• USE IN SPECIAL CASES:  
Pregnancy- Use only if potential benefits 
outweigh the hazards to the fetus (Catgegory 
D). Even though clinical experience is 
limited; amitriptyline has been reported to 
cause limb reduction anomalies in fetus (Drug 
Facts & Comparisons. 2000). 
Lactation- TCAs are excreted in breast milk 
in low concentrations. Clinical effects of 
exposure to infant are not known. Use is not 
recommended, unless clearly indicated. 
Children- Not recommended for children less 
than 12 yrs old. Although some prescribe 
amitriptyline to children for enurisis, 
imipramine is more commonly used 
worldwide. (Refer to imipramine.) 
Renal Disease- Use caution, the drug is 
excreted primarily in urine. Need to reduce 
doses in patients with significantly impaired 
renal functions. 
Liver Disease- Avoid drug in severe liver 
disease. Use with caution and reduce doses in 
patients with hepatic impairment. Metabolism 
of the drug may be impaired leading to drug 
accumulation. It is metabolized to the active 
metabolite nortriptyline. 
• PRECAUTIONS AND WARNINGS: 
-Due to the high incidence of 
anticholinergic side effects, use caution in 
patients with a history of urinary retention, 
angle-closure glaucoma or increased 
intraocular pressure, in patients receiving 
anticholinergic medications (antiparkinson 
agents), patient with cardiovascular 
disorders (since TCAs may produce 
arrhythmia, and increase frequencies and 
severity of angina and other problems). 
-Psychiatric patients with schizophrenic or 
paranoid cases may exhibit a worsening of 
psychosis with TCA therapy. The 
possibility of suicide in depressed patients 
remains during treatment until significant 
remission occurs. Monitor patients.  Patient 
should not have easy access to large 
quantities of drug, prescribe small quantity 
each time (one month supply at a time until 
patient is stabilized). 
-Sexual dysfunction in males, and weight 
gain may be the major side effects that 
cause non-compliance. Warn patients. 
• ADVERSE EFFECTS: 
Drowsiness, sedation, dizziness, restless-
ness; need to warn patient against 
hazardous activities like driving or 
operating machinery till response to the 
drug is known. Orthostatic hypotension; 
advise patient to change position slowly, 
tachycardia, ECG changes, blurred vision, 
dry mouth; increased fluid intake, increased 
appetite (especially to sweets) leading to 
weight gain, constipation, urinary retention, 
urine discoloration, interference with sexual 
function, interference with blood sugar 
levels; elevation or lowering has occurred, 
need to warn diabetic patients. Occasional 
reports or photosensitivity, metallic taste of 
the mouth, and convulsions have been 
noted. 
• INTERACTIONS: 
Overview of Amitriptyline 
Drug-Drug Interaction 
Drug Interaction 
Alcohol Will enhance the sedative 
effect. Advise patient not to 
drink or eat foods/ medicines 
that contain it while on this 
medication. 
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Anti-
epileptics 
(phenytoin) 
Has antagonistic effect, 
lowered seizure threshold, and 
reduced antidepressant effect. 
Do not administer 
concomitantly 
Anti-
hypertensives
and diuretics 
Increased hypotensive effect. 
Do not administer at the same 
time; use caution. 
Cimetidine Increases serum level of TCAs, 
increasing anti-cholinergic 
symptoms. Avoid use, 
ranitidine might be a better 
alternative. 
MAO 
Inhibitors 
Concomitant use is 
contraindicated. It has been 
reported to cause hyperpyretic 
crisis, severe convulsions and 
death. Do not administer TCAs 
with or within 2 weeks of 
MAO Inhibitors use. 
Oral contra-
ceptives 
(OCs) 
Inhibit the hepatic metabolism 
of TCAs and may increase 
their plasma levels, especially 
estrogen. Also steroids have 
same effect. Use caution. 
Thyroid 
medication 
Patients on these need close 
supervision because of 
possibility of cardiovascular 
toxicity, including arrhythmia. 
 
• OVERDOSE: 
Children are reportedly more sensitive than 
adults to acute overdose. Consider any 
overdose in infants or young children as 
serious and potentially fatal. 
Symptoms include confusion, agitation and 
hallucinations. Seizures are common. 
Flushing, dry mouth, dilated pupils, cardiac 
arrhythmia, depressed myocardial 
contractility, heart rate and coronary blood 
flow. 
Treatment; Hospitalize and closely observe 
with ECG monitoring, even when the 
amount ingested is thought to be small. 
• BRANDS: 
Amyvil (JePharm), Elavil (Stuart), Endep 
(Roche), Elatrol/Elatrolet (Assia/Riesesl), 
Tryptal/ Tryptalette (Unipharm). 
________________________ 
 
2)  Imipramine P 
 
• DRUG SUMMARY: 
Imipramine is a CNS psychotherapeutic, 
tricyclic (tertiary amine) antidepressant; 
TCA. It has the same mechanism of action 
as amitriptyline, but somewhat has less 
sedative properties. 
• INDICATIONS: 
Depressive illness, treatment of panic 
attacks.  Nocturnal enuresis in children. 
• CONTRAINDICATIONS: 
Same as Amitriptyline. 
• DOSAGE FORMS: 
Tablets. 
• RECOMMENDED DOSAGE: 
Adult: Start with 75 mg/day PO h.s. or in 
divided doses, increased if needed to 150 
mg/d in divided doses;  max. 200 mg/d. 
Adolescents and elderly: initially 30-40 
mg/d, not to exceed 100 mg/d. 
Child: For childhood enuresis: 25 mg PO 
h.s. 
< 12 years may increase to 50 mg nightly; 
max. dose is 2.5 mg/kg/d. 
> 12 years may increase to 75 mg nightly;  
max. dose is 2.5 mg/kg/d. 
 
Directions: For children treated for 
enuresis; institute a drug free period 
following an adequate therapeutic trial with 
a favorable response. Gradually tapering 
dosage may reduce tendency to relapse. 
Children who relapse after drug 
discontinuation do not always respond to a 
subsequent course. 
*Follow same directions as amitriptyline. 
• USE IN SPECIAL CASES:  
Pregnancy- Avoid use unless potential 
benefit outweighs the potential hazard to the 
fetus (Category D). There have been clinical 
reports of congenital malformation associated 
with imipramine. 
Lactation- Caution should be exercised. 
TCAs are excreted in breast milk. 
Children- TCAs are used (mainly imipramine 
but amitriptyline can be used) to treat 
enuresis in children ≥ 6 years, mainly on 
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special occasion such as sleeping away from 
home or patients not responding to non-
pharmacologic therapy. 
Non-pharmacological approaches such as 
bladder retention training, motivational 
therapy and behavior modification are 
preferred and have a lower relapse rate. But 
many physicians and patients’ families prefer 
drug therapy for fast response. Do not exceed 
2.5 mg/kg/d.  
Proper follow-up of such cases is important to 
prevent relapse, and long-term therapy is 
controversial. Effectiveness of imipramine in 
children for conditions other than nocturnal 
enuresis has not been established. 
Renal Disease- Use with caution especially in 
patients with significantly impaired renal 
function. 
Liver Disease- Use with caution and reduce 
dose to avoid accumulation of the drug. It is 
metabolized to desipramine (an active 
metabolite) by the liver.  
• PRECAUTIONS AND WARNINGS, 
INTERACTIONS, OVERDOSE: 
Same as amitriptyline. 
• ADVERSE EFFECTS: 
Same as amitriptyline, with less sedation. 
• BRANDS: 
Tofranil (Ciba-Geigy), Primonil (Teva). 
______________________ 
 
3)  Fluoxetine 
 
• DRUG SUMMARY: 
Fluoxetine is a selective serotonin reuptake 
inhibitor (SSRI) antidepressant. A 
phenylpropylamine derivative chemically 
unrelated to the TCAs, with a very long 
half-life compared with other anti-
depressants. Antidepressant effect is 
presumed to be linked to its inhibition of 
CNS presynaptic neuronal uptake of 
serotonin. SSRIs are less sedating than 
TCAs, with few antimuscarinic effects and 
with low cardiotoxicity.  
• INDICATIONS: 
Primary indication is for depression. Other 
uses include obesity, bulimia nervosa, and 
obsessive compulsive disorder (OCD). 
• CONTRAINDICATIONS: 
Hypersensitivity to SSRIs. In combination 
to a MAO inhibitor or within 14 days or 
discontinuing a MAO inhibitor. 
• DOSAGE FORMS: 
Tablets. 
• RECOMMENDED DOSAGE: 
Adult:  20 mg/d PO in the morning time.  
May increase to a max. 80 mg/d in 2 
divided doses;  morning and noon.  
Child:  Not used in children. 
 
Directions: While patients may notice an 
improvement with therapy in 1-4 weeks, 
advise patients to continue therapy as 
directed. Approximately 2-3 weeks are 
required for SSRI therapeutic effects. 
*Food does not affect systemic 
bioavailability of fluoxetine, so it may be 
given with or without food. 
*If patient missed a dose, take as soon as 
remember, unless too close to the next 
dosing interval. Do not double the dose. 
*Provide suicidal or potentially suicidal 
patients with small quantities of the 
prescribed medication to avoid possible 
overdose, especially when starting therapy. 
• USE IN SPECIAL CASES: 
Pregnancy- Avoid unless potential of benefit 
outweighs potential hazards.  There are no 
adequate and well-controlled studies in 
pregnant women; but it was reported that 
5.5% of 228 women who took fluoxetine the 
1st trimester delivered infants with structural 
anomalities  (Category C). 
Lactation- Exercise caution. Fluoxetine is 
excreted in breast milk. One case only 
reported indicated that infant showed 
increased irritability.  
Children- Safety and efficacy of SSRIs in 
children < 18 yrs. old have not been 
established.   
Renal Disease- Use with caution. Additional 
accumulation of drug or metabolite has 
occurred with severely impaired renal 
function, with chronic use. Use a lower or 
less frequent dose. 
Liver Disease- Use with caution in severe 
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liver impairment. SSRIs are extensively 
metabolized in the liver, (fluoxetine to active 
metabolite norfluoxetine), elimination is 
prolonged. Reduce initial dose with less 
frequent dosing intervals. Alternate-day 
dosing has been recommended for patients 
with significant hepatic impairment. 
• PRECAUTIONS AND WARNINGS: 
-In patients receiving MAOIs in 
combination with SSRIs, serious sometimes 
fatal, reactions have occurred including 
hyperthermia, rigidity, seizures, extreme 
agitation progressing to delirium and coma. 
-Rash and accompanying events; instruct 
patient that a rash could be a sign of a 
serious group of adverse effects, and should 
notify physician if noted. Most patients 
improved after discontinuation of 
medication.  
-Significant weight loss, especially in 
underweight depressed patients, has 
occurred.  Monitor weight loss particularly 
in elderly or nutritionally compromised 
patients. 
-Observe and report increased anxiety, 
nervousness or insomnia, modification of 
drug dose may be needed. Warn patients 
with a history of seizures to use appropriate 
safety precautions if taking this medication. 
• ADVERSE EFFECTS:  
Commonly observed: nervousness, 
insomnia, drowsiness confusion, and 
fatigue, anxiety, anorexia, nausea, dry 
mouth, diarrhea/loose stools, and excessive 
sweating.   
Other less common: palpitations, angina, 
postural hypotension, tachycardia, 
delusions, neck pain, bone pain, hyper-
ventilation, pneumonia, acne, alopecia, dry 
skin, urticaria, eye pain, mydriasis, 
abnormal ejaculation, amenorrhea, urinary 
incontinence/ retention/ urgency, anemia, 
hypoglycemia and hypothyroidism.  
• INTERACTIONS: 
Overview of Fluoxetine 
Drug-Drug Interaction 
Drug Interaction 
MAO 
Inhibitors 
Use is contraindicated.  If 
patient was placed on an 
SSRI serious, sometimes fatal 
reactions, may occur. 
TCAs, anti-
histamines 
and 
carbama-
zepine 
All enhance toxicity and side 
effects of SSRIs.  Do not use 
concurrently. 
Tryptrophan 
(L-trypto-
phan) 
May produce symptoms 
related to both central and 
peripheral toxicity. Do not 
use concurrently. 
 
• OVERDOSE: 
Symptoms: Nausea and vomiting are 
prominent, also agitation, restlessness, 
hypomania and other signs of CNS 
excitation. 
Treatment: There is no specific antidote. 
Activated charcoal with sorbitol may be as 
or more effective than emesis or lavage. 
Refer to emergency room for management. 
• BRANDS: 
Affectine (Taro), Flutine (Teva), Fluoxicare 
(Pharmacare), Prizma (Unipharm), Prozac 
(Dista/Eli Lilly). 
______________________ 
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B)  HYPNOTICS AND ANXIOLYTICS 
 
The primary use of drugs classified in this 
group is to encourage calmness (anxiolytics 
or sedative), or to produce sleep (sedative 
hypnotics). When symptoms become 
intolerable or interfere with the treatment of 
the underlying disease and counseling is 
not sufficiently effective, drug treatment 
can be considered as a means of helping 
patients. Specific cases such as phobias, 
panic disorder, obsessive-compulsive 
disorders (OCD) need further evaluation 
and specific drug regimens.   
Patients with insomnia should be 
counseled about non-pharmacological 
measures before starting a drug regimen, 
such as: 
• Avoidance of stimulants before retiring. 
• Maintenance of a proper diet. 
• Initiation of an exercise program. 
• Avoidance of stressful or anxiety 
provoking situations. 
• Maintaining a stable schedule; time of 
going to bed, avoiding mid-day naps. 
• Not eating heavy meals before going to 
bed. 
When evaluating a patient with a sleeping 
disorder, cases that need to be ruled out 
include: 
• Medication induced insomnia: use of 
sympathomimetics such as pseudoephedrine, 
or other medication like fluoxetine, or 
methylphenidate. 
• Substance abuse; alcohol, cocaine, 
amphetamines, and narcotics. 
• Medical conditions; sleep apnea, 
hyperthyroidism, gastroesophogeal reflux or 
CHF. 
Benzodiazepines are closest to the ideal 
hypnotics, and are the most commonly used 
group. Alternative drugs such as 
barbiturates (e.g. phenobarbitol) or 
meprobamate, have a high risk of abuse 
potential as well as producing a number of 
serious and potentially lethal interactions 
with other drugs. They are not 
recommended unless there is no other 
choice. They do not induce liver enzymes, 
and their effectiveness may be reduced by 
smoking tobacco. When used for insomnia, 
may cause early morning awakening and 
next day restlessness.  
The main differences within the family 
relate to potency and duration. Table-8.2 
gives some examples of available drugs and 
compares them.  
Diazepam and Lorazepam will be discussed 
as the prototypes of this group of drugs. 
Other drugs in this group include: 
Chlordiazepoxide, Clonazepam, Clorazepate, 
Halazepam, Prazepam, and Nitrazepam.  
 
Table – 8.2:  Some  Examples  of  Benzodiazepines 
Drug Potency Onset Duration Route of elimination 
Alprazolam High Fast Short Hepatic metabolism with some active 
metabolites 
Clobazam Low Moderate Short Hepatic metabolism with active metabolites 
Diazepam  Low Very Fast Intermediate Hepatic metabolism with active metabolites 
Lorazepam High Fast Short Hepatic metabolism with inactive 
metabolites 
Oxazepam Low Slow Short Hepatic metabolism with inactive 
metabolites 
Triazolam  Low Fast Short Hepatic metabolism with small amounts 
excreted unchanged in urine) 
 
 
 
Psychoactive Drugs 
 181
1)  Diazepam WHO,P                                           . 
 
• DRUG SUMMARY: 
Diazepam is a CNS agent, very fast acting 
benzodiazepine, anticonvulsant, anxiolytic-
hypnotic. It appears to act at both the limbic 
and subcortical levels of the CNS.   
• INDICATIONS: 
Used for management of anxiety disorders 
or for short-term relief of the symptoms of 
anxiety.  
Also used as adjunct for the relief of 
skeletal muscle spasms (muscle relaxant), 
and in status epilepticus and severe 
recurrent seizures. 
• CONTRAINDICATIONS: 
Hypersensitivity to benzodiazepines, 
psychoses, oral dose in children < 6 
months, acute narrow-angle glaucoma, 
respiratory depression, during or within 14 
days of a MAO inhibitor therapy. 
• DOSAGE FORMS: 
Tablets,  injection. 
• RECOMMENDED DOSAGE: 
Adult:  Dose should be individualized for 
each person, and be increased cautiously to 
avoid adverse effects. 
Recommended doses for anxiety disorders/ 
depending on severity: 2-10 mg PO b.i.d. to 
q.i.d. 
 
Elderly or presence of debilitating 
disease:  2-2.5 mg q.i.d. or b.i.d., increased 
gradually if needed and tolerated. 
Child: > 6 yrs. old;  1 - 2.5 mg PO b.i.d. or 
t.i.d.,  or  not to exceed 0.12-0.8 mg/kg/d 
given 3-4 times a day. 
In status epilepticus or severe convulsive 
seizures, diazepam is given initially 
intravenously, where facilities of 
resuscitations are not immediately 
available, with caution because of the risk 
of respiratory depression.  Small doses are 
given: Adults: 5-10 m initially, may be 
repeated at 10-15 min. to a max. of 30 mg 
if necessary. Therapy may be repeated in 2-
4 hrs.  Children > 5 yrs: 1 mg every 2-5 
minutes up to max. 10 mg. 
 
Directions: May be taken with food or 
water if stomach upset occurs. 
*Concomitant ingestion of diazepam with 
antacid may alter the rate of absorption. If 
antacid is to be taken it should be 1 h. 
before or 2 hrs. after diazepam. 
administration. 
*Durg should not be discontinued abruptly, 
this might cause withdrawal syndrome. If a 
dose is missed, it should be taken as soon 
as remembered, unless too close to next 
dose. The next dose should be taken only. 
Do not double the dose. 
*Maximum effect requires 1-2 weeks; 
patient tolerance to therapeutic effects may 
develop after 4 weeks. 
• USE IN SPECIAL CASES: 
Pregnancy- Risk-benefit issue (Category D). 
Benzodiazepines freely cross the placenta and 
accumulate in fetal circulation. If patient 
becomes pregnant during therapy, discuss 
possibility of discontinuing the drug. 
Neonatal withdrawal has been reported as 
well as prolonged CNS depression. 
Lactation- Avoid use during breast-feeding. 
Benzodiazepines are excreted in breast milk. 
Chronic diazepam use in nursing mothers 
reportedly caused infant to become lethargic 
and lose weight.  
Children- Oral dose is contraindicated in < 6 
months.  > 6 months: the initial dose should 
be small, increased gradually as tolerated. 
Hypotension is rare, however cardiac 
complications have been noted, use caution. 
Safety of injectable not established in 
neonates < 30 days of age. 
Renal + Liver Disease- Use with caution, 
decrease dose to avoid accumulation. The 
drug is metabolized in the liver to active 
metabolite, and excreted primarily in the 
urine. 
• PRECAUTIONS AND WARNINGS: 
-Caution in epilepsy, psychoses, mental 
depression, drug abuse, impaired hepatic or 
renal function, and addiction-prone 
individuals. Use extreme caution in elderly, 
and patient with chronic obstructive 
pulmonary disease (COPD). 
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-Long term use (> 4 months); effectiveness 
has not been assessed, need to periodically 
evaluate your patient. 
-Dependence and withdrawal: Prolonged 
use of therapeutic doses can be habit-
forming, tolerance or psychological and 
physical dependence may occur. 
Withdrawal syndrome has occurred after as 
little as 4-6 weeks of treatment.  Symptoms 
may appear 8-12 hours after the last dose; 
and can range from dysphoria to muscle 
twitch and sweating, to tremor and 
convulsions. When discontinuing the drug, 
especially for long-term therapy patients, 
decrease the dose gradually over 4-8 weeks. 
-Paradoxical reactions, i.e. excitement, 
aggression, stimulation of acute rage have 
occurred in psychiatric patients and 
hyperactive aggressive children. 
• ADVERSE EFFECTS: 
Drowsiness, sedation, confusion, dizziness, 
vertigo, headache (warn patient not to 
perform hazardous activity like driving or 
operating machinery until full effect of the 
drug is known). Benzodiazepines can cause 
vivid nightmare or sleep terrors. Also, 
hypotension, blurred vision, diplopia, 
constipation, dry mouth, nausea, menstrual 
irregularities, tachycardia, and edema are 
possible. 
• INTERACTIONS: 
Overview of  
Drug-Drug Interaction 
Elimination of benzodiazepines may be 
decreased by the following drugs due to the 
inhibition of hepatic metabolism, need to use 
caution: 
-Cimetidine         -Oral Contraceptives 
-Isoniazid         -Fluoxetine 
-Ketoconazole         -Metoprolol 
-Propoxyphene            -Valproic acid 
Drug Interaction 
Alcohol & 
anti-
depressants 
(barbiturate, 
narcotics) 
Increase CNS depression. 
Avoid alcohol use with this 
medication. 
 
Oral 
contraceptive
May result in prolongation of 
benzodiazepines t1/2; a 
reduction in benzodiazepine 
may be needed. 
Digoxin Digoxin serum concentration 
may increase, need to monitor 
digoxin levels. 
Ranitidine May reduce GI absorption of 
diazepines, do not use 
concomitantly. 
 
• OVERDOSE: 
Symptoms: mild; including drowsiness, 
confusion, impaired co-ordination, 
diminished reflexes and lethargy.  Serious; 
include ataxia, hypotonia, hypotension, 
hypnosis, coma, and rarely death. 
Treatment: Induce vomiting if it has not 
occurred. Refer to hospital as soon as 
possible. Ipecac and gastric lavage are 
needed with the general supportive 
measures. 
• BRANDS: 
Assival (Teva), Disopam (Dexxon), Harmonal 
(JCL), Serepam (Birzeit), Valium (Roche). 
_____________________ 
 
2)  Lorazepam 
 
• DRUG SUMMARY: 
Lorazepam is an intermediate-acting 
benzodiazepine, anxiolytic and sedative-
hypnotic.  
• INDICATIONS: 
Labeled use: management of anxiety 
disorders and short-term use to relief 
symptoms of anxiety associated with 
depressive symptoms. Preanesthetic 
medication, to reduce anxiety and recall of 
events related to day of surgery. 
Other uses: antiepileptic, chemotherapy-
induced nausea and vomiting, chronic 
insomnia, alcohol withdrawal.  
• CONTRAINDICATIONS: 
Hypersensitivity to benzodiazepines, 
psychoses, acute narrow-angle glaucoma, 
during or within 14 days of a MAOI 
therapy, PO use for children <12 years, and 
in shock and coma cases. 
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• DOSAGE FORMS: 
Tablets,  injection. 
• RECOMMENDED DOSAGE: 
Adult:  Antianxiety: 
2-6 mg/day PO in divided doses, take largest 
dose at bedtime;  max. 10 mg/day. 
 Insomnia: 
2-4 mg PO at bedtime. 
Child:  Use is not recommended. 
 
Directions: May take with food or water if 
GI upset occurs. 
*Do not increase dose without consulting 
doctor. If need to increase dosage, increase 
the nighttime dose before the daytime. 
*If patient can sleep without this 
medication, discuss discontinuing the drug. 
Do not stop taking the medication abruptly, 
taper off over a few weeks if patient has 
been using it for prolonged therapy. 
*Advise your patients to avoid large 
volume intake of coffee. Anxiolytic effects 
of lorazepam can be altered even by 500 
mg caffeine (1 cup = 125-250 mg). 
• USE IN SPECIAL CASES:  
Pregnancy- Risk benefit issue (Category D). 
Benzodiazepines freely cross the placenta and 
accumulate in fetal circulation. If patient 
becomes pregnant during therapy, discuss 
possibility of discontinuing the drug. 
Neonatal withdrawal has been reported as 
well as prolonged CNS depression. 
Lactation- Use is not recommended. It is not 
known whether it is excreted in breast milk as 
with other benzodiazepines. 
Children- < 18 yrs. old do not use injection, 
Safety and efficacy for use in < 12 yrs. orally 
has not been established. 
Renal + Liver Disease- Use with caution. The 
drug is not metabolized to active metabolites, 
it is safer to use than other benzodiazepines in 
patient with mild liver disease. It is excreted 
in the urine. 
• PRECAUTIONS AND WARNINGS: 
Same as diazepam. 
• ADVERSE EFFECTS: 
Same as diazepam. 
• INTERACTIONS: 
Same as diazepam. 
Smoking and caffeine decrease sedative 
and antianxiety effects. 
• OVERDOSE: 
Same as diazepam. 
• BRANDS: 
Ativan (Wyeth-Ayerst), Lorivan (Dexxon), 
Lorocare (Pharmacare). 
____________________________ 
 
C)  NEUROLEPTICS 
 
Antipsychotic drugs are also known as 
neuroleptics and as major tranquilizers. 
They generally tranquilize without 
impairing consciousness and without 
causing paradoxical excitement, but they 
should not be regarded merely as 
tranquilizers. They can be used for short 
term to calm down disturbed patients 
whatever the underlying psychopathology, 
which may be brain damage, mania, toxic 
delirium, agitation, depression, or anxiety. 
Specialists, according to certain criteria, 
diagnose psychotic conditions. Symptoms 
must be present for 6 months or more for 
the diagnosis to be made. Anti-psychotic 
drugs relieve Ford-psychotic symptoms, 
and prevent relapse. 
Extrapyramidal symptoms are the most 
troublesome side effects of antipsychotic 
agents. They depend partly on the dose, 
partly on the type of drugs, and on the 
patients susceptibility.  They consist of: 
• Parkinsonian symptoms (including 
rigidity and tremor), which may occur 
gradually and are reversible. 
• Dystonia (abnormal spasms of the face, 
tongue, and body movement) which may 
appear after only a few doses. 
• Akathisia (restlessness) may resemble 
an exacerbation of the condition being 
treated. 
• Tardive Dyskinesia: involuntary oral-
facial movements, choreiform movement of 
the extremities, which is the most serious. 
Medication should be discontinued if such 
symptoms occur. 
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Table-8.3 lists examples of available 
antipsychotic drugs. In this section 
chlorpromazine and haloperidol will be 
discussed as the main drugs used. 
 
Table- 8.3:  Available Antipsychotic Drugs 
 Phenothiazines- Aliphatic Thioxanthenes 
   Chlorpromazine   Chlorprothixene 
   Promazine   Thiothixene 
   Triuoperazine Butyrophenone 
 Phenothiazines- Piperidines   Haloperidol 
   Thioridazine Dihydroindolone 
   Mesoridazine   Molindone 
 Phenothiazines- Piperazines Dibenzodiazepine
   Acetophenazine   Clozapine 
   Perphenazine Benzisoxazole 
   Prochlorperazine   Resperidone 
   Fluphenazine Benzamide 
   Trifluoperazine   Sulpiride 
 
 
1)  Chlorpromazine WHO,P 
 
• DRUG SUMMARY:  
Chlorpromazine (CPZ) is a CNS agent, 
antipsychotic (neuroleptic/tranquilizer) 
agent, belonging to the aliphatic pheno-
thiazine derivatives. Mechanism of action 
is not clearly understood, but is believed to 
be due to the blocking of dopamine 
receptors within the CNS. 
• INDICATIONS: 
To control the manic phase of manic-
depressive illness, for symptomatic 
management of psychotic disorders 
including schizophrenia. Also indicated for 
the control of nausea and vomiting, and 
relief of intractable hiccups. 
• CONTRAINDICATIONS: 
Do not use CPZ in comatose or severely 
depressed states. Hypersensitivity, cross 
sensitivity between phenothiazines may 
occur. Bone marrow depression, blood 
dyscrasias, liver damage, withdrawal from 
alcohol, severe hypotension or hyper-
tension, and closed-angle glaucoma. 
• DOSAGE FORMS: 
Tablets, injection. 
• RECOMMENDED DOSAGE: 
Adult: Psychotic disorders, agitation; 
PO:  25-100 mg t.i.d. or q.i.d., 
Usual dose 75-300 mg/day, but may need 
up to 1000 mg/day for psychosis. 
IV/IM:  25-50 mg up to 600 mg q. 4-6 h. 
Nausea and vomiting, intractable 
hiccups; 
PO:  25-50 mg t.i.d. or q.i.d.  prn. 
Elderly or debilitated need third to half 
adult dose. 
Child ( > 6 mon.): 
Psychotic disorders, agitation; 
PO: 0.5 mg/kg q. 4-6 h. prn., up to 500 
mg/day. 
IV:  0.5 mg/kg q. 6-8 h. prn. 
Nausea and vomiting; 
PO:  0.5 mg/kg q. 4-6 h. 
IV/IM: 0.5 mg/kg q. 6-8 h. prn., up to 40 
mg/day. 
 
Directions: Chlorpromazine should be 
taken with food or a full glass of water or 
milk (240 ml), to reduce possibility of 
gastric irritation. 
*Some patients may fail to experience 
improvement until 7-8 weeks into therapy, 
therefore may not be compliant. Stress 
necessity of keeping appointments for 
follow up, and maintaining dose regimens. 
Do not increase dose more than once 
weekly if needed, the drug needs 4-7 days 
to reach steady state levels.  
*When deciding to discontinue medication 
after prolonged therapy, taper off dose over 
several weeks to avoid onset of 
extrapyramidal symptoms.  
*CPZ may cause urine discoloration, 
caution patient. 
*Avoid prolonged exposure to sunlight or 
use sunscreens, since photosensitivity 
reactions may occur, as well as increased 
susceptibility to heat stroke. 
*Need to discontinue medication if any of 
the following occur:  sore throat, fever, skin 
rashes, tremor, impaired vision or jaundice. 
*Smoking increases metabolism of 
phenothiazines resulting in more rapid 
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clearance of the drug. Higher dosage in 
smokers may be required.  Advise patient 
to stop or at least reduce smoking if 
possible. 
• USE IN SPECIAL CASES:  
Pregnancy- Use CPZ only when potential 
benefits outweigh potential hazards to the 
fetus (Category C). Safety for use during 
pregnancy has not been established. 
Lactation- CPZ has been detected in breast 
milk.  Safety for use in nursing mothers has 
not been established. Infant should be 
observed for sedation. 
Children- In general phenothiazines are not 
recommend for children < 6 months of age 
except when potentially lifesaving. 
Renal Disease- Administer cautiously to those 
with diminished renal function.  Monitor 
renal function in long term therapy, lower 
dose or discontinue if BUN becomes 
abnormal. 
Liver Disease- Use with caution. The drug is 
metabolized in the liver. 
• PRECAUTIONS AND WARNINGS: 
-Neuroleptic malignant syndrome (NMS) 
reportedly occurs more frequently than 
recognized (more in men).  It is potentially 
fatal, but can be reversible if recognized 
and treated early. It resembles severe form 
of parkinsonian muscle rigidity, autonomic 
instability, hyperthermia, labile blood 
pressure, diaphoresis and altered mental 
status that could progress to coma, acute 
respiratory or renal failure or 
cardiovascular collapse. Symptoms of NMS 
can appear suddenly after initiation of 
therapy or after months of taking 
neuroleptic medication. To treat, one needs 
to stop the drug immediately and give 
intensive symptomatic and supportive care. 
-Tardative dyskinesia, a syndrome 
consisting of potentially irreversible, 
involuntary movements.  Prevalence 
appears highest among the elderly, 
especially women.  Risk is increased as the 
duration of treatment and the total 
cumulative dose of the drug administered 
increase. Due to this fact, always prescribe 
neuroleptics in a way to minimize 
occurrence of NMS. In patients who require 
chronic treatment, use the smallest-
effective dose and the shortest duration of 
treatment producing satisfactory clinical 
response. Periodically re-evaluate the need 
for continued treatment. If signs and 
symptoms appear, consider drug 
discontinuation. 
-Various blood dyscrasias have occurred.  
If sore throat or other signs of infection 
occur, or if white cell and differential count 
indicate cellular depression, stop treatment 
and institute an antibiotic and other suitable 
therapy. 
-Use caution in patients with cardiovascular 
disease, worsening of angina patients has 
been noted, pulse rate has increased, 
hypotensive phenomena with patients 
receiving antipsychotics all have been 
noted.   
-Abrupt withdrawal of the drug or 
deliberate dose skipping, especially after 
prolonged therapy with large doses can 
cause onset of extrapyramidal symptoms, 
and severe GI disturbances.  Taper the dose 
when deciding to discontinue.  
-Diabetic or prediabetic patients should be 
monitored for reduced glucose tolerance 
and loss of diabetes control.  Warn these 
patients. 
• ADVERSE EFFECTS:  
Extra-pyramidal effects are the most 
troublesome and unpredictable, i.e. 
dystonia, akathisia and tardative dyskinesia, 
in phenothiazine therapy (refer to 
introduction of neuroleptics).  
Other effects include dry mouth, 
constipation, nasal congestion, drowsiness 
(caution patient against performing 
hazardous activities like driving or 
operating machines until full response to 
the drug is known), disturbances in 
temperature control and endocrine function 
(monitor diabetic and thyroid patients and 
adjust dosing regimens), lower convulsion 
threshold (might need to increase 
anticonvulsant dose and do not administer at 
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the same time), postural hypotension- 
especially after parenteral therapy, 
cholestatic jaundice, photo-sensitization 
(avoid over exposure to sun or sunlamp), 
blood dyscrasis, and skin reaction. Perform 
CBC, liver function tests, urinalysis, and 
EEG periodically during prolonged therapy. 
• INTERACTIONS: 
Overview of Chlorpromazine 
Drug-Drug Interaction 
Drug Interaction 
Alcohol Co-administration may 
result in additive CNS 
depression, as well as 
increased occurrence of 
extra pyramidal reactions, 
alcoholic drinks or drugs 
containing alcohol should 
not be coadministered; while 
taking this medication. 
Antacids and 
anti-
diarrheals 
Decrease absorption, space 
administration 2 hrs before 
or after administration of 
CPZ. 
Anti-
histamines; 
(astemizole & 
 terfenadine) 
and anti-
malarials 
Concomitant use with these 
drugs may increase risk of 
ventricular arrhythmia. 
Anti-
depressants 
TCAs and SSRIs increased 
plasma concentrations of 
them, or of the 
phenothiazine, increasing 
side effects. Avoid 
concomitant use. 
Epinephrine 
and norepi-
nephrine 
Effects of these may be 
antagonized by CPZ. Do not 
coadminister these drugs. 
Warn patients from OTC 
use. 
Propranolol Co-administration results in 
increased plasma levels of 
both drugs, leading to hypo-
tension. Use extreme 
caution. 
 
• OVERDOSE: 
Symptoms primarily include CNS 
depression to the point of somnolence, deep 
sleep to coma. Hypotenison and 
extrapyramidal symptoms may occur, as 
well as agitation, convulsions, fever, 
hypothermia, hyperthermia, and cardiac 
arrhythmias.   
Treatment includes supportive measures. 
Emetics are unlikely to be of value, take to 
emergency room. 
• BRANDS: 
Largactil (Rhone-Poulenc Rorer), Taroctyl 
(Taro), Thorazine (SKF). 
________________________ 
 
2)  Haloperidol WHO,P 
 
• DRUG SUMMARY: 
A CNS agent, a potent, long acting 
butyrophenone derivative, with anti-
psychotic (tranquilizer) effects. Haloperidol 
is pharmacologically similar to those of 
piperazine phenothiazines but with 
somewhat higher incidence of extra-
pyramidal effects, and less hypotensive and 
relatively low sedative activity. Exerts 
strong antiemetic effects and impairs 
central thermoregulation. Produces weak 
central anticholinergic effects and transient 
orthostatic hypotension. Action thought to 
be related to competitive blockade of post-
synaptic dopamine receptors in the brain. 
• INDICATIONS: 
Psychotic disorder management. Tourette’s 
disorder, severe behavioral problems in 
children with combative, explosive hyper-
excitability, also in hyperactive children 
(short-term treatment) who show excessive 
motor activity with combative, impulsive 
mood or aggression. For patients with 
chronic schizophrenia requiring prolonged 
parenteral neuroleptic therapy. It can also 
be used as an antiemetic in small doses. 
• CONTRAINDICATIONS: 
Parkinson’s disease, seizure disorders, 
coma, alcoholism, severe mental 
depression, thyrotoxicosis and hyper-
sensitivity. 
• DOSAGE FORMS: 
Tablets, injection. 
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• RECOMMENDED DOSAGE: 
Adult:  Psychosis; 
PO: 0.2-5 mg b.i.d. or t.i.d. 
IM: 2-5 mg q. 4-8 h. prn. 
Severe Psychosis; 
PO: 3-5 mg b.i.d. or t.i.d., may need up to 
max. 100 mg/day. 
IM: 2-5 mg, may repeat q.h. prn.  (Also for 
severe vomiting).  
Child (3-12 y. or weight 15-40 kg): 
Psychosis: 
PO: initially 0.5 mg/day (25-50 mcg/kg/d) 
divided to b.i.d. or t.i.d., may increase by 
increments of 0.5 each 5-7 days, until up to 
0.15 mcg/kg/d or therapeutic effect is 
obtained,  (max. of 10 mg/d). 
(Do not give IM) 
Behavioral Disorders, Agitation/ 
Hyperkinesia; 
PO only: 0.03-0.075 mg/kg/d, severe cases 
may require more, use only for short-term 
administration. 
 
Directions: Individualize dosage.  
*Debilitated or geriatric patients, and those 
with a history of adverse reactions to 
neurolepics, require less haloperidol. 
*Tablets may be taken with a full glass of 
water or with food or milk.   
*Injection should be administered by deep 
IM injection into the gluteus. Do not 
exceed 3 ml per injection site. 
*Dosing regimen should be tapered when 
therapy is to be discontinued. Abrupt 
termination of treatment can initiate 
extrapyramidal symptoms. 
*Advise patient not to drive a car or engage 
in other activities requiring mental alertness 
and physical co-ordination until drug 
response is known. 
*Because of long half-life of haloperidol, 
therapeutic effects are slow to develop in 
early therapy.  4-7 days are required to 
reach steady state levels, therefore do not 
make more than weekly dosage adjustments 
in chronic therapy. Re-evaluate every 6 
weeks. 
• USE IN SPECIAL CASES:  
Pregnancy- Same as chlorpromazine, 
(Category C). 
Lactation- Haloperidol is excreted in breast 
milk, but safety in nursing mothers has not 
been established. Adverse effects in the 
infants have not been reported. 
Children- Not used for children < 3 yrs. old. 
Renal Disease- Use caution, 40% of the drug 
is excreted in urine within 5 days. 
Liver Disease- Use caution, the drug is 
metabolized in the liver. 
• PRECAUTIONS AND WARNINGS:   
Same as chlorpromazine. 
• ADVERSE EFFECTS: 
Same as chlorpromazine, but with less 
sedation and fewer antimuscarinic 
symptoms. 
• INTERACTIONS and OVERDOSE: 
Same as chlorpromazine. 
• BRANDS: 
Haldol (McNeil-CPC), Halidol (Abic), Haloper 
(CTI), Peridol (Eastern Chem.), Peridor 
(Unipharm). 
 
 
____________________________ 
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Anticonvulsant / Antiepileptic Drugs:  
SEIZURES  
 
The terms seizures and convulsion maybe 
used interchangeable with epilepsy. A 
seizure (convulsion) is defined as a 
paroxysmal involuntary disturbance of 
brain function that maybe manifested as an 
impairment or loss of consciousness, 
abnormal motor activity, behavioral 
abnormalities, sensory disturbances, or 
autonomic dysfunction. Epilepsy is the 
condition of having chronic recurrent 
seizures. A seizure originates in unstable 
cell membranes, or its surrounding 
supporting cells. This causes a small 
number of cells to fire spontaneously. 
When this activity transmits to adjoining 
areas, a seizure occurs. Seizures are nearly 
always correlated with abnormal and 
excessive discharges in the brain. This can 
be detected and recorded on an electro-
encephalogram (EEG). 
When evaluating a patient, one should 
attempt to define factors that have resulted 
in the convulsion and to provide a detailed 
description of the seizure, so as to classify 
its type. The first step in the management 
of epilepsy is to confirm that the patient 
has a seizure disorder, and not a condition 
that mimics it. Then we need to identify 
what are the causes to remedy them. 
Antiepileptic drugs either prevent the 
spontaneous firing or inhibit the 
propagation of abnormal firing. 
Recent studies have shown that up to 70% 
of newly diagnosed children and adults can 
be successfully treated (complete control of 
seizure for several years) with anti-epileptic 
drugs. After 2-5 years of successful 
treatment drugs can be withdrawn in about 
70% of children and 60% of adults without 
relapse (WHO. 1997). Up to 30% of 
patients may not respond to drug therapy. 
The object of treatment in epilepsy is to 
prevent the occurrence of seizures by 
maintaining an effective plasma 
concentration of the medication. Careful 
adjustment of doses is necessary. Always 
start with low doses and increase gradually 
until seizures are controlled, or there are 
over-dose effects.  Dosage increase should 
not occur until there has been enough time 
for steady state concentration. Patients 
should be warned that activities requiring 
alertness could be affected.  Alcohol and 
other CNS depressants may aggravate 
these effects and should be avoided. 
Therapy with several antiepileptic drugs 
concurrently (polypharmacy) should be 
generally avoided. Patients are best 
controlled with a single antiepileptic.  The 
most appropriate choice of drug depends of 
the type of epilepsy. Table-8.4 summarizes 
the recommended agents for certain cases. 
Combination drug regimen should be 
added only if seizures continue despite 
high plasma concentration or toxic effects. 
Abrupt withdrawal of antiepileptics should 
be avoided since this may precipitate 
severe rebound seizures. Reduce dose in 
stages, even if it may take months.  
Changing from one drug regimen to 
another should be made cautiously.   
In recent years, several new anti-
epileptic agents have reached the market to 
treat very specific conditions as 
monotherapy or combination. Such drugs 
include lamotrigine, gabapentin, vigabatrin, 
oxcarbazepine and zonisamide. Due to the 
high cost and insufficient post-marketing 
data about these agents, they will not be 
discussed at this time. 
[Advise patient to carry medical 
identification card or jewellery bearing 
information about the diagnosis or 
medications in use, in case of emergency.] 
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Table – 8.4:  Summary for Use of Antiseizure Medication (monotherapy) 
Seizure Type Primary Agent Secondary Agent 
Partial seizures Carbamazepine (#1) 
Clobazam 
Phenytoin, Valproic acid 
Phenobarbital 
Tonic-clonic 
(Grand mal) 
Carbamazepine (#1) 
Phenytoin, or Valproic Acid 
Primidone/Phenobarbital 
Clobazam 
Absence seizures 
(Petit mal) 
Ethosuximide (#1) 
Valproic acid 
Clonazepam,  
Lamotrigine 
Myoclonic, Atonic Valproic acid 
Clobazam 
Phenytoin 
Clonazepam 
Lamotrigine 
Status Epilepticus 
(Initial therapy) 
Diazepam IV Lorazepam IV 
 
 #1:  First choice for treatment. 
Reference: Seear M, editor. The pocket pediatrician (low price edition). Cambridge: 
Cambridge University Press, 1997; p. 356. 
 
 
 
Pregnancy and lactation: There is an 
increased risk of birth defects with the use 
of anticonvulsants.  In view of the risk of 
neural tube and other defects, patients who 
may become pregnant should be informed 
of the risk and referred for advice.  
Pregnant patients should be offered 
counseling and antenatal screening. 
Nevertheless, the advantage of using proper 
antiepileptic drugs during pregnancy 
outweighs the disadvantage.  
Antiepileptic therapy may become less 
effective in pregnancy because the drugs 
are cleared from the body. Hence, doses 
may have to be increased in some drugs.  
To counteract the risk of neural tube 
defects, adequate folate supplements are 
advised for women before and during 
pregnancy.  In view of the risk of neonatal 
bleeding with carbamazepine, phenol-
barbital and phenytoins, prophylactic 
vitamin k1 (phytomenadione) is 
recommended for the neonate and the 
mother before delivery.  Antiepileptic drugs 
can be used safely during lactation, with the 
exception of phenobarbital and 
ethosuximide. 
Table-8.5 gives a summary of the 
available agents and compares their 
pharmacokinetic characteristics. 
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Table-8.5:  Summary of Antiepileptic Drugs and Their Characteristics 
Drug CBZ CLZ ESX PHNOB PHNY VALP 
Character inostilbene benzo-diazepine succinimide barbiturate hydantoin 
nahlanot 
related to 
any 
Half-life 
(hrs.) 15 - 20 20 - 60 ∼ 60 50 - 120 8 - 60 8 - 12 
Therapeutic 
blood level 
(mcg/ml) 
4 - 12 20-70 mg/ml 40 - 100 15 - 40 10 - 20 50 - 100 
Time (hr) to 
steady-state 2 - 4 5 - 10 10 - 15 14 - 28 5 - 10 2 - 4 
Pregnancy Cat. C Cat. D Cat. C Cat. D Cat. D Cat. D 
Lactation excreted, caution 
excreted, 
avoid 
excreted, 
avoid 
excreted, 
avoid 
excreted, 
caution 
excreted, 
caution 
Children* NE  < 6 y NE, caution NE, < 3 y caution all safe no < 2 y 
Renal 
Disease caution 
warning, 
avoid caution 
contra-
indicated caution 
caution, 
avoid 
Hepatic 
Disease caution 
caution, 
warn in 
severe 
cases 
caution caution, avoid caution avoid 
 
 * Safety and efficacy; NE: not established. 
 - CBZ: carbamazepine, CLZ: clonazepam, ESX: ethosuximide, PHNOB: phenobarbital, PHNY: 
phenytoin, VALP: valproic acid. 
 - Refer to the individual monographs for more detail.
 
 
1)  Carbamazepine  WHO,P 
 
• DRUG SUMMARY:   
Carbamazepine (CBZ) is an inostilbene 
derivative related to the Tricyclic 
Antidepressants (TCAs). Its mechanism of 
action is not clearly known. CBZ has a 
wider therapeutic index than phenytoin. 
The relationship between dose and plasma 
concentration is linear, but monitoring 
plasma concentration is important in 
determining optimum dosage.  
• INDICATIONS:   
CBZ is used as first line treatment in 
simple and complex partial (temporal lobe) 
seizures, generalized tonic-clonic (Grand 
mal). It can be used for most types of 
epilepsy except absence seizures.  
Other cases that CBZ is used for (even 
though there is no specific indication) 
include: psychiatric disorders, including 
prophylaxis for manic-depressive illness, 
trigeminal neuralgia pain, resistant 
schizophrenia, dyscontrol symptoms, and 
management of alcohol withdrawal. 
• CONTRAINDICATIONS:  
Hypersensitivity to CBZ or to TCAs.  
Patient with atrioventricular conduction 
abnormalities (unless paced). Patient on 
MAOI regimens or within 2 weeks of 
MAOI therapy. 
• DOSAGE FORMS: 
Tablets, suspension. 
• RECOMMENDED DOSAGE: 
Adult:  100-200 mg PO b.i.d. increased by 
200 or 400 every 2 to 3 days.  
In frail or elderly patients: 50 mg PO b.i.d. 
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Maintenance usual dose; 800 - 1200 mg/d 
in divided doses;  max. 1600 mg/d. 
Child:  < 6 yrs.: initially 10-20 mg/kg/d, 
given b.i.d or t.i.d (suspension q.i.d), then 
increased at 5-7 day intervals; maintenance 
dose not to exceed 35 mg/kg/d. 
6-12 yrs.: 100 mg PO b.i.d. (50 mg 4 times 
daily of suspension). gradually increased at 
increments of 20%, not to exceed 1000 
mg/d (maybe calculated on basis of 20-30 
mg/kg/d in 3 or 4 divided doses/day). 
 
Directions: Start dosing low then increase 
over 1-2 wks, until clinical benefit.   
*Time to reach steady state for the drug: 2-
4 days. 
*Therapeutic blood level:  4-12 mcg/ml.   
*CBZ suspension will produce higher peak 
levels than the same dose given as the 
tablet, therefore start with low doses (i.e. 
Child 6-12 years ½ tsp q.i.d.), then increase 
slowly. 
*Shake suspension well before use, and do 
not administer it with other liquid 
medicinal agents or diluents.  
*Administer with food. 
*Regular patient visits should be scheduled 
to check progress, and perform lab tests. 
*When adding CBZ to existing anti-
convulsant therapy, gradually do so, 
monitoring the other drug that may be 
gradually decreased (phenytoin increased). 
• USE IN SPECIAL CASES: 
Pregnancy- Use only when potential benefit 
outweighs the risk of teratogenesis/ 
congenital malformation potential including 
Spina Bifida, Category C. 
Lactation- Use with caution. CBZ is excreted 
in breast milk. Because of potential serious 
side effects, decide whether to discontinue 
nursing or to discontinue drug taking into 
account the importance of drug to mother.  
Children- Safety and efficacy are not 
established for children < 6 years old. 
Renal Disease- Use with caution, the drug is 
eliminated in urine and feces. Prescribe CBZ 
if benefit outweighs risk of use. 
Liver Disease- Use with caution, since CBZ 
is metabolized in liver to active metabolites, 
and can induce liver microsomal enzymes. 
• PRECAUTIONS AND WARNINGS: 
-Use caution in patients with bone marrow 
depression, hypertension, history of hepatic 
or cardiac disease.  
-Patients on oral contraceptives should be 
informed that CBZ may cause break 
through bleeding and may affect the 
reliability of oral contraceptive. Use 
alternative contraceptive methods. 
• ADVERSE EFFECTS: 
GI disturbances, dizziness, drowsiness, 
visual disturbances (especially double vision 
associated with peak plasma concentration), 
constipation, anorexia, cholestatic jaundice 
are common side effects, most should 
decrease within few days of therapy. Other 
effects that may occur include acute renal 
failure, agranulocytosis, aplastic anemia, 
thrombocytopenia, hypothyroidism, and 
other blood disorders. 
Patients should be monitored every 6 
months. 
• INTERACTIONS: 
Overview of Carbamazepine 
Drug-Drug Interaction 
Drug Interaction 
Anti- 
Epiletpics 
CBZ may increase level of 
lithium, and markedly 
decrease the levels of other 
antiepiletpics.  
CBZ and phenytoin may 
mutually enhance one 
another’s metabolism. 
Erythromycin
or  
Isoniazid  
May increase the effects of 
CBZ. Avoid combination if 
possible; otherwise monitor 
serum CBZ concentration to 
avoid toxicity. 
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Barbiturates (i.e. phenobarbital, primidone) 
are liver enzyme inducers 
thus when CBZ is given 
concurrently, CBZ levels are 
decreased due to increased 
metabolism thus increased 
rate of clearance. No loss of 
seizure control has been 
reported, but avoid 
concomitant use of 
barbiturates unless clearly 
indicated, and the patient’s 
CZB blood levels and thera-
peutic efficacy should be 
observed very closely then. 
Oral anti-
coagulants 
and 
theophylline 
CBZ may decrease the 
effects of oral anticoagulants 
and theophylline, use with 
caution. 
 
• OVERDOSE: 
Symptoms and signs first appear after 1-3 
hours.  Neuromuscular disturbances are the 
most prominent symptoms. Cardiovascular 
disorders are generally mild, unless very 
high doses (> 60 g) have been ingested. 
Other symptoms include: irregular 
breathing, respiratory depression, hypo-
tension, nausea, vomiting, and urinary 
retention.   
Treatment: There is no specific antidote. 
Need to irrigate the stomach repeatedly 
even if more than 4 hours have passed 
following ingestion. Charcoal adminis-
tration is effective in enhancing the 
elimination; 50-100 g can be given initially 
followed by 25 g q. 4 h. 
• BRANDS: 
Carbi (Alphapharm/Genmedix), Tegrepine 
(JePharm), Tegretol (Ciba-Geigy), Teril (Taro). 
_________________________ 
 
2)  Clonazepam WHO,P 
 
• DRUG SUMMARY: 
Clonazepam is a CNS drug, 
benzodiazepine derivative with strong 
anticonvulsant activity and several other 
pharmacological properties characteristic of 
the drug class.  It suppresses spike and 
wave discharge in absence seizures, and 
decreases amplitude, frequency, duration, 
and spread of discharge in minor motor 
seizures.  Its sedative side-effects may be 
prominent. 
• INDICATIONS:   
Indicated for use alone or with other drugs 
in absence seizures, myoclonic and akinetic 
seizures, and Lennox-Gastaut syndrome. 
Also in absence seizures not responding to 
succinimides or valproic acid, infantile 
spasms and restless legs. 
• CONTRAINDICATIONS:   
Hypersensitivity to benzodiazepines, 
respiratory depression, porphyria, acute 
narrow-angle glaucoma, and breast-feeding. 
• DOSAGE FORMS: 
Tablets, drops. 
• RECOMMENDED DOSAGE: 
Adult: 1.5 mg/d PO in 3 divided doses, 
increased by 0.5-1 mg every 3 days, until 
seizures are controlled or until intolerable 
side effects, max. 20 mg/d.   
Child:  (up to 10 y or 30 kg) 
0.01-0.03 mg/kg/d (not to exceed 0.05 
mg/kg/d) in 3 divided doses, may be 
increased to 0.25-0.5 mg/kg every 3 days; 
max. 0.2 mg/kg/d or 3 mg daily. 
 
Directions: This drug needs 5-10 days to 
reach steady state concentrations.   
*Therapeutic blood level ranges from 20-
70 ng/ml. 
*If doses cannot be equally divided, the 
largest dose should be given at bedtime. 
*May take with food or water if stomach 
upset occurs.  
*Up to 30% of patients have shown a loss 
of anticonvulsant activity within 3 months 
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of administration. Dosage adjustment might 
be needed. 
*Patient should be advised not to stop 
taking medication abruptly, and if missed a 
dose can take it as soon as remembered, or 
if too close to next dose, just take then. The 
dose should not be doubled (2 tablets taken 
at the same time). 
• USE IN SPECIAL CASES: 
Pregnancy- Use only if benefit of treatment 
outweighs risk to fetus (Category D). Benzo-
diazepines and their metabolites cross the 
placenta freely and can accumulate in the 
fetal circulation, causing malformation, 
neonatal drowsiness and withdrawal 
symptoms. 
Lactation- Contraindicated use; lethargy and 
weight loss may occur in infant. Benzo-
diazepines are excreted in breast milk and can 
accumulate in circulation, since neonate 
cannot metabolize the drug. 
Children- Use with caution, since long term 
use on growth and development is unknown. 
Use smaller doses if have to use. 
Renal Disease- Warning, in case of presence 
of severe impaired renal function. The drug is 
excreted primarily in urine, with half-life of 
18-40 hrs. 
Liver Disease- Use with caution, drug is 
metabolized in the liver. Use smaller doses. 
Warning in severe cases; can precipitate 
coma. 
• PRECAUTIONS AND WARNINGS: 
-Use caution in renal disease, COPD, drug 
controlled open-angle glaucoma, children 
(because of unknown consequences of 
long-term use on growth and development), 
and mixed seizure disorders. 
-Prolonged use of therapeutic doses can 
lead to dependence. 
-Withdrawal syndrome has occurred after 
as little as 4-6 weeks of treatment. Do not 
discontinue drug abruptly, decrease 
gradually over 4-8 weeks if patient has 
been on medication for prolonged time.  
Withdrawal symptoms include:  
convulsions, tremor, abdominal and muscle 
cramps, vomiting and sweating. 
• ADVERSE EFFECTS:   
Most common: drowsiness, sedation and 
dizziness; (advise patient not to drive or 
engage in activities requiring mental 
alertness and physical co-ordination until 
the drug reaction is fully known), ataxia, 
behavioral changes, hyperactivity, 
irritability, aggressiveness, violent 
behavior, disobedience, bronchial 
hypersecretion, rash and thrombocytopenia. 
• INTERACTIONS: 
Overview of Clonazepam  
Drug-Drug Interaction 
Drug Interaction 
Alcohol and 
Other CNS 
depressants 
Concomitant use of these with 
clonazepam will increase 
sedation and CNS depression. 
Antacids Use of antacids may alter the 
rate of absorption, do not use 
concomitantly, space ad-
ministration time if needed. 
Anti-
epileptics 
Use with other antiepileptics 
accelerates metabolism of 
clonazepam, reduce its effect, 
phenytoin levels may 
increase. Monitor blood levels. 
Antihyper-
tensives 
Concomitant use enhance 
hypotensive effect, use with 
caution. 
Opioid 
analgesics,  
& muscle 
relaxants 
(baclofen) 
These enhance sedative 
effects. Use with caution. 
 
• OVERDOSE:   
Symptoms: drowsiness, confusion, 
somnolence, impaired co-ordination, 
diminished reflexes and lethargy. Severe 
cases cause serious symptoms like 
hypotonia, hypotension, hypnosis, coma 
but rarely death.   
Treatment: induce vomiting if it has not 
occurred spontaneously, employ general 
supportive measures, along with immediate 
gastric lavage or ipecac, follow with 
activated charcoal administration and a 
saline cathartic. 
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• BRANDS: 
Clonex (Teva), Klonopin/ Rivotril (Roche). 
_____________________ 
 
3)  Ethosuximide WHO,P 
 
• DRUG SUMMARY: 
Ethosuximide is a succinimide anti-
convulsant that reduces frequency of 
epileptic attacks. There is little information 
about its mechanism of action. Unlike 
phenytoin and carbamazepine, it does not 
inhibit voltage-gated Na+ channels; unlike 
phenobarbital and clonazepam, it does not 
enhance the postsynaptic actions of GABA. 
• INDICATIONS:  
Treatment of choice for absence seizure 
(petit mal); which is its only indication. 
• CONTRAINDICATIONS: 
Hypersensitivity to succinimides, severe 
liver or renal disease. 
• DOSAGE FORMS: 
Capsules, syrup. 
• RECOMMENDED DOSAGE: 
Adult: 20 mg/kg/d or 250 mg b.i.d. PO, 
may increase every 4-7 days by 250 mg 
prn.; max. dose of 1.5 g/d should be 
administered under direct specialized 
medical supervision. 
Child:  6-12 y;  Same as adult, optimal 
dose is 20 mg/kg/d. 
3-6 y;  250 mg/d, may increase every 4-7 
days prn.; max. 20 mg/kg/d or 1 g/d. 
 
Directions: Therapeutic levels are from 40 
- 100 ug/ml. Inadequate dosage is the major 
cause of therapeutic failure. 
*Start at 20 mg/kg/d to get lowest effective 
therapeutic level and titrate up as needed. 
*May be taken with food if GI distress 
occurs.   
*Warn patient not to discontinue 
medication abruptly or change dosage, 
except on doctor’s advice. This may 
precipitate a seizure.  
• USE IN SPECIAL CASES: 
Pregnancy- Ethosuximide may be terato-
genic, elevated incidence of birth defects, risk 
vs. benefit evaluation has to be made 
(Category C). 
Lactation- Avoid. Significant amount has 
been detected in breast milk. Hyper-
excitability and poor suckling have been 
reported in infant. 
Children- Safety in children  < 3 y. has not 
been established. 
Renal Disease- Use with caution. 20% of 
drug is excreted unchanged via the kidney. 
Abnormal renal function has been reported in 
humans while using this medication. Perform 
urinalysis periodically. 
Liver Disease- Use with caution. The drug is 
metabolized in the liver. Abnormal liver 
function has been reported. Administer with 
extreme caution to patients with known liver 
disease, and perform liver tests periodically. 
• PRECAUTIONS AND WARNINGS: 
-Hematologic effects; blood dyscrasias 
(some fatal) have occurred, therefore, 
perform periodic blood counts. If signs or 
symptoms of infection (i.e. sore throat, 
fever) develop, consider blood counts at 
that point.   
-Dosage adjustment or changes should be 
done slowly. Abrupt withdrawal of 
anticonvulsant medication may precipitate 
absence status. 
-Need to order blood, liver or renal tests if 
any of the following occur:  Skin rash, joint 
pain, unusual bleeding or bruising, 
unexplained fever, and/or blurred vision. 
Advise patient to report any of these. 
Recommend strict caution against 
pregnancy as your patient starts on this 
medication, with hormonal and non-
hormonal methods. 
• ADVERSE EFFECTS: 
Most common; GI upset (take with food to 
lower incidence), anorexia and weight loss 
(advise patient to monitor weight on a 
weekly basis, if excessive loss, might need 
to lower the dose), epigastric distress, 
hiccups, drowsiness, dizziness (warn 
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against hazardous tasks such as driving or 
operating machinery) and headache. 
Rarely, psychotic states, rashes including 
erythema multiforme, Stevens Johnson 
Syndrome, lupus erythematosus, and blood 
dyscrasias have been reported. 
• INTERACTIONS: 
Overview of Ethosuximide 
Drug-Drug Interaction 
Drug Interaction 
Anti-
bacterials 
Isoniazid increases plasma 
level of ethosuximide, high 
risk of toxicity. Avoid 
concomitant use. 
Anti-
depressants 
and anti-
psychotics 
These have antagonistic 
effects; the convulsive 
threshold may be lowered. 
Use with caution. 
Other anti-
epileptics 
Use with other antiepileptics 
enhance toxicity and effect, 
increase sedation, i.e. CBZ 
decreases ethosuximide level, 
phenytoin level is increased. 
Monitor patient carefully 
until you stabilize condition. 
 
• OVERDOSE: 
Symptoms of acute ethosuximide overdose 
include: confusion, sleepiness, 
unsteadiness, coma with slow, shallow 
respiration, hypotension, hypo- or hyper-
thermia, absent reflexes, nausea, vomiting, 
coma with respiratory depression can 
occur. 
Treatment includes usual supportive 
measures, charcoal, hemoperfusion, hemo-
dialysis may be indicated.  
• BRANDS: 
Zarontin (Park-Davis). 
___________________________ 
 
 
4)  Phenobarbital WHO,P 
 
• DRUG SUMMARY: 
Phenobarbital/Phenobarbitone is a long-
acting barbiturate, that is classified as a 
CNS agent, anticonvulsant, sedative 
hypnotic.  Phenobarbital limits the spread 
of seizure activity by causing an increase in 
the threshold for motor cortex stimuli, its 
activity is not related to the sedative effect.  
It exerts maximal anticonvulsant action at 
doses below those required for hypnosis, 
this has made its clinical utility as an 
antiepileptic accepted. It is the drug of 
choice for febrile and neonatal seizures. 
Tolerance or psychological and physical 
dependence may occur with continued use. 
Restrict use, limit prescribing and 
dispensing to the amount required for the 
interval until the next appointment.   
• INDICATIONS:  
As an anticonvulsant; use for treatment of 
partial and generalized tonic-clonic (grand 
mal), cortical focal seizures, and in 
prolonged (≥ 15 min.) febrile convulsions 
or recurrent convulsions in neonates and 
young children. Not used for absence 
seizures. Also used as injection in 
emergency control associated with status 
epilepticus unresponsive to diazepam, 
tetanus and toxic reactions. Used as 
hypnotic sedative for short-term (2 wks.) 
treatment of insomnia. 
• CONTRAINDICATIONS:   
Sensitivity to barbiturates, manifest hepatic 
or familial history of porphyria, severe 
respiratory or renal disease, history of 
previous addiction to sedative hypnotics, 
and pregnancy. 
• DOSAGE FORMS: 
Tablets, suppository. 
• RECOMMENDED DOSAGE: 
Adult: 60-180 mg/day PO; max. 6 mg/kg/d 
in divided doses.  
(For acute convulsions 200-320 mg IM or 
IV, repeated q. 6 h. as necessary). 
Child: 3-8 mg/kg/day PO.  
(In Status Epilepticus 15-20 mg/kg IV over 
10-15 min.). 
 
Directions: Therapeutic serum concent-
rations of 15-40 ug/ml produce anti-
convulsant activity in most patients; these 
are usually reached after 2-3 weeks of 
therapy. 
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• USE IN SPECIAL CASES: 
Pregnancy- Avoid use. Barbiturates are 
reported teratogenic drugs, (Category D). 
Barbiturates readily cross the placental 
barrier and distribute throughout fetal tissues. 
Withdrawal symptoms occur in infants born 
to mothers who have received the drug during 
the last trimester. Neonatal coagulation 
defects that may cause bleeding within 24 h 
of birth have been associated with barbiturate 
use as well, Vitamin K should be given then. 
Lactation- Avoid use. Small amounts are 
excreted in breast milk. Drowsiness in 
nursing infant has been reported. 
Children- Barbiturates repeatedly produce 
excitement rather than depression in some 
people. They may produce irritability, 
aggression, and cognitive deficits in children. 
Significantly lower IQs were noted after long 
term use, for up to 6 months from 
discontinuation of therapy. For infants who 
develop physical dependence, phenobarbital 
can be given, and after withdrawal symptoms 
are relieved, gradually decrease the dosage, 
until you completely withdraw the 
medication over 2-3 weeks.  
Renal Disease- Contraindicated in patients 
with impaired renal function. Barbiturates are 
excreted either partially or completely 
unchanged in the urine. 
Liver Disease- Do not use in patients showing 
premonitory signs of hepatic coma. 
Barbiturates are metabolized primarily by 
hepatic microsomal enzymes. Administer 
with caution and initially in reduced doses in 
susceptible hepatic disease patients. 
• PRECAUTIONS AND WARNINGS: 
-Use caution in impaired hepatic, 
respiratory functions, and in patients with 
diabetes mellitus. Elderly and children 
sometimes have paradoxical response 
(behavioural disturbances and hyperkinesia), 
inform family members. 
-Warn patient to avoid potentially 
hazardous activities until full response to 
the drug is known. 
-Patient should inform the doctor if any of 
the following occur: fever, sore throat, 
mouth sores, easy bruising or bleeding, tiny 
broken blood vessels under the skin. 
-Phenobarbital increases incidence of 
osteomlacia, rickets, and anemia. Advise 
patient to increase intake of vitamin D-
fortified foods (i.e. milk) and folate intake 
(fresh green leafy vegetables, fruits, etc.) or 
take supplements if deficiency symptoms 
occur. 
-Caution patients to adhere to barbiturates 
regimen, intervals between doses should 
not be changed. Patient should not stop 
taking drug abruptly because of danger of 
withdrawal symptoms (8-12 h. after last 
dose), which can precipitate status 
epilepticus, or death. 
• ADVERSE EFFECTS: 
Drowsiness, headache, dizziness, nystag-
mus, ataxia, anemia, osteomalacia (vitamin 
D and folic acid deficiencies), liver 
damage, paradox excitement and 
hyperactivity in children, dulled intellect, 
restlessness and confusion in the elderly. 
• INTERACTIONS: 
Overview of Phenobarbital 
Drug-Drug Interaction 
Drug Interaction 
Alcohol Alcohol should not be 
consumed while taking 
phenobarbital due to additive 
CNS effects, may severely 
impair judgment and abilities, 
and possible death. 
Anti-
depressants 
These potentiate adverse 
effects of phenobarbital. Use 
caution. 
Oral contra-
ceptives 
Phenobarbital increases 
metabolism of OC, need to use 
alternative methods of 
contraception in addition or 
instead of hormonal OC to 
prevent pregnancy. 
Oral anti-
coagulants, 
anticonvul-
sants, 
corticosteroids, 
digoxin 
Phenobarbital may decrease 
absorption or increase 
metabolism of these drugs; 
patients might need dosage 
adjustments and monitoring. 
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• OVERDOSE: 
Symptoms: Onset of symptoms may not 
occur until several hours after pheno-
barbital ingestion. CNS and respiratory 
depression, constriction of the pupils, 
ataxia, tachycardia, hypotension, lower 
body temperature and coma.  
Treatment is mainly supportive.  Maintain 
adequate airway with assisted respiration 
and oxygen administration as necessary.  If 
the patient is conscious and has not lost the 
gag reflex, emesis may be induced with 
ipecac. After completion of vomiting, 
administer 30 gm of activated charcoal in a 
glass of water.  If emesis is not possible 
perform gastric lavage and continue with 
the supportive and symptomatic treatment 
measures as required. 
• BRANDS: 
Phenobarb (Eastern Chem.), Phenobarbital 
(Rekah). 
__________________ 
 
 
5)  Phenytoin WHO,P 
 
• DRUG SUMMARY: 
Phenytoin is a CNS agent, anticonvulsant, 
cardiovascular and antiarrhythmic agent, 
hydantoin derivative chemically related to 
phenobarbital. The mechanism of action is 
not exactly known. It has a narrow 
therapeutic index and the relation between 
dose and plasma concentration is non-
linear; therefore, a small dose increase may 
produce large rise in plasma concentration 
with acute toxic side effects.  
• INDICATIONS: 
Epilepsy; status epileptics, grand mal 
(tonic-clonic) and partial seizures.   
Also it is used as an antiarrhythmic agent. 
• CONTRAINDICATIONS: 
Pregnancy, hypersensitivity to hydantoin 
products, sinus bradycardia, complete or 
incomplete heart block. 
• DOSAGE FORMS: 
Capsule, pediatric suspension. 
• RECOMMENDED DOSAGE: 
Adult: 100 mg (125 mg suspension) PO 
t.i.d., increased gradually by 100 mg/wk. 
until seizures are controlled.  
Can start with a loading dose of up to 15-18 
mg/kg or 1 g. 
Usual maintenance dose: 300-400 mg/d;  
max. dose 600 mg/d.  
Child:  initially 5 mg/kg in 2-3 divided 
doses may be increase gradually to max. 
300 mg/d after the therapeutic level is 
reached. 
Usual maintenance dose: 4-8 mg/kg/d. 
 
Directions: Start with small dose and 
gradually increase. Time to reach steady 
state for the drug is 5-10 days.  Therapeutic 
blood level;  10-20 mcg/ml.   
*Treatment must continue as long as 
condition continues.  
*If the patient has been free of seizures for 
several years, then the drug should be 
slowly withdrawn. Do not stop medication 
abruptly which may precipitate status 
epilepticus, reduce gradually. 
*Take medication with food to reduce GI 
upset possibility. 
• USE IN SPECIAL CASES: 
Pregnancy- Avoid use. Teratogenic effects 
have been reported (Category D). CBZ might 
be safer to use. 
Lactation- Use with caution, phenytoin is 
excreted in small amounts. Drowsiness and 
decreased suckling activity have been 
reported in one infant. But therapeutic levels 
have little risk to the nursing infant. 
Children- Safe. The absorption of oral 
phenytoin is slower in pediatrics and is poor 
in neonates. Monitor carefully to avoid 
toxicity. 
Renal Disease- Use caution, metabolites are 
excreted by the kidney. 
Liver Disease- Reduce dose to avoid toxicity. 
Phenytoins are metabolized in the liver and 
can induce liver microsomal enzymes. 
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• PRECAUTIONS AND WARNINGS: 
-Caution use in impaired hepatic and renal 
function, alcoholism, and severe 
myocardial insufficiency.   
-Adjustment of phenytoin dosage for 
patients on insulin or of sulfonylurea 
dosage may be necessary. Patients on 
prolonged therapy should have adequate 
intake of vitamin D containing foods.   
-Observe for symptoms of folic acid 
deficiency; neuropathy or mental dys-
function. Advise patient not to change drug 
brand when refilling prescription. 
Differences in brands can alter phenytoin 
serum levels (change bioavailability).   
• ADVERSE EFFECTS: 
Usually dose related; drowsiness, dizziness, 
ataxia, confusion, GI disturbances. Also 
hirsutism, gingival hyperplasia (very 
common, need to advice patient on proper 
oral hygiene), blood dyscrasias, folate 
deficiency, megaloblastic anemia, osteo-
malacia due to interference with vitamin D 
metabolism. 
• INTERACTIONS: 
Overview  of  Phenytoin 
Drug-Drug Interaction 
Drug Interaction 
Antacids Antacids decrease effect of 
hydantoins. If there is a need 
to administer an antacid, give 
1 hr before or 2 hrs after 
phenytoin administration. 
Chloram-
phenicol, 
isoniazid,  
and benzo-
diazipines 
Marked inhibition of the 
metabolism of these drugs 
may occur. Use with 
caution. 
TCAs, 
phenyl-
butazone, 
valproic acid 
and 
salicylates 
Phenytoin may displace these 
drugs.  Use with caution. 
Influenza 
vaccine 
Using this vaccine during 
phenytoin treatment may 
increase seizure activity.  Use 
caution, and monitor patient 
if need to give the vaccine. 
 
• OVERDOSE:  
Lethal dose in adults is estimated to be 2-5 g. 
Symptoms include nystagmus, ataxia, 
tremor hyperflexia, lethargy, slurred 
speech, nausea and vomiting.  Patient may 
become comatose and hypotensive. 
Treatment: Supportive measures are 
required to prevent respiratory or 
circulatory depression. Hemodialysis can 
be considered since phenytoin is not 
completely bound to plasma proteins. 
Repeat dose of activated charcoal by mouth 
to enhance elimination. 
• BRANDS:  
Dilantin / Epanutin (Park Davis). 
______________________ 
 
6)  Valproic Acid WHO,P 
 (and derivatives) 
 
• DRUG SUMMARY:   
(Divalproex sodium, sodium valproate) 
Valproic acid (VA) is an antiepileptic 
agent, chemically unrelated to other drugs. 
Its mode of action is not fully understood 
but may involve a modification in levels of 
GABA in the brain. Plasma concentrations 
are not a useful index of efficacy. Need to 
monitor patient’s therapeutic response. 
• INDICATIONS: 
Epilepsy; effective in both absence and 
mixed types of generalized seizures. 
• CONTRAINDICATIONS: 
Hepatic disease or significant hepatic 
dysfunction, and hypersensitivity to 
valproic acid. 
• DOSAGE FORMS: 
Tablets as sodium valproate; capsule: 
valproic acid; syrup (200mg/5ml), solution 
(200mg/ml): sodium valproate. 
• RECOMMENDED DOSAGE:  
(Doses should be adjusted to the needs of 
individual patients to achieve adequate 
control of seizures). 
Adult: 15 mg/kg/d in divided total daily 
doses, increase at 1 week intervals by 5-10 
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mg/kg/d, until seizures are controlled.  
Max. dose 60 mg/kg/d. 
Child:  For children up to 20 kg  or  about 
4 yrs.; initially start with 10-15 mg/kg/d in 
divided doses.  Increase gradually (in 5-10 
mg/kg/wk) to therapeutic effects.  (range 
20-30 mg/kg/d).  
For children > 20 kg; initially 400 mg/d in 
divided doses, increased gradually to 20-30 
mg/kg/d;  max. 35 mg/kg/d.  
 
Directions: If GI disturbances occur, may 
administer this drug with food.   
*Dose should be gradually increased over a 
couple of weeks. 
*Time of administration (intervals) should 
be standardized for patients to avoid 
inappropriate fluctuations in plasma 
concentrations.   
*The drug is readily absorbed from the GI 
tract, and needs 2-4 days to reach steady 
state. Therapeutic blood level ranges from 
50 - 100 mcg/ml. 
• USE IN SPECIAL CASES: 
Pregnancy- Need to evaluate benefit/risk 
situation (Category D). Increased risk of 
neural tube defects, neonatal bleeding and 
hepatotoxicity in the fetus. 
Lactation- Use with caution. Concentration 
of VA in breast milk are 1-10 % of serum 
concentrations. It is not known what effect 
this would have on a nursing infant. 
Children- Children < 2 yrs. are at increased 
risk of developing fatal hepatotoxicity, 
especially those with history of liver disease, 
metabolic disorder, or are on multiple 
anticonvulsants. 
Renal Disease- Use with caution. Excretion is 
primarily in urine. Need to avoid 
accumulation. 
Liver Disease- Avoid use. Contraindicated in 
active or severe liver disease states. Can 
precipitate hepatotoxicity or liver failure in 
susceptible patients. The drug is metabolized 
in the liver, and is a liver enzyme inducer. 
• PRECAUTIONS AND WARNINGS: 
- Liver function tests should be done at 
least every 2 months especially during 
first 6 months of therapy. 
− Tell patient not to stop taking 
medication without consultation, and to 
take medication the same time every day. 
− In elderly, due to a decrease in unbound 
clearance of valproate, reduce starting dose, 
and base therapeutic dose on clinical 
response. 
− Inform diabetic patient that VA may 
cause a false positive test for urine ketones. 
• ADVERSE EFFECTS: 
GI disturbances, increased or decreased 
appetite and weight, transient hair loss, 
headache, CNS depression (advise patient 
not to engage in hazardous activities like 
driving or operating heavy machinery until 
they know that they don’t become drowsy 
from taking the drug), drowsiness, 
emotional upset, and prolonged bleeding 
time. Rarely in children: mental stimulation, 
aggressiveness and hyperactivity has been 
reported. 
• OVERDOSE: 
Symptoms: May result in somnolence, heart 
block, visual hallucinations, and deep 
coma. Treatment: Valproic acid is absorbed 
very rapidly, efficacy of gastric lavage 
varies with time since ingestion. Use 
general supportive measures and carefully 
maintain adequate urinary output. 
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• INTERACTIONS: 
Overview of Valproic 
Drug-Drug Interaction 
Drug Interaction 
Phenytoin, 
carba-
mazepine, 
or pheno-
barbital 
Concomitant administration 
of hepatic enzyme inducers 
such as phenytoin, CBZ, or 
phenobarb., may enhance the 
metabolism of valproic acid.  
In turn, valproic acid has been 
reported to cause rises in 
phenobarb. (and primidone) 
concentrations in plasma. The 
interaction between VA and 
phenytoin is complex and 
involves inhibition of 
phenytoin metabolism as well 
as competition for protein 
binding sites. 
 
 
Warfarin Valproic acid can displace 
warfarin from protein 
binding sites, need to monitor 
coagulation tests. Unlike 
phenytoin and CBZ, valproic 
acid does not induce hepatic 
enzymes. 
 
• BRANDS: 
Depakote (Abbott), Depalept (CTI), Valporal 
(Teva). 
_____________________ 
 
7)  Diazepam WHO,P 
 
• DRUG SUMMARY: 
Diazepam is a CNS agent, very fast acting 
benzodiazepine, anticonvulsant, anxiolytic-
hypnotic. Refer to page 181 for monograph. 
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Antiparkinsons drugs: 
PARKINSON’S DISEASE 
 
Parkinsonism is a neurological disease that 
is characterized by tremor, rigidity, akinesia 
and disorders of posture and equilibrium. It 
is a progressive degeneration of pigment-
containing cells of the substantia nigra 
leading to deficiency of dopamine. The 
onset is slow and progressive with 
symptoms advancing over months to years. 
Diagnosis is based on clinical presentation, 
where at least 2 of tremor, bradykinesia or 
rigidity must be present.  Patient disability 
can be classified by the Hoehn and Yahr 
scale as; early (stage 1 and 2), middle 
(stage 3), or advance (stages 4 or 5) 
Parkinson (Drug & Therapeutic Prespective, 
2001). 
Current therapy for Parkinson’s is 
palliative (will ease the symptoms only but 
does not cure). Drug therapy is aimed at 
correcting or modifying the neuro-
transmitter defects by inhibiting the effect 
of acetylcholine or enhancing the effect of 
dopamine. The goal is to provide maximum 
relief from symptoms and mobility of the 
patient.  Drug therapy is initiated when the 
patients find that their symptoms interfere 
with their functional status. All patients 
with gait impairment postural instability 
should be treated, as these symptoms can 
lead to falls and serious injury. Therefore, 
functional status is what determines 
therapy.  Treatment philosophy: do not start 
or increase the doses of drugs until there is 
loss of function. 
Up-to-this-date, there are no neuro-
protective agents that have demonstrated to 
be effective in preventing or slowing the 
development of symptoms in this disease, 
thus improving the quality and expectancy 
of life of most patients, and research is 
undergoing in this field. About 10-20% of 
patients are unresponsive to current 
treatments (BNF 2001, p. 237).  
Drugs that are used to treat Parkinson 
disease symptoms are divided into two 
groups:  
First, the anticholinergic drugs 
(include antimuscarinic) which are most 
useful in improving symptoms of tremor 
and rigidity. Patients with minimal 
symptoms (mostly young onset) benefit 
from them. These agents seem to be equally 
effective.  
The second group consists of the 
dopaminergic agents, which combat the 
dopamine deficiency. Effectiveness of 
medication varies from one individual to 
the other. Levodopa has been the gold 
standard for treatment, even with many new 
drug classes being discovered. It remains 
the most effective agent and maintains a 
key role in the management of 
Parkinsonism (Drug & Therapeutic 
Perspective, 2001). However the on-off 
phenomenon and dyskinesia associated 
with the long-term dose lead to the greater 
use of alternative drugs. 
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A)  ANTICHOLINERGIC DRUGS 
 
1)  Benztropine Mesylate 
 
• DRUG SUMMARY:   
A synthetic centrally acting anticholinergic 
(antimuscurinic) agent, that is chemically 
similar to atropine and diphenhydramine.  
Acts by diminishing excess cholinergic 
effect associated with dopamine deficiency.  
Suppresses tremor and rigidity, but does not 
alleviate tardive dyskinesia. (It is similar to 
benzhexol/ trihexyphenidyl, but excreted 
more slowly). 
• INDICATIONS: 
For use in the therapy of all forms of 
parkinsonism. May also be used to control 
of extrapyramidal disorders (except 
dyskinesia) due to neuroleptic drugs like 
phenothiazines, haloperidol.  Commonly 
used with levodopa therapy.  
• CONTRAINDICATIONS: 
Hypersensitivity to the drug, angle-closure 
type glaucoma, obstructive disease of GU 
or GI tracts, susceptibility to tachycardia, 
and children < 3 years of age. 
• DOSAGE FORMS: 
Tablets. 
• RECOMMENDED DOSAGE: 
Adult:  0.5-1 mg/d PO gradually increase in 
increments of 0.5 at 5-6 day intervals, to 
the smallest amount necessary for optimal 
relief of parkinsonism;  max. 6 mg/d. 
1-2 mg PO b.i.d. for extrapyramidal 
reactions. 
 
Directions: Onset needs 1 h., and duration 
6-10 h. 
*Administer immediately after meals to 
prevent GI irritation.   
*Patients taking drug at bedtime have 
shown greater relief and better compliance.   
• USE IN SPECIAL CASES: 
Pregnancy- Use when clearly needed and 
potential benefits outweigh potential hazards 
to fetus (Category C). Safety for use during 
pregnancy has not been established. 
Lactation- Use with caution. An inhibitory 
effect on lactation will occur. Safety on 
lactating infant has not been established. 
Children- Contraindicated in children < 3 
yrs.  Safety and efficacy in older children 
have not been established. 
Renal Disease- Use with caution. Safety has 
not been established 
Liver Disease- Use with caution. Safety has 
not been established. 
• PRECAUTIONS AND WARNINGS: 
-Rapid or pounding heart beat, confusion, 
eye pain or rash may be an indication of 
hypersensitivity. 
-In geriatric patients (> 60 yrs) of age, the 
possibility of increased sensitivity 
increases. Strict dosage regulations are 
required.   
-Mental confusion, disorientation, and 
psychotic-like symptoms may develop.   
-Antihistamines (e.g. diphenhydramine) 
have mild antiparkinsons effect and can be 
useful in patients with minimal symptoms.   
-Caution in cardiovascular disease, hepatic 
or/and renal impairment.   
-Avoid abrupt discontinuation of treatment.   
-Advise the patient to use caution in hot 
weather to avoid heat stroke or heat 
exhaustion. 
• ADVERSE EFFECTS:   
Dry mouth; which can be relieved by 
sucking hard candy, chewing gum or 
adequate fluid intake. Difficult urination or 
constipation may occur; stool softeners can 
be used. Also sedation, drowsiness, 
restlessness, mental confusion, tachycardia, 
decreased sweating (increased 
susceptibility to heat stroke), and blurred 
vision. 
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• INTERACTIONS:   
Overview  of  Benztropine 
Drug-Drug Interactions 
Drug Interaction 
Alcohol, 
CNS 
depressants 
These have additive sedative 
and depressant effects. Warn 
patients about the side effects, 
if they have to be given 
concomitantly. 
Amantadine, 
TCAs, MAO 
inhibitors, 
and 
quinidine 
These have additive 
anticholinergic effects.  
Monitor patients response if 
concomitant use cannot be 
avoided, and adjust the 
anticholinergic drug dose 
accordingly. 
Digoxin Serum level of digoxin may 
be increased, use caution, 
monitor levels to avoid 
toxicity. 
Haloperidol Effects are variable. A 
delayed reaction may occur, 
where worsening of schizo-
phrenic symptoms occur. 
Avoid concomitant use. If 
cannot avoid, monitor 
patients routinely and closely, 
and tailor haloperidol dose as 
necessary. 
Pheno-
thiazines 
Therapeutic action of 
phenothiazines may be 
decreased. Tailor the dose of 
the phenothiazine as needed. 
 
• OVERDOSE:   
Symptoms: Characterized by the adverse 
reactions. Can include: circulatory collapse, 
cardiac arrest, respiratory depression or 
arrest, toxic psychosis, shock, coma, stupor, 
foul smelling breath, dilated and sluggish 
pupils.   
Treatment: Immediately following 
ingestion, remove remaining drug from the 
stomach by inducing emesis, or by gastric 
lavage (unless patient with convulsive or 
psychotic state). Activated charcoal is an 
effective adsorbent. Treatment is symp-
tomatic, need advanced life support setting. 
• BRANDS: 
Cogentin (MSD). 
___________________ 
 
2)  Trihexyphenidyl P 
 
• DRUG SUMMARY: 
Trihexyphenidyl HCl, or Benzhexol, is a 
synthetic tertiary amine, anticholinergic, 
antimuscarinic agent similar to atropine. 
Synthetic anticholinergics have more 
selective CNS activity than naturally 
occurring belladonna alkaloids, so they 
cause fewer side effects. It acts by blocking 
excess acetylcholine at certain cerebral 
synaptic sites. 
• INDICATIONS:    
Adjunct in treatment of all forms of 
parkinsonism. It is also used in controlling 
extrapyramidal disorders (except tardive 
dyskinesia) due to neuroleptic medication. 
• CONTRAINDICATIONS:   
Hypersensitivity, narrow-angle glaucoma, 
pyloric or duodenal obstruction, prostatic 
hypertrophy or bladder-neck obstructions, 
and megacolon. 
• DOSAGE FORMS: 
Tablets, elixir. 
• RECOMMENDED DOSAGE: 
Adult: 1-2 mg the first day, increase by 2 
mg increment at intervals of 3-5 days, until 
total usual dose of 6-10 mg is given daily;  
max. 15 mg/d. 
 
Directions: Dosage should be 
individualized, initial dose should be low 
and increased gradually. May be taken 
before or after meals depending on how 
patient reacts.  
*Elderly > 60 years; better to give them 
after meals since they are more sensitive to 
the drug. If cause excess mouth dryness, 
better to administer before meals unless 
causes nausea. 
*Trihexyphenidyl is best tolerated at 3 
divided doses, given at meal times. High 
doses may be divided into 4 parts: 
mealtimes and bedtime. 
*Need to reduce dose if use concomitantly 
with levodopa. Trihexyphenidyl 3-6 mg/d 
in divided doses is adequate in this case. 
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*When substituting for another anti-
cholinergic drug, usual procedure is partial 
substitution initially, with progressive 
reduction in other medications as the dose 
of trihexyphenidyl is increased. 
• USE IN SPECIAL CASES:: 
Pregnancy- To be used only if potential 
benefits justify the potential risks (Category 
C).  Risk cannot be ruled out. 
Lactation- Safety has not been established. 
An inhibitory effect on lactation may occur. 
Infants are usually sensitive to anti-
cholinergic agents, hence better to stop use of 
medication.   
Children- Safety and efficacy have not been 
established. 
Renal Disease- Use with caution. The drug is 
excreted in urine. Safety has not been 
established. 
Liver Disease- Use with caution, safety has 
not been established. 
• PRECAUTIONS & WARNINGS:   
Same as benztropine. 
• ADVERSE EFFECTS & OVERDOSE: 
Same as benztropine. 
• INTERACTIONS: 
Overview  of  Trihexyphenidyl 
Drug-Drug Interactions 
Drug Interaction 
Chlorprom-
azine, 
haloperidol, 
and pheno-
thiazines 
Trihexyphenidyl reduces 
effect of these.  
Do not administer together 
unless clearly indicated (see 
interactions of benztropine). 
Digoxin Increases bioavailability of 
digoxin, monitor levels of 
digoxin to prevent toxicity 
and tailor dose as needed. 
MAO 
Inhibitors 
These potentiate action of 
trihexyphenidyl, avoid use 
concomitantly. 
 
• Brands: 
Artane (Lederle), Parkizol (JePharm.), Partane 
(Taro). 
__________________________ 
 
 
B)  DOPAMINERGIC  DRUGS 
 
1)  Amantadine 
 
• DRUG SUMMARY:   
A synthetic primary amine, antiviral agent 
that has modest antiparkinson effect. It 
improves bradykinetic disabilities, as well 
as tremor and rigidity. Its exact mechanism 
is not clear, but thought to be due to 
increase release of dopamine. It is less 
effective than levodopa, but slightly more 
effective than anticholinergic agents are.  It 
has the advantage of having a low 
incidence of side effects.   
• INDICATIONS:  
Parkinson’s Disease/Syndrome, drug 
induced extra-pyramidal reactions, 
idiopathic or post encephalitic cases, as 
initial therapy or as adjunct with 
anticholinergic drugs or levodopa.   
Also used for prophylaxis and symptomatic 
treatment of influenza A infections.  
• CONTRAINDICATIONS:   
Hypersensitivity to amantadine.  
• DOSAGE FORMS: 
Tablets, capsules. 
• RECOMMENDED DOSAGE: 
Adult:  100 mg 1-2 times/day;   
max. 400 mg/day. 
 
 
Dosing Guidelines in Renal Impairment 
Cl Cr 
(ml/min./
1.73m2) 
Suggested Maintenance 
regimen 
> 80 100 mg b.i.d. 
60 200 mg/100 mg, on alternate days 
50-40 100 mg/day 
30 200 mg twice weekly 
20 100 mg three times weekly 
 
Directions: Start with 100 mg/day, then 
after one to several wks., increase if patient 
has other serious illness or is on other 
antiparkinsonism medication.   
*Use with levodopa has been shown to 
exhibit rapid effect.   
*After few months a patient might show 
decreased efficacy, may increase dose or 
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temporarily discontinue drug for several 
weeks.   
*If patient is not responding, other 
antiparkinson drugs might be necessary. 
• USE IN SPECIAL CASES: 
Pregnancy- Avoid. There are no adequate or 
well-controlled studies of amantadine in 
pregnant women (Category C). 
Lactation- Use caution. It is excreted in 
breast milk, but safety has not been 
established. 
Children- Safety and efficacy are not 
established. 
Renal Disease- 90% of drug is excreted in 
urine unchanged. Elimination is prolonged in 
renal insufficiency. Dose reduction is 
necessary in renal impairment to prevent 
accumulation. Refer to recommended dosage. 
Liver Disease- Use Caution. The drug is not 
metabolized, most of it is eliminated from the 
body unchanged. 
• PRECAUTIONS AND WARNINGS:   
-Use caution in patients with history of 
epilepsy or other type seizures.   
-Dose reduction of amantadine is 
recommended, in patients with hepatic 
disease, psychosis, congestive heart failure 
(CHF), peripheral edema, and renal 
impairment. 
• ADVERSE EFFECTS:  
Usually dose related; dizziness, light-
headedness, difficulty in concentrating, 
insomnia, irritability, dry mouth, 
constipation, and orthostatic hypotension. 
• OVERDOSE:   
Symptoms include nausea or vomiting, 
anorexia, CNS effects, tremor, blurred 
vision, possible convulsions.   
Treatment: There is no specific antidote.  
Refer to emergency room immediately.  For 
CNS toxicity: IV physostigmine may be 
administered. Apply supportive measures 
along with immediate gastric lavage or 
induction of emesis. Force fluids, IV if 
necessary. Acidification of urine to increase 
elimination of drug from the body maybe 
used. 
• INTERACTIONS: 
Overview  of  Amantadine 
Drug-Drug Interactions 
Drug Interaction 
Anti-
cholinergic 
drugs 
Anticholinergic side effects 
may be increased. If cannot 
avoid concomitant use, 
monitor patient’s response 
and adjust doses accordingly. 
Hydrochloro
thiazide plus 
triamterene 
This combination decreases 
urinary excretion of 
amantadine. Use with caution. 
Quinidine 
derivatives 
These may inhibit renal 
clearance of amantadine in 
males (but not females), 
increasing risk of amantadine 
toxicity. Use with caution in 
males. 
Thiazide 
diuretics 
These may increase the risk 
for developing adverse effects 
of amantadine. Use with 
caution. 
 
• BRANDS: 
A-parkin (Dexxon), Partivel (Trima), 
Symmetrel (Ciba-Geigy). 
_____________________ 
 
 2)  Bromocriptine P 
 
• DRUG SUMMARY:   
Bromocriptine mesylate is a semi-synthetic 
potent dopamine receptor agonist. The 
dopaminergic neurons are involved in the 
control of motor function. Bromocriptine 
acts by direct stimulation of surviving 
dopamine receptors. It should be reserved 
for patients for whom levodopa alone is no 
longer adequate or can’t be tolerated. If 
patients did not respond to levodopa, they 
are poor candidates for bromocriptine. 
Bromocriptine relieves akinesia, rigidity 
and tremor.  Some studies have shown that 
using bromocriptine as first-choice sole 
therapy in earlier stages of disease has 
improved disability. But there is a decline 
in efficacy with long term use. Addition of 
levodopa then may be necessary.  
 
 
 
 206
• INDICATIONS:   
Parkinsonism, but not drug induced 
extrapyramidal symptoms.  
Also used for endocrine disorders (i.e. 
acromegaly, amenorrhea, galactorrhea). 
• CONTRAINDICATIONS:   
Hypersensitivity to ergot alkaloids, severe 
ischemic heart disease, pituitary tumor, and 
glaucoma. Bromocriptine may cause first-
dose phenomenon that can trigger sudden 
cardiovascular collapse. Do not use in 
patients with a history of myocardial 
infarction (MI) or severe arrhythmia. 
• DOSAGE FORMS: 
Tablets. 
• RECOMMENDED DOSAGE: 
Adult: Initially 1.25 mg twice daily, titrate 
every 2 wks. by 2.5 mg/d to ensure that the 
lowest dosage producing an optimal 
therapeutic response is not exceeded.   
Usual range is 10 - 40 mg/day.  
(Safety of dosages exceeding 100 mg/d has 
not been demonstrated.) 
 
Directions: Take with meals to avoid GI 
disturbances.   
*Always start with lowest dose possible 
and titrate up.  
*Do not discontinue drug abruptly.  
• USE IN SPECIAL CASES: 
Pregnancy- Avoid. Discontinue medication 
without delay if patient should get pregnant 
during therapy (Category B). 
Lactation- Avoid. Bromocriptine prevents 
lactation, therefore, do not administer to 
mothers who want to breast-feed.  
Children-  Safety and efficacy in children < 
15 years have not been established. 
Renal Disease- Use with caution. Safety has 
not been established.  85% of drug is 
excreted in feces in 5 days, while only 3-
6% is eliminated in urine. 
Liver Disease- The drug is metabolized in 
the liver. Use with caution in patients with 
liver disorders. 
• PRECAUTIONS AND WARNINGS:   
-Some patients are very sensitive to the 
hypotensive effect of the drug, and may 
even collapse within an hour of the first 
dose. Advise patient to take first dose with 
food and in bed. Patients often tolerate 
subsequent doses well.   
-Warn patients against driving or operating 
machinery due to the side effects especially 
early in therapy (the dizziness, drowsiness, 
and hypotension). 
-Use caution in renal and hepatic 
dysfunction. 
-Need to perform periodic evaluation of 
hepatic, renal, hematopoietic and 
cardiovascular systems with long term 
therapy. 
• ADVERSE EFFECTS: 
Mostly are dose related. Headaches, 
dizziness, light-headedness, sedation, 
dyskinesia, depression, or mania, delusions, 
orthostatic hypotension, palpitation, 
arrhythmia, constipation or diarrhea, nasal 
congestion, and abdominal pain. Painless 
digital vasospasm is a common 
complication of long term treatment 
(usually in treatment of acromegaly), that 
can be reversed with lowering dose; advise 
patient to avoid exposure to cold. 
• INTERACTIONS: 
Overview  of  Bromocriptine 
Drug-Drug Interactions 
Drug Interaction 
Alcohol Bromocriptine decreases 
tolerance to alcohol, advise 
patient not to drink while on 
this medication. 
Antihyper-
tensive 
These agents add to hypo-
tensive effect, use caution, 
inform patient not to change 
body position very quickly 
when rising or sitting down. 
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Oral 
Contra-
ceptives 
May interfere with action of 
the drug. Avoid use 
concomitantly. Advise patient 
to use alternative measures of 
contraception. 
Pheno-
thiazines 
These decrease the efficacy 
of bromocriptine. Use 
caution. 
Sympatho-
mimetics 
These increase/exacerbate the 
side effects of bromocriptine 
like tachycardia and cardiac 
dysfunction. 
 
• OVERDOSE:   
Treatment: Acute overdose, employ general 
supportive measures, along with immediate 
gastric lavage. Administer IV fluids and 
maintain an adequate airway. Monitor ECG 
to observe any developments of arrhythmia.  
• BRANDS:   
Lactopar (Birzeit), Parilac (Teva), Parlodel 
(Sandoz). 
_______________ 
 
3) Carbidopa/Levodopa WHO,P 
 
• DRUG SUMMARY:   
Co-careldopa, is a mixture of carbidopa and 
levodopa. Levodopa is a metabolic 
precursor of dopamine, a catecholamine 
neurotransmitter, which unlike dopamine 
readily crosses the blood brain barrier. 
Levodopa, being a dopaminergic agent, 
combats the dopamine deficiency in 
Parkinson’s.  
Carbidopa, a derivative of methyldopa, is a 
peripheral dopa-decarboxylase inhibitor. 
Decarboxylase inhibitors, (i.e. carbidopa, 
benserazide) are given with levodopa. 
When levodopa is given alone, large doses 
must be administered to compensate for 
peripheral decarboxylation to provide 
adequate amounts of dopamine at the 
appropriate sites. Decarboxylase inhibitors 
prevent the metabolism of levodopa and 
thereby make more levodopa available to 
transport to the brain. The decarboxylase 
inhibitors do not cross the blood brain 
barrier and therefore do not affect 
metabolism of levodopa in the brain. The 
addition of carbidopa reduces the amount 
of levodopa required by about 75% because 
levodopa plasma levels and t½ are 
increased. This decreases the incidence of 
side effects like nausea and vomiting 
associated with levodopa. A disadvantage 
is an increased incidence of abnormal 
involuntary movement. 
• INDICATIONS: 
Symptomatic treatment of idiopathic, 
postencephalitic Parkinson’s disease, and 
parkinsonism following carbon monoxide 
and manganese intoxication. 
• CONTRAINDICATIONS:   
Hypersensitivity to carbidopa or levodopa, 
narrow angle glaucoma, and history of 
suspected melanoma. 
• DOSAGE FORMS:   
The mixture is expressed in x/y proportions, 
where  x  and  y  are the strengths in 
milligrams of carbidopa and levodopa 
respectively. 
Tablets:  10/100, 25/100, 25/250  
• RECOMMENDED DOSAGE: 
Adult: For patients not currently 
receiving levodopa: 
1 tablet carbidopa 10 mg/ levodopa 100 mg 
or 25/100 t.i.d. increased by 1 tablet q.d. or 
q.o.d up to 6 tablets/day. 
For patients receiving levodopa already: 
1 tablet of 25/250 t.i.d. or q.i.d., adjusted by 
0.5 or 1 tablet, up to 8 tablets/day, or  max. 
200 mg carbidopa. 
 
Directions: The optimum daily dose must 
be determined by careful titration in each 
individual patient. When transferring 
patients from levodopa, 3 tablets of 
carbidopa/levodopa 25/250 should be 
substituted for 4 g levodopa.  The levodopa 
should be discontinued 8-12 hrs before-
hand.   
*Therapeutic effects may take few weeks.   
*Administer with food if GI upset occurs. 
*Avoid vitamin products containing 
vitamin B6 (pyridoxine), due to drug-drug 
interactions. 
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• USE IN SPECIAL CASES: 
Pregnancy- Use only when clearly needed 
(Category C). Effects in pregnancy are 
unknown, both levodopa and carbidopa have 
caused malformations in rabbits. 
Lactation- Avoid. Do not administer to 
nursing mothers, the drug is widely 
distributed in most tissues and excreted in 
breast milk. 
Children- Safety for use in children < 18 
years is not established for carbidopa.  Safety 
for use in children < 12 years is not 
established for levodopa. 
Renal Disease- The drug is excreted in urine.  
Use caution in renal disorders. 
Liver Disease- Use with caution. 
• PRECAUTIONS AND WARNINGS:  
-Use caution in cardiovascular, hepatic, 
pulmonary or renal disorders, history of 
peptic ulcer, psychiatric states, endocrine 
diseases, seizure disorders. 
-Monitor vital signs particularly during 
period of dosage adjustment, and report 
alterations in BP, pulse and respiratory rate, 
behavior changes.   
-Uncontrollable movements of the face, 
eyelids, mouth, tongue, arms, hands or legs, 
mood or mental changes, irregular 
heartbeat or palpitations, severe or 
persistent nausea and vomiting can be signs 
of intolerance to the medication.   
-For diabetic patients: warn patient that the 
medication may interfere with urine tests 
for sugar or ketones, causing false results. 
• ADVERSE EFFECTS:  
Are those of enhanced levodopa effects; 
involuntary movements (dyskinetic, 
dystonic, choreiform), muscle twitching, 
headache, dizziness, confusion, insomnia, 
mental disturbances, suicidal tendencies in 
psychiatric patients, blurred vision, 
diplopia, nausea, dry mouth, dysphagia, 
dark urine, urinary frequency, hoarseness, 
hemolytic and nonhemolytic anemia. 
Elevations of liver function;  BUN, AST, 
ALT, LDH, alkaline phosphates have been 
reported. 
 
• INTERACTIONS: 
Overview  of  Co-careldopa 
Drug-Drug Interactions 
Drug Interaction 
Anti-
cholinergic 
agents 
These may enhance levodopa 
effects, but can exacerbate 
involuntary movements. If 
necessary increase levodopa 
or decrease anticholinergic. 
Iron salts, 
Oral 
The pharmacologic effect of 
levodopa may be decreased. 
If necessary to coadminister, 
observe patient’s response 
and increase the co-carledopa 
accordingly. 
MAOI It may precipitate hyper-
tensive crisis. Avoid 
concomitant use. 
Methyldopa Increases hypotensive CNS 
effects. Use with caution. 
Pheno-
thiazines, 
haloperidol 
These may antagonize effects 
of levodopa. 
Phenytoin, 
papaverine 
These may interfere with 
levodopa effects. Avoid use 
unless clearly indicated; 
monitor patient’s response. 
Pyridoxine 
(B6) 
Reduces effectiveness of 
levodopa; avoid concomitant 
use. 
Tricyclic 
antidepress
ants 
TCAs potentiate postural 
hypotension. Use with 
caution. 
 
• OVERDOSE: 
Same as bromocriptine. 
• BRANDS:   
Dopicar (Assia/Riesel), Sinemet (Dupont 
Pharm). 
 
________________________
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OPTHALMIC PREPARATIONS 
 
The eye is vulnerable to any external insult. 
Common problems that are seen include 
infections (conjunctivitis-red eye, and 
trachoma), injury or burns, allergy and 
glaucoma (raised intraocular pressure in the 
eye). 
Eye drops and eye ointments are the 
most commonly used dosage forms for the 
management of eye problems.  Eye drops 
penetrate the globe, probably through the 
cornea, in order to produce their therapeutic 
effect.  
Some eye drops have systemic effects 
that result from the absorption of the drug 
into the general circulation.  This occurs 
either through the conjunctival vessels, or 
from the nasal mucosa after the excess of 
the preparation has drained down through 
the tear duct.  These systemic effects are 
usually undesirable. For example, timolol 
(a β-blocker) administered as eye drops 
may induce bronchospasm or bradycardia 
in susceptible individuals.  Eye ointments 
are often applied to lid margins, or may 
also be used in the conjunctival sac for 
other conditions especially when a 
prolonged action is required.  
When two different preparations in the 
form of eye-drops are required at the same 
time of the day, for example pilocarpine 
and timolol in glaucoma, dilution and 
overflow may occur when one immediately 
follows the other. The patient should 
therefore leave an interval of a few minutes 
between the two drugs.  At night, an eye 
ointment for the second drug will reduce 
the problem. 
In addition to these two dosage forms, 
we have eye lotions that are used for the 
irrigation of the conjunctival sac. They act 
mechanically to flush out irritants or 
foreign bodies as a first aid treatment.   
Preparations for the eye should be sterile 
when issued.  For routine use, they are 
supplied in multiple-application containers 
for individual use. Eye-drops contain a 
suitable preservative, never-the-less, they 
should not be used for more than 4 weeks 
after opening the container   (unless stated 
specifically by the manufacturer). After that, a 
new container should be opened (if 
treatment has to be continued) and the old 
one should be discarded. 
Note: Generally it is unadvisable for 
patients to continue to wear contact lenses-
unless medically indicated when receiving eye-
drops. Some drugs can spoil hydrophilic soft 
lenses. Therefore, unless eye-drops are 
specifically indicated as safe to use with 
hydrophilic contact lenses, the lenses should be 
removed before instillation and not worn during 
the period of treatment. 
 
A)  ANTI-INFECTIVE 
PREPARATIONS 
 
Infections of the eye can be due to bacteria 
or viruses. Most acute eye infections can be 
treated topically. Ideally, eye-drops should 
be instilled very frequently (at least every 2 
hours). In order to avoid sleeping 
disturbances, one can use eye-ointment for 
nighttime because of its longer duration of 
action. An eye-ointment will also soften 
crusts that cause the lids and eyelashes to 
adhere together when the patient is asleep. 
A small quantity of eye ointment is applied 
to the eye or inside the lower lid.  
It is very important to educate the 
patient of prevention of the spread of eye 
infections; minimize physical contact with 
other people, do not use same handkerchief 
or towel, a child should not attend school 
until the infection is cured. 
 
This chapter will discuss some 
antibiotics used in ophthalmic preparations 
and some antiviral agents that are used 
mainly in ophthalmic herpes infections. 
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1)  Antibiotics                             . 
 
• DRUG SUMMARY: 
It is preferred to use antibiotics that are 
rarely used to treat systemic infections (see 
precautions below). Always take in 
consideration the possibility of systemic 
absorption and systemic effects of these 
antibiotics. Some of the most commonly 
used antibiotics have a wide spectrum of 
activity, these include:  
Tetracycline WHO,P Chloramphenicol 
WHO,P, Framycetin, Gentamicin WHO,P, 
and Neomycin.   
Norfloxacin has a spectrum of activity 
similar to that of gentamicin.  Gentamicin 
and tobramycin are effective for treating 
infections due to Pseudomonas aeruginosa.  
Fusidic acid is useful in the treatment of 
infections caused by Staphylococcus spp.  
Note:  
1) Propamidine isethionate is of little value 
in bacterial infections, but is specific for the 
treatment of acanthamoeba keratitis that is 
a rare but devastating condition. Mercuric 
oxide eye ointment, even for short periods, 
is NOT recommended. 
2) Many antibiotic preparations contain a 
corticosteroid. Such mixtures should not be 
used unless a patient is under close 
specialist supervision. They should not be 
prescribed for undiagnosed ‘red eye’ which 
is sometimes caused by herpes simplex.  
• INDICATIONS: 
Trachoma, ocular infections: Treatment of 
superficial ocular infections involving the 
conjunctiva or cornea due to strains of 
microorganisms susceptible to the 
antibiotics. 
Table-9.1 indicates the main used 
antibiotics for the treatment of eye 
infections. 
• DOSAGE FORM: 
Drops, ointments and tablets. 
 
Table-9.1:  Antibiotics Used  
For Eye Infections 
Medication Indication 
Erythro-
mycin 
Prophylaxis of ophthalmia 
neonatorum due to Neisseria 
gonorrhoeae or Chlamydia 
trachomatis. 
Chloram-
phenicol 
Use only in those serious 
infections for which less 
potentially dangerous drugs 
are ineffective or contra-
indicated. 
Chlortetra
-cycline 
Local treatment for infections, 
including trachoma. 
Tetracycline 
HCl  
Massive (endemic areas) 
trachoma (recommended by 
WHO). 
*For detailed information about these 
antibiotics, refer to anti-infective chapter. 
 
• CONTRAINDICATIONS: 
Hypersensitivity to any component of these 
products; epithelial herpes simplex keratitis 
(dendritic keratitis); vaccinia; varicella; 
mycobacterial infections of the eye; fungal 
diseases of the ocular structure; use of 
steroid combinations after uncomplicated 
removal of a corneal foreign body. 
• RECOMMENDED DOSAGES: 
Eye-drops: Apply at least every 2 hours; 
reduce frequency as infection is controlled; 
continue for 48 hrs. after healing. 
Eye-ointment: Apply either at night (if eye-
drops used during the day) or 3-4 times 
daily (if eye-ointment used alone).  
Short-term courses with tetracyclines can 
be used for control of bacterial infections 
during seasonal epidemics of con-
junctivitis, and may be repeated annually. 
Directions: Tilt the head back, place 
medication in conjunctival sac and close 
eyes. To reduce systemic absorption, apply 
light finger pressure on lacrimal sac for 1 
min. following instillation; this retards 
passage of drops via nasolacrimal duct into 
areas of potential absorption, such as: nasal 
and pharyngeal mucosa. Eye-ointments are 
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often applied to lid margins for blepharitis, 
they may also be used in the conjunctival 
sac for other conditions especially where a 
prolonged action is required. To avoid 
contamination, do not let the tip of 
container touch any surface.  Close cap 
well after using. 
In case of Trachoma: 
-Tetracycline hydrochloride eye ointment 
applied to both eyes twice daily for 5 
consecutive days or once daily for 10 days, 
each month for 6 months.  
-Chlorotetracycline eye ointment may also 
be used. Chloramphenicol is not as 
effective.  
-For active trachoma in the individual, one 
or both of the following is/are effective:  
(i) For adults, orally administered sulphon-
amides for 2 weeks; for children, 
erythromycin should be used.  
(ii) Tetracycline eye ointment three times 
daily for 6 weeks.  Also see drug summery 
above. 
• USE IN SPECIAL CASES: 
Pregnancy- Use only when clearly indicated. 
Avoid fluoroquinolones and chloramphenicol. 
Category B; erythromycin, tobramycin.  
Category C; gentamicin, tetracyclines, 
ciprofloxacin, norfloxacin, ofloxacin, and 
polymyxin B.   
Safety of eye preparations for use during 
pregnancy has not been established. 
Lactation- It is not known whether 
ciprofloxacin, norfloxacin, or ofloxacin 
appear in breast milk following ophthalmic 
use. Exercise caution when administering 
ciprofloxacin to a nursing mother. Because 
of the potential for adverse reactions in 
nursing infants from norfloxacin, ofloxacin, 
chloramphenicol, and tobramycin; decide 
whether to discontinue nursing or 
discontinue the drug, taking into account 
the importance of the drug to the mother.  
Children- Tobramycin is safe and effective 
in children. Safety and efficacy of 
ophthalmic fluoroquinolones in infants < 1 
y., and polymyxin-B/trimethoprim in 
infants < 2 mon. have not been established.  
• PRECAUTIONS AND WARNINGS: 
1. Sensitization might occur from the 
topical use of an antibiotic, this may 
contraindicate the later use of the drug in 
serious infections. For this reason it is 
preferred that the antibiotics used topically 
are ones that are not ordinarily used 
systemically. Also there is a possibility of 
cross-sensitivity to occur. 
2. Hematopoietic toxicity has occurred 
occasionally with the systemic use of 
chloramphenicol and rarely with topical 
administration. 
3. Do not use topical antibiotics in deep-
seated ocular infections or in those that are 
likely to become systemic. Use of 
antibiotics (especially prolonged or repeated 
therapy) may result in bacterial or fungal 
overgrowth of non-susceptible organisms. 
Such growth may lead to a secondary 
infection. 
• ADVERSE EFFECTS: 
*Sensitivity reactions such as transient 
irritation, burning, stinging, itching, 
inflammation, etc. 
*Chloramphenicol: Grey-syndrome in 
infants, hematological events including 
aplastic anemia have been reported, but it is 
rare; and transient stinging. 
*Aminoglycosides: Localized ocular toxicity 
and hypersensitivity, lid itching, lid swelling, 
conjunctival erythema, etc. 
*Fluoroquinolones: White crystalline 
precipitates (it resolves in most patients 
within 2 weeks), lid margin crusting, 
conjunctival hyperemia, bad/bitter taste in 
the mouth, allergic reactions, lid edema, 
tearing, corneal staining, photophobia, 
corneal infiltrates, nausea, decreased vision, 
chemosis.   
• OVERDOSE: 
Symptoms: Most include exaggerated side 
effects of each category.  Symptoms of 
tobramycin overdose include punctate 
keratitis, erythema, increased lacrimation, 
edema, and lid itching. These may be 
similar to adverse reactions. 
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Treatment: A topical overdose of any 
antibiotic may be flushed from the eyes 
with warm tap water.  
• BRANDS: 
Refer to price list. 
___________________ 
 
2)  Antivirals 
 
Herpes simplex infections are the most 
common ophthalmic viral infections.  They 
produce, for example, dendritic corneal 
ulcer and can be treated with acyclovir; 
alternatively idoxuridine may be used.  
Treatment has to be started early in the 
infection for the antiviral agent to be 
effective and inhibit the replicating virus. 
 
Idoxuridine WHO 
 
• DRUG SUMMARY: 
Idoxuridine is a pyrimidine nucleoside used 
in the topical and ophthalmic treatment of 
viral infections. It inhibits replication of the 
virus. 
• INDICATIONS: 
Herpes simplex keratitis: Epithelial 
infections (especially initial attacks), 
characterized by the presence of dendritic 
ulcers, respond better than stromal 
infections.  
• CONTRAINDICATIONS: 
Hypersensitivity to idoxuridine or any 
component of the formulation. 
• DOSAGE FORMS: 
Drops, ointments. 
• RECOMMENDED DOSAGE: 
There are two different schedules as 
indicated in table-9.2.  
 
Note: Topical corticosteroids may be used 
with idoxuridine in some conditions as 
indicated by the specialist. It is important to 
continue idoxuridine therapy a few days after 
the steroids have been withdrawn (see 
precautions and warnings). 
 
Table-9.2:  Schedules for Recommended Doses 
of Idoxuridine 
Primary 
Schedule 
Initially, place 1 drop into 
infected eye(s) every hour during 
the day and q. 2 h. at night. 
Continue until corneal ulcers have 
healed, usually within 7 days. 
Then reduce dosage to 1 q. 2 h. 
during the day and q4h at night.  
To minimize recurrences, 
continue therapy at this reduced 
dosage for 3-7 days after 
complete healing.  
Max. treatment period is ≤ 21 d. 
Alternative 
Schedule 
Instill 1 drop every minute for 5 
minutes. Repeat q. 4 h., day and 
night. Maximum treatment is for 
21 days, or for 3-5 days after 
healing is complete. 
 
Directions: For optimal results, keep 
infected tissues saturated with the antiviral. 
• USE IN SPECIAL CASES: 
Pregnancy- Idoxuridine crosses the placenta 
barrier and produces fetal malformations 
when administered topically to the eyes of 
pregnant rabbits in clinical doses and when 
administered by various routes in high doses 
to other rodents. Safety for use during 
pregnancy has not been established.  
Use only if clearly needed and when the 
potential benefits outweigh the potential 
hazards to the fetus (Category C). 
Lactation- It is not known whether 
idoxuridine is excreted in breast milk. 
Because of the potential for tumorigenicity 
shown for idoxuridine in animal studies, 
decide whether to discontinue nursing or to 
discontinue the drug, taking into account the 
importance of the drug to the mother. 
Children- Safety and efficacy have not been 
established.  
• PRECAUTIONS AND WARNINGS: 
1. May cause sensitivity to bright light;  his 
may be minimized by wearing sun glasses. 
2. Recurrences of infection may be seen if 
medication is not continued for 5-7 days 
after the epithelial lesion has apparently 
healed. 
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3. Corticosteroids can accelerate the 
spread of a viral infection and are usually 
contraindicated in herpes simplex epithelial 
infections. 
4. Some strains of herpes simplex appear 
to be resistant.  
• ADVERSE EFFECTS: 
Occasional irritation, pain pruritus, 
inflammation or edema of the eyes or lids, 
allergic reactions, photophobia, corneal 
clouding, stippling, and punctate defects in 
the corneal epithelium.  
• INTERACTIONS: 
Boric acid containing solutions: Co-
administration may result in a precipitate 
formation which may cause irritation. 
• OVERDOSE: 
Local: Overdose will not ordinarily cause 
acute problems. Should accidental over 
dosage in the eye(s) occur, flush with water 
or normal saline. 
Accidental ingestion: Animal data indicate 
that the minimum systemic dose that will 
produce toxic effects is many times greater 
than the quantity in a commercial bottle. 
Also metabolic breakdown and excretion 
take place very rapidly. Thus, no untoward 
consequences should be expected from 
accidental ingestion of even an entire bottle 
of the solution.  Drink fluid to dilute. 
• BRANDS: 
Virusan (Teva). 
____________________ 
 
B)  ANTI-INFLAMMATORY 
PREPARATIONS 
 
Inflammatory problems of the eye are best 
treated by corticosteroids. In addition other 
anti-inflammatory preparations are used.  In 
this chapter, these drugs will be discussed.  
 
 
1)  Corticosteroids 
 
• DRUG SUMMARY: 
Corticosteroids can be used topically, by 
subconjunctival injection, and systemically 
to treat uveitis and scleritis; they are also 
used to treat inflammation following eye 
operations.  
Topical corticosteroids should normally be 
used only under expert supervision and they 
should not be prescribed for undiagnosed 
‘red eye’.   
There are two main dangers from topical 
corticosteroids. First the ‘red eye’ may be 
caused by herpes simplex virus that 
produces a dendritic ulcer; corticosteroids 
aggravate the condition which may lead to 
loss of vision or even loss of the eye.  
Second, arising from the use of eye-drop 
formulation, a ‘steroid glaucoma’ may be 
produced, after a few weeks of treatment, 
especially in patients predisposed to 
chronic simple glaucoma. 
 
Use of a combination product containing a 
corticosteroid with an anti-infective is 
rarely justified. 
 
There are large numbers of corticosteroidal 
preparations that are used in ophthalmic 
preparations. Examples of these 
corticosteroids are: betamethasone, dexa-
methasone, fluorometholone, hydrocortisone 
acetate, and prednisolone.   
All have similar indications, cautions, and 
side effects.  
 
Betamethasone WHO,P  
Will be discussed as the prototype of this 
group. 
• INDICATIONS: 
Local treatment of inflammation. 
• CONTRAINDICATIONS: 
Acute superficial herpes simplex keratitis; 
fungal disease of ocular structures; 
vaccinia, varicella and most other viral 
diseases of the cornea and conjunctiva; 
ocular tuberculosis; hypersensitivity; after 
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uncomplicated removal of a superficial 
corneal foreign body. 
• DOSAGE FORMS: 
Tablets, drops, ointments. 
• RECOMMENDED DOSAGE: 
Treatment duration varies with type of 
lesion and may extend from a few days to 
several weeks, depending on therapeutic 
response.   
Relapse may occur if therapy is reduced too 
rapidly; taper dose over several days.  
(Relapses are more common in chronic 
active lesions than in self-limited 
conditions that usually respond to re-
treatment). 
Suspensions and solutions: Instill 1 to 2 
drops into the conjunctival sac every hour 
during the day and every 2 hours during the 
night. When a favorable response is 
observed, reduce dosage to 1 drop every 4 
hours.  Later, 1 drop 3 to 4 times daily may 
suffice to control symptoms. For post-
operative inflammation, instill 1 to 2 drops 
4 times daily beginning 24 hours after 
surgery; continue throughout the first 2 
weeks of the postoperative period. 
Ointments:  Apply a thin coating in the 
lower conjunctival sac 3 or 4 times a day. 
When a favorable response is observed, 
reduce the number of daily applications to 
twice, and later to once a day as a 
maintenance dose if sufficient to control 
symptoms. Ointments are particularly 
convenient when an eye pad is used and 
may be the preparation of choice when 
prolonged contact of drug with ocular 
tissue is needed.   
• USE IN SPECIAL CASES: 
Pregnancy- Use only when clearly indicated 
and when potential benefits outweigh 
potential hazards (Category C). 
Lactation- It is not known whether topical 
steroids are excreted in breast milk. Exercise 
caution when administering to a nursing 
mother. 
Children- Safety and efficacy have not been 
established in children. 
• PRECAUTIONS AND WARNINGS: 
-If there is moderate to severe inflam-
mation, use higher strengths.  Under certain 
conditions systemic therapy may be 
required. 
-Prolonged use may result in glaucoma, 
elevated IOP, optic nerve damage, defects 
in visual acuity and field of vision, 
posterior subcapsular cataract formation, or 
secondary ocular infections from pathogens 
liberated from ocular tissues. 
-Acute untreated eye infection may be 
masked or activity enhanced by steroids. 
Fungal infections of the cornea have been 
reported with long-term local steroid 
applications. Therefore suspect fungal 
invasion in any persistent corneal ulceration 
where a steroid has been used, or is being 
used.  
• ADVERSE EFFECTS: 
Glaucoma (elevated IOP) with optic nerve 
damage, loss of visual acuity and field 
defects; posterior subcapsular cataract 
formation; secondary ocular infection from 
pathogens, including herpes simplex 
liberated from ocular tissues; exacerbation 
of viral and fungal corneal infections; 
transient stinging or burning; blurred 
vision, discharge, discomfort, ocular pain, 
foreign body sensation, hyperemia, and 
pruritis. 
• BRANDS: 
Refer to price list. 
__________________ 
 
 
2)  Other Anti-Inflammatory  
      Preparations 
 
Other preparations used for the topical 
treatment of inflammation and allergic 
conjunctivitis include antihistamines, 
oxyphenbutazone, and sodium cromo-
glycate. From these agents sodium 
cromoglycate will be discussed. 
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Sodium Cromoglycate  P 
(Cromolyn Sodium) 
 
• DRUG SUMMARY: 
It has been shown that cromolyn sodium 
inhibits the degranulation of sensitized mast 
cells that occurs after the exposure to 
specific antigens. Cromolyn has no intrinsic 
vasoconstrictor, antihistaminic or anti-
inflammatory activity. 
• INDICATIONS: 
Conjunctivitis: Treatment of vernal kerato-
conjunctivitis, vernal conjunctivitis, and 
vernal keratitis. 
• CONTRAINDICATIONS: 
Hypersensitivity to cromolyn or to any of 
the other ingredients. 
• DOSAGE FORMS: 
Drops, ointment. 
• RECOMMENDED DOSAGE: 
1 or 2 drops in each eye for 4 to 6 times a 
day at regular intervals.  One drop of 2% 
contains approximately 1.6 mg cromolyn 
sodium. 
 
Directions: The effect of cromolyn sodium 
therapy is dependent on its administration 
at regular intervals, as directed. 
• USE IN SPECIAL CASES: 
Pregnancy- There are no adequate and well-
controlled studies in pregnant women. Use 
during pregnancy only if clearly needed 
(Category B). 
Lactation- It is not known whether the drug is 
excreted in breast milk. Exercise caution 
when cromolyn is administered to a nursing 
woman. 
Children- Safety and efficacy in children < 4 
years of age have not been established. 
• PRECAUTIONS AND WARNINGS: 
1. Patients may experience a transient 
stinging or burning sensation following 
instillation of cromolyn. 
2. The recommended frequency of 
administration should not be exceeded. 
Symptomatic response to therapy 
(decreased itching, tearing, redness, and 
discharge) is usually evident within a few 
days, but longer treatment for up to 6 weeks 
is sometimes required. Once a symptomatic 
improvement has been established, 
continue therapy for as long as needed to 
sustain improvement. 
3. Corticosteroids may be used 
concomitantly with cromolyn ophthalmic 
solution. 
• ADVERSE EFFECTS: 
Transient ocular stinging or burning upon 
instillation is the most common side effect.  
• BRANDS: 
Opticrom (Fisons). 
_________________________ 
 
C)  β-BLOCKERS 
 
Glaucoma is a condition characterized by 
an increase in the intraocular pressure 
(IOP). It is primarily a disease of middle 
age. In most cases the rise in the ocular 
pressure is due to the reduction in the 
aqueous humor outflow while the inflow 
remains constant. 
Glaucoma is treated by the application of 
eye-drops containing β-blockers, miotics, 
or adrenaline (and guanethidine). Also 
acetazolamide and dichlorphenamide are 
given by mouth in emergency or before 
surgery, mannitol may be given by 
intravenous infusion.  
Probably the most common condition is 
chronic simple glaucoma where the 
obstruction is in the trabecular meshwork.  
It is commonly first treated with a topical 
β-blocker and other drugs added as 
necessary to control the intraocular 
pressure, e.g. adrenaline or pilocarpine. 
The most commonly used β-blocker for the 
treatment of glaucoma is Timolol. 
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1)  Timolol WHO,P 
 
• DRUG SUMMARY: 
The exact mechanism of its ocular 
antihypertensive action is not established, 
but it appears to be a reduction of aqueous 
production. However, some studies show a 
slight increase in outflow facility with 
timolol. 
• INDICATIONS: 
Glaucoma: Lowering IOP in patients with 
chronic open-angle glaucoma. They are 
mainly used in chronic simple glaucoma. 
• CONTRAINDICATIONS: 
Bronchial asthma, a history of bronchial 
asthma or severe chronic obstructive 
pulmonary disease; sinus bradycardia; 
second-degree and third-degree AV block; 
overt cardiac failure; cardiogenic shock; 
hypersensitivity to any component of the 
products.  
• DOSAGE FORMS: 
Drops of 0.25% and 0.5%. 
• RECOMMENDED DOSAGE: 
Initial therapy: 1 drop of 0.25% twice 
daily. If clinical response is not adequate, 
change the dosage to 1 drop of 0.5% 
solution twice a day. If the IOP is 
maintained at satisfactory levels, change 
the dose to 1 drop once a day. Since the 
pressure-lowering response may require a 
few weeks to stabilize, evaluation should 
include a determination of IOP after 
approximately 4 weeks of treatment. 
Replacement therapy (single agent):  
When the patient is transferred from one 
topical ophthalmic β-blocker to timolol, 
discontinue that agent after proper dosing 
on one day, and start treatment the next day 
with 1 drop of 0.25% timolol twice daily. 
Increase to 1 drop of 0.5% solution twice a 
day if response is inadequate. When 
changing from an agent other than an 
ophthalmic β-blocker, on the first day 
continue with the agent being used and add 
1 drop 0.25% timolol twice daily. The next 
day, discontinue the previously used agent 
completely and continue with timolol. If a 
higher dosage is required, substitute 1 drop 
0.5% twice daily. 
Replacement therapy (multiple agents):  
When transferring a patient from several 
concomitantly administered agents, indivi-
dualize dosage. If any of the agents is an 
ophthalmic β-blocker, discontinue it before 
starting timolol. Adjust 1 agent at a time, at 
intervals of not less than 1 week. Continue 
the agents being used and add 1 drop of 
0.25% twice a day. The next day, 
discontinue one of the other agents. 
Decrease or discontinue remaining agents 
according to patient response. If a higher 
dosage is required, use 1 drop of 0.5% 
timolol twice daily.  
Directions: Tilt head back, place 
medication in conjunctival sac, and close 
eyes. To reduce systemic absorption, apply 
light finger pressure on lacrimal sac for 1 
min. following instillation; this retards 
passage of drops via nasolacrimal duct into 
areas of potential absorption such as nasal 
and pharyngeal mucosa.  
• USE IN SPECIAL CASES: 
Pregnancy- There have been no adequate and 
well-controlled studies in pregnant women. 
Use during pregnancy only if the potential 
benefits outweigh potential hazards to the 
fetus (Category C). 
Lactation- Topical timolol is excreted in 
milk. Because of the potential for serious 
adverse reactions from timolol in nursing 
infants, decide whether to discontinue 
nursing or discontinue the drug taking into 
account the importance of the drug to the 
mother. 
Children- Safety and efficacy for use in 
children have not been established. 
• PRECAUTIONS AND WARNINGS: 
-Systemic absorption may follow topical 
application. Therefore the same adverse 
reactions found with systemic β-blockers 
may occur with topical use (refer to β-
blockers in the cardiovascular chapter). 
-It can reduce resting and maximal exercise 
heart rate even in healthy subjects. Also it 
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might precipitate cardiac failure. 
Discontinue at the first sign or symptom of 
cardiac failure. 
-Non-allergic bronchospasm patients or 
patients with a history of chronic bronchitis 
or emphysema should receive β-blockers 
with caution since they may block 
bronchodilation produced by catechol-
amine stimulation of β2-receptors. 
-Withdraw β-blockers before major 
surgery, since their use then is 
controversial. 
-Administer with caution to patients subject 
to spontaneous hypoglycemia or to diabetic 
patients. It may mask the signs and 
symptoms of acute hypoglycemia. 
-β-blockers may mask the signs of 
hyperthyroidism (e.g., tachycardia).  
Manage patients suspected of developing 
thyrotoxicosis carefully to avoid abrupt 
withdrawal of β-blockers that might 
precipitate a thyroid storm. 
-Use with caution in patients with 
cerebrovascular insufficiency. 
-The immediate objective in the treatment 
of angle-closure glaucoma is to reopen the 
angle by constricting the pupil with 
miotics. β-blockers have little or no effect 
on the pupil. When they are used to reduce 
elevated IOP in angle-closure glaucoma, 
use with a miotic. 
-β-blockers may potentiate muscle 
weakness. 
-Diminished responsiveness to timolol after 
prolonged therapy has been reported.  
• ADVERSE EFFECTS: 
Ophthalmic adverse effects as:   
Ocular irritation including conjunctivitis; 
blepharitis; keratitis; blepharoptosis; 
decreased corneal sensitivity; visual 
disturbances including refractive changes 
(due in some cases to withdrawal of 
miotics); diplopia; ptosis. In addition, 
systemic side effects may occur from the 
systemic absorption of timolol, these 
include: bradycardia, heart failure, 
bronchospasm, peripheral vasoconstriction, 
GI disturbances, fatigue, and sleep 
disturbances. 
• INTERACTIONS: 
Overview  of  Timolol 
Drug-Drug Interactions 
Drug Interaction 
Other β-
blockers 
(oral) 
Use caution due to the 
potential for additive systemic 
effects. 
Epinephrine 
(ophthalmic)
Use of epinephrine with 
topical β-blockers is 
controversial. Some reports 
indicate that the initial 
effectiveness of the combi-
nation decreases over time. 
Quinidine One case of sinus bradycardia 
has been reported with the 
coadministration of ophth. 
timolol. 
Verapamil Coadministration of ophth. 
timolol has caused brady-
cardia and asystole 
 
• OVERDOSE: 
Symptoms: With excess use, or an 
overdose, systemic β-blockers side effect 
such as bradycardia, hypotension, 
bronchospasm and acute cardiac failure 
may occur. If these occur, discontinue 
therapy and initiate appropriate supportive 
therapy.  
Treatment: If ocular overdosage occurs, 
flush eye(s) with water or normal saline. If 
accidentally ingested, efforts to decrease 
further absorption may be appropriate 
(gastric lavage). 
• BRANDS: 
Sinoptic (Eastern Chem.), Tiloptic 
(Assia/Riesel), Timolin (JePharm). 
___________________ 
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D)  MYDRIATICS & 
CYCLOPLEGICS 
 
Anticholinergic agents block the response 
of the sphincter muscle of the iris and the 
muscle of the ciliary body to cholinergic 
stimulation, producing papillary dilation 
(mydriasis) and paralysis of ciliary muscles 
(cycloplegia). They vary in potency and 
duration of action. Short acting, relatively 
weak mydriatics, such as tropicamide 0.5% 
(duration of action 3 hr.), facilitate the 
examination of the fundus of the eye. 
Cyclopentolate 1% (duration of action up 
to 24 hrs.) or atropine (duration of action 7 
days or longer) are preferable for producing 
cycloplegia for refraction in young 
children. 
 
1)  Atropine Sulphate WHO,P 
 
• INDICATIONS: 
-For cycloplegic refraction and for dilating 
the pupil in inflammatory conditions of the 
iris and uveal tract. 
-Treatment of iridocyclitis mainly to 
prevent posterior synechiae, often with 
phenylephrine 10% eye-drops (2.5% in 
children, elderly, and those with cardiac 
disease). 
 
 
• CONTRAINDICATIONS: 
Primary glaucoma or a tendency toward 
glaucoma (e.g., narrow anterior chamber 
angle); hypersensitivity to belladonna 
alkaloids or any component of the products; 
adhesions (synechiae) between the iris and 
the lens; children who have previously had a 
severe systemic reaction to atropine. 
• DOSAGE FORMS: 
Drops, ointment. 
• RECOMMENDED DOSAGE: 
See table -9.3. 
Directions: To avoid contamination, do not 
touch the dropper’s tip to any surface and 
replace cap after using. Keep out of the 
reach of children; wash your own hands 
and the child’s following administration; 
keep away from heat. 
• USE IN SPECIAL CASES: 
Pregnancy- Safety for use during pregnancy 
has not been established. Give to a pregnant 
woman only if clearly needed (Category C). 
Lactation- It may be detectable, in very small 
amounts, in breast milk. But even though it is 
compatible with breast-feeding. 
Children- Use with extreme caution in 
infants and small children.  Excessive use in 
children and in certain susceptible individuals 
may produce systemic toxic symptoms. 
 
 
Table-9.3:  Recommended Doses of Atroptine Sulphate 
Uveitis Instill 1 or 2 drops of 1% solution into the eye(s) up to 4 times daily. Adults 
Refraction Instill 1 or 2 drops of 1% solution into eye(s) 1 hr before refracting. 
Uveitis Instill 1 or 2 drops of 0.5% solution into the eye(s) up to 3 times daily. 
Solution 
Children 
Refraction 
Instill 1 or 2 drops of 0.5% solution into the 
eye(s) twice daily for 1 to 3 days before 
examination. 
Ointment 
Apply a small amount in the conjunctival sac up to 3 times daily. 
Compress the lacrimal sac by digital pressure for several minutes after 
instillation. 
Note:  Individuals with heavily pigmented irises may require larger doses. 
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• PRECAUTIONS AND WARNINGS: 
-Use it with caution in the elderly and 
others where increased IOP may be 
encountered. 
-Determine the IO tension and the depth of 
the angle of the anterior chamber before 
and during use to avoid glaucoma attacks. 
-Avoid excessive systemic absorption by 
compressing the lacrimal sac by digital 
pressure for 1 to 3 min. after instillation. 
-Use cycloplegics with caution in Down’s 
syndrome patients and in children with 
brain damage. 
-May produce drowsiness, blurred vision or 
sensitivity to light (due to dilated pupils); 
observe caution while driving or 
performing other tasks requiring alertness, 
coordination or physical dexterity. 
-May cause sensitivity to light. Protect eyes 
in bright illumination during dilation. 
• ADVERSE EFFECTS: 
Local: Increased IOP; transient 
stinging/burning; irritation with pro-longed 
use (e.g., allergic lid reactions, hyperemia, 
conjunctivitis, etc.). 
Systemic: Dryness of the mouth and skin; 
blurred vision; photophobia with or without 
corneal staining; tachycardia; headache; 
parasympathetic stimulation; somnolence; 
visual hallucinations. In addition to other 
toxic manifestations of antichlolinergic 
drugs. 
• OVERDOSE: 
Ocular: If ocular overdosage occurs, flush 
eye(s) with water or normal saline. Use of a 
topical miotic may be required.  
If accidentally ingested, treat with 
symptomatic and supportive care.. 
Systemic: If symptoms develop (see 
adverse reactions), patients usually recover 
spontaneously when the drug is 
discontinued. In cases of severe toxicity, 
give physostigmine salicylate. Have 
atropine (1 mg) available for immediate 
injection if physostigmine causes 
bradycardia, convulsions or broncho-
constriction. 
• BRANDS: 
Atrospan (Fisher), Atroped (Eastern Chem.). 
 
 
 
E)  MISCELLANEOUS OPHTHALMIC PREPARATIONS USED 
 
These agents should be prescribed by specialists and can be summarized in the following table: 
 
Name of the Drug Indication 
Acetylcysteine Tear deficiency, impaired mucus production. 
Diclofenac sodium 
Inhibition of intraoperative miosis during cataract surgery (but 
does not possess intrinsic mydriatic properties); postoperative 
inflammation in cataract surgery.  
Hydroxyethylcellulose Tear deficiency. 
Lignocaine HCl Local anesthetic. 
Liquid paraffin Tear deficiency. 
Oxybuprocaine HCl Local anesthetic. 
Proxymetacaine HCl Local anesthetic. 
Zinc sulphate Treatment of excessive lacrimation. 
 
__________________________________ 
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OTIC PREPARATIONS 
 
Most patients that attend a clinic with an 
ear problem tend to be children. The most 
common diseases that affect the ears are 
otitis externa, otitis media and 
accumulation of waxy secretions in the 
external ear.  Otitis media can further be 
subdivided into acute otitis media without 
effusion, acute otitis media with effusion, 
chronic suppurative otitis media, which 
implies a non-intact tympanic membrane 
with 6 weeks (some references say 2 
weeks) or more of middle ear drainage. 
Although viruses cause some ear 
infections, bacteria cause most. There have 
been increasing reports of resistance to 
antimicrobial agents that are used for the 
common bacterial causes for ear infections 
(Strep. pneumoniae, H. influenzae and M. 
catarrhalis). The rates of these are different 
between countries. Because of this, there 
have been various debates on use of 
antibiotics for treatment of ear infections 
(especially otitis media).  Risks and 
benefits have to be outweighed for each 
case. [BMJ. 1997(12 July);315:98-102]. 
There is sufficient information to support 
encouragement of breast-feeding and 
avoidance of tobacco smoke so as to 
prevent occurrences of ear infections in 
children.  Preliminary results suggest that 
multivalent pneumococcal conjugate 
vaccines that are immunogenic in infants 
and children older than 2 months are 
efficacious in preventing otitis media 
caused by serotypes of Strep. pneumoniae 
contained in this vaccine.  
In this chapter, general treatments for the 
previously mentioned diseases will be 
discussed. Each category of agents; anti-
infective agents, analgesics and earwax 
removers will be discussed within the 
disease of concern. 
 
A)  DRUGS USED FOR OTITS 
EXTERNA 
 
Otitis Externa (OE): a disorder in which 
there is an infection or inflammation of the 
external ear and ear canal (auditory meatal 
skin). More commonly seen in teenagers 
and young adults.  There is often a history 
of recent exposure to water (i.e. swimming 
in polluted water) or mechanical ear trauma 
from scratching or foreign objects in the 
ear.  
The two most common presentations are 
otalgia (ear pain) that can range from 
pruritis to severe pain that is exacerbated 
by motion of the ear including chewing and 
by manipulation of the pinna and pressure 
on the tragus, and otorrhea (discharge in or 
coming from the external auditory canal). 
If the inflammation is severe it can cause 
aural fullness and loss of hearing.  The 
most common cause of otitis externa is 
bacterial infection mainly Pseudomonas 
aeuroginosa but also Staphylococcus 
aureus, Entorobacter and other bacteria 
can cause it, fungal growth such as 
Candida and Aspergillus can cause 10% of 
the cases. It can also result from 
noninfectious dermatological cause such as 
eczema or psoriasis. 
It is important to exclude an underlying 
chronic otitis media before treatment is 
commenced. Many cases recover after 
thorough cleansing of the external ear canal 
by suction, or dry mopping. A frequent 
problem in resistant cases is the difficulty 
in applying lotions and ointments 
satisfactory to the relatively inaccessible 
affected skin. The most effective method is 
to introduce a ribbon gauze dressing 
soaked with corticosteroid eardrops or 
with an astringent such as aluminium 
acetate solution or 2% acetic acid.  When 
this is not practical, the ear should be 
gently cleaned with a probe covered in 
cotton wool and the patient encouraged to 
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lie with the affected ear uppermost for ten 
minutes after the canal has been filled with 
adequate quantity of one of the above 
mentioned solutions. 
A topical anti-infective is usually used 
for treatment that is not used systemically 
(such as neomycin), for only about a week 
(as excessive use may result in fungal 
infections; and these may be difficult to 
treat and require expert advice), unless the 
eardrum is perforated. Chloramphenicol 
may also be used. Solutions containing an 
anti-infective and a corticosteroid are used 
for treating cases where infection is present 
with inflammation and eczema. 
When a resistant Staphylococcal 
infection (a boil) is present in the external 
auditory meatus, flucloxacillin is the drug 
of choice. The skin of the pinna adjacent to 
the ear canal is often affected by eczema, 
and topical corticosteroid creams and 
ointments are then required and should be 
applied five or six times daily.  Prolonged 
use should be avoided. 
Ear drops and ointments should be 
applied using 3-4 drops of a liquid 
preparation or a similar quantity of 
ointment, warmed if necessary, inserted 
into the affected ear four times daily except 
for fluoroquinolones which are applied 
twice daily. The duration is for 3 days 
beyond the cessation of symptoms 
(typically 5-7 days) but in severe cases 10-
14 days may be required. . If discharge is 
profuse, eardrops applied directly may be 
washed away; in these circumstances the 
ear canal should be carefully cleaned and a 
1 cm gauze wick impregnated with the 
eardrops should be introduced into it. 
Note: When OE is treated topically with 
preparations containing chlorhexidine, 
aminoglycosides (e.g. neomycin), or 
polymyxins, in patients who have a 
perforation of the tympanic membrane, 
there is an increased risk of drug-induced 
autotoxicity (deafness). It is therefore 
important to ensure that there is no 
perforation in such patients before 
prescribing these preparations.  
In the presence of a perforation, refer 
patient to a specialist, where there may be 
closer supervision if drops are needed in 
Otitis media. 
 
B)  DRUGS USED FOR OTITIS 
MEDIA 
 
Otitis Media (OM): is an infection and/or 
inflammation of the middle ear (area 
behind the eardrum-typmanic membrane). 
OM is the second most prevalent disease of 
childhood after respiratory tract infections. 
It frequently occurs with respiratory 
infections. 
Infants and children are at highest risk 
for OM with the peak between 6-13 months 
and incidence decreases with age with a 
marked decrease after 6 years. The 
incidence is higher in boys, children in 
large daycare setting, those exposed to 
second hand smoke, non-breast fed infants 
and those with HIV or biological sibling or 
parent with a significant history of OM, 
and those with craniofacial anomalies, and 
more in winter months.  
The most commonly identified pathogens 
are Streptococcus pneumoniae (30-50%), 
non-typable H. influenzae (20-30%) and 
Moraxella catarrhalis (1-2%), viruses 
cause a minority of the disease. 
Diagnosis of OM is based on clinical 
symptoms which are: otalgia, fever, 
hearing loss, generalized malaise and 
otoscopic findings which include a 
hyperemic, opaque bulging tympanic 
membrane with poor mobility, purulent 
otorrhea with perforated tympanic 
membrane may be present. 
 
Local treatment of acute otitis media is 
ineffective and there is no place for drops 
containing a local anesthetic or an 
antibiotic. Culture of any discharge is 
helpful in selecting the appropriate 
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treatment; simple analgesics such as 
paracetamol are used to relieve pain.  
Treatment:  Some experts recommend 
watchful waiting for 24-48 hours after 
diagnosis of acute otitis media for patients 
older than 2 year and giving simple 
analgesia provided that close follow up is 
feasible since OM has high rate of 
spontaneous resolution in 60-80%of the 
cases. The recommendation of the 
American Academy of Pediatrics is to treat 
all cases of OM by giving a 5-7 days 
course of antimicrobial agents in certain 
children 2 years of age or older. Younger 
children and children with underlying 
condition such as craniofacial anomalies, 
chronic or recurrent OM or perforation of 
tympanic membrane should receive 
standard 10 day course (Red Book, 2000). 
Patients assessed at low risk for Strep. 
pneumonia resistance can be treated with 
usual dose amoxicillin 40-45 mg/kg/day in 
3 divided doses.  
Risk factor for resistance include: recent 
antibiotic exposure, age < 2 years, and day 
care attendance. For patients at high risk 
for resistance or with treatment failures 
when assessed after 3-5 days, suitable 
alternative drugs include: high dose 
amoxicillin 80-90 mg/kg/day in 2 or 3 
divided doses is recommended (drug of 
choice) or high dose amoxicillin 
clavulanate (80-90 mg/kg/day) of 
amoxicillin component or cefuroxime 
axetil (30 mg/kg/day in 2 divided doses). 
For penicillin resistant cases erythromycin, 
erythromycin-sulfisoxazole and in severe 
cases or treatment failure clarythromycin 
can be given.  
Even after the infection is cured, the 
middle ear fluid may persist for weeks or 
months, and in the majority of cases, clears 
spontaneously.  Treatment is indicated if 
effusions persist for 3 months or more. 
In recurrent acute otitis media, which is 
defined as 3 or more distinct and well 
documented episodes in 6 months or 4 
episodes in 1 year, a daily dose of a 
prophylactic antibiotic (sulfisoxaole 
50mg/kg/day or amoxicillin 20mg/kg/day 
once daily) at bed time during the winter 
months can be tried but routine use of 
prophylaxis has come into question due to 
emergence of many resistant bacteria so it 
should be reserved for selected cases. 
 
Chronic suppurative otitis media implies 
a non-intact tympanic membrane 
(perforation or tympanostomy tube present) 
within 6 weeks or more of middle ear 
drainage (BMJ 2000; 321:126-127).  In other 
books it is defined if more than 2 weeks.  
Any acute ear infection may become 
chronic, and can be more dangerous than 
acute ear infection because if prolonged or 
repeated, it may cause permanent damage 
to the ear.  Chronic infection may show 
less severe symptoms.  The bacteria that 
cause chronic infection are often different 
from those that cause acute ear infection. 
Usually the causative agents are 
Pseudomonas, Bacteroides, Staph. aureus 
and proteus.  Topical ear drops have been 
shown to be more effective than systemic 
antibiotics. Among the topical drops 
quinolone antibiotics have been shown to 
be more effective than aminoglycoside and 
less ototoxic. Ofloxacin drops are 
approved for children older than 1 year. If 
topical antibiotics fail, parenteral 
ceftazidime or imepenem should be used. 
Surgery is usually needed as well after 
control for infection. (BMJ 2000; 321: 126-
127).  Such cases should be under specialist 
supervision. It is important that antibiotic 
treatment does not replace drying the ear.  
It is also important to teach how to wick, so 
as to dry the ear. No cotton-tipped 
applicator or sticks should be used. 
Repeated courses of antibiotics should not 
be given for draining ear. It is preferred to 
take culture before starting treatment to 
know the organism and the susceptibility to 
antibiotics.  
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C)  DRUGS USED FOR EAR WAX  
 
Ear Wax: Wax-block or cerumen-
impaction is the blockage of the ear canal 
with cerumen (wax). The ear canal is lined 
with hair follicles and glands that produce a 
waxy oil called cerumen.  This protects the 
ear by trapping dust, microorganisms, and 
foreign particles, and prevents them from 
entering and damaging the ear.  The wax 
usually makes its way to the opening of the 
ear where it falls out or is removed by 
washing.  
In some people, the glands produce more 
wax than can be easily excreted out the ear. 
This extra wax may harden within the ear 
canal and block the ear.  More commonly, 
the ear canal may be clogged by wax when 
attempting to clean the ear causing 
blockage as it goes deeper into the canal.  
Wax blockage may cause perforated 
eardrum, otitis media, otitis external as 
well as hearing loss if not treated. 
Wax may be removed by syringing with 
body temperature water (cold or hot water 
may cause a response consisting of brief 
but severe dizziness or vertigo). If 
necessary, wax can be softed before 
syringing with simple remedies such as 
olive oil or almond oil.  The patient should 
lie with the affected ear facing upward for 
5 to 10 minutes after a generous amount of 
the solution has been introduced into the 
ear. Some proprietary preparations 
containing organic solvents can cause 
irritation of the meatal skin, but they are 
not more effective than other indicated 
preparations that are less likely to cause 
irritation. 
Note: Syringing is best avoided in patients 
with a history of recurring otitis externa, a 
perforated eardrum, or previous ear 
surgery.  A person who has hearing only in 
one ear should not have that ear syringed 
because even a very slight risk of damage 
is unacceptable in this situation. 
An available product in our market is 
Cerumol , which contains chlorbutol 5%, 
paradichlorobenzene 2%, and arachis oil 
57%.  
 
Notes: 
1) For detailed information about all the 
mentioned medication in the following 
table, refer to the related chapters, i.e. 
anti-infective preparations, analgesics and 
steroids. 
2) Betamethasone and prednisolone sodium 
phosphate are both contra-indicated if an 
infection is present. 
3) Sensitivity to the anti-infective or solvent 
may occur and resistance to antibacterials 
is a possibility with prolonged use. 
4) Chloramphenicol eardrops contain 
propylene glycol and cause sensitivity in 
about 10% of patients (the eye ointment 
can be used instead). 
 
Table-10.3 gives a summary of agents/ 
products that are used in ear problems in 
our market. 
 
_______________________________________________ 
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Table-10.3: The following table contains some of the drugs on the market for  
The Treatment of Otitis Media, Otitis Externa, and Ear Wax Accumulation. 
 
Drug Class Indications Administration Cautions Side effects 
Amoxicillin Anti-infective Treatment for 
OM 
Orally:  40-50 
mg/kg/day, 
divided into t.i.d. 
Be aware of 
bacterial 
resistance. May 
not be active 
against 
Moraxella. 
Refer to anti-
infectives 
chapter.  
Co-trimoxazole 
 
Anti-infective Treatment for 
OM 
Oral: 10 
mg/kg/dose 
given b.i.d. 
Do not 
administer in 
infants less than 
1 month old 
who are 
premature or 
jaundiced. 
Refer to anti-
infectives 
chapter. 
Erythromycin Anti-infective Treatment for 
OM, for 
penicillin 
sensitive 
patients 
Orally: 50 
mg/kg/day, divided 
q. 6 h., 4 times daily
 
Avoid 
prolonged use. 
May not be 
active against 
H. Influenzae. 
Refer to anti-
infectives 
chapter. 
Chloram-
phenicol 
Anti-infective 
preparation 
Bacterial 
infection in 
OE 
Apply 2-3 times 
daily 
Avoid 
prolonged use 
High 
incidence of 
sensitivity 
reaction to 
vehicle. 
Clotrimazole Anti-infective 
preparation 
Fungal 
infection in 
OE 
 
Apply 2-3 times 
daily continuing 
for at least 14 days 
after disappearance 
of infection 
 Occasional 
skin irritation 
or sensitivity. 
Gentamicin Anti-infective 
preparation 
Bacterial 
infection in 
OE 
Apply 3-4 times 
daily and at night 
Avoid 
prolonged use; 
risk of 
ototoxicity 
increased if 
perforated 
eardrum  
Local 
sensitivity. 
Neomycin 
Sulphate 
Anti-infective 
preparation 
Bacterial 
infection in 
OE and OM 
Apply eardrops  
q. 2-3 h.; ear 
ointment 2-4 times 
daily. 
Reduce frequency  
of application when 
relief is obtained  
Avoid 
prolonged use; 
slight risk of 
ototoxicity 
increased if 
perforated 
eardrum  
Local 
sensitivity. 
Tetracycline 
Hydrochloride 
Anti-infective 
preparation 
Bacterial 
infection in 
OE 
Apply q. 2 h. Avoid 
prolonged use 
Local 
sensitivity; 
stains skin 
and clothing. 
Beta-
methasone 
Sodium 
Phosphate 
Anti-
inflammatory 
preparations 
Eczematous 
inflammation 
in OE 
Apply q. 2-4 h.; 
reduce frequency of 
application when 
relief is obtained 
Avoid 
prolonged use. 
Steroid 
glaucoma in 
predisposed 
patients. 
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Prednisolone 
Sodium 
Phosphate 
Anti-
inflammatory 
preparations 
Aczematous 
inflammation 
in OE 
Apply q. 2-3 h.; 
reduce frequency of 
application when 
relief is obtained 
Avoid 
prolonged use.   
Steroid 
glaucoma in 
predisposed 
patients. 
Aluminum 
Acetate 
Astringent 
preparations 
Inflammation 
in OE 
Apply drops, or  use 
on a wick - 
Local 
sensitivity. 
Cerumol 
(paradichloro-
benzene, 
benzocaine, 
chlorobutanol , 
ol-terebinth) 
Ear wax 
remover 
Occlusion or 
Partial 
occlusion of 
external 
auditory Meatus 
due to Wax 
Instill 5 drops into 
ear with cotton 
wool plug and 
leave for 10-30 
min. 
Avoid 
prolonged use 
Local 
irritation, 
pain. 
Warm 
purified water Ear wax 
remover 
Soft, little waxy 
ear 
Applied once Vertigo may 
occur rarely 
Must be at 
body 
temperature 
Oils  
(olive, almond) 
Ear wax 
softners and 
remover 
Hard wax-
lubricant, 
alleviate itching
Applied once - Use 2-3 days 
only. 
 
 
 
_______________________________ 
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A)  EMOLLIENTS, HUMECTANTS 
1.  Vaseline 
2.  Glycerin 
 
B)  ANTIPRURITICS, ANTIHISTAMINES, LOCAL ANESTHETICS 
1.  Zinc Oxide / Calamine 
2.  Lignocaine / Benzocaine 
 
C)  ANTIFUNGALS 
1.  Miconazole 
2.  Ketoconazole 
3.  Tolnaftate 
 
D)  ANTIBACTERIALS 
1.  Oxytetracycline 
2.  Neomycin/Gentamicin 
 
E)  ANTIVIRALS 
1.  Acyclovir 
 
F)  ANTISEPTICS / DISINFECTANTS 
1.  Ethyl Alcohol 
2.  Povidone-Iodine 
3.  Cetrimide 
4.  Chlorhexidine 
 
G)  ANTIPARASITICS 
1.  Scabicides: Benzyl Benzoate, Crotamiton 
2.  Pediculicides: Malathion, Lindane 
 
H)  KERATOLYTIC AGENTS 
1.  Salicylic Acid 
2.  Sulfur 
 
I)  MISCELLANEOUS 
1.  Topical corticosteroids: Betamethasone Valerate 
2.  Preparations for acne:  Retinoic Acid/Tretinoin, Benzoyl Perxoide 
3.  Sunscreens 
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Dermatological Preparations 
 
A large number of drugs are available for 
topical skin therapeutics.  Many of the 
preparations available should be 
prescribed by dermatologists, to ensure 
expert advice and supervision. The 
“vehicle” of a preparation refers to the 
carrier-base that brings the drug into close 
contact with the skin. Both the vehicle and 
the active ingredients are important in 
treating skin disease. Skin preparations may 
contain preservatives, anti-oxidants, 
perfumes and coloring agents that may give 
rise to adverse reactions. Before choosing a 
specific preparation, factors such as 
cosmetic acceptability to the patient, 
suitability for the condition, safety and 
stability should be considered. 
 
• Creams are chosen for wet and 
weeping skin conditions. They are 
cosmetically acceptable and have proved 
good delivery systems for various drugs. 
Generally, creams are cosmetically more 
acceptable than ointments as they are less 
greasy and easier to apply. 
• Ointments are greasy preparations, 
suitable for chronic dry skin lesions.  They 
are more occlusive than creams, promoting 
hydration and the penetration of specific 
drugs, but are disadvantageous in oozing 
conditions. 
• Lotions may be preferred to creams or 
ointments when it is intended to apply a 
thin layer of the preparation over a large or 
hairy area. 
• Powders may contain one or more 
active ingredients with or without auxiliary 
substances. They are useful as adjunctive 
agents, intended to be applied to skin for 
therapeutic, prophylactic or lubricant 
purposes. They are used in folds where 
friction may occur between opposing skin 
surfaces. They should not be applied in 
areas that are very moist as they tend to 
cake and abrade the skin. 
When there is skin irritation, the 
underlying cause of irritation should be 
always sought and appropriate antipruritic 
therapy instituted. Although topical 
antibiotic agents may be valuable in the 
management of some infected skin 
conditions such as impetigo and infected 
eczema, they should not be used 
indiscriminately, thus resulting in the 
emergence of resistant bacterial strains. As 
for topical steroids, they are used 
frequently for the symptomatic relief and 
control of inflammatory and allergic skin 
conditions, and they are often prescribed 
without regard for the appropriateness of 
the indication, the potential for adverse 
effects or proper concern for the potency of 
the preparation. Topical corticosteroids 
should generally not be used in the 
presence of bacterial (including 
tuberculosis), fungal or viral infections of 
the skin. 
Excessive drying and defatting of the 
skin should be avoided, e.g., hot baths, 
alcoholic skin preparations, detergents and 
alkaline soaps. 
_______________ 
 
A)  EMOLLIENTS & 
HUMECTANTS 
 
Emollients/Barriers are occlusive agents or 
moisturizers used to prevent or relieve the 
signs and symptoms of dry skin. Emollients 
are used to rehydrate and soothe the skin, 
and are valuable in all conditions 
characterized by dryness, scaling and 
cracking of the skin.  Frequent application 
is usually needed and continued 
prophylactic use is recommended.   
The oily nature of these emollients 
promote water retention because the 
moisture of the skin cannot pass through 
the oily film.  The frequency of application 
depends on the degree of dryness of the 
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skin. The most common emollients are 
petrolatum jelly (vaseline), lanolin, and 
liquid petrolatum (mineral oil).  Lanolin 
and mineral oil are not very effectively 
used for the treatment of dry skin. 
However, combinations with other 
formulations are very common. 
Humectants are hydrating agents that 
draw water into the stratum corneum to 
hydrate the skin.  They are used in 
conjunction with emollients to treat and 
prevent dry skin. The difference between an 
emollient and a humectant is that an 
emollient retains the water that is already 
in the skin while a humectant adds water to 
the skin.  The most common humectants 
available are: glycerin, propylene glycol, 
and phospholipids. 
 
 
1)  Vaseline 
 
• DRUG SUMMARY: 
Vaseline or petrolatum jelly is one of the 
most effective emollients available. It is not 
very well tolerated by patients due to its 
greasiness and staining properties. It can 
also be used in conjunction with other 
products as an ointment base. 
• INDICATIONS: 
For treatment and prevention of dry skin. 
• CONTRAINDICATIONS: 
Hypersensitivity to petrolatum. 
• DOSAGE FORMS: 
Ointment. 
• RECOMMENDED DOSAGE: 
Directions: to be applied to affected area(s) 
as needed. Frequency of application 
depends on how dry the skin is.  It can be 
used with hydrating agents like glycerin in 
order to hydrate the skin more effectively.  
*In some cases it is recommended to advise 
the patient to hydrate the skin by soaking 
the affected area in water for 5-10 min., 
then patting it dry and applying vaseline to 
it. 
• PRECAUTIONS AND WARNINGS: 
Petrolatum should not be applied over 
puncture wounds, infections, or lacerations 
because its high occlusive ability may lead 
to inflammations and infections.  Excessive 
hydration should also be avoided. Use 
caution when applied around the nasal 
mucosa because it can obstruct breathing. 
• ADVERSE EFFECTS: 
Adverse effects are rarely seen with the 
topical use of vaseline, however acne is 
possible. 
• BRANDS: 
Petroleum Jelly, Vaseline. 
______________________ 
 
 
2)  Glycerin 
 
• DRUG SUMMARY: 
Glycerin is one of the most common 
hydrating agents. In addition to its 
hydrating effect, glycerin provides 
lubrication to the skin surface.  
It is indicated for use in the treatment and 
prevention of dry skin.  It can also be used 
as a skin protectant and as a solvent for 
different pharmaceutical agents. The only 
contraindication for use is hypersensitivity 
to glycerin. 
 ______________________ 
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B)  ANTIPRURITICS, 
ANTIHISTAMINES & LOCAL 
ANESTHETICS 
 
Pruritis or itching may occur with any type 
of systemic or skin disease. Pruritis can 
cause redness, local irritation and 
sometimes lesions if untreated.  It can also 
be a form of dermatitis. Several 
pharmaceutical products are available for 
the treatment of pruritis depending on the 
cause of it. Most formulations are available 
as combined products. The key in the 
treatment is to identify and then 
discontinue the aggravating factor of the 
itching before initiating therapy. The 
mentioned drugs are some of the most 
common ingredients found in antipruritic 
products. 
 
1)  Zinc Oxide / Calamine WHO,P 
 
• DRUG SUMMARY: 
Zinc oxide is an astringent with antipruritic 
properties. It is combined with ferric oxide 
to make calamine. Calamine is a pink 
colored powder that is not soluble in water.  
It has astringent, antiseptic, antibacterial, 
and antipruritic action.  When applied to 
the skin, the evaporation of water produces 
a cooling effect and the oozing of watery 
discharge is reduced. 
• INDICATIONS: 
It can be used in mild cases of dermatitis 
and poison ivy. In some cases calamine can 
be used to treat diaper rash and to relieve 
the itching caused by chicken pox.  It is 
generally used as an antipruritic agent. 
• CONTRAINDICATIONS: 
Hypersensitivity to any of the ingredients. 
• DOSAGE FORMS: 
Lotion, ointment, cream. 
• RECOMMENDED DOSAGE: 
To be applied to the affected area(s) as 
needed (3-4 times/day). 
Directions: it is safe for use in infants, 
children and adults.   
*Avoid contact with the eye(s). Flush with 
running water if contact with the eyes 
occurs. 
• PRECAUTIONS AND WARNINGS:   
For external use only. It should not be 
applied to ulcers or infected skin lesions 
associated with pus. 
• ADVERSE EFFECTS: 
Rare adverse effects are noted which include: 
local irritation, burning, and stinging.  
• BRANDS: 
Adinol Ointment (Teva), Caladerm (JePharm), 
Calatrim Lotion (Trima), Dyprotex (Mediline), 
Calamine Lotion (Sam-On). 
____________________ 
 
2)  Lignocaine / Benzocaine 
 
• DRUG SUMMARY: 
Lignocaine is a topical local anesthetic that 
temporarily relieve pain by preventing the 
transmission of nerve impulses.  
• INDICATIONS: 
For the temporary relief of pain, burning, 
itching, discomfort, and irritations in local 
skin disorders. It can also be used for local 
anesthesia of mucous membranes including 
oral, nasal and laryngeal membranes as 
well as anal pruritis and hemorrhoids. 
• CONTRAINDICATIONS: 
Hypersensitivity to any of these products.  
• DOSAGE FORMS: 
Ointment, cream, spray, lozenges, gel. 
• RECOMMENDED DOSAGE: 
To be applied to the affected area as 
needed.  
Directions: Use the minimal amount 
possible to avoid systemic side effects. 
*Do not apply oint./creams/gel to the eyes. 
*Lozenges should be sucked and not 
chewed for soothing laryngeal discomfort. 
*When using the oral anesthetic applied to 
the mouth and throat (like the lozenges or 
spray), use caution while swallowing food. 
Ingestion of food should be delayed for 1 
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hour after using these products to prevent 
choking. 
• USE IN SPECIAL CASES:  
Pregnancy- Use when the benefits outweigh 
the potential hazards to the fetus, (Category 
C). Safety for use during pregnancy has not 
been established yet. One or two applications 
will not cause harm. 
Lactation- Use caution. Sufficient data is not 
available.  
Children- Not to be used in infant < 1 y. of 
age.  Safe in children > 1 y., but decrease the 
dose depending on the age, body-weight and 
physical condition. 
• PRECAUTIONS AND WARNINGS:   
- Use the minimal effective dosage to avoid 
systemic absorption and side effects. 
• ADVERSE EFFECTS: 
Adverse effects are dose related. Local 
adverse effects might include: burning, 
stinging, and tenderness. Cutaneous lesions, 
urticaria, edema, contact dermatitis are also 
noticeable. Anaphylactic reactions and 
shock can also result from hypersensitivity. 
• INTERACTIONS:   
*Class I antiarrhythmic agents: caution 
should be exercised when using these 
agents together since the toxic effects are 
increased (synergistic action). 
• OVERDOSE: 
Systemic absorption may occur due to 
overdosage with topical treatment. CNS 
(convulsions) and cardiovascular (hypo-
tension) complications can occur.  Refer to 
an emergency setting for symptomatic and 
supportive care. 
• BTRANDS: 
Esracain (Rafa), Xylene. 
____________________________ 
 
C)  ANTIFUNGALS 
 
One of the most common skin diseases are 
fungal infections. They can occur anywhere 
in the body especially the areas that are 
mostly wet or sweaty. Such areas include 
the soles of the feet, between the toes, and 
the diaper area in infants/ children/ and 
even adults . . . etc.   
In most cases, topical antifungals are 
used. Ideally, skin infections should be 
examined by a dermatologist to confirm 
diagnosis before the treatment is begun.  
The primary effect of most antifungal drugs 
is to prevent colonization of new tissue by 
the organisms. The crucial factor for the 
successful treatment of skin fungal 
infections is to understand the kinetics of 
turnover of epidermal cells. In some 
complicated cases oral antifungals are 
needed to treat the fungal infections. 
There are a lot of products containing 
antifungal agents on the market.  Studies 
have not proven superiority of one product 
over the other in treating most localized 
infections of the skin. Topical antifungal 
agents include the broad spectrum 
imidazoles and triazoles (i.e. butoconazole, 
clotrimazole WHO,P, econazole, ketoconazole, 
miconazole WHO,P, terconazole, nyastatinP  
(for candidal infections only), and 
tolnaftate.  
 
Miconazole will be used as the prototype 
for the imidazole antifungal agents.   
[For more information about the oral anti-
fungal agents available, refer to the anti-
infectives chapter.] 
 
1)  Miconazole WHO,P 
 
• DRUG SUMMARY: 
Miconazole is an imidazole derivative 
broad spectrum antifungal agent.  It inhibits 
growth of different vulvovaginal 
candidiasis (Moniliasis and vaginal yeast 
infections) and dermatophytes such as 
Candida ablicans, Trichophyton rubrum 
and active forms of Tinea versicolor . . . 
etc.  It exerts fungicidal effect by altering 
the permeability of the fungal cell 
membrane.  
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• INDICATIONS: 
Tinea pedis (athlete’s foot), Tinea cruris 
(jock itch), Tinea corporis (ringworm) and 
vaginal and cutaneous candidas. 
• CONTRAINDICATIONS: 
Hypersensitivity to miconazole. 
• DOSAGE FORMS: 
Cream, powder, lotion, oral gel; 
suppositories/ ovules and cream for vaginal 
use. 
• RECOMMENDED DOSAGE: 
Directions: Apply to affected skin areas 
twice a day (morning and night) for 2 
weeks. If treating tinea pedis use for 1 
month. 
*For vaginal use: use supp./ovules daily at 
bedtime for 3 days; cream twice a day, for 
7 days. 
*For external use only.  Avoid contact with 
the eyes. 
• USE IN SPECIAL CASES:  
Pregnancy- Avoid unless clearly needed 
(Category B), specially in first trimester. 
There have been reports of birth defects (i.e. 
cardiovascular, oral clefts, spina bifida and 
hypospadias), observed when product was 
used vaginally during the first trimester, but 
no solid data is available to associate 
miconazole with congenital defects. 
Lactation- Not enough clinical information is 
available, use caution when applying on a 
nursing mother. 
• PRECAUTIONS AND WARNINGS:   
Discontinue if severe irritation occurs. 
Vaginal products may interact with latex 
products including diaphragm and 
condoms.  Warn patients. 
• ADVERSE EFFECTS: 
Irritation, burning, and allergic contact 
dermatitis. 
• INTERACTIONS:   
No drug interactions have been noted with 
topical use of miconazole. 
• OVERDOSE: 
Refer to the anti-infectives chapter. 
• BRANDS: 
Daktarin/Gyno-Daktarin (Abic/Janssen), Daktazole 
(JePharm), Fungazole (Pharmacare), Fungitirin 
(BPC). 
__________________________ 
 
2)  Ketoconazole 
 
• DRUG SUMMARY: 
Ketoconazole is another imidazole broad-
spectrum antifungal agent. It works by 
altering the permeability of the cell 
membrane of different types of fungus and 
yeast. It is significantly better absorbed 
after oral administration than other 
imidazoles, but has been associated with 
hepatotoxicity. 
• INDICATIONS: 
Cream: for the treatment of tinea corporis 
(ringworm), tinea cruris (jock itch) and 
timea pedis (athlete’s foot). 
Shampoo: reduction of scaling due to 
dandruff, seborrhoic dermatitis and 
Pityriasis versicolor (Tinea versicolor). 
• CONTRAINDICATIONS: 
Hypersensitivity to this group of antifungal 
agents. 
• DOSAGE FORMS: 
Cream, shampoo (both 2%). 
• RECOMMENDED DOSAGE: 
*Cream: Apply to affected area and 
surroundings once daily. Results can be 
seen as soon as treatment is initiated.   
Use for at least 2 weeks to reduce the 
possibility of recurrence.  
Tenia pedis may require 6 weeks of 
treatment. 
When used to treat seborrheic dermatitis it 
should be applied twice a day for up to 4 
weeks or when improvement is seen. 
*Shampoo: Moisten hair and scalp 
thoroughly with water, then apply a 
sufficient amount to produce enough lather.  
Massage throughout the scalp and hair for 
around one minute.  
Rinse hair thoroughly with warm water.   
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Repeat as before but leave it on for an 
additional 3 minutes and rinse thoroughly.  
Dry hair with towel or warm airflow.   
Shampoo hair twice a week for 4 weeks 
with at least 3 days between each 
shampooing. 
For Pityriasis versicolor it should be used 
once daily for five days. 
*For external use only. Avoid contact with 
the eyes. 
• USE IN SPECIAL CASES:  
Pregnancy- Use only if the potential benefits 
outweigh the potential hazards on the fetus 
(Category C); sufficient studies are 
unavailable. 
Lactation- Safety has not been established 
yet. Use caution when used in nursing 
mothers. 
Children- Safety and efficacy in children has 
not been established yet.  
• PRECAUTIONS AND WARNINGS: 
Discontinue if sensitivity reactions occur. 
The cream contains sulfites that might 
cause hypersensitivity reactions in 
susceptible individuals. 
Shampoo might cause removal of the curls 
in permanently waved hair.  
• ADVERSE EFFECTS: 
Cream: Severe irritation, pruritis, stinging, 
and allergic reactions. 
Shampoo: increase in normal hair loss, 
abnormal hair texture, irritation, mild 
dryness of skin, itching, and dryness/ 
oiliness of hair and scalp. 
• INTERACTIONS:   
Overview of Ketoconazole 
Drug-Drug Interaction 
Drug Interaction 
Astemizole 
and 
terfenidine 
These antihistamines should be 
avoided even with the topically 
administered ketoconazole. 
Severe cardiovascular adverse 
reactions may occur.  
 
• OVERDOSE: 
Shampoo: if ingested, employ supportive 
measures; gastric lavage with sodium 
bicarbonate. 
• BRANDS:  
Nizoral (Abic/Jennsen) 
__________________ 
 
3)  Tolnaftate 
 
• DRUG SUMMARY: 
Tolnaftate is effective in the treatment of 
superficial fungus infections of the skin. 
Because of its superficial action it might be 
administered with oral anti-fungal agents 
like Griseofulvin [for more information 
refer to the anti-infectives chapter], or 
Ketoconazole. 
• INDICATIONS: 
It is effective for the treatment of Tenia 
pedis (athlete’s foot), Tenia cruris (jock 
itch), and Corporis (ringworm). It can also 
be used for preventing superficial fungal 
infections. This agent is not suitable for 
deep infections of the nails or hair follicles. 
• CONTRAINDICATIONS: 
Hypersensitivity to the drug or product. 
• DOSAGE FORMS: 
Cream, solution, gel, powder (all as 1%). 
• RECOMMENDED DOSAGE: 
Directions: Apply to affected areas twice a 
day for 2 to 4 weeks. Only small quantities 
are required. 
*Affected areas should be clean and dry 
before application of the product. 
*For external use only.  
*Avoid contact with the eyes. 
• PRECAUTIONS AND WARNINGS:   
If no improvement is seen within 4 weeks, 
patient should be re-evaluated. 
• ADVERSE EFFECTS: 
Mild irritation and allergic reactions might 
occur (rarely).  
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• OVERDOSE: 
Incidents of toxicity with topical use are 
very rare.  If it occurs use symptomatic and 
supportive care. 
• BRANDS: 
Athletes Foot (Scholl), Pitrex (Teva), Tinaderm 
(Shering), Tinasol (Fischer). 
_____________________ 
 
 
D)  ANTIBACTERIALS 
 
Antibacterials are used to treat and prevent 
topical infections. Different kinds of 
antibiotics are used depending on the type 
of organism. Since there are a lot of 
products on the market, remember these 
points: 
 
• Although topical antibiotics are 
indicated for infective skin conditions, they 
should not be used indiscriminately, thus 
resulting in the emergence of resistant 
bacterial strains, which precludes future 
systemic use of the antibiotic.  Mupirocin 
(Bactroban®) is an example of a commonly 
used broad spectrum topical antibiotic 
which  is abused. Resistant Staph. aureus to 
mupirocin are emerging. Mupirocin should 
not be used as a first-line agent or in 
hospitals, and should be used when other 
topicals (i.e. tetracyclines) fail. When used, 
avoid use for longer than 10 days. 
• Use of combination products of an 
antibiotic and corticosteroids should be 
avoided in bacterial infections. 
 
 
1)  Oxytetracycline 
 
• DRUG SUMMARY: 
Oxytetracycline is a broad-spectrum 
tetracycline antibiotic that inhibits protein 
synthesis.  It is usually used in combination 
with polymixin B.  Its use may be limited 
because it oxidizes and turns the skin 
yellowish-brown. 
• INDICATIONS: 
Used for infection prophylaxis in minor 
cuts, wounds, burns, and skin abrasions.  It 
also aids in healing and treating superficial 
infections of the skin. 
• CONTRAINDICATIONS: 
Hypersensitivity to the drug. 
• DOSAGE FORMS: 
Ointment. 
• RECOMMENDED DOSAGE: 
Directions: Apply to infected area(s) 1 to 4 
times a day. Cover with sterile bandage if 
needed. 
*For external use only. Not to be used on 
the eyes; there are special preparations for 
ophthalmic use.  
• PRECAUTIONS AND WARNINGS: 
Long term use may lead to overgrowth of 
non-susceptible bacteria or fungi. 
Discontinue if redness, irritation, swelling 
or pain persists or increases, or if secondary 
infections occur. The ointment might stain 
clothes. 
• ADVERSE EFFECTS: 
Yellow to brown stains may occur on the 
skin as mentioned above.  Skin irritation 
and rash might occur in some cases. Hyper-
sensitivity reactions are very common. 
• BRANDS: 
Jordacycline (Jordan), Oxycin (BPC), Tetracare 
(Pharmacare), Tetrapharm (JePharm), Teva-
cycline Derm (Teva). 
_______________________ 
 
2)  Neomycin WHO,P or Gentamicin 
 
• DRUG SUMMARY: 
Neomycin and Gentamicin are aminogly-
coside antibiotics that are active against 
gram negative bacteria as well as 
Staphylococcus infections. They work by 
inhibiting protein synthesis, they are 
bactericidal. Resistance for neomycin is 
very common and limits its use. Because of 
the resistance factor it is mostly used in 
combinations with other antibiotics such as 
polymixin B and/or bacitracin. Use of these 
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agents on large areas of the skin should be 
avoided especially in children, in the 
elderly and in those with impaired renal 
function, due to risk of nephrotoxicity and 
ototoxicity. Patients sensitive to neomycin 
may be treated with gentamicin. 
• INDICATIONS: 
Used for the prevention and the treatment 
of infections secondary to minor cuts, 
wounds, burns, and skin abrasions. 
• CONTRAINDICATIONS: 
Hypersensitivity to drug. 
• DOSAGE FORMS:  
Cream, ointment. 
• RECOMMENDED DOSAGE: 
Directions: Apply to infected area(s) 1 to 4 
times a day.  Covering the infected area(s) 
with sterile bandage is possible. 
• PRECAUTIONS AND WARNINGS:   
-Hypersensitivity reactions are very 
common.  
-Chronic use of topical aminoglycoside 
antibiotics increases the possibility of 
sensitization. Discontinue use if symptoms 
of hypersensitivity appear. 
-Use with care in treating burns and trophic 
ulceration because it can lead to systemic 
absorption and systemic adverse effects, 
especially in children and in renal impaired 
patients. 
• ADVERSE EFFECTS: 
Ototoxicity and nephrotoxicity are common 
especially if applied to large areas for long 
periods of time for this group of drugs. 
Possible photosensitization with gentamicin 
has been reported. 
• BRANDS: 
Garamycin (Schering), Gentatrim (Trima), 
Garamine (Jordan Chemical Lab).  
_________________________ 
 
 
E)  ANTIVIRALS 
 
Antiviral drugs should be only 
prescribed by a specialist. Cases of 
recurrent labial and genital herpes simplex 
should be treated as early as possible. 
[For more information about systemic 
antivirals, refer to the anti-infectives chapter.] 
 
1)  Acyclovir 
 
• DRUG SUMMARY: 
Acyclovir (also written as aciclovir) is an 
antiviral that inhibits the viral DNA 
replication. It is only effective if started at 
onset of infection. Some decrease in the 
duration of viral shedding has been noted. 
• INDICATIONS: 
It is used for the management of initial and 
recurrent episodes of herpes genitalis and in 
genital and labial cases of herpes simplex 
viral infections as injection. 
Acyclovir is not a cure for herpes simplex 
infections, it might benefit in treating 
recurrent attacks. 
• CONTRAINDICATIONS: 
Hypersensitivity to the drug. 
• DOSAGE FORMS: 
Cream, ointment. 
• RECOMMENDED DOSAGE:  
Directions: Apply to infected area(s) every 
3 hours (or 6 times a day) for 7 days. 
Application should start as early as 
possible (as soon as the signs and 
symptoms occur).  
*Use rubber gloves when applying to 
lesions to prevent the spreading of the 
lesions to other area(s) in the body or 
transmitting the virus to other individuals.  
*The ointment should thoroughly cover all 
lesions.   
*For external use only.  Avoid use on the 
eyes; special preparation available for eyes.   
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• USE IN SPECIAL CASES: 
Pregnancy- Use only if the potential benefits 
outweigh the potential hazards on the fetus 
(Category C). Well-controlled clinical studies 
on pregnant women have not been done. 
Lactation- It is not known whether it is 
excreted in the breast milk. Use caution when 
used on nursing mothers. 
• PRECAUTIONS AND WARNINGS: 
Dose should not be exceeded. No data is 
available that proves that acyclovir prevents 
the transmission of the infections to other 
people, or prevent recurrence infections 
when applied in the absence of signs and 
symptoms. Not to be used to prevent 
recurrent HSV infection. 
• ADVERSE EFFECTS: 
Mild pain, burning/stinging, pruritis, rash, 
and vulvitis. 
• BRANDS:  
Virax (BPC), Zovirax (GlaxoWellcome). 
_________________________ 
 
 
F)  ANTISEPTICS/ 
DISINFECTANTS 
 
Antiseptics and disinfectants are generally 
used to destroy and inhibit the growth of 
pathogenic micro-organisms.  There is no 
clear difference between them. 
The term antiseptic is used to a 
chemical agent that destroys or inhibits 
micro-organisms on living tissues having 
the effect of limiting or preventing the 
harmful results of infection. 
However a disinfectant is a chemical 
agent that destroys microorganisms, but it 
does not necessarily kill all the micro-
organisms, but reduces them to a level that 
is not harmful.  It can be applied to the 
living tissues as well as inanimate objects.  
 
 
1)  Ethyl Alcohol (Ethanol) P 
 
• DRUG SUMMARY: 
It is a widely used antiseptic and a 
disinfectant that exerts bactericidal and 
fungicidal action in concentrations at 70%. 
In concentrations above 80% its 
bactericidal effect is low. It has virucidal 
action at 90%.  It is less effective against 
HBV viruses.  
Used as an antiseptic agent before 
injections to prevent topical infections. It is 
not a desirable wound antiseptic because it 
causes irritation in already damaged tissues, 
and may delay healing. 
• CAUTION: The solution is flammable. 
Avoid use on broken skin and the eyes. 
Intended for external use only.  
• ADVERSE EFFECTS: may include 
local irritation, burning and stinging 
especially in cases when it is used on open 
wounds or on broken skin. 
_____________________ 
 
2)  Povidone-Iodine WHO,P 
 
• DRUG SUMMARY: 
A disinfectant and antiseptic that is active 
against bacteria, fungi, viruses, protozoa, 
and cysts.  Concentrations of 4-10 % are 
available in the market.  
• INDICATIONS: 
As an antiseptic and disinfectant for the 
treatment and prevention of contaminated 
wounds and for pre-operative preparation 
of the skin and mucous membranes. It also 
acts as a disinfectant for the equipment 
used in the operation. 
• CONTRAINDICATIONS: 
Hypersensitivity to the drug, should not be 
used on patients with non-toxic nodular 
colloid goiter. 
• DOSAGE FORMS: 
Solution, powder, ointment (10% povidone 
iodine=1% iodine). 
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• RECOMMENDED DOSAGE: 
Directions: To be applied on the skin or 
mucous membrane. Ointment maybe 
applied to affected area 2-4 times daily. 
*Disinfecting the equipment should be 
done according to regular protocols taken 
by the institution. 
*For external use only, not to be applied on 
open skin. Avoid contact with the eye(s). 
• PRECAUTIONS AND WARNINGS: 
Avoid use in pregnancy and lactation.  
Neonatal hypothyroidism has been 
reported. 
• ADVERSE EFFECTS: 
Local irritation, itching, and pruritis are 
possible but rare.  When applied to severe 
burns or to large areas systemic adverse 
reactions might occur. 
• BRANDS:  
Betadine (Rafa), Iodocare (Pharmacare), Iodo-
Vit (Vitamed), Polydine (Fischer). 
_______________ 
 
3)  Cetrimide 
 
• DRUG SUMMARY: 
Cetrimide is an antiseptic with great 
bacterial activity against gram-positive 
bacteria. In higher concentrations it is 
active against gram-negative bacteria. It has 
variable activity against fungus and viruses.  
• INDICATIONS: 
It is used as an antiseptic for cleansing skin, 
wounds, and burns.  It is mainly used in 
combination with other agents like 
chlorhexidine (explained below). It is also a 
component of some shampoos to remove 
scales in seborrhea.  
• CONTRAINDICATIONS: 
Hypersensitivity to the drug. 
• DOSAGE FORMS: 
Solution: 0.1-1% (further dilution is required 
before use), cream: 0.5% 
• PRECAUTIONS AND WARNINGS:   
For external use only. Avoid contact with 
the eyes.  
It is susceptible to contamination with 
micro-organisms therefore precautionary 
measures should be taken. Avoid use in 
body cavities. 
Hypersensitivity reactions are common 
after repeated use. 
• ADVERSE EFFECTS: 
Irritation is possible but rare. It usually 
occurs after several applications. There 
have been rare reports of burns due to 
concentrated solutions of cetrimide. 
• OVERDOSE: 
If ingested, cetrimide causes nausea, 
vomiting, esophageal damage and necrosis. 
It can also cause cyanosis, depression of the 
CNS, hypotension, coma, and it might lead 
to death. Treat ingestion by treating the 
symptoms, avoid emesis and lavage. 
• BRANDS:  
Capillon (Gramse), Cetrimide (Vitamed). 
(refer to the price list for other products) 
________________ 
 
4)  Chlorhexidine WHO,P 
 
• DRUG SUMMARY: 
It is an antiseptic and a disinfectant 
effective against a wide range of bacteria 
(excluding bacteria that cause tuberculosis), 
fungi, and viruses. It is available as a 
gluconate and an acetate salt.  
• INDICATIONS: 
Used to disinfect the skin, wounds, burns, 
and to clean instruments and hard surfaces. 
It is used as a surgical scrub, hand rinse and 
wipes. The chlorhexidine wipes are used as 
a cleanser for acne vulgaris. It is also used 
as a mouthwash to prevent gingivitis and to 
prevent plaque.  
It is found in combinations with other 
antiseptics especially cetrimide (refer to 
cetrimide). 
• CONTRAINDICATIONS: 
Hypersensitivity to the drug. 
• DOSAGE FORMS:  
Solution, mouthwash, dental gel, cream. 
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• RECOMMENDED DOSAGE:  
*As a disinfectant: for emergency 
disinfection of clean instruments, emerse 
the instruments in a 0.5% solution of the 
gluconate or the acetate mixed with 70% 
alcohol. For storage and disinfection 
emerse for 30 minutes in 0.05% solution. 
*As an antiseptic: chlorhexidine gluconate 
(0.05% aqueous solution) is used to 
disinfect wounds, burns, and other damaged 
skin disorders.  
*As a mouthwash: 0.2% chlorhexidine 
gluconate is used twice a day after brushing 
and flossing. 
*As a dental gel: 1% chlorhexidine 
gluconate is used after brushing with the 
normal tooth paste twice a day.  
*For external use only.   
*Keep out of the eyes and ears (when using 
the topical solution).  
*Avoid exposing it to excessive heat. 
• USE IN SPECIAL CASES:  
Pregnancy- Use with caution. No data is 
available about the use of chlorhexidine in 
pregnant women.  
Lactation- Use with caution. There has been 
some reports about the excretion of 
chlorhexidine in breast milk. Use only 
when the benefit of its use outweighs the 
risk on the infant.  
• PRECAUTIONS AND WARNINGS: 
-Do not use on a regular basis on wounds 
involving more than the superficial layer of 
the skin.  It might cause deafness if applied 
in the middle ear. 
-When using the mouthwash do not 
swallow solution, only use it as a gargle. 
• ADVERSE EFFECTS: 
Irritation, dermatitis, photosensitivity, and 
deafness. 
• BRANDS: 
Bactosept concentrate/ Bactroscrub (Vitamide), 
Uniscrub (Seton). 
__________________________ 
 
G)  ANTIPARASITICS 
 
Scabies: It is a parasitic skin infestation 
caused by Sarcoptes scabiei. It burrows 
itself beneath the stratum corneum. It does 
not bite or sting, but it is characterized by 
secondary inflammation and intense 
itching. It is usually associated with poor 
hygiene, crowded conditions, and venereal 
disease. It is usually transmitted through 
bodily contact with an infested host, 
clothing, bedding or toilet use.  
Pediculosis: is an infestation with lice. 
There are three types:  Pediculosis capitis 
caused by head louse, Pediculosis corporis 
caused by body louse and Pediculosis pubis 
caused by crab louse.  
 
In treating infected patients it is important 
to examine contacts for evidence of 
infection and treat accordingly. Emphasis 
on proper hygiene (i.e. changing sheets and 
towels) for preventing reinfestation is 
essential. It may be recommended to treat 
family members in close contact for 
preventive measures. 
 
Scabicides and Pediculicides are used for 
therapy of these infections. 
 
 
1)  SCABICIDES  
 
a)  Benzyl Benzoate WHO,P 
 
• INDICATIONS: 
It is used in the eradication of scabies.  It is 
also used as a pediculicide. 
• CONTRAINDICATIONS: 
Hypersensitivity to the drug. 
• DOSAGE FORMS: 
Lotions and emulsions. 
• RECOMMENDED DOSAGE: 
Apply to the whole body from the neck 
down after a bath.   
Directions: *The concentrated lotion is 
applied to adults, while the diluted lotion is 
required for infants and children (other 
products are preferred for their use). 
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Individual product instructions should be 
followed. Another coat may be applied 
when the first application dries up.   
*The residue should be washed off after 24 
hours.  
*A second application may be required 
after 5 days.   
*Clothing and bedding should be cleaned in 
boiling water to prevent re-infestation.  
• PRECAUTIONS AND WARNINGS: 
For external use only.  Avoid contact with 
the eye(s) and face. 
Safety for use in pregnancy (Category C) 
and lactation is not established. Use only if 
clearly needed. 
• ADVERSE EFFECTS: 
It might irritate the skin, mucous membrane 
and the eye(s). 
• OVERDOSE: 
If ingested, it stimulates the CNS and 
causes convulsions.   
Treatment involves gastric lavage and 
symptomatic measures. 
• BRANDS: 
Benzocide (Trima), Scabicide (BPC), Scabiex 
(Rekah). 
__________________ 
 
b)  Crotamiton 
 
• DRUG SUMMARY: 
It is used as an antipruritic for itch due to 
scabicides, however, it is not really known 
how it exerts its effect. 
• INDICATIONS: 
Used for the eradication of scabies and 
symptomatic treatment of pruritis due to 
scabies. 
• CONTRAINDICATIONS: 
Hypersensitivity to the drug. 
• DOSAGE FORMS: 
Cream, lotion. 
• RECOMMENDED DOSAGE: 
Directions: After bathing, apply to the 
whole body from the neck down. A second 
application is advisable in 24 hours. A 
cleansing bath is required after 48 hours 
after the last application.   
*Change clothing and linen the next 
morning to prevent reinfestation.  
*For external use only.   
• USE IN SPECIAL CASES:  
Pregnancy- Avoid use. It is not known 
whether it can cause fetal harm, use on 
pregnant women only if clearly needed 
(Category C). 
Lactation- Use caution. No clinical studies 
are available concerning the use of it in 
breast-feeding mothers. 
Children- Safety and efficacy for use in 
children have not been established. 
• PRECAUTIONS AND WARNINGS: 
Do not apply to acutely inflamed skin, the 
eyes or mouth. If severe irritation occurs 
discontinue use.  Do not apply near the 
eyes, mouth, and mucous membrane. 
• ADVERSE EFFECTS:  
Local irritation and allergic sensitivity 
reactions might occur.  
• OVERDOSE: 
If ingested it can cause convulsions, 
nausea, vomiting, abdominal pain, burning 
and irritation of oral esophageal and gastric 
mucousa. Do not induce vomiting.  Take to 
the hospital for supportive and symp-
tomatic care. When applying large amounts 
of it topically to children it might cause 
cyanosis. 
• BRANDS:   
Crutex (BPC), Eurax (Novartis C.H.), Scabicin 
(Fischer). 
______________________ 
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2)  PEDICULICIDES 
 
a)  Malathion 
 
• DRUG SUMMARY: 
Malathion is a lousicidal and ovicidal that 
is dispensed by prescription only. The 
advantage of its use is that it is less toxic 
than other products because it rapidly 
hydrolyzes and detoxifies.  
• INDICATIONS: 
Treatment of head lice and their ova. 
• CONTRAINDICATIONS: 
Sensitivity to it or any of its products. 
• DOSAGE FORMS:  
Lotion 0.5%. 
• RECOMMENDED DOSAGE:  
Directions: Apply to dry hair and rub 
gently until the scalp moistens. Allow it to 
dry naturally. Do not cover or use any 
heat to dry it up.  After 8 to 12 hours rinse 
hair and apply a non-medicated shampoo. 
Rinse, then comb hair with a fine toothed 
comb to remove dead lice and eggs.  Repeat 
within 7 to 9 days if required. 
• USE IN SPECIAL CASES:  
Pregnancy- Use during pregnancy only if 
clearly needed (Category B). 
Lactation- Exercise caution when using in 
nursing mothers. It is not known whether it is 
excreted in breast milk. 
Children-  Safety and efficacy in children < 2 
years of age have not been established. 
However the use of it in children between the 
ages of 2 and 11 years of age had shown no 
documented problems.   
• PRECAUTIONS AND WARNINGS: 
-It contains flammable alcohol. The lotion 
should not be exposed to open flames or 
electric heat.  Do not smoke while applying 
lotion or while hair is wet.  
-For external use only. Avoid contact with 
the eyes. If it gets in the eye accidentally, 
flush immediately with running water. 
• ADVERSE EFFECTS: 
Irritation of the scalp has occurred. Other 
adverse effects are rare. 
• INTERACTIONS: 
Exposure to carbamate or organo-
phosphate-type insecticides or pesticides 
when using malathion may increase the 
possibility of systemic absorption. Advise 
patients using malathion to protect them-
selves from these insecticides or pesticides. 
Other interactions are possible if per-
cutaneous absorption of malathion occurs. 
• OVERDOSE: 
Oral ingestion of malathion may cause 
systemic adverse reactions. These reactions 
are delayed reactions that can occur 12 
hours after ingestion.  
Symptoms of overdose include- Abdominal 
cramps, anxiety, unsteadiness, confusion, 
diarrhea, labored breathing, dizziness, 
watery eyes, pinpoint pupil, seizures and 
bradycardia.  
Treatment- Induce vomiting promptly or 
lavage the stomach with 5 % sodium 
bicarbonate solution.  
Severe respiratory distress is one of the 
most serious overdose symptoms, requiring 
artificial respiration and doses of IV or IM 
atropine. 
Patient should be observed continuously for 
signs of deterioration due to delayed 
absorption. 
• BRANDS: 
Nouryl (Chefaro), Prioderm (NAPP/Rafa). 
________________________ 
 
b)  Lindane 
 
• DRUG SUMMARY: 
Lindane (Gamma Benzene Hexachloride) is 
an ectoparasiticide and an ovicide; kills 
scabies and their eggs. It is not used for 
prevention.  It is a 2nd line treatement for 
those who cannot tolerate other safer 
agents, or treatment with other products has 
failed. 
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• INDICATIONS: 
Treatment of Pediculus capitis (head lice) 
and Pediculus pubis (crab lice) and their 
ova. The cream and lotion are also 
indicated for scabies. 
• CONTRAINDICATIONS: 
Hypersensitivity to the active ingredient or 
the product.  It is also contraindicated in 
neonates since it is easily absorbed from 
their skin, and in patients with known 
seizures disorders. 
• DOSAGE FORMS:  
Lotion, cream, shampoo (all as 1%). 
• RECOMMENDED DOSAGE: 
Rubber gloves should be worn during the 
application of lindane products. 
*Cream and lotion: Scabies-  Apply a thin 
layer to dry skin, to the whole body from 
the neck down, rub thoroughly.  Leave on 
for 8 to 12 hours then wash thoroughly with 
warm water (not hot). One application 
should be curative.  
*Lotion: Pediculosis Pubis- Apply a 
sufficient quantity to cover the hair and the 
skin in the pubic area and other infested 
areas like the thighs, trunk and axillary 
region. Leave in place for 12 hours then 
wash thoroughly. Reapplication is not 
necessary unless living lice is found. It can 
be reapplied after 7 days. Sexual partner 
should be treated concurrently. 
*Lotion: Pediculosis Capitis- Apply a 
sufficient quantity to cover the affected 
areas. Rub into the scalp and hair and leave 
in place for 12 hours then wash thoroughly. 
Reapplication is not necessary unless living 
lice is found. It can be reapplied after 7 
days.  
*Shampoo: Pediculosis Capitis and Pubis- 
Apply a sufficient quantity to dry hair. 
Work thoroughly into the hair and keep in 
place for 4 minutes. Add small amounts of 
water until a lather forms. Rinse hair and 
then towel dry. Comb hair with a fine 
toothed comb, to remove the nits and nit 
shells. 
• USE IN SPECIAL CASES:  
Pregnancy- It should not be used more than 
once during pregnancy. There are no 
adequate studies in pregnant women, but use 
is not contraindicated (Category B). 
Lactation- Lindane is secreted in breast milk 
in low concentrations when applied. The low 
concentrations make it unlikely that it will 
cause serious adverse reactions. If necessary, 
advise the patient to use an alternative 
method of feeding for 2 days. 
Children- Contraindicated in neonates. In 
young children, lindane tends to get absorbed 
from the skin more than in adults. There is a 
potential of CNS toxicity when it is applied 
topically. Seizures have occurred after 
excessive use or ingestion of lindane. It 
should not be used prophylactically. 
• PRECAUTIONS AND WARNINGS:   
For external use only as directed.   
Use extreme caution in elderly or patients 
weighing less than 50 kg (110 lbs). 
Avoid contact with the eyes or face, if it 
occurs flush eyes or face with water 
immediately.  Avoid use on open cuts or 
broken skin. 
Oils and creams used simultaneously with 
lindane can enhance its absorption.  If an 
oil based product is used on the hair, it 
should be washed out and hair should be 
dried before using lindane. 
• ADVERSE EFFECTS:  
Adverse reactions include:  CNS adverse 
effects ranging from dizziness to 
seizures/convulsions and death (especially 
after misuse of the product).  
Irritation from lindane can cause 
eczematous eruptions. 
Itching, redness, swelling, burning or skin 
rash may occur, and must not be confused 
with ineffective treatment. 
• OVERDOSE: 
As mentioned above, CNS adverse 
reactions occur after extensive use or oral 
ingestion of lindane causing seizure attacks 
and even death.  
Treatment of the overdose includes gastric 
lavage, or speed gastric emptying by using 
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saline cathartics.  Treat seizure attacks with 
phenobarbital or diazepam.  
• BRANDS:   
Bicide (Fischer), Parazine (Al-Razi). 
__________________________ 
 
 
H)  KERATOLYTIC AGENTS 
 
A keratolytic agent is an agent used to 
dissolve or break down keratin. These 
agents are used for several skin conditions 
including warts, corns, seborrhea, and even 
used in some anti-dandruff products.  
 
 
1)  Salicylic Acid WHO 
 
• DRUG SUMMARY: 
A keratolytic agent that is considered safe 
and effective. It produces desquamation of 
the horny layer of skin, while not affecting 
the structure of the epidermis. It causes the 
epithelium to swell, soften, macerate and 
then desquamate.  
• INDICATIONS: 
Salicylic Acid is used as an aid in the 
removal of extra keratin in hyperkeratotic 
skin disorders, such as plantar warts, 
psoriasis, calluses and corns. It is also used 
alone or in combinations to treat dandruff, 
seborrheic dermatitis, acne, and tinea 
infections.  
• CONTRAINDICATIONS: 
Hypersensitivity to salicylic acid or any of 
its components.   
It is also contraindicated in infants, 
diabetics, and patients with impaired 
circulation. It should not be used for 
birthmarks or warts with hair growing from 
them, genital or facial warts, or warts on 
mucous membranes.  It should not be used 
on broken, irritated or infected skin.  
• DOSAGE FORMS:  
Solution 17%, ointment 3%, cream 2%, gel 
17%. 
• RECOMMENDED DOSAGE:  
For specific instructions for use of these 
products, refer to individual product 
labeling by the manufacturer. 
Directions: For external use only.   
*Soak the affected area with warm water 
for 5 minutes before application to enhance 
the effect. Then apply to affected area. 
Remove any loose tissue with brush or 
cloth then dry thoroughly. 
*If treating warts, improvement should 
occur in 1 or 2 weeks and maximum results 
should be expected in 4 to 6 weeks. Some 
warts might take up to 12 weeks to go 
away. Apply only on the wart or affected 
area. Avoid application to the skin 
surrounding it. 
• USE IN SPECIAL CASES:  
Pregnancy- Use during pregnancy if the 
potential benefits outweigh the potential risks 
on the fetus (Category C). There are no 
adequate studies in pregnant women. 
Lactation- Use with caution. No well-
controlled studies have been performed to 
prove if topical salicylic acid is excreted in 
breast milk. 
• PRECAUTIONS AND WARNINGS:   
Avoid contact with the eyes, mucous 
membranes, and normal skin surrounding 
the warts. If contact with eyes or mucous 
membranes occurs, immediately flush with 
water for 15 minutes. 
Avoid inhaling salicylic acid vapor. 
Prolonged use over large areas especially in 
young children and patients with hepatic or 
renal impairment may cause salicylate 
toxicity (for more details refer to overdose). 
• ADVERSE EFFECTS:  
Local irritation may occur from contact 
with normal skin surrounding the affected 
area. If irritation occurs, temporarily 
discontinue then resume use with caution. 
• INTERACTIONS: 
Interactions have been reported with the 
use of topical salicylates.  
[Refer to the NSAIDs chapter for more details.] 
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• OVERDOSE: 
Salicylate toxicity may occur with 
prolonged use especially in young children 
or with patients with renal or hepatic 
impairment.  
Be aware of the symptoms of salicylate 
toxicity that includes: nausea, vomiting, 
dizziness, loss of hearing, tinnitis, lethargy, 
hyperpnea, diarrhea, and psychic 
disturbances.  Discontinue use of the drug.  
• BRANDS: 
Oxy-clean (SK-Beecham), Salatac (Dermal 
Labs), Zino Pads (Scholl), Salisol-2 (Rekah). 
___________________________ 
 
2)  Sulfur 
 
• DRUG SUMMARY: 
Sulfur is a keratolytic agent that provides 
peeling and drying actions. It is also a mild 
antiseptic, a mild antifungal and a 
parasiticide. Because of these properties 
this agent is found in many preparations 
combined with other drugs for the 
treatment of acne, dandruff, seborrhoeic 
conditions, scabies, and superficial fungal 
infections. It is also used in some creams 
for oily skin. 
It can cause hypersensitivity reactions as 
well as discoloration of certain metals, so 
use caution when applied. 
_____________________ 
 
I)  MISCELLANEOUS 
 
a)  PREPARATIONS FOR 
     ECZEMA: 
 
Eczema is a superficial skin disorder 
characterized by redness, edema, oozing, 
crusting, scaling and itching. Eczema and 
dermatitis are usually used interchange-
ably. Causes of eczema/dermatitis include: 
allergens, irritants, infections and in some 
cases the cause is unknown. 
The treatment of such conditions 
depends on the cause and the type of 
eczema the patient has. In the initial stages, 
before starting the treatment, one should 
find out the cause of these conditions. Then 
the first step is to avoid the causative 
agent.  
Agents that can be used in treating the 
dermatitis include: 
1. Bath products/oatmeal baths and oil baths 
(mineral or vegetable oil) 
2. Emollients and moisturizers (vaseline, 
petrolatum or lanolin) 
3.  Astringents (witch hazel) 
4. Antipruritics and protectants (zinc oxide 
and calamine) 
5. Keratin-softening agents (urea and alpha 
hydroxy-acid/ lactic acid). 
 
Patients with moderate to severe 
conditions should be referred to a 
dermatologist for initiation of appropriate 
therapy. Avoid use of topical cortico-
steroids at the primary care level, 
especially in infants and children.  
______________ 
 
b)  PREPARATIONS FOR  
     PSORIASIS: 
 
Psoriasis is a chronic recurrent disease 
characterized by dry silvery scaling plaques 
of various sizes. Under these plaques there 
are flat topped pink/red lesions. Lesions 
appear in small areas of the body for short 
periods of time with unpredictable 
remissions and exacerbations.  Since there 
are several types of psoriasis, this skin 
disorder is better managed by a 
dermatologist, to avoid misdiagnosis and 
further complications.  
The duration of psoriasis is variable. 
Lesions may last a lifetime or may 
disappear quickly causing either hypo-
pigmentation or hyper-pigmentation.  
The most important factor in the 
treatment of psoriasis is to relieve its 
symptoms. The agents available do not 
cure psoriasis, they only reduce its severity 
and its symptoms.  The most common 
symptom of psoriasis is dry skin 
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accompanied with pruritis. Gentle rubbing 
of emollients with or without hydrating 
agents, or oatmeal baths might help ease 
the itching and remove the scales.   
Each stage of the disease is treated 
differently. Acute psoriatic onset, 
characterized by severe erythematous 
lesions, calls for soothing local therapy 
with emollients. Tars, salicylic acid, and 
aggressive UV radiation therapy must be 
avoided at this stage because of potential 
irritant effect. As the acute process subsides 
and the usual thick-scaled plaques appear, 
more potent therapy with agents such as 
keratolytics may be used. 
 
c)  PREPARATIONS FOR  
     SEBORRHEA: 
 
Seborrhea is a form of dermatitis 
characterized by a group of eruptions 
occurring in the areas of the greatest 
sebaceous gland (i.e. the scalp, face, and 
trunk). 
Seborrhea usually occurs in hairy areas 
especially in the scalp; it appears like a dull 
yellowish-red lesion with oily appearing 
scales. Pruritis is very common.  There are 
many different kinds of seborrhea including 
seborrhea capitis; which is the most 
common type of seborrhea. Seborrhea 
might occur in newborns and infants during 
the first 12 weeks of life and it is called 
cradle cap. It often clears up by 8-12 
months of age.  Seborrhea is sometimes 
considered as an extension of dandruff. 
However, dandruff is considered as a stable 
condition while seborrhea fluctuates in 
severity. 
The treatment of seborrhea is generally 
the same as dandruff but with some 
exceptions. Frequent cleansing with a non-
medicated shampoo should be tried first.  
If there is no response, seborrhea should be 
treated with shampoos containing 
pyrithione zinc, selenium sulfide, salicylic 
acid and coal tar.   
Topical steroids are used for the 
management of seborrhea in cases when all 
the other shampoos did not work.  
Hydrocortisone lotion for example should 
be applied once daily until the symptoms 
decrease then used intermittently to avoid 
exacerbation. Long term use of 
hydrocortisone is not recommended. A 
more potent topical steroid is sometimes 
indicated when hydrocortisone fails to 
work.  
 
1) TOPICAL CORTICOSTEROIDS 
 
• DRUG SUMMARY: 
Topical corticosteroids are a group of 
agents used for their anti-inflammatory 
activities. They act against most causes of 
inflammation including mechanical, 
chemical microbiological and immuno-
logical. When applied to an inflamed site it 
causes a decrease in edema, erythema and 
pruritis. Most available products used 
contain Betamethasone. 
 
Betamethasone Valerate WHO,P 
 
• INDICATIONS: 
Betamethasone is used in relieving 
inflammations and pruritis for different 
forms of dermatitis, eczema, psoriasis, and 
first- and second-degree burns. It can be 
used alone or as adjunctive treatment 
depending on the case. 
Corticosteroids in combination with 
antifungals to relieve yeast infections, and 
with antibiotics to relieve secondary 
dermatoses are marketed.  But combination 
products of these should be avoided unless 
clearly indicated. 
Different bases (like ointment, cream, lotion, 
gel ...etc.) might change the potency and the 
indication of the agent (refer to table-11.1). 
• CONTRAINDICATIONS: 
Hypersensitivity to any corticosteroid. 
Monotherapy in primary bacterial 
infections such as impetigo, paryonchia, 
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erysipelas, cellulitis, angular cheilitis, 
erythrasma, treatment of rosacea, perioral 
dermatitis or acne; use on the face, groin or 
axilla; and prolonged ophthalmic use. 
• DOSAGE FORMS:   
Refer to table-11.1. 
• RECOMMENDED DOSAGE:  
Directions: To be applied sparingly to 
affected areas 2 to 4 times a day.  
*For external use only.  Avoid contact with 
the eyes unless indicated. 
*Some studies show that applying cortico-
steroids once or twice a day is as effective 
as three or more. Some researches advise 
applying it twice a day until clinical 
response is achieved and then only as 
frequently as needed to control the 
condition.  
*Short term or intermittent therapy (every 
other day, or once a week, or 3 to 4 
consecutive days per week) may be more 
effective and cause fewer adverse effects 
than continuous regimens using lower 
potency products. 
*Use low potency agents in children, on 
large areas, and on body sites especially 
prone to steroid damage such as face, 
scrotum, axilla, flexures and skin folds.  
Reserve higher potency agents for areas 
and conditions resistant to treatment with 
milder agents. 
• USE IN SPECIAL CASES:  
Pregnancy- Use in pregnancy only if the 
potential benefits outweigh the potential 
hazards on the fetus (Category C). 
Corticosteroids are teratogenic in animals 
when administered systemically at relatively 
low dosages. The more potent corticosteroids 
are teratogenic after dermal application in 
animals. No well-controlled studies have been 
done on pregnant women. 
Lactation- Exercise caution. It is not known 
whether topical corticosteroids could result in 
sufficient systemic absorption to produce 
detectable quantities in breast milk. 
Children- Children may be more susceptible 
to topical corticosteroid-induced HPA axis 
suppression and Cushing-syndrome. Limit 
administration to the least amount compatible 
with effective therapy. Chronic corticosteroid 
therapy may interfere with the growth and 
development of children. 
• PRECAUTIONS AND WARNINGS:   
-Systemic absorption of topical cortico-
steroids has produced reversible HPA axis 
suppression, Cushing’s syndrome, hyper-
glycemia and glycosuria. Conditions that 
increase systemic absorption include: 
application of potent corticosteroids, use 
over large areas, prolonged use, and 
occlusive dressings.  
-Local irritation may occur and requires 
discontinuation of the agent. Allergic 
contact dermatitis might develop especially 
when applied to dry skin or open wounds. 
Avoid using potent corticosteroids on the 
face, groin and axillae. It might result in 
atrophic changes. 
-Do not use topical corticosteroids as sole 
therapy on widespread plaque psoriasis. It 
has been reported that withdrawal of the 
treatment of psoriasis with corticosteroids 
may provoke pustular psoriasis. 
-The use of corticosteroids on infection 
sites might worsen the infection. 
Discontinue the use of corticosteroids and 
apply an antifungal or an antibacterial 
agent.   
-Occlusive dressings might increase the 
chance of bacterial infections. Use 
appropriate measures. 
• ADVERSE EFFECTS: 
Local burning, itching, irritation, erythema, 
dryness, pruritis, hypopigmentation, 
allergic contact dermatitis, numbness of 
fingers, stinging, cracking, skin atrophy, 
secondary infections, maceration of the 
skin. 
Prolonged application around the eyes can 
cause cataracts, and glaucoma.  
 
(Systemic adverse reactions are common. 
Refer to Chapter 1: anti-inflammatories 
drugs for more details.) 
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Table–11.1:  Relative Potency of Selected 
Topical Corticosteroidal Products 
DRUG DOSAGE FORM CONCENT- RATION 
I. Very High potency 
    Augmented betamethasone dipropionate 
     Clobetasol propionate 
     Diflorasone diacetate 
 
Ointment 
Cream, Ointment 
Ointment 
 
0.05% 
0.05% 
0.05% 
II. High potency 
      Augmented betamethasone dipropionate 
      Betamethasone dipropionate 
      Bethamethasone valerate 
      Diflorasone diacetate 
       
  Fluocinonide 
      Fluocinolone acetonide 
      Triamcinolone acetonide 
      Desoximetasone 
 
Cream 
Cream, Ointment 
Ointment 
Cream, Ointment 
(emollient base) 
Cream, Ointment, Gel 
Cream  
Ointment 
Cream, Ointment 
Gel 
 
0.05% 
0.05% 
0.1% 
 
0.05% 
0.05% 
0.2% 
0.1% 
0.25% 
0.05% 
III. Medium potency 
      Betamethasone dipropionate 
       Betamethasone valerate 
       Fluocinolone acetonide 
       Triamcinolone acetonide 
 
 
       Fluticasone propionate 
       
        Desoximethasone  
 
Lotion 
Cream 
Cream, Ointment 
Cream , Ointment 
Lotion 
Cream, Ointment 
Lotion 
Cream, Ointment 
Cream,  
Ointment 
Cream 
 
0.05% 
0.1% 
0.025% 
0.025% 
0.1% 
0.5% 
0.05% 
0.005% 
0.05% 
IV. Low potency 
      Desonide 
       Dexamethasone sodium phosphate 
       Fluocinolone acetonide 
       Hydrocortisone 
 
 
       Hydrocortisone acetate 
 
Cream 
Cream 
Cream, Solution 
Lotion 
Solution 
Cream, Ointment 
Lotion 
Cream, Ointment 
 
0.05% 
0.1% 
0.01% 
0.25% 
1% 
0.5%, 1%, 
2.5% 
0.5%, 1% 
 * Drug Facts and Comparisons, 2000:1633-34. 
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2)  PREPARATIONS FOR ACNE 
 
Acne vulgaris is the most common 
adolescent skin disorder. It is an 
inflammatory pilosebaceous disease that 
involves oil glands and hair follicles of the 
skin, primarily on the face and trunk. Acne 
occurs due to an interaction between 
hormones, keratinization, sebum, and 
bacteria which determines the severity of 
the acne.  Acne is rarely cured, but its 
symptoms can be controlled.  Agents will 
reduce symptoms and minimize permanent 
scarring.  
 
The management of acne depends on its 
severity.  Some researches indicate that 
acne can be aggravated by different kinds 
of food such as peanuts, chocolate, fats and 
carbohydrates in an indirect way. So dietary 
restrictions can be the first step in the 
management of acne.  The skin should be 
cleansed from excess sebum, the ducts 
should be unblocked, and the pilo-
sebaceous orifice should not be closed. The 
patient should avoid any cosmetics that are 
oil based. The agents that can be used can 
be either topical or oral agents depending 
on the severity of the lesions.  
There is another kind of acne called 
‘deep’ acne, which causes deep lesions and 
requires vigorous treatment. In these cases 
a referral to a dermatologist is required to 
decrease scarring and help prevent further 
lesions. Oral antibiotics and isotretinoin 
might be required. 
The treatment of acne depends on the 
severity of the condition. Superficial acne 
may be treated with washing the affected 
areas at least twice a day with medicated or 
non-medicated soap. For more complicated 
cases or in cases of superfacial pustular 
acne refer the patient to a dermatologist. 
 
In this section the most used products 
for the treatment of acne are discussed. 
 
 
Retinoic Acid (Tretinoin) 
 
• DRUG SUMMARY: 
Retinoic acid is a vitamin A acid with an 
unknown mode of action.  It is reported that 
it increases the turnover of follicular 
epithelial cells and stimulates mitotic 
activity. 
• INDICATIONS: 
Used for topical treatment of acne vulgaris. 
It can also be used to improve spots and 
wrinkles. 
• CONTRAINDICATIONS: 
Hypersensitivity to it or any of its 
metabolites. 
• DOSAGE FORMS:   
Cream, gel, solution. 
• RECOMMENDED DOSAGE: 
Directions: Apply once a day, before 
bedtime, to the entire affected area. Hands 
should be washed thoroughly after 
applying.  
*If irritation occurs after application, apply 
every other day to minimize the irritation.  
Local erythema and peeling might occur at 
the application site. 
*During the early weeks of therapy, 
exacerbation of inflammatory lesions may 
occur due to the action of the medication on 
deep, previously undetected lesions; which 
is not a reason to discontinue therapy.  
*Therapeutic results should be seen after 2 
to 3 weeks, but in some cases it might take 
up to 6 weeks.  
*Patients may use cosmetics, but the face 
should be washed out and cleansed before 
applying Tretinoin.  
*Keep away from the eyes, mouth, angles 
of the nose, and mucous membranes. 
• USE IN SPECIAL CASES:  
Pregnancy- Elevated serum concentrations of 
retinoic acid in early gestation are considered 
teratogenic in humans. Because topical 
preparation administration (if occlusive 
dressings are not used) has relatively poor 
systemic absorption, it is thought not to be of 
significant risk to the fetus. Congenital 
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malformations have rarely been reported 
following topical use, but without conclusive 
evidence. Use should be avoided (Category 
C). 
Lactation- Exercise caution. It is not known 
whether topical corticosteroids could result in 
sufficient systemic absorption to produce 
detectable quantities in breast milk. The 
minimal absorption that could result 
precludes any clinically significant amounts 
in breast milk. It is preferably to avoid use. 
• PRECAUTIONS AND WARNINGS: 
-Avoid excessive application since it might 
worsen the condition.  Application of a thin 
layer on the affected area should be enough 
to give good results. 
-Sun exposure should be minimized or 
avoided when applying tretinoin.  
Sunscreen products are recommended to 
avoid sunburns and irritation. 
• ADVERSE EFFECTS: 
Sensitive skin may become red, inflamed, 
and blistered.  Discontinuation of tretinoin 
is advised until the skin improves.  
Decreasing the frequency of application 
might be helpful. 
Temporary hyper- or hypo-pigmentation is 
possible. All adverse effects have been 
reversible upon discontinuation. 
• INTERACTIONS:   
Significant skin irritation might occur when 
using other anti-acne topical products such 
as sulfur, benzoyl peroxide, or salicylic 
acid. 
Medicated soaps, cleansers, and astringents 
containing high percentage of alcohol, 
might have an extensive drying effect 
which might increase irritation and interact 
with tretinoin. 
• OVERDOSE: 
Oral ingestion of tretinoin may lead to the 
same side effects as those of vitamin A oral 
intake. (for more details refer to the 
vitamins & minerals chapter.) 
• BRANDS: 
Locacid (Fabre/Mediline), Retavit (CTI/CTS), 
Retin-A (Cilag/JC Health Care). 
____________________________ 
 
Benzoyl Perxoide 
 
• DRUG SUMMARY: 
Benzoyl peroxide is an antibacterial agent. 
It removes excess sebum, reduces fatty 
acids and lipids produced by the causative 
bacteria, and causes peeling and drying. 
• INDICATIONS: 
Treatment of mild to moderate acne 
vulgaris and oily skin.  It might be used in 
severe acne as an adjunct with other agents 
such as antibiotics, sulfur/salicylic acid 
preparations. 
• CONTRAINDICATIONS:  
Hypersensitivity to the drug. Patients 
allergic to benzoic acid or its derivatives 
might be allergic to benzoyl peroxide. 
• DOSAGE FORMS:  
Liquid: 2.5%, 5%, 10% (used as wash). 
• RECOMMENDED DOSAGE:  
Directions: Prior washing of the affected 
area with medicated or non-medicated soap 
is required.  
*For external use only. Avoid contact with 
the eyelids, lips, mucous membranes and 
damaged skin.  
*When used as a cleanser, wash once or 
twice a day, rinse thoroughly and pat dry.  
*Control the amount of drying and peeling 
by modifying dose frequency or 
concentration. 
*When used as the primary treatment of 
acne: apply once daily; gradually increase 
to 2-3 times a day if needed.  If excessive 
dryness occurs, dosage should be reduced.  
*In some cases severe irritation might 
develop causing discontinuation of therapy 
until the irritation clears.  Resume therapy 
with less frequent application. 
• USE IN SPECIAL CASES:  
Pregnancy- Use in pregnant women only if 
clearly needed.  It is not known whether 
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benzoyl peroxide can cause fetal harm when 
used by pregnant women (Category C). 
Regular use should be avoided.  
Lactation- It is not known whether benzoyl 
peroxide is excreted in breast milk. 
Administer with caution to nursing mothers. 
Children- Safety and efficacy in children 
under 12 yrs. have not been established. 
• PRECAUTIONS AND WARNINGS: 
-Benzoyl peroxide is an oxidizing agent 
that might bleach the hair or colored fabric. 
-Some of these products contain sulfites, 
which might cause allergic reactions in 
susceptible patients.  Use caution or avoid 
its use in patients allergic to sulfites.  
-Some studies indicate that it is a tumor 
promoter, however, there is no evidence 
that the drug is a carcinogen in humans. 
• ADVERSE EFFECTS: 
Excessive drying, peeling, erythema, and 
possible edema. Allergic contact dermatitis 
has occurred in some cases. 
• INTERACTIONS:   
Tretinoin use with benzoyl peroxide might 
cause excessive skin irritation. 
• OVERDOSE: 
Symptoms include: excessive scaling, 
erythema or edema. 
Treatment of overdose starts by 
discontinuing of application. Reinstate 
application at reduced dosage after signs 
and symptoms disappear. To increase the 
healing of the irritation, use emollients and 
cool compresses or topical corticosteroids 
in severe cases. 
• BRANDS:  
Acne Mask (Neutrogena/Lapidot), Akneroxid 
(Hermal Chemie), OXY (SK-Beecham). 
__________________________ 
 
3) SUNSCREENS 
 
Ultraviolet (UV) light is the most energetic 
and thus potentially the most damaging to 
human skin. UV light is differentiated into 
UVC (200-290 nm), UVB (290-320), and 
UVA rays (320-400 nm). Traditional 
thinking has long held that UVA was much 
safer than UVB.  UVB was known as 
tanning vs. UVB which was burning. Now, 
it is realized that UVA is just as damaging. 
UVB radiation is absorbed primarily by the 
epidermis, while the longer wavelengths of 
UVA penetrate the skin more deeply-into 
the dermis-where they may damage 
underlying structures including blood 
vessels. 
Protection from UV rays can be 
achieved by three means: avoiding 
exposure to sunlight; by remaining out of 
the sun, covering the skin with protective 
clothing, and using chemical agents on the 
skin to absorb or block solar rays. 
Chemical agents that block or absorb 
UV rays have been categorized traditionally 
as physical (inorganic) sunblocks or 
chemical organic sunscreens (see table 
11.2). This is based on their mechanism of 
action in protecting the skin against UV 
radiation.  
Physical sunscreens are opaque 
formulations that reflect, scatter, absorb, 
and/or physically block radiation. They are 
important because they block the entire UV 
spectrum. They are best used in protecting 
localized, sun sensitive areas such as the 
nose, lips, nasal mucosa, and shoulder. 
Their effectiveness depends on the 
thickness of application. They can be messy 
and cosmetically unappealing for 
application over large areas of the body. 
Chemical sunscreens work by absorbing 
and thus blocking the transmission of UV 
radiation to the epidermis. These are more 
varied in characteristics than physical 
sunscreens. They can be useful for daily 
application over a prolonged period and 
most are cosmetically acceptable 
preparations. 
Products available contain combinations 
of these agents to cover most UV radiation. 
Sunscreens are divided into different 
kinds or strengths depending on the Sun 
Protection Factor (SPF). The SPF is the 
sunscreen’s effectiveness in protecting 
against sunburn; the SPF value is the length 
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of time an individual may be exposed to 
UV radiation when a sunscreen is applied, 
compared to when it is not, and not get 
burned (minimal erythema). The range 
extends from a value of 2 (minimal) to (45 
ultra-high protection). An SPF-15 
sunscreen absorbs 93% of UV radiation, 
while increasing the SPF to 30 raises it to 
96.7%.  
Skin types differ from person to person. 
That is why there are different types of 
sunscreens to suit these different types of 
skin. Also, certain medication use (table 
11.3) can cause photosensitivity (photo-
allergy or phototoxicity) that one should 
caution patients about, and advise use of 
protective sun measures.  
Sunscreen products maybe used safely 
on infants younger than 6 months of age 
when adequate clothing and shading are not 
available. 
It is also important to note that products 
are labeled as water-resistant or water-proof 
(very water-resistant), depending on the 
ability to bind to the skin, and their 
resistance to removal by sweating, exercise 
or swimming (substantivity). Water-
resistant products remain effective in water 
for at least 40 minutes, while  water-proof  
last 80 minutes.  
Advise people to use sunscreens 
correctly, since many use an insufficient 
quantity resulting in less than expected 
protection. Application should be 15-30 
min before going into the sun, and 
reapplied 3-4 times if exercising outdoors 
or swimming. Cotton clothes provide best 
protection as long as they don’t become 
wet. Protection is needed even on cloudy 
days because 60-80 % of UV rays can pass 
through clouds.  
 
Topical sunscreen products are 
considered complementary drugs in the 
WHO essential drug list, without any 
specific agents listed. 
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Table 11.2: Available Physical (Inorganic) and Organic Sunscreens * 
Physical Agents Range of protection Special notes 
Titanium dioxide 290-700 nm 
Zinc Oxide 290-700 nm 
Provide best protection against UV light from 
reaching the skin. They can cause folliculitis, 
acne, and may stain clothing. 
Organic Sunscreen Agents 
Aminobenzoic acid (PABA) 260-313 nm Provide acceptable efficacy against UVB, but transmits most UVA. 
PABA esters:  
Padimate O 
 
290-315 nm 
Esters are more acceptable products because 
they are less irritating and can be more 
substantive.  
Cinnamates: 
Octylmethoxycinnamate 
Cinoxate 
 
280-310 nm 
270-328 nm 
Their effectiveness depends mainly on the 
properties of the vehicle used. May cause or 
aggravate eczema or acne. 
Salicylates: 
Homosalicylate 
Octyl salicylate 
Triethanolamine salicylate 
 
290-315 nm 
260-310 nm 
296-320 nm 
They are week sunscreens, therefore must be 
used in higher concentrations. They do not 
bind well to the skin and maybe removed 
easily by sweat. 
Avobenzone (Parasol 1784) 310-400 nm Block long wave UVA. 
Benzophennones: 
Oxybenzone 
Dioxybenzone 
Sulisobenzone 
 
270-350 nm 
206-380 nm 
 
They are often combined with other sunscreens 
to provide broader UVA protection. They are 
reported to aggravate eczema or acne. 
Anthranilites:  
menthyl anthranilate 
 
322-350 nm 
Weak UV blocker, so it is combined with 
other sunscreen agents. 
 
* Kim HI, Ghalai FE, Tennessen WW.  Here comes the sun. Contmp Pediatr. 1997;14:41-69. 
 
 
 
Table-11.3:  A Partial List of Drugs that May Cause Photosensitivity 
Medications Examples 
Antihistamines cyproheptadine, diphenhydramine 
Anti-infectives tetracycline, nalidixic acid, sulfonamides 
Antipsychotic agents phenothiazines, haloperidol 
Diuretics thiazides, acetazolamide, amiloride 
NSAIDs phenylbutazone, ketoprofen, naproxen 
Miscellaneous captopril, carbamazepine, quinidine, oral 
contraceptives, amiodarone, coal tar 
 
(For  more information about these agents, refer to each individual agent in previous chapters) 
_________________________________ 
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A)  VITAMINS 
1.  Fat-Soluble Vitamins 
Vitamins A, D, E, K 
2.  Water-Soluble Vitamins 
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A)  VITAMINS 
 
Vitamins are potent non-caloric, organic 
compounds that are essential in small 
quantities for the specific body functions of 
growth, maintenance, and reproduction. 
Because most vitamins (with the exception 
of vitamin D) cannot be synthesized by the 
body in sufficient quantities to meet 
metabolic needs, they must be supplied by 
food or supplementation. The only disease 
a vitamin can cure is the one caused by a 
deficiency of that vitamin.  The best 
vitamin sources are the natural ones (i.e. 
vegetables and fruits).  However, the way 
the food is prepared, served and stored have 
major influence on its nutritional value. 
Guidelines for the clinical assessment of 
nutritional status include: evaluation of 
growth, development, fitness, medical and 
dietary history observations of signs 
consistent with deficiencies. 
The Recommended Dietary Allowances 
(RDAs) are levels of daily intake of 
essential nutrients that, based on scientific 
knowledge, the Food and Nutrition Board 
Judges approved to be adequate to meet the 
known nutrient needs of most healthy 
persons.  They are not requirements, they 
are recommended daily intakes of certain 
essential nutrients.  Based on available 
scientific knowledge, they are considered to 
be adequate. They vary for age and sex, 
with extra allowances for women during 
pregnancy and lactation, as well as from 
one country to another.  They also don’t 
apply to cover therapeutic nutritional 
requirements in cases of disease or other 
abnormal states (i.e., metabolic disorders, 
weight reduction, drug therapy . . .). 
Although it is generally believed that 
vitamins are harmless, there are real 
dangers related to the use of some of them.  
Excessive use of one or more vitamins 
may causes toxicity (i.e. Vitamin D), or 
may cause relative deficiencies of other 
essential micro-nutrients (i.e. salts and 
minerals).  
Vitamins are classified in 2 categories: 
fat soluble vitamins and water-soluble 
vitamins.   
Fat soluble vitamins (i.e. A, D, E, K) 
generally occur in fats and oils of foods.  
Once absorbed they are stored in the liver 
and fatty tissue until the body needs them. 
Since they are stored and excess can be 
taken in, especially in the form of 
supplements, toxicity can occur.  For 
example, high dose of vitamin A, can 
produce loss of appetite, itching, loss of 
weight and enlarged liver and spleen (refer 
to toxicity symptoms of other vitamins). 
All other vitamins are water soluble 
vitamins (i.e. B, C,...).  Cooking and over-
washing can take them out of the foods.  
The body absorbs them easily, and just as 
easily excretes them in the urine, so adverse 
effects are diminished.  Nonetheless some 
water-soluble vitamins can still cause 
diarrhea by irritating the intestines (i.e. 
doses of vitamin C > 1 gm/d), or interfere 
with common laboratory results (also 
vitamin C). 
Access to good nutrition should be the 
priority for public health in all countries.  
Encouraging individual and government 
spending on unnecessary vitamin 
preparations does not contribute to the 
public health need. It is wrong to suggest 
that a capsule or tablet can replace the 
nutrients in foods, and it diverts efforts to 
solve problems of hunger, malnutrition and 
vitamin imbalances. 
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Table 12.1:  Fat Soluble Vitamins 
Vitamin 
(other names) 
Natural  
Sources 
Deficiency  
Symptoms 
Toxicity  
Symptoms Comments 
V
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A
 
W
H
O
 
 
(
R
e
t
i
n
o
l
,
 
r
e
t
i
n
a
l
,
 
c
a
r
o
t
e
n
e
)
 
Fortified dairy products, 
eggs, liver, spinach and 
other dark leafy greens, 
deep orange fruits and 
vegetables. 
Impaired growth, painful 
joints, cracked teeth, 
depression, night blindness, 
spots, and possibly anemia 
(microcytic). 
Red blood cell breakage, nose bleeds, 
bone pain, headaches, abdominal 
cramps and pain, vomiting, diarrhea, 
over-reactivity of immune system, 
blurred vision, loss of appetite, dry 
skin, liver and spleen enlargement as 
well as bone and joint pain. 
In cases of deficiency;   
Adult dose:   
10000-20000 IU/d for 2 months. 
Child (1-8 y): 
5000-10000 IU/d for 2 months. 
RDA=child: 400-700 mcg RE, adult males: 
1000 mcg, female: 800 mcg. 
V
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l
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Self-synthesis with 
sunlight, fortified milk, 
eggs, liver, and sardines.
Rickets;   (Ca abnormalities), 
abnormal growth, misshaped 
bones (bowing of the legs), 
joint pain, malformed teeth, 
muscle spasm, osteomalacia. 
Raised blood calcium, excessive thirst, 
headaches, irritability, loss of appetite, 
kidney stones, mental and physical 
retardation. 
 
 
* Effectiveness of supplements 
depends on adequate Ca intake. 
Supplements containing > 100 IU are not 
advisable.   
* Doses of 400 IU (10 mcg of 
cholecalciferol) are not advisable unless 
there is a specific disease state. 
* Dose for Rickets is 1000-4000 IU. 
Avoid use of supplements in infants and 
children who have adequate exposure to 
sunlight or a normal diet. 
RDA=10 mcg cholcalciferol  (100 IU). 
V
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Polysaturated plant oils 
(margarine, salad 
dressings), green and 
leafy vegetables, wheat 
germ, nuts and seeds. 
Red blood cell breakage, 
anemia, degeneration of 
nervous and muscular 
systems, weakness, leg 
cramps, fibrocystic breast 
disease. 
Nausea, headache, blurred vision, 
flatulence and diarrhea.   
With doses of  ≥ 1000 IU/ 24h chronic 
use it augments the effects of anti-
clotting medication. 
300-400 IU/24 hours prescribed for 
deficiencies. 
There is no evidence that it is protective 
against arterio-sclerosis, cancer, pulmonary 
damage, heart disease, peptic ulcer, burns, 
or inflammation of skin disorders. 
RDA= child: 10 IU, males and pregnant 
females: 15, females:12, lactating females: 
16-18. 
V
i
t
a
m
i
n
 
K
 
(
P
h
y
l
l
o
q
u
i
n
o
n
e
,
 
p
h
y
t
o
n
a
-
d
i
o
n
e
)
 Bacterial synthesis in 
the digestive tract, 
liver, green leafy 
vegetables, cabbage 
type vegetables, milk. 
Deficiency is always 
associated with pathologic 
conditions;  may be due to 
malabsorption syndrome or 
liver disease. Hemorrhaging 
is the most common 
symptom. 
Interference with anti-clotting 
medication, vitamin K analogues may 
cause jaundice.  Hemolytic anemia, 
hyperbilirubinemia have been reported 
with large doses in newborns. 
Vitamin K supplementation will not 
counteract the anticoagulant effect of 
heparin, but it counteracts the effects of  
warfarin. 
RDA=child: 15-45 mcg (according to age) 
Adult males: 65-80 mcg 
Adult females: 45-65 mcg. 
 
 
 
 
 
 
Table 12.2:  Use in Special Cases 
Vitamin Pregnancy Lactation Renal Disease Liver Disease 
A Safety of amounts > 5000 IU/d 
during pregnancy has not been 
established.  Avoid use in excessive 
doses, animal reproduction studies 
have shown fetal abnormalities. 
RDA for nursing mothers is 
6000 IU.   
Human milk supplies sufficient 
Vit. A for infants unless 
maternal diet is grossly 
inadequate. 
Vit. A toxicity and elevated plasma 
Ca and alkaline phosphatase 
concentrations have been reported in 
chronic renal failure patients. 
It is stored and metabolized in 
the liver.  In liver cirrhosis 
Vit. A deficiency can occur, 
and supplementation is 
recommended. 
D Safety in amount > 400 IU/d is not 
established.  Avoid larger doses, 
animal studies have shown fetal 
abnormalities. 
Vit. D is excreted in breast milk 
in limited amounts. Monitor 
infants’ serum Ca concentration 
if mother is taking large doses to 
avoid hypercalcemia in the child. 
The kidney of uremic patients might 
not be able to adequately synthesize 
calcetriol (the active hormone 
formed form precursor of Vit. D).  
Hypocalcemia and secondary 
hyperparathyroidism that can lead to 
metabolic bone disease of renal 
failure. 
Elevated liver enzyme tests 
can occur with high doses.  
Use caution. 
E Safety is not established.  No 
reported teratogenicities in human or 
animal studies. 
No harmful effects have been 
noted. 
No harmful effects have been noted. Use caution with high doses. 
K It crosses the placenta, but not 
reported to cause harm to the fetus, 
or affect the reproduction capacity. 
It is excreted in breast milk.  Use 
only when clearly needed. 
Use caution with high doses. Repeated large doses of Vit. K 
may further depress liver 
function. 
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Table 12.3:  Selected Water Soluble Vitamins 
Vitamin 
(other names) 
Natural  
Sources 
Deficiency  
Symptoms 
Toxicity  
Symptoms Comments 
V
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n
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a
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Pork, ham, liver, 
whole grains, 
legumes, nuts. 
Beriberi, edema, enlarged heart, 
abnormal heart rhythms, wasting, 
weakness, difficulty walking, loss of 
reflexes, mental confusion, and 
paralysis. 
No symptoms reported 
with doses of up to 500 
mg. 
Alcoholism and high carbohydrate diet may be 
causes of thiamin deficiency. 
Dose for Beriberi is 25 mg  b.i.d. or  t.i.d. for 5 
days, followed by daily dose of 5 mg for 1 
month.   
RDA= child: 0.7-1.3 mg, adult males: 1.5 mg,  
adult females: 1.1 mg. 
V
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Milk, yogurt, meat, 
banana, leafy green 
vegetables, lentils, 
whole-grain, or 
enriched breads and 
cereals. 
Cracks at corners of mouth, 
hypersensitivity to light, reddening of 
cornea, and skin rashes.  Severe cases 
include convulsions, sideroblastic 
anemia, and peripheral neuropathy. 
No toxicity has been 
reported.  High doses of 
200-600 mg have been 
shown to inhibit prolactin. 
For deficiency, a dose of 50-200 mg/24 hours 
may be required  
RDA= child: 1-1.7 mg,  
adult males: 2 mg,  
adult females: 1.5 mg.  
V
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Animal products:  
meat, fish, milk, 
cheese, eggs,  . . . 
etc. 
Anemia (large-cell type-macrocytic 
anemia), smooth tongue, fatigue, 
hypersensitivity reactions of the 
skin, neurological abnormalities: 
ataxia, parasthesia, hyporeflexia, 
Babinski, clonus and coma. 
No toxicity symptoms 
known. 
Anemia can be due to lack of intrinsic factor 
necessary for absorption.  Supplementation is of 
no use.    
May mimic folate deficiency.  
***Need to exclude folate deficiency anemia 
before starting to supplement with B12 
therapy***.  
 
RDA= child: 0.7-2 ug,  
adult males and females 2 ug. 
N
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 Milk, eggs, meat, 
poultry, fish, whole 
grain and enriched 
breads and cereals, 
and all protein-
containing foods. 
 
Pellagra, diarrhea, black-smooth 
tongue, irritability, loss of appetite, 
dizziness, mental confusion 
progressing  to psychosis or 
delirium, flaky skin rash on areas 
exposed to sun. 
Diarrhea, heartburn, ulcer 
irritation, vomiting, 
dizziness, painful flush 
and rash (niacin rush), 
sweating, abnormal liver 
function, low blood 
pressure. 
Dose for Pellagra:  300-500 mg/d, in divided 
doses. 
For hyperlipidemias, in doses of 1-2 g t.i.d. 
RDA= child: 9-17 mg,  
adult male: 20 mg,  
adult female: 15 mg. 
 
 
 
 
Vitamin 
(other names) 
Natural  
Sources 
Deficiency  
Symptoms 
Toxicity  
Symptoms 
Comments 
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Leafy green 
vegetables, legumes, 
seeds, liver, yeast, 
lean beef. 
Anemia (macrocytic or 
megaloblasitic), GI disorders, 
suppression of immune system, 
smooth red tongue, depression, 
mental confusion, irritability 
and forgetfulness, fainting 
(masks vitamin B12 deficiency). 
No toxicity reported. 
 
* Folic acid in doses > 0.1 mg 
daily may obscure pernicious 
anemia in that hematological 
remission can occur while 
neurologic manifestations 
remain progressive. 
(Food canning, long exposure to heat, and 
extensive refining may destroy 50-100% of 
naturally occurring folic acid.) 
Correction of deficiency is usually 1 mg/24 hrs. 
***Rule out pernicious anemia before 
administration of Folic acid.*** 
 
In populations with moderate to high prevalence 
anemia dose is 0.5 mg/24 hours (WHO recom-
mendations). 
Doses > 1 mg are not necessary except in some 
life-threatening hematological disease. 
RDA= child: 50-150 ug, adult male: 200 ug,  
adult female: 150-180 ug 
 
In pregnant women: The RDA for folate is 0.4 
mg/24 hrs, and 0.8 mg/24 hrs if clinical 
symptoms are present. Studies have proved that 
folic acid supplementation can decrease the 
incidence of neural tube defect; it should be 
started before conception and continued until 12 
weeks of pregnancy. The dose 0.4 mg, and 4 mg 
in those with previous history of neural tube 
defect. 
V
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Citrus fruit, cabbage 
type vegetables, dark 
green vegetables, 
strawberries, 
peppers, lettuce, 
tomatoes, potatoes, 
and mangos. 
Scurvy, anemia (microcytic), 
pinpoint hemorrhages, 
suppression of immune system, 
bleeding gums, loosened teeth, 
muscle degeneration and pain, 
hysteria, bone fragility, rough 
skin, failure of wounds to heal. 
Nausea, abdominal cramps, 
diarrhea, excessive urination, 
fatigue, insomnia, rashes, 
interference with medical 
tests, aggravation of gout 
symptoms. 
Claims for use as prevention of common cold 
have been unsupported by well designed-
controlled studies. 
 
Doses of > 200 mg are rarely indicated, even 
though most products on the market contain > 
500 mg! 
High doses of 1 g/24 hours, increase side 
effects. 
RDA= child: 40-50mg, adult: 60mg. 
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Table 12.4:  Use in Special Cases 
Vitamin Pregnancy Lactation Renal Disease Liver Disease 
B1 Safe.  Studies have not shown an 
increased risk of fetal 
abnormalities.   
It is not known if the drug is 
excreted in breast milk.  No 
harmful effects have been 
reported. 
Excess thiamin is excreted in 
the urine.   
No harmful effects have been 
reported. 
In patients with liver disease 
(cirrhosis, encephalopathy) there 
is an increased need for thiamin 
use. 
B6 Requirements are increased during pregnancy and lactation to 2.0-2.5 
mg/d.  Do not use excessive amounts during lactating  
( > 10 mg/tablet) since pyridoxine may inhibit lactation by prolactin 
suppression. 
It is metabolized in the liver and excreted in the urine.  Use caution 
if using doses larger than RDAs. 
 
B12 Requirements are increased during pregnancy and lactation to 2.6 
mcg/24 hours.  No harmful effects were reported. (Max. amount 
absorbed from a single oral dose is 1-5 mcg.)    
No reports of harmful effects in these cases.  Use caution in severe 
cases. 
C It is not known whether it can 
cause fetal harm or can affect 
reproduction capacity.  Do not take 
very large doses. 
Ascorbic acid is excreted in 
breast milk, but no harmful 
effects have been reported. 
No reports of toxicity.  
Folic 
Acid 
Safe.  Pregnant women are more 
prone to develop folate deficiency, 
leading to complications of 
pregnancy and fetal abnormalities. 
Studies in pregnant women have 
not shown any harmful effects with 
the increased dose 
recommendations. (See table 12.3) 
> 1 mg doses are not necessary. 
Folic acid is excreted in breast 
milk, without any harmful 
effects to the nursing child.  
RDAs during lactation are 
0.26-0.28 mg/day. 
No reports harmful effects. 
 
Niacin Use of doses larger than RDAs in pregnancy and lactation have not 
been studied for safety.  Use only when clearly needed. 
 
Use caution.  1/3 of the dose is 
excreted unchanged in the urine. 
Prolonged use of very high doses  
(> 6 g/24 hrs.) can cause liver 
damage.  
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Minerals constitute about 4% of body 
weight.  Minerals are present in the body in a 
diverse array of organic compounds such as 
phosphoproteins, phospholipids, hemoglobin, 
and thyroxin, in inorganic compounds such 
as sodium chloride, potassium chloride, 
calcium and phosphate as free ions.  They are 
involved in regulating cell membrane 
permeability, osmotic pressure, and acid-base 
and water balance in the body. 
Unlike vitamins, minerals exist in plants 
in varying amounts, according to the 
composition of the soil in which the plant is 
grown. 
Vitamins and minerals, particularly iron, 
are regularly prescribed or taken during 
pregnancy.  The belief that because they are 
‘natural’ substances and are harmless, causes 
a lot of overuse.  The need for iron 
supplementation in pregnant women, is a 
controversial subject. It is important to note 
that international agencies such as WHO and 
UNICEF strongly promote and support the 
routine iron supplementation during 
pregnancy. That is especially done in those 
countries where pregnant women are more 
likely to be or become anemic due to 
poverty, malaria epidemics and/or high 
prevalence rates of intestinal parasites.  
However, many industrialized countries have 
abandoned this policy preferring a selective 
iron supplementation according to the 
patient’s need.   
Most pregnant women have a lower iron 
level in the blood since the mother’s blood 
volume is increased in order to supply the 
growing baby.  The human body, if not 
malnourished, has large reserves of iron in 
the liver and bone marrow, and during 
pregnancy these stores are used.  But the 
demands made on women’s bodies from 
blood loss due to early, frequent and closely 
spaced pregnancies make them vulnerable to 
nutritional deficiencies, especially anemia. 
WHO definition of anemia for pregnant 
women is when hemoglobin blood level is 
below 11 g/100 ml (hemoglobin > 80%). The 
WHO has suggested that all pregnant women 
in high-risk areas receive iron supplements 
(due to the large numbers who suffer iron-
deficiency anemia), especially during the last 
four to five months of pregnancy.  Iron 
supplementation, however, is a curative 
approach, and emphasis should be on 
prevention. 
Administration of combination 
preparations of iron with folate, B12 or cobalt 
has little justification in a pregnant woman 
unless clearly indicated.  It is better to 
identify type of anemia of the patient 
before prescribing or recommending 
supplementation when possible. 
Furthermore, when supplementation is 
implemented, it should not keep out further 
regular Hb-level tests and follow-ups of 
antenatal visits to assure efficacy, better 
compliance in taking the treatment and 
giving proper dietary counseling. 
The major mineral content of the skeleton 
consists of calcium and phosphorous.  Ca is 
another element that requires special 
attention in women’s health.  Since women 
are 6-8 times more likely to get osteoporosis 
(often known as brittle bone disease) than 
men, it is important to start prevention 
measures including education to all women 
at high risk (refer to the RDAs table for 
needs at the different stages). 
There are no sufficient studies or data on 
our region that records prevalence of 
nutritional deficiencies.  The primary health 
care provider’s role is to screen and prevent 
such cases when possible.  The improvement 
of general nutrition is the most important in 
all, whether children or women before and 
during pregnancy, as well as giving 
supplementation when needed. 
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Table 12.5:  Summary of Selected Minerals 
Mineral Natural Sources Deficiency Symptoms Toxicity Symptoms Comments 
Ca WHO,P 
(calcium) 
Milk and milk products, 
small fish (canned 
sardines with bones), 
bean curd, broccoli, 
beets, greens and 
legumes. 
Stunted growth in 
children, adult bone loss 
(osteoporosis). 
Excess Ca is excreted except in 
hormonal imbalance states. 
 
* It has not been shown that Ca causes 
fetal harm when taken as supplements. 
Absorption of supplements varies between Ca 
salts.  Ca carbonate has the highest content of 
elemental Ca. Side effects include GI 
disturbances such as nausea and constipation. 
RDA= child: 800 mg, adult: 800 mg-1200 mg. 
Fe WHO,P 
(iron) 
Red meat, fish, poultry, 
shellfish, eggs, legumes, 
dried fruits, green 
leaves. 
 
* People with normal 
Fe levels should not 
take Fe supplements 
chronically. 
Fatigue, weakness, iron 
deficiency (pernicious) 
anemia, split or spoon-
shaped nails, sore tongue, 
dyspnea on exertion, 
palpation. 
Acute overdose of 200 mg/kg may be 
fatal.   
 
Iron overload:  infections, liver 
injury, possible increased risk of heart 
attack, acidosis, bloody stools, and 
shock. 
Supplements may cause GI discomfort, 
nausea, diarrhea or constipation, and dark 
stool.  Advise patient to eat foods rich in fiber 
to prevent diarrhea or constipation. 
* Sustained release or enteric-coated 
preparation reduce the amount of available 
iron, since they transport iron beyond the 
place of absorption, the duodenum. 
RDA= child: 10 mg, adult male: 10-12 mg, 
adult female: 15 mg. 
Pregnant: 30 mg. 
F WHO 
(fluorine) 
Municipal water (not to 
exceed 2-8 parts per 
million), mouthwash. 
(Each city should test 
their water supply for F 
levels). 
Dental decay, increased 
risk of osteoporosis as the 
person gets older. 
Salivation, abdominal pain, vomiting, 
diarrhea, dehydration, thirst, tremor, 
mental irritability, dental fluorosis 
(molting of tooth enamel) with chronic 
over dosage of Ca & F. 
F  supplements can be given to children as a 
preventive measure for dental decay in areas 
with low F level in the water. 
RDA= child: 0.7-2 mg, adult male: 4 mg, 
adult female: 3 mg. 
I WHO 
(iodine) 
Salt water, fish, 
vegetables produced in 
soil with high content of 
iodide. 
Hypothyroidism (goiter), 
cretinism. 
Depressed thyroid activity.  Chronic 
intoxication (iodism), include 
unpleasant taste burning in mouth or 
throat, soreness of the teeth and gums, 
swelling of eyes lids. 
Iodine supplements should be only 
administered under direct medical supervision. 
Iodide (the reduced form of iodine) crosses the 
placenta readily. 
RDA= 70-150 ug, adult: 150ug 
K 
(potassium) 
All whole/fresh foods:  
meats, milk, fruits 
(especially bananas), 
vegetables, grains, 
legumes. 
Deficiency accompanies 
dehydration, causes 
muscular weakness, 
paralysis and confusion.  
Can cause death. 
Muscular weakness, triggers vomiting, 
irregular heart beats in susceptible 
patients.   
In patients with renal failure do not use 
to avoid hyperkalemia or cardiac arrest! 
GI discomfort  (i.e. nausea, diarrhea, etc.) are 
common side effects of supplements.  Can 
decrease by taking the potassium supplements 
with meal. 
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Table 12.6:  Significant Drug Interactions 
Vitamin/
Mineral Drug involved Description 
Cholestyramine Absorption of Vit. A is reduced. 
Mineral Oil Use of mineral oil interferes with the intestinal absorption of Vit. A.  A 
Oral contraceptives These significantly increase plasma Vit. A levels.   
Levodopa Pyridoxine (B6) reduces effectiveness of levodopa.  Avoid 
supplementation that contain > 5 mg pyridoxine/24 hours in such 
patients. B6 
Phenobarbital, 
phenytoin 
Serum levels of these drugs maybe decreased, leading to sub-
therapeutic levels.  Advise patients taking these drugs not to take high 
dose supplements.  
Aminosalicylic 
acid 
The biologic and therapeutic action of Vit. B12 may be reduced.  There 
is no need to administer aminosalicylic acid to patients with B12 
deficiency (megaloblastic anemia), who are taking supplementation.  
An abnormal Schilling test and false symptoms of Vit. B12  deficiency 
may also occur. 
B12 
Alcohol Excessive alcohol intake (longer than 2 weeks) may cause 
malabsorption of vitamin B12.  
Oral estrogen Ascorbic acid increases serum levels of estrogen contained in oral 
contraceptives or estrogen replacement therapy, leading to increased 
adverse effects.  Warn patient against intake of high doses of Vit. C 
supplements. 
Warfarin The anticoagulant action of warfarin may be reduced.  Do not co-
administer Vit. C in large doses. 
C 
Glucose lab. tests Doses of ≥ 500 mg Vit. C, will cause false negative urine glucose tests.  
Advise patient against intake of this vitamin supplementation 48-72 
hours before conducting blood/urine tests. 
Antacids/Mg 
containing 
Hypermagnesemia may develop in patients with chronic renal disease. 
Digitalis 
Glycosides 
Hypercalcemia in patients on digitalis may precipitate cardiac 
arrhythmias.  Patients on Digoxin should avoid use of high doses of 
Vit. D supplements. 
D 
 
Mineral oil, 
Cholestyramine 
Reduce absorption of Vit. D, especially with prolonged use.   Monitor 
patients who are taking these drugs chronically, for signs of deficiency. 
E Oral anticoagulants 
High doses of Vit. E increases the effect of anticoagulants, so it 
increases the risk of bleeding. 
K Anticoagulants Anticoagulant effects are antagonized by Vit. K.  Physicians should warn patients against taking supplements while on this medication. 
Aminosalicylic 
acid 
Decreased serum folate levels may occur during concurrent use.  Avoid 
concomitant use unless clearly needed. 
Folic Acid Hydantoins If folic acid is required (refer to drug interactions), need to monitor 
serum hydantoin (i.e. phenytoin) levels to avoid lower therapeutic levels 
of the anticonvulsant, and adjust dosage as needed. 
Lovastatin It has been reported that co-administration of niacin have resulted in 
rhabdomyolysis (a fatal disease marked by destruction or degeneration 
of skeletal muscles).  Avoid co-administration. Niacin 
Sulfinpyrazone Uricosuric effect may be inhibited by nicotinic acid.  Advise patient 
against taking large dose supplementation if using this medication. 
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Atenolol Bioavailability of atenolol may be decreased, resulting in decreased 
beta blockade.  Warn patients against large dose supplementation. 
Caffeine High intake of beverages containing caffeine (> 10 cups/day of 
coffee) increases loss of Ca though the urine. 
Iron Salts GI absorption of iron may be reduced.  If both minerals are indicated 
for use, space out their administration time, or use Ca carbonate and 
not another Ca salt. 
Tetracyclines The absorption and serum levels of tetracyclines may be decreased, 
decreasing its anti-infective response.  Do not co-administer.  Warn 
patients. 
Ca salts 
 
Verapamil High doses of Ca supplements increase the toxicity of verapamil.  
This can be reversed by discontinuing the Ca salts (supplement). 
Antacids 
Cimitidine 
GI absorption of iron is reduced.  Do not administer at the same time 
interval. 
Ascorbic acid Ascorbic acid may enhance the absorption of Iron from the GI, but 
this increase may not be significant. 
Levodopa, 
Penicillamine, 
Quinolones 
Marked reduction of the absorption of this medication , may be due 
to chelation or complex formation with iron.  Do not co-administer. 
Tetracyclines Co-administration decreases absorption of both drugs, due to 
complex formation.  Do not co-administer, and warn the patient. 
Fe Salts 
Coffee, tea Consumption of these with a meal or 1 hour after the meal, may 
significantly inhibit the absorption of dietary iron.  Warn your 
patients. 
F Dairy products Do not administer fluoride supplements with dairy products.  Calcium fluoride is formed, which is poorly absorbed. 
I Lithium carbonate Concomitant use may result in hypothyroidism.  Do not co-administer. 
ACE Inhibitors Concurrent use may result in hyperkalemia.  Do not use concomitantly. 
Potassium-sparing 
diuretics 
These diuretics will increase potassium retention and can produce 
severe hyperkalemia.  Do not use concomitantly. 
K Digitalis Use caution in these patients.  Potassium antagonizes digitalis 
preparations.  A decrease in K level favor digoxin binding, 
increasing the likelihood of digitalis toxicity. Increased K levels 
decreases digitalis binding and decreases digitoxin effect.  Be very 
careful. 
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Table 12.7:  Possible Drug Induced  
Nutritional Deficiencies With Chronic Use 
Drug Group Drug Nutrient Depleted 
Diuretics Thiazides 
Furosemide 
Potassium, zinc, magnesium 
Calcium, potassium, magnesium 
Antihypertensives Hydralazine Vitamin B6 (Peripheral neuropathy) 
Anticonvulsants Phenytoin Vitamin D (Rickets, osteomalacia) 
Folate  (megaloblastic anemia) 
Anticoagulants Warfarin Vitamin K 
Anti-ulcer Cimetidine, 
ranitidine (with 
long-term use) 
Vitamin B12 (pernicious anemia) 
Antibiotics Tetracycline Calcium, Vitamin K 
Anti-tubercular Isoniazid Vitamin B6, niacin, vitamin D 
Antihyperlipidemic  Cholestyramine Fat 
Vitamin A, Vitamin K, B12 and folate. 
Analgesics Aspirin Ascorbic acid, potassium, iron. 
Anti-inflammatory Colchicine 
Sulfasalazine 
Fat, Vitamin B12. 
Folate 
Antineoplastic, 
antipsoriatic 
Methotrexate Folate, Vitamin B12, fat. 
Laxatives Mineral oil 
Phenolphthalein 
(bisacodyl) 
Vitamins A, D, E, K, Calcium & 
phosphorus. 
Vitamin D, calcium, potassium. 
 
 
 
______________________________ 
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Chapter  13:   VACCINES 
 
 
 
 
1)  BCG (Bacille Calmette-Guerin) 
 
2)  OPV / IPV (Oral and Inactivated Poliomyelitis Vaccines) 
 
3)  Tetanus Vaccine 
 
4)  DPT Vaccine (Diphtheria, Pertussis and Tetanus) 
 
5)  Measles Vaccine 
 
6)  MMR Vaccine  
 
7)  Hepatitis B Vaccine 
 
8)  Influenza Vaccine 
 
9)  Hib Vaccine (Haemophilus Influenza Type B) 
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VACCINATION AND IMMUNIZATION 
 
The vaccination and immunization terms 
are often used interchangeably. 
Vaccination is a term that denotes the 
administration of any vaccine.  
Immunization is a more inclusive term 
denoting the process of inducing or 
providing immunity artificially by 
administering a vaccine.  Immunization can 
be active or passive.  Active immunization 
is protection produced by the person’s own 
immune system, as response to the 
administration of a vaccine or toxoid. This 
type of immunity is usually permanent. 
Passive immunization means protection by 
products produced by an animal or human, 
that are transferred to another human as a 
vaccine. This protection usually disappears 
over time.  (CDC, 1995). 
 
There are three sources of antibody used 
in passive immunization vaccines:  
[1] homologous pooled human antibody-
immune globulin, [2] homologous human 
hyperimmune globulin, [3] heterologous 
hyperimmune serum- antitoxin. 
 
Vaccines are classified into two basic types:  
Live attenuated vaccines that can be viral or 
bacterial (i.e., measles, mumps, oral polio, 
BCG), and inactivated vaccines that are 
composed of either whole or fraction, 
protein-based or polysaccharide-based, of 
either viruses or bacteria (i.e., influenza, 
pertussis, hepatitis B, tetanus, haemophilus 
influenzae type b). 
 
Vaccines may come from different 
sources of pharmaceutical companies, and 
it is important to follow the directions of 
the manufacturer for administration, 
storage …etc, for each product. Vaccines 
have different inert (non-active) 
ingredients/ additives that can vary not only 
between different active material, but also 
from one manufacturer to another.  If the 
recipient is sensitive to one of these 
additives, allergic reactions can occur.  
Some of the terms that we should be 
familiar with include: 
 
Suspending fluids: These may be sterile 
water or saline or complex fluids containing 
small amount of protein or other 
constituents derived from the medium or 
biologic system in which the vaccine is 
produced (e.g. serum proteins, egg antigens, 
cell-culture-derived antigens). 
Preservative, stabilizers, and antibiotics:  
These components of vaccines, antitoxins, 
and globulins are used to inhibit or prevent 
bacterial growth in viral cultures of the final 
product or to stabilize the antigens or 
antibodies.  Allergic reactions can occur if 
the recipient is sensitive to one of these 
additives (e.g. phenols, albumin, glycine, 
and neomycin). 
Adjuvants: Many antigens evoke 
insufficient immunologic responses when 
given in the natural state. Efforts to enhance 
immuno-genicity include mixing antigens 
with a variety of substances or adjutants 
(e.g. aluminum phosphate or hydroxide). 
Vaccines containing adjuvant must be 
injected deep into the muscle mass; they 
should not be administered subcutaneously 
or intradermally because this can cause 
local irritation, inflammation, granuloma 
formation, or necrosis. 
 
Route of Administration:  
It is important to refer to each product label 
for the proper site of administration. 
Subcutaneous (SC) injections are usually 
administered into the thigh of infants and in 
the deltoid area of older children and adults. 
Intradermal (ID) injections are generally 
given on the volar aspect of the forearm, 
except for human diploid-cell-rabies-
vaccine, with which reactions are less 
severe in the deltoid area. The preferred 
sites for Intra-muscular (IM) injections are 
the anterolateral aspect of the upper thigh 
and the deltoid muscle of the upper arm.  
The buttock should not be used routinely as 
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a vaccination site for infants, children, or 
adults because of the risk of injury to the 
sciatic nerve. 
 
Administration in Special Cases:  
Vaccination During Pregnancy: There is 
no evidence that any live vaccine (including 
Rubella) causes birth defects. The concern 
of infecting the fetus is theoretical. 
However, since there is a theoretical 
possibility, live vaccine should not be given 
to pregnant women (except O PV in some 
cases). 
 
There is no convincing evidence of risk 
from vaccinating pregnant women with 
inactivated virus or bacteria vaccines, 
toxoids, or IG preparations; therefore, in 
high risk areas the vaccine should be given.  
Tetanus and diphtheria toxoids are the only 
immunobiologic agents routinely indicated 
for susceptible pregnant women. Hepatitis 
B, influenza and pneumococcal vaccines 
are recommended for women at high risk 
for infection and for complication of 
influenza and pneumococcal disease. 
 
Vaccination of Preterm Infants: Infants 
born prematurely, regardless of birthweight, 
should be vaccinated at the same 
chronological age and according to the 
same schedule and precautions as full-term 
infants and children. Birthweight and size 
are not factors in deciding if a child is to be 
vaccinated or not, except in hepatitis B 
vaccine as first dose should be given when 
the infant is 2 kg as seroconversion rate 
were lower in those less than 2 kg (Red 
Book, 2000). 
 
Vaccination and Breast-Feeding: neither 
live or killed vaccines affect the safety of 
breast-feeding for mothers or infants. 
Breast-feeding does not adversely affect 
immunization and is not contraindicated for 
any vaccine. Breast-fed infants should be 
vaccinated according to routine 
recommended schedules. 
 
Vaccinating Immunocompromized Persons: 
Severe complications have followed 
vaccination with live, attenuated virus 
vaccines and live bacterial vaccines among 
these patients. Killed or inactivated 
vaccines do not cause danger to such 
patients, and can be administered as 
recommended for healthy persons.  
In general patients with asymptomatic-HIV, 
or limited immune system (i.e. asplenia or 
renal failure) should not receive live 
vaccines, expect for measles, mumps and 
rubella. For persons with symptomatic-HIV 
infection, MMR can be administered since 
there are accumulating evidence of its 
safety. 
Vaccination during chemotherapy or 
radiation therapy should be avoided 
because antibody response is poor. Patients 
with leukemia in remission whose 
chemotherapy has been terminated for 3 
months may receive live-virus vaccines. 
Vaccines that are contraindicated for use in 
patients with severe immunocompromized 
states that are symptomatic-HIV infected 
persons or not HIV-related (i.e. leukemia, 
lymphoma) include: BCG, OPV, and 
yellow fever. Such patients who are 
exposed to measles should receive immune 
globulin (IG) regardless of prior 
vaccination status. 
 
Vaccination of Persons with Hemophilia:  
People with bleeding disorders such as 
hemophilia are at risk of hematomas if 
given intramuscular injections. In such 
patients using the subcutaneous or 
intradermal route for the vaccines should be 
done. Some products may only be given 
intramuscularly; therefore, the 
manufacturer should be contacted for clear 
guidelines.  
 
Spacing and Timing of Vaccines:   
Some vaccines require administration of 
more than one dose for development of an 
adequate antibody response, and some 
vaccines require booster doses to maintain 
protection. Intervals between doses that are 
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longer than those recommended do not lead 
to a reduction in the final antibody levels. 
Therefore, it is not necessary to restart an 
interrupted series or add extra doses of 
vaccine (except oral typhoid). In contrast, 
giving doses of a vaccine at less than 
recommended intervals may lessen the 
antibody response and should be avoided. 
Doses given at less than recommended 
intervals should not be counted as part of a 
primary series. 
 
Many vaccines can safely and effectively 
be given simultaneously (on the same day, 
not at the same site).  [See tables-13.1 & 
13.2]. 
 
1. Simultaneous administration:  
In general, an inactivated vaccine can be 
given either simultaneously or at any time 
before or after a different inactivated or a 
live vaccine. They can be administered at 
separate sites. Simultaneous administration 
of the most widely used live and inactivated 
vaccines has not resulted in improved 
antibody response or increased rates of 
adverse reactions. Simultaneous routine 
administration of MMR, DPT, OPV and 
IPV is recommended. There are no contra-
indications to simultaneous administration 
of any vaccine except with cholera and 
yellow fever vaccines. 
2. Non-simultaneous administration:  
When vaccines commonly associated with 
local or systemic side effects are given 
simultaneously, the side effects may be 
increased or exaggerated. Whenever 
possible, these vaccines should be given on 
separate occasions. 
-Live-virus vaccines can interfere with the 
response of a tuberculin test.  Tuberculin 
testing can be done either on the same day 
that the live-virus vaccines are administered 
or 4-6 weeks afterwards.   
-If administration of an IG preparation 
becomes necessary because of imminent 
exposure to disease, live-virus vaccines can 
be given simultaneously with the IG 
product, with the recognition that vaccine-
induced immunity might be compromised. 
The vaccine should be administered at a site 
remote from that chosen for the IG 
inoculation. Vaccination should be repeated 
about 3 months later unless serologic 
testing indicates that specific antibodies 
have been produced. 
-Live attenuated vaccine viruses might not 
replicate successfully, and antibody 
response could be diminished when the 
vaccine given after IG preparations. killed 
vaccines can be given simultaneously or at 
any time before or after an IG product is 
used. 
 
 
Table–13.1:  Guidelines for Spacing  
Live and Killed Antigen Administration 
Antigen 
combination 
Recommended minimum 
interval between doses 
≥ 2 killed 
antigens 
No spacing. May be given 
simultaneously or at any 
interval between doses. 
Killed 
and live 
antigens 
No spacing required. 
≥ 2 live 
antigens 
4 wk minimum interval if 
not administered 
simultaneously 
 
If a child is not up-to-date on his or her 
vaccination, it may be necessary to 
“accelerate” the normal schedule in order to 
catch up. In this situation it is important to 
know how closely the doses can be spaced 
and still be effective for that specific case. 
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Table - 13.2. Guidelines for Spacing the Administration of  
IG Preparations and Vaccines 
Simultaneous administration: 
immunobiologic combination 
Recommended minimum interval  
between doses 
IG and killed antigen None. Given at different sites or at any time between doses. 
IG and live antigen 
Should generally not be given simultaneously. If 
unavoidable to do so, give at different sites and 
revaccinate or test for seroconversion in 3 
months. 
Non-simultaneous administration: 
immunobiologic administration 
First Second 
Recommended minimum interval 
between doses 
IG Killed antigen None 
Killed antigen IG None 
IG Live antigen 6 weeks and preferably 3 months. (3 mon. for measles) 
Live antigen IG 2 weeks. 
 
 
The WHO Expanded Program of 
Immunization (EPI) has established 
recommendations for immunizing infants, 
children, and adults that are based on 
characteristics of vaccines, scientific 
knowledge about the principles of active 
and passive immunization, and judgments 
by public health officials and specialists in 
clinical and preventive medicine. Each 
country would modify the list according to 
its needs. Recommendations for 
immunizations practice scientific evidence 
of benefits, costs, and risks to achieve 
optimal levels of protection against 
infectious diseases.   
 
 
[See EPI diseases, vaccine types and 
recommendations in tables-13.3, 4 & 5, and 
Palestinian recommendations in table-13.6].
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Table – 13.3:  Epidemiology of the  EPI  Target Disease 
Disease Agent Reservoir Spread Transmissible Period 
Subclinical 
Infection 
Duration of Natural 
Immunity 
Risk Factors for 
Infection 
Tuberculosis Mycobacerium 
tuberculosis 
Humans Airborne droplet 
nuclei from sputum 
positive person 
As long as 
sputum acid fast 
Bacilli positive 
Common but not 
important in 
transmission 
Not known. 
Reactivation of old 
infection commonly 
causes disease 
Low access to care, 
Immunodeficiency 
Malnutrition 
Alcoholism 
Diabetes 
Diphtheria Toxin producing 
bacterium  
(C. diphtheria) 
Humans Close contact; 
respiratory or 
cutaneous 
Usually < 2 wks. 
Some chronic 
carriers 
Common Usually lifelong Crowding 
Low socioeconomic 
status 
Tetanus Toxin producing 
bacterium  
(Cl. Tetani) 
Animal 
intestines 
soil 
Spores enter body 
through wounds/ 
umbilical cord 
No person-person 
transmission 
No No immunity 
induced by 
infection 
Contamination of 
umbilical cord  
Agricultural work 
Pertussis 
(Whooping-
cough) 
Bacterium  
(B. Pertussis) 
Humans Close respiratory 
contact 
Usually < 3 wks. 
(starts before 
whoop is apparent) 
Mild illness 
common may be 
not be diagnosed 
Usually lifelong Young age 
Crowding 
Poliomyelitis 
(Polio) 
Virus (serotypes 
1,2 and 3) 
Humans Fecal-oral, close 
respiratory contact 
Few days before 
and after acute 
symptoms 
100-200 sub-
clinical infections 
for each paralytic 
case 
Type-specific 
immunity, 
lifelong 
Poor environmental 
hygiene 
Measles Virus Humans Close respiratory 
contact and 
aerosolized droplets 
4 days before, until 
2 days after rash 
May occur  Lifelong Crowding 
Low socioeconomic 
status 
Yellow 
fever 
Virus Humans 
Monkeys 
Mosquito-borne 
infections 
Common in 
endemic areas 
- Lifelong Mosquitoes 
Occupation 
Hepatitis B Virus Humans Perinatal; child-
child; blood; sexual 
spread 
Chronic carriers > 
30 yrs. 
Common, 
especially in 
infants 
If develops, lifelong HbeAg+ mother 
Multiple sex partners; 
IVDU, working with 
blood products. 
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Table – 13.4:  Characteristics of EPI Vaccines 
Disease Nature of vaccine 
Minimum potency  
per dose Form 
Contains 
Additives/Adjuvants 
No. of 
doses* and 
route 
Heat stability 
Tuberculosis Attenuated 
bovis 
50,000 to one million live 
particles 
Freeze dried None 1 ID Medium in dried 
form, low in 
reconstituted form 
Diphtheria Toxoid At least 30 IU Fluid Al(OH)3/AlOP4 / Usually 
thimerosal (merthiolate) 
3 IM High 
Tetanus Toxoid At least 40 IU in TT and 60 
IU for T-component in DPT 
when tested in mice 
Fluid Al(OH)3/AlOP4 / Usually 
thimerosal 
3 IM High 
Pertussis Killed whole 
cell pertussis 
bacterium 
At least 4 IU Fluid Al(OH)3/AlOP4 / Usually 
thimerosal 
3 IM Medium 
Poliomyelitis Attenuated live 
viruses of 3 
types 
Type 1 > 1 million 
Type 2 > 100,000 
Type 3 > 600,000 
 infectious units 
Fluid None/ Stabilizer; 
Magnesium chloride or 
sucrose 
4 Oral Low 
Measles Attenuated live 
virus 
At least 1000 infectious 
units 
Powder for 
injection 
Small amount of 
antibiotic & stabilizers 
1 S/C Medium in dried 
form, low in 
reconstituted form 
Yellow fever Attenuated live 
virus 
At least 1000 mouse LD50 
or the equivalent in PFU 
Powder for 
injection 
Stabilizing substances 1 S/C Medium in dried 
form, low in 
reconstituted form 
Hepatitis B HbsAg 2.5 to 20 mcg of HbsAg Fluid Al(OH)3/AlOP4 / Usually 
thimerosal 
3 IM High 
 
* Refer to individual drug monographs for scheduel and doses. 
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Table – 13.5:  Reported Vaccine Efficacy and Duration 
Vaccine Vaccine efficacy Duration of immunity after  primary series 
BCG 20-80% vs. TB 
75-86% vs. meningitis and miliary TB. 
Unknown; some evidence that immunity wanes 
with time. 
Diphtheria 
Toxoid 
97% clinical efficacy. Antitoxin levels decrease after 10 years from the 
last dose. A booster administered every 10 years (as 
Td) may be administered. 
Tetanus Toxoid A complete tetanus toxoid series provides 100% efficacy.  3 doses are protective for 5 yrs;  
5 doses may provide >20 years of protection. 
Boosters are recommended every 10 years. 
Pertussis 71- 84% protection. Estimate vary widely; efficacy higher 
against severe disease.  
Unknown; evidence that it wanes with time. 
IPV > 90% of recipients develop protective antibodies to all three 
poliovirus types after 2 doses, and at least 99% are immune 
following 3 doses.  Less local GI immunity is produced. 
Duration of immunity not known with certainty but 
provides protection for many years after a complete 
series. 
OPV A single dose produces about 50% of immunity. Three doses 
produce immunity to all 3 poliovirus types in > 95% of recipients. 
Produces local GI-intestinal and pharyngeal immunity. 
As with other live virus vaccines, immunity is 
probably life-long. 
Measles > 95% at 12 months of age:  98% at 15 months of age 
(approx. 2-5% of children fail to respond to MMR 1st dose). 
Lifelong if boosted by wild virus circulating. 
Rubella 95% aged 12 months and older after a single dose. > 90% of vaccinated persons have protection for at 
least 15 years. Some studies indicted that one dose 
confers lifelong protection. 
Hepatitis B 80-100% effective in preventing infection or clinical hepatitis in 
those who receive the complete course (3) of vaccine.   
(90-95% adequate antibody response in healthy adults, infants and 
adolescents. 75-95% effective in newborns from HepaAg+ mothers. 
90% respond after age 40, 75% develop protection by the age of 60.) 
> 13 years; further follow-up is ongoing. 
Influenza 90% protection from illness of healthy young adults.   
30-40% effective in preventing illness among frail elderly 
persons, and 80% effective in preventing death. 
Immunity following inactivated influenza 
vaccination rarely exceeds 1 year, depending on the 
vaccine starin(s). 
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Table – 13.6:  Palestinian Immunization Schedule 
Vaccine Dose Route Site Course MOH Ages UNRWA Ages 
BCG 0.05  ml Intradermal Left upper arm -Primary -On first registration -At birth 
OPV 2 drops Oral Mouth -Primary series 
-Booster 
-Booster 
-At 2,4,6 mon. of age 
-At 12 mon. of age 
-At school entry 
-At 2,4,6 of age 
-At 12 mon. of age 
IPV 1 ml Subcutaneous Left upper arm -2 doses -At 1&2 mon. of age -At 1&2 mon. of age 
DPT 0.5 ml Intramuscular Lateral aspect of 
the thigh 
-Primary series 
-Booster 
-At 2,4,6 mon. of age 
-At 12-15 month of age 
-At school entry 
-At 2,4,6 mon. of age 
-At 12 months. 
Measles 0.5 ml Subcutaneous Left upper arm -3 doses -At 9 mon. -At 9 mon. 
Hepatitis 
B 
0.5 ml Intramuscular Lateral aspect of 
the thigh 
-Primary -At 0, 1,6 mon. of age -At birth, 1,6 mon. of 
age 
MMR 0.5 ml Subcutaneous Left upper arm -Primary -At 15 mon. of age -At 15 mon. of age 
TT 0.5 ml Intramuscular Left upper arm -Booster 
-During 
pregnancy 
-For 3rd  prep. or 9th grade 
-For primigravida & 5 yrs. 
later 
-At first pregnancy * 
-After 5 years of the 
first pregnancy 
Td 0.5 ml Intramuscular Left upper arm -Booster -Every 10 years, persons ≥ 
7 yrs of age. 
-Wound management 
-At 15 yrs of age, 
ninth grade 
 
 
 
 
*In case documentary evidence could be provided that full coverage has been attained, 3 primary series plus one booster 
and 2 doses of TT at school age (no need for additional boosters). 
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1)  BCG WHO,P 
 (Bacille Calmette-Guerin) 
 
• VACCINE SUMMARY: 
BCG is a strain of tubercle bacillus that is 
used to prepare the vaccine against TB. 
BCG vaccine, a live attenuated vaccine, 
gives good protection in children, mainly 
against miliary and meningeal tuberculosis. 
EPI recommends that all countries with 
high incidence of TB infection should 
immunize with a single dose of BCG at or 
soon after birth. 
• INDICATIONS: 
Vaccine used for immunization against TB. 
• CONTRAINDICATIONS: 
In patients with symptomatic HIV 
infection, or other severe immune 
deficiency disease including high doses of 
corticosteroids or chemotherapy drugs. 
• RECOMMENDED DOSAGE: 
Refer to tables-4, 5 & 6.   
Always follow direction for reconstitution 
by the manufacturer. 
Once reconstituted, the vaccine must be 
protected from light, kept cold and 
discarded at the end of the day. 
• USE IN SPECIAL CASES:  
Refer to introduction.  
Immunization of asymptomatic HIV 
infants is advised when the risk of 
tuberculosis is high. 
• PRECAUTIONS AND WARNINGS, 
INTERACTIONS: 
-When given properly, this vaccine is 
extremely safe. 
A small red tender swelling about 10 mm 
may appear at the site of injection within 
about 2 weeks (since BCG bacteria grow 
slowly), which may also become an ulcer. 
The ulcer heals by itself, and leaves a small 
scar, which is a good indicator that the 
child has had the vaccine later on. If no 
scar develops, the dose must be repeated. 
-Multiple repeat doses of BCG are not 
recommended. 
-Patients on long-term systemic high doses 
of corticosteroids will have reduced 
immune response. Physicians should use 
caution in such patients; administer the 
vaccine not less than 3 weeks after 
discontinuation of the steroid therapy. 
• ADVERSE EFFECTS & OVERDOSE: 
Simple swelling and ulceration at the site 
of injection may occur, as well as cold 
abscess. Lymphatic glands swelling is most 
likely to occur if the needle used was not 
sterile, the needle was injected too deep, or 
the dose was large or there is a problem in 
the manufactured vaccine. In such cases 
refer the child for symptomatic treatment. 
_________________________ 
 
2)  OPV / IPV WHO,P 
    Oral Poliomyelitis Vaccine/  
    (Inactivated Poliomyelitis Vaccine) 
 
• VACCINE SUMMARY: 
Polio is almost eradicated; therefore, 
measures are implemented to assure that all 
the population must continue to be covered 
with vaccination. Two kinds of vaccines 
exist; OPV (the oral-live virus) and IPV 
(the inactivated-injectable virus). OPV is 
made of a weakened live polio virus. IPV 
is made of polio virus that has been killed. 
It cannot cause polio. IPV is more 
expensive, but may be recommended for 
pregnant women, people with an impaired 
immune system, and adults who have not 
been immunized previously. Immunization 
against polio forms a part of the WHO’s 
EPI. 
• INDICATIONS: 
An immunization against poliomyelitis (for 
prevention of permanent crippling, 
paralysis, and sometimes even death). 
• CONTRAINDICATIONS: 
In patients with history of hyper-sensitivity 
reaction to the vaccine, and immuno-
compromized patients. OPV should not be 
given to anyone in a family with a known 
family history of immunodeficiency until 
the immune status of all family members is 
documented. 
 
 
Vaccines 
277 
• DOSAGE FORMS: 
OPV-liquid bottle with dropper.  IPV-vial. 
• RECOMMENDED DOSAGE: 
Refer to tables 13.4, 5 & 6.  
-The OPV bottle dropper should not touch 
the child’s tongue/mouth.  If the child spits 
the drop out, give another dose.  
-Doses may vary between different 
manufacturers; instruction on the label of 
the vaccine should always be checked. 
-If child misses the usual time for a dose, 
the next dose can be given as soon as 
possible.  Immunity will be good, even if 
there is a delay.  There is no need to repeat 
earlier doses. 
-A single dose of IPV does not result in 
significant protection, therefore at least 2 
doses of IPV must be given. 
-The minimum interval between the first 3 
doses of IPV, OPV, or any combination of 
IPV and OPV is four weeks. 
-If ≥ 2 doses of OPV have been given, 
there is little benefit in switching to IPV. 
• USE IN SPECIAL CASES:  
Refer to introduction.  
• PRECAUTIONS AND WARNINGS, 
INTERACTIONS: 
-The presence of a minor infection is not a 
contraindication. In patients with acute 
fever, persistent vomiting or diarrhea, the 
vaccine should be postponed. If the child 
has diarrhea when OPV is given, the 
vaccine may not work so well, because the 
organism that causes diarrhea may 
interfere. An extra dose of OPV may be 
given four weeks after the normal course is 
administered. 
-When children in the household receive 
OPV, immunocompromised household 
contacts or adults who are not adequately 
vaccinated against polio are at small risk of 
contracting polio disease.  
-OPV can be given simultaneously with 
any other childhood vaccines. 
-Under no circumstances should OPV 
administered by injection. 
-Administration of OPV to patients 
receiving corticosteroids or radiation 
therapy, may result in insufficient response 
to OPV.  IPV may be administered in such 
cases. 
• ADVERSE EFFECTS & OVERDOSE: 
Usually there are no side effects with OPV. 
Vaccine-associated paralytic polio (VAPP) 
is extremely small (~ one case/1.4 million 
first dose receivers).  VAPP is more likely 
to occur in persons ≥ 18 years of age than 
in children. 
_________________________ 
 
3)  Tetanus Vaccine WHO,P 
 
• VACCINE SUMMARY: 
Tetanus vaccines stimulate the production 
of the protective antitoxin. Complete and 
appropriate times vaccination is nearly 
100% effective in the prevention of 
tetanus. The vaccine is usually given to 
children as a combination with diphtheria 
and pertussis vaccines. Immunization 
against tetanus forms a part of the WHO’s 
EPI. 
• INDICATIONS: 
Vaccine used as active immunization 
against tetanus (prevention of muscles to 
spasm or lockjaw). 
• CONTRAINDICATIONS: 
Acute febrile illness, history of severe 
hypersensitivity or convulsions. 
• DOSAGE FORMS: 
Vial. 
• RECOMMENDED DOSAGE: 
Refer to tables-15.4, 5 & 6.   
-Always follow directions for recon-
stitution by the manufacturer. 
Immunization of women can start at any 
stage of pregnancy. Tetanus toxoid (TT) 
does not harm the fetus. See table 15.7 on 
schedule of TT for women of child-bearing 
age. 
-The need for tetanus vaccine in wound 
management depends on both the condition 
and the patient’s immunization history. A 
dose of tetanus is only recommended if the 
risk of infection is considered high. If more 
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than 10 yrs. have passed, a reinforcing dose 
should be given. 
• USE IN SPECIAL CASES:  
Refer to the introduction.  
• PRECAUTIONS AND WARNINGS, 
INTERACTIONS: 
-Vaccination should be postponed in 
patients with acute febrile illness. 
-Booster doses should not generally be 
given at intervals of less than 10 years 
because of increased risk of severe local 
reactions. 
• ADVERSE EFFECTS & OVERDOSE: 
Pain, redness and swelling at the site of the 
injection may occur; this should go away 
by itself and needs no treatment. 
Anaphylaxis and neurological reactions 
have rarely occurred.  
_________________________ 
 
4)  DPT WHO,P 
 (Diphtheria, Pertussis, and Tetanus  
 Vaccines) 
 
• VACCINE SUMMARY: 
These vaccines are available as 
combinations so as to be given 
simultaneously. 
The DPT (or DTP) vaccine is a "3-in-1" 
vaccine that protects against diphtheria 
(which may lead to pneumonia, heart failure, 
and paralysis), pertussis (whooping cough 
which could lead to pneumonia or bronchitis), 
and tetanus. It can be given to children less 
than 7 years old. 
The DT vaccine is a "2-in-1" vaccine that 
does not contain pertussis, can be given to 
children less than 7 years old. 
The Td vaccine is the "adult" vaccine. It is 
a "2-in-1" vaccine that protects against 
tetanus and diphtheria. It contains a slightly 
different dose of diphtheria vaccine than 
the DT vaccine. It can be given to anyone 
older than 7 years old.  
• INDICATIONS: 
DPT vaccine is used for active immunization 
against the bacterial infections of diphtheria,  
pertussis, and tetanus. TT or Td may be 
given to an adult as prevention of tetanus 
from wound or injury that breaks the skin. 
• CONTRAINDICATIONS: 
In patients with severe hypersensitivity 
history to the vaccine; history of 
convulsion or shock in the following three 
days after the vaccination, encephalopathy 
within 7 days for P component of DPT. 
• DOSAGE FORMS: 
Vial. 
• RECOMMENDED DOSAGE: 
Refer to table 13.4,5&6. In general DPT is 
administered in four doses, and a booster. 
Booster is given every 20 years as Td. 
-Table 13.7 shows the duration of the 
immunity of different schedules for DPT 
vaccination. 
-Always follow direction for adminis-
tration by the manufacturer. 
-If child misses a dose of DPT, the next 
dose can be given at any time after four 
weeks of the first dose. There is no need to 
repeat earlier doses. 
 
Table – 13.7:  Expected Duration of 
Immunity after Different Immunization 
Schedules 
Schedule Duration of immunity (age) 
A) 3 DPT in infancy  5 years 
B) 4 DPT infancy and 2nd 
year 8 years 
C) As in B plus one DT 
at school entry 18 years 
D) As in C plus one DT 
at school leaving 40 years 
E) Two DT at School 
     (if no A→D) 10 years 
F) 3 DT at school  
     (if no A→D) 15 years 
G) 5TT as recommended 
by EPI 40 years 
 
• USE IN SPECIAL CASES:  
Refer to introduction. 
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• PRECAUTIONS AND WARNINGS, 
INTERACTIONS: 
-For children above 10 years or adults a 
specially diluted adsorbed vaccine is used. 
-DPT should not be used in persons with a 
history of neurologic disorders. 
-Use caution in children who had 
symptoms of: collapse or shock-like state 
within 48 hours of previous dose, elevated 
temp. of 40.5 or more within 48 hours of 
dose, and persistant inconsolable cry for 
more than 3 hrs. 
• ADVERSE EFFECTS & OVERDOSE: 
Slight fever and crying may occur but of no 
significance. Fever that does not resolve 
within one day, or starts 24 hours after a 
dose of DPT is not due to the vaccine. 
Local mild reaction such as swelling, 
redness or tenderness at the injection site 
may occur.  Rarely convulsions have been 
reported due to the pertussis part of DPT. 
_________________________ 
 
5)  Measles Vaccine WHO,P 
 
• VACCINE SUMMARY: 
This vaccine is available as a single 
vaccine or as a combination. In most 
countries, including Palestine, measles 
vaccine is used as a combination with 
mumps and rubella- (MMR) vaccine. 
• INDICATIONS: 
Measles vaccine is used as active 
immunization against measles. 
• CONTRAINDICATIONS: 
In patients with history of anaphylactic 
reactions or systemic hypersensitivity to 
neomycin, acute febrile illness including 
active untreated TB, and within 3 months 
of administration of IG, whole blood, or 
other blood products containing antibodies. 
• DOSAGE FORMS: 
Vial. 
• RECOMMENDED DOSAGE: 
Refer to table-4, 5 & 6.  
• USE IN SPECIAL CASES:  
Refer to introduction.  
• PRECAUTIONS AND WARNINGS, 
INTERACTIONS: 
-Use extreme caution in patients with mild  
hypersensitivity to eggs or neomycin. 
-Always follow direction for reconstitution 
by the manufacturer. 
-Administration to children less than 9 
months of age makes only 50% of the 
vaccine effective. If a 6 month old baby is 
seriously exposed to measles, then the 
vaccine may be given as long as another 
dose is administered when the child is nine 
months old. 
-There are conflicting reports about effect 
of vitamin A supplementation on reducing 
the response to the measles vaccine.  
• ADVERSE EFFECTS: 
Mainly fever and rash may occur. A fever 
may develop 5-10 days after the 
vaccination, and may last 1-2 days; a 
simple analgesic may be administered if 
the fever is high. 
_________________________ 
 
6)  MMR Vaccine WHO,P 
 (Measles, Mumps and Rubella) 
 
• VACCINE SUMMARY: 
The MMR vaccine is a "3-in-1" vaccine 
that protects against measles, mumps, and 
rubella. MMR should be given irrespective 
of previous measles vaccine, or history of 
measles, mumps, or rubella infection. 
• INDICATIONS: 
The vaccine is used for active 
immunization against measles, mumps and 
rubella. 
• CONTRAINDICATIONS: 
Patients with anaphylactic reactions to 
eggs, gelatin or neomycin. Children who 
have received another live vaccine by 
injection within 3 weeks.  
• DOSAGE FORMS: 
Freeze-dried vial. 
• RECOMMENDED DOSAGE: 
Refer to table-4, 5 & 6.  
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Dose should be reconstituted with the 
diluent as indicated by the manufacturer, 
and used within one hour. 
• USE IN SPECIAL CASES:  
Refer to introduction.  
Women known to be pregnant should not 
receive the vaccine. Pregnancy should be 
avoided for 2 months following receipt of 
the measles vaccine, and 3 months 
following MMR vaccine.  
• PRECAUTIONS AND WARNINGS, 
INTERACTIONS: 
-Use caution in patients with history of 
hypersensitivity to eggs, gelatin, or 
neomycin streptomycin. 
-In children with untreated malignant 
disease or altered immunity, and those 
receiving immunosuppressive drugs or 
radiotherapy, or high dose corticosteroids.  
-MMR vaccine should not be given within 
three months of an injection of IG. 
-If MMR is to be given to adult women, 
pregnancy should be avoided for 3 month 
(as for rubella vaccine). 
-MMR and other measles-containing 
vaccines are not recommended for HIV-
infected persons with evidence of severe 
immunosuppression. 
• ADVERSE EFFECTS: 
As with measles; malaise, fever, and/or 
rash may occur, most commonly after 
vaccination and lasting about 2-3 days. 
Parotid swelling may occur usually in the 
third week; children with post vaccination 
symptoms are not infectious.  
_________________________ 
 
7)  Hepatitis B Vaccine WHO,P 
 
• VACCINE SUMMARY: 
Hepatitis B vaccine contains inactivated 
hepatitis B virus (HBV) surface antigen 
(HbsAg) adsorbed on aluminum hydroxide 
adjuvant. It is made biosynthetically from 
yeast cells using recombinant DNA 
techniques. EPI recommends this vaccine 
in high incidence areas of Hepatitis B 
infections. 
• INDICATIONS: 
Hepatitis B vaccines are used for active 
immunization against HBV infections in 
persons at high risk of contracting the 
disease. 
• CONTRAINDICATIONS: 
Serious allergic reaction to a prior dose of 
of this vaccine, or a vaccine component. 
Such allergic reactions are rare. 
• DOSAGE FORMS: 
Vial. 
• RECOMMENDED DOSAGE: 
Refer to table-15.4, 5 & 6. Hepatitis B 
vaccine is given as a series of three 
injections (shots). 
-There are 2 different manufacturers that 
produce Hep. B vaccines. Vaccines made 
by different manufacturers are inter-
changeable as long as the manufacturer’s 
dosage recommendations are always 
followed. {Note that Recombivax HB dose is 
5 ug (0.5 ml), while Engerix-B dose is 10 ug 
(0.5 ml) for persons < 20 years of age.} 
-Most preparations are intended for 
intramuscular use only. Do not administer 
intravenously or intradermally unless there 
are clear directions from the manufacturer.  
-The vial should be stored at 2 – 8 ºC, and 
not freezed. 
• USE IN SPECIAL CASES:  
Refer to introduction. No information is 
available about the safety of the vaccine in 
pregnant women.  However, because the 
vaccine contains only particles that do not 
cause HBV infection, there should be no 
risk. Since the vaccine does not contain a 
live virus, it may be used in cases of 
immunodeficiency. However, response to 
the vaccination in such persons may be 
suboptimal. 
• PRECAUTIONS AND WARNINGS, 
INTERACTIONS: 
-It takes 6 months to confirm if there is 
adequate protection from the vaccine. 
 
 
Vaccines 
281 
-The vaccine should be used with caution 
in patients with severely compromised 
cardiopulmonary status. 
• ADVERSE EFFECTS & OVERDOSE: 
When given properly the vaccine is 
extremely safe. The most common side 
effect observed is soreness at the injection 
site.  
If the vaccine is administered too deep, 
local reaction, ulcers and regional 
lymphadentitis may occur. 
There have been rare reports of myalgia or 
arthralgia, neurological, abnormal liver 
function and dermatological side effects. 
______________________ 
 
8)  Influenza Vaccine WHO 
 
• VACCINE SUMMARY: 
Inactive influenza vaccines are used for 
active immunization against influenza. 
Because of the periodic changes in the 
surface antigens of influenza virus, the 
WHO makes annual recommendations 
concerning the antigenic nature of this 
vaccine. Medical personals need to be 
updated every year with the changes. This 
vaccine is listed in the WHO 10th EDL for 
use in specific groups of individuals.  
Influenza vaccine comes as whole-virus, 
split-virus, or purified surface antigen. 
Only split-virus or purified surface antigen 
vaccine should be used in children because 
these forms of the vaccine do not cause as 
much fever as whole-virus vaccine. 
• INDICATIONS: 
As a measure to prevent influenza 
infection, specially in high risk groups such 
as elderly, persons with chronic disorder of 
the cardiovascular, pulmonary, and/or renal 
system, severe anemia, compromised 
immune function, that are at risk of severe 
complications or dying after an influenza 
infection. 
• CONTRAINDICATIONS: 
Persons with a history of any signs and 
symptoms of anaphylactic reactions (hives, 
swelling of the mouth and throat, difficulty 
breathing, hypotension or shock) after 
eating eggs or egg products. 
• DOSAGE FORMS: 
Vials. 
• RECOMMENDED DOSAGE: 
For adults and children > 3 years; 0.5 ml 
given IM or deep SC (0.25 ml to children 
< 3 yrs). Vaccination produces immunity 
after about 14 days, lasting for about 6 
months to 1 year, therefore vaccine is 
administered annually during October-
November. Children aged 6 mon. - 9 yrs. 
receiving the vaccine for the first time, 
should get 2 doses at 1 mon. interval. 
• USE IN SPECIAL CASES:  
Refer to introduction.  
Babies as young as 6 months can get 
influenza vaccine. Children may have 
more side effects with influenza vaccine 
compared to adults (See Vaccine Summary). 
Only the split-virus vaccine should be used 
in children. 
Administration to pregnant women is 
considered safe, but may be administered 
after the first trimester as a precaution to 
minimize any concern of theoretical risk. 
• PRECAUTIONS AND WARNINGS, 
INTERACTIONS: 
-Persons with acute febrile illnesses 
normally should not be vaccinated until 
their symptoms have cleared. 
-Use caution in patients with allergy to 
thimerosal or sulfite additives. 
-Certain drugs activity has been reported to 
be enhanced with administration of 
influenza vaccine: the anticoagulant 
warfarin, phenytoin and theophylline. Use 
vaccine with caution. 
• ADVERSE EFFECTS & OVERDOSE: 
Local reactions such as pain, erythema, 
swelling or/and itching at the site of 
injections have been reported.  Mild 
systemic reactions such as headache, 
abdominal pain, muscle aches and 
dizziness have occurred.  Rarely neurologic 
symptoms have occurred. 
_______________________ 
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9)  Hib Vaccine 
 (Haemophilus Influenzae Type B) 
 
• VACCINE SUMMARY: 
Hib vaccine is used for active 
immunization against Haemophilus 
influenzae type b infections, a gram (-) 
bacteria, one of the major causes of 
meningitis and other severe systemic 
illness in young children (< 5 yrs). This 
polysaccharide (or related oligasaccharide) 
vaccine is linked to a protein carrier to 
form a conjugate vaccine, so as to enhance 
immunogenicity effect compared with non-
conjugated vaccine. At this time, the EPI 
has not adopted routine use of this vaccine 
until full cost data analysis would be 
available. 
• INDICATIONS: 
Vaccination against Haemophilus influenzae 
type b infections. 
• CONTRAINDICATIONS: 
In immunocompromized individuals. 
• DOSAGE FORMS: 
Freeze dried preparation. 
• RECOMMENDED DOSAGE: 
-There are different schedules for 
vaccination according to the product. 
Always refer to the manufacturer’s 
directions. In general, the conjugate 
vaccine is given by deep subcutaneous or 
intramuscular injection in doses of 0.5 ml, 
for 3 to 4 doses. The vaccine may be given 
at 2-4 months, 4-6 months and 12-15 
months of age. 
Hib vaccination schedule:  
-HibTITER: 3 doses, 2 months apart, 
starting at 2 months of age, with a 
booster at 12-15 months of age. 
-PedvaxHIB: 2 doses, 2 months starting 
at 2 months of age, with a booster at 
12-15 months of age. 
-ProHIBIT:  1 dose at 15 months to 5 
years of age, no booster needed. 
-Children aged 13-48 months should be 
given a single dose since they are at lower 
risk and the vaccine is effective after a 
single dose in this age group. Routine use 
in older children > 5 years or adults is not 
recommended. 
-Vaccine may be given simultaneously 
with DPT, measles, BCG or Hep B, as well 
as with IG. 
• USE IN SPECIAL CASES:  
The safety of the vaccine for pregnant 
women has not been established. On 
theoretical grounds, avoid vaccination 
unless there is a substantial risk of 
infection of the women.  
• PRECAUTIONS AND WARNINGS, 
INTERACTIONS: 
Use caution in patients with 
hypersensitivity to eggs, diphtheria toxoid, 
and thimerosal additive. 
• ADVERSE EFFECTS & OVERDOSE: 
These are very mild, and may include 
headache, myalgia, low grade fever (1 out 
of 100 doses) or other minor symptoms. 
Very rarely encephalitis has followed 
vaccination, generally in infants under 9 
months of age. 
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Daktazol, 139, 234 
Daonil, 151, A21 
Declamide, 151 
 
 
 
 
Decongestants, 81 
Deltasone, 160 
Depakote, 200 
Depalept, 200 
Deraline, 29, A4 
Dermatological 
Preparations, 230, A30 
Desipramine, 174, 176 
Desogestrel, 165 
Dexamethasone, 157 
Dexamol, 6, A1, A13 
Dextromethorphan, 87 
Dextrothyroxine, 149 
Diabeta, 151 
Diasix, 25 
Diazepam, 180, 181, A26 
Dichlorphenamide, 216 
Diclofen, 10 
Diclofenac, 7, 220, A2 
Diflorasone, 248 
Digitalis glycosides, 46 
Digitoxin, 46 
Digoxin, 46, 61, A6 
Dilantin, 198 
Dilatam/dilapress, 37 
Diloxanide furoate, 135 
Diltiazem, 20, 41, 149, A5 
Dioxybenzone, 253 
Diphenhydramine, 78 
Dipyrone, 3 
Diseptyl, 122 
Disopam, 182 
Disopyramide, 38 
Disoramin, 79 
Disothiazide, 23 
Diuretics, 22, 46, A4 
Docusate, 69 
Dopaminergic Agents, 201 
Dopicar, 208 
Doxepin, 174 
Doxycycline, 64, 116 
DPT, 273, 278, A40 
Duracef, 116 
Dyprotex, 232 
E 
Econazole, 233 
Elatrol/Elatrolet, 177 
Elavil, 177 
Electrosubs, 67 
Eltroxin, A21 
Emergency Pill, 171 
Emestop, 62 
Emollients, 230 
E-Mycin, 120 
Enalapril, 31 
Encainide, 38 
Endep, 177 
Engerix, 284, A41 
Enoxacin, 125 
Entogyl, 133 
Epanutin, 198, A24 
Ephedrine sulphate, 74 
Erytab, 120 
Erythrocare, 120 
Erythrocin, 120 
Erythrolet, 120 
Erythromycin, 118, A17 
Erythroped, 120 
Erythropharm, 120 
Erythroteva, 120 
Esidrex, 23 
Esmolol, 27, 38 
Esracain, 233 
Estrogens, 164 
Ethacrynic acid, 23 
Ethambutol, 127, 131 
Ethanol, 238 
Ethinyl estradiol, 164, 171 
Ethosuximide, 194, A24 
Ethyl alcohol, 238 
Ethynodiol, 165 
Expanded Program of 
Immunization, 271 
Expectorants, 84, A10 
F 
Famotidine, 55 
Fat Soluble Vitamins, 257, 
A35 
Febramol, 6, A1 
Fedral, 95 
Felcol, 12 
Feldene, 12 
Felodipine, 33 
Femulen, 169, A23 
Fenoxypen, 108 
Flagy, 133, A19 
Flecainide, 38 
Floxin, 126 
Flucloxacillin, 105, 108, 
223, A15 
Fludrocortisone, 156 
Fluorine/Fluoride, 265, A36 
Fluorometholone, 214 
Fluoroquinolones, 125, A18 
Fluosinolone, 248 
Fluoxetine, 174, 178, A26 
Fluoxicare, 179 
Flutine, 179 
Fluvoxamine, 174 
Folic acid, 260, 261, A35 
Fungazole, 234 
Fungitirin, 234 
Furadantin, 124 
Furamide, 135 
Furosemide/Frusemide, 20, 
23, A4 
Furovite, 25 
Fusid, 25, A4 
G 
Gabapentin, 188 
Garamine, 237 
Garamycin, 237 
Gastro-Intestinal Drugs, 53, 
A7 
Gemfibrozil, 49 
Gentamicin, 211, 236, A27, 
A31 
Gentatrim, 237 
Gestodene, 165 
GI-Care, 58 
Glibenclamide/ Glyburide, 
144, 149, A21 
Glibetic, 151 
Gliclazide, 144 
Glimepiride, 144 
Glipizide, 144 
Gluben, 151 
Glucocare, 151 
Glucomet, 153 
Glucomin, 153 
Gluconil, 151 
Glucophage, 153 
Glycerin, 69, 71, 73, 231, 
A9 
Glyceryl guaiacolate, 84 
Glyphillin, 94 
Granexin, 125 
Grifulin, 140 
Griseofulvin, 139 
Guaifenesin, 84 
 
 
 
 
Guanethidine, 20, 216 
Gynera, 167, A22 
Gyno-Daktarin, 139 
Gyno-Daktazol, 139 
H 
H2-antagonists, 54, 55 
Halazepam, 180 
Haldol, 187 
Halidol, 187 
Haloper, 187 
Haloperidol, 61, 184, 186, 
A26 
Harmonal, 182 
Hemoral, 74 
Hep. B vaccine, 280, A41 
Hib vaccine, 282 
HibTITER, 282 
Hiconcil, 111 
Hismal, 80 
Hismanal, 80 
Homosalicylate, 253 
Humulin, 149 
Hydralazine, 20 
Hydran 60, 67 
Hydrochlorothiazide, 20, 
22, A4 
Hydrocortisone, 73, 97, 
156, 248 
Hydrocortisone acetate, 214 
Hydroxyethylcellulose, 220 
Hyocine N-butyl Bromide, 
60, A8 
Hypnotics, 180, A26 
I 
Ibufen, 9 
Ibuprofen, 7, 8, A2 
Ikacor/Ikapress, 36 
Imipramine, 177, A26 
Imodium, 68 
Indapamide, 22 
Indocaps, 11 
Indocin, 11 
Indomed, 11 
Indomethacin, 7, A3 
Indopharm, 11 
Indovis, 11 
Influenza vaccine, 93, 281, 
A41 
Inhibace, 33 
Insulin, 146, A21 
Iodine, 266, A31 
Iodocare, 239 
Iodo-Vit, 239 
IPV, 276 
Iron, 264, 265, A36, A37 
Isardipine, 33 
Isocarboxide, 174 
Isocardide, 42 
Isofen, 9 
Isoniazid, 127, 128, A19 
Isophane insulin, 144 
Isophane-NPH, 146 
Isoproterenol, 94 
Isordil, 42 
Isosorbide dinitrate, 41, A5 
Isosorbide mononitrate, 41 
Isotard, 42 
IUD, 162 
J 
Jeflex, 116 
Jordacycline, 236 
K 
K, 267 
Keflex, 116 
Ketoconazole, 234, A31 
Klonopin, 194 
L 
Labetolol, 27 
Lactase, 64 
Lactopar, 207 
Lactulose, 69 
Lahistan, 80 
Lamotrigine, 188 
Lanoxin, 48 
Lansoprazole, 55 
Largactil, 186 
Lasix, 25 
Laxatives, 68, 69, A9 
Levodopa, 207 
Levofloxacin, 125 
Levonorgestrel, 165, 170, 
A22 
Levothyroxine, 153 
Levozem, 37 
Lidocaine, 40 
Lignocaine, 220, 232 
Lindane, 242 
Lipastop, 68 
Lipid Lowering Drugs, 48, 
A6 
Liquidone, 144 
Lisinopril, 31 
Lispro, 146 
Lispro insulin, 144 
Lithium, 175 
Locacid, 250 
Local Anesthetics, 72 
Locid, 59 
Lomefloxacin, 125 
Lomudal, 97 
Loop diuretics, 23 
Loperamide, 67, A8 
Loperid, 68 
Lorainide, 38 
Loratadine, 78 
Lorazepam, 180, 182, A26 
Lorivan, 183 
Lorocare, 183 
Losec, 59 
Lovastatin, 49, 52 
M 
Maalox, 57 
Macrodantin, 124 
Macrofuran, 124 
Macrolides, 93 
Magnagel, 57 
Magnicillin, 109 
Malathion, 241 
MAO Inhibitors, 149 
Maprotiline, 174 
Measles Vaccine, 274, 276, 
A40 
Meclizine/Meclozine, 61,  
63, A8 
Medroxy-progesterone 
acetate, 169 
Megacare, 109 
Megalat, 35 
Mepral, 59 
Mestranol, 164 
Metamucil, 72 
Metaproterenol, 94 
Metformin, 144, 145, 151, 
A21 
 
 
 
 
Methicillin, 108 
Methylcellulose, 69 
Metoclopramide, 61, A8 
Metolazone, 22 
Metoprolol, 27, A41 
Metrocare, 133 
Metrogyl, 133 
Metronidazole, 55, 132, 
A19 
Metrozole, 133 
Metyrosine, 20 
Mexiletine, 38 
Mg/Al Salt, 56, A7 
Miconazole, 138, 233, A20, 
A30 
Microdiol, 167 
Miglitol, 144 
Mineral oil, 73 
Minerals, 264, A35 
Minocycline, 116 
Minoxidil, 20 
Miphar, 25 
MMR vaccine, 274, 279, 
A40 
Moclobemide, 174 
Mono-Amine Oxidase 
Inhibitors, 174 
Moricizine, 38 
Motrin, 9 
Moxepharm, 111 
Moxypen, 111 
Moxyvit, 111 
Mucolytics, 88, A11 
Mupirocin, 236, A31 
Mycobutin, 130 
N 
Nadolol, 27 
Nalcrom, 97 
Nalidixic acid, 124, A18 
Naphazoline, 81 
Naproxen, 7, A2 
Nasivin, 83 
Nazal Decongestants, A10 
Nefazodone, 174 
NegGram, 125 
Neomycin, 223, 236 
Neuroleptics, 183 
Niacin, 261 
Niclosamide, 136 
Nicotinic Acid, 49 
Nifedipine, 20, 34, 41, A5 
Nimodipine, 33 
Nisoldipine, 33 
Nitrates, 40 
Nitrazepam, 180 
Nitrofurantoin, 122, A18 
Nitroprusside, 20 
Nizatidine, 55 
Nizoral, 235 
Nonoxinol ‘9’, 163 
Nordette, 167, A22 
Norethisterone, 165 
Norfloxacin, 125 
Norgestimate, 165 
Norlip, 50 
Normalol, 30 
Normiten, 30 
Norplant, 171 
Nortriptyline, 174, 176 
Nosacare, 83 
Nouryl, 242 
Novolin, 149 
Novomit, 62 
NSAIDs, 2, 7, 8, 9, 10, 12, 
16, A2 
Nurofen, 9 
Nystatin, 137, 233, A19 
O 
Octyl salicylate, 253 
Ofloxacin, 125, 212, 224 
Ogmin, 112 
Omeprazole, 55, 58, A7 
Opthalmic Preparations, 
210, A27 
Opticrom, 216 
OPV, 274, 276 
Oral Rehydrating Salt 
(ORS), 66, 67, A8 
Otic Preparations, 222, A29 
Oxazepam, 180 
Oxcarbazepine, 188 
Oxprenolol, 27 
OXY, 251 
Oxybenzone, 253 
Oxybuprocaine, 220 
Oxycin, 236 
Oxy-clean, 244 
Oxymetazoline, 81, 82, 
A10 
Oxytetracycline, 236, A31 
P 
Padimate O, 253 
Pamol, 6 
Pantoprazole, 55 
Paracare, 6 
Paracetamol, 5, A1 
Parafin, 69 
Paramol, 6 
Paramolan, 6 
Paravomine, 63 
Parazine, 243 
Parilac, 207 
Parlodel, 207 
Paroxetine, 174 
Partivel, 205 
Pathoprim, 122 
PedvaxHIB, 286 
Penbutolol, 27 
Penibrin, 111 
Penicillins, 105, A15 
Pentrexyl, 111 
Peridol, 187 
Peridor, 187 
Petrolatum, 231 
Pharmaprim, 122 
Phenelzine, 174 
Phenobarb, 197 
Phenobarbital, 195 
Phenobarbitone, 195 
Phenolphthalein, 69 
Phenoxymethyl-penicillin, 
105 
Phenylephrine, 73, 81, A13 
Phenylpropanolamine, 81, 
A13 
Phenytoin, 38, 177, 190, 
191, 197, A24 
Pilocarpine, 216 
Pindolol, 27 
Pioglitazone, 144 
Pirox, 12 
Piroxicam, 7, 11, A3 
Pitrex, 236 
Pivampicillin, 109 
Polycarbophil, 69 
Polydine, 239 
Polymixin B, 212, 236 
Potassium, 266 
Potassium-Sparing 
Diuretics, 25 
Povidone-Iodine, 238, A31 
 
 
 
 
Pramin, 62 
Prazepam, 180 
Prazosin, 20 
Prednisolone, 157, 214, 225 
Prednisone, 98, 157, 158, 
160, A12 
Prednitab, 160 
Prelosec, 59 
Pressolat, 35 
Primonil, 178 
Prioderm, 242 
Prizma, 179 
Probenecid, 11 
Probucol, 49 
Procainamide, 38 
Procaine Penicillin, 107 
Procar, 40 
Prochlorperazine, 61, 184 
Procyoxylene, 74 
Progesterones, 164, 168 
Progestin-Only Products, 
168, A23 
ProHIBIT, 286 
Prolol, 29 
Promazine, 184 
Promethazine, 61, 78 
Propranolol, 20, 27, 30, 41, 
A4 
Propylthiocil, 156 
Propylthiouracil, 155, A21 
Protectants, 73 
Proton Pump Inhibitors, 54 
Protriptyline, 174 
Proxymetacaine, 220 
Prozac, 179 
Pseudoephedrine, 81, 83, 
A10 
Psychotheraputic  Drugs, 
173, A26 
Psyllium, 69, 71, A9 
Pyrazinamide, 12, 127, 131 
Pyrithione Zinc, 246 
Pyrocard, 16 
Q 
Questran, 51 
Quinapril, 31 
Quinidine, 40 
R 
Rabeprazole, 55 
Rafapen, 108 
Ramipril, 31 
Randin, 58 
Ranitidine, 57 
Ratidine, 58 
Razimol, 6 
Recombivax HB, 284 
Reglan, 62 
Rehidrat, 67 
Repaglinide, 144 
Reserpine, 20 
Resperidone, 184 
Respiratory  Drugs, 75 
Resprim, 122 
Resyl, 85 
Retavit, 250 
Retin-A, 250 
Retinoic Acid, 249 
Rhinoclir, 83 
Rhumacare, 10 
Rifampin/rifampicin, 127, 
129, A19 
Rimactan, 130 
Rivotril, 194 
Robutussin, 85 
Rosiglitazone, 144 
Rufenal, 10 
S 
Salbutamol, 94, A12 
Salbuvent, 95 
Salicylates, 149 
Salicylic Acid, 246, 244, 
A32 
Salisol-2, 244 
Saralasin, 20 
Scabicide, 241 
Scabiex, 241 
Scobutyl, 61 
Scopal, 61 
Selective Serotonin 
Reuptake Inhibitors, 174 
Selenium Sulfide, 246 
Senna, 69 
Serepam, 182 
Sertraline, 174 
Simigel, 57 
Simovil, 52 
Simvastatin, 49, 52 
Sincomen, 26 
Sinemet, 208 
Sinoptic, 218 
Somophyllin, 94 
Sotalol, 27, 38 
Sparfloxacin, 125 
Spermicides, 163 
Spironolactone, 20, 25, A4 
Sporofulvin, 140 
Stomagel, 57 
Stopit, 68 
Sulfatrim, 122 
Sulfinpyrazone, 14 
Sulfisoxaole, 224 
Sulfonylureas, 144 
Sulfur, 245 
Sulisobenzone, 253 
Sulphonamide, 120 
Sulpiride, 184 
Sulprim, 122 
Sunscreen Products, 252, 
A34 
Supradyn, A39 
Symmetrel, 205 
T 
Taroctyl, 186 
Td vaccine, 282, A40 
Tegrepine, 192 
Tegretol, 192 
Temocillin, 109 
Terconazole, 233 
Teril, 192 
Tetanus vaccines, 281, A40 
Tetracare, 236 
Tetracyclines, 116, 212, 
A17, A31 
Tetrapharm, 118, 236 
Tevacycline, 118, 236 
Theo-dur, 94 
Theopharm, 94 
Theophylline, 15, 91, A11 
Theotard, 94 
Theotrim, 94 
Thiazide, 149 
Thiazolidinediones, 145 
Thioridazine, 184 
Thioxanthenes, 184 
Thorazine, 186 
 
 
 
 
Thyroid Hormones, 93, 
149, 153 
Thyroxine, 153, A21 
Tiloptic, 218 
Timolin, 218 
Timolol, 27, 217, A28 
Tinaderm, 236 
Tinasol, 236 
Titanium dioxide, 253 
Tobramycin, 212 
Tocainide, 38 
Tofranil, 178 
Tolazamide, 144 
Tolbutamide, 150 
Tolnaftate, 233, 235, A31 
Topical Antifungals, 233 
Topical corticosteroids, 246 
Torsemide, 23 
Tranquilizers, 186 
Tranylcypromine, 174 
Trazodone, 174 
Tretinoin, 249 
Triamcinolone, 157, 248 
Triamterene, 25 
Triazolam, 180 
Trichonazole, 133 
Tricyclic Antidepressants, 
174 
Trihexyphenidyl, 202 
Trimethoprim, 120 
Trimpramine, 174 
Triprolidine, 78 
Troglitazone, 144 
Trufen, 9 
Tryptal/Tryptalette, 177 
Tylenol, 6 
U 
U-Gram, 125 
Ulcer Healing Drugs, 54 
Uniscrub, 240 
Urantoin, 124 
Uricnase, 14 
Urigram, 125 
Urix, 25 
V 
Vaccines, 268, A40 
Valium, 182 
Valporal, 200 
Valproate, 198 
Valproic Acid, 198 
Vaseline, 231, 245, A30 
Vasoconstrictors, 72 
Venlafaxine, 174 
Ventocare, 95 
Ventolin, 95 
Ventomin,95 
Verac, 36 
Verapamil, 20, 35, 41, A5 
Vermacare, 136 
Vermazol, 136 
Vermox, 136 
Viarex Inhaler, 98 
Vicrom, 97 
Vical, A39 
Vigabatrin, 188 
Virax, 238 
Vitamin A, 257, A35 
Vitamin B1, 259 
Vitamin B12, 259 
Vitamin B6, 259 
Vitamin C, 260 
Vitamin D, 198, 257 
Vitamin E, 257 
Vitamin K, 257 
Vitamins, 256, A35, A37 
Vitapen, 111 
Volmax, 95 
Voltaren, 10 
Voltin, 10 
W 
Warfarin, 43 
Water Soluble Vitamins, 
256, A35 
White petrolatum, 73 
Wormex, 136 
X 
Xylene, 233 
Xylometazoline, 81, 82 
Z 
Zadstat, 133 
Zantab, 58 
Zantac, 58 
Zarontin, 195 
Zinc oxide, 73, 232, 253 
Zinc sulphate, 220 
Zino Pads, 244 
Zocor, 52 
Zovirax, 141, 238 
Zylol, 14 
 
 
 
 A- 1 
 
 
Appendix A – Price List 
 
 
 
 
 
 
 
 
This list of drugs is based on the September 2002 cost price list from 
Palestinian drugstores and pharmacies. Drug prices constantly 
change in the Palestinian market so this information is to be used 
only as a guide for health professionals. 
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ANALGESICS, ANTIPYRETICS, NON-STEROIDAL 
ANTI-INFLAMMATORY, AND ANTIGOUT DRUGS 
 
G
en
er
ic
 
N
am
e  
BRAND NAME 
 
STRENGTH 
 
DOSAGE 
FORM 
 
MANUFAC-
TURER 
SELLING  
PRICE (NIS)/  
# OF DOSAGE 
FORM 
A) Analgesics, Antipyretics, and Non-Steroidal Anti-Inflammatory Agents 
A
ce
ty
lsa
lic
yl
ic
 A
ci
d 
(A
SA
) 
ACETOSAL 300mg 
500mg 
Tab. 
Tab. 
Rekah 9.00/40 
10.00/20 
ALKA SELTZER 324mg  Efferv. Tab. Agis 8.00/10 
ASCRIPTIN  
(ASA with antacid) 
ASA 325mg 
AlOH 75mg 
MgOH 75mg 
Tab. RP Rorer 21.00/100 
ASPIRIN 81 
ASPIRIN 
81mg 
100mg  
E.C. Tab. 
Tab. 
Bayer 16.00/30 
10.00/30 
BABY ASPIRIN 100mg Chew. Tab. JCL 6.00/20 
CARTIA 100mg  Tab. SK Beecham 16.00/28 
MICROPIRIN 75mg Tab. Dexxon 30.00/10 
TEVAPIRIN 100mg E.C. Tab. Teva 11.00/30 
Pa
ra
ce
ta
m
ol
 
ABROL 500mg Tab. Rekah 5.00/30 
ABROLET 150mg 
250mg 
Supp. Rekah 
 
10.00/12 
14.00/5 
ACAMOL 500mg Tab. Teva 11.00/20 
ACAMOLI 80mg 
150mg 
125mg/5ml 
Chew. Tab. 
Supp. 
Syr. (Stwbry) 
Teva 
 
13.00/50 
12.00/12 
13.00/100ml 
ALDOLOR 500mg 
100mg/ml 
120mg/5ml 
Tab. 
Drops 
Syp. Sugar free 
CTI 14.00/50 
13.00/20ml 
 8.00/110ml 
DEXAMOL 500mg Cap. Dexxon 27.00/50 
DEXAMOL KID 250mg 
125mg/5ml 
Chew. Tab. 
Syp (Stwbry 
or Cola) 
Dexxon 12.50/20 
12.00/115ml 
FEBRAMOL 500mg 
120mg/5ml 
150mg 
300mg 
Tab. 
Syp (Stwbry) 
Supp. 
Supp. 
BPC 5.00/20 
7.00/100ml 
5.00/6 
7.00/6 
OTAMOL 500 mg 
120mg/5ml 
300mg 
Tab. 
Syp  (Stwbry) 
Suppository 
JePharm 5.00/20 
9.00/120ml 
5.00/5 
PAMOL 150mg 
300mg 
500mg 
125mg/5ml 
Supp. 
Supp. 
Supp. 
Syrup 
Eastern Chem. 5.00/5 
5.00/5 
8.00/5 
7.00/100ml 
PARACARE 500mg  Tab. 
Syrup 
Pharmacare 4.00/20 
7.50/100ml 
 A- 4 
PARAMOL 500mg 
125mg/ml 
150mg 
300mg 
500mg 
30mg 
Tab. 
Syrup 
Supp. 
Supp. 
Supp. 
Chew. Tab. 
JCL 5.00/20 
7.00/100ml 
3.00/5 
3.50/5 
6.50/5 
10.00/20 
Ib
up
ro
fe
n 
ADEX 200 
ADEX 400 
200mg 
400mg 
Cap. Dexxon 13.60/30 
22.00/30 
ARTOFEN 200mg 
400mg 
600mg 
Tab. 
Tab. 
Tab. 
Teva 12.00/20 
22.00/50 
22.00/30 
BRUFEN 400 400mg Tab. Boots 16.00/30  
IBUFEN 400mg 
600mg 
Cap. 
Cap. 
Dexxon 13.00/30 
18.30/30 
ISOFEN 200mg 
400mg 
Tab. JCL 7.00/20 
15.00/20 
NUROFEN 200mg Tab. Boots 16.00/12  
24.00/24 
TRUFEN 200mg 
400mg 
600mg 
100mg/5ml 
Tab. 
Tab. 
Tab. 
Susp. (Orange) 
JePharm 5.00/20 
10.00/20 
8.00/20 
15.00/100ml 
N
ap
ro
xe
n 
APO-NAPROXEN 250mg 
500mg 
Tab. Apotex 33.00/30 
65.00/30 
NAPREX 250mg 
500mg 
500mg 
Tab. 
Tab. 
Supp. 
BPC 20.00/20 
12.50/10 
18.50/12 
NAPROXI  250mg 
500mg 
Tab. 
Tab.  
Gerard 29.00/5 
29.00/5 
NAXYN 250mg 
500mg 
500mg 
Tab. 
Tab. 
Supp. 
Teva 59.00/50 
26.00/30 
38.30/12 
D
ic
lo
fe
na
c 
ABITRENE 25mg 
50mg 
100mg 
Tab. 
Supp. 
S.R. Tab. 
Abic 8.00/20 
19.00/10 
12.00/10 
BETAREN 25mg 
50mg 
Tab. 
Tab. 
Dexxon 
 
13.00/30 
27.00/30 
BETAREN S.R. 100mg S.R. Tab. Dexxon 16.00/10 
DICLOFEN 25mg 
50mg 
100mg 
12.5mg 
75mg 
100mg 
1% 
Tab. 
Tab. 
S.R. Tab. 
Supp. 
Supp. 
Supp. 
Gel 
JePharm 16.50/30 
23.00/30 
15.00/10 
11.00/6 
28.00/10 
42.00/15 
14.00/30g 
RHUMACARE 50mg 
1% 
Tab. 
Gel 
Pharmacare 22.00/30 
18.00/50gm 
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RUFENAL 25mg 
50mg 
100mg 
100mg 
1% 
Tab. 
Tab. 
S.R. Tab. 
Supp. 
Gel  
BPC 12.00/30 
20.00/30 
12.00/10 
27.00/12 
13.50/30g 
VOLTAREN 25mg 
50mg 
1%  
Tab. 
Supp. 
Gel  
Novartis 52.00/30 
28.00/10 
18.00/20g 
34.00/50g 
VOLTAREN S.R. 100mg S.R. Tab. Novartis 54.50/10 
VOLTIN 50mg 
100mg 
Supp. Eastern Chem. 18.00/10 
26.00/12 
In
do
m
et
ha
ci
n 
INDOCAPS 25mg 
100mg 
Cap.  
Supp. 
JCL 10.00/24 
13.00/10 
INDOCIN 25mg 
100mg 
Cap. 
Supp. 
Eastern Chem. 9.00/20 
15.00/12 
INDOLIN 25mg 
100mg 
Cap. 
Supp. 
BPC 8.50/20 
17.00/12 
7.00/6 
INDOMED 25mg 
100mg 
Cap. 
Supp. 
Assia 18.00/30 
20.00/12 
INDOMED S.R. 75mg S.R. Caps Assia 37.00/10 
INDOPHARM 25mg 
75mg 
100mg 
Cap. 
S.R. Cap. 
Supp. 
JePharm 7.50/20 
17.50/16 
18.00/12 
INDOTARD 75mg S.R. Cap. CTI 35.50/10 
INDOVIS 25mg Cap. CTI 15.00/30 
Pi
ro
xi
ca
m
 
FELCOL 10mg 
20mg 
Cap. Eastern Chem. 21.00/20 
29.00/20 
FELDENE 20mg 
20mg 
0.5% 
Cap. 
Suppository 
Gel. 
Pfizer 121.0040/30 
51.00/12 
26.00/25gm 
PIROX 20mg 
20mg 
0.5% 
Cap. 
Supp.  
Gel 
JePharm 33.00/20 
24.00/6 
17.00/30g 
Antigout Agents 
A
llo
pu
ri
no
l ALLORIL 100mg 
300mg 
Tab. Dexxon 35.50/50 
35.50/20 
ZYLOL 100mg 
300mg 
Tab. Teva 43.00/50 
43.00/20 
URICNASE 100mg Tab. BPC Not in private 
market /20 
Su
lfi
n-
 
py
ra
zo
ne
 ANTURAN 100mg 
200mg 
Tab. Novartis 124.00/100 
93.00/50 
PYROCARD 100mg Tab. Trima 88.00/100 
C
ol
ch
i- 
ci
ne
 
COLCHICINE 0.5mg Tab. Rafa 10.00/30 
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CARDIOVASCULAR DRUGS 
 
G
en
er
ic
 
N
am
e  BRAND NAME 
 
STRENGTH 
 
DOSAGE 
FORM 
 
MANUFACT-
URER 
SELLING  
PRICE (NIS)/  
# OF DOSAGE 
FORM 
Diuretics 
H
C
-
T
H
Z
 DISOTHIAZIDE 25mg  Tab. Dexxon 28.00/50 
ESIDREX 25mg  Tab. Novartis 23.00/20 
Fu
ro
se
m
id
e 
DIASIX 40mg Tab. JCL 8.50/20 
FUROVITE 40mg Tab. Vitamed 12.50/25 
FUSID 40mg 
100mg 
Tab. Teva 34.00/50 
131.00/100 
LASIX 40mg Tab. HMR 24.00/20 
MIPHAR 40mg Tab. Pharbita 13.00/50 
URIX 40mg Tab. BPC 13.00/20 
Si
rp
no
l-
ac
to
ne
 ALDACTONE 25m 
100mg 
Tab. Searle 29.00/20 
46.00/10 
ALDOSPIRONE 25mg 
100mg 
Tab. Teva 18.00/20  
61.00/20 
Beta-Blockers 
Pr
op
ra
no
lo
l 
BLOCADRIL 10mg 
40mg 
Tab. BPC 6.50/20 
9.50/20 
DERALIN 10mg 
40mg 
Tab. Abic 8.00/30 
11.00/30 
PROLOL 10mg 
40mg 
Tab. Dexxon 5.50/50 
14.00/50 
SLOW DERALIN 80mg 
160mg 
S. R. Cap.  Abic 61.00/30 
114.00/30 
A
te
no
lo
l 
ATENI 50mg 
100mg 
Tab. Generics 43.00/30 
60.00/30 
COROTENOL 50mg 
100mg 
Tab. JePharm 52.00/50 
20.00/50 
NORMALOL 25mg 
50mg 
100mg 
Tab. Dexxon 9.00/30 
13.00/30 
18.00/30 
NORMITEN 25mg 
50mg 
100mg 
Tab. Abic 11.00/30 
11.00/30 
11.00/30 
Angiotensin Converting Enzyme Inhibitors 
C
ap
to
pr
il 
CAPOTEN  12.5mg 
25mg 
50mg 
Tab. BMS 255.00/100 
261.00/90 
455.00/90 
CARDIOPRIL 25mg 
50mg 
Tab. BCP 10.00/20 
15.00/20 
INHIBACE 12.5mg 
25mg 
50mg 
Tab. Pharma-Best 40.00/100 
45.00/90 
84.00/90 
 A- 7 
Calcium Channel Blockers 
N
ife
di
pi
ne
 
ANGILAT 10mg 
20mg 
10mg 
Tab. 
Tab. 
Soft gel Cap. 
BPC 20.00/30 
40.00/30 
35.00/75 
MEGALAT 10mg Cap. Agis 66.00/90 
OSMO-ADALAT 30mg 
60mg 
S.R. Tab. Pharma-Clal 138.00/30 
209.00/30 
PRESSOLAT 10mg 
20mg 
Tab.  Agis 40.50/20 
51.00/20 
V
er
ap
am
il 
IKACOR 40mg 
80mg 
120mg 
Tab. Teva 15.00/50 
25.00/50 
36.00/50 
IKAPRESS 180mg 
240mg 
S.R. Tab. Teva 90.40/30 
35.50/30 
VERACOR 40mg 
80mg 
120mg 
Tab. Dexxon 17.00/60 
29.00/60 
44.00/60 
D
ilt
ia
ze
m
 
DILAPRESS 120mg S.R. Tab. Abic 78.00/30 
DILATAM 30mg 
60mg 
120mg 
240mg 
Tab. 
Tab. 
S.R. Tab. 
S.R. Tab. 
Abic 11.00/30 
20.00/30 
82.00/30 
112.50/30 
LEVOZEM 30mg 
60mg 
90mg 
Tab. Dexxon 33.50/30 
38.00/20 
45.00/20 
Other Cardiac Agents 
A
m
io
d-
ar
on
e AMIODACORE 200mg 150mg 
Tab. 
Amp. 
CTI 24.00/30 
          /6 
PROCOR 200mg Tab. Unipharm 34.00/30 
Is
os
or
bi
de
 D
in
itr
at
e 
CORDIL  2.5mg 
5mg 
10mg 
20mg 
40mg 
Subling. Tab. 
Subling. Tab. 
Tab. 
Tab. 
S.R. Tab. 
Dexxon 5.50/40 
6.00/40 
9.00/50 
12.00/50 
46.00/25 
ISOCARDIDE 2.5mg 
5mg 
10mg 
20mg 
30mg 
Subling. Tab. 
Subling. Tab. 
Tab. 
Tab. 
Tab. 
Sam-On 5.00/40 
7.00/40 
7.00/40 
8.00/40 
10.00/40 
ISORDIL 10mg  Tab. Wyeth Ayerst 46.00/100 
ISOTARD 20mg 
40mg 
60mg 
S.R. Cap. CTI 14.00/20 
22.50/20 
32.00/20 
W
ar
fa
ri
n COUMADIN NA 
 
5mg  Tab. Taro 19.00/20 
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D
ig
ox
in
 
4BDIGOXINZORI 0.25mg Tab. Teva 12.00/40. 
LANOXIN 0.25mg 
0.05mg/ml 
Tab. 
Elixir GSK 
27.72/100 
55.00/50ml 
LIPID LOWERING DRUG 
Fibric Acids 
Be
za
fib
ra
te
 BEZALIP 200mg Tab. Boehringer 91.00/100 
BEZALIP RETARD 400mg Long Acting 
Tab. 
Boehringer 52.00/30 
NORLIP 100mg 
200mg 
Tab. Unipharm 75.00/100 
73.20/50 
Bile Acid Sequestrants 
C
ho
le
st
y 
ra
m
in
e CHOL-LESS 4 gram Sachets Rafa 94.00/50 
QUESTRAN  4 gram Sachets Mead- 
Johnson 
144.00/5  
HMG-CoA Reductase Inhibitors 
Si
m
va
-
st
at
in
 5BSIMOVIL 5mg 
10mg 
20mg 
40mg 
Tab. Assia/ Riesel 148.00/30 
98.00/30 
142.00/30 
768.00/30 
Fl
uv
sa
- 
st
at
in
 6BLESCOL 20mg 
40mg 
Tab.  BMS 108.00/28 
145.00/28 
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GASTROINTESTINAL DRUGS 
 
 
G
en
er
ic
 
N
am
e 
 
BRAND NAME 
 
STRENGTH 
 
DOSAGE 
FORM 
 
MANUFACT-
URER 
SELLING 
PRICE (NIS)/  
# OF DOSAGE 
FORM 
Antacids & Ulcer-Healing 
M
g/
A
l S
al
ts
 
MAALOX Al-hydroxide 
225mg 
Mg-hydroxide 
200mg/5ml 
Suspension Rorer 24.00/355ml 
MAALOX NO.1 Al-hydroxide 
200mg,  
Mg-hydroxide 
200mg/5ml 
Tab. Rorer 25.00/100 
MAALOX PLUS Al-hydroxide 
225mg 
Mg-hydroxide 
200mg/5ml 
Simethicone 
Suspension 
Tab. 
Rorer 27.00/355ml 
25.00/50 
MAGNAGEL Al-hydroxide 
6.0%  Mg-
trisilicate 7.5%  
Suspension JePharm 17.00/355ml 
 
MAGNAGEL Al-hydroxide 
200mg 
Mg-trisilicate 
300mg 
Chewable 
Tab. 
JePharm 63.00/400 
STOMAGEL Al-hydroxide 
500mg 
Mg-trisilicate 
750mg/ 15 ml 
Suspension JCL Not produced 
any more. 
R
an
iti
di
ne
 
GI-CARE 150 mg Tab. Pharmacare 14.00/20 
RANDIN 150mg Tab. JePharm 14.50/20 
RATIDINE 150mg 
300 mg 
Tab. BPC 16.00/20 
34.00/20 
ZANTAB 150mg 
300 mg 
Tab. Teva 14.00/20 
14.00/10 
ZANTAC 150mg 
300mg 
Efferv. Tab. GSK 90.00/20 85.00/10 
ZANTAC 150mg 
300 mg 
Tab. GSK 81.00/20 
75.00/10 
O
m
ep
ra
zo
le
 
LOCID 20 mg Cap.  JePharm 49.00/14 
LOSEC 10mg 
20mg 
Cap. Abic 284.90/30 
224.00/14 
MARIAL 10mg 
20mg 
Cap.  JCL 30.00/14 
55.00/14 
MEPRAL 20 mg Cap.  BPC 50.00/14 
PEPTICUM 20 mg Cap. Pharmacare 60.00/15 
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Antispasmodics/Anticholinergics 
H
yo
ci
ne
 N
-
Bu
ty
l B
ro
m
id
e KOLIK Hyosciamine 
Sulfate 0.125 
gm, alcohol 
0.3ml/ml 
Drops JCL 9.00/10ml 
SCOBUTYL Hyocine N-butyl 
bromide 10 mg 
Tab. JePharm 9.00/20 
Anti-Emetics 
M
et
ac
lo
pr
am
id
e 
EMESTOP 10 mg 
5mg/5ml 
Tab. 
Syrup 
BPC 12.00/20 
6.00/30ml  
NOVOMIT 10 mg 
5mg/5ml 
Tab. 
Syrup 
JePharm 9.00/20 
8.00/60ml 
PRAMIN 10 mg 
5mg/5ml 
5mg 
20 mg 
Tab. 
Syrup 
Supp. 
Supp. 
Rafa 19.00/30 
8.00/60ml 
11.00/6 
11.00/6 
M
ec
liz
in
e/
  
M
ec
lo
zi
ne
 ANCOZINE Meclozine 15mg 
Pyridoxine 30mg 
Supp. BPC 9.00/6 
 
ANCOZINE Meclozine 25mg 
Pyridoxine 50mg 
Tab. BPC 12.00/20 
PARAVOMINE Meclozine 25mg 
Pyridoxine 50mg 
Tab. JCL 14.00/20 
Anti-Diarrhoeal 
O
ra
l R
eh
yd
ra
tio
n 
Sa
lts
 
ELECTRO-SUBS NaCl  3.50g 
Na Bicarbonate 
2.50g 
KCl  1.50g 
Glucose  20g 
Sachet BPC 4.00/sachet 
HYDRAN NaCl  2.00g 
Trisodium- Citrate 
2.58g 
KCl   1.49g 
Dextrose  30g 
Sachet Teva 23.00/3 sachets 
ORSET L.S. Glucose  
140mmol/L 
Na+  56 mmol/L 
K+  0 mmol/L 
Citrate  30 mmol/L 
Cl-  46 mmol/L 
Efferv. Tab. Novartis 24.00/10 
Lo
pe
ra
m
id
e 
DIACARE 2 mg Caps Pharmacare 10.00/8 
IMODIUM 2 mg Caps JanssenCilag 26.00/10 
IMODIUM CAPLET 2 mg Cap. JanssenCilag 20.00/10 
IMODIUM 
SOLUTION 2 mg Solution JanssenCilag 22.00/100ml 
STOPIT 2 mg Caps Rafa 16.00/10 
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Laxatives 
Bi
sa
co
- 
dy
l BISALAX 5mg 10 mg 
Supp. JCL 5.50/5 
8.00/5 
LAXADIN 5 mg E.C. Tab. Teva 15.00/50 
G
ly
ce
-  
   
ri
n 
GLYCERINE Glycerin 2.7g 
Glycerin 
Supp. adult 
Supp. child 
Rekah 11.00/20 
7.00/5 
Ps
yl
l- 
iu
m
  
METAMUCIL 
 
Psyllium 
 
Powder 
 
Searle 
 
13.00/100g 
Anti-Hemorrhoids 
D
iff
er
en
t  
Pr
ep
ar
at
io
ns
 
ANUSOL Bismuth 
subgalate 59mg, 
Bismuth ox. 
24mg, Balsam 
peru 49mg,  
ZnO 296 mg. 
Supp. Park Davis 18.00/12 
ANUSOL Bismuth sub-
galate 2.25g, 
Bismuth ox 
0.875g, Balsam 
peru 1.875g,  
ZnO 
10.75g/100g. 
Ointment 
 
Park Davis 17.00/25g 
 
HEMORAL H.C. Hydrocortisone 
acetate 0.5%, 
Lidocaine  
HCl 1.5%,  
ZnO 3% 
Bismuth 
subgalate 4%  
Supp. JCL 13.00/6 
HEMORAL H.C. Hydrocortisone 
acetate 0.5%, 
Lidocaine HCl 
1.5%, ZnO 5%, 
Bismuth 
subgalate 2%  
Ointment JCL 13.00/30g 
PROCTOCARE Fluocinolone 
Acetonide 0.1%, 
Lidocaine HCL 
20 mg 
Ointment Pharmacare 15.00/15g 
PROCTOCEDYL Hydrocortisone 
0.5% 
Cinchocaine-  
HCl 0.5% 
Ointment 
Supp. 
HMR 11.00/15g 
11.00/12 
PROCTO-GLYVENOL Tribenosid 
400mg 
Lindocain  
40mg 
Cream 
Supp. 
Novartis 26.00/30g 
29.00/10 
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RESPIRATORY DRUGS 
 
G
en
er
ic
 
N
am
e 
 
BRAND NAME 
 
STRENGTH 
 
DOSAGE 
FORM 
 
MANUFACT-
URER 
SELLING 
PRICE (NIS)/  
# OF DOSAGE 
FORM 
COLD PREPARATIONS 
Antihistamines 
C
hl
or
ph
en
ir
am
in
e AHISTON 2mg   Tab. Teva 7.00/20 
ALLERGON 3mg/5ml 
2mg 
Syrup 
Tab. 
JCL 10.00/100ml 
7.00/20 
ANAPHYL 3mg/5ml 
2mg 
Syrup 
Tab. 
Sam-On 8.00/120ml 
5.00/20 
CLOROYATE 3mg/5ml 
2mg 
Syrup 
Tab. 
Pharmacare Not in market 
DISORAMIN  2mg Tab. Dexxon 4.00/20 
A
st
em
- 
iz
ol
e 
HISMANAL  
(No longer available in 
market.) 
10mg 
1mg/ml 
Tab. 
Syrup 
Janssen 60.00/20 
38.00/100ml 
LAHISTAN 10mg Tab. BCP 34.00/20 
Nasal Decongestants 
O
xy
m
et
az
ol
in
e 
ALRIN 0.05% Nasal Drops 
Nasal Spray 
Teva 7.50/10cc 
10.00/15cc 
NASIVIN 0.025% 
0.05% 
Nasal Drops 
Nasal Drops 
Nasal Spray 
Merck 9.00/10cc 
12.00/10cc 
14.00/10cc 
RHINOCLIR 0.05% Nasal Spray Agis 11.00/20ml 
NOSACARE 0.05% Nasal Spray Pharmacare 7.50/15cc 
Ps
eu
do
-
ep
he
dr
in
e OTRINOL 120mg SR Retard Cap. Novartis 22.00/10 
SINUFED 30mg/5ml 
60mg 
Syrup 
Tab. 
Trima 19.00/115ml 
15.00/20 
TAROPHED 30mg/5ml Syrup Taro 18.00/120ml 
Expectorants 
G
ua
if-
en
es
in
 ROBITUSSIN 100mg/5ml Syrup A.H.Robins 20.00/20ml 
RESYL  (sugar free) 100mg/5ml Syrup Novartis 17.00/100ml 
Antitussives / Cough Suppressants 
C
od
ei
ne
 
Ph
os
ph
at
e CODEINE 
PHOSPHATE 
20mg Tab. Rekah 9.00/10 
CODICAL 20mg Tab. Sam-On 9.00/10 
PARACOD 20mg codeine 
325mg APA 
Tab. Pharmacare 12.00/20 
Dextromethorphan HBr: Available only in combinations products in the market. 
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Mucolytics 
A
ce
ty
lc
ys
te
in
e 
AGISOLVAN 200mg Granules 
(Sachets) 
Agis 12.00/12 
MUCOMYST 200mg Granules 
(Sachets) 
Mead-Johnson 101.48/3 
SIRAN 200 200mg Powder Sach. 
Effervs. Tab. 
Temmler 
Pharma 
40.00/30 
40.00/30 
BISOLVAN 8mg 
4mg/5ml 
Tab. 
Elixir 
Boehringer  19.00/20 
24.00/100ml 
Br
om
-
he
xi
ne
 MUCOCARE 8mg 
2mg/1ml  
Tab. 
Elixir 
Pharmacare 15.00/20 
18.00/50ml 
SOLVEX 8mg Tab. Teva 19.00/20 
BRONCHODIALATORS AND ASTHMA MEDICATIONS 
Th
eo
ph
yl
lin
e 
GLYPHYLLIN Theoph. Na 
Glycinate 250mg 
Tab. Teva 17.00/60 
THEO-DUR Theoph. Anhy. 
200mg 
300mg 
S.R. Tab. Key Pharm.  
44.00/100 
53.00/100 
THEOTARD Theoph. Anhy.  
50mg 
75mg 
100mg 
200mg 
300mg 
S. R. Cap. CTI  
12.50/30 
13.00/30 
13.00/30 
20.50/50 
23.00/30 
THEOTRIM Theoph. Anhy. 
100mg 
200mg 
300mg 
S.R. Tab. Trima  
10.00/30 
19.00/30 
24.00/30 
THEOPHARM Theoph. Anhy.  
100mg 
200mg 
300mg  
S. R. Tab. JePharm  
13.00/50 
19.00/50 
25.00/50 
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Sa
lb
ut
am
ol
 / 
A
lb
ut
er
ol
 
VENTOCARE 2mg 
2mg/5ml 
Tab. 
Syrup 
Pharmacare 4.00/20 
10.00/180ml 
VENTOLIN 2mg 
2mg/5ml 
100mcg/inhal. 
Tab. 
Syrup 
Aero. Spray 
GSK 32.00/100 
14.00/150ml 
18.00/200doses 
VENTOLIN RESPI-
RATOR SOLUTION 
5mg/ml Solution for 
Nebulizer 
GSK 29.00/20cc 
VOLMAX 4mg 
8mg 
Tab. GSK 30.00.50/14 
36.00/14 
FEDRAL 4mg 
2mg/5ml 
Tab. 
Syrup 
Eastern Chem. 5.00/20 
7.00/100ml 
C
ro
m
ol
yn
 S
od
iu
m
  
(N
a 
C
ro
m
og
ly
ca
te
) CROMUNAL 1mg/inhal. Inhaler Agis  
LOMUDAL 20mg Gelatin Caps Fisons 68.00/30 
LOMUDAL 
NEBULISER 
SOLUTION 
20mg Solution Fisons 144.00/48ml 
NALCROM 100mg Cap. Fisons 156.00/100 
VICROM 1mg/inhal. Inhaler Fisons  
Be
cl
om
et
ha
so
ne
 
D
ip
ro
pi
on
at
e 
BECLOFORTE 250mcg/inhal. Inhaler GSK 
43.70/200 
metered doses 
BECONASE 50mcg/inhal. Nasal 
Aerosol 
GSK      
BECOTIDE 50mcg/inhal. Inhaler GSK 58.00/200 
metered doses 
RHINOCORT 50mcg/spray Nasal Spray Agis 50.00/200 
sprays 
VIAREX 50mcg/inhal. Inhaler Schering 49.00/200 
Pr
ed
ni
so
ne
 PREDNITAB 5mg 
20mg 
Tab. BPC 14.00/40 
25.00/20 
PREDNITONE 5mg 
20mg 
Tab. Vitamed  
33.00/30 
PREDNISONE 5mg 
20mg 
Tab. Rekah 14.00/10 
45.00/30 
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Widely Used Combination Products 
 
ACTIFED SYRUP Pseudoeph. 60mg 
Triprolidine 2.5mg 
Syrup 
 GSK 
18.00/100ml 
ACTIFED 
EXPECTORANT 
Pseudoeph. 30mg 
Triprolidine 1.25mg 
Gauifenasin 100mg 
Syrup GSK 19.00/100ml 
ALCINAL Dextromethorph. 
7.5mg 
Guiaphen. 105mg 
Chlorphenar. 1mg 
Phenylprop. 12.5mg 
Syrup 
Cap. 
Rekah 14.00/115ml 
17.00/20 
COLDEX Caffeine 30mg 
Chlorphenar. 2mg 
Phenylepher. 10mg 
Paracetamol 300mg 
Tab. Teva 12.00/20 
M
U
LT
I-
IN
G
R
ED
IE
N
TS
 COLDEX-NIGHT Dextromethor. 10mg 
Ephedrin. 8mg 
Chlorphen. 1mg 
Paracetamol 600mg 
Elixir Teva 18.00/60 ml 
DEXAMOL COLD 
(Day care) 
Dextromethor. 10mg 
Guiaphen. 200mg 
Pseudoeph. 25mg 
Paracetamol 325mg 
Cap. Dexxon 19.50/30 
DEXAMOL COLD 
(Night care) 
Dextromethor. 10mg 
Chlorphenar. 2mg 
Pseudoeph.  25mg 
Paracetamol 500mg 
Cap. Dexxon 6.50/10 
DEXAMOL SINUS Pseudoeph. 25mg 
Paracetamol 500mg 
Cap. Dexxon 40.00/ 
FEBRACOLD S.R. Pseudoeph. 120mg 
Chlorphenir. 8mg 
S.R. Cap. BPC 10.00/8 
 FLU Chlorphenir. 2.5mg 
Phenyleph. 10mg 
Paracetamol 300mg 
Ascorbic Acid 100mg 
Caffeine 30mg 
Tab. JePharm 12.00/20 
 FLU Each 5ml contain: 
Chlorphenir. 1mg 
Phenylephrine 2mg 
Syrup JCL 12.00/60ml 
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M
U
L
T
I-
IN
G
R
ED
IE
N
TS
 
FORMULA  444 Each 5ml contains: 
Dextromethor. 10mg 
Phenylpropan. 
12.5mg 
Glycerly guaicolate 
100mg 
Syrup JePharm 12.50/120ml 
HISTADEX Each 5ml contain: 
Dexchlorphenir. 1mg 
Pseudoeph.  25mg 
Syrup Vitamid 15.00/115ml 
HISTAFED  Pseudoeph.  60mg 
Triprolidine 2.5mg 
Drags 
Syrup 
Trima 16.00/20 
18.00/115ml 
NUSSIDEX Pseudoephe.  25mg 
Dexchlorphen. 1mg 
Tab. 
Syrup 
Teva 15.00/20 
15.00/115ml 
PARAFLU Chlorphenir. 2.5mg 
Phenyleph. 10mg 
Paracetamol 300mg 
Ascorbic Acid 100mg 
Caffeine 30mg 
Tab. JCL 9.50/20 
PARAFLU Each 5ml contain: 
Chlorphenir. 1mg 
Phenylephrine 2mg 
Syrup JCL 14.00/60ml 
PULMADRIN  Each 5ml contain: 
Pseudoeph. 30mg 
Triprolidine 1.25mg 
Syrup BPC 10.00/100ml 
TRICOLD Paracetamol 350mg 
Phenlephr. 10mg 
Dextrometh. 7.5mg 
Cap. Agis 14.00/20 
TUSSIBAL 
EXPECTORANT 
Each 5ml Contain: 
Guaifenesin 100mg 
Pseudoeph. 30mg 
Triprolidine 1.25mg 
Syrup JePharm 13.50/100ml 
TUSSIBAL 
HONEY 
Each 5ml contain: 
Pseudoeph. 30mg 
Dextrometh. 10mg 
Triprolidine 1.25mg 
Syrup JePharm 14.00/100ml 
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ANTI-INFECTIVES 
 
G
en
er
ic
 
Na
m
e  
BRAND NAME 
 
STRENGTH 
 
DOSAGE 
FORM 
 
MANUFACT-
URER 
SELLING 
PRICE (NIS)/  
# OF DOSAGE 
FORM 
ANTI-BACTERIALS 
Penicillins 
Ph
en
ox
ym
et
hy
lp
en
ic
ill
in
 
RAFAPEN V-K 250mg 
500mg 
125mg/5ml 
250mg/5ml 
Tab. 
Tab. 
Susp. 
Susp. 
Rafa 12.20/40 
22.00/30 
4.00/60ml 
8.00/60ml 
RAFAPEN MEGA 990mg Cap. Rafa 32.00/20 
ORACILLIN 250mg 
500mg 
125mg/5ml 
250mg/5ml 
Tab. 
Tab. 
Susp. 
Susp. 
JePharm 7.00/20 
14.00/20 
7.00/100ml 
11.00/100ml 
BEPEN V.K. 250mg 
500mg 
250mg/5ml 
Tab. 
Tab. 
Susp. 
BPC 6.00/20 
13.50/20 
10.00/100ml 
C
lo
xa
ci
lli
n 
LOXAVIT 250mg 
500mg 
Cap. Vitamed 6.50/10 
20.00/10 
ORBENIL 250mg 
500mg 
125mg/5ml 
250mg/5ml 
Cap. 
Cap. 
Syrup 
Syrup 
Teva 8.70/12 
12.00/10 
14.00/60ml 
21.30/60ml 
A
m
pi
ci
lli
n 
PENIBRIN 250mg 
500mg 
125mg/5ml 
250mg/5ml 
Cap. 
Cap. 
Susp. 
Susp. 
Teva 5.30/12 
8.20/10 
4.10/60ml 
8.50/60ml 
PENTREXYL 125mg/5ml 
250mg/5ml 
Susp. BMS 4.00/60ml 
5.00/60ml 
BROADA-CILLIN 250mg 
500mg 
125mg/5ml 
250mg/5ml 
Cap. 
Cap. 
Susp. 
Susp. 
BPC 8.00/16 
12.00/16 
5.50/60ml 
8.00/60ml 
AMPIPHARM 250mg 
500mg 
125mg/5ml 
250mg/5ml 
Cap. 
Cap. 
Susp. 
Susp. 
JePharm 7.00/16 
12.00/16 
5.00/60ml 
8.00/60ml 
A
m
pi
ci
lli
n 
+ 
Fl
uc
ox
ac
ill
in
 MAGNICILLIN  250+250mg 
250+500mg 
Caps BCP 20.00/16 
30.00/16 
MEGACARE 
 
500+250mg 
250+125 
mg/5ml 
Cap. 
Susp. 
Pharmacare 30.00/16 
18.00/60ml 
23.00/100ml 
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A
m
ox
ic
ill
in
 
AMOXICARE 250mg 
500mg 
125mg/5ml 
250mg/5ml 
250mg/5ml 
Cap. 
Cap. 
Susp. 
Susp. 
Susp. 
Pharmacare 9.00/16 
14.00/16 
9.00/100ml 
12.00/100ml 
9.00/60ml 
AMOXITID 250mg 
500mg 
750mg 
125mg/5ml 
250mg/5ml 
Cap. 
Cap. 
Cap. 
Susp. 
Susp. 
BPC 
 
8.50/16 
13.50/16 
14.50/12 
8.50/60ml 
8.50/60ml 
HICONCIL 250mg 
500mg 
125mg/5ml 
250mg/5ml 
Cap. 
Cap. 
Susp. 
Susp. 
Mead-
Johnson 
11.00/12 
12.00/12 
8.00/60ml 
11.00/60ml 
MOXYPEN 250mg 
500mg 
125mg/5ml 
250mg/5ml 
Cap. 
Cap. 
Susp. 
Susp. 
Teva 13.00/12 
10.00/10 
8.00/60ml 
10.00/60ml 
MOXYVIT 250mg 
500mg 
125mg/5ml 
250mg/5ml 
Cap. 
Cap. 
Susp. 
Susp. 
Vitamed 15.00/10 
20.00/20 
8.10/60ml 
10.00/60ml 
MOXEPHARM 250mg 
500mg 
125mg/5ml 
250mg/5ml 
Cap. 
Cap. 
Susp. 
Susp. 
JePharm 9.00/16 
13.50/16 
9.00/100ml 
10.00/100ml 
A
m
ox
ic
ill
in
 &
 
C
la
vu
lin
ic
 A
ci
d 
AUGMENTIN 250-125mg 
500-125mg 
875-125mg 
457-75mg 
250-62.5mg/5ml 
125-31.25mg/5ml 
Tab. 
Tab. 
Tab. 
Susp. 
Susp. 
Susp. 
GSK 85.00/20 
128.00/20 
128.00/14 
70.00/70ml 
70.00/100ml 
46.00/100ml 
AUGMENTIN-Duo 400-57mg 
Sugar Free 
Susp. GSK 46.00/35ml 
CURAM 625 500-125 mg 
125-31.25mg /5ml 
FC Tab. 
Susp. 
Sandoz 50.00/20 
26.00/100ml 
OGMIN 250-62.5mg/5ml 
125-31.25mg/5ml 
Susp. 
Susp. 
BPC 50.00/100ml 
35.00/100ml 
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Cephalosporins 
C
ep
ha
le
xi
n 
CEFORAL 250mg 
500mg 
125mg/5ml 
250mg/5ml 
Cap. 
Cap. 
Susp. 
Susp. 
Teva 19.00/12 
38.10/12 
14.60/60ml 
27.60/60ml 
CEFACARE 500mg 
250mg/5ml 
Cap. 
Susp. 
Pharmacare 29.00/16 
16.00/60ml 
CEFALEX 250mg 
500mg 
125mg/5ml 
250mg/5ml 
Cap. 
Cap. 
Susp. 
Susp. 
BPC 
 
18.00/16 
29.00/16 
10.00/100ml 
21.00/100ml 
CEFOVIT 250mg 
500mg 
125mg/5ml 
250mg/5ml 
Cap. 
Cap. 
Susp. 
Susp. 
Vitamed 11.00/10 
22.00/10 
12.00/60ml 
19.00/60ml 
C
ep
ha
le
xi
n 
KEFLEX 500mg 
125mg/5ml 
250mg/5ml 
Cap. 
Susp. 
Susp. 
Lilly 71.00/20 
27.00/100ml 
37.00/100ml 
JEFLEX 250mg 
500mg 
125mg/5ml 
250mg/5ml 
Cap. 
Cap. 
Susp. 
Susp. 
JePharm 18.00/16 
30.00/16 
10.00/60ml 
15.50/60ml 
C
ef
ac
lo
r 
CECLOR 250mg 
500mg 
750mg MR* 
125mg/5ml 
250mg/5ml 
Cap. 
Caps  
Cap. 
Susp. 
Susp. 
Lilly 
 
* (modified 
release) 
48.00/12 
62.00/12 
73.00/12 
36.00/60ml 
54.00/60ml 
C
ef
ad
ro
xi
l CEFADROX 500mg 
125mg/5ml 
250mg/5ml 
Tab. 
Susp. 
Susp. 
BPC 31.00/12 
12.00/60ml 
20.00/60ml 
BIODROXIL 500mg Cap. Sandoz 43.00/12 
Tetracyclines 
Te
tr
ac
yc
lin
e TEVA-CYCLINE 250mg Cap. Teva 6.00/20 
BRIMO-CYCLIN 250mg 
500mg 
Cap. BPC 5.50/16 
10.00/16 
TETRA-PHARM 250mg 
500mg 
Cap. JePharm 5.00/16 
10.00/16 
Macrolides 
Er
yt
hr
om
yc
in
 ERYC 
(Erythromycin base) 
250mg Cap. Taro 26.00/20 
ERYTHROCIN 
FILMTAB 
(Erythromycin 
stearate)   
250mg Tab. Abbott 59.50/100ml 
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ERYTHRO-TEVA 
(Erythromycin 
Stearate) 
250mg 
500mg 
125mg/5ml 
200mg/5ml 
400mg/5ml 
Tab. 
Tab. 
Susp. 
Susp. 
Susp. 
Teva 11.00/12 
21.40/10 
11.00/60ml 
13.40/60ml 
25.00/60ml 
ERYTHROTAB 
(Erythromycin 
Stearate) 
250mg 
Tab. BPC 18.00/24 
ERYTHRO-PHARM 
(Erythromycin 
Ethylsuccinate) 
125mg/5ml 
200mg/5ml 
Susp. 
Susp. 
JePharm 8.00/60ml 
12.00/60ml 
ERYTHROLET 
(Erythromycin 
Ethylsuccinate) 
25mg/5ml 
200mg/5ml 
Susp. 
Susp. 
BPC 8.00/60ml 
11.50/60ml 
ERYTHROCARE 
(Erythromycin 
Ethylsuccinate) 
200mg/5ml 
400mg/5ml 
Susp. 
Susp. 
Pharmacare 10.50/60ml 
20.00/60ml 
Trimethoprim & Sulphonamindes 
TM
P/
SM
X
 
(S
tre
ng
th
 w
rit
te
n 
as
 T
M
P/
SM
X
) DISEPTYL 80mg/400mg 
40mg/200mg, 5ml 
Tab. 
Susp. 
Rekah 10.00/20 
11.00/100ml 
RESPRIM 80mg/400mg 
160mg/800mg 
40mg/200mg,  5ml 
Tab. 
Tab. 
Susp. 
Teva 13.10/20 
10.90/10 
10.90/100ml 
SULFATRIM 80mg/400mg 
160mg/800mg 
40mg/200mg, 5ml 
Tab. 
Tab. 
Susp. 
Vitamed 6.20/20 
21.80/20 
10.00/100ml 
SULPRIM 80mg/400mg 
160mg/800mg 
40mg/200mg, 5ml 
Tab. 
Tab. 
Susp. 
JePharm 10.50/20 
10.50/10 
10.00/100ml 
Antibacterials for UTI 
N
itr
of
ur
an
to
in
 MACRODANTIN 50mg 
100mg 
Macro-
crystal Cap. 
Procter & 
Gamble 
213.00/100 
427.00/100 
URANTOIN 
 
100mg Tab. Rafa 41.84/500 
MACRO-FURAN 100mg Cap. BPC 35.00/24 
N
al
id
ix
ic
 A
ci
d 
NEGGRAM 250mg/5ml 
250mg 
500mg 
1000mg 
Susp. 
Tab. 
Tab. 
Tab. 
Sterling-
Winthrop 
256.00/160ml 
95.00/56 
140.00/56 
301.00/100 
URIGRAM 500mg Tab. Trima 76.20/60 
U-GRAM 250mg 
500mg 
250mg/5ml 
Tab. 
Tab. 
Susp. 
JePharm 45.00/50 
90.00/50 
43.00/100ml 
 
 
 
 
 A- 21 
 
C
ip
ro
flo
xa
ci
n 
CIPROCARE 250mg 
500mg 
Tab. Pharmacare 27.00/10 
50.00/15 
CIPROGIS 125mg 
250mg 
500mg 
750mg 
Tab. Agis 24.00/6 
69.00/10 
175.00/10 
252.65/10 
FLOXIN 250mg 
500mg 
Tab. JePharm 68.00/20 
68.00/10 
ANTI-TUBERCULOSIS 
Is
on
ia
- 
zi
de
 ISONIAZID 
 
 
50mg Tab. Rekah 73.70/50 
R
ifa
m
- 
pi
ci
n 
RIMACTAN 150mg 
300mg 
100mg/5ml 
 
Cap. 
Cap. 
Syrup 
Sandoz 250.70/80 
250.70/40 
74.00/50ml 
Py
ra
zi
n-
 
am
id
e Not available in local 
pharmacies. 
 
 
   - 
E
th
am
- 
bu
to
l MYAMBUTOL 100mg 
400mg 
Tab. Lederle 62.90/100 
123.70/100 
ANTI-PARASITICS 
M
et
ro
ni
da
zo
le
 
FLAGYL 250mg 
500mg 
125mg/5ml 
Oral Tab. 
Vag. Tab. 
Susp. 
Specia 14.00/20 
18.00/10 
26.00/120ml 
METROGYL 250mg 
500mg 
Oral Tab. 
Vag. Tab. 
Teva 6.30/20 
6.00/10 
METROZOLE 250mg 
500mg 
125mg/5ml 
1000mg 
Tab. 
Tab. 
Susp. 
Vag. Supp. 
BPC 6.00/20 
15.00/ 
14.00/100ml 
14.00/6 
ENTOGYL 250mg 
125mg/5ml 
Tab. 
Susp. 
JePharm 7.50/20 
15.00/120ml 
M
eb
en
d-
az
ol
e 
VERMOX 100mg 
100mg/5ml 
Tab. 
Susp. 
Abic 11.00/10 
14.00/30ml 
VERMAZOL 100mg 
100mg/5ml 
Tab. 
Susp. 
JePharm 10.00/6 
12.00/30ml 
N
ic
lo
s-
am
id
e YOMESAN 500mg Tab. Bayer 20.00/4 
A
lb
en
d-
az
ol
e 
ESKAZOLE 
 
 
 
400mg Tab. GSK 591.00/60 
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ANTI-FUNGALS 
N
ys
ta
tin
 NYSTATIN  100,000 U  
500,000 U 
100,000 U/ml 
Vag. Tab. 
Drags 
Mixture 
Taro 14.50/10 
42.00/28 
35.00/30ml 
CANDISTAN 100,000 U 
100,000 U/ml 
Vag. Tab. 
Oral Drops 
BPC 8.50/15 
9.00/12ml 
M
ic
on
az
ol
e 
N
itr
at
e 
DAKTARIN ORAL 
GEL 
2% Gel Abic 41.00/40g 
 
GYNO-DAKTARIN 1200mg Ovule 
(vaginal 
inserts) 
Abic 35.50/3 
DAKTAZOL ORAL 
GEL 
2% Gel JePharm 12.00/40g 
FUNGAZOLE 2% Cream Pharmacare 10.00/15g 
GYNO-DAKTAZOL 2% Vaginal 
Cream 
JePharm 30.00/40g 
GYNO-DAKTAZOL 
OVULES 
400mg Ovules JePharm 21.00/3 
G
ri
se
o-
fu
lv
in
 GRIFULIN  FORTE 
 
125mg Tab. Teva 24.00/60 
SPORO-FULVIN 125mg 
125mg/5ml 
Tab. 
Susp. 
JCL 17.50/20 
17.50/100ml 
ANTI-VIRALS 
A
cy
cl
ov
ir
 
SUPRAVIRAN 800mg 
200mg/5ml 
Tab. 
Susp. 
Pharmacare 110.00/35 
55.00/125ml 
ZOVIRAX 200mg 
400mg 
200mg/5ml 
Tab. 
Tab. 
Susp. 
GSK 48.00/25 
138.00/70 
307.00/125ml 
VIRAX 200mg Tab. BPC Not in private 
pharmacies 
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ENDOCRINE  DISORDER  DRUGS 
 
G
en
er
ic
 
N
am
e 
BRAND NAME STRENGTH 
 
DOSAGE 
FORM 
 
MANUFACT-
URER 
SELLING 
PRICE (NIS)/  
# OF DOSAGE 
FORM 
ANTIDIABETICS 
Insulin 
R
eg
ul
ar
 
In
su
lin
 NOVOLIN  R Regular 
Insulin 
IV or IM Novo Nordisk 120.00/10ml 
HUMULIN  R Regular 
Insulin 
IV or IM Lilly 102.00/10ml 
N
PH
 NOVOLIN  N NPH IM Novo Nordisk 120.00/10ml 
HUMULIN  N NPH IM Lilly 120.00/10ml 
Oral agents 
G
lib
en
cl
am
id
e/
 
G
ly
bu
ri
de
 
DAONIL 5mg Tab. HMR 62.00/100 
DECLAMIDE 5mg Tab. JCL 7.00/20 
GLUCOCARE 5mg Tab. Pharmacare 8.00/30 
GLUCONIL 5mg Tab. JePharm 7.00/30 
GLIBETIC 5mg Tab. Teva 10.00/30 
M
et
-
fo
rm
in
- GLUCOPHAGE 850mg Tab. BMS 15.00/30 
GLUCOMET 850mg Tab. BPC 10.00/30 
THYROID DISORDERS 
Th
yr
o-
 
xi
ne
 ELTROXIN 50mcg 
100mcg 
Tab. GSK 16.00/100 
19.00/100 
PT
U
 PROPYL- 
THIOCIL 
50mg Tab. Teva 12.00/30 
CORTICOSTEROIDS 
Refer to Prednisone in the Respiratory Chapter price list. 
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CONTRACEPTIVE  PREPARATIONS 
 
G
en
er
ic
 
N
am
e  BRAND NAME 
 
STRENGTH/ 
DOSAGE FORM 
 
MANUFACT-
URER 
SELLING 
PRICE (NIS)/  
# OF DOSAGE 
FORM 
Combined Contraceptive Agents 
E
th
in
yl
oe
st
ra
di
ol
 &
 
G
es
to
de
ne
 
GYNERA Ethinyloestradiol 0.03mg 
Gestodene 0.075mg 
 
Schering  27.00 
(21 Tab. sachet)  
MINULET Ethinyloestradiol 0.03mg 
Gestodene 0.075mg 
 
 
Wyeth 24.90 
(21 Tab. 
sachet) 
N
or
et
hi
st
er
on
e 
&
 
th
in
yl
oe
st
ra
di
ol
  MINOVLAR 
(mono-phasic): 
Norethisterone 1mg 
Ethinyloestradiol 0.05mg 
 
 
Schering  
(21 Tab. 
sachet) 
OVYSMEN 
(mono-phasic): 
Norethisterone 0.5mg 
Ethinyloestradiol 0.035mg 
 
Ortho 30.00 
(21 Tab. 
sachet) 
N
or
et
hi
st
er
on
e 
&
 
Et
hi
ny
lo
es
tr
ad
io
l  
TRINOVUM 
(Triphasic) 
7 Tab.:  
Norethisterone 0.5mg 
Ethinyloestradiol 35mcg 
7 Tab.: 
Norethisterone 0.75mg 
Ethinyloestradiol 35mcg 
7 Tab.: 
Norethisterone 1mg  
Ethinyloestradiol 35mcg  
Ortho 29.00 
(21 Tab. 
sachet) 
L
ev
on
or
ge
st
re
l &
 
E
th
in
yl
oe
st
ra
di
ol
 MICROGYNON 
(mono-phasic) 
Levonorgestrel 0.15mg 
Ethinyloestradiol 0.03mg 
 
Schering 13.50 
(21 Tab. 
sachet) 
NORDETTE 
(mono-phasic) 
Levonorgestrel 0.15mg 
Ethinyloestradiol 0.03ml 
Wyeth 13.00 
(28 Tab. 
sachet) 
Le
vo
no
rg
es
tr
el
 &
 
Et
hi
ny
lo
es
tr
ad
io
l 
LOGYNON 
(tri-phasic) 
6 Tab.:  
Levonorgestrel 0.05mg 
Ethinyloestradiol 0.03mg 
5 Tab.: 
Levonorgestrel 0.075mg 
Ethinyloestradiol 0.04mg 
10 Tab.: 
Levonorgestrel 0.125mg 
Ethinyloestradiol 0.03mg  
Schering 17.00 
(21 Tab. 
sachet) 
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TRINORDIOL 
(tri-phasic) 
6 Tab.:  
Levonorgestrel 0.05mg 
Ethinyloestradiol  0.03mg 
5 Tab.: 
Levonorgestrel 0.075mg 
Ethinyloestradiol 0.04mg 
10 Tab.: 
Levonorgestrel 0.125mg 
Ethinyloestradiol 0.03mg 
Wyeth 19.00 
(21 tab. sachet) 
Progestin Only Products 
Pr
og
es
tin
 FEMULEN Ethynodiol diacetate 0.5mg 
(28 Tab.) 
Searle 19.00 
(28 tab. sachet) 
DEPO-PROVERA Medroxy-progesterone 
Acetate 150 mg/ml  
(Vial, IM) 
Upjohn 49.00/ 1 ml 
(one dose vial) 
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ANTIEPILEPTICS 
 
 
G
en
er
ic
 
N
am
e 
BRAND NAME STRENGTH 
 
DOSAGE 
FORM 
 
MANUFACT-
URER 
SELLING 
PRICE (NIS)/  
# OF DOSAGE 
FORM 
C
ar
ba
m
az
ep
in
e 
CARBI 
 
200mg Tab. AlphaPharm 33.50/50 
TEGRETOL 200mg 
100mg/5ml 
200mg CR 
400mg CR 
Tab. 
Syrup 
Tab. 
Tab. 
Novartis 87.00/50 
44.00/250ml 
70.00/50 
70.00/30 
TEGREPINE 200mg Tab. JePharm 47.00/50 
TERIL  200mg 
400mg 
Tab. Taro 65.00/50 
54.00/30 
C
lo
na
ze
-p
am
 KLONOPIN/ 
RIVOTRIL 
2.5mg/ml Drops Roche 25.50/10ml 
CLONEX 0.5mg 
2mg 
Tab. Teva 10.00/30 
19.00/30 
ES
X
. ZARONTIN 250mg Cap.  
Syrup 
Parke-Davis 53.00/50 
73.00/300ml 
Ph
en
ob
ar
b.
 
PHENOBARB 100mg 
15mg 
 
Tab. 
Tab. 
Eastern Chem. 15.00/40 
8.00/40 
Ph
en
y-
to
in
 EPANUTIN 50mg 
100mg 
30mg/5ml 
Cap. 
Cap. 
Susp. 
Parke-Davis 130.00/500 
34.00/100 
19.85/100ml 
V
al
pr
oi
c 
 
ac
id
 
DEPALEPT 200mg 
500mg 
200mg/ml 
200mg/5ml 
Tab. 
Tab. 
Solution 
Syrup 
CTI 55.90/40 
129.00/40 
41.00/50ml 
21.00/110ml 
VALPORAL 200mg 
200mg/5ml 
Cap.  
Syrup 
Teva 41.10/40 
14.10/100ml 
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ANTIPARKINSONISM 
 
 
G
en
er
ic
 
N
am
e 
BRAND NAME STRENGTH 
 
DOSAGE 
FORM 
 
MANUFACT-
URER 
SELLING 
PRICE (NIS)/  
# OF DOSAGE 
FORM 
Anticholinergics 
Be
nz
o-
Tr
op
in
e COGENTIN 2mg Tab. MSD             /20 
Not available in 
the private 
market. 
Tr
ih
ex
y-
Ph
en
id
yl
 ARTANE 2mg 
5mg 
Tab. Lederle 34.00/100 
38.00/100 
PARTANE 2mg 
5mg 
Tab.  Taro 7.50/50 
11.00/50 
Dopaminergic Drugs 
A
m
an
t-
ad
in
e PARITREL 100mg Tab. Trima 47.00/20 
SYMMETREL 100mg Cap. Novartis 44.00/20 
Br
om
o-
cr
ip
tin
e LACTOPAR 2.5mg Tab.  BCP 65.00/30 
PARILAC 2.5mg 
10mg 
Tab.  
 
Teva 102.00/30 
214.00/20 
PARLODEL 2.5mg Tab.  Novartis 107.00/30 
C
ar
bi
do
pa
/ 
Le
vo
do
pa
 
SINEMET-110 10mg/ 
100mg 
Tab.  Dupont Not available 
in the market 
SINEMET-275 25mg/ 
250mg 
Tab.  Pharm. Not available 
in the market 
SINEMET CR 50mg/ 
200mg 
Tab. Pharm. 111.30/30 
DOPICAR 25mg/ 
250mg 
Tab. Assia/Riesel 76.00/30 
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PSYCHOACTIVE  DRUGS 
 
G
en
er
ic
 
N
am
e  BRAND NAME 
 
STRENGTH 
 
DOSAGE 
FORM 
 
MANUFACT-
URER 
SELLING 
PRICE (NIS)/  
# OF DOSAGE 
FORM 
Antidepressants 
A
m
itr
ip
ty
lin
e AMYVIL 25mg Tab. JePharm Not in private 
market. 
ELATROL 25mg Tab. Assia/Riesel 12.50/50 
ELATROLET 10mg Tab. Assia/Riesel 9.00/50 
TRYPTAL 25mg Drags Unipharm 9.00/50 
TRYPTA-LETTE 10mg Drags Unipharm 4.00/50 
Im
ip
r-
am
in
e PRIMONIL 25mg Tab. Teva 9.00/50 
TOFRANIL  25mg Tab. Novartis 37.00/50 
Fl
uo
xe
tin
e 
AFFECTINE 20mg Cap. Taro 66.10/28 
FLUOXICARE 20mg Cap. Pharmacare 26.00/14 
FLUTINE 20mg Caps Teva  67.50/30 
PRIZMA 20mg 
40mg 
Tab. Unipharm 67.00/30 
126.50/20 
PROZAC 20mg Cap. Lilly 101.00/14 
216.10/28 
Hypnotics And Anxiolytics 
D
ia
ze
pa
m
 
ASSIVAL 2mg 
10mg 
Tab. Teva 4.00/30 
10.00/30 
DIAZ 2mg 
5mg 
10mg 
Tab. Taro 3.80/30 
6.70/30 
10.30/30 
DISOPAM 2mg 
5mg 
10mg 
Tab. Dexxon 2.80/30 
4.80/30 
6.00/30 
HARMONAL 2mg 
5mg 
Tab. JCL 3.00/20 
3.50/20 
SEREPAM 2mg  
5mg 
10mg 
Tab. BPC 3.50/20 
4.50/20 
5.00/20 
Lo
ra
-
ze
pa
m
 LORIVAN  1mg Tab. Dexxon 14.00/50 
LOROCARE 1mg 
2.5mg 
Tab. Pharmacare 8.00/40 
8.50/20 
Neuroleptics 
C
PZ
 
TAROCTYL 25mg 
100mg 
Tab. Taro 17.00/50 
20.00/50 
H
al
o-
pe
ri
do
l HALIDOL/HALDOL 5mg 
2mg/ml 
Tab. 
Drops 
Abic 35.25/60 
12.87/15ml 
PERIDOL  5mg Tab.  Eastern Chem. 9.00/20 
PERIDOR 1mg Tab. Unipharm 14.40/60 
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OPTHALMIC  PREPARATIONS 
 
G
en
er
ic
 
N
am
e  BRAND NAME 
 
STRENGTH 
 
DOSAGE 
FORM 
 
MANUFACT-
URER 
SELLING 
PRICE (NIS)/  
# OF DOSAGE 
FORM 
1BANTI-INFECTIVES 
Antibiotics 
C
hl
or
am
ph
en
ic
ol
 CHLOROCETIN 5% 
0.5% 
Eye Drops.  
Eye Oint. 
Eastern Chem. 10.00/7ml 
7.00/3.6g 
CHLOROPTIC 0.5%  Eye Drops  Allergan 17.50/10ml 
SYNTHO-MYCINE 5%  Eye Oint. Abic 6.00/4g 
LOMIXIN 5mg/ml Eye Drops Jordan 9.00/10ml 
RAMACETINE 5% Eye Oint. 
Eye Drops 
BCP 8.00/3.5g 
5.50/10ml 
Te
tr
ac
yc
lin
es
 JORDACYCLINE 0.5% Oxy. Eye Oint. JCL 7.5.00/4g 
OXYCIN 0.5% Oxy. Eye Oint. BCP 5.00/3.5g 
RECYCLINE 1% Tetrac. Eye Oint. Rekah 14.00/3.5g 
TEVACYCLINE 1% Tetrac. Eye Oint. Teva 9.00/3.5g 
G
en
ta
- 
m
yc
in
 GARAMYCIN 
OPHTHALMIC 
0.3% Solution Schering 
Plough 
9.00/5ml 
GENTICIN 0.3% Eye Drops JePharm 10.00/5ml 
Antivirals 
Id
ox
-
ur
id
in
e VIRUSAN 1mg 
5mg  
Eye Drops 
Eye Oint. 
Teva 7.00/7ml 
17.00/5g 
Anti-Inflammatory Preparations 
C
or
tic
os
te
ro
id
 
OPTISOLONE 0.5% Pred-
nisolone 
Eye Drops JePharm 9.00/5ml 
PREDNICORT 0.12% 
1%  
Prednisolone 
acetate 
Drops 
Forte 
Drops 
Eastern Chem.  13.00/7ml 
19.00/7ml 
STERODEX 0.1% Dexa-
methasone 
Eye Drops Fischer 11.00/5ml 
ULTRACORTENOL 0.5% Predni-
solone 
trimethyl-
acetate 
Eye Oint. 
Eye Drops 
Novartis 23.00/5ml 
C
ro
m
o-
gl
yc
at
e OPTICROM 2% Eye Drops  Fisons 71.00/13.5ml 
 A- 30 
 
Beta-Blockers 
Ti
m
ol
ol
 
M
al
ea
te
 
TILOPTIC 0.25%  
0.5% 
Eye Drops Assia/Riesel 14.00/5ml 
14.00/5ml 
SINOPTIC 0.25% 
0.5% 
Eye Drops Eastern Chem. 10.00/5ml 
12.00/5ml 
TIMOLIN 0.25% 
0.5% 
Eye Drops JePharm 14.00/5ml 
18.00/5ml 
Mydriatics and Cycloplegics 
A
tr
op
in
e 
Su
lfa
te
 ATROSPAN 1% Eye Drops Fischer 10.00/10ml 
ATROPED 1% Eye Drops Eastern 
Chemical 
10.00/10ml 
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OTIC  PREPARATIONS 
 
G
en
er
ic
 
N
am
e 
BRAND NAME STRENGTH 
 
DOSAGE 
FORM 
 
MANUFACT-
URER 
SELLING 
PRICE (NIS)/  
# OF DOSAGE 
FORM 
Ear Wax Removers 
C
er
um
ol
 
CERUMOL Paradichloro-
benzene 2g 
Benzocaine 2.7g 
Chlorbutol 5g 
Ol-terebinth 
10cc/100cc 
Drops Tamar 24.00/11ml 
Most anti-infective and anti-inflammatory otic products  
are available in combination products: 
C
om
bi
na
tio
n 
 P
ro
du
ct
s 
BETNESOL  0.1% Beta-
methasone 
Drops GSK 8.00/5ml 
DEX-OTIC Each 1ml contains: 
Dexamethasone 
1mg 
Neomycin 5mg 
Polymyxin 10,000 
IU 
Drops Teva 11.00/5ml 
HYCOMYCIN Hydrocortisone 
1.5%  
Neomycin 0.5% 
Drops 
Ointment 
Teva 9.00/5ml 
9.00/3.5g 
NOVOCORT Dexamethasone 
0.1% 
Neomycin 0.5% 
Polymyxin B 
0.119% 
Drops JCL 10.00/10ml 
OTOCORT Dexamethasone 
1mg 
Neomycin 5mg 
Polymyxin B 
10,000 IU/ml 
Drops BCP 10.00/5ml 
OTOSPORIN Polymyxin-  
B 10,000 IU 
Neomycin 5mg 
Hydrocortisone 
10mg/ml 
Drops GSK 51.00/5ml 
POLYMICIN Polymyxin B  
2500 IU 
Chloramphenicol 
0.2% w/v 
Drops JePharm 10.00/5ml 
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DERMATOLOGICALS 
 
G
en
er
ic
 
N
am
e 
BRAND NAME STRENGTH 
 
DOSAGE 
FORM 
 
MANUFACT-
URER 
SELLING 
PRICE (NIS)/  
# OF DOSAGE 
FORM 
General 
V
as
el
in
e 
JOHNSON’S JELLY 100% pure 
Petroleum 
Jelly Johnson & 
Johnson 
12.00/250g 
VASELINE 100% pure 
Petroleum 
Jelly Elida 
Faaberge 
15.00/212g 
VESALINE (scented) 100% pure 
Petroleum 
Gel Medix 6.00/50g 
WHITE PETROLEUM  White 
petroleum 
Jelly Lader 12.00/200g 
Zi
nc
 O
xi
de
/C
al
am
in
e 
ADINOL 
(includes mineral oil, + 
vaseline.) 
40%  ZnO Ointment Teva 13.00/100 
CALADERM  12.5% 
Calamine 
8%  ZnO 
Cream 
Lotion 
JePharm 10.00/30g 
10.00/100ml 
CALAMINE 15%  Cal. 
5%   ZnO 
Lotion Sam-On 9.00/100ml 
CALATRIM 15% Cal. 
5%   ZnO 
Lotion Trima 12.00/100ml 
DYPROTEX 40%  ZnO Medicated 
Pads 
Mediline 17.00/30g 
Li
gn
oc
ai
ne
 
ESRACAIN 5% Lignoc. Ointment Rafa 11.00/20g 
ESRACAIN JELLY 2% Lignoc. Jelly Rafa 10.00/30g 
XYLENE 2% Lignoc. Gel BPC 8.00/40g 
Antifungals 
M
ic
on
az
ol
e 
N
itr
at
e 
DAKTARIN 2% Cream  
Lotion 
Abic 22.00/15g 
22.00/20ml 
DAKTAZOL 2% Cream  
Oral gel 
JePharm 10.00/15gm 
17.00/40gm 
FUNGAZOLE 2% Cream Pharmacare 9.50/15gm 
FUNGITRIN 2% Cream 
Oral gel 
BPC 10.00/15gm 
14.00/30gm 
C
lo
tr
im
az
ol
e 
AGISTEN 1% Cream 
Lotion 
Agis 17.00/20g 
20.00/15ml 
MYCOHER-MAL 1% Cream 
Solution 
Neopharm 20.00/20g 
22.80/20ml 
CANESTEN/ 
AGISTIN 
1% Cream 
Solution 
Agis/Bayer 17.00/20g 
20.00/20ml 
CANAZOLE 1% Cream JePharm 13.00/20mg 
CANDIZONE 1% Cream BCP 15.00/15gm 
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K
et
o-
co
na
zo
le
 
NIZORAL 2% Cream Abic 40.00/15gm 
NIZORAL 2% Shampoo Abic 48.00/100ml 
To
ln
af
ta
te
 
ATHLETES FOOT 1% Powder Scholl 25.70/80g 
PITREX 1%  Ointment 
Solution 
Teva 17.00/15g 
17.00/10ml 
TINADERM 1%  Solution Schering Not in the market. 
Antibacterials 
O
xy
te
tr
ac
yc
lin
e/
 
Te
tr
ac
yc
lin
e 
RECYCLINE 3% Oxy. Ointment Rekah 14.00/14g 
TETRACARE 3% Oxy. Ointment Pharmacare 6.00/20g 
TETRAPHARM  3% Oxy. Ointment JePharm 7.50/20g 
OXYCIN 3% 
Tetracyc. 
Ointment BCP 5.00/18g 
JORDA-CYCLINE 3% 
Tetracyc. 
Ointment JCL 7.50/16g 
G
en
ta
m
yc
in
 GARAMYCIN 0.1% Genta. Cream 
Ointment 
Schering 13.00/15g 
13.00/15g 
GENTATRIM 0.1% Genta. Cream 
Ointment 
Trima 15.00/15g 
15.00/15g 
GARAMINE 0.1% Genta. Cream JCL 12.00/16g 
M
up
ir
-
oc
in
 BACTROBAN 2%  Ointment GSK 48.00/15g 
Antivirals 
A
cy
cl
ov
ir
 SUPRAVIRAN 5% 
 
Cream Pharmacare Not in market 
yet. 
ZOVIRAX 5% Cream GSK 34.00/2g 
146.00/10g 
Antiseptics/Disinfectants 
E
th
yl
 
A
lc
oh
ol
 
ETHYL ALCOHOL Different containers, depending on hospital or pharmacy. 
Po
vi
do
ne
-I
od
in
e BETADINE 10%  
(1% iodine) 
Ointment 
Solution 
Rafa  
44.00/1L 
POLYDINE 10%  
 
Solution 
Tincture 
Fischer 10.00/20ml 
IODOCARE 10% Solution- 
Mouthwash 
Pharmacare  
9.00/100ml 
IOSEPT 10% Solution BPC 11.00/100ml 
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C
et
ri
m
id
e 
&
 C
hl
or
he
xi
di
ne
 
CARE 
first aid solution 
 
 
 
0.5% Cetrim. 
0.05% Chlorh. 
Solution Pharmacare 3.00/100ml 
CARE 15%  
first aid solution 
15% Cetrim. 
1.5% Chlorh. 
Solution Pharmacare Not sold in 
private 
pharmacies. 
CETRIN 15% Cetrim. 
1.5% Chlorh. 
Concentrated 
solution 
Vitamid 52.00/1L 
SAVIOR 
first aid solution 
0.5% Cetrim. 
0.05% Chlorh. 
Solution Travenol 7.00/100ml 
TISEPT 0.15% Cetrim. 
0.015% Chlorh. 
Solution Seton 100ml 
Not sold in 
pharmacies. 
UNISCRUB 4% Chlorh. Solution Seton 45.00/500ml 
Antiparasitics 
Be
nz
yl
 
Be
nz
oa
te
 BENZOCIDE 12.5% 
25% 
Lotion Trima 30.00/100ml 
SCABICIDE 25% Emulsion BCP 12.00/100ml 
SCABIEX 25% Emulsion Rekah  
C
ro
ta
m
ito
n 
CRUTEX 10% Crotam. Cream 
Lotion 
BCP 14.50/20gm 
12.50/50ml 
DUO-SCABIL 10% Crotam. 
8% Sulfur 
Cream Agis 26.00/20g 
EURAX 10% Crotam. Cream 
Lotion 
Novartis 15.00/20g 
25.00/50ml 
SCABICIN 10% Crotam. Lotion Fischer 24.00/100ml 
Li
nd
-
an
e BICIDE 1% Lindane Cream Fischer 25.00/50ml 
PARAZINE  1% Lindane Cream  al-Razi 24.00/200g 
M
al
- 
th
io
n 
NOURYL 0.5% Lotion Chefaro Not available in 
WB market. 
PRIODERM 1% Cream- 
Shampoo 
Napp/Rafa 17.00/40g 
Keratolytic Agents 
Sa
lic
yl
ic
 A
ci
d 
OXY CLEAN 
medicated soap 
3.5 % Sal. 
acid 
Soap GSK 17.00/Bar 
SALATAC  12% Sal. acid Gel Dermal Labs 58.00/8g 
ZINO PADS 40% Sal. acid Pads Scholl 8.00/5 pads 
SALISOL-2 
(contains ethanol 
70%) 
2% Sal. acid Solution Rekah 10.00/100ml 
Su
lfu
r 
Not available as single agent products. 
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Miscellaneous 
C
or
tic
os
te
ro
id
s 
BETACARE 0.1% Beta-
methasone 
Valerate 
Cream Pharmacare 10.00/15gm 
BETACORT-V 0.1% Beta-
methasone 
Valerate 
Cream JCL 7.00/16gm 
BETACORTEN 0.1% Beta-
methasone 
17-valerate 
Cream 
Ointment 
Trima 10.00/15g 
10.00/15g 
BETAMESONE 0.1% Beta-
methasone 
Valerate 
Cream 
Ointment 
JePharm 7.00/15g 
7.00/15g 
BETNOVATE 0.1% Beta-
methasone 
17-valerate 
Cream  
Ointment 
GSK 10.00/15g 
10.00/15g 
DERMOVATE 0.05% 
Clobetazole 
propionate 
Cream 
Ointment 
GSK 24.00/25g 
28.00/25g 
PSORIDERM 0.05% 
Clobetazole 
propionate 
Ointment BPC 17.00/25g 
VALECORT 0.1% Beta-
methasone 
Valerate 
Cream 
Ointment 
BPC 12.00/15g 
8.50/15g 
R
et
in
oi
c 
A
ci
d 
LOCACID 0.5% 
0.1% 
Cream 
Lotion 
Fabre/Mediline 40.00/30g 
40.00/15ml 
RETAVIT 0.05% 
0.025% 
0.05% 
0.025% 
Cream 
 
Gel 
CTI 36.00/20g 
20.00/20g 
36.00/20g 
20.00/20g 
RETIN-A 0.05% 
0.025% 
Cream JanssenCilag 49.00/30g 
40.00/30g 
AIROL 0.05% Cream 
Lotion 
Roche 35.00/20g 
52.00/50ml 
Be
nz
oy
l 
Pe
ro
xi
de
 OXY 
 
 
5% 
10% 
Vanishing -
cream 
GSK 39.00/28g 
39.00/28g 
ACNEMASK 5% Lotion Neutrogena 22.00/ 
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Sunscreens  
7BThere are various products available in pharmacies that a person can choose from, 
which range in price (20-90NIS) and SPF (6-45) that cannot all be listed.  But some 
examples include: 
V
ar
io
us
 In
gr
ed
ie
nt
s 
CAPITOL SOLEIL 
SUN BLOCK 
SPF 15 
SPF 25 
SPF 45 
Face Cream Vichy 79.00/50ml 
79.00/50ml 
84.00/50ml 
HYDROSOL SPF 6 
SPF15 
SPF 25 
Lotion Henkel/Raed 21.00/125ml 
25.00/125ml 
29.00/125ml 
ULTRASOL SPF 15 
SPF 25 
SPF 34 
SPF 45 
Cream Dr. Fisher 25.00/50g 
30.00/50g 
35.00/50g 
40.00/50g 
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VITAMINS  AND  MINERALS 
 
 
G
en
er
ic
 
N
am
e 
BRAND NAME STRENGTH 
 
DOSAGE 
FORM 
 
MANUFACT-
URER 
SELLING 
PRICE (NIS)/  
# OF DOSAGE 
FORM 
Fat Soluble Vitamins available as single products 
R
et
in
ol
 AVIPUR Vitamin A 
50,000U  
Drags Taro 17.00/30 
A
lp
ha
-to
co
ph
er
ol
 &
 
th
in
yl
oe
st
ra
di
ol
  
EPHYNAL Vitamin E 
100mg 
Chewable-
Drags 
Roche 27.00/30 
EVITOL  Vitamin E 
100mg 
200mg 
Tab. Teva  
12.00/30 
19.00/30 
SANATOGEN Vitamin E 
100mg 
Tab. Fisons 12.00/ 
VITAMIN  E/ 
(with wheat germ oil) 
200IU/ 200mg 
400IU/ 20mg 
600IU/ 66mg 
Cap. Burton 
Feingold 
42.00/45 caps 
59.00/40 
62.00/60 
Water Soluble Vitamins available as single products 
Py
ri
do
xi
ne
 ANACRODYNE Vitamin B6 
30,100mg 
Tab. Rekah 13.00/ 
B. SIX 300 Vitamin B6  
300mg 
Tab. Sam-On 33.00/30 
A
sc
or
bi
c 
A
ci
d 
C 500 Vitamin C 
500mg 
Tab. Rekah 22.00/100 
REDOXON Vitamin C 
1000mg 
Efferves. 
Tab. 
Roche 16.00/10 
VI-C 500 Vitamin C 
500mg 
Chewable 
Tab. 
Sam-On 10.00/10 
VITASCARBOL Vitamin C 
500mg 
Lozenges Specia 7.00/12 
Fo
lic
 
A
ci
d FOLIC ACID Folic Acid 
5mg 
Tab. Sam-On 15.00/30 
V
it.
 B
3 NICOLAR Niacin/ 
Nicotinic 
Acid 500mg 
Tab. Armour 263.00/100 
Minerals 
NOTE: The strengths below are expressed in their elemental equivalence. 
(i.e. 600mg of elemental calcium is equivalent to 1500mg of calcium carbonate) 
C
al
ci
um
 CALTRATE 600 Ca Carbonate 
600mg 
Enteric 
Coated Tab. 
Lederle 57.00/60 
TUMS Ca Carbonate 
500mg 
Chewable 
Tab. GSK 
17.00/36 
29.00/75 
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Ir
on
 
FERRO 15 Ferrous 
Gluconate 
15mg/5ml 
Syrup Sam-On 16.00/120ml 
FERRO 23 Ferrous 
Gluconate 
23mg/5ml 
Syrup Sam-On 18.00/120ml 
FERRO-GRAD Ferrous 
Sulfate 105mg 
Tab. Abbott 17.00/30 
SLOW-FE Ferrous 
Sulfate 50mg 
Slow Release 
Tab. 
Novartis 10.00/28 
Fl
uo
ri
de
 
FLUDEN Na Floride 
0.5mg 
Tab. Rekah 8.00/100 
FLUVIUM-20 Na Floride 
20mg 
Tab. Rekah 26.00/60 
TEETH TOUGH Na Floride 
0.25mg/2 drops 
Oral drops Vitamed        /50ml 
ZYMAFLUOR Na Floride 
0.25 
1 mg 
Tab. Novartis 18.00/100 
Po
ta
ss
iu
m
 
SLOW-K Potassium Cl 
600mg (equiv. 
to 315 mg K+) 
 
Slow 
Release 
Tab. 
Novartis 17.00/100 
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Vitamins and Minerals Available in COMBINATION PRODUCTS 
G
en
er
ic
 
N
am
e  
2B RAND NAME 
 
3BDOSAGE FORM/ 
STRENGTH 
 
MANUFACT-
URER 
SELLING 
PRICE (NIS)/  
# OF DOSAGE 
FORM 
 
CALCIUM SANDOZ 
+ VIT C 
(Efferves. Tab.) 
Vit. C 1000mg 
Ca Gluconate 578mg, 
Ca Lactate 422mg, 
Cal Carbonate 327mg 
Novartis 18.00/10 
 
CAl-C-VITA (Effervesc. Tab.)  
Vit. C 1000mg 
Ca  250mg 
Vit. D 300 IU 
Vit. B6 15mg 
Citric Acid 1350mg 
Roche 20.00/10 
 
CALTRATE 600+ 
VIT. D. 
(Enteric Coated Tab.) 
Ca Carbonate 1500 eq. to 
600mg elemental Ca. + 
Vit. D 125 IU 
Lederle 57.00/60 
 
CENTRUM-V (Tab.) 
Vit. A 5000 IU,   Vit. E  30 IU 
Vit. C 90mg,    Vit. B1 2.25mg 
Vit. B2 2.6mg,  Vit. B6  3mg 
Vit. B12  9mcg,  Vit. D 400 IU 
Folic Acid 400mcg 
Niacin 20mg,     Biotin 45mcg 
Vit. B5 10mg,    Ca  16mg  
Phosphorus 125mg 
Iodine 27mg,     Mg 100mg 
Copper 3mg,     Mn 7.5mg 
K   7.5mg,         Zn  22.5mg 
Lederle 55.00/30 
 
CENTRUM JUNIOR 
ADVANCED + IRON 
(Chewable Tab. ) 
Vit. A 5000 IU,  Vit. D 400 IU 
Vit. E 30 IU,      Vit. C 60mg 
Vit. B6  2mg,      Vit. B12 6mcg 
Vit. K 10mcg,    Biotin 45mcg 
Folic Acid 400mcg 
Thiamine 1.5mg, Vit. B5 10mg 
Vit. B2 1.7mg,     Niacin 20mg 
Iron 18mg,           Mg  40mg 
Iodine 150mcg,   Copper  2mg 
Phosphorus 50mg, Ca 108mg 
Zn 15mg,   Chromium 20mcg 
Mn 1mg 
Lederle 49.00/30 
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CENTRUM PLUS (Tab.) 
Vit. A 4000 IU,    Vit. E 30 IU 
Betacarotene 1000IU 
Vit. C 60mg,      Vit. B1 1.5mg 
Vit. B2  1.7mg,  Vit. B6  2mg 
Vit. B12  6mcg,  Vit. D 400 IU 
Vit. K 25mcg,    Niacin 20mg 
Folic Acid 400mcg 
Biotin 30mcg,    Vit. B5  10mg 
P 150mg,            Ca 194mg, 
Iodine 150mcg,  Iron 18mg 
Mg 100mg,        Mn  2.5mg 
Cu  2mg,            Zinc 15mg 
Cr  25mcg,         Se 60mcg 
Molybedenum 60mcg 
Nickel 5mcg 
Lederle 55.00/30 
 
KIDDI (SYRUP) 
Vit. A 2000 IU  Vit. D2 400 IU 
Vit. B1  10mg,    Vit. B2  6mg, 
Vit. B12 10mcg,    Vit. B6 3mg 
Ca  39        Phosphorous 61 mg 
Lycine  pharmaton 200mg 
Nicotinamide sugar excip 10ml 
Pharmaton 40.00/100ml 
 
MATERNA 
ENHANCE 
FORMULA 
(Tab.) 
Vit. A 5000 IU,   Vit. B1  3mg 
Vit. B2  3.4mg,    Vit. B5 10mg 
Vit. B12 12mcg,   Vit. B6 10mg 
Vit. D 400 IU,     Vit. E 30 IU 
Niacin  20mg,     Biotin 30mcg 
Iron 60mg,           Ca 250mg 
Iodine 150mcg,    Mg 25mg 
Copper 2mg,         Zn  25mg 
Chromium 25mg,  Mn 5mg 
Molybdenum25mcg 
Lederle 140.00/100 
48.00/30 
 
ORACAL-D (Cap.) 
Ca Carbonate 1500 eqv. to 
600mg elemental Ca. + 
Vit. D 125 IU 
BPC 35.00 /50 
 
POLYVIT (Drags) 
Vit. A 5000 IU,    Vit. B1  5mg 
Vit. B2  3mg,        Vit. B6  1mg 
Vit. B12 20mcg,     Vit. C 50mg 
Vit. D 400 IU,      Vit. B5  3mg 
Folic Acid 2mg,     Niacin 25mg 
Iron 3.3mg,           Ca  60mg 
P  40mg,               Mn 167mcg 
Mg 6.67mg 
Taro 66.00/30 
 SLOW-FOLIC 
(Tab.) Ferrous sulphate 160mg 
(eq. to 50 mg Fe), Folic acid 
400 mcg 
Novartis  15.00 /28 
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STRESSTAB. (Tab.) 
Vit. E 30 IU,     Vit. C 600mg 
Vit. B1  15mg,   Vit. B2  15mg 
Vit. B6 25mg,    Vit. B12 12mcg 
Niacin 100mg,  Vit. B5  20mg 
Folic Acid 400mcg 
Lederle 40.00/30 
 
STRESSTAB. 600 
WITH IRON 
(Tab.) 
Vit. E 30 IU,     Vit. C 600mg 
Vit. B1  15mg,   Vit. B2  15mg 
Vit. B6 25mg,    Vit. B12 12mcg 
Niacin 100mg,  Vit. B5  20mg 
Folic Acid 400mcg 
Iron 27mg 
Lederle 36.00/30 
 
SUPRADYN  N (Drags, Efferves. Tab.) 
Vit. A 3333 IU,   Vit. B1 20mg 
Vit. B2  5mg,       Vit. B6  10mg 
Vit. B12 5mcg,     Vit. C 150mg 
Vit. D 500 IU,     Vit. E 10mg 
Vit. B5 11.6mg,   Niacin 50mg 
Folic Acid 1mg,  Biotin 0.25 
Ca,    Iron,        Mg,       Mn, 
Phosphorus,        Copper 
Molybdenum,      Zinc 
Roche 35.00/30 
 
VI-DAYLIN PLUS 
IRON 
(Syrup) 
Vit. A 2500 IU,  Vit. D 400 IU 
Vit. E 15 IU,      Vit. C 600mg 
Vit. B1 1.05mg,  Vit. B2  1.2mg 
Vit. B12  4.5mcg, Vit. B6 1.05mg 
Niacin 13.5 mg,   Iron 10mg 
Abbott 33.00/240 
 
MINOVIT (Tab.)  
Vit. A 800 IU,    Vit. D 400 IU 
Vit. E 0.75MG,  Vit. C 25mg 
Folic Acid 0.1mg, Vit. B1 5mg 
Vit. B2  1mg,      Vit. B5  6mg 
Vit. B12  1mcg,   Vit. B6  2mg 
Ferrous Ammon. Citrate 3mg 
Ca 40mg,            Niacin 6mg 
Mg 20mg,           Mn 4mg 
JePharm 14.00./30 
 
ABECIDEN (Tab.)  
Vit. A 5000 IU,  Vit. B1 2.5mg 
Vit. B2  2.5mg,   Vit. B6  2mg 
Vit. B12 10mcg,  Vit. C 50mg 
Vit. D 400 IU,    Vit. E 30 IU 
Niacin 30mg,     Vit. B5  3mg 
Folic Acid 0.8mg 
Ca 125mg,         Iron 18mg 
Mg 10mg,          Iodine  0.15mg 
BPC 18.00/30 
 VICAL 
(Efferves. Tab.) 
Vit. C 1000mg,   Ca 250mg 
Vit. D 300 IU,    Vit. B6  15mg 
BPC 14.00/10 
 
There are several other products that contain various vitamins and minerals in other concentrations, or in 
combination with herbal or amino acids (i.e. ginseng, lysine, pantothenate) that will not be listed.  
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VACCINES 
 
G
en
er
ic
 
N
am
e  BRAND NAME 
 
STRENGTH 
 
DOSAGE 
FORM 
 
MANUFACT
-URER 
SELLING 
PRICE (NIS)/  
# OF DOSAGE 
FORM 
B
C
G
 BCG As recommended 
by WHO 
 
   
O
PV
 POLIO SABIN 
 
As recommended 
by WHO 
 
Oral use 
only 
GSK 19.59/1 dose 
amp. 
IP
V
 
IMOVAX POLIO 
 
0.5 ml contains 
inactivated poliovirus 
type 1,2 &3 for one 
immunization dose. 
SC or IM Pasteur 
Merieux 
 
Te
ta
nu
s 
TETANOL 0.5 ml contains 
tetanus toxoid at 
least 40 IU. 
Suspension 
given IM 
or deep SC 
Chiron 
Gehring 
 
TETANUS 
TOXOID PTAP 
0.5 ml tetanus 
toxoid as recom-
mended by WHO 
Suspension 
for IM 
Rafa 4.00/1 dose 
ampoule 
D
PT
 
D.T.COQ 
 
Purified diphtheria 
toxoid at least 30 IU 
Purified tetanus 
toxoid at least 60 IU 
Bordetella pertussis at 
least 4 IU 
Suspension 
for injection 
given IM or 
deep SC 
Rhone 
Poulenc 
group 
 
DiTePer 
ANATOXAL 
BERNA 
 
Purified adsorbed 
diphtheria-tetanus-
Pertussis at least 
20,000 million- 
Toxoids 
Suspension 
for injection 
given IM or 
deep SC 
Swiss Serum 
and Vaccine 
Institute 
Berne 
 
M
ea
sle
s RIMEVAX 
 
Not less than 1.000 
TCID50 of the 
Schwarz strain 
Lyophilized 
powder to be 
reconstituted 
for SC only 
GSK 48.50/1 dose 
vial 
M
M
R
 
MMR VACCINE  
 
Live attenuated 
strains of Edmonston-
Zagreb measles, 
mumps and Wistar 
RA 27/3 rubella virus. 
Freeze-
Dried vial 
for dilution 
given by 
deep SC 
Serum 
Institute of 
India LTD 
 
TRIMOVAX 
MERIEUX 
Live hyper-attenuated 
measles (Schwarz 
strain), mumps (Urabe 
9 strain), rubella 
(RA27/3M strain) 
Powder for 
dilution 
given SC or 
IM. 
Pasteur 
Merieux 
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H
ep
at
iti
s B
 
ENERGIX-B Pediatric: 10 ug in 
0.5ml rDNA 
hepatitis 
Adult: 20ug/1ml 
Solution 
for IM use 
GSK 77.00/1 dose 
vial for child. 
102.00/1 dose 
vial for adult. 
EUVAX B Inj. 
 
Purified HBs 
Antigen 10 ug in 
0.5 ml 
Susp. for 
IM use 
only 
LG 
Chemical 
Ltd. 
 
HEPAVAX-GENE 
RECOMBINANT 
10 ug of HbsAG in 
0.5 ml 
IM injection 
only 
Korea Green 
Cross Corp 
 
In
flu
en
za
 
va
cc
in
e 
Every season there 
is a different 
preparation 
depending on 
influenza strains. 
- Solution 
for IM use  
 Price range 
from 25 - 35 
NIS./1 dose 
vial. 
H
ib
 
V
ac
ci
ne
 HibTitter 
 
Haemophilus-b 
saccharide 10ug in 
0.5ml (Diphtheria 
CRM 197 protein 
conjugate) 
Solution 
for IM 
only 
Lederle Lab 122.00/1 dose 
vial  
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Appendix B - Definitions 
 
0BWord Definition 
Absorption The passage of the drug from its site of administration into the 
blood. 
Acquired Resistance Bacteria can become resistant by incorporating a “resistance 
factor” into their genes to render the antibiotic ineffective. 
Antibiotics Agents derived from natural substances. 
Antitoxin A solution of antibodies derived from the serum of animals 
immunized with specific antigens (e.g. diphtheria antitoxin and 
botulinum antitoxin) used to achieve passive immunity or for 
treatment. 
Autoinfection Infection by an organism existing within the body or transferred 
from one part of the body to another part. 
Bactericidal Agents that kill the microorganism. 
Bacteriostatic Agents that inhibit the growth of the microorganisms by 
producing reversible changes. This delay in the growth will give 
the immune system the chance to get rid of the microorganism. 
Bioavailability The fraction of the drug that reaches its action sites after 
administration by any route. It is the rate and extent of absorption of a 
drug from a dosage form as determined by its concentration/time 
curve in the systemic circulation or by its excretion in the urine. 
Bioequivalence When the same 2 dosage forms for the same active ingredient in 
the same dose give the same bioavailability criteria, i.e. the same 
maximum concentration (Cmax) at the same time (Tmax), that is 
their rates and extent of absorption do not show significant 
differences.  
Blood Dyscrasia A pathologic condition manifested by fever, sore mouth or throat, 
unexplained fatigue and easy bruising or bleeding. 
Broad Spectrum The range of activity extends to many micro-organisms.  
(e.g. Tetracyclines depress G+ve, G-ve, Rickettsiae and Chlamydiae.) 
Chemical 
Equivalence 
When the same 2 dosage forms for the same active ingredient 
contain the same amount of the active ingredient, obtained after 
chemical analysis. 
Coenzyme It is a dissociable, low-molecular weight, non-proteinaceous 
organic compound (often nucleotide) participating in enzymatic 
reactions as acceptor or donor of chemical groups or electrons. 
Compliance Faithful adherence by the patient to the prescriber’s instructions. 
Cross Resistance The passage of the acquired resistance to another bacterium.  
Cross-Sensitivity When a person is severely allergic to a certain drug, he/she might as 
well be sensitive to another drug which is similar in chemical 
structure or in pharmacological effect. e.g. Aspirin and other 
NSAIDs. 
Cumulative Effect Increase in drug effect that results when intake of repeated doses 
exceeds the rate of drug elimination form the body. 
Distribution The delivery of the drug to the tissues. 
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Disulfiram Type 
Reaction 
An antabuse type reaction, that presents with symptoms such as facial 
flushing, pounding, headache, sweating, slurred speech, abdominal 
cramps, nausea, vomiting, tachycardia, fever, drop in blood pressure, 
dyspnea, and sense of chest constriction; symptoms may last up to 24 
hours. 
Drug Any substance presented for treating, curing or preventing disease in 
human beings or in animals. A drug may also be used for making a 
medical diagnosis or for restoring, correcting, or modifying 
physiological functions. 
Elimination The process by which the drug’s concentration decreases in the 
body by metabolism and excretion. 
Enzyme Induction Stimulation of microsomal enzymes by a drug resulting in 
metabolism acceleration leading to decreased activity.  
Excipient Any component of a finished dosage form other than the indicated 
therapeutic active ingredient(s). 
Excretion The process whereby drugs are transferred from the internal to the 
external environment. The principal organs involved in this 
process are the kidneys, lungs, biliary system and intestines. 
Half-life (t1/2) Time required for concentration of a drug in the body to decrease 
by 50%.  Half-life also represents time necessary to reach steady 
state or to decline from steady state after a change in dosing 
regimens. 
Immune Globulin 
(IG) 
A sterile solution containing antibodies from human blood. It is 
obtained by cold ethanol fractionation of large pools of blood 
plasma and contains 15-18% protein.  
Metabolism The process by which the drugs are modified in the body into a 
more or less water-soluble-substance, or more or less toxic 
substances. 
Milliequivalent Unit 
(meq) 
It is related to the total number of ionic charges in solution and 
also takes into account the valiance of the ions. Thus, it measures 
the amount of chemical activity of an electrolyte.  
Me-too drug It is a compound that is structurally very similar to already known 
drugs, with only minor pharmacological differences. 
Narrow Spectrum Agents that kill the microorganism.  The range of activity for this 
antibiotic is small. It affects 1-2 micro-organisms only.  
(For example, Penicillin-G affects G+ve organisms and Neisseriae.) 
Pharmacodynamics The process of interaction of drugs with the cells.  It includes: the 
binding of drugs to cells, their uptake, and intracellular 
metabolism, dose response relationships as well as therapeutic 
effects. (The effect of the drug on the body). 
Pharmacokinetics The process of handling of a drug within the body, which includes 
its absorption, distribution, metabolism, and excretion. (The effect 
of the body on the drug; or the drug fate in the body). 
Photosensitivity Drug induced skin changes resulting in unusual susceptibility to 
effects of sunlight or ultraviolet light. 
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Procurement Selecting suppliers, placing and monitoring orders, checking 
delivery quantities and quality, and paying suppliers. 
Prodrug Any compound that undergoes biotransformation before 
exhibiting its pharmacological effects. Prodrugs can thus be 
viewed as drugs containing specialized non-toxic protective 
groups used in a transient manner to alter or to eliminate 
undesirable properties in the parent molecule.  
Pulmonary Edema Excessive fluid in the lung tissue manifesting one or more of the 
following: shortness of breath, cyanosis, persistent productive 
cough (frothy sputum may be blood tinged), expiratory rales (?), 
restlessness, increased heart rate, sense of chest pressure and/or 
anxiety. 
Superinfection / 
Suprainfection 
A new infection by an organism different from the initial 
infection being treated by antimicrobial therapy, presented by one 
or more of the following: black, hairy tongue, glossitis, stomatitis, 
anal itching, loose foul-smelling stools, vaginal itching or 
discharge, sudden fever, cough. 
Therapeutic 
Equivalence 
When the same 2 dosage forms for the same active ingredient 
provide the same therapeutic effect and safety. 
Therapeutic Window/ 
Therapeutic Index 
(TI) 
Range of drug concentration level, within which a particular drug 
has its safest and optimal therapeutic effects, that is, the limits 
between therapeutic and toxic response to a drug. 
Tolerance Decreased responsiveness to pharmacodynamic action of a drug 
that occurs during repeated administration of constant drug doses.  
Larger or more frequent doses or both are required to achieve the 
same effects observed with initial dosing. 
Toxoid A modified bacterial toxin that has been rendered nontoxic but 
retains the ability to stimulate the formation of antitoxin. 
Urinary Secretion The process by which drugs are secreted from the plasma into the 
kidney tubules (ex. Pen. G) in order to be excreted by the urine. 
Vaccine A suspension of live (usually attenuated) or inactivated 
microorganism (bacteria, viruses, or rickettsiae) or fraction of 
them, administered to induce immunity and thereby prevent 
infectious disease. 
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Appendix C 
Summary of drugs used for allergic reactions or anaphylactic shock 
 
Allergic reactions, anaphylactic shock and conditions such as angioedema are medical 
emergencies that need immediate action to avoid cardiovascular collapse and/or death.  
Prompt treatments of possible laryngioedema, bronchspasm and/or hypotension are required. 
   
 
1. Vital signs 
Maintain an open airway; give oxygen by 
mask, restore blood pressure.   
 
2. A sympathomimetic as first line 
treatment 
Epinephrine (adrenaline) 1:1000 given IM 
Adult 500 microgram (0.5 ml) 
Child 6 mon.-6 yrs. 120 microgram (0.12 ml) 
Child 6-12 yrs. 250 microgram (0.25 ml) 
Infant  < 6 mon. 50 microgram (0.05 ml) 
 
The dose may be repeated several times if 
necessary at 5 minute intervals, according 
to the blood pressure, pulse and 
respiratory function.   
 
When patient is severely ill (i.e. shock) 
and there is doubt about adequacy of the 
circulation and absorption from the IM 
route, IV administration can be given 
slowly in a dose of 500 microgram (5 ml 
of the dilute 1:10,000 epinephrine) at a 
rate of 100 microgram per minute, until a 
response has been obtained.  Half doses 
of adrenaline (epinephrine) may be safer 
for patients on amitriptyline, imipramine, 
or beta-blocker. 
 
If cardiac arrest occurs, 1:10,000 
epinephrine in a dose of 10 ml by IV is 
preferred through a central line. Atropine 
3 mg IV as single dose maybe 
administered or other cardiac drugs as 
case requires.   
3. Antihistamines 
Administer   promethazine or chlor-
phinarime by slow IV over 1 min. 
Promethazine:  Adult 25-200 mg/d, Child: 
1 mg/kg/d, deep IM or slow IV injection. 
 
4. Corticosteroids 
Steroids do not have an immediate effect 
on the symptoms but are useful in 
reducing or eliminating further 
deterioration.  Hydrocortisone by slow IV 
may be administered as follows: 
Adult  100-300 mg 
Child up to 1 year 25 mg 
Child 1-5 yrs.  50 mg 
Child > 5 yrs. 100 mg 
 
5. Intravenous fluids 
Start infusion with sodium chloride: 0.5-1 
liter during the first hour. Repeat if 
necessary until circulation, tissue 
perfusion and blood pressure improve. 
 
6. Asthma like symptoms 
Bronchospasm unresponsive to 
epinephrine: Salbutamol nebulized, 1 mL 
salbutamol respirator solution + 1 mL 
0.9% sodium chloride solution. Repeated 
2–4 hourly if necessary OR continue with 
salbutamol, oral, 0.15 mg/kg 6 hourly for 
24 hours. 
Can administer aminophylline 5 mg/kg IV 
over 20 mins. if salbutamol is not 
available.
 
 
* Refer to individual drug monographs for further details about individual drugs. 
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Appendix D  
Local Manufactures 
 
 
Birzeit Palestine Pharmaceutical Company 
(BPC) 
P.O Box 20, Birzeit, Palestine 
Tel: (970)-2-295-6581,  
Fax: (970)-2-295-3253 
E-mail: bpc@uppm.org 
Gama Chemical Company (GCC) 
P.O. Box 782, Beitunia, Palestine 
Tel: (970)-2-290-0911,  
Fax: (970)-2-290-0064 
E-mail: gcc@uppm.org 
Jerusalem Pharmaceutical Company 
(JEPHARM) 
P.O. Box 3570, el-Bireh, Palestine 
Tel: (970)-2-240-6550,  
Fax: (970)-2-240-3246 
E-mail: jpharm@palnet.com, 
jepharm@uppm.org 
 
 
Jordan Chemical Laboratory  
P.O. Box 58, Beit Jala, Palestine 
Tel: (970)-2-274-2855, 277-6880, 277-6881  
Fax: (970)-2-274-1072  
E-mail: info@jclaboratory.com, jcl@uppm.org 
MEGAPHARM 
Industrial Zone, Beit Hanoun, Gaza Strip 
Tel: (970)-8-245-5011, 245-5012,  
Fax: (970)-8-245-5051 
E-mail: megapharm@palnet.com,  
megapharm@uppm.org 
Pharmacare Ltd Company (Pharmacare) 
P.O. Box 677, Ramallah, Palestine 
Tel: (970)-2-290-0980/1,  
Fax: (970)-2-290-5189 
E-mail: pharmacare@pharmacare-ltd.com,  
pharmacare@uppm.org 
 
Registered Local Drug Stores 
 
 
 
Act Medical Co., Jerusalem 
Tel:  026799048, Fax: 026782818 
al-Azouni Trading D.S., Nablus 
Tel: 092372296/2377231, Fax: 092371312 
al-Barghouti Co. D.S.,  Ramallah 
Tel:  022985957 
al-Basheer D.S., Bethlehem 
Tel:  022776666, Fax: 022742402 
al-Du’wali D.S., Ramallah 
Tel: 022955797, 022955026 
al-Hayya D.S., Jenin 
Telfax:  062503074 
al-Hayya D.S., Ramallah 
Tel: 022989444, Fax: 022989444 
al-Nour Medical Co. D.S., Jerusalem 
Tel:  022349788, Fax: 02  2349775  
al-Ram D.S., Jerusalem 
Tel:  022349839, Fax:  022349735 
al-Rasheed D.S., Nablus 
Tel:  092388101, Fax:  2381894  
al-Razi D.S., Ramallah 
Tel: 022956395, Fax: 022956396 
al-Salameh D.S., Jerusalem 
Tel:  not available. 
al-Shak'a D.S., Nablus 
Tel:  092382660, Fax: 092381420 
al-Thulathia D.S. Co., Nablus 
Tel: 092385304, Fax: 092385304 
al-Walid Medical Trading Co., Ramallah 
Tel: 022956416, Fax: 022956413 
al-Watani D.S., Bethlehem 
Telfax:  022747033  
al-Wihda D.S., Nablus 
Tel: 0962382534, Fax: 2385820 
Beit Hanina D.S., Jerusalem 
Tel: 025857918, Fax: 025856257 
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Bethlehem Medical D.S., Bethlehem 
Tel:  022742906, Fax: 02  2777414  
Dana D.S., Jerusalem 
Tel:  022348616  
DespoMed Co., Jerusalem 
Tel: 025834075/6, Fax: 025834077 
F.A. Hanna D.S., Ramallah 
Tel:  026284985, Fax: 026284987 
Hikmat for Medicines D.S., Hebron 
Tel:  022234177 
Ibn al-Haytham D.S , Hebron 
Tel:  022228550, Fax:  022226767 
Ibn Sina D.S., Nablus 
Tel:  092378159, Fax: 092372264  
Intermed Co., Ramallah 
Tel:  026283822, Fax: 026272661 
InterPal Co. for Medical Imports, Gaza 
Tel:  082822728, Fax: 082822718 
Khalil al-Rahman D.S., Hebron 
Tel:  022219366 
Lyn Co. for Medical Equipment, Beitunia 
Tel:  022902193, Fax: 022902204 
Masrouji Trading Co., al-Bireh 
Tel:  022404060, Fax: 022403958 
MediPharm Co. for Medical Needs, 
Bethlehem 
Tel:  022775245, Fax: 022775244 
MediSerf D.S., Tulkarem 
Telfax:  09 2676433 
MSS, Beitunia 
Tel:  022959372/3/4, Fax: 022959375 
Nablus Co. for Med. Equipment, Nablus 
Tel:  092389965, Fax: 092389966 
Naseeb al-Jadeed D.S., Bethlehem 
Tel:  022774044, Fax:  022774045 
Nazal D.S., Ramallah 
Telfax:  022955990 
Nobil Co. for Medical Equipment, Ramallah 
Tel:  022900251, Fax:  022900890 
NutriPharm D.S., Hebron 
Telfax:  022226440 
Omnipal Co. for Trade & Marketing, al-Bireh 
Tel:  022958018, Fax:  022958019 
Palestinian-British Co. for Trading & 
Contracting, Gaza 
Tel: 082837708/ 082822726,  
Fax:  082823967 
Pharmacare D.S., Jerusalem 
Tel:  025813515 
Razan D.S., Ramallah 
Telfax:  022985698  
Riyam D.S., Jerusalem 
Tel:  025810288, Fax:  025819047 
Sami Anabtawi D.S., Nablus 
Tel:  092374006, Fax:  092370237 
Siamco for Medicines and Trade, Ramallah 
Tel:  022963246, Fax: 0229559949 
Sufian Med. Equipment Company, Jerusalem 
Tel:  022796863, Fax: 026263521 
Sukhtyan Brothers Co., Nablus 
Tel:  09  2377718 , Fax:  092387234 
Sun Trading Co, Nablus 
Tel:  092397181, Fax:  092397184 
Tulkarem D.S., Tulkarem 
Tel:  092382821 
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A 
α-Methyldopa, 24 
Abeciden , A41 
Abitren, 11, A4 
Abrolet, 7 
Acamol, 7, A3 
Acamoli, 7 
Acarbose, 157 
ACE Inhibitors, 34, 50, A6 
Acebutolol, 42 
Acetaminophen, 6 
Acetazolamide, 235 
Acetic Acid, 243 
Acetohexamide, 157 
Acetosal, 6 
Acetylcysteine, 97, 239, A13 
Acetylsalicylic Acid, 4, A3 
Acne Mask, 274 
Acrivistine, 87 
Acyclovir, 151, 260, A33 
Adalat, 39 
Adenosine, 42 
Adinol, 255 
Advil, 10 
Aerolin, 104 
Affectine, 196 
Ahiston, 88 
Albendazole, 148 
Albuterol, 103 
Alcinal, A15 
Aldactone, 30 
Aldosprine, 30 
Alka Seltzer, 6 
Allergon, 88 
Allopurinol, 13, 102 
Alloril, 15 
Alprazolam, 197 
Alrin, 92 
Aluminium/Aluminum 
Acetate Solution, 243 
Amantadine, 221, A27 
Amiloride, 29 
Aminobenzoic Acid, 276 
Amiodacore, 44 
Amiodarone, 42, A7 
Amitriptyline, 192, A48 
Ammonium Chloride, 93 
Amoxi, 122 
Amoxicare, 122 
Amoxicillin, 120, 245, A18 
Ampicillin, 120, A17 
Ampipharm, 122 
Ampitricine, 122 
Amyvil, 194 
Anabolic Steroids, 162 
Analgesics, 3 
Anaphyl, 88 
Ancozine, 70 
Angilat, 39 
ANTACIDS, 61, 62 
ANTHRANILITES, 276 
ANTIARRHYTHMIC, 214 
Anticholinergic Drugs, 66, 
218, A27 
ANTIDEPRESSANTS, 191 
ANTIDIABETIC DRUGS, 
157, A23 
ANTIDIARRHEAL AGENT, 
74, A10 
ANTIEMETICS, 68, A10 
ANTIEPILEPTIC, 205, A26 
ANTIFUNGALS, 148, 256, 
A22 
ANTIGOUT AGENTS, 13 
ANTI-HEMORRHOIDAL, 
79, 80, A11 
Antihistamines, 86, A13 
ANTIHYPERTENSIVES, 
23, A6 
ANTI-INFECTIVES, 113, 
A17 
ANTIPARASITICS, 143 
ANTIPARKINSONS 
DRUGS, 218, A27 
ANTIPYRETIC, 3 
ANTI-TUBERCULOSIS, 
137, 138, A21 
ANTITUSSIVES, 94, A12 
Antivert, 70 
ANTIVIRAL AGENT, 151, 
A22 
Anturane, 17 
Anusol, 80 
ANXIOLYTICS, 197 
A-parkin, 222 
Apomoxyn, 122 
Aprical, 39 
Artane, A27 
Artofen, 10 
Ascorbic Acid, 285, A37 
Asmalin, 104 
Aspirin, 3, 13, 47, A3 
Assival, 199, A29 
Astemizole, 87, 88, A12 
ASTHMA MEDICATION, 
97, A13 
ASTRINGENTS, 80 
Ateni, 34 
Atenolol, 33, A6 
Athletes Foot, 259 
Ativan, 200 
Atroped, 239 
Atropine, 66, A30 
Atrospan, 239 
Augmentin, 123, A18 
Avobenzone, 276 
B 
β-Blockers, 31, 162 
Baby Aspirin, 6, A3 
Bacampicillin, 120 
Bacitracin, 259 
Bacloforte Inhaler, 107 
Bactosept, 263 
Bactrim, 133 
Bactroban, 259 
Bactroscrub, 263 
Barbiturates, 197 
BCG Vaccine, 303 
Beclomethasone, 106, A14 
Beconase Nasal, 107 
Becotide Inhaler, 107 
Benazepril, 35 
Benzene Hexachloride, 265 
Benzhexol, 219 
Benzocaine, 79 
Benzocide, 264 
Benzodiazepines, 197, 199 
Benzophennones, 276 
Benzoyl Peroxide, 273 
Benzthiazide, 26 
 Benzyl Benzoate, 263, A34 
Benzylkonium Chloride, 178 
Benzylpenicillin, 116 
Bepen, 119 
Betadine, 262 
Betamethasone, 170, 233, 
246, 269, 271, A35 
Betaren, 11 
Bezafibrate, 53, A8 
Bezalip, 54 
Bicide, 267 
Bisacodyl, 77, A11 
Bisoprolol, 31 
Blocardril, 33 
Bonine, 70 
Bretylium, 42 
Brimocyclin, 129 
Bristamycin, 131 
Broadacillin, 122 
Bromhexine, 97, A13 
Bromocriptine, 222, A27 
Brompheniramine, 87 
Brufen, 10 
Buffered Aspirin, 6 
Bumetanide, 27 
Bupropion, 191 
Butoconazole, 256 
C 
Ca Salts, 290 
Caladerm, 255, A32 
Calamine, 80, 255, 268, A32 
Calatrim, 255 
Cal-C-Vita, A39 
Calcium, 288, A39 
Calcium Channel Blockers, 
37, A7 
Caltrate, A39 
Candistan, 149 
Capillon, 262 
Caplenal, 15 
Capoten, 37 
Captopril, 15, 24, 35, A6 
Carbamazepine, 207, A26 
Carbi, 209 
Carbidopa, 224, A27 
CARDIOVASCULAR  
DRUGS, 21, A6 
Cardopril, 37 
Cartia, 6, A3 
Cascara, 76 
Castor oil, 76, 77 
Ceclor, 127, A19 
Cefacare, 127 
Cefaclor, 125, 126, A19 
Cefadrox, 127 
Cefadroxil, 125, 126 
Cefalex, 127, A19 
Cefamandole, 125 
Cefazolin, 125 
Cefoperazone, 125 
Ceforal, 127 
Ceforanid, 125 
Cefotaxime, 125 
Cefotetan, 125 
Cefovit, 127 
Cefoxitin, 125 
Ceftazidime, 125 
Ceftizoxime, 125 
Ceftriaxone, 125 
Cefuroxime Axetil, 125, 245 
Centrum, A39 
Celiprolol, 31 
Cephalexin, 124, 126, A19 
Cephalosporins, 124, A19 
Cephalothin, 125 
Cephapirin, 125 
Cephradine, 125 
Cerumol, A31 
Cetrimide, 262 
Chloramphenicol, 203, 244, 
A29 
Chlorbutol, 246 
Chlordiazepoxide, 197 
Chlorhexidine, 244, 262, A34 
Chlorotetracycline, 231 
Chlorothiazide, 26 
Chlorpheniramine, 86, A12, 
A48 
Chlorpromazine, 201, A28 
Chlorpropamide, 157 
Chlorthalidone, 26 
Cholestyramine, 53, 54 
Chol-Less, 55 
Cilazapril, 35 
Cinnamates, 276 
Cinoxacin, 136 
Cinoxate, 276 
Ciprocare, 137 
Ciprofloxacin, 136, 231, A21 
Ciprogis, 137 
Ciproxin, 137 
Citalopram, 191 
Clamoxin, 120 
Clarithromycin, 62, 130, 245 
Clemastine, 87 
Clobazam, 197 
Clobetasol, 271 
Clofibrate, 53 
Clomipramine, 191 
Clonazepam, 197, 209, A26 
Clonex, 211 
Cloroyate, 88 
Clotrimazole, 256, A32 
Cloxacillin, 116, A18 
Clozapine, 201 
Co-amoxiclav, 122, A18 
Co-careldopa, 224, A27 
Cocoa Butter, 80 
Codeine, 94, 96 
Codical, 96 
Cogentin, 220 
Colchicine, 13, 17, 18, A5 
Colestipol, 55 
Coldex, A16 
Colifibrate, 162 
CONTRACEPTIVES, 162, 
A24 
Copper IUDs, 177 
Cordil, 46 
Cordorone, 44 
Corotenol, 34 
Corotrend, 39 
Corticosteroids, 162, 230, 
233, 269, A29 
Cortisone, 170 
Co-trimoxazole, 131 
Cough Suppressants, 94 
Coumadin, 49 
COX-2, 8 
Cromoglycate, 104 
Cromolyn, 104, 235, A14 
Cromunal, 106 
Crotamiton, 264 
Curam, 123 
Cyproheptadine, 87 
D 
Dakatrin, 150 
Daktarin, 257 
Daktazol, 150 
 Daktazole, 257 
Daonil, 164, A23 
Declamide, 164 
DECONGESTANTS, 90, 
A12 
Deltasone, 173 
Depakote, 217 
Depalept, 217 
Depo-provera, A25 
Deraline, 33, A6 
DERMATOLOGICAL 
PREPARATIONS, 253, 
A32 
Desipramine, 191, 193 
Desogestrel, 180 
Dexamethasone, 170 
Dexamol, 7, A3, A15 
Dextromethorphan, 96 
Dextrothyroxine, 162 
Diabeta, 164 
Diasix, 29 
Diazepam, 197, 198, 217, 
A28 
Dichlorphenamide, 235 
Diclofen, 11 
Diclofenac, 8, 239, A4 
Diflorasone, 271 
Digitalis Glycosides, 50 
Digitoxin, 50 
Digoxin, 50, 68, A8 
Dilantin, 215 
Dilatam/Dilapress, 41 
Diloxanide Furoate, 146 
Diltiazem, 24, 45, 162 
Dioxybenzone, 276 
Diphenhydramine, 87 
Dipyrone, 4 
Diseptyl, 133 
Disopam, 199 
Disopyramide, 42 
Disoramin, 88 
Disothiazide, 27 
DIURETICS, 26, 50 
Docusate, 76 
Dopaminergic Agents, 218 
Dopicar, 225 
Doxepin, 191 
Doxycyline, 71, 127, 128 
DPT, 305, A45 
DTP, 297 
Duracef, 127 
Dyprotex, 255 
E 
Econazole, 256 
Elatrol/Elatrolet, 194 
Elavil, 194 
Electrosubs, 74 
Eltroxin, A24 
Emergency Pills, 186 
Emestop, 69 
Emollients, 253 
E-Mycin, 131 
Enalapril, 35 
Encainide, 42 
Endep, 194 
Engerix, 307, A46 
Enoxacin, 136 
Entogyl, 144 
Epanutin, 215, A27 
Ephedrine Sulphate, 81 
Epinephrine, A48 
Erytab, 131 
Erythrocare, 131 
Erythrocin, 131 
Erythrolet, 131 
Erythromycin, 129, A20 
Erythroped, 131 
Erythropharm, 131 
Erythroteva, 131 
Esidrex, 27 
Esmolol, 31, 42 
Esracain, 256 
Estrogens, 179, A24 
Ethacrynic Acid, 27 
Ethambutol, 138, 142 
Ethanol, 261 
Ethinyl Estradiol, 176, 186, 
A24 
Ethosuximide, 211, A26 
Ethyl Alcohol, 261 
Ethynodiol, 180 
Expanded Program of 
Immunization, 298 
Expectorants, 93, A12 
F 
Famotidine, 62 
Fat Soluble Vitamins, 281, 
A39 
Febracold, A15 
Febramol, 7 
Fedral, 104 
Felcol, 13 
Feldene, 13 
Felodipine, 37 
Femulen, 184, A25 
Fenoxypen, 119 
Ferro-Grad, A38 
Flagy, 144 
Flecainide, 42 
Florine, A38 
Floxin, 137 
Flu, A16 
Fluden, A38 
Flucloxacillin, 116, 119, 
244, A17 
Fludrocortisone, 169 
Fluorine, 288 
Fluorometholone, 233 
Fluoroquinolones, 136 
Fluosinolone, 271 
Fluoxetine, 191, 195, A28 
Fluoxicare, 196 
Flutine, 196 
Fluvoxamine, 191 
Fluvsa, A8 
Folic Acid, 285, A39 
Fungazole, 257, A23 
Fungitirin, 257 
Furadantin, 135 
Furamide, 146 
Furosemide/Frusemide, 24, 
27, A6 
Furovite, 29 
Fusid, 29, A6 
G 
Gabapentin, 205 
Garamine, 260 
Garamycin, 260 
GASTRO-INTESTINAL 
DRUGS, 59, A9 
Gemfibrozil, 53 
Gentamicin, 230, 259 
Gentatrim, 260 
Gestodene, 180 
GI-Care, 65, A9 
Glibenclamide/Glyburide, 
157, 162, A23 
 Glibetic, 164 
Gliclazide, 157 
Glimepiride, 157 
Glipizide, 157 
Gluben, 164 
Glucocare, 164 
Glucomet, 166 
Glucomin, 166 
Gluconil, 164, A23 
Glucophage, 166 
Glycerin, 76, 78, 80, 254, 
A11 
Glyceryl Guaiacolate, 93 
Glyphillin, 103 
Granexin, 136 
Grifulin, 151 
Griseofulvin, 150 
Guaifenesin, 93 
Guanethidine, 24, 235 
Gynera, 182, A24 
Gyno-Daktarin, 150 
Gyno-Daktazol, 150 
H 
H2-antagonists, 61 
Halazepam, 197 
Haldol, 204 
Halidol, 204 
Haloper, 204 
Haloperidol, 68, 201, 203, 
A28 
Harmonal, 199 
Hemoral, 81, A11 
Hep. B Vaccine, 307, A43 
Hib Vaccine, 309 
HibTITER, 309 
Hiconcil, 122, A18 
Hismal, 89 
Hismanal, 89 
Histafed, A17 
Homosalicylate, 276 
Humulin, 162 
Hydralazine, 24 
Hydran-60, 74 
Hydrochlorothiazide, 24, 26 
Hydrocortisone, 80, 106, 169, 
233, 271, A11, A48 
Hydrosol, A38 
Hydroxyethylcellulose, 239 
Hyocine N-butyl Bromide, 
67, A11 
HYPNOTICS, 197, A28 
I 
Ibufen, 10 
Ibuprofen, 8, 9, A4 
Ikacor/Ikapress, 40 
Imipramine, 194, A28 
Imodium, 75 
Imovax, A42 
Indapamide, 26 
Indocaps, 12 
Indocin, 12 
Indomed, 12 
Indomethacin, 8, A5 
Indopharm, 12 
Indovis, 12 
Influenza Vaccines, 102, 308, 
A43 
Inhibace, 37 
Insulin, 159 
Iodine, 288 
Iodocare, 262 
Iodo-Vit, 262 
IPV, 303 
Iron, 287, 288 
Isardipine, 37 
Isocarboxide, 191 
Isocardide, 46 
Isofen, 10 
Isoniazid, 138, 139 
Isophane Insulin, 157 
Isophane- NPH, 159 
Isoproterenol, 103 
Isordil, 46 
Isosorbide Dinitrate, 45 
Isosorbide Mononitrate, 45 
Isotard, 46 
IUD, 177 
J 
Jeflex, 127 
Jordacycline, 259 
K 
Keflex, 127 
Ketoconazole, 257, A33 
Kiddi, A43 
Klonopin, 211 
L 
Labetolol, 31 
Lactase, 71 
Lactopar, 224, A27 
Lactulose, 76 
Lahistan, 89 
Lamotrigine, 205 
Lanoxin, 52 
Lansoprazole, 62 
Largactil, 203 
Lasix, 29 
LAXATIVES, 75, A11 
Levodopa, 224 
Levofloxacin, 136 
Levonorgestrel, 180, 185, 
A24 
Levothyroxine, 166 
Levozem, 41 
Lidocaine, 44 
Lignocaine, 239, 255, A32 
Lindane, 265, A36 
Lipastop, 75 
LIPID LOWERING DRUGS, 
52, A8 
Liquidone, 157 
Lisinopril, 35 
Lispro Insulin, 157, 159 
Lithium, 192 
Locacid, 273, A37 
LOCAL ANESTHETICS, 79 
Locid, 66 
Logynon, A25 
Lomefloxacin, 136 
Lomudal, 106 
Loop Diuretics, 27 
Loperamide, 74, A11 
Loperid, 75 
Lorainide, 42 
Loratadine, 87 
Lorazepam, 197, 199, A29 
Lorivan, 200 
Lorocare, 200 
Losec, 66 
Lovastatin, 53, 56 
 M 
Maalox, 64 
Macrodantin, 135 
Macrofuran, 135 
Macrolides, 102, A19 
Magnagel, 64 
Magnicillin, 120 
Malathion, 265 
Maprotiline, 191 
Marial, A9 
Measles Vaccine, 306, A42 
Meclizine/Meclozine, 68, 70, 
A10 
Medroxy-Progesterone 
Acetate, 184 
Megacare, 120 
Megalat, 39 
Mepral, 66, A10 
Mestranol, 179 
Metamucil, 79 
Metaproterenol, 103 
Metformin, 157, 158, 164, 
A23 
Methicillin, 119 
Methylcellulose, 76 
Metoclopramide, 68, A10 
Metolazone, 26 
Metoprolol, 31, 45 
Metrocare, 144 
Metrogyl, 144 
Metronidazole, 62, 143 
Metrozole, 144 
Metyrosine, 24 
Mexiletine, 42 
Mg/Al Salt, 63, A9 
Miconazole, 149, 256, A22, 
A32 
Microdiol, 182 
Microgynon, A24 
Miglitol, 157 
Mineral Oil, 80 
Minerals, 287 
Minocycline, 127 
Minovit, A44 
Minovlar, A24 
Minoxidil, 24 
Minulet, A24 
Miphar, 29 
MMR Vaccine, 296, 306, 
A42 
Moclobemide, 191 
Mono-Amine Oxidase 
Inhibitors, 162, 191 
Moricizine, 42 
Motrin, 10 
Moxalactam, 125 
Moxepharm, 122 
Moxypen, 122 
Moxyvit, 122 
MUCOLYTICS, 97, A13 
Mupirocin, 259 
Mycobutin, 141 
N 
Nadolol, 31 
Nalcrom, 106 
Nalidixic Acid, 135, A21 
Naphazoline, 90 
Naproxen, 8,A4 
Nasivin, 92 
Nefazodone, 191 
NegGram, 136 
Neomycin, 244, 259 
NEUROLEPTICS, 200 
Niacin, 284 
Niclosamide, 147 
Nicotinic Acid, 53 
Nifedipine, 24, 38, 45, A7 
Nimodipine, 37 
Nisoldipine, 37 
Nitrates, 44 
Nitrazepam, 197 
Nitrofurantoin, 133, A21 
Nitroprusside, 24 
Nizatidine, 62 
Nizoral, 258 
Nonoxinol ‘9’, 178 
Nordette, 182, A24 
Norethisterone, 180 
Norfloxacin, 136 
Norgestimate, 180 
Norlip, 54 
Normalol, 34 
Normiten, 34, A6 
Norplant, 186 
Nortriptyline, 191, 193 
Nosacare, 92 
Nouryl, 265 
Novocort, A31 
Novolin, 162 
Novomit, 69 
NSAIDs, 3, 8, 9, 10, 11, 13, 
17, A4, A5 
Nurofen, 10 
Nystatin, 148, 256, A22 
O 
Octyl Salicylate, 276 
Ofloxacin, 136, 231, 245 
Ogmin, 123 
Omeprazole, 62, 65, A9 
OPTHALMIC 
PREPARATIONS, 229, 
A31 
Opticrom, 235 
OPV, 303 
Oracal-D, A43 
Oral Rehydrating Salt (ORS), 
73, 74, A10 
Ovysem, A25 
Orset, 74 
OTIC PREPARATIONS, 243 
Oxazepam, 197 
Oxcarbazepine, 205 
Oxprenolol, 31 
OXY, 274 
Oxybenzone, 276 
Oxybuprocaine, 239 
Oxycin, 259 
Oxy-clean, 268 
Oxymetazoline, 90, 91, A13 
Oxytetracycline, 259, A33 
P 
Padimate O, 276 
Pamol, 7, A3 
Pantoprazole, 62 
Paracare, 7 
Paracetamol, 6, A3 
Parafin, 76 
Paraflu, A17 
Paramol, 7 
Paramolan, 7 
Paravomine, 70, A10 
Parazine, 267 
Parilac, 224 
Parlodel, 224 
Paroxetine, 191 
Partivel, 222 
 Pathoprim, 133 
PedvaxHIB, 309 
Penbutolol, 31 
Penibrin, 122 
Penicillins, 115, A18 
Pentrexyl, 122 
Peridol, 204, A29 
Peridor, 204 
Petrolatum, 254 
Pharmaprim, 133 
Phenelzine, 191 
Phenobarb, 214 
Phenobarbital/ Pheno-
barbitone, 212, A26 
Phenolphthalein, 76 
Phenoxymethyl-Penicillin, 
116 
Phenylephrine, 80, 90 
Phenylpropanolamine, 90 
Phenytoin, 42, 194, 207, 208, 
214, A26 
Pilocarpine, 235 
Pindolol, 31 
Pioglitazone, 157 
Pirox, 13 
Piroxicam, 8, 12, A5 
Pitrex, 259 
Pivampicillin, 120 
Polio Vaccines, 303, A42 
Polycarbophil, 76 
Polydine, 262 
Polymixin B, 231, 259 
Potassium, 288, 289 
Potassium-Sparing Diuretics, 
29 
Povidone-Iodine, 261, A33 
Pramin, 69 
Prazepam, 197 
Prazosin, 24 
Prednisolone, 170, 233, 246 
Prednisone, 107, 170, 171, 
173, A14 
Prednitab, 173 
Prelosec, 66 
Pressolat, 39 
Primonil, 195 
Prioderm, 265 
Prizma, 196 
Probenecid, 12, 13 
Probucol, 53 
Procainamide, 42 
Procaine Penicillin, 118 
Procar, 44 
Prochlorperazine, 68, 201 
Procyoxylene, 81 
Progesterone, 179, 183 
Progestin-Only Products, 
183, A25 
ProHIBIT, 309 
Prolol, 33 
Promazine, 201 
Promethazine, 68, 87, A48 
Propranolol, 24, 31, 34, 42, 
45, A6 
Propylthiocil, 169 
Propylthiouracil, 168 
Proton Pump Inhibitors, 61, 
62, A9 
Protriptyline, 191 
Proxymetacaine, 239 
Prozac, 196 
Pseudoephedrine, 90, 92, 
A12 
PSYCHOTHERAPEUTIC 
DRUGS, 189, A28 
Psyllium, 76, 78, A11 
Pulmadrine, A17 
Pyrazinamide, 13, 138, 142 
Pyrithione Zinc, 269 
Pyrocard, 17 
Q 
Questran, 55 
Quinapril, 35 
Quinidine, 44 
R 
Rabeprazole, 62 
Rafapen, 119, A17 
Ramipril, 35 
Randin, 65 
Ranitidine, 64,  
Ratidine, 65 
Razimol, 7 
Recombivax HB, 307 
Reglan, 69 
Rehidrat, 74 
Repaglinide, 157 
Reserpine, 24 
Resperidone, 201 
RESPIRATORY  DRUGS, 
83, A12 
Resprim, 133 
Resyl, 94 
Retavit, 273 
Retin-A, 273 
Retinoic Acid, 272, A35 
Rhinoclir, 92 
Rhumacare, 11 
Rifampin/Rifampicin, 138, 
140, A21 
Rimactan, 141 
Rimevax, A45 
Rivotril, 211 
Robutussin, 94 
Rosiglitazone, 157 
Rufenal, 11 
S 
Salbutamol, 103, A14, A48 
Salbuvent, 104 
Salicylates, 162 
Salicylic Acid, 267, 269, A34 
Salisol-2, 268 
Saralasin, 24 
Scabicide, 264 
Scabiex, 264 
Scobutyl, 68 
Scopal, 68 
Selective Serotonin Reuptake 
Inhibitors, 191 
Selenium Sulfide, 269 
Senna, 76 
Serepam, 199 
Sertraline, 191 
Simigel, 64 
Simovil, 56 
Simvastatin, 53, 56, A8 
Sincomen, 30 
Sinemet, 225 
Sinoptic, 237 
Slow-Fe, A38 
Slow-Folic, A40 
Slow-K, A38 
Somophyllin, 103 
Sotalol, 31, 42 
Sparfloxacin, 136 
Spermicides, 178 
Spironolactone, 24, 29, A6 
Sporofulvin, 151 
 Stomagel, 64 
Stopit, 75 
StressTab, A41 
Sulfatrim, 133 
Sulfinpyrazone, 15 
Sulfisoxaole, 245 
Sulfonylureas, 157 
Sulfur, 268 
Sulisobenzone, 276 
Sulphonamide, 131 
Sulpiride, 201 
Sulprim, 133 
SUNSCREEN PRODUCTS, 
275, A36 
Supradyn, A41 
Symmetrel, 222 
T 
Taroctyl, 203 
Td Vaccine, 305 
Tegrepine, 209 
Tegretol, 209 
Temocillin, 120 
Terconazole, 256 
Teril, 209 
Tetanus Vaccines, 304, A42 
Tetracare, 259 
Tetracycline, 127, 231, A19, 
A29 
Tetrapharm, 129, 259 
Tevacycline, 129, 259 
Theo-dur, 103 
Theopharm, 103 
Theophylline, 16, 100, A13 
Theotard, 103 
Theotrim, 103 
Thiazide, 162 
Thiazolidinediones, 158 
Thioridazine, 201 
Thioxanthenes, 201 
Thorazine, 203 
THYROID DRUGS, 166 
Thyroid Hormone, 102, 162 
Thyroxine, 166, 186 
Tiloptic, 237 
Timolin, 237 
Timolol, 31, 236, A30 
Tinaderm, 259 
Tinasol, 259 
Titanium Dioxide, 276 
Tobramycin, 231 
Tocainide, 42 
Tofranil, 195, A28 
Tolazamide, 157 
Tolbutamide, 163 
Tolnaftate, 256, 258, A33 
Torsemide, 27 
Tranquilizer, 203 
Tranylcypromine, 191 
Trazodone, 191 
Tretinoin, 272 
Triamcinolone, 170, 271 
Triamterene, 29 
Triazolam, 197 
Tricold, A17 
Trichonazole, 144 
Tricyclic Antidepressants, 
191, A28 
Trihexyphenidyl, 219 
Trimethoprim, 131, A20 
Trimpramine, 191 
Trinordiol, A25 
Triprolidine, 87 
Troglitazone, 157 
Trufen, 10 
Tums, A37 
Tussibal, A16 
Tryptal/Tryptalette, 194 
Tylenol, 7 
U 
U-Gram, 136, A20 
ULCER HEALING DRUGS, 
61 
Ultrasol, A36 
Uniscrub, 263 
Urantoin, 135 
Urigram, 136, A20 
Urix, 29, A6 
V 
VACCINES, 295, A45 
Valium, 199 
Valporal, 217 
Valproate, 215 
Valproic Acid, 215, A26 
Vaseline, 254, 268 
Venlafaxine, 191 
Ventocare, 104 
Ventolin, 104 
Verac, 40 
Verapamil, 24, 39, 45 
Vermacare, 147 
Vermazol, 147 
Vermox, 147 
Viarex Inhaler, 107 
Vical , A41 
Vicrom, 106 
Vigabatrin, 205 
Vitamin A, 282 
Vitamin B1, 284 
Vitamin B12, 284 
Vitamin B6, 284 
Vitamin C, 285 
Vitamin D, 215 
Vitamin D, 282 
Vitamin E, 282 
Vitamin K, 282 
VITAMINS, 281, A37, A39 
Vitapen, 122 
Volmax, 104 
Voltaren, 11 
Voltin, 11 
W 
Warfarin, 47, A7 
Water Soluble Vitamins, 281 
White Petrolatum, 80 
X 
Xylene, 256 
Xylometazoline, 90, 91 
Z 
Zadstat, 144 
Zantab, 65 
Zantac, 65 
Zarontin, 212, A26 
Zinc Oxide, 80, 255, 276, A32 
Zinc Sulphate, 239 
Zino Pads, 268 
Zocor, 56 
Zovirax, 152, 261, A22, A33 
Zylol, 15 
Zymafluor, A38 
  
 
 
